

SCORE OVER LENGTH SEARCHES

Attached is a score over length search. This search was developed to overcome limitations in most standard search systems which favor large sequences with high scoring, but lesser overall identity over smaller sequences with higher overall identity. This search is especially useful for relatively small nucleic acid or polypeptide target sequences (antisense, fragments, probes, primers, RNAi, epitopes, haptens, etc.) claimed functionally via a form of hybridization and/or identity language and having defined upper and lower polynucleotide and or polypeptide length limits.

The score over length search is performed by first running the query sequence using examiner-specified identity and polynucleotide or protein length limit parameters, and saving 65,000 hits and 0 alignments from each desired database. The resulting output is reformatted using a Microsoft Word macro and is imported into Excel. The summary table data are then sorted by the ratio of score of each hit sequence divided by its length and the accession numbers for all hits below the examiner's desired score over length parameters are deleted. The remaining accession numbers are used to pull the corresponding sequences from the databases into subdatabases enriched for good hits and the query sequence is re-run against these subdatabases to yield the final results.

The score over length cutoff for this search is 759.

Examiner Please Note: This cover sheet should be included when submitting results to be scanned.

THIS PAGE BLANK (USPTO)

Osaka University

Query Match	Score	DB
1.8%	43	1
100.0%	NC	0.40

Query Match	1.8%;	Score 43;	DB 1;	Length 43
Best Local Similarity	100.0%;	Pred. No. 0.49;		

Matches 43; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1149 ATTGGTTGGCCCATCTTCATNGTCGAGGCTCTTCT 1191
 Db 43 ATTGGTTGGCCCATCTTCATNGTCGAGGCTCTTCT 1

RESULT 3
 CL680542/c
 LOCUS
 DEFINITION CL680542 24 bp DNA linear GSS 09-JUL-2004
 PRI0129C.F01_2 - PRI0129C.BR (24) Mixed stage fosmid library of P.
 pacificus var. California Pristionchus pacificus genomic, genomic
 survey sequence.

ACCESSION CL680542
 VERSION CL680542
 KEYWORDS GI:50187453
 SOURCE GSS.
 ORGANISM Pristionchus pacificus
 Pristionchus pacificus
 Eukaryota; Metazoa; Nematoda; Chromadorea; Diplogasterida;
 Neodiplogasteridae; Pristionchus.

REFERENCE 1 (bases 1 to 24)
 Srinivasan,J., Otto,G.W., Kahlow,U., Geisler,R. and Sommer,R.J.
 AppAB: an Acedb database for the nematode satellite organism
 Pristionchus pacificus
 Nucleic Acids Res. 32 (1), D421-D422 (2004)
 JOURNAL Contact: Sommer RJ
 COMMENT Evolutionary Biology
 Max-Planck-Institute for Developmental Biology
 Spemannstr. 37-39, Tuebingen D-72076, Germany
 Tel: 00497071601371
 Fax: 00497071601498
 Email: ralf.sommer@tuebingen.mpg.de
 This library was generated at Caltech, Pasadena, USA and end
 sequenced at Vancouver, Canada.
 Seq primer: T7
 Class: fosmid ends.
 Location/Qualifiers

FEATURES
 source 1..24
 /organism="Pristionchus pacificus"
 /mol_type="genomic DNA"
 /strain="California"
 /db_xref="taxon:54126"
 /clone_lib="Mixed stage fosmid library of P. pacificus
 var. California"
 /note="Vector: pBplfos-5 Fosmid vector"

Query Match 0.8%; Score 18.2; DB 1; Length 24;
 Best Local Similarity 87.0%; Pred. No. 5.1;
 Matches 20; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 5 GGGACGCCAGCGCGCGCTGC 27
 Db 24 GGTAGCGCCAGCGCGCGCAGC 2

RESULT 4
 CF921149
 LOCUS
 DEFINITION CF921149 20 bp mRNA linear EST 05-NOV-2003
 gmrhrw3-06_A05_1.047 Soybean root hair subtraced cDNA library
 gmrhrw3 Glycine max cDNA, mRNA sequence.

ACCESSION CF921149
 VERSION CF921149
 KEYWORDS GI:38191943
 SOURCE EST.
 ORGANISM Glycine max (soybean)
 Glycine max
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eustosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae;
 Glycine.

REFERENCE 1 (bases 1 to 20)
 Scheffler,B.E., Huang,S., Liu,X., Nguyen,H., Duke,M. and Stacey,G.
 AUTHORS
 TITLE Expressed sequence tags from soybean root hair subtractive cDNA
 library

JOURNAL Unpublished (2003)
 COMMENT Contact: Gary Stacey
 University of Missouri
 108 Waters Hall, Columbia, MO 65211, USA
 Tel: 573-884-4752
 Fax: 573-882-0588
 Email: stacey@missouri.edu
 Single pass sequence
 Seq primer: T7

FEATURES
 source Location/Qualifiers
 1..20
 /organism="Glycine max"
 /mol_type="mRNA"
 /cultivar="Williams 82"
 /db_xref="taxon:3847"
 /tissue_type="root hairs"
 /clone_lib="Soybean root hair subtraced cDNA library
 gmrhrw3"
 /note="Organ: root hairs; Vector: PCR2-1 Topo; cDNA clones
 generated from soybean root hair tissue treated with
 Bradyrhizobium japonicum for 3 hours."

Query Match 0.7%; Score 15.8; DB 1; Length 20;
 Best Local Similarity 89.5%; Pred. No. 6.7;
 Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 447 GTCCTCCAGTGGGCTCTGT 465
 Db 1 GTGCTCCAGAGGTTCTGT 19

RESULT 5
 AA954509
 LOCUS
 DEFINITION AA954509 19 bp mRNA linear EST 23-JUN-1998
 on81d05.s1 Soares_NFL_T.GBC.S1 Homo sapiens cDNA clone
 IMAGE:1563081 3' similar to TR:Q24035 Q24035 ENA POLYPEPTIDE.
 ;contains element MSRI repetitive element;; mRNA sequence.

ACCESSION AA954509
 VERSION AA954509
 KEYWORDS GI:3118204
 SOURCE EST.
 ORGANISM Homo sapiens (human)
 Homo sapiens
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
 NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap.
 1 (bases 1 to 19)
 JOURNAL National Cancer Institute, Cancer Genome Anatomy Project (CGAP),
 Tumor Gene Index
 Unpublished (1997)
 COMMENT Contact: Robert Strausberg, Ph.D.
 Email: cgaps-remail.nih.gov
 This clone is available royalty-free through LNL; contact the
 IMAGE Consortium (info@image.lln.gov) for further information.
 Trace considered overall poor quality
 Insert Length: 754 Std Error: 0.00
 Seq primer: -40m3 fwd. ET from Amersham
 High quality sequence stop: 1.
 Location/Qualifiers

FEATURES
 source 1..19
 /organism="Homo sapiens"
 /mol_type="mRNA"
 /db_xref="taxon:9606"
 /clone="IMAGE:1563081"
 /lab_host="DH10B"
 /clone_lib="Soares_NFL_T.GBC.S1"
 /note="Organ: pooled; Vector: pT73D-Pac (Pharmacia) with
 a modified polylinker; Site 1: Not 1; Site 2: Eco RI;
 Equal amounts of plasmid DNA from three normalized
 libraries (fetal lung NH419W, testis NHT, and B-cell1
 NCI-CGAP-GCBI) were mixed, and ss circles were made in
 vitro. Following HAP purification, this DNA was used as
 tracer in a subtractive hybridization reaction. The driver
 was PCR-amplified cDNAs from pools of 5,000 clones made

from the same 3 libraries. The pools consisted of
I.M.A.G.E. clones 297480-302087, 682632-687239,
726408-728711, and 729096-731399. Subtraction by Bento
Soares and M. Fatima Bonaldo."

Query Match 0.6%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 7.1;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 147 CCTGTGGCCCGGGGGGCC 163
Db 1 CCCAGGCCCGGGGGGCC 17

Search completed: August 8, 2005, 10:02:53
Job time : 0.001 secs

THIS PAGE BLANK (USPTO)

107	24	1.0	24	1	US-10-013-906A-293	Sequence 293, App	c 180	20	0.8	20	1	US-10-643-801-30	Sequence 30, App1
c 108	24	1.0	24	1	US-10-013-906A-294	Sequence 294, App	c 181	20	0.8	20	1	US-10-643-801-31	Sequence 31, App1
c 109	24	1.0	24	1	US-10-015-388A-293	Sequence 293, App	c 182	20	0.8	20	1	US-10-643-801-32	Sequence 32, App1
c 110	24	1.0	24	1	US-10-015-388A-294	Sequence 294, App	c 183	20	0.8	20	1	US-10-643-801-33	Sequence 33, App1
c 111	24	1.0	24	1	US-10-012-753A-293	Sequence 293, App	c 184	20	0.8	20	1	US-10-643-801-34	Sequence 34, App1
c 112	24	1.0	24	1	US-10-012-753A-294	Sequence 294, App	c 185	20	0.8	20	1	US-10-643-801-35	Sequence 35, App1
c 113	24	1.0	24	1	US-10-015-385A-293	Sequence 293, App	c 186	20	0.8	20	1	US-10-643-801-36	Sequence 36, App1
c 114	24	1.0	24	1	US-10-015-385A-294	Sequence 294, App	c 187	20	0.8	20	1	US-10-643-801-37	Sequence 37, App1
c 115	24	1.0	24	1	US-10-007-236A-293	Sequence 293, App	c 188	20	0.8	20	1	US-10-643-801-38	Sequence 38, App1
c 116	24	1.0	24	1	US-10-007-236A-294	Sequence 294, App	c 189	20	0.8	20	1	US-10-643-801-39	Sequence 39, App1
c 117	24	1.0	24	1	US-10-015-389A-293	Sequence 293, App	c 190	20	0.8	20	1	US-10-643-801-40	Sequence 40, App1
c 118	24	1.0	24	1	US-10-015-389A-294	Sequence 294, App	c 191	20	0.8	20	1	US-10-643-801-41	Sequence 41, App1
c 119	24	1.0	24	1	US-10-015-519A-293	Sequence 293, App	c 192	20	0.8	20	1	US-10-643-801-42	Sequence 42, App1
c 120	24	1.0	24	1	US-10-015-519A-294	Sequence 294, App	c 193	20	0.8	20	1	US-10-643-801-43	Sequence 43, App1
c 121	24	1.0	24	1	US-10-013-915A-293	Sequence 293, App	c 194	20	0.8	20	1	US-10-643-801-44	Sequence 44, App1
c 122	24	1.0	24	1	US-10-013-915A-294	Sequence 294, App	c 195	20	0.8	20	1	US-10-643-801-45	Sequence 45, App1
c 123	24	1.0	24	1	US-10-015-394A-293	Sequence 293, App	c 196	20	0.8	20	1	US-10-643-801-46	Sequence 46, App1
c 124	24	1.0	24	1	US-10-015-394A-294	Sequence 294, App	c 197	20	0.8	20	1	US-10-643-801-47	Sequence 47, App1
c 125	24	1.0	24	1	US-10-015-390A-293	Sequence 293, App	c 198	20	0.8	20	1	US-10-643-801-48	Sequence 48, App1
c 126	24	1.0	24	1	US-10-015-390A-294	Sequence 294, App	c 199	20	0.8	20	1	US-10-643-801-49	Sequence 49, App1
c 127	24	1.0	24	1	US-10-006-746A-293	Sequence 293, App	c 200	20	0.8	20	1	US-10-643-801-50	Sequence 50, App1
c 128	24	1.0	24	1	US-10-006-746A-294	Sequence 294, App	c 201	20	0.8	20	1	US-10-643-801-51	Sequence 51, App1
c 129	24	1.0	24	1	US-10-026-254A-293	Sequence 293, App	c 202	20	0.8	20	1	US-10-643-801-52	Sequence 52, App1
c 130	24	1.0	24	1	US-10-026-254A-294	Sequence 294, App	c 203	20	0.8	20	1	US-10-643-801-53	Sequence 53, App1
c 131	24	1.0	24	1	US-10-011-795A-293	Sequence 293, App	c 204	20	0.8	20	1	US-10-643-801-54	Sequence 54, App1
c 132	24	1.0	24	1	US-10-011-795A-294	Sequence 294, App	c 205	20	0.8	20	1	US-10-643-801-55	Sequence 55, App1
c 133	24	1.0	24	1	US-10-012-231A-293	Sequence 293, App	c 206	20	0.8	20	1	US-10-643-801-56	Sequence 56, App1
c 134	24	1.0	24	1	US-10-012-231A-294	Sequence 294, App	c 207	20	0.8	20	1	US-10-643-801-57	Sequence 57, App1
c 135	24	1.0	24	1	US-10-015-395A-293	Sequence 293, App	c 208	20	0.8	20	1	US-10-643-801-58	Sequence 58, App1
c 136	24	1.0	24	1	US-10-015-395A-294	Sequence 294, App	c 209	20	0.8	20	1	US-10-643-801-59	Sequence 59, App1
c 137	24	1.0	24	1	US-10-012-149A-293	Sequence 293, App	c 210	20	0.8	20	1	US-10-643-801-60	Sequence 60, App1
c 138	24	1.0	24	1	US-10-012-149A-294	Sequence 294, App	c 211	20	0.8	20	1	US-10-643-801-61	Sequence 61, App1
c 139	24	1.0	24	1	US-10-643-801-6	Sequence 6, App1	c 212	20	0.8	20	1	US-10-643-801-71	Sequence 71, App1
c 140	23.4	1.0	25	1	US-10-719-900-684231	Sequence 684231, Sequence 761465,	c 213	20	0.8	20	1	US-10-643-801-73	Sequence 73, App1
c 141	23.4	1.0	25	1	US-10-719-900-761465	Sequence 761465, Sequence 19410, A	c 214	20	0.8	20	1	US-10-643-801-75	Sequence 75, App1
c 142	23.4	1.0	25	1	US-10-719-956-19410	Sequence 19410, A Sequence 102353,	c 215	20	0.8	20	1	US-10-643-801-77	Sequence 77, App1
c 143	23.4	1.0	25	1	US-10-719-956-102353	Sequence 102353, Sequence 145295,	c 216	20	0.8	20	1	US-10-643-801-76	Sequence 76, App1
c 144	23.4	1.0	25	1	US-10-719-956-145295	Sequence 145295, Sequence 323131,	c 217	20	0.8	20	1	US-10-643-801-77	Sequence 77, App1
c 145	23.4	1.0	25	1	US-10-719-956-323131	Sequence 323131, Sequence 22, App1	c 218	20	0.8	20	1	US-10-643-801-78	Sequence 78, App1
c 146	23	1.0	23	1	US-10-278-733-22	Sequence 22, App1 Sequence 5, App1	c 219	20	0.8	20	1	US-10-643-801-79	Sequence 79, App1
c 147	22	0.9	22	1	US-10-324-618-25	Sequence 5, App1 Sequence 25, App1	c 220	20	0.8	20	1	US-10-643-801-80	Sequence 80, App1
c 148	22	0.9	22	1	US-10-643-801-5	Sequence 25, App1 Sequence 7, App1	c 221	20	0.8	20	1	US-10-643-801-81	Sequence 81, App1
c 149	22	0.9	22	1	US-10-643-801-7	Sequence 7, App1 Sequence 23, App1	c 222	20	0.8	20	1	US-10-643-801-82	Sequence 82, App1
c 150	22	0.9	22	1	US-10-883-760-23	Sequence 23, App1 Sequence 16467, A	c 223	20	0.8	20	1	US-10-643-801-83	Sequence 83, App1
c 151	21.8	0.9	25	1	US-10-719-900-16467	Sequence 16467, A Sequence 811307,	c 224	20	0.8	20	1	US-10-643-801-84	Sequence 84, App1
c 152	21.8	0.9	25	1	US-10-719-900-811307	Sequence 811307, Sequence 880907,	c 225	20	0.8	20	1	US-10-643-801-85	Sequence 85, App1
c 153	21.8	0.9	25	1	US-10-719-900-880907	Sequence 880907, Sequence 19409, A	c 226	20	0.8	20	1	US-10-643-801-86	Sequence 86, App1
c 154	21.8	0.9	25	1	US-10-719-956-19409	Sequence 19409, A Sequence 102354,	c 227	20	0.8	20	1	US-10-643-801-87	Sequence 87, App1
c 155	21.8	0.9	25	1	US-10-719-956-102354	Sequence 102354, Sequence 145296,	c 228	20	0.8	20	1	US-10-643-801-88	Sequence 88, App1
c 156	21.8	0.9	25	1	US-10-719-956-145296	Sequence 145296, Sequence 630251,	c 229	20	0.8	20	1	US-10-643-801-89	Sequence 89, App1
c 157	21.8	0.9	25	1	US-10-719-956-630251	Sequence 630251, Sequence 16468, A	c 230	20	0.8	20	1	US-10-643-801-89	Sequence 89, App1
c 158	20.2	0.8	25	1	US-10-719-900-16468	Sequence 16468, A Sequence 263580,	c 231	20	0.8	20	1	US-10-643-801-90	Sequence 90, App1
c 159	20.2	0.8	25	1	US-10-719-900-263580	Sequence 263580, Sequence 407646,	c 232	20	0.8	20	1	US-10-643-801-91	Sequence 91, App1
c 160	20.2	0.8	25	1	US-10-719-900-407646	Sequence 407646, Sequence 539350,	c 233	20	0.8	20	1	US-10-643-801-92	Sequence 92, App1
c 161	20.2	0.8	25	1	US-10-719-900-539350	Sequence 539350, Sequence 539351,	c 234	20	0.8	20	1	US-10-643-801-93	Sequence 93, App1
c 162	20.2	0.8	25	1	US-10-719-900-539351	Sequence 539351, Sequence 811305,	c 235	20	0.8	20	1	US-10-643-801-94	Sequence 94, App1
c 163	20.2	0.8	25	1	US-10-719-900-811305	Sequence 811305, Sequence 832328,	c 236	20	0.8	20	1	US-10-643-801-95	Sequence 95, App1
c 164	20.2	0.8	25	1	US-10-719-900-832328	Sequence 832328, Sequence 880908,	c 237	20	0.8	20	1	US-10-643-801-96	Sequence 96, App1
c 165	20.2	0.8	25	1	US-10-719-900-880908	Sequence 880908, Sequence 70482, A	c 238	20	0.8	20	1	US-10-643-801-97	Sequence 97, App1
c 166	20.2	0.8	25	1	US-10-719-956-70482	Sequence 70482, A Sequence 630252,	c 239	20	0.8	20	1	US-10-643-801-143	Sequence 143, App
c 167	20.2	0.8	25	1	US-10-719-956-630252	Sequence 630252, Sequence 26, App1	c 240	20	0.8	20	1	US-10-643-801-144	Sequence 144, App
c 168	20	0.8	20	1	US-10-324-618-26	Sequence 26, App1 Sequence 379, App	c 241	20	0.8	20	1	US-10-643-801-145	Sequence 145, App
c 169	20	0.8	20	1	US-10-307-817-379	Sequence 379, App Sequence 20, App1	c 242	20	0.8	20	1	US-10-643-801-146	Sequence 146, App
c 170	20	0.8	20	1	US-10-643-801-20	Sequence 20, App1 Sequence 21, App1	c 243	20	0.8	20	1	US-10-643-801-147	Sequence 147, App
c 171	20	0.8	20	1	US-10-643-801-21	Sequence 21, App1 Sequence 22, App1	c 244	20	0.8	20	1	US-10-643-801-148	Sequence 148, App
c 172	20	0.8	20	1	US-10-643-801-22	Sequence 22, App1 Sequence 23, App1	c 245	20	0.8	20	1	US-10-643-801-149	Sequence 149, App
c 173	20	0.8	20	1	US-10-643-801-23	Sequence 23, App1 Sequence 24, App1	c 246	20	0.8	20	1	US-10-643-801-150	Sequence 150, App
c 174	20	0.8	20	1	US-10-643-801-24	Sequence 24, App1 Sequence 25, App1	c 247	20	0.8	20	1	US-10-643-801-151	Sequence 151, App
c 175	20	0.8	20	1	US-10-643-801-25	Sequence 25, App1 Sequence 26, App1	c 248	20	0.8	20	1	US-10-643-801-152	Sequence 152, App
c 176	20	0.8	20	1	US-10-643-801-26	Sequence 26, App1 Sequence 27, App1	c 249	20	0.8	20	1	US-10-643-801-153	Sequence 153, App
c 177	20	0.8	20	1	US-10-643-801-27	Sequence 27, App1 Sequence 28, App1	c 250	20	0.8	20	1	US-10-643-801-154	Sequence 154, App
c 178	20	0.8	20	1	US-10-643-801-28	Sequence 28, App1 Sequence 29, App1	c 251	20	0.8	20	1	US-10-643-801-155	Sequence 155, App
c 179	20	0.8	20	1	US-10-643-801-29	Sequence 29, App1	c 252	20	0.8	20	1	US-10-643-801-156	Sequence 156, App

253	20	0.8	20	1	US-10-643-801-157	Sequence 157, App	16.8	0.7	20	1	US-10-818-939-27	Sequence 27, Appl
254	20	0.8	20	1	US-10-643-801-158	Sequence 158, App	16.8	0.7	20	1	US-10-643-801-105	Sequence 106, App
255	20	0.8	20	1	US-10-643-801-159	Sequence 159, App	16.8	0.7	20	1	US-10-643-801-109	Sequence 109, App
256	20	0.8	20	1	US-10-643-801-160	Sequence 160, App	16.8	0.7	20	1	US-10-643-801-113	Sequence 113, App
257	20	0.8	20	1	US-10-643-801-161	Sequence 161, App	16.8	0.7	20	1	US-10-643-801-114	Sequence 114, App
258	20	0.8	20	1	US-10-643-801-162	Sequence 162, App	16.8	0.7	20	1	US-10-643-801-122	Sequence 122, App
259	20	0.8	20	1	US-10-643-801-163	Sequence 163, App	16.8	0.7	20	1	US-10-643-801-215	Sequence 215, App
260	20	0.8	20	1	US-10-643-801-164	Sequence 164, App	16.8	0.7	20	1	US-10-643-801-216	Sequence 216, App
261	20	0.8	20	1	US-10-643-801-165	Sequence 165, App	16.8	0.7	20	1	US-10-643-801-220	Sequence 220, App
262	20	0.8	20	1	US-10-643-801-166	Sequence 166, App	16.8	0.7	21	1	US-09-005-243-16	Sequence 16, Appl
263	20	0.8	20	1	US-10-643-801-167	Sequence 167, App	16.8	0.7	21	1	US-09-224-683-16	Sequence 16, Appl
264	20	0.8	20	1	US-10-643-801-168	Sequence 168, App	16.8	0.7	21	1	US-10-113-916-13	Sequence 13, Appl
265	20	0.8	20	1	US-10-643-801-169	Sequence 169, App	16.8	0.7	21	1	US-10-175-608-16	Sequence 16, Appl
266	20	0.8	20	1	US-10-643-801-170	Sequence 170, App	16.8	0.7	21	1	US-10-791-074-13	Sequence 13, Appl
267	20	0.8	20	1	US-10-643-801-171	Sequence 171, App	16.8	0.7	21	1	US-10-620-644-16	Sequence 16, Appl
268	20	0.8	20	1	US-10-643-801-172	Sequence 172, App	16.8	0.7	22	1	US-10-491-786-41	Sequence 41, Appl
269	20	0.8	20	1	US-10-643-801-173	Sequence 173, App	16.4	0.7	21	1	US-10-223-598-39	Sequence 39, Appl
270	20	0.8	20	1	US-10-643-801-174	Sequence 174, App	16.4	0.7	21	1	US-10-786-720-2516	Sequence 1409, Ap
271	20	0.8	20	1	US-10-643-801-182	Sequence 182, App	16.4	0.7	21	1	US-10-786-720-2516	Sequence 2516, Ap
272	20	0.8	20	1	US-10-643-801-183	Sequence 183, App	16.4	0.7	21	1	US-10-751-736-41385	Sequence 41385, A
273	20	0.8	20	1	US-10-643-801-184	Sequence 184, App	16.4	0.7	21	1	US-10-751-736-42150	Sequence 42150, A
274	20	0.8	20	1	US-10-643-801-185	Sequence 185, App	16.4	0.7	21	1	US-10-799-369-36	Sequence 36, Appl
275	20	0.8	20	1	US-10-643-801-186	Sequence 186, App	16.4	0.7	21	1	US-10-800-350-339	Sequence 359, App
276	20	0.8	20	1	US-10-643-801-187	Sequence 187, App	16.4	0.7	21	1	US-10-800-077-359	Sequence 359, App
277	20	0.8	20	1	US-10-643-801-188	Sequence 188, App	16.2	0.7	21	1	US-10-625-153-4	Sequence 4, Appl
278	20	0.8	20	1	US-10-643-801-189	Sequence 189, App	16.2	0.7	21	1	US-10-786-720-20417	Sequence 20417, A
279	20	0.8	20	1	US-10-643-801-190	Sequence 190, App	16.2	0.7	21	1	US-10-751-736-14616	Sequence 14616, A
280	20	0.8	20	1	US-10-643-801-191	Sequence 191, App	16.2	0.7	21	1	US-10-751-736-15119	Sequence 15119, A
281	20	0.8	20	1	US-10-643-801-192	Sequence 192, App	16.2	0.7	21	1	US-10-751-736-19221	Sequence 19221, A
282	20	0.8	20	1	US-10-643-801-193	Sequence 193, App	16.2	0.7	21	1	US-10-751-736-42616	Sequence 42616, A
283	20	0.8	20	1	US-10-643-801-194	Sequence 194, App	16.2	0.7	21	1	US-10-751-736-43132	Sequence 43132, A
284	20	0.8	20	1	US-10-643-801-195	Sequence 195, App	16.2	0.7	21	1	US-10-751-736-43411	Sequence 43411, A
285	20	0.8	20	1	US-10-643-801-196	Sequence 196, App	16	0.7	17	1	US-10-712-627-331	Sequence 391, App
286	20	0.8	20	1	US-10-643-801-197	Sequence 197, App	16	0.7	19	1	US-10-483-289A-85	Sequence 85, Appl
287	20	0.8	20	1	US-10-643-801-198	Sequence 198, App	15.8	0.7	19	1	US-10-180-781-80	Sequence 80, Appl
288	20	0.8	20	1	US-10-643-801-199	Sequence 199, App	15.8	0.7	20	1	US-08-771-737-8	Sequence 8, Appl
289	20	0.8	20	1	US-10-643-801-200	Sequence 200, App	15.8	0.7	20	1	US-09-954-936-8	Sequence 8, Appl
290	20	0.8	20	1	US-10-643-801-201	Sequence 201, App	15.8	0.7	20	1	US-09-972-607-12	Sequence 12, Appl
291	20	0.8	20	1	US-10-643-801-202	Sequence 202, App	15.8	0.7	20	1	US-10-376-566-63	Sequence 63, Appl
292	20	0.8	20	1	US-10-643-801-203	Sequence 203, App	15.8	0.7	20	1	US-10-455-229-22	Sequence 22, Appl
293	20	0.8	20	1	US-10-643-801-204	Sequence 204, App	15.8	0.7	20	1	US-10-628-841-12	Sequence 12, Appl
294	20	0.8	20	1	US-10-643-801-205	Sequence 205, App	15.8	0.7	20	1	US-10-749-075-8	Sequence 8, Appl
295	20	0.8	20	1	US-10-643-801-206	Sequence 206, App	15.8	0.7	20	1	US-10-643-801-111	Sequence 11, App
296	20	0.8	20	1	US-10-643-801-207	Sequence 207, App	15.8	0.7	20	1	US-10-257-158A-6237	Sequence 6237, Ap
297	20	0.8	20	1	US-10-643-801-208	Sequence 208, App	15.8	0.7	21	1	US-10-432-422-20	Sequence 20, Appl
298	20	0.8	20	1	US-10-643-801-209	Sequence 209, App	15.8	0.7	21	1	US-10-786-720-12520	Sequence 12520, A
299	20	0.8	20	1	US-10-643-801-210	Sequence 210, App	15.8	0.7	21	1	US-10-786-720-12521	Sequence 12521, A
300	20	0.8	20	1	US-10-643-801-211	Sequence 211, App	15.8	0.7	21	1	US-10-786-720-12522	Sequence 12522, A
301	20	0.8	20	1	US-10-643-801-212	Sequence 212, App	15.8	0.7	21	1	US-10-786-720-20416	Sequence 20416, A
302	20	0.8	20	1	US-10-643-801-213	Sequence 213, App	15.8	0.7	21	1	US-10-786-720-20418	Sequence 20418, A
303	19.4	0.8	25	1	US-10-719-956-301629	Sequence 301629, Sequence 885846,	15.8	0.6	17	1	US-10-751-736-14685	Sequence 18465, A
304	19.2	0.8	25	1	US-10-719-900-885846	Sequence 52073, A	15.8	0.7	21	1	US-10-751-736-14082	Sequence 40402, A
305	19.2	0.8	25	1	US-10-809-189-52073	Sequence 52073, A	15.8	0.7	21	1	US-10-751-736-44617	Sequence 42617, A
306	19.2	0.8	25	1	US-10-956-157-170437	Sequence 170437, Sequence 194173,	15.8	0.6	17	1	US-10-847-918-17319	Sequence 12719, A
307	19.2	0.8	25	1	US-10-719-956-226834	Sequence 226834, Sequence 503590,	15.4	0.6	17	1	US-09-866-108-2021	Sequence 2021, Ap
308	18.8	0.8	25	1	US-10-719-900-194173	Sequence 194173, Sequence 503590,	15.4	0.6	17	1	US-09-866-108-2842	Sequence 2842, Ap
309	18.8	0.8	25	1	US-10-719-900-903590	Sequence 903590, Sequence 451896,	15.4	0.6	17	1	US-10-238-700-2	Sequence 2, Appl
310	18.8	0.8	25	1	US-10-719-956-30682	Sequence 30682, A	15.4	0.6	17	1	US-10-712-672-330	Sequence 390, App
311	18.8	0.8	25	1	US-10-719-956-451896	Sequence 451896, Sequence 1108, App	15.4	0.6	17	1	US-10-723-361-2021	Sequence 2021, App
312	18.4	0.8	20	1	US-10-643-801-110	Sequence 1108, App	15.4	0.6	17	1	US-10-723-361-2842	Sequence 2842, Ap
313	18.4	0.8	20	1	US-10-643-801-111	Sequence 110, App	15.4	0.6	17	1	US-10-498-466-1757	Sequence 1757, Ap
314	18.4	0.8	20	1	US-10-643-801-115	Sequence 115, App	15.4	0.6	17	1	US-10-498-466-1759	Sequence 1759, Ap
315	18.4	0.8	20	1	US-10-643-801-117	Sequence 117, App	15.4	0.6	17	1	US-10-724-270-2	Sequence 2, Appl
316	18.4	0.8	20	1	US-10-643-801-119	Sequence 119, App	15.4	0.6	17	1	US-10-353-461-2	Sequence 2, Appl
317	18.4	0.8	20	1	US-10-643-801-217	Sequence 217, App	15.4	0.6	20	1	US-10-303-266-15	Sequence 15, Appl
318	17.4	0.7	19	1	US-10-278-733-24	Sequence 24, Appl	15.4	0.6	20	1	US-10-874-242-13	Sequence 13, Appl
319	17.4	0.7	20	1	US-10-643-801-141	Sequence 141, App	15.2	0.6	20	1	US-09-373-938-10	Sequence 10, Appl
320	17.2	0.7	22	1	US-10-229-834A-11	Sequence 11, Appl	15.2	0.6	20	1	US-09-784-674-552	Sequence 552, App
321	17.2	0.7	22	1	US-10-806-782-20	Sequence 20, Appl	15.2	0.6	20	1	US-09-784-674-553	Sequence 553, App
322	17	0.7	21	1	US-10-349-143-11680	Sequence 11680, A	15.2	0.6	20	1	US-10-080-797-8	Sequence 8, Appl
323	16.8	0.7	20	1	US-09-733-294A-40	Sequence 40, Appl	15.2	0.6	20	1	US-10-057-5550-80	Sequence 80, Appl
324	16.8	0.7	20	1	US-10-174-175-15	Sequence 15, Appl	15.2	0.6	20	1	US-10-037-182-22	Sequence 22, Appl
325	16.8	0.7	20	1	US-10-174-175-52	Sequence 52, Appl	15.2	0.6	20	1	US-10-045-360-16	Sequence 16, Appl

C 399	15.2	0.6	20	1	US-10-176-277-16	Sequence 16, Appl
C 400	15.2	0.6	20	1	US-10-176-277-20	Sequence 20, Appl
C 401	15.2	0.6	20	1	US-10-176-277-53	Sequence 53, Appl
C 402	15.2	0.6	20	1	US-10-176-277-56	Sequence 56, Appl
C 403	15.2	0.6	20	1	US-10-186-157-76	Sequence 76, Appl
C 404	15.2	0.6	20	1	US-10-289-762-3356	Sequence 3356, Ap
C 405	15.2	0.6	20	1	US-10-210-838-36	Sequence 36, Appl
C 406	15.2	0.6	20	1	US-10-210-838-141	Sequence 141, Appl
C 407	15.2	0.6	20	1	US-10-348-346-16	Sequence 16, Appl
C 408	15.2	0.6	20	1	US-10-273-826-24	Sequence 24, Appl
C 409	15.2	0.6	20	1	US-10-274-347-24	Sequence 24, Appl
C 410	15.2	0.6	20	1	US-10-280-183A-459	Sequence 459, App
C 411	15.2	0.6	20	1	US-10-300-424-77	Sequence 77, Appl
C 412	15.2	0.6	20	1	US-10-300-424-124	Sequence 124, Appl
C 413	15.2	0.6	20	1	US-10-300-399-28	Sequence 28, Appl
C 414	15.2	0.6	20	1	US-10-300-399-105	Sequence 105, App
C 415	15.2	0.6	20	1	US-10-688-706-316	Sequence 316, App
C 416	15.2	0.6	20	1	US-10-688-706-2458	Sequence 2458, Ap
C 417	15.2	0.6	20	1	US-10-316-459-16	Sequence 16, Appl
C 418	15.2	0.6	20	1	US-10-316-459-94	Sequence 94, Appl
C 419	15.2	0.6	20	1	US-10-671-395-1546	Sequence 1546, Ap
C 420	15.2	0.6	20	1	US-10-666-909-14	Sequence 14, Appl
C 421	15.2	0.6	20	1	US-10-666-909-62	Sequence 62, Appl
C 422	15.2	0.6	20	1	US-10-744-055-16	Sequence 16, Appl
C 423	15.2	0.6	20	1	US-10-877-231-552	Sequence 552, App
C 424	15.2	0.6	20	1	US-10-877-231-553	Sequence 553, App
C 425	15.2	0.6	20	1	US-10-643-801-107	Sequence 107, App
C 426	15.2	0.6	20	1	US-10-643-801-116	Sequence 116, App
C 427	15.2	0.6	20	1	US-10-831-901A-117	Sequence 117, Ap
C 428	15.2	0.6	20	1	US-10-831-901A-118	Sequence 118, Ap
C 429	15.2	0.6	20	1	US-10-831-901A-119	Sequence 119, Ap
C 430	15.2	0.6	20	1	US-10-831-901A-1720	Sequence 1720, Ap
C 431	15.2	0.6	20	1	US-10-018-320A-13	Sequence 13, Appl
C 432	15	0.6	17	1	US-09-961-077-153	Sequence 153, App
C 433	15	0.6	17	1	US-09-961-077-155	Sequence 155, App
C 434	15	0.6	17	1	US-10-156-306-6949	Sequence 6949, Ap
C 435	15	0.6	17	1	US-10-156-306-6950	Sequence 6950, Ap
C 436	15	0.6	17	1	US-10-238-700-2764	Sequence 2764, Ap
C 437	15	0.6	17	1	US-10-498-462-1758	Sequence 1758, Ap
C 438	15	0.6	17	1	US-10-724-270-1443	Sequence 1443, Ap
C 439	15	0.6	20	1	US-09-938-689-14	Sequence 14, Appl
C 440	14.8	0.6	18	1	US-08-887-505-145	Sequence 145, Appl
C 441	14.8	0.6	18	1	US-10-297-068-352	Sequence 352, App
C 442	14.8	0.6	18	1	US-10-813-203-1	Sequence 1, Appl
C 443	14.8	0.6	19	1	US-08-983-605-55	Sequence 55, Appl
C 444	14.8	0.6	19	1	US-09-901-484A-476	Sequence 476, App
C 445	14.8	0.6	19	1	US-09-966-147-22	Sequence 22, Appl
C 446	14.8	0.6	19	1	US-09-853-526-476	Sequence 476, App
C 447	14.8	0.6	19	1	US-09-864-954D-8	Sequence 8, Appl
C 448	14.8	0.6	19	1	US-10-045-360-17	Sequence 17, Appl
C 449	14.8	0.6	19	1	US-10-374-469-22	Sequence 22, Appl
C 450	14.8	0.6	19	1	US-10-698-597-22	Sequence 22, Appl
C 451	14.8	0.6	19	1	US-10-348-346-17	Sequence 17, Appl
C 452	14.8	0.6	19	1	US-10-683-990-57	Sequence 57, Appl
C 453	14.8	0.6	19	1	US-10-683-990-154	Sequence 154, App
C 454	14.8	0.6	19	1	US-10-744-055-17	Sequence 17, Appl
C 455	14.8	0.6	19	1	US-10-923-115-3	Sequence 3, Appl
C 456	14.8	0.6	19	1	US-10-923-115-119	Sequence 119, App
C 457	14.8	0.6	19	1	US-10-888-226-288	Sequence 288, App
C 458	14.8	0.6	19	1	US-10-888-226-702	Sequence 702, App
C 459	14.8	0.6	19	1	US-10-505-030-4	Sequence 4, Appl
C 460	14.8	0.6	19	1	US-10-697-527-55	Sequence 55, Appl
C 461	14.8	0.6	19	1	US-10-923-522-6	Sequence 6, Appl
C 462	14.8	0.6	19	1	US-10-923-522-269	Sequence 269, App
C 463	14.8	0.6	19	1	US-10-923-522-568	Sequence 568, App
C 464	14.8	0.6	19	1	US-10-923-522-887	Sequence 887, App

ALIGNMENTS

RESULT 1
US-09-908-975-16614/C

Query Match		1.2%: Score 28; DB 1; Length 28;
Best Local Similarity		100.0%; Pred. No. 46; Mismatches 0; Indels 0; Gaps 0;
Matches		28; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	1800	CCACGCTGCTAGTCTGAAGTGCAG 1827
Db	1	CCACGCTGCTAGTCTGAAGTGCAG 28
RESULT 3		
US-10-307-817-378		
Query Match		2.5%: Score 60; DB 1; Length 60;
Best Local Similarity		100.0%; Pred. No. 0.2; Mismatches 0; Indels 0; Gaps 0;
Matches		60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy	1767	ACTTCTCATACAGCCCTTATTCACATACCCACGCTGCTAGTCTGAAGTGC 1826
Db	60	ACTTCTCATACAGCCCTTATTCACATACCCACGCTGCTAGTCTGAAGTGC 1
RESULT 2		
US-10-324-618-27		
Sequence 27, Application US/10324618		
Publication No. US20030170691A1		
GENERAL INFORMATION:		
APPLICANT: Gimeno, Ruth		
APPLICANT: Wu, Zhidan		
APPLICANT: Kapeller-Liebermann, Rosana		
APPLICANT: Hubbard, Brian K.		
TITLE OF INVENTION: HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2		
TITLE OF INVENTION: (DGAT2) FAMILY MEMBERS AND USES THEREFOR		
FILE REFERENCE: MP101-263P2RM		
CURRENT APPLICATION NUMBER: US/10/324,618		
CURRENT FILING DATE: 2002-12-19		
PRIOR APPLICATION NUMBER: 60/341,947		
PRIOR FILING DATE: 2002-12-19		
PRIOR APPLICATION NUMBER: 60/411,859		
PRIOR FILING DATE: 2002-09-19		
NUMBER OF SEQ ID NOS: 65		
SOFTWARE: FastSeq for Windows Version 4.0		
SEQ ID NO 27		
LENGTH: 28		
TYPE: DNA		
ORGANISM: Artificial Sequence		
FEATURE:		
OTHER INFORMATION: 86606 probe		
US-10-324-618-27		


```
; Sequence 378, Application US/10307817
; Publication No. US20040058338A1
; GENERAL INFORMATION:
; APPLICANT: Agee et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-502C
; CURRENT APPLICATION NUMBER: US/10/307,817
; CURRENT FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 682
; SOFTWARE: Curaseq1st version 0.1
; SEQ ID NO 378
; LENGTH: 27
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-307-817-378

Query Match      1.4%; Score 26; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 65;
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1167 ATCTTCATGTCGAGGCTCTTCTC 1192
DB      2 ATCTTCATGTCGAGGCTCTTCTC 27

RESULT 4
US-10-719-900-684232
; Sequence 684232, Application US/107199900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 684232
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-684232

Query Match      1.0%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1469 GTCATGGGTCTCTGTGGGTATTTA 1493
DB      1 GTCATGGGTCTCTGTGGGTATTTA 25

RESULT 5
US-10-719-900-761464
; Sequence 761464, Application US/107199900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 761464
; LENGTH: 25
; TYPE: DNA
```

```
; ORGANISM: Mus musculus
US-10-719-900-761464

Query Match      1.0%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1314 TACATGAGAGCCCTGTGAAGCTCT 1338
DB      1 TACATGAGAGCCCTGTGAAGCTCT 25

RESULT 6
US-10-719-956-323130
; Sequence 323130, Application US/107199956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 323130
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-323130

Query Match      1.0%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 71;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1296 GACCTGTACACACCATGTACATGG 1320
DB      1 GACCTGTACACACCATGTACATGG 25

RESULT 7
US-09-946-374-293
; Sequence 293, Application US/09946374
; Publication No. US20030073129A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tumas, Daniel
; APPLICANT: Watanabe, Colin K.
; APPLICANT: Williams, P. Mickey
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C1
; CURRENT APPLICATION NUMBER: US/09/946,374
; CURRENT FILING DATE: 2001-09-04
; PRIOR APPLICATION NUMBER: 60/098716
```

[illegible]

```

; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0;
Indels 0; Gaps 0;

Qy 1041 GCTGACCTGGTCCCATCTACTCC 1064
Db 1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 8
US-09-946-374-294/C
; Sequence 294, Application US/09946374
; Publication No. US20030073129A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Roy, Margaret Ann
; APPLICANT: Smith, Victoria
; APPLICANT: Stewart, Timothy A.
; APPLICANT: Tuma, Daniel
; APPLICANT: Williams, Colin K.
; APPLICANT: Wood, William I.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: F2830P1C1
; CURRENT APPLICATION NUMBER: US/09/946,374
; PRIOR FILING DATE: 2001-09-04
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
```

```

; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
```

;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101472
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101474
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101475
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101476
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101477
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101479
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101743
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101741
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101915
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101916
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/102207
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102240
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102307
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102330
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102331
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102484
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102487
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102570
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102571
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102684
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102687
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102965
;; PRIOR FILING DATE: 1998-10-02
;; PRIOR APPLICATION NUMBER: 60/103258
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103314
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103315
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103328
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103395
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103396
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103449
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103401
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103678
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103679
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103711
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/104257
;; PRIOR FILING DATE: 1998-10-14

;; PRIOR APPLICATION NUMBER: 60/104987
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105000
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105002
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105104
;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/105169
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105266
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105693
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105694
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105807

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 GGAGGTGTCATGGGTCTGTGGG 1486
Db 24 GGAGGTGTCATGGGTCTGTGGG 1

RESULT 9
US-10-006-856A-293
; Sequence 293, Application US/10006856A
; Publication No. US20030044841A1
; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.
;; APPLICANT: Botstein, David
;; APPLICANT: Desnoyers, Luc
;; APPLICANT: Baton, Dan I.
;; APPLICANT: Ferrara, Napoleone
;; APPLICANT: Fong, Sherman
;; APPLICANT: Gao, Wei-Qiang
;; APPLICANT: Goddard, Audrey
;; APPLICANT: Godowski, Paul J.
;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
;; TITLE OF INVENTION: Acids Encoding the Same
;; FILE REFERENCE: P2830P1C14
;; CURRENT APPLICATION NUMBER: US/10/006,856A
;; CURRENT FILING DATE: 2002-05-10
;; NUMBER OF SEQ ID NOS: 477
;; Prior Application removed - See File Wrapper or Palm
;; SEQ ID NO 293
;; LENGTH: 24
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-856A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGTTCCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 10
US-10-006-856A-294/C
; Sequence 294, Application US/10006856A

```
/ Publication No. US20030044841A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830PIC14
/ CURRENT APPLICATION NUMBER: US/10/006,856A
/ CURRENT FILING DATE: 2002-05-10
/ NUMBER OF SEQ ID NOS: 477
/ Prior Application removed - See File Wrapper or Palm
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-856A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTCAATGGGTCTGTGGG 1486
DB      24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 11
US-10-006-818A-293
/ Sequence 293, Application US/10006818A
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830PIC14
/ CURRENT APPLICATION NUMBER: US/10/006,818A
/ CURRENT FILING DATE: 2001-12-06
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-818A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTTCCTACTCTCC 1064
DB      1 GCTGACCTGGTTCCTACTCTCC 24

RESULT 12
US-10-006-818A-294/c
/ Sequence 294, Application US/10006818A
/ Publication No. US20030054406A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830PIC14
/ CURRENT APPLICATION NUMBER: US/10/006,818A
/ CURRENT FILING DATE: 2001-12-06
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-818A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTCAATGGGTCTGTGGG 1486
DB      24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 13
US-10-006-485A-293
/ Sequence 293, Application US/10006485A
/ Publication No. US20030064062A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
```

1	TITLE OF INVENTION: Acid Encoding the Same
2	FILE REFERENCE: P28301PC
3	CURRENT APPLICATION NUMBER: US/10/006,485A
4	CURRENT FILING DATE: 2001-12-06
5	PRIOR APPLICATION NUMBER: 60/098716
6	PRIOR FILING DATE: 1998-09-01
7	PRIOR APPLICATION NUMBER: 60/098723
8	PRIOR FILING DATE: 1998-09-01
9	PRIOR APPLICATION NUMBER: 60/098749
10	PRIOR FILING DATE: 1998-09-01
11	PRIOR APPLICATION NUMBER: 60/098750
12	PRIOR FILING DATE: 1998-09-01
13	PRIOR APPLICATION NUMBER: 60/098803
14	PRIOR FILING DATE: 1998-09-02
15	PRIOR APPLICATION NUMBER: 60/098821
16	PRIOR FILING DATE: 1998-09-02
17	PRIOR APPLICATION NUMBER: 60/098843
18	PRIOR FILING DATE: 1998-09-02
19	PRIOR APPLICATION NUMBER: 60/099336
20	PRIOR FILING DATE: 1998-09-09
21	PRIOR APPLICATION NUMBER: 60/099596
22	PRIOR FILING DATE: 1998-09-09
23	PRIOR APPLICATION NUMBER: 60/099598
24	PRIOR FILING DATE: 1998-09-09
25	PRIOR APPLICATION NUMBER: 60/099602
26	PRIOR FILING DATE: 1998-09-09
27	PRIOR APPLICATION NUMBER: 60/099642
28	PRIOR FILING DATE: 1998-09-09
29	PRIOR APPLICATION NUMBER: 60/099741
30	PRIOR FILING DATE: 1998-09-10
31	PRIOR APPLICATION NUMBER: 60/099754
32	PRIOR FILING DATE: 1998-09-10
33	PRIOR APPLICATION NUMBER: 60/099763
34	PRIOR FILING DATE: 1998-09-10
35	PRIOR APPLICATION NUMBER: 60/099792
36	PRIOR FILING DATE: 1998-09-10
37	PRIOR APPLICATION NUMBER: 60/099808
38	PRIOR FILING DATE: 1998-09-10
39	PRIOR APPLICATION NUMBER: 60/099812
40	PRIOR FILING DATE: 1998-09-10
41	PRIOR APPLICATION NUMBER: 60/099815
42	PRIOR FILING DATE: 1998-09-10
43	PRIOR APPLICATION NUMBER: 60/099816
44	PRIOR FILING DATE: 1998-09-10
45	PRIOR APPLICATION NUMBER: 60/100385
46	PRIOR FILING DATE: 1998-09-15
47	PRIOR APPLICATION NUMBER: 60/100388
48	PRIOR FILING DATE: 1998-09-15
49	PRIOR APPLICATION NUMBER: 60/100390
50	PRIOR FILING DATE: 1998-09-15
51	PRIOR APPLICATION NUMBER: 60/100584
52	PRIOR FILING DATE: 1998-09-16
53	PRIOR APPLICATION NUMBER: 60/100627
54	PRIOR FILING DATE: 1998-09-16
55	PRIOR APPLICATION NUMBER: 60/100661
56	PRIOR FILING DATE: 1998-09-16
57	PRIOR APPLICATION NUMBER: 60/100662
58	PRIOR FILING DATE: 1998-09-16
59	PRIOR APPLICATION NUMBER: 60/100664
60	PRIOR FILING DATE: 1998-09-16
61	PRIOR APPLICATION NUMBER: 60/100683
62	PRIOR FILING DATE: 1998-09-17
63	PRIOR APPLICATION NUMBER: 60/100684
64	PRIOR FILING DATE: 1998-09-17
65	PRIOR APPLICATION NUMBER: 60/100710
66	PRIOR FILING DATE: 1998-09-17
67	PRIOR APPLICATION NUMBER: 60/100711
68	PRIOR FILING DATE: 1998-09-17
69	PRIOR APPLICATION NUMBER: 60/100848
70	PRIOR FILING DATE: 1998-09-18
71	PRIOR APPLICATION NUMBER: 60/100849
72	PRIOR FILING DATE: 1998-09-18
73	PRIOR APPLICATION NUMBER: 60/100919

PRIOR FILING DATE:	1998-09-17
PRIOR APPLICATION NUMBER:	60/100930
PRIOR FILING DATE:	1998-09-17
PRIOR APPLICATION NUMBER:	60/101044
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/101066
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/101071
PRIOR FILING DATE:	1998-09-18
PRIOR APPLICATION NUMBER:	60/101279
PRIOR FILING DATE:	1998-09-22
PRIOR APPLICATION NUMBER:	60/101471
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101472
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101474
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101475
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101476
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/101738
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101741
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101743
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101915
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101916
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/102207
PRIOR FILING DATE:	1998-09-29
PRIOR APPLICATION NUMBER:	60/102240
PRIOR FILING DATE:	1998-09-29
PRIOR APPLICATION NUMBER:	60/102307
PRIOR FILING DATE:	1998-09-29
PRIOR APPLICATION NUMBER:	60/102330
PRIOR FILING DATE:	1998-09-29
PRIOR APPLICATION NUMBER:	60/102331
PRIOR FILING DATE:	1998-09-29
PRIOR APPLICATION NUMBER:	60/102484
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102487
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102570
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102571
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102644
PRIOR FILING DATE:	1998-10-01
PRIOR APPLICATION NUMBER:	60/102687
PRIOR FILING DATE:	1998-10-01
PRIOR APPLICATION NUMBER:	60/102965
PRIOR FILING DATE:	1998-10-02
PRIOR APPLICATION NUMBER:	60/103256
PRIOR FILING DATE:	1998-10-06
PRIOR APPLICATION NUMBER:	60/103314
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103315
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103328
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103395
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103396
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103401
PRIOR FILING DATE:	1998-10-07

```

; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103633
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105861
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

```

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 82;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGGTCCCATCTACTCC 1064
 Db 1 CCTGACCTGGTCCCATCTACTCC 24

```

RESULT 14
; Sequence 294, Application US/10006485A
; Publication No. US2003006462A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Boctstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secretion and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C9
; CURRENT APPLICATION NUMBER: US/10/006,485A
; PRIOR FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723

```

```

; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18

```

;; PRIOR APPLICATION NUMBER: 60/101071
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101279
;; PRIOR FILING DATE: 1998-09-22
;; PRIOR APPLICATION NUMBER: 60/101471
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101472
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101474
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101475
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101476
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101477
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101479
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101738
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101741
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101743
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101915
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101916
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/102207
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102240
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102307
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102330
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102331
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102484
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102487
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102570
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102571
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102684
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102687
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102965
;; PRIOR FILING DATE: 1998-10-02
;; PRIOR APPLICATION NUMBER: 60/103258
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103314
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103315
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103348
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103395
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103396
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103401
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103449
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103633
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103678
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103679

;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103711
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/104257
;; PRIOR FILING DATE: 1998-10-14
;; PRIOR APPLICATION NUMBER: 60/104987
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105000
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105002
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105104
;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/105169
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105266
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105693
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105694
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105807
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105881
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105882
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/106023
;; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 GGAAGTGTATGGTGTCTGTGGG 1486
Db 24 GGAAGTGTATGGTGTCTGTGGG 1

RESULT 15
US-10-013-907A-293
; Sequence 293, Application US/10013907A
; Publication No. US20030064925A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC34
; CURRENT APPLICATION NUMBER: US/10/013,907A
; PRIOR FILING DATE: 2001-12-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-907A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGTTCCCATCTACTCC 1064
DB 1 GGTGACCTGTTCCCATCTACTCC 24

RESULT 16

US-10-013-907A-294/c
Sequence 294, Application US/10013907A
Publication No. US20030064925A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC34
CURRENT APPLICATION NUMBER: US/10/013,907A
CURRENT FILING DATE: 2001-12-10
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-907A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTGATGGGTCTGTGGG 1486
DB 24 GGAAGTGTGATGGGTCTGTGGG 1

RESULT 17

US-10-015-499A-293
Sequence 293, Application US/10015499A
Publication No. US20030065142A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC34
CURRENT APPLICATION NUMBER: US/10/015,499A
CURRENT FILING DATE: 2001-12-11
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 293
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-499A-293

FILE REFERENCE: P2830PIC42
CURRENT APPLICATION NUMBER: US/10/015,499A
CURRENT FILING DATE: 2001-12-11
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 293
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-499A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGTTCCCATCTACTCC 1064
DB 1 GGTGACCTGTTCCCATCTACTCC 24

RESULT 18

US-10-015-499A-294/c
Sequence 294, Application US/10015499A
Publication No. US20030065142A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC42
CURRENT APPLICATION NUMBER: US/10/015,499A
CURRENT FILING DATE: 2001-12-11
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-499A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTGATGGGTCTGTGGG 1486
DB 24 GGAAGTGTGATGGGTCTGTGGG 1

RESULT 19

US-10-015-393A-293
Sequence 293, Application US/10015393A
Publication No. US20030069179A1

GENERAL INFORMATION:

APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc

```

; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C46
; CURRENT APPLICATION NUMBER: US/10/015,393A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-393A-293

```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

```

```

RESULT 20
US-10-015-393A-294/c
; Sequence 294, Application US/10015393A
; Publication No. US20030069179A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C46
; CURRENT APPLICATION NUMBER: US/10/015,393A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-393A-294

```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1463 GGAAGTCATGGGTGTCTGTGGG 1486
Db      24 GGAAGTCATGGGTGTCTGTGGG 1

```

```

RESULT 21
US-10-015-869A-293
; Sequence 293, Application US/10015869A
; Publication No. US20030073130A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C45
; CURRENT APPLICATION NUMBER: US/10/015,869A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-869A-293

```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

```

```

RESULT 22
US-10-015-869A-294/c
; Sequence 294, Application US/10015869A
; Publication No. US20030073130A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C45
; CURRENT APPLICATION NUMBER: US/10/015,869A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm

```


PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTCCATCTACTCC 1064
DB 1 GGTGACCTGGTCCATCTACTCC 24

RESULT 26
US-10-006-116A-294/C
Sequence 294, Application US/10006116A
Publication No. US20030082626A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferreira, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Acidic Encoding and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C15
CURRENT APPLICATION NUMBER: US/10/006,116A
CURRENT FILING DATE: 2001-12-16
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741

PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24

```
; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101915
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102207
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102240
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102307
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102330
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102331
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102484
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102487
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102570
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102571
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102684
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102687
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102965
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: 60/103258
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103314
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103315
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103328
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103395
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103396
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103401
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103633
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807
```

```
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28
```

```
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1463 GGAGTGTGATGGGTGTGTGGG 1486
Db 24 GGAGTGTGATGGGTGTGTGGG 1
```

```
RESULT 27
```

```
US-10-006-117A-293
; Sequence 293, Application US/10006117A
; Publication No. US20030082627A1
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC13
; CURRENT APPLICATION NUMBER: US/10/006,117A
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION removed - See File Wrapper or Palm
; PRIOR FILING DATE: 2001-07-09
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-117A-293
```

```
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1041 GGTGACCTGGTCCCATCTACTCC 1064
Db 1 GGTGACCTGGTCCCATCTACTCC 24
```

```
RESULT 28
```

```
US-10-006-117A-294/C
; Sequence 294, Application US/10006117A
; Publication No. US20030082627A1
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
```


PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103338
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169

PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTCCATCTACTCC 1064
DB 1 GGTGACCTGGTCCATCTACTCC 24

RESULT 30
US-10-017-527A-294/C
Sequence 294, Application US/10017527A
Publication No. US20030082628A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guirney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PLC63
CURRENT FILING DATE: 2001-12-13
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09

[illegible]

PRIOR FILING DATE:	1998-09-26
PRIOR APPLICATION NUMBER:	60/101743Z
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101915S
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101916B
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/102207T
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/102244A
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/102307V
PRIOR FILING DATE:	1998-09-23
PRIOR APPLICATION NUMBER:	60/102488H
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102487F
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102570T
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102571I
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102684R
PRIOR FILING DATE:	1998-10-01
PRIOR APPLICATION NUMBER:	60/102685E
PRIOR FILING DATE:	1998-10-02
PRIOR APPLICATION NUMBER:	60/102686A
PRIOR FILING DATE:	1998-10-06
PRIOR APPLICATION NUMBER:	60/102687M
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103315J
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103328H
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103341A
PRIOR FILING DATE:	1998-10-06
PRIOR APPLICATION NUMBER:	60/103449N
PRIOR FILING DATE:	1998-10-06
PRIOR APPLICATION NUMBER:	60/103633K
PRIOR FILING DATE:	1998-10-08
PRIOR APPLICATION NUMBER:	60/103678H
PRIOR FILING DATE:	1998-10-08
PRIOR APPLICATION NUMBER:	60/103679P
PRIOR FILING DATE:	1998-10-08
PRIOR APPLICATION NUMBER:	60/103711I
PRIOR FILING DATE:	1998-10-08
PRIOR APPLICATION NUMBER:	60/104257F
PRIOR FILING DATE:	1998-10-14
PRIOR APPLICATION NUMBER:	60/104987F
PRIOR FILING DATE:	1998-10-20
PRIOR APPLICATION NUMBER:	60/105000U
PRIOR FILING DATE:	1998-10-20
PRIOR APPLICATION NUMBER:	60/105002G
PRIOR FILING DATE:	1998-10-20
PRIOR APPLICATION NUMBER:	60/105104A
PRIOR FILING DATE:	1998-10-21
PRIOR APPLICATION NUMBER:	60/105169N
PRIOR FILING DATE:	1998-10-22
PRIOR APPLICATION NUMBER:	60/105266G
PRIOR FILING DATE:	1998-10-22
PRIOR APPLICATION NUMBER:	60/105653J
PRIOR FILING DATE:	1998-10-26
PRIOR APPLICATION NUMBER:	60/105694A
PRIOR FILING DATE:	1998-10-26

```

; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGCATGGTGTCTGTGGG 1486
DB      24 GGAAGTGCATGGTGTCTGTGGG 1

RESULT 31
US-10-013-913A-293
; Sequence 293, Application US/10013913A
; Publication No. US20030083462A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC40
; CURRENT APPLICATION NUMBER: US/10/013,913A
; CURRENT FILING DATE: 2002-07-15
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-013-913A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGCTTCCCATCTACTCC 1064
DB      1 GCTGACCTGCTTCCCATCTACTCC 24

RESULT 32
US-10-013-913A-294/C
; Sequence 294, Application US/10013913A
; Publication No. US20030083462A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC6
; CURRENT APPLICATION NUMBER: US/10/007,194A
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09

; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC6
; CURRENT APPLICATION NUMBER: US/10/007,194A
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09

; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC6
; CURRENT APPLICATION NUMBER: US/10/007,194A
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
```



```

; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 34
US-10-007-194A-294/c
; Sequence 294, Application US/10007194A
; Publication No. US20030092061A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C6
; CURRENT APPLICATION NUMBER: US/10/007,194A
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
```

```

; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101479
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
```

; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101915
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102207
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102240
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102307
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102330
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102331
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102484
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102487
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102570
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102571
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102684
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102687
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102965
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: 60/103258
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103314
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103315
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103328
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103395
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103396
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103401
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103633
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807

; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGTGTGATGCGTGTGTGTGCG 1486
|||||
Db 24 GGAGTGTGATGCGTGTGTGTGCG 1

RESULT 35
US-10-013-430A-293
; Sequence 293, Application US/10013430A
; Publication No. US20030092883A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C31
; CURRENT APPLICATION NUMBER: US/10/013,430A
; PRIOR FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293

; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-430A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGCTCCATCTATCC 1064
|||||
Db 1 GGTGACCTGCTCCATCTATCC 24

RESULT 36
US-10-013-430A-294/C
; Sequence 294, Application US/10013430A
; Publication No. US20030092883A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C31
; CURRENT APPLICATION NUMBER: US/10/013,430A
; PRIOR FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-430A-293

```
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830PIC31
/ CURRENT APPLICATION NUMBER: US/10/013,430A
/ PRIOR FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-430A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1463 GGAGGTGTCATGGGTCTGTGTGG 1486
Db      24  GGAGGTGTCATGGGTCTGTGTGG 1

RESULT 37
US-10-011-671A-293
/ Sequence 293 / Application US/10011671A
/ Publication No. US2003006954A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830PIC27
/ CURRENT APPLICATION NUMBER: US/10/011,671A
/ PRIOR FILING DATE: 2002-06-10
/ PRIOR APPLICATION NUMBER: 60/098716
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098723
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098749
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098750
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098803
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/098821
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/098843
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/099536
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099596
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099598
```

```
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099602
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099642
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099741
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099754
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099763
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099792
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099808
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099812
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099815
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099816
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/100385
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100388
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100390
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100584
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100627
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100661
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100662
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100664
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100683
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100684
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100710
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100711
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100848
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/100849
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/100919
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100930
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/101014
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/101068
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/101071
/ PRIOR FILING DATE: 1998-09-18
/ PRIOR APPLICATION NUMBER: 60/101279
/ PRIOR FILING DATE: 1998-09-22
/ PRIOR APPLICATION NUMBER: 60/101471
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101472
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101474
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101475
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101476
/ PRIOR FILING DATE: 1998-09-23
/ PRIOR APPLICATION NUMBER: 60/101477
/ PRIOR FILING DATE: 1998-09-23
```

PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266

PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GGTGACCTGGTTCCTACTCTCC 1064
Db 1 GGTGACCTGGTTCCTACTCTCC 24

RESULT 38
US-10-011-671A-294/c
Sequence 294, Application US/10011671A
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Baton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC27
CURRENT APPLICATION NUMBER: US/10/011,671A
PRIOR FILING DATE: 2002-06-10
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10

1	PRIOR APPLICATION NUMBER: 60/099754
2	PRIOR FILING DATE: 1998-09-10
3	PRIOR APPLICATION NUMBER: 60/099763
4	PRIOR FILING DATE: 1998-09-10
5	PRIOR APPLICATION NUMBER: 60/099792
6	PRIOR FILING DATE: 1998-09-10
7	PRIOR APPLICATION NUMBER: 60/099808
8	PRIOR FILING DATE: 1998-09-10
9	PRIOR APPLICATION NUMBER: 60/099812
10	PRIOR FILING DATE: 1998-09-10
11	PRIOR APPLICATION NUMBER: 60/099815
12	PRIOR FILING DATE: 1998-09-10
13	PRIOR APPLICATION NUMBER: 60/099816
14	PRIOR FILING DATE: 1998-09-10
15	PRIOR APPLICATION NUMBER: 60/100385
16	PRIOR FILING DATE: 1998-09-15
17	PRIOR APPLICATION NUMBER: 60/100388
18	PRIOR FILING DATE: 1998-09-15
19	PRIOR APPLICATION NUMBER: 60/100380
20	PRIOR FILING DATE: 1998-09-15
21	PRIOR APPLICATION NUMBER: 60/100584
22	PRIOR FILING DATE: 1998-09-16
23	PRIOR APPLICATION NUMBER: 60/100627
24	PRIOR FILING DATE: 1998-09-16
25	PRIOR APPLICATION NUMBER: 60/100616
26	PRIOR FILING DATE: 1998-09-16
27	PRIOR APPLICATION NUMBER: 60/100654
28	PRIOR FILING DATE: 1998-09-16
29	PRIOR APPLICATION NUMBER: 60/100683
30	PRIOR FILING DATE: 1998-09-17
31	PRIOR APPLICATION NUMBER: 60/100684
32	PRIOR FILING DATE: 1998-09-17
33	PRIOR APPLICATION NUMBER: 60/100710
34	PRIOR FILING DATE: 1998-09-17
35	PRIOR APPLICATION NUMBER: 60/100711
36	PRIOR FILING DATE: 1998-09-17
37	PRIOR APPLICATION NUMBER: 60/100848
38	PRIOR FILING DATE: 1998-09-18
39	PRIOR APPLICATION NUMBER: 60/100849
40	PRIOR FILING DATE: 1998-09-18
41	PRIOR APPLICATION NUMBER: 60/100919
42	PRIOR FILING DATE: 1998-09-17
43	PRIOR APPLICATION NUMBER: 60/100930
44	PRIOR FILING DATE: 1998-09-17
45	PRIOR APPLICATION NUMBER: 60/101014
46	PRIOR FILING DATE: 1998-09-18
47	PRIOR APPLICATION NUMBER: 60/101068
48	PRIOR FILING DATE: 1998-09-18
49	PRIOR APPLICATION NUMBER: 60/101071
50	PRIOR FILING DATE: 1998-09-18
51	PRIOR APPLICATION NUMBER: 60/101279
52	PRIOR FILING DATE: 1998-09-22
53	PRIOR APPLICATION NUMBER: 60/101471
54	PRIOR FILING DATE: 1998-09-23
55	PRIOR APPLICATION NUMBER: 60/101472
56	PRIOR FILING DATE: 1998-09-23
57	PRIOR APPLICATION NUMBER: 60/101474
58	PRIOR FILING DATE: 1998-09-23
59	PRIOR APPLICATION NUMBER: 60/101475
60	PRIOR FILING DATE: 1998-09-23
61	PRIOR APPLICATION NUMBER: 60/101476
62	PRIOR FILING DATE: 1998-09-23
63	PRIOR APPLICATION NUMBER: 60/101477
64	PRIOR FILING DATE: 1998-09-23
65	PRIOR APPLICATION NUMBER: 60/101479
66	PRIOR FILING DATE: 1998-09-23
67	PRIOR APPLICATION NUMBER: 60/101738
68	PRIOR FILING DATE: 1998-09-24
69	PRIOR APPLICATION NUMBER: 60/101741
70	PRIOR FILING DATE: 1998-09-24
71	PRIOR APPLICATION NUMBER: 60/101743

PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101915
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/101916
PRIOR FILING DATE:	1998-09-24
PRIOR APPLICATION NUMBER:	60/102027
PRIOR FILING DATE:	1998-09-29
PRIOR APPLICATION NUMBER:	60/102240
PRIOR FILING DATE:	1998-09-29
PRIOR APPLICATION NUMBER:	60/102307
PRIOR FILING DATE:	1998-09-29
PRIOR APPLICATION NUMBER:	60/102330
PRIOR FILING DATE:	1998-09-29
PRIOR APPLICATION NUMBER:	60/102331
PRIOR FILING DATE:	1998-09-29
PRIOR APPLICATION NUMBER:	60/102484
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102487
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102570
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102571
PRIOR FILING DATE:	1998-09-30
PRIOR APPLICATION NUMBER:	60/102655
PRIOR FILING DATE:	1998-10-02
PRIOR APPLICATION NUMBER:	60/103258
PRIOR FILING DATE:	1998-10-06
PRIOR APPLICATION NUMBER:	60/103314
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103315
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103328
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103395
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103396
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103401
PRIOR FILING DATE:	1998-10-07
PRIOR APPLICATION NUMBER:	60/103449
PRIOR FILING DATE:	1998-10-06
PRIOR APPLICATION NUMBER:	60/103633
PRIOR FILING DATE:	1998-10-08
PRIOR APPLICATION NUMBER:	60/103678
PRIOR FILING DATE:	1998-10-08
PRIOR APPLICATION NUMBER:	60/103679
PRIOR FILING DATE:	1998-10-08
PRIOR APPLICATION NUMBER:	60/103711
PRIOR FILING DATE:	1998-10-08
PRIOR APPLICATION NUMBER:	60/104257
PRIOR FILING DATE:	1998-10-14
PRIOR APPLICATION NUMBER:	60/104987
PRIOR FILING DATE:	1998-10-20
PRIOR APPLICATION NUMBER:	60/105000
PRIOR FILING DATE:	1998-10-20
PRIOR APPLICATION NUMBER:	60/105002
PRIOR FILING DATE:	1998-10-20
PRIOR APPLICATION NUMBER:	60/105104
PRIOR FILING DATE:	1998-10-21
PRIOR APPLICATION NUMBER:	60/105169
PRIOR FILING DATE:	1998-10-22
PRIOR APPLICATION NUMBER:	60/105266
PRIOR FILING DATE:	1998-10-22
PRIOR APPLICATION NUMBER:	60/105633
PRIOR FILING DATE:	1998-10-26
PRIOR APPLICATION NUMBER:	60/105694
PRIOR FILING DATE:	1998-10-26
PRIOR APPLICATION NUMBER:	60/105807
PRIOR FILING DATE:	1998-10-27

;; PRIOR APPLICATION NUMBER: 60/105891
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105892
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/106023
;; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCAATGGGTCTGTGGG 1486

DB 24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 39
US-10-012-755A-293

;; Sequence 293, Application US/10012755A
;; Publication No. US20030096955A1

;; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.

;; APPLICANT: Botstein, David

;; APPLICANT: Desnovers, Luc

;; APPLICANT: Eaton, Dan L.

;; APPLICANT: Ferrara, Napoleone

;; APPLICANT: Gao, Wei-Qiang

;; APPLICANT: Goddard, Audrey

;; APPLICANT: Godowski, Paul J.

;; APPLICANT: Grimaldi, Christopher J.

;; APPLICANT: Gurney, Austin L.

;; APPLICANT: Hillan, Kenneth J.

;; APPLICANT: Pan, James

;; APPLICANT: Paoni, Nicholas F.

;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

;; FILE REFERENCE: P2830PIC28

;; CURRENT APPLICATION NUMBER: US/10/012,755A

;; CURRENT FILING DATE: 2002-06-10

;; Prior Application removed - See File Wrapper or Palm

;; NUMBER OF SEQ ID NOS: 477

;; SEQ ID NO 293

;; LENGTH: 24

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-012-755A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTCC 1064

DB 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 40
US-10-012-755A-294/C

;; Sequence 294, Application US/10012755A
;; Publication No. US20030096955A1

;; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.

;; APPLICANT: Botstein, David

;; APPLICANT: Desnovers, Luc

;; APPLICANT: Eaton, Dan L.

;; APPLICANT: Ferrara, Napoleone

;; APPLICANT: Gao, Wei-Qiang

;; APPLICANT: Goddard, Audrey

;; APPLICANT: Godowski, Paul J.

;; APPLICANT: Grimaldi, Christopher J.
;; APPLICANT: Gurney, Austin L.
;; APPLICANT: Hillan, Kenneth J.
;; APPLICANT: Pan, James
;; APPLICANT: Paoni, Nicholas F.
;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

;; FILE REFERENCE: P2830PIC28
;; CURRENT APPLICATION NUMBER: US/10/012,755A
;; CURRENT FILING DATE: 2002-06-10
;; Prior Application removed - See File Wrapper or Palm

;; NUMBER OF SEQ ID NOS: 477

;; SEQ ID NO 294

;; LENGTH: 24

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-012-755A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCAATGGGTCTGTGGG 1486

DB 24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 41
US-10-015-386A-293

;; Sequence 293, Application US/10015386A
;; Publication No. US2003009625A1

;; GENERAL INFORMATION:

;; APPLICANT: Baker, Kevin P.

;; APPLICANT: Botstein, David

;; APPLICANT: Desnovers, Luc

;; APPLICANT: Eaton, Dan L.

;; APPLICANT: Ferrara, Napoleone

;; APPLICANT: Gao, Wei-Qiang

;; APPLICANT: Goddard, Audrey

;; APPLICANT: Godowski, Paul J.

;; APPLICANT: Grimaldi, Christopher J.

;; APPLICANT: Gurney, Austin L.

;; APPLICANT: Hillan, Kenneth J.

;; APPLICANT: Pan, James

;; APPLICANT: Paoni, Nicholas F.

;; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

;; FILE REFERENCE: P2830PIC28

;; CURRENT APPLICATION NUMBER: US/10/015,386A

;; CURRENT FILING DATE: 2001-12-12

;; Prior Application removed - See File Wrapper or Palm

;; NUMBER OF SEQ ID NOS: 477

;; SEQ ID NO 293

;; LENGTH: 24

;; TYPE: DNA

;; ORGANISM: Artificial Sequence

;; FEATURE:

;; OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-015-386A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTCC 1064

DB 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 42

```
US-10-015-386A-294/c
; Sequence 294, Application US/10015386A
; Publication No. US20030099625A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC55
; CURRENT APPLICATION NUMBER: US/10/015,386A
; PRIOR FILING DATE: 2001-12-12
; Prior Application removed - See file wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-386A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTGATGGGTCTGTGGG 1486
DB      24  GGAGTGTGATGGGTCTGTGGG 1

RESULT 43
US-10-011-692A-293
; Sequence 293, Application US/10011692A
; Publication No. US20030109672A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC30
; CURRENT APPLICATION NUMBER: US/10/011,692A
; PRIOR FILING DATE: 2001-12-07
; Prior application removed - See file wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
```

```
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-692A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GGTGACCTGGTTCCTACTCC 1064
DB      1  GGTGACCTGGTTCCTACTCC 24

RESULT 44
US-10-011-692A-294/c
; Sequence 294, Application US/10011692A
; Publication No. US20030109672A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC30
; CURRENT APPLICATION NUMBER: US/10/011,692A
; PRIOR FILING DATE: 2001-12-07
; Prior application removed - See file wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-692A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTGATGGGTCTGTGGG 1486
DB      24  GGAGTGTGATGGGTCTGTGGG 1

RESULT 45
US-10-006-768A-293
; Sequence 293, Application US/10006768A
; Publication No. US20030113793A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
```

```

; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC10
; CURRENT APPLICATION NUMBER: US/10/006,768A
; NUMBER OF SEQ ID NOS: 477
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-768A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTCCATCTACTCC 1064
Db      1 GCTGACCTGGTCCATCTACTCC 24

RESULT 46
US-10-006-768A-294/C
; Sequence 294, Application US/10006768A
; Publication No. US20030113793A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC10
; CURRENT APPLICATION NUMBER: US/10/006,768A
; NUMBER OF SEQ ID NOS: 477
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-768A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGCATGGGTCTGTGTGGG 1486
Db      24 GGAAGTGCATGGGTCTGTGTGGG 1

RESULT 47
US-10-017-610A-293
; Sequence 293, Application US/10017610A
; Publication No. US20030113795A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC64
; CURRENT APPLICATION NUMBER: US/10/017,610A
; NUMBER OF SEQ ID NOS: 60
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 295
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-610A-293

Query Match      1.0%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      601 GGTGACCTGGTCCATCTACTCC 624
Db      1 GGTGACCTGGTCCATCTACTCC 24

RESULT 48
US-10-017-610A-293
; Sequence 293, Application US/10017610A
; Publication No. US20030113795A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC64
; CURRENT APPLICATION NUMBER: US/10/017,610A
; NUMBER OF SEQ ID NOS: 60
; Prior Application removed - See File Wrapper or Palm
; SEQ ID NO 295
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-610A-293

Query Match      1.0%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      601 GGTGACCTGGTCCATCTACTCC 624
Db      1 GGTGACCTGGTCCATCTACTCC 24
```

PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965

PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Fred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGATTCCCATCTACTCC 1064
DB 1 GCTGACCTGATTCCCATCTACTCC 24

RESULT 48
US-10-017-610A-294/c
Sequence 294, Application US/10017610A
Publication No. US20030113795A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang

APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
TITLE OF INVENTION: Acids Encoding the Same
FILE REFERENCE: P2830PIC64
CURRENT APPLICATION NUMBER: US/10/017,610A
CURRENT FILING DATE: 2001-12-13
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710

PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07

```
/ PRIOR APPLICATION NUMBER: 60/103328
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103395
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103396
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103401
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103449
/ PRIOR FILING DATE: 1998-10-06
/ PRIOR APPLICATION NUMBER: 60/103633
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103678
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103679
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103711
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/104257
/ PRIOR FILING DATE: 1998-10-14
/ PRIOR APPLICATION NUMBER: 60/104987
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105000
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105002
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105104
/ PRIOR FILING DATE: 1998-10-21
/ PRIOR APPLICATION NUMBER: 60/105169
/ PRIOR FILING DATE: 1998-10-22
/ PRIOR APPLICATION NUMBER: 60/105266
/ PRIOR FILING DATE: 1998-10-22
/ PRIOR APPLICATION NUMBER: 60/105693
/ PRIOR FILING DATE: 1998-10-26
/ PRIOR APPLICATION NUMBER: 60/105694
/ PRIOR FILING DATE: 1998-10-26
/ PRIOR APPLICATION NUMBER: 60/105807
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/105881
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/105882
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/106023
/ PRIOR FILING DATE: 1998-10-28

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1463 GGAAGTGCATGGGTCGTCTGTGGG 1486
Db      24  GGAAGTGCATGGGTCGTCTGTGGG 1
```

```
RESULT 49
US-10-006-063A-293
; Sequence 293, Application US/10006063A
; Publication No. US20030114652A1
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
```

```
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC3
/ CURRENT APPLICATION NUMBER: US/10/006,063A
/ CURRENT FILING DATE: 2002-03-15
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-063A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1041 GCTGACCTGGTTCCCATCTACTCC 1064
Db      1  GCTGACCTGGTTCCCATCTACTCC 24
```

```
RESULT 50
US-10-006-063A-294/c
; Sequence 294, Application US/10006063A
; Publication No. US20030114652A1
```

```
; GENERAL INFORMATION:
```

```
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC3
/ CURRENT APPLICATION NUMBER: US/10/006,063A
/ CURRENT FILING DATE: 2002-03-15
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-063A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1463 GGAAGTGCATGGGTCGTCTGTGGG 1486
Db      24  GGAAGTGCATGGGTCGTCTGTGGG 1
```

```
RESULT 51
```

```
US-10-020-063A-293
```

```
; Sequence 293, Application US/10020063A
; Publication No. US20030119097A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
```

```
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C65
; CURRENT APPLICATION NUMBER: US/10/020,063A
; PRIOR FILING DATE: 2002-09-04
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-020-063A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTCCCATCTACTCC 1064
DB      1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 52
US-10-020-063A-294/c
; Sequence 294, Application US/10020063A
; Publication No. US20030119097A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
```

```
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C65
; CURRENT APPLICATION NUMBER: US/10/020,063A
; PRIOR FILING DATE: 2002-09-04
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-020-063A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTCAATGGGTCTGTGGG 1486
DB      24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 53
US-10-015-391A-293
; Sequence 293, Application US/10015391A
; Publication No. US20030120053A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C59
; CURRENT APPLICATION NUMBER: US/10/015,391A
; PRIOR FILING DATE: 2001-12-12
; Remaining Prior Application data removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
```

```
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-391A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1041 GCTGACCTGGTTCCTACTCTCC 1064
Db      1 GCTGACCTGGTTCCTACTCTCC 24
```

```
RESULT 54
US-10-015-391A-294/c
; Sequence 294, Application US/10015391A
; Publication No. US20030120053A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC59
; CURRENT APPLICATION NUMBER: US/10/015,391A
; CURRENT FILING DATE: 2001-12-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-391A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1463 GGAAGTGTCAATGGGTCTGTGGG 1486
Db      24 GGAAGTGTCAATGGGTCTGTGGG 1
```

```
RESULT 55
US-10-017-407A-293
; Sequence 293, Application US/10017407A
; Publication No. US20030125535A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
```

```
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC61
; CURRENT APPLICATION NUMBER: US/10/017,407A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-407A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1041 GCTGACCTGGTTCCTACTCTCC 1064
Db      1 GCTGACCTGGTTCCTACTCTCC 24
```

```
RESULT 56
US-10-017-407A-294/c
; Sequence 294, Application US/10017407A
; Publication No. US20030125535A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC61
; CURRENT APPLICATION NUMBER: US/10/017,407A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-407A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1463 GGAAGTGTCAATGGGTCTGTGGG 1486
Db      24 GGAAGTGTCAATGGGTCTGTGGG 1
```



```
RESULT 57
US-10-011-833A-293
; Sequence 293, Application US/10011833A
; Publication No. US20030129650A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C22
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US/10/011,833A
; CURRENT APPLICATION NUMBER: US/10/011,833A
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
US-10-011-833A-293
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGCTGCCATCTACTCC 1064
DB 1 GCTGACCTGCTGCCATCTACTCC 24

RESULT 58
US-10-011-833A-294/C
; Sequence 294, Application US/10011833A
; Publication No. US20030129650A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C22
; CURRENT FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US/10/011,833A
; CURRENT APPLICATION NUMBER: US/10/011,833A
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-011-833A-294
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGTGTCAATGGGTCTGTGGG 1486
DB 24 GGAGTGTCAATGGGTCTGTGGG 1

RESULT 59
US-10-006-041A-293
; Sequence 293, Application US/10006041A
; Publication No. US20030130490A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C8
; CURRENT FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: US/10/006,041A
; CURRENT APPLICATION NUMBER: US/10/006,041A
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
US-10-006-041A-293
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGCTGCCATCTACTCC 1064
DB 1 GCTGACCTGCTGCCATCTACTCC 24

RESULT 60
US-10-006-041A-294/C
; Sequence 294, Application US/10006041A
; Publication No. US20030130490A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
```

```
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ TITLE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830P1C38
/ CURRENT APPLICATION NUMBER: US/10/006,041A
/ CURRENT FILING DATE: 2001-12-06
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-006-041A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1463 GGAAGTGTCTGCGTGTCTGTGGG 1486
Db      24  GGAAGTGTCTGCGTGTCTGTGGG 1

RESULT 61
US-10-015-822A-293
/ Sequence 293, Application US/10015822A
/ Publication No. US20030130491A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Baton, Dan 1.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ TITLE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830P1C38
/ CURRENT APPLICATION NUMBER: US/10/015,822A
/ CURRENT FILING DATE: 2002-06-10
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-822A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1041 GCTGACCTGTGTTCCCATCTACTCC 1064
Db      1  GCTGACCTGTGTTCCCATCTACTCC 24

RESULT 62
US-10-015-822A-294/C
/ Sequence 294, Application US/10015822A
/ Publication No. US20030130491A1
```

```
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Baton, Dan 1.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ TITLE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830P1C38
/ CURRENT APPLICATION NUMBER: US/10/015,822A
/ CURRENT FILING DATE: 2002-06-10
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-822A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy      1463 GGAAGTGTCTGCGTGTCTGTGGG 1486
Db      24  GGAAGTGTCTGCGTGTCTGTGGG 1

RESULT 63
US-10-015-387A-293
/ Sequence 293, Application US/10015387A
/ Publication No. US20030135034A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Baton, Dan 1.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ TITLE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830P1C38
/ CURRENT APPLICATION NUMBER: US/10/015,387A
/ CURRENT FILING DATE: 2001-12-12
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-387A-293
```

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTCCCATCTACTCC 1064
DB 1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 64

US-10-015-387A-294/c

; Sequence 294, Application US/10015387A

; Publication No. US20030135034A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan 1.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2830PIC54

; CURRENT APPLICATION NUMBER: US/10/015.387A

; CURRENT FILING DATE: 2001-12-12

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 477

; SEQ ID NO 294

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-015-387A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTGGTCTGTGGG 1486
DB 24 GGAAGTGTCTGGTCTGTGGG 1

RESULT 65

US-10-006-130A-293

; Sequence 293, Application US/10006130A

; Publication No. US20030148375A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan 1.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2830PIC54

; CURRENT APPLICATION NUMBER: US/10/006.130A

; CURRENT FILING DATE: 2002-03-19

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 477

; SEQ ID NO 294

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-006-130A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTGGTCTGTGGG 1486
DB 24 GGAAGTGTCTGGTCTGTGGG 1

RESULT 66

US-10-006-130A-294/c

; Sequence 294, Application US/10006130A

; Publication No. US20030148375A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan 1.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2830PIC7

; CURRENT APPLICATION NUMBER: US/10/006.130A

; CURRENT FILING DATE: 2002-03-19

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 477

; SEQ ID NO 294

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-006-130A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTGGTCTGTGGG 1486
DB 24 GGAAGTGTCTGGTCTGTGGG 1

RESULT 67

US-10-006-172A-293

; Sequence 293, Application US/10006172A

; Publication No. US20030153000A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan 1.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurney, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2830PIC7

; CURRENT APPLICATION NUMBER: US/10/006.130A

; CURRENT FILING DATE: 2002-03-19

; Prior Application removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 477

; SEQ ID NO 294

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-006-172A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTGGTCTGTGGG 1486
DB 24 GGAAGTGTCTGGTCTGTGGG 1

APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C11
CURRENT APPLICATION NUMBER: US/10/006,172A
CURRENT FILING DATE: 2002-03-19
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683

PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06

```
/ PRIOR APPLICATION NUMBER: 60/103314
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103315
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103328
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103395
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103396
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103401
/ PRIOR FILING DATE: 1998-10-07
/ PRIOR APPLICATION NUMBER: 60/103449
/ PRIOR FILING DATE: 1998-10-06
/ PRIOR APPLICATION NUMBER: 60/103633
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103678
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103679
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/103711
/ PRIOR FILING DATE: 1998-10-08
/ PRIOR APPLICATION NUMBER: 60/104257
/ PRIOR FILING DATE: 1998-10-14
/ PRIOR APPLICATION NUMBER: 60/104987
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105000
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105002
/ PRIOR FILING DATE: 1998-10-20
/ PRIOR APPLICATION NUMBER: 60/105104
/ PRIOR FILING DATE: 1998-10-21
/ PRIOR APPLICATION NUMBER: 60/105169
/ PRIOR FILING DATE: 1998-10-22
/ PRIOR APPLICATION NUMBER: 60/105266
/ PRIOR FILING DATE: 1998-10-22
/ PRIOR APPLICATION NUMBER: 60/105693
/ PRIOR FILING DATE: 1998-10-26
/ PRIOR APPLICATION NUMBER: 60/105694
/ PRIOR FILING DATE: 1998-10-26
/ PRIOR APPLICATION NUMBER: 60/105807
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/105881
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/105882
/ PRIOR FILING DATE: 1998-10-27
/ PRIOR APPLICATION NUMBER: 60/106023
/ PRIOR FILING DATE: 1998-10-28

Query Match      1 0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred.No. 82;
Matches 24; Conservative 0; Mismatches 0;
Indels 0; Gaps 0;
```

```
Qy      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 68
US-10-006-172A-294/c
/ Sequence 294, Application US/10006172A
/ Publication No. US20030153000A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
```

```
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Peoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C11
/ CURRENT APPLICATION NUMBER: US/10/006,172A
/ CURRENT FILING DATE: 2002-03-19
/ PRIOR APPLICATION NUMBER: 60/098716
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098723
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098749
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098750
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098803
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/098821
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/098843
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/099536
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099596
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099598
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099602
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099642
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099741
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099754
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099763
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099792
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099808
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099812
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099815
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099816
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/100385
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100388
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100390
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100584
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100627
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100661
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100662
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100664
/ PRIOR FILING DATE: 1998-09-16
/ PRIOR APPLICATION NUMBER: 60/100683
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100684
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100710
/ PRIOR FILING DATE: 1998-09-17
/ PRIOR APPLICATION NUMBER: 60/100711
/ PRIOR FILING DATE: 1998-09-17
```

;; PRIOR APPLICATION NUMBER: 60/100848
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100849
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100919
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100930
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/101014
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101068
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101071
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101279
;; PRIOR FILING DATE: 1998-09-22
;; PRIOR APPLICATION NUMBER: 60/101471
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101472
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101474
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101475
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101476
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101477
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101479
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101728
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101741
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101743
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101915
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101916
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/102207
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102240
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102307
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102330
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102331
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102484
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102487
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102570
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102571
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102684
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102687
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102965
;; PRIOR FILING DATE: 1998-10-02
;; PRIOR APPLICATION NUMBER: 60/103258
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103314
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103315
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103328
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103395

;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103396
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103401
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103449
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103633
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103678
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103679
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103711
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/104257
;; PRIOR FILING DATE: 1998-10-14
;; PRIOR APPLICATION NUMBER: 60/104987
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105000
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105002
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105104
;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/105169
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105266
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105693
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105694
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105807
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105881
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105882
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/106023
;; PRIOR FILING DATE: 1998-10-28

Query Match Best Local Similarity 1.0%; Score 24; DB 1; Length 24;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTATCGGTGTCTGTGGG 1486
DB 24 GGAAGTGTATCGGTGTCTGTGGG 1

RESULT 69
US-10-017-253A-293
Sequence 293, Application US/10017253A
Publication No. US20030166055A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Grimaldi, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gueney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
Acids Encoding the Same
FILE REFERENCE: P2830PIC62

```

; CURRENT APPLICATION NUMBER: US/10/017,253A
; CURRENT FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098726
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-253A-293

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
DB      1 GCTGACCTGTTCCCATCTACTCC 24

```

```

RESULT 70
US-10-017-253A-294/c
; Sequence 294, Application US/10017253A
; Publication No. US2003016055A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C62
; CURRENT APPLICATION NUMBER: US/10/017,253A
; CURRENT FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098726
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01

```

```

; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-253A-294

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1463 GGAGTGTGATGGTGTCTGTGGG 1486
DB      24 GGAGTGTGATGGTGTCTGTGGG 1

```

```

RESULT 71
US-10-015-392A-293
; Sequence 293, Application US/10015392A
; Publication No. US2003016690A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C58
; CURRENT APPLICATION NUMBER: US/10/015,392A
; CURRENT FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09

```

```
;; PRIOR APPLICATION NUMBER: 60/099598
;; PRIOR FILING DATE: 1998-09-09
;; Remaining Prior Application data removed - See File Wrapper or PALM.
;; NUMBER OF SEQ ID NOS: 477
;; SEQ ID NO 293
;; LENGTH: 24
;; TYPE: DNA
;; ORGANISM: Artificial Sequence
;; FEATURE:
;; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-392A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
DB      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 72
US-10-015-392A-294/C
; Sequence 294, Application US/10015392A
; Publication No. US2003016901A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Pan, James
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C58
; CURRENT APPLICATION NUMBER: US/10/015.392A
; PRIOR FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
```

```
US-10-015-392A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGCATGAGGTCTCTGTGGG 1486
DB      24 GGAAGTGCATGAGGTCTCTGTGGG 1

RESULT 73
US-10-017-306A-293
; Sequence 293, Application US/10017306A
; Publication No. US20030170718A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Pan, James
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C66
; CURRENT APPLICATION NUMBER: US/10/017.306A
; PRIOR FILING DATE: 2002-06-10
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-306A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
DB      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 74
US-10-017-306A-294/C
; Sequence 294, Application US/10017306A
; Publication No. US20030170718A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Paoni, Nicholas F.
; APPLICANT: Pan, James
```



```

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C66
; CURRENT APPLICATION NUMBER: US/10/017,306A
; PRIOR FILING DATE: 2002-06-10
; Prior Application removed - See file wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-017-306A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTGATGGGTGTCTGTGGG 1486
DB      24  GGAAGTGTGATGGGTGTCTGTGGG 1

RESULT 75
US-10-017-867A-293
; Sequence 293, Application US/10017867A
; Publication No. US20030180792A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C60
; CURRENT APPLICATION NUMBER: US/10/017,867A
; CURRENT FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
```

```

; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101479
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
```

;; PRIOR APPLICATION NUMBER: 60/101743
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101915
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101916
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/102207
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102240
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102307
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102330
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102331
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102484
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102487
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102570
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102571
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102684
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102687
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102965
;; PRIOR FILING DATE: 1998-10-02
;; PRIOR APPLICATION NUMBER: 60/103258
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103314
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103315
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103328
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103395
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103396
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103401
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103449
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103633
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103678
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103679
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103711
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/104257
;; PRIOR FILING DATE: 1998-10-14
;; PRIOR APPLICATION NUMBER: 60/104987
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105000
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105002
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105104
;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/105169
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105266
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105693
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105694
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105807

;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105881
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105882
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/106023
;; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTCC 1064
|||||
Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 76
US-10-017-867A-294/C
; Sequence 294, Application US/10017867A
; Publication No. US20030180792A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Baton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC60
; CURRENT FILING DATE: 2001-12-13
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCAATGGGTCTGTGGG 1486
DB 24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 77
US-10-012-064A-293
; Sequence 293, Application US/10012064A
; Publication No. US20030180836A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C19
; CURRENT APPLICATION NUMBER: US/10/012,064A
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-064A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTCC 1064
DB 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 78
US-10-012-064A-294/C
; Sequence 294, Application US/10012064A
; Publication No. US20030180836A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C19
; CURRENT APPLICATION NUMBER: US/10/012,064A
; PRIOR FILING DATE: 2002-07-15
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-064A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCAATGGGTCTGTGGG 1486
DB 24 GGAAGTGTCAATGGGTCTGTGGG 1

RESULT 79
US-10-013-909A-293
; Sequence 293, Application US/10013909A
; Publication No. US20030186318A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone

```

; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C35
; CURRENT APPLICATION NUMBER: US/10/013,909A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-013-909A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1041 GCTGACCTGGTCCCATCTACTCC 1064
DB      1 GCTGACCTGGTCCCATCTACTCC 24
```

```

RESULT 80
; US-10-013-909A-294/c
; Sequence 294, Application US/10013909A
; Publication No. US20030186318A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C35
; CURRENT APPLICATION NUMBER: US/10/013,909A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-013-909A-294
```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1463 GGAAGTGTCAATGGGTGTGTGGG 1486
|||||
```

```

DB      24 GGAAGTGTCAATGGGTGTGTGGG 1
* 1463 1486
RESULT 81
; US-10-015-671A-293
; Sequence 293, Application US/10015671A
; Publication No. US20030186319A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C47
; CURRENT APPLICATION NUMBER: US/10/015,671A
; CURRENT FILING DATE: 2001-12-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
; US-10-015-671A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1041 GCTGACCTGGTCCCATCTACTCC 1064
DB      1 GCTGACCTGGTCCCATCTACTCC 24
```

```

RESULT 82
; US-10-015-671A-294/c
; Sequence 294, Application US/10015671A
; Publication No. US20030186319A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C47
; CURRENT APPLICATION NUMBER: US/10/015,671A
; CURRENT FILING DATE: 2001-12-11
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
```

```
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-671A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGCATGGGTCTGTCTGGG 1486
Db      24  GGAAGTGCATGGGTCTGTCTGGG 1

RESULT 83
US-10-015-610A-293
; Sequence 293, Application US/10015610A
; Publication No. US20030186361A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C52
; CURRENT APPLICATION NUMBER: US/10/015,610A
; CURRENT FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-610A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1041 GCTGACCTGGTTCCCATCTACTCC 1064
Db      1    GCTGACCTGGTTCCCATCTACTCC 24

RESULT 84
US-10-015-610A-294/C
; Sequence 294, Application US/10015610A
; Publication No. US20030186361A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C52
; CURRENT APPLICATION NUMBER: US/10/015,610A
; CURRENT FILING DATE: 2001-12-12
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-610A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGCATGGGTCTGTCTGGG 1486
Db      24  GGAAGTGCATGGGTCTGTCTGGG 1

RESULT 85
US-10-012-137A-293
; Sequence 293, Application US/10012137A
; Publication No. US20030187189A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC29
; CURRENT APPLICATION NUMBER: US/10/012,137A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-137A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGCTGCCATCTACTCC 1064
Db      1 GCTGACCTGCTGCCATCTACTCC 24

RESULT 86
US-10-012-137A-294/c
; Sequence 294, Application US/10012137A
; Publication No. US20030187189A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC29
; CURRENT APPLICATION NUMBER: US/10/012,137A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-137A-294
```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1463 GGAAGTGCATGGGTCTGTGGG 1486
Db      24 GGAAGTGCATGGGTCTGTGGG 1

RESULT 87
US-10-012-752A-293
; Sequence 293, Application US/10012752A
; Publication No. US20030187190A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC24
; CURRENT APPLICATION NUMBER: US/10/012,752A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-752A-293

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGCTGCCATCTACTCC 1064
Db      1 GCTGACCTGCTGCCATCTACTCC 24

RESULT 88
US-10-012-752A-294/c
; Sequence 294, Application US/10012752A
; Publication No. US20030187190A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC29
; CURRENT APPLICATION NUMBER: US/10/012,752A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-752A-294
```

```

; FILE REFERENCE: P2830P1C24
; CURRENT APPLICATION NUMBER: US/10/012,752A
; CURRENT FILING DATE: 2002-06-25
; Prior application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-752A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTGATGGGTCTGTGTGGG 1486
Db      24 GGAGTGTGATGGGTCTGTGTGGG 1

RESULT 89
US-10-012-754A-293
; Sequence 293, Application US/10012754A
; Publication No. US20030187191A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C18
; CURRENT APPLICATION NUMBER: US/10/012,754A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-754A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGATGCCATCTACTCC 1064
Db      1 GCTGACCTGATGCCATCTACTCC 24

RESULT 90
US-10-012-754A-294/c
; Sequence 294, Application US/10012754A
; Publication No. US20030187191A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
```

```

; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C18
; CURRENT APPLICATION NUMBER: US/10/012,754A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-754A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTGATGGGTCTGTGTGGG 1486
Db      24 GGAGTGTGATGGGTCTGTGTGGG 1

RESULT 91
US-10-013-910A-293
; Sequence 293, Application US/10013910A
; Publication No. US20030187192A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C13
; CURRENT APPLICATION NUMBER: US/10/013,910A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-910A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```


QY 1041 GCTGACCTGGTTCCTACTACTCC 1064
|||||
Db 1 GCTGACCTGGTTCCTACTACTCC 24

RESULT 92
US-10-013-910A-294/c
Sequence 294, Application US/100139110A
Publication No. US20030187192A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C3
CURRENT APPLICATION NUMBER: US/10/013,910A
CURRENT FILING DATE: 2002-06-25
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-910A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGCATGGGTCTGTGTGGG 1486
|||||
Db 24 GGAAGTGCATGGGTCTGTGTGGG 1

RESULT 93
US-10-013-911A-293
Sequence 293, Application US/10013911A
Publication No. US20030187193A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C3
CURRENT APPLICATION NUMBER: US/10/013,911A
CURRENT FILING DATE: 2001-12-10
Prior Application removed - See File Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 293
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-911A-293

Prior Filing Date: 1998-09-01
Prior Application Number: 60/098723
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098749
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098750
Prior Filing Date: 1998-09-01
Prior Application Number: 60/098803
Prior Filing Date: 1998-09-02
Prior Application Number: 60/098821
Prior Filing Date: 1998-09-02
Prior Application Number: 60/098843
Prior Filing Date: 1998-09-02
Prior Application Number: 60/099536
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099556
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099598
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099602
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099642
Prior Filing Date: 1998-09-09
Prior Application Number: 60/099741
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099754
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099763
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099792
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099808
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099812
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099815
Prior Filing Date: 1998-09-10
Prior Application Number: 60/099816
Prior Filing Date: 1998-09-10
Prior Application Number: 60/100385
Prior Filing Date: 1998-09-15
Prior Application Number: 60/100388
Prior Filing Date: 1998-09-15
Prior Application Number: 60/100390
Prior Filing Date: 1998-09-15
Prior Application Number: 60/100584
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100627
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100661
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100662
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100664
Prior Filing Date: 1998-09-16
Prior Application Number: 60/100683
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100684
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100710
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100711
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100848
Prior Filing Date: 1998-09-18
Prior Application Number: 60/100849
Prior Filing Date: 1998-09-18
Prior Application Number: 60/100919
Prior Filing Date: 1998-09-17
Prior Application Number: 60/100930
Prior Filing Date: 1998-09-17
Prior Application Number: 60/101014
Prior Filing Date: 1998-09-18

; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101479
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101915
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102207
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102240
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102307
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102330
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102331
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102484
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102487
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102570
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102571
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102684
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102687
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102965
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: 60/103258
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103314
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103315
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103348
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103395
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103396
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103401
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103633
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678

; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGTTCCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 94
US-10-013-911A-294/c
; Sequence 294, Application US/10013911A
; Publication No. US20030187193A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C39
; CURRENT APPLICATION NUMBER: US/10/013,911A
; CURRENT FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01


```
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGGTGTCATGGGTCTGTGTGG 1486
Db      24 GGAGGTGTCATGGGTCTGTGTGG 1

RESULT 95
US-10-013-912A-293
; Sequence 293, Application US/10013912A
; Publication No. US20030187194A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C32
; CURRENT APPLICATION NUMBER: US/10/013,912A
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
```

```
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-912A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GGTGACCTGTTCCCATCTACTCC 1064
Db      1 GGTGACCTGTTCCCATCTACTCC 24

RESULT 96
US-10-013-912A-294/C
; Sequence 294, Application US/10013912A
; Publication No. US20030187194A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C32
; CURRENT APPLICATION NUMBER: US/10/013,912A
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-912A-294
```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1463 GGAAGTGTCTATGGGTCTGTGTGGG 1486
          |||||||
          24 GGAAGTGTCTATGGGTCTGTGTGGG 1
```

RESULT 97

```

US-10-015-653A-293
; Sequence 293, Application US/10015653A
; Publication No. US20030187195A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
```

```

; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC43
; CURRENT APPLICATION NUMBER: US/10/015,653A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
```

```

; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
```

```

; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-653A-293
```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1041 GGTGACCTGGTTCCTACTACTCC 1064
          |||||||
          1 GGTGACCTGGTTCCTACTACTCC 24
```

RESULT 98

```

US-10-015-653A-294/C
; Sequence 294, Application US/10015653A
; Publication No. US20030187195A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
```

```

; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC43
; CURRENT APPLICATION NUMBER: US/10/015,653A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
```

```

; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-653A-294
```

RESULT 99

```

US-10-012-101B-293
; Sequence 293, Application US/10012101B
; Publication No. US20030187239A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC6
; CURRENT APPLICATION NUMBER: US/10/012,101B
; CURRENT FILING DATE: 2001-12-06
; Prior Application removed - See File Wrapper or Palm
```

```

; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-101B-293
```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1463 GGAAGTGTCTATGGGTCTGTGTGGG 1486
          |||||||
          24 GGAAGTGTCTATGGGTCTGTGTGGG 1
```

RESULT 100

```

US-10-012-101B-294/C
; Sequence 294, Application US/10012101B
; Publication No. US20030187239A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC6
; CURRENT APPLICATION NUMBER: US/10/012,101B
; CURRENT FILING DATE: 2001-12-06
; Prior Application removed - See File Wrapper or Palm
```

```

; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```

; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-101B-294
```

```

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      1041 GGTGACCTGGTTCCTACTACTCC 1064
          |||||||
          1 GGTGACCTGGTTCCTACTACTCC 24
```

RESULT 100

```

US-10-012-101B-294/C
; Sequence 294, Application US/10012101B
```

```
; Publication No. US20030187239A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC6
; CURRENT APPLICATION NUMBER: US/10/012,101B
; PRIORITY FILING DATE: 2001-12-06
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-101B-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTATGGGTGTCTGTGGG 1486
DB      24  GGAAGTGTATGGGTGTCTGTGGG 1

RESULT 101
US-10-015-480A-293
; Sequence 293, Application US/10015480A
; Publication No. US20030190667A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC50
; CURRENT APPLICATION NUMBER: US/10/015,480A
; PRIORITY FILING DATE: 2002-06-25
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-480A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCCATCTACTCC 1064
DB      1  GCTGACCTGTTCCCATCTACTCC 24

RESULT 102
US-10-015-480A-294/c
; Sequence 294, Application US/10015480A
; Publication No. US20030190667A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC50
; CURRENT APPLICATION NUMBER: US/10/015,480A
; PRIORITY FILING DATE: 2002-06-25
; Prior Application removed - See file Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-480A-294

Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTATGGGTGTCTGTGGG 1486
DB      24  GGAAGTGTATGGGTGTCTGTGGG 1

RESULT 103
US-10-015-715A-293
; Sequence 293, Application US/10015715A
; Publication No. US20030190668A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
```

```

; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC56
; CURRENT APPLICATION NUMBER: US/10/015,715A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-715A-293

Query Match
Best Local Similarity 100.0%; Score 24; DB 1; Length 24;
Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTCCCATCTACTCC 1064
DB 1 GGTGACCTGGTCCCATCTACTCC 24

RESULT 104
US-10-015-715A-294/c
; Sequence 294, Application US/10015715A
; Publication No. US20030190668A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC56
; CURRENT APPLICATION NUMBER: US/10/015,715A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-715A-294

Query Match
Best Local Similarity 100.0%; Score 24; DB 1; Length 24;
Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGGTCTCATGGGTCTCTGTGGG 1486
DB 24 GGAGGTCTCATGGGTCTCTGTGGG 1

RESULT 105
US-10-012-237A-293
; Sequence 293, Application US/10012237A
; Publication No. US20030191281A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
```

```

; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC21
; CURRENT APPLICATION NUMBER: US/10/012,237A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-237A-294

Query Match
Best Local Similarity 100.0%; Score 24; DB 1; Length 24;
Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTCCCATCTACTCC 1064
DB 1 GGTGACCTGGTCCCATCTACTCC 24

RESULT 106
US-10-012-237A-294/c
; Sequence 294, Application US/10012237A
; Publication No. US20030191281A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830PIC21
; CURRENT APPLICATION NUMBER: US/10/012,237A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-237A-294

Query Match
Best Local Similarity 100.0%; Score 24; DB 1; Length 24;
Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

OY 1463 GGAAGTGTATGGGTGTGTGTGG 1486
|||||
Db 24 GGAAGTGTATGGGTGTGTGTGG 1

RESULT 107
US-10-013-906A-293
Sequence 293, Application US/10013906A
Publication No. US20030191282A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnovers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Guiney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830PIC36
CURRENT APPLICATION NUMBER: US/10/013,906A
CURRENT FILING DATE: 2002-06-10
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388

PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100683
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30

PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTTCCTACTATCC 1064
DB 1 GGTGACCTGGTTCCTACTATCC 24

RESULT 108

US-10-013-906A-294/c
Sequence 294, Application US/10013906A
Publication No. US20030191282A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan I.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C36
CURRENT FILING DATE: US/10/013, 906A
PRIOR FILING DATE: 2002-06-10
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099602
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099642
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099741
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099754
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099763
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099792
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099808
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099812
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099815
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/099816
PRIOR FILING DATE: 1998-09-10
PRIOR APPLICATION NUMBER: 60/100385
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100388
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100390
PRIOR FILING DATE: 1998-09-15
PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16

;; PRIOR APPLICATION NUMBER: 60/100661
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100662
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100664
;; PRIOR FILING DATE: 1998-09-16
;; PRIOR APPLICATION NUMBER: 60/100683
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100684
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100710
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100711
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100848
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100849
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/100919
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/100930
;; PRIOR FILING DATE: 1998-09-17
;; PRIOR APPLICATION NUMBER: 60/101014
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101068
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101071
;; PRIOR FILING DATE: 1998-09-18
;; PRIOR APPLICATION NUMBER: 60/101279
;; PRIOR FILING DATE: 1998-09-22
;; PRIOR APPLICATION NUMBER: 60/101471
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101472
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101474
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101475
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101476
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101477
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101479
;; PRIOR FILING DATE: 1998-09-23
;; PRIOR APPLICATION NUMBER: 60/101738
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101741
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101743
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101915
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/101916
;; PRIOR FILING DATE: 1998-09-24
;; PRIOR APPLICATION NUMBER: 60/102207
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102240
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102307
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102330
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102331
;; PRIOR FILING DATE: 1998-09-29
;; PRIOR APPLICATION NUMBER: 60/102484
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102487
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102510
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102571
;; PRIOR FILING DATE: 1998-09-30
;; PRIOR APPLICATION NUMBER: 60/102684

;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102687
;; PRIOR FILING DATE: 1998-10-01
;; PRIOR APPLICATION NUMBER: 60/102965
;; PRIOR FILING DATE: 1998-10-02
;; PRIOR APPLICATION NUMBER: 60/103258
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103314
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103315
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103328
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103395
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103396
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103401
;; PRIOR FILING DATE: 1998-10-07
;; PRIOR APPLICATION NUMBER: 60/103449
;; PRIOR FILING DATE: 1998-10-06
;; PRIOR APPLICATION NUMBER: 60/103633
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103678
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103679
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/103711
;; PRIOR FILING DATE: 1998-10-08
;; PRIOR APPLICATION NUMBER: 60/104257
;; PRIOR FILING DATE: 1998-10-14
;; PRIOR APPLICATION NUMBER: 60/104987
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105000
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105002
;; PRIOR FILING DATE: 1998-10-20
;; PRIOR APPLICATION NUMBER: 60/105104
;; PRIOR FILING DATE: 1998-10-21
;; PRIOR APPLICATION NUMBER: 60/105169
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105266
;; PRIOR FILING DATE: 1998-10-22
;; PRIOR APPLICATION NUMBER: 60/105693
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105694
;; PRIOR FILING DATE: 1998-10-26
;; PRIOR APPLICATION NUMBER: 60/105807
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105881
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/105882
;; PRIOR FILING DATE: 1998-10-27
;; PRIOR APPLICATION NUMBER: 60/106023
;; PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 GGAAGTGTCAATGGGTGTCTGTGG 1486
|||||
Db 24 GGAAGTGTCAATGGGTGTCTGTGG 1

RESULT 109
US-10-015-388A-293
; Sequence 293, Application US/10015388A
; Publication No. US2003019299A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc

```

; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C44
; CURRENT APPLICATION NUMBER: US/10/015,388A
; PRIOR APPLICATION: 2002-07-15
; NUMBER OF SEQ ID NOS: 477
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-388A-293

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1041 GGTGACCTGGTCCCATCTACTCC 1064
DB      1 GGTGACCTGGTCCCATCTACTCC 24

```

```

RESULT 110
US-10-015-388A-294/c
; Sequence 294, Application US/10015388A
; Publication No. US20030191299A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C44
; CURRENT APPLICATION NUMBER: US/10/015,388A
; PRIOR APPLICATION: 2002-07-15
; NUMBER OF SEQ ID NOS: 477
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-388A-294

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1463 GGAAGTGTATGGGTGTCTGTGGG 1486
DB      1 GGAAGTGTATGGGTGTCTGTGGG 1

```

```

RESULT 111
US-10-012-753A-293
; Sequence 293, Application US/10012753A
; Publication No. US20030195334A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C17
; CURRENT APPLICATION NUMBER: US/10/012,753A
; PRIOR APPLICATION: 2001-12-07
; NUMBER OF SEQ ID NOS: 477
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-753A-293

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY      1041 GGTGACCTGGTCCCATCTACTCC 1064
DB      1 GGTGACCTGGTCCCATCTACTCC 24

```

```

RESULT 112
US-10-012-753A-294/c
; Sequence 294, Application US/10012753A
; Publication No. US20030195334A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C17
; CURRENT APPLICATION NUMBER: US/10/012,753A
; PRIOR APPLICATION: 2001-12-07
; NUMBER OF SEQ ID NOS: 477
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-753A-294

```

```
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-753A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1463 GGAAGTGCATGGGTCTGTGGG 1486

Db 24 GGAAGTGCATGGGTCTGTGGG 1

RESULT 113

US-10-015-385A-293

```
/ Sequence 293, Application US/10015385A
/ Publication No. US20030195347A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Baton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey J.
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C51
/ CURRENT APPLICATION NUMBER: US/10/015,385A
/ CURRENT FILING DATE: 2002-07-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-385A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1041 GCTGACCTGTTCCATCTACTCC 1064

Db 1 GCTGACCTGTTCCATCTACTCC 24

RESULT 114

US-10-015-385A-294/c

```
/ Sequence 294, Application US/10015385A
/ Publication No. US20030195347A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
```

```
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C51
/ CURRENT APPLICATION NUMBER: US/10/015,385A
/ CURRENT FILING DATE: 2002-07-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-385A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1463 GGAAGTGCATGGGTCTGTGGG 1486

Db 24 GGAAGTGCATGGGTCTGTGGG 1

RESULT 115

US-10-007-236A-293

```
/ Sequence 293, Application US/10007236A
/ Publication No. US2003019893A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Baton, Dan L.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey J.
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830P1C12
/ CURRENT APPLICATION NUMBER: US/10/007,236A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-007-236A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1041 GCTGACCTGTTCCATCTACTCC 1064

Db 1 GCTGACCTGTTCCATCTACTCC 24

```
RESULT 116
US-10-007-236A-294/C
; Sequence 294, Application US/10007236A
; Publication No. US20030198993A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C12
; CURRENT APPLICATION NUMBER: US/10/007,236A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-007-236A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTCTATGGGTCTGTCTGGG 1486
DB      24 GGAGTGTCTATGGGTCTGTCTGGG 1

RESULT 117
US-10-015-389A-293
; Sequence 293, Application US/10015389A
; Publication No. US20030199675A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C48
; CURRENT APPLICATION NUMBER: US/10/015,389A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-389A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGTTCCATCTACTCC 1064
DB      1 GCTGACCTGTTCCATCTACTCC 24

RESULT 118
US-10-015-389A-294/C
; Sequence 294, Application US/10015389A
; Publication No. US20030199675A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C48
; CURRENT APPLICATION NUMBER: US/10/015,389A
; CURRENT FILING DATE: 2002-06-25
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-389A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAGTGTCTATGGGTCTGTCTGGG 1486
DB      24 GGAGTGTCTATGGGTCTGTCTGGG 1

RESULT 119
US-10-015-519A-293
; Sequence 293, Application US/10015519A
; Publication No. US20030203401A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
```

```
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC49
/ CURRENT APPLICATION NUMBER: US/10/015,519A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-519A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 120
US-10-015-519A-294/c
/ Sequence 294, Application US/10015519A
/ Publication No. US20030203401A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC49
/ CURRENT APPLICATION NUMBER: US/10/015,519A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-519A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1463 GGAAGTGTATGGGTGTCTGTGGG 1486
Db      24 GGAAGTGTATGGGTGTCTGTGGG 1

RESULT 121
US-10-013-915A-293
/ Sequence 293, Application US/10013915A
```

```
/ Publication No. US20030204053A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC37
/ CURRENT APPLICATION NUMBER: US/10/013,915A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-915A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1041 GCTGACCTGTTCCCATCTACTCC 1064
Db      1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 122
US-10-013-915A-294/c
/ Sequence 294, Application US/10013915A
/ Publication No. US20030204053A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnoyers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE OF INVENTION: Acids Encoding the Same
/ FILE REFERENCE: P2830PIC37
/ CURRENT APPLICATION NUMBER: US/10/013,915A
/ CURRENT FILING DATE: 2002-06-25
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-013-915A-294
```

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTATGGGTCTGTGGG 1486
DB 24 GGAAGTGTCTATGGGTCTGTGGG 1

RESULT 123

US-10-015-394A-293
; Sequence 293, Application US/10015394A
; Publication No. US20030204054A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C41
; CURRENT APPLICATION NUMBER: US/10/015,394A
; CURRENT FILING DATE: 2001-12-11
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-394A-293

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTTCCTACTCTCC 1064
DB 1 GGTGACCTGGTTCCTACTCTCC 24

RESULT 124

US-10-015-394A-294/C
; Sequence 294, Application US/10015394A
; Publication No. US20030204054A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830P1C41
; CURRENT APPLICATION NUMBER: US/10/015,394A
; CURRENT FILING DATE: 2001-12-11
; PRIOR APPLICATION NUMBER: 60/098716
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-394A-294

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCTATGGGTCTGTGGG 1486
DB 24 GGAAGTGTCTATGGGTCTGTGGG 1

RESULT 125

US-10-015-390A-293
; Sequence 293, Application US/10015390A
; Publication No. US20030216562A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone

```
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830PIC53
/ CURRENT APPLICATION NUMBER: US/10/015,390A
/ CURRENT FILING DATE: 2002-07-15
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 293
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-390A-293
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1041 GCTGACCTGTGTCCTCACTACTCC 1064
DB      1 GCTGACCTGTGTCCTCACTACTCC 24
```

```
RESULT 126
US-10-015-390A-294/c
/ Sequence 294, Application US/10015390A
/ Publication No. US20030216562A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830PIC53
/ CURRENT APPLICATION NUMBER: US/10/015,390A
/ CURRENT FILING DATE: 2002-07-15
/ Prior Application removed - See File Wrapper or Palm
/ NUMBER OF SEQ ID NOS: 477
/ SEQ ID NO 294
/ LENGTH: 24
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-390A-294
```

```
Query Match          1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1463 GGAAGTGTCAATGGGTCTGTCTGGG 1486
          |||||
```

```
DB      24 GGAAGTGTCAATGGGTCTGTCTGGG 1
RESULT 127
US-10-006-746A-293
/ Sequence 293, Application US/10006746A
/ Publication No. US20030220471A1
/ GENERAL INFORMATION:
/ APPLICANT: Baker, Kevin P.
/ APPLICANT: Botstein, David
/ APPLICANT: Desnovers, Luc
/ APPLICANT: Eaton, Dan I.
/ APPLICANT: Ferrara, Napoleone
/ APPLICANT: Fong, Sherman
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Goddard, Audrey
/ APPLICANT: Godowski, Paul J.
/ APPLICANT: Grimaldi, Christopher J.
/ APPLICANT: Gurney, Austin L.
/ APPLICANT: Hillan, Kenneth J.
/ APPLICANT: Pan, James
/ APPLICANT: Paoni, Nicholas F.
/ TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
/ FILE REFERENCE: P2830PIC5
/ CURRENT APPLICATION NUMBER: US/10/006,746A
/ CURRENT FILING DATE: 2001-12-06
/ PRIOR APPLICATION NUMBER: 60/098716
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098723
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098749
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098750
/ PRIOR FILING DATE: 1998-09-01
/ PRIOR APPLICATION NUMBER: 60/098803
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/098821
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/098843
/ PRIOR FILING DATE: 1998-09-02
/ PRIOR APPLICATION NUMBER: 60/099536
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099596
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099598
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099602
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099642
/ PRIOR FILING DATE: 1998-09-09
/ PRIOR APPLICATION NUMBER: 60/099741
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099754
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099763
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099792
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099808
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099812
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099815
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/099816
/ PRIOR FILING DATE: 1998-09-10
/ PRIOR APPLICATION NUMBER: 60/100385
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100388
/ PRIOR FILING DATE: 1998-09-15
/ PRIOR APPLICATION NUMBER: 60/100390
/ PRIOR FILING DATE: 1998-09-15
```


PRIOR APPLICATION NUMBER: 60/100584
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100627
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100661
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100662
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100664
PRIOR FILING DATE: 1998-09-16
PRIOR APPLICATION NUMBER: 60/100663
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100684
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100710
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100711
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100848
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100849
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/100919
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/100930
PRIOR FILING DATE: 1998-09-17
PRIOR APPLICATION NUMBER: 60/101014
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101068
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101071
PRIOR FILING DATE: 1998-09-18
PRIOR APPLICATION NUMBER: 60/101279
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: 60/101471
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101472
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101474
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101475
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101476
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101477
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101479
PRIOR FILING DATE: 1998-09-23
PRIOR APPLICATION NUMBER: 60/101738
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101741
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101743
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101915
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/101916
PRIOR FILING DATE: 1998-09-24
PRIOR APPLICATION NUMBER: 60/102207
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102240
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102307
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102330
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102331
PRIOR FILING DATE: 1998-09-29
PRIOR APPLICATION NUMBER: 60/102484
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102487
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102570

PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102571
PRIOR FILING DATE: 1998-09-30
PRIOR APPLICATION NUMBER: 60/102684
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102687
PRIOR FILING DATE: 1998-10-01
PRIOR APPLICATION NUMBER: 60/102965
PRIOR FILING DATE: 1998-10-02
PRIOR APPLICATION NUMBER: 60/103258
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103314
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103315
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103328
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103395
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103396
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103401
PRIOR FILING DATE: 1998-10-07
PRIOR APPLICATION NUMBER: 60/103449
PRIOR FILING DATE: 1998-10-06
PRIOR APPLICATION NUMBER: 60/103633
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103678
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103679
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/103711
PRIOR FILING DATE: 1998-10-08
PRIOR APPLICATION NUMBER: 60/104257
PRIOR FILING DATE: 1998-10-14
PRIOR APPLICATION NUMBER: 60/104987
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105000
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105002
PRIOR FILING DATE: 1998-10-20
PRIOR APPLICATION NUMBER: 60/105104
PRIOR FILING DATE: 1998-10-21
PRIOR APPLICATION NUMBER: 60/105169
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105266
PRIOR FILING DATE: 1998-10-22
PRIOR APPLICATION NUMBER: 60/105693
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105694
PRIOR FILING DATE: 1998-10-26
PRIOR APPLICATION NUMBER: 60/105807
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105881
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/105882
PRIOR FILING DATE: 1998-10-27
PRIOR APPLICATION NUMBER: 60/106023
PRIOR FILING DATE: 1998-10-28

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCATCTACTCC 1064
|||||
Db 1 GCTGACCTGTTCCATCTACTCC 24

RESULT 128
US-10-006-746A-294/C
; Sequence 294, Application US/10006746A
; Publication No. US20030220471A1

```

; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnovers, Luc
; APPLICANT: Eaton, Dan 1.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Guiney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C5
; CURRENT FILING DATE: 2001-12-06
; PRIOR APPLICATION NUMBER: US/10/006,746A
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099602
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099642
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099741
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099754
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099763
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099792
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099808
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099812
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099815
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/099816
; PRIOR FILING DATE: 1998-09-10
; PRIOR APPLICATION NUMBER: 60/100385
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100388
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100390
; PRIOR FILING DATE: 1998-09-15
; PRIOR APPLICATION NUMBER: 60/100584
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100627
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100661
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100662

```

```

; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100664
; PRIOR FILING DATE: 1998-09-16
; PRIOR APPLICATION NUMBER: 60/100683
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100684
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100710
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100711
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100848
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100849
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/100919
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/100930
; PRIOR FILING DATE: 1998-09-17
; PRIOR APPLICATION NUMBER: 60/101014
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101068
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101071
; PRIOR FILING DATE: 1998-09-18
; PRIOR APPLICATION NUMBER: 60/101279
; PRIOR FILING DATE: 1998-09-22
; PRIOR APPLICATION NUMBER: 60/101471
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101472
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101474
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101475
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101476
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101477
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101479
; PRIOR FILING DATE: 1998-09-23
; PRIOR APPLICATION NUMBER: 60/101738
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101741
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101743
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101915
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/101916
; PRIOR FILING DATE: 1998-09-24
; PRIOR APPLICATION NUMBER: 60/102207
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102240
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102307
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102330
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102331
; PRIOR FILING DATE: 1998-09-29
; PRIOR APPLICATION NUMBER: 60/102484
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102487
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102570
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102571
; PRIOR FILING DATE: 1998-09-30
; PRIOR APPLICATION NUMBER: 60/102684
; PRIOR FILING DATE: 1998-10-01
; PRIOR APPLICATION NUMBER: 60/102687
; PRIOR FILING DATE: 1998-10-01

```

```

; PRIOR APPLICATION NUMBER: 60/102965
; PRIOR FILING DATE: 1998-10-02
; PRIOR APPLICATION NUMBER: 60/103258
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103314
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103315
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103328
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103395
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103396
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103401
; PRIOR FILING DATE: 1998-10-07
; PRIOR APPLICATION NUMBER: 60/103449
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 60/103633
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103678
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103679
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/103711
; PRIOR FILING DATE: 1998-10-08
; PRIOR APPLICATION NUMBER: 60/104257
; PRIOR FILING DATE: 1998-10-14
; PRIOR APPLICATION NUMBER: 60/104987
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105000
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105002
; PRIOR FILING DATE: 1998-10-20
; PRIOR APPLICATION NUMBER: 60/105104
; PRIOR FILING DATE: 1998-10-21
; PRIOR APPLICATION NUMBER: 60/105169
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105266
; PRIOR FILING DATE: 1998-10-22
; PRIOR APPLICATION NUMBER: 60/105693
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105694
; PRIOR FILING DATE: 1998-10-26
; PRIOR APPLICATION NUMBER: 60/105807
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105881
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/105882
; PRIOR FILING DATE: 1998-10-27
; PRIOR APPLICATION NUMBER: 60/106023
; PRIOR FILING DATE: 1998-10-28

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1463 GGAAGTGTCAATGGTGTCTGTGGG 1486
Db      24  GGAAGTGTCAATGGTGTCTGTGGG 1

```

```

RESULT 129
US-10-226-254A-293
; Sequence 293, Application US/10226254A
; Publication No. US20030224478A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman

```

```

; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; FILE REFERENCE: P2830P1C68
; TITLE OF INVENTION: Acids Encoding the Same
; CURRENT FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US/10/226,254A
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098723
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098749
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098750
; PRIOR FILING DATE: 1998-09-01
; PRIOR APPLICATION NUMBER: 60/098803
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098821
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/098843
; PRIOR FILING DATE: 1998-09-02
; PRIOR APPLICATION NUMBER: 60/099536
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099596
; PRIOR FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: 60/099598
; PRIOR FILING DATE: 1998-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-226-254A-293

```

```

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY      1041 GGTGACCTGTTCCCATCTACTCC 1064
Db      1  GGTGACCTGTTCCCATCTACTCC 24

```

```

RESULT 130
US-10-226-254A-294/C
; Sequence 294, Application US/10226254A
; Publication No. US20030224478A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan L.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same

```

```
FILE REFERENCE: P2830P1C68
CURRENT APPLICATION NUMBER: US/10/226,254A
CURRENT FILING DATE: 2002-08-21
PRIOR APPLICATION NUMBER: 60/098716
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098723
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098749
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098750
PRIOR FILING DATE: 1998-09-01
PRIOR APPLICATION NUMBER: 60/098803
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098821
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/098843
PRIOR FILING DATE: 1998-09-02
PRIOR APPLICATION NUMBER: 60/099536
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099596
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 60/099598
PRIOR FILING DATE: 1998-09-09
Remaining Prior Application data removed - See file Wrapper or PALM.
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-226-254A-294
```

```
Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1463 GGAAGTGCATGGGTCTGTGGG 1486

DB 24 GGAAGTGCATGGGTCTGTGGG 1

```
RESULT 131
US-10-011-795A-293
Sequence 293, Application US/10011795A
Publication No. US20040005626A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, Nicholas F.
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C25
CURRENT APPLICATION NUMBER: US/10/011,795A
CURRENT FILING DATE: 2001-12-07
Prior application removed - See file Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 293
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
```

OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-011-795A-293

```
Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1041 GCTGACCTGGTTCCTACTCTCC 1064

DB 1 GCTGACCTGGTTCCTACTCTCC 24

RESULT 132
US-10-011-795A-294/C

```
Sequence 294, Application US/10011795A
Publication No. US20040005626A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
APPLICANT: Paoni, Nicholas F.
TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
FILE REFERENCE: P2830P1C25
CURRENT APPLICATION NUMBER: US/10/011,795A
CURRENT FILING DATE: 2001-12-07
Prior application removed - See file Wrapper or Palm
NUMBER OF SEQ ID NOS: 477
SEQ ID NO 294
LENGTH: 24
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
```

OTHER INFORMATION: Synthetic oligonucleotide probe

US-10-011-795A-294

```
Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1463 GGAAGTGCATGGGTCTGTGGG 1486

DB 24 GGAAGTGCATGGGTCTGTGGG 1

```
RESULT 133
US-10-012-231A-293
Sequence 293, Application US/10012231A
Publication No. US20040014130A1
GENERAL INFORMATION:
APPLICANT: Baker, Kevin P.
APPLICANT: Botstein, David
APPLICANT: Desnoyers, Luc
APPLICANT: Eaton, Dan L.
APPLICANT: Ferrara, Napoleone
APPLICANT: Fong, Sherman
APPLICANT: Gao, Wei-Qiang
APPLICANT: Goddard, Audrey
APPLICANT: Godowski, Paul J.
APPLICANT: Grimaldi, Christopher J.
APPLICANT: Gurney, Austin L.
APPLICANT: Hillan, Kenneth J.
APPLICANT: Pan, James
```

```

; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC23
; CURRENT APPLICATION NUMBER: US/10/012,231A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-231A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTCCCATCTACTCC 1064
DB      1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 134
US-10-012-231A-294/c
; Sequence 294, Application US/10012231A
; Publication No. US20040014130A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC23
; CURRENT APPLICATION NUMBER: US/10/012,231A
; CURRENT FILING DATE: 2002-06-10
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-012-231A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1463 GGAAGTGTCAATGGGTGTCTGTGGG 1486
DB      24 GGAAGTGTCAATGGGTGTCTGTGGG 1

RESULT 135
US-10-015-395A-293
; Sequence 293, Application US/10015395A
; Publication No. US20040073015A1
; GENERAL INFORMATION:
```

```

; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC57
; CURRENT APPLICATION NUMBER: US/10/015,395A
; CURRENT FILING DATE: 2001-12-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 293
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-395A-293

Query Match      1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1041 GCTGACCTGGTCCCATCTACTCC 1064
DB      1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 136
US-10-015-395A-294/c
; Sequence 294, Application US/10015395A
; Publication No. US20040073015A1
; GENERAL INFORMATION:
; APPLICANT: Baker, Kevin P.
; APPLICANT: Botstein, David
; APPLICANT: Desnoyers, Luc
; APPLICANT: Eaton, Dan I.
; APPLICANT: Ferrara, Napoleone
; APPLICANT: Fong, Sherman
; APPLICANT: Gao, Wei-Qiang
; APPLICANT: Goddard, Audrey
; APPLICANT: Godowski, Paul J.
; APPLICANT: Grimaldi, Christopher J.
; APPLICANT: Gurney, Austin L.
; APPLICANT: Hillan, Kenneth J.
; APPLICANT: Pan, James
; APPLICANT: Paoni, Nicholas F.
; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic
; TITLE OF INVENTION: Acids Encoding the Same
; FILE REFERENCE: P2830PIC57
; CURRENT APPLICATION NUMBER: US/10/015,395A
; CURRENT FILING DATE: 2001-12-12
; Prior Application removed - See File Wrapper or Palm
; NUMBER OF SEQ ID NOS: 477
; SEQ ID NO 294
; LENGTH: 24
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide probe
US-10-015-395A-294

Query Match      1.0%; Score 24; DB 1; Length 24;
```

Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGCATGGTGTCTGTGGG 1486

DB 24 GGAAGTGCATGGTGTCTGTGGG 1

RESULT 137

US-10-012-149A-293
; Sequence 293, Application US/10012149A
; Publication No. US20050043520A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan I.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurtey, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2830P1C26

; CURRENT APPLICATION NUMBER: US/10/012,149A

; CURRENT FILING DATE: 2002-06-25

; PRIOR APPLICATION removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 477

; SEQ ID NO 293

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide probe

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTTCCTCACTCTCC 1064

DB 1 GCTGACCTGGTTCCTCACTCTCC 24

RESULT 138

US-10-012-149A-294/C

; Sequence 294, Application US/10012149A

; Publication No. US20050043520A1

; GENERAL INFORMATION:

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnovers, Luc

; APPLICANT: Eaton, Dan I.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gao, Wei-Qiang

; APPLICANT: Goddard, Audrey

; APPLICANT: Grimaldi, Christopher J.

; APPLICANT: Gurtey, Austin L.

; APPLICANT: Hillan, Kenneth J.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; FILE REFERENCE: P2830P1C26

; CURRENT APPLICATION NUMBER: US/10/012,149A

; CURRENT FILING DATE: 2002-06-25

; PRIOR APPLICATION removed - See File Wrapper or Palm

; NUMBER OF SEQ ID NOS: 477

; SEQ ID NO 294

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic oligonucleotide probe

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGCATGGTGTCTGTGGG 1486

DB 24 GGAAGTGCATGGTGTCTGTGGG 1

RESULT 139

US-10-643-801-6/C

; Sequence 6, Application US/10643801

; Publication No. US20050043524A1

; GENERAL INFORMATION:

; APPLICANT: Sanjay Bhanot

; APPLICANT: Kenneth W. Dobie

; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

; FILE REFERENCE: RTS-0678US

; CURRENT APPLICATION NUMBER: US/10/643,801

; CURRENT FILING DATE: 2003-08-18

; NUMBER OF SEQ ID NOS: 230

; SEQ ID NO 6

; LENGTH: 24

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: PCR Primer

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 82;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 838 TGTGAGGAGTACTGATGTCGTG 861

DB 24 TGTGAGGAGTACTGATGTCGTG 1

RESULT 140

US-10-719-900-684231

; Sequence 684231, Application US/10719900

; Publication No. US20050026164A1

; GENERAL INFORMATION:

; APPLICANT: Xue Mei Zhou

; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

; FILE REFERENCE: 3528.1

; CURRENT APPLICATION NUMBER: US/10/719,900

; CURRENT FILING DATE: 2003-11-20

; PRIOR APPLICATION NUMBER: 60/427,808

; PRIOR FILING DATE: 2002 11 20

; NUMBER OF SEQ ID NOS: 982914

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

; SEQ ID NO 684231

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Mus musculus

US-10-719-900-684231

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1469 GTCATGGGTCTGTGGGTATTTA 1493
|||||
Db 1 GTCATGGGTCTGTGGGTATTTA 25

RESULT 141
US-10-719-900-761465
; Sequence 761465, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 761465
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-761465

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1314 TACATGAGGCGCTGTGAAGCTCT 1338
|||||
Db 1 TACATGAGGCGCTGTGAAGCTCT 25

RESULT 142
US-10-719-956-19410
; Sequence 19410, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 19410
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-19410

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1457 AAATTGGAAGTCTCATGCTGTCT 1481
|||||
Db 1 AAATTGGAAGTCTCATGCTGTCT 25

RESULT 143
US-10-719-956-102353
; Sequence 102353, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956

; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 102353
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-102353

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1285 AGCAAGACATCGACTGTACACAC 1309
|||||
Db 1 AGCAAGACATCGACTGTACACAC 25

RESULT 144
US-10-719-956-145295
; Sequence 145295, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 145295
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-145295

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1321 AGCCCTGTGAAGCTCTTGACAA 1345
|||||
Db 1 AGCCCTGTGTGAAGCTCTTGACAA 25

RESULT 145
US-10-719-956-323131
; Sequence 323131, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 323131
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-323131

Query Match 1.0%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 97;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;


```

; GENERAL INFORMATION:
; APPLICANT: Yadav, Narendra
; TITLE OF INVENTION: ACYLTRANSFERASES FOR ALTERATION OF POLYUNSATURATED FATTY ACIDS
; FILE REFERENCE: CL2302 US NA
; CURRENT APPLICATION NUMBER: US/10/883,760
; CURRENT FILING DATE: 2004-07-06
; NUMBER OF SEQ ID NOS: 86
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 29
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer P7
; NAME/KEY: misc_feature
; LOCATION: (24)..(24)
; OTHER INFORMATION: n is a, c, g, or t
US-10-883-760-23

Query Match          0.9%; Score 22; DB 1; Length 29;
Best Local Similarity 75.9%; Pred. No. 1.5e+02;
Matches 22; Conservative 3; Mismatches 4; Indels 0; Gaps 0;

QY      693 AACTATATCTTTGGATACACCCCCCATGG 721
DB      1 AACTACATCTTCGGCTAAYCAVCCNCAAG 29

RESULT 151
US-10-719-900-16467
; Sequence 16467, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 16467
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-16467

Query Match          0.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1008 AAGGCTTTGTGAAGCTGGCCCTGC 1032
DB      1 AAGGCTTTGTGAAGCTGGCCCTGC 25

RESULT 152
US-10-719-900-811306
; Sequence 811306, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 982914
```

```

; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 811306
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-811306

Query Match          0.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1138 TCCGAGAAATACATTGCTTGGCCCC 1162
DB      1 TCCAGAGATATATTGCTTGGCCCC 25

RESULT 153
US-10-719-900-880907
; Sequence 880907, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 880907
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-880907

Query Match          0.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1270 TGGAGCACCACCAACCCAGCAAGACAT 1294
DB      1 TGGAGCACCACCAACCCAGAAAGACAT 25

RESULT 154
US-10-719-956-19409
; Sequence 19409, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002.11.20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 19409
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-19409

Query Match          0.9%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.3e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1457 AAATTGGAAGTGTATGGGTGCT 1481
DB      1 AAATTGGAAGCTCATGGGTGCT 25
```

```
RESULT 155
US-10-719-956-102354
; Sequence 102354, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 102354
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-102354

Query Match
Best Local Similarity 0.9%; Score 21.8; DB 1; Length 25;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1285 AGCAAGACATCGACCTGTACCAACAC 1309
DB 1 AGAAAGACATCGTCTGTACCAACAC 25

RESULT 156
US-10-719-956-145296
; Sequence 145296, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 145296
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-145296

Query Match
Best Local Similarity 0.9%; Score 21.8; DB 1; Length 25;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1321 AGGCCTGTGTAAGCTCTTGACAA 1345
DB 1 AGGCCTGTGTAAGCTCTTGACAA 25

RESULT 157
US-10-719-956-630251
; Sequence 630251, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
```

```
; SEQ ID NO 630251
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-630251

Query Match
Best Local Similarity 0.9%; Score 21.8; DB 1; Length 25;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1270 TGGACACCCCAACCCAGCAAGACAT 1294
DB 1 TGGACACCCCAACCCAGCAAGACAT 25

RESULT 158
US-10-719-900-16468
; Sequence 16468, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 16468
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-16468

Query Match
Best Local Similarity 0.8%; Score 20.2; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1008 AAGGCTTGTGAAGCTGACCCTGC 1032
DB 1 AAGGCTTGTGTAGCTGACCCTGC 25

RESULT 159
US-10-719-900-263580
; Sequence 263580, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 263580
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-263580

Query Match
Best Local Similarity 0.8%; Score 20.2; DB 1; Length 25;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1036 ATGAGCTGACCTGGTCCCATCTA 1060
DB 1 ATGAGCTGATCTGGTCCCATCTA 25
```

```
RESULT 160
US-10-719-900-407646
; Sequence 407646, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 407646
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-407646

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1286 GCAAGACATGACCTGTACACACC 1310
DB      1 GAAAGACATGACCTGTACCATGCC 25

RESULT 161
US-10-719-900-539350
; Sequence 539350, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 539350
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-539350

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      987 GCAGTACCTGCGAAGCCGCAAG 1011
DB      1 GCAGTACCTGGAAGACCGCAAG 25

RESULT 162
US-10-719-900-539351
; Sequence 539351, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 539351
```

```
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-539351

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      987 GCAGTACCTGCGAAGCCGCAAG 1011
DB      1 GCAGTACCTGTGAAGACCGCAAG 25

RESULT 163
US-10-719-900-811305
; Sequence 811305, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 811305
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-811305

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1138 TCAGAAATACATTGTTTCGCCCC 1162
DB      1 TCAGAAATATATATGTTTCGCCCC 25

RESULT 164
US-10-719-900-832328
; Sequence 832328, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 832328
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-832328

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      2232 TCTGACGACAGATTAGTTCGAAG 2256
DB      1 TCTGACGACGAGAGTTTCCAATG 25

RESULT 165
```

```
US-10-719-900-880908
; Sequence 880908, Application US/10719950
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 880908
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-880908

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1270 TGGAGCACCACCAAGCAGACAT 1294
Db      1 TGGAGCACCACCAAGCAGACAT 25

RESULT 166
US-10-719-956-70482
; Sequence 70482, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 70482
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-70482

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1348 ACAAGACCAAGTGGCCTCCCGA 1372
Db      1 ACAAGACCAAAATCGGCCTCCAGA 25

RESULT 167
US-10-719-956-630252
; Sequence 630252, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 630252
; LENGTH: 25
```

```
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-630252

Query Match      0.8%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 1.7e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1270 TGGAGCACCACCAAGCAGACAT 1294
Db      1 TGGAGCACCACCAAGCAGACAT 25

RESULT 168
US-10-324-618-26/C
; Sequence 26, Application US/10324618
; Publication No. US20030170691A1
; GENERAL INFORMATION:
; APPLICANT: Gimeno, Ruth
; APPLICANT: Wu, Zhidan
; APPLICANT: Kapeller-Libermann, Rosana
; APPLICANT: Hubbard, Brian K.
; TITLE OF INVENTION: HOWAN DIACYLGLYCEROL ACYLTRANSFERASE 2
; FILE REFERENCE: MPI01-263P2RM
; CURRENT APPLICATION NUMBER: US/10/324,618
; PRIOR FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: 60/341,947
; PRIOR FILING DATE: 2002-12-19
; PRIOR APPLICATION NUMBER: 60/411,859
; PRIOR FILING DATE: 2002-09-19
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: 86606 reverse primer
US-10-324-618-26

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1831 CAGTTCTCTGCCAAGGGA 1850
Db      20 CAGTTCTCTGCCAAGGGA 1

RESULT 169
US-10-307-817-379/C
; Sequence 379, Application US/10307817
; Publication No. US20040058338A1
; GENERAL INFORMATION:
; APPLICANT: Agee et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-502C
; CURRENT APPLICATION NUMBER: US/10/307,817
; PRIOR FILING DATE: 2002-12-02
; NUMBER OF SEQ ID NOS: 682
; SOFTWARE: CuraseqList version 0.1
; SEQ ID NO 379
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer/Probe
US-10-307-817-379

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Qy 1218 TACTCAAGCCATCACCAC 1237
Db 20 TACTCAAGCCATCACCAC 1

RESULT 170
US-10-643-801-20/c
; Sequence 20, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-20

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 579 CCCAGAAAGGTGCGACGAG 598
Db 20 CCCAGAAAGGTGCGACGAG 1

RESULT 171
US-10-643-801-21/c
; Sequence 21, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-21

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 639 CGAGACTACTTCCCATCCA 658
Db 20 CGAGACTACTTCCCATCCA 1

RESULT 172
US-10-643-801-22/c
; Sequence 22, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US

; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-22

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 644 CTACTTCCCATCCAGCTGG 663
Db 20 CTACTTCCCATCCAGCTGG 1

RESULT 173
US-10-643-801-23/c
; Sequence 23, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-23

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 649 TTCCCATCCAGCTGTGAAG 668
Db 20 TTCCCATCCAGCTGTGAAG 1

RESULT 174
US-10-643-801-24/c
; Sequence 24, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-24

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 654 ATCCAGCTGTTGAAGACACA 673
|||||
DB 20 ATCCAGCTGTTGAAGACACA 1

RESULT 175
US-10-643-801-25/c
; Sequence 25, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-25

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 659 GCTGTGAAGACACACACC 678
|||||
DB 20 GCTGTGAAGACACACACC 1

RESULT 176
US-10-643-801-26/c
; Sequence 26, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-26

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 664 TGAAGACACCAACTGCTG 683
|||||
DB 20 TGAAGACACCAACTGCTG 1

RESULT 177
US-10-643-801-27/c
; Sequence 27, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801

; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-27

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 ACACCAACCTGTCACAC 688
|||||
DB 20 ACACCAACCTGTCACAC 1

RESULT 178
US-10-643-801-28/c
; Sequence 28, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-28

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 CAACCTGTCACACAGGA 693
|||||
DB 20 CAACCTGTCACACAGGA 1

RESULT 179
US-10-643-801-29/c
; Sequence 29, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 29
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-29

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 679 TGCTGACCAACGAACTAT 698

Db 20 TGCTGACCAGCACTAT 1

RESULT 180
US-10-643-801-30/c
; Sequence 30, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-30

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;
Indels 0;
QY 684 ACCACCAGCACTATCTT 703
Db 20 ACCACCAGCACTATCTT 1

RESULT 181
US-10-643-801-31/c
; Sequence 31, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-31

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;
Indels 0;
QY 689 CAGGAAGCACTATCTTTGGAT 708
Db 20 CAGGAAGCACTATCTTTGGAT 1

RESULT 182
US-10-643-801-32/c
; Sequence 32, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18

; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-32

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;
Indels 0;
QY 694 ACTATATCTTTGGATACAC 713
Db 20 ACTATATCTTTGGATACAC 1

RESULT 183
US-10-643-801-33/c
; Sequence 33, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-33

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;
Indels 0;
QY 723 ATCATGGCCTGGGTCCTT 742
Db 20 ATCATGGCCTGGGTCCTT 1

RESULT 184
US-10-643-801-34/c
; Sequence 34, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 34
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-34

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Gaps 0;
Indels 0;
QY 846 GAGTACCTGATGTCGAGG 865

Db 20 GAGTACCTGATGTCGGAGG 1

RESULT 185
US-10-643-801-35/c
; Sequence 35, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-35

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 909 AAGATGGAGTGGCAATGC 928
Db 20 AAGATGGAGTGGCAATGC 1

RESULT 186
US-10-643-801-36/c
; Sequence 36, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-36

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 914 TGGAGTGGCAATGCTATCA 923
Db 20 TGGAGTGGCAATGCTATCA 1

RESULT 187
US-10-643-801-37/c
; Sequence 37, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230

; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-37

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 919 GTGGCAATGCTATCATCATC 938
Db 20 GTGGCAATGCTATCATCATC 1

RESULT 188
US-10-643-801-38/c
; Sequence 38, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-38

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 924 AATGCTATCATCATCGTGT 943
Db 20 AATGCTATCATCATCGTGT 1

RESULT 189
US-10-643-801-39/c
; Sequence 39, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-39

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 963 CTGAGCTCAGTCCCTGGCAA 982
Db 20 CTGAGCTCAGTCCCTGGCAA 1


```
RESULT 190
US-10-643-801-40/c
; Sequence 40, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-40

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1110 TCCTGGGGCGGATGGTCCA 1129
DB 20 TCCTGGGGCGGATGGTCCA 1

RESULT 191
US-10-643-801-41/c
; Sequence 41, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-41

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 GGGCCGATGGGTCCAGAGA 1134
DB 20 GGGCCGATGGGTCCAGAGA 1

RESULT 192
US-10-643-801-42/c
; Sequence 42, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 42
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-42

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1120 GATGGGTCCAGAGAGTTC 1139
DB 20 GATGGGTCCAGAGAGTTC 1

RESULT 193
US-10-643-801-43/c
; Sequence 43, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-43

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1125 GTCCAGAGAGAGTTCAGAA 1144
DB 20 GTCCAGAGAGAGTTCAGAA 1

RESULT 194
US-10-643-801-44/c
; Sequence 44, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-44

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Pred. No. 1.4e+02; Mismatches 0; Indels 0; Gaps 0;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1197 GACACCTGGGGGCTGTGCC 1216
DB 20 GACACCTGGGGGCTGTGCC 1
```

```
RESULT 195
US-10-643-801-45/C
; Sequence 45, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-45

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1202 CTGGGGGCTGTGCTCCTACT 1221
DB      20 CTGGGGGCTGTGCTCCTACT 1

RESULT 196
US-10-643-801-46/C
; Sequence 46, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-46

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1207 GGCTGTGCTTACTCCAG 1226
DB      20 GGCTGTGCTTACTCCAG 1

RESULT 197
US-10-643-801-47/C
; Sequence 47, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 47
; LENGTH: 20

; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-47

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1309 CCATGTACATGAGGCCCTG 1328
DB      20 CCATGTACATGAGGCCCTG 1

RESULT 198
US-10-643-801-48/C
; Sequence 48, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-48

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1314 TACATGAGGCCCTGTGAA 1333
DB      20 TACATGAGGCCCTGTGAA 1

RESULT 199
US-10-643-801-49/C
; Sequence 49, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-49

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1319 GGAGGCTGTGTGAAGCTCT 1338
DB      20 GGAGGCTGTGTGAAGCTCT 1
```

```
RESULT 200
US-10-643-801-50/c
; Sequence 50, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-50

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1469 GTCATGGGTCCTCTGCGGTT 1488
Db      20 GTCATGGGTCCTCTGCGGTT 1

RESULT 201
US-10-643-801-51/c
; Sequence 51, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-51

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1474 GCGTGCTCTGCGGTTATTTA 1493
Db      20 GCGTGCTCTGCGGTTATTTA 1

RESULT 202
US-10-643-801-52/c
; Sequence 52, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-52

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1479 TCTGCGGTTATTTAAAGA 1498
Db      20 TCTGCGGTTATTTAAAGA 1

RESULT 203
US-10-643-801-62/c
; Sequence 62, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-62

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      46 GGCTGTTTCTTCGCGCCAC 65
Db      20 GGCTGTTTCTTCGCGCCAC 1

RESULT 204
US-10-643-801-63/c
; Sequence 63, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-63

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      134 GCTTCGCGGAAGCCCTGCG 153
Db      20 GCTTCGCGGAAGCCCTGCG 1

RESULT 205
```

```
US-10-643-801-64/c
; Sequence 64, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-64
```

```
Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      222 GCTTCAGCCATGAAGACCTT 241
      |||||
DB      20 GCTTCAGCCATGAAGACCTT 1
```

```
RESULT 206
US-10-643-801-65/c
; Sequence 65, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-65
```

```
Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      246 GCCGCTACTCCGCGGTCTT 265
      |||||
DB      20 GCCGCTACTCCGCGGTCTT 1
```

```
RESULT 207
US-10-643-801-66/c
; Sequence 66, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-66
```

```
Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      441 ATCTCAGTGTCTCAGTGGGT 460
      |||||
DB      20 ATCTCAGTGTCTCAGTGGGT 1
```

```
RESULT 208
US-10-643-801-67/c
; Sequence 67, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-67
```

```
Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      855 ATGTCTGAGGATATCTGCC 874
      |||||
DB      20 ATGTCTGAGGATATCTGCC 1
```

```
RESULT 209
US-10-643-801-68/c
; Sequence 68, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-68
```

```
Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      987 GCAGTCACCTGCGGACCG 1006
      |||||
DB      20 GCAGTCACCTGCGGACCG 1
```

```
RESULT 210
US-10-643-801-69/c
```

```
; Sequence 69, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-69

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1387 AGGTGAAGTGAAGCCAGCCTT 1406
DB      20 AGGTGAAGTGAAGCCAGCCTT 1

RESULT 211
US-10-643-801-70/c
; Sequence 70, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-70

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1401 AGCCTTCGGGGCCCACTCCC 1420
DB      20 AGCCTTCGGGGCCCACTCCC 1

RESULT 212
US-10-643-801-71/c
; Sequence 71, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-71/c

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-71

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1414 AACTCCCTGAGAGACCAGC 1433
DB      20 AACTCCCTGAGAGACCAGC 1

RESULT 213
US-10-643-801-72/c
; Sequence 72, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-72

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1449 TGCTCTGTAAATTGGAGT 1468
DB      20 TGCTCTGTAAATTGGAGT 1

RESULT 214
US-10-643-801-73/c
; Sequence 73, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-73

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1584 GCTTGCCCTGTCTAGTGG 1603
DB      20 GCTTGCCCTGTCTAGTGG 1

RESULT 215
US-10-643-801-74/c
; Sequence 74, Application US/10643801
```

```
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-74

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1635 AGCTAACCTCTCTCTCTCCC 1654
DB      20 AGCTAACCTCTCTCTCTCCC 1

RESULT 216
US-10-643-801-75/c
; Sequence 75, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-75

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1647 TTCTTCCCTTCCGAGTGA 1666
DB      20 TTCTTCCCTTCCGAGTGA 1

RESULT 217
US-10-643-801-76/c
; Sequence 76, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide

US-10-643-801-76

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1679 AGCTTCTTGGGAGAGAGG 1698
DB      20 AGCTTCTTGGGAGAGAGG 1

RESULT 218
US-10-643-801-77/c
; Sequence 77, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 77
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-77

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1707 TAGTGACTTGACCACTTAG 1726
DB      20 TAGTGACTTGACCACTTAG 1

RESULT 219
US-10-643-801-78/c
; Sequence 78, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-78

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1724 TAGATGATTCACTTTTGCC 1743
DB      20 TAGATGATTCACTTTTGCC 1

RESULT 220
US-10-643-801-79/c
; Sequence 79, Application US/10643801
; Publication No. US20050043524A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 79
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-79

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1743 CCTAGGATGAGAGCGGAA 1762
DB      20 CCTAGGATGAGAGCGGAA 1

RESULT 221
US-10-643-801-80/c
; Sequence 80, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-80

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1763 AGCCACTTCTCATCAAGCC 1782
DB      20 AGCCACTTCTCATCAAGCC 1

RESULT 222
US-10-643-801-81/c
; Sequence 81, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 81
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-81

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1802 ACGCTGCTAGTCTGAAA 1821
DB      20 ACGCTGCTAGTCTGAAA 1

RESULT 223
US-10-643-801-82/c
; Sequence 82, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 82
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-82

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1946 CCTAGTCACTCATATCGAG 1965
DB      20 CCTAGTCACTCATATCGAG 1

RESULT 224
US-10-643-801-83/c
; Sequence 83, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 83
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-83

Query Match      0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1969 GGACTGGCTCCAGATGAG 1988
DB      20 GGACTGGCTCCAGATGAG 1

RESULT 225
US-10-643-801-84/c
; Sequence 84, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
```

```
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-067805
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-84
```

```
Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1974 GGCCTCCAGGATGAGGATGG 1993
Db      20 GGCCTCCAGGATGAGGATGG 1
```

```
RESULT 226
US-10-643-801-85/c
; Sequence 85, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-067805
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 85
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-85
```

```
Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      1989 GATGGGGGTGGCAATGACAC 2008
Db      20 GATGGGGGTGGCAATGACAC 1
```

```
RESULT 227
US-10-643-801-86/c
; Sequence 86, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-067805
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 86
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-86
```

```
Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      2055 GCCGCCACCATGAGCTAGGT 2074
Db      20 GCCGCCACCATGAGCTAGGT 1
```

```
RESULT 228
US-10-643-801-87/c
; Sequence 87, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-067805
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 87
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-87
```

```
Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      2067 AGCTAGGTGAGTACTGCT 2086
Db      20 AGCTAGGTGAGTACTGCT 1
```

```
RESULT 229
US-10-643-801-88/c
; Sequence 88, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-067805
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 88
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-88
```

```
Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy      2088 TTCTTGGGTGGCTGATGAC 2107
Db      20 TTCTTGGGTGGCTGATGAC 1
```

```
RESULT 230
US-10-643-801-89/c
; Sequence 89, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
```


APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 89
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-89

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2125 TCAGCCTTGCCCTGAGAC 2144
DB 20 TCAGCCTTGCCCTGAGAC 1

RESULT 231
US-10-643-801-90/C
Sequence 90, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 90
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-90

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2137 TGGAGCAGATGCTTACTGCT 2156
DB 20 TGGAGCAGATGCTTACTGCT 1

RESULT 232
US-10-643-801-91/C
Sequence 91, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 91
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-91

Query Match 0.8%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred.No.1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 2143 ACATGCTTACTGTGGCCCTC 2162
DB 20 ACATGCTTACTGTGGCCCTC 1

RESULT 233
US-10-643-801-92/C
Sequence 92, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 92
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-92

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2150 TACTGTGCTTCAGCTTTC 2169
DB 20 TACTGTGCTTCAGCTTTC 1

RESULT 234
US-10-643-801-93/C
Sequence 93, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 93
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-93

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2184 AGATTCTGATGTGAGGAG 2203
DB 20 AGATTCTGATGTGAGGAG 1

RESULT 235
US-10-643-801-94/C
Sequence 94, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
APPLICANT: Kenneth W. Dobie

```
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18.
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 94
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-94

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2220 GGGGCGCTGGCCTTCTGAGCA 2239
Db      20 GGGGCGCTGGCCTTCTGAGCA 1

RESULT 236
US-10-643-801-95/c
/ Sequence 95, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 95
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-95

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2242 AGATTAGTTCCAAGCAGGT 2261
Db      20 AGATTAGTTCCAAGCAGGT 1

RESULT 237
US-10-643-801-96/c
/ Sequence 96, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 96
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-96

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2269 GAACCAAGCCCTCCTTTC 2288
Db      20 GAACCAAGCCCTCCTTTC 1

RESULT 238
US-10-643-801-97/c
/ Sequence 97, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 97
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-97

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      2367 TTGCACCATGTCAGACTTTT 2386
Db      20 TTGCACCATGTCAGACTTTT 1

RESULT 239
US-10-643-801-143
/ Sequence 143, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 143
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-143

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      579 CCCAAGAAAGGTGCAGAG 598
Db      1 CCCAAGAAAGGTGCAGAG 20

RESULT 240
US-10-643-801-144
/ Sequence 144, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
```

;; CURRENT APPLICATION NUMBER: US/10/643,801
;; CURRENT FILING DATE: 2003-08-18
;; NUMBER OF SEQ ID NOS: 230
;; SEQ ID NO 144
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: H. sapiens
;; FEATURE:
US-10-643-801-144

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 639 CGAGACTCTTCCCATCCA 658
DB 1 CGAGACTCTTCCCATCCA 20

RESULT 241
US-10-643-801-145

;; Sequence 145, Application US/10643801
;; Publication No. US20050043524A1
;; GENERAL INFORMATION:
;; APPLICANT: Sanjay Bhanot
;; APPLICANT: Kenneth W. Dobie
;; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
;; FILE REFERENCE: RTS-0678US
;; CURRENT APPLICATION NUMBER: US/10/643,801
;; CURRENT FILING DATE: 2003-08-18
;; NUMBER OF SEQ ID NOS: 230
;; SEQ ID NO 145
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: H. sapiens
;; FEATURE:
US-10-643-801-145

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 649 TTCCCATCCAGCTGTGAAG 668
DB 1 TTCCCATCCAGCTGTGAAG 20

RESULT 242
US-10-643-801-146

;; Sequence 146, Application US/10643801
;; Publication No. US20050043524A1
;; GENERAL INFORMATION:
;; APPLICANT: Sanjay Bhanot
;; APPLICANT: Kenneth W. Dobie
;; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
;; FILE REFERENCE: RTS-0678US
;; CURRENT APPLICATION NUMBER: US/10/643,801
;; CURRENT FILING DATE: 2003-08-18
;; NUMBER OF SEQ ID NOS: 230
;; SEQ ID NO 146
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: H. sapiens
;; FEATURE:
US-10-643-801-146

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 654 ATCCAGCTGTGTAAGACACA 673
DB 1 ATCCAGCTGTGTAAGACACA 20

RESULT 243
US-10-643-801-147

;; Sequence 147, Application US/10643801
;; Publication No. US20050043524A1
;; GENERAL INFORMATION:
;; APPLICANT: Sanjay Bhanot
;; APPLICANT: Kenneth W. Dobie
;; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
;; FILE REFERENCE: RTS-0678US
;; CURRENT APPLICATION NUMBER: US/10/643,801
;; CURRENT FILING DATE: 2003-08-18
;; NUMBER OF SEQ ID NOS: 230
;; SEQ ID NO 147
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: H. sapiens
;; FEATURE:
US-10-643-801-147

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 659 GCTGTGAAGACACACACC 678
DB 1 GCTGTGAAGACACACACC 20

RESULT 244
US-10-643-801-148

;; Sequence 148, Application US/10643801
;; Publication No. US20050043524A1
;; GENERAL INFORMATION:
;; APPLICANT: Sanjay Bhanot
;; APPLICANT: Kenneth W. Dobie
;; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
;; FILE REFERENCE: RTS-0678US
;; CURRENT APPLICATION NUMBER: US/10/643,801
;; CURRENT FILING DATE: 2003-08-18
;; NUMBER OF SEQ ID NOS: 230
;; SEQ ID NO 148
;; LENGTH: 20
;; TYPE: DNA
;; ORGANISM: H. sapiens
;; FEATURE:
US-10-643-801-148

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 664 TGAAGACACACACTGCTG 683
DB 1 TGAAGACACACACTGCTG 20

RESULT 245
US-10-643-801-149

;; Sequence 149, Application US/10643801
;; Publication No. US20050043524A1
;; GENERAL INFORMATION:
;; APPLICANT: Sanjay Bhanot
;; APPLICANT: Kenneth W. Dobie
;; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
;; FILE REFERENCE: RTS-0678US
;; CURRENT APPLICATION NUMBER: US/10/643,801
;; CURRENT FILING DATE: 2003-08-18
;; NUMBER OF SEQ ID NOS: 230
;; SEQ ID NO 149
;; LENGTH: 20
;; TYPE: DNA

```

; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-149

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 669 ACACACCACTGCTGACCCAC 688
DB 1 ACACACCACTGCTGACCCAC 20

RESULT 246
US-10-643-801-150
; Sequence 150, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 150
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-150

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 674 CAACCTGCTGACCCACGGA 693
DB 1 CAACCTGCTGACCCACGGA 20

RESULT 247
US-10-643-801-151
; Sequence 151, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 151
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-151

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 679 TGCCTGACCCACGGAACCTAT 698
DB 1 TGCCTGACCCACGGAACCTAT 20

RESULT 248
US-10-643-801-152
; Sequence 152, Application US/10643801
; Publication No. US20050043524A1
```

```

; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 152
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-152

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 684 ACCACCAAGAACTATATCTT 703
DB 1 ACCACCAAGAACTATATCTT 20

RESULT 249
US-10-643-801-153
; Sequence 153, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 153
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-153

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 689 CAGGAACCTATATCTTTGGAT 708
DB 1 CAGGAACCTATATCTTTGGAT 20

RESULT 250
US-10-643-801-154
; Sequence 154, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 154
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-154

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 694 ACTATATCTTGGATACCAC 713
Db 1 ACTATATCTTGGATACCAC 20

RESULT 251
US-10-643-801-155
; Sequence 155, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 155
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-155

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 723 ATCATGGGCTGGGTCCTT 742
Db 1 ATCATGGGCTGGGTCCTT 20

RESULT 252
US-10-643-801-156
; Sequence 156, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 156
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-156

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 846 GAGTACCTGATGCTGGAGG 865
Db 1 GAGTACCTGATGCTGGAGG 20

; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 157
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-157

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 909 AAGATGGAGTGGCAATGC 928
Db 1 AAGATGGAGTGGCAATGC 20

RESULT 254
US-10-643-801-158
; Sequence 158, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 158
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-158

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 914 TGGAGTGGCAATGCTATCA 933
Db 1 TGGAGTGGCAATGCTATCA 20

RESULT 255
US-10-643-801-159
; Sequence 159, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 159
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-159

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 919 GTGGCAATGCTATCATC 938
Db 1 GTGGCAATGCTATCATC 20

RESULT 256
US-10-643-801-160
; Sequence 160, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 160
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-160

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 924 AATGCTATCATCATCGTGGT 943
|||||
Db 1 AATGCTATCATCATCGTGGT 20

RESULT 257
US-10-643-801-161
; Sequence 161, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 161
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-161

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 963 CTGAGCTCCATGCTGGCAA 982
|||||
Db 1 CTGAGCTCCATGCTGGCAA 20

RESULT 258
US-10-643-801-162
; Sequence 162, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 162
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens

; FEATURE:
US-10-643-801-162

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1110 TCCTGGGGCCGATGGTCCA 1129
|||||
Db 1 TCCTGGGGCCGATGGTCCA 20

RESULT 259
US-10-643-801-163
; Sequence 163, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 163
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-163

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 GGGCCGATGGTCCAGAGA 1134
|||||
Db 1 GGGCCGATGGTCCAGAGA 20

RESULT 260
US-10-643-801-164
; Sequence 164, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 164
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-164

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1120 GATGGTCCAGAGAAGTTC 1139
|||||
Db 1 GATGGTCCAGAGAAGTTC 20

RESULT 261
US-10-643-801-165
; Sequence 165, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:

```
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 165
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-165
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1125 GTCCAGAGAGTTCAGAA 1144
Db 1 GTCCAGAGAGTTCAGAA 20
```

```
RESULT 262
US-10-643-801-166
; Sequence 166, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 166
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-166
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1197 GACACCTGGGGCTGTGCC 1216
Db 1 GACACCTGGGGCTGTGCC 20
```

```
RESULT 263
US-10-643-801-167
; Sequence 167, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 167
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-167
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1202 CTGGGGGCTGTGCCCTACT 1221
Db 1 CTGGGGGCTGTGCCCTACT 20
```

```
RESULT 264
US-10-643-801-168
; Sequence 168, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 168
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-168
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1207 GGCTGGTCCCTACTCCAG 1226
Db 1 GGCTGGTCCCTACTCCAG 20
```

```
RESULT 265
US-10-643-801-169
; Sequence 169, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 169
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-169
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1309 CCATGTACATGAGGCCCTG 1328
Db 1 CCATGTACATGAGGCCCTG 20
```

```
RESULT 266
US-10-643-801-170
; Sequence 170, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 170
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-170
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 170
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
/ FEATURE:
```

```
US-10-643-801-170
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1314 TACATGAGGCCCTGCTGAA 1333
      |||
      1 TACATGAGGCCCTGCTGAA 20
```

```
RESULT 267
US-10-643-801-171
```

```
/ Sequence 171, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
```

```
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
```

```
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
```

```
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 171
```

```
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
```

```
/ FEATURE:
US-10-643-801-171
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1319 GGAGGCCCTGTGTGAGCTCT 1338
      |||
      1 GGAGGCCCTGTGTGAGCTCT 20
```

```
RESULT 268
US-10-643-801-172
```

```
/ Sequence 172, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
```

```
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
```

```
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
```

```
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 172
```

```
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
```

```
/ FEATURE:
US-10-643-801-172
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1469 GTTCATGGGTCTGTGGGTT 1488
      |||
      1 GTTCATGGGTCTGTGGGTT 20
```

```
RESULT 269
US-10-643-801-173
```

```
/ Sequence 173, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
```

```
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
```

```
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
```

```
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 173
```

```
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
```

```
/ FEATURE:
US-10-643-801-173
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1474 GGGTGTCTGTGGGTTATTTA 1493
      |||
      1 GGGTGTCTGTGGGTTATTTA 20
```

```
RESULT 270
US-10-643-801-174
```

```
/ Sequence 174, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
```

```
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
```

```
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
```

```
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 174
```

```
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
```

```
/ FEATURE:
US-10-643-801-174
```

```
Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1479 TCTGTGGTTATTTAAAGA 1498
      |||
      1 TCTGTGGTTATTTAAAGA 20
```

```
RESULT 271
US-10-643-801-182
```

```
/ Sequence 182, Application US/10643801
/ Publication No. US20050043524A1
/ GENERAL INFORMATION:
```

```
/ APPLICANT: Sanjay Bhanot
/ APPLICANT: Kenneth W. Dobie
```

```
/ TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
/ FILE REFERENCE: RTS-0678US
```

```
/ CURRENT APPLICATION NUMBER: US/10/643,801
/ CURRENT FILING DATE: 2003-08-18
```

```
/ NUMBER OF SEQ ID NOS: 230
/ SEQ ID NO 182
```

```
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: H. sapiens
```

```
/ FEATURE:
```


US-10-643-801-182

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 46 GGCTGTTCTCTCGCCGAC 65
|||||
DB 1 GGCTGTTCTCTCGCCGAC 20

RESULT 272

US-10-643-801-183
; Sequence 183, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 183
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-183

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 134 GCTCTGCGGAGCCCTGGC 153
|||||
DB 1 GCTCTGCGGAGCCCTGGC 20

RESULT 273

US-10-643-801-184
; Sequence 184, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 184
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-184

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 222 GCTTCAGCCATGAACCTT 241
|||||
DB 1 GCTTCAGCCATGAACCTT 20

RESULT 274

US-10-643-801-185
; Sequence 185, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot

; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 185
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-185

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 246 GCCGCTACTCGGGGTCTT 265
|||||
DB 1 GCCGCTACTCGGGGTCTT 20

RESULT 275

US-10-643-801-186
; Sequence 186, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 186
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-186

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 441 ATCTAGTGTCTCAGTGGT 460
|||||
DB 1 ATCTAGTGTCTCAGTGGT 20

RESULT 276

US-10-643-801-187
; Sequence 187, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 187
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-187

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 987 GCAGTCACCTCGGACCG 1006
|||
DB 1 GCAGTCACCTCGGACCG 20

RESULT 277
US-10-643-801-188
; Sequence 188, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 188
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-188

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1387 AGGTGAACCTGAGCCACCTT 1406
|||
DB 1 AGGTGAACCTGAGCCACCTT 20

RESULT 278
US-10-643-801-189
; Sequence 189, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 189
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-189

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1401 AGCCTCGGGGCACTCCC 1420
|||
DB 1 AGCCTCGGGGCACTCCC 20

RESULT 279
US-10-643-801-190
; Sequence 190, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230

; SEQ ID NO 190
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-190

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1414 AACTCCCTGGAGGACCGC 1433
|||
DB 1 AACTCCCTGGAGGACCGC 20

RESULT 280
US-10-643-801-191
; Sequence 191, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 191
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-191

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1449 TGCTCTGTAATTGGAGT 1468
|||
DB 1 TGCTCTGTAATTGGAGT 20

RESULT 281
US-10-643-801-192
; Sequence 192, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 192
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-192

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1584 GCTTCCTGTTCTAGTGG 1603
|||
DB 1 GCTTCCTGTTCTAGTGG 20

RESULT 282

```
US-10-643-801-193
; Sequence 193, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 193
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-193

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1647 TTCTTCCCTTCCGAGTGA 1666
DB 1 TTCTTCCCTTCCGAGTGA 20

RESULT 283
US-10-643-801-194
; Sequence 194, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 194
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-194

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1679 AGTCTTCTTGGGAGAGAGG 1698
DB 1 AGTCTTCTTGGGAGAGAGG 20

RESULT 284
US-10-643-801-195
; Sequence 195, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 195
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-195

US-10-643-801-196
; Sequence 196, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 196
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-196

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1724 TAGATGATTCACCTTTTGGC 1743
DB 1 TAGATGATTCACCTTTTGGC 20

RESULT 286
US-10-643-801-197
; Sequence 197, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 197
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-197

Query Match
Best Local Similarity 100.0%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1763 ACCCACTTCTCATACAGCC 1782
DB 1 ACCCACTTCTCATACAGCC 20

RESULT 287
US-10-643-801-198
; Sequence 198, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
```

```
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 198
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-198

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1802  ACGCTGCTAGTCTGAAA 1821
DB      1  ACGCTGCTAGTCTGAAA 20

RESULT 288
US-10-643-801-199
; Sequence 199, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 199
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-199

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1946  CCTAGTCACTCATATCGAG 1965
DB      1  CCTAGTCACTCATATCGAG 20

RESULT 289
US-10-643-801-200
; Sequence 200, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 200
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-200

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1969  GGACTGCTCCAGATGAG 1988
```

```
DB      1  GGACTGCTCCAGATGAG 20

RESULT 290
US-10-643-801-201
; Sequence 201, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 201
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-201

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1974  GGCTCCAGATGAGATGG 1993
DB      1  GGCTCCAGATGAGATGG 20

RESULT 291
US-10-643-801-202
; Sequence 202, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 202
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-643-801-202

Query Match          0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1989  GATGGGGTGGCATGACAC 2008
DB      1  GATGGGGTGGCATGACAC 20

RESULT 292
US-10-643-801-203
; Sequence 203, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 203
```

LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-203

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2055 GCCGCCACCATGAGCTAGCT 2074
DB 1 GCCGCCACCATGAGCTAGCT 20

RESULT 293
US-10-643-801-204

Sequence 204, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 204
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-204

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2067 AGCTAGGTGAGTAACTAGCT 2086
DB 1 AGCTAGGTGAGTAACTAGCT 20

RESULT 294
US-10-643-801-205

Sequence 205, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 205
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-205

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2088 TTCTTGGGTGGCTGATGAC 2107
DB 1 TTCTTGGGTGGCTGATGAC 20

RESULT 295
US-10-643-801-206

Sequence 206, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 206
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-206

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2125 TCAGCCTTGCCCTGAGCAC 2144
DB 1 TCAGCCTTGCCCTGAGCAC 20

RESULT 296
US-10-643-801-207

Sequence 207, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 207
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-207

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2137 TGGAGCAGTGGCTTACTGCT 2156
DB 1 TGGAGCAGTGGCTTACTGCT 20

RESULT 297
US-10-643-801-208

Sequence 208, Application US/10643801
Publication No. US20050043524A1
GENERAL INFORMATION:
APPLICANT: Sanjay Bhanot
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 208
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-643-801-208

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2143 ACATGCTTACTGTGCTTC 2162
DB 1 ACATGCTTACTGTGCTTC 20

RESULT 298
US-10-643-801-209

; Sequence 209, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:

; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 209
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-209

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2150 TACTGTGCTTCAGTTTAC 2169
DB 1 TACTGTGCTTCAGTTTAC 20

RESULT 299
US-10-643-801-210

; Sequence 210, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 210
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-210

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2220 GGAGGCTGCTTCAGCA 2239
DB 1 GGAGGCTGCTTCAGCA 20

RESULT 300
US-10-643-801-211

; Sequence 211, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION

; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 211
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-211

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2242 AGATTAGTTCAGACAGT 2261
DB 1 AGATTAGTTCAGACAGT 20

RESULT 301
US-10-643-801-212

; Sequence 212, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 212
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-212

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2269 GAACCCAGCTTCACCTTTC 2288
DB 1 GAACCCAGCTTCACCTTTC 20

RESULT 302
US-10-643-801-213

; Sequence 213, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 213
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:

US-10-643-801-213

Query Match 0.8%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2367 TTGACACATGTCAGACTTTT 2386
DB 1 TTGACACATGTCAGACTTTT 20

Db 1 TTGCACCATGTGACACTTTT 20

RESULT 303

US-10-719-956-301629/c

Sequence 301629, Application US/10719956

PUBLICATION NO. US20040146910A1

GENERAL INFORMATION:

APPLICANT: Xue Mei Zhou

TITLE OF INVENTION: Methods of Genetic Analysis of Rat

FILE REFERENCE: 3527.1

CURRENT APPLICATION NUMBER: US/10/719,956

PRIOR FILING DATE: 2003-11-20

PRIOR APPLICATION NUMBER: 60/427,836

PRIOR FILING DATE: 2002-11-20

NUMBER OF SEQ ID NOS: 699466

SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

SEQ ID NO 301629

LENGTH: 25

TYPE: DNA

ORGANISM: Rattus norvegicus

US-10-719-956-301629

Query Match 0.8%; Score 19.4; DB 1; Length 25;

Best Local Similarity 95.2%; Pred. No. 2e+02;

Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 801 TACCTGCTACTGCGAGGC 821

Db 24 TACCTGCTACTGCGAGGC 4

RESULT 304

US-10-719-900-885846/c

Sequence 885846, Application US/10719900

PUBLICATION NO. US2005026164A1

GENERAL INFORMATION:

APPLICANT: Xue Mei Zhou

TITLE OF INVENTION: Methods of Genetic Analysis of Mouse

FILE REFERENCE: 3528.1

CURRENT APPLICATION NUMBER: US/10/719,900

PRIOR FILING DATE: 2003-11-20

PRIOR APPLICATION NUMBER: 60/427,808

PRIOR FILING DATE: 2002-11-20

NUMBER OF SEQ ID NOS: 982914

SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

SEQ ID NO 885846

LENGTH: 25

TYPE: DNA

ORGANISM: Mus musculus

US-10-719-900-885846

Query Match 0.8%; Score 19.2; DB 1; Length 25;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 742 TCTGCACTTCGACGAGGCCA 765

Db 24 TCTGCACTTCGACGAGGCCA 1

RESULT 305

US-10-809-189-52073/c

Sequence 52073, Application US/10809189

PUBLICATION NO. US20050048531A1

GENERAL INFORMATION:

APPLICANT: Michael Mittmann

APPLICANT: David Mack

APPLICANT: David Lockhart

APPLICANT: Affymetrix, Inc.

TITLE OF INVENTION: Methods of Genetic Analysis

FILE REFERENCE: 3101.1

CURRENT APPLICATION NUMBER: US/10/809,189

; CURRENT FILING DATE: 2004-03-25

; PRIOR APPLICATION NUMBER: US/09/396,196

; PRIOR FILING DATE: 1999-09-15

; PRIOR APPLICATION NUMBER: 60/100,678

; PRIOR FILING DATE: 1998-09-17

; NUMBER OF SEQ ID NOS: 127806

; SOFTWARE: FastSeq for windows Version 4.0

; SEQ ID NO 52073

; LENGTH: 25

; TYPE: DNA

; ORGANISM: mus musculus

US-10-809-189-52073

Query Match 0.8%; Score 19.2; DB 1; Length 25;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1311 ATGTACATGAGGCGCTGTGANG 1334

Db 25 ATGTACATGAGGCGCTGTGANG 2

RESULT 306

US-10-956-157-170437

Sequence 170437, Application US/10956157

PUBLICATION NO. US20050118625A1

GENERAL INFORMATION:

APPLICANT: Wyeth

APPLICANT: Mounts, William

TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

FILE REFERENCE: 031896-043000 (AM 101081)

CURRENT APPLICATION NUMBER: US/10/956,157

CURRENT FILING DATE: 2004-10-04

NUMBER OF SEQ ID NOS: 319805

SOFTWARE: PatentIn version 3.2

SEQ ID NO 170437

LENGTH: 25

TYPE: DNA

ORGANISM: Probe Sequence

US-10-956-157-170437

Query Match 0.8%; Score 19.2; DB 1; Length 25;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;

Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1413 CAATCCTCGAGGAGAACAGCTGC 1436

Db 1 CAATCCTCGAGGAGAACAGCTGC 24

RESULT 307

US-10-719-956-226834

Sequence 226834, Application US/10719956

PUBLICATION NO. US20040146910A1

GENERAL INFORMATION:

APPLICANT: Xue Mei Zhou

TITLE OF INVENTION: Methods of Genetic Analysis of Rat

FILE REFERENCE: 3527.1

CURRENT APPLICATION NUMBER: US/10/719,956

PRIOR FILING DATE: 2003-11-20

PRIOR APPLICATION NUMBER: 60/427,836

PRIOR FILING DATE: 2002-11-20

NUMBER OF SEQ ID NOS: 699466

SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1

SEQ ID NO 226834

LENGTH: 25

TYPE: DNA

ORGANISM: Rattus norvegicus

US-10-719-956-226834

Query Match 0.8%; Score 19.2; DB 1; Length 25;

Best Local Similarity 87.5%; Pred. No. 2.1e+02;

```
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1235 CACTGTTGGGAGAGCCCATC 1258
DB 1 CACTGTTATGGGAGAGCTTTAC 24

RESULT 308
US-10-719-900-194173/c
; Sequence 194173, Application US/107199900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 194173
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-194173

Query Match 0.8%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2205 GATCCTCTTCAGAGGGGCTT 2226
DB 22 GATCCTCTTCAGAGGGGCTT 1

RESULT 309
US-10-719-900-903590
; Sequence 903590, Application US/107199900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 903590
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-903590

Query Match 0.8%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 544 TCTACTTCACTTGCTGGTGTT 565
DB 3 TCTACTTGACTTGGCTGAGTT 24

RESULT 310
US-10-719-956-30682
; Sequence 30682, Application US/107199956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
```

```
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 30682
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-30682

Query Match 0.8%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 213 ACTGGGCGGCTTCAGCCATGA 234
DB 2 ACTGGGCGGCTGCACCATGA 23

RESULT 311
US-10-719-956-451896
; Sequence 451896, Application US/107199956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 451896
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-451896

Query Match 0.8%; Score 18.8; DB 1; Length 25;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1474 GGGGCTGCTGGGTATTATAA 1495
DB 1 GGGAGTCTGGGTTCTTAAA 22

RESULT 312
US-10-643-801-108/c
; Sequence 108, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-067805
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 108
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-108

Query Match 0.8%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```


QY 481 GAGTGGCTGCAGTGCATC 500
| | | | | | | | | | | | | | | | | | | | | |
DB 20 GAGTGGCTGCAGTGCATC 1

RESULT 313
US-10-643-801-110/c
; Sequence 110, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 110
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-110

Query Match 0.8%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 855 ATGCTGAGGTATCTGCC 874
| | | | | | | | | | | | | | | | | | | | | |
DB 20 ATGCTGAGGTATCTGCC 1

RESULT 314
US-10-643-801-115/c
; Sequence 115, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 115
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-115

Query Match 0.8%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1171 TCCATGTCGAGGCTCTTC 1190
| | | | | | | | | | | | | | | | | | | | | |
DB 20 TCCATGTCGAGGCTCTTC 1

RESULT 315
US-10-643-801-117/c
; Sequence 117, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US

; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 117
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-117

Query Match 0.8%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1264 CCAAGCTGAGCACCACCC 1283
| | | | | | | | | | | | | | | | | | | | | |
DB 20 CCAAGCTGAGCACCACCC 1

RESULT 316
US-10-643-801-119/c
; Sequence 119, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 119
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-119

Query Match 0.8%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1385 GGAGTGAACTGACCCAGCC 1404
| | | | | | | | | | | | | | | | | | | | | |
DB 20 GGAGTGAACTGACCCAGCC 1

RESULT 317
US-10-643-801-217
; Sequence 217, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 217
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
US-10-643-801-217

Query Match 0.8%; Score 18.4; DB 1; Length 20;
Best Local Similarity 95.0%; Pred. No. 1.9e+02;
Matches 19; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1171 TCCATGTCGAGGCTCTTC 1190

Db 1 TCCATGCGGAGGCTTCTTC 20

```
RESULT 318
US-10-278-733-24
; Sequence 24, Application US/10278733
; Publication No. US20030100480A1
; GENERAL INFORMATION:
; APPLICANT: Smith, Steven
; APPLICANT: Chen, Hubert
; APPLICANT: Farese, Robert V Jr
; TITLE OF INVENTION: Methods and compositions for modulating
; TITLE OF INVENTION: sebaceous glands
; FILE REFERENCE: UCAL-105C1P4
; CURRENT APPLICATION NUMBER: US/10/278,733
; CURRENT FILING DATE: 2002-10-21
; PRIOR APPLICATION NUMBER: 10/040,315
; PRIOR FILING DATE: 2001-10-29
; PRIOR APPLICATION NUMBER: 09/339,472
; PRIOR FILING DATE: 1999-06-23
; PRIOR APPLICATION NUMBER: 60/107,771
; PRIOR FILING DATE: 1998-11-09
; PRIOR APPLICATION NUMBER: PCT/US98/17883
; PRIOR FILING DATE: 1998-08-28
; PRIOR APPLICATION NUMBER: 09/103,754
; PRIOR FILING DATE: 1998-06-24
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic oligonucleotide primer
US-10-278-733-24
```

```
Query Match
Best Local Similarity 0.7%; Score 17.4; DB 1; Length 19;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 980 CAGAATGCAGTCACCCCTG 998
Db 1 CAAGACGCGAGTCACCCCTG 19

RESULT 319
US-10-643-801-141/c
; Sequence 141, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-141
```

```
Query Match
Best Local Similarity 0.7%; Score 17.4; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2372 CCATGTCAGACTTTGTAT 2390
Db 19 CCATGTCAGACTTTGTAT 1
```

```
RESULT 320
US-10-229-834A-11
; Sequence 11, Application US/10229834A
; Publication No. US20030150003A1
; GENERAL INFORMATION:
; APPLICANT: Lawrence Berkeley National Laboratory
; APPLICANT: Rubin, Edward
; APPLICANT: Pennacchio, Len
; TITLE OF INVENTION: A novel apolipoprotein gene involved in lipid metabolism
; FILE REFERENCE: IB-1709
; CURRENT APPLICATION NUMBER: US/10/229,834A
; CURRENT FILING DATE: 2002-08-27
; PRIOR APPLICATION NUMBER: US 60/318,219
; PRIOR FILING DATE: 2001-08-27
; NUMBER OF SEQ ID NOS: 48
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-229-834A-11
```

```
Query Match
Best Local Similarity 0.7%; Score 17.2; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1173 CATGTCGAGGCTCTCTCTCT 1194
Db 1 CAGGTCGAGGCTCTCTCTCTCT 22
```

```
RESULT 321
US-10-806-782-20/c
; Sequence 20, Application US/10806782
; Publication No. US20040166061A1
; GENERAL INFORMATION:
; APPLICANT: Eberback, Sven
; APPLICANT: Carlsson, Peter
; TITLE OF INVENTION: Animal Model
; FILE REFERENCE: 10806-117A
; CURRENT APPLICATION NUMBER: US/10/806,782
; CURRENT FILING DATE: 2004-03-23
; PRIOR APPLICATION NUMBER: US/09/587,945
; PRIOR FILING DATE: 2000-06-06
; PRIOR APPLICATION NUMBER: US 60/190,692
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/085,380
; PRIOR FILING DATE: 1998-05-26
; PRIOR APPLICATION NUMBER: SE 9701963-2
; PRIOR FILING DATE: 1997-05-26
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: 3' primer
US-10-806-782-20
```

```
Query Match
Best Local Similarity 0.7%; Score 17.2; DB 1; Length 22;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 239 CCTATGCGCGCTACTCCGGG 260
Db 22 CCTATGCGCGCTACTCCGGG 1
```

```
RESULT 322
US-10-349-143-11680
```

```
; Sequence 11680, Application US/10349143
; Publication No. US20040005584A1
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marra
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020C01
; CURRENT APPLICATION NUMBER: US/10/349,143
; PRIOR FILING DATE: 2003-01-21
; PRIOR APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 09/298,850
; PRIOR FILING DATE: EARLIER FILING DATE: 1999-04-21
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/109,732
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-11-23
; PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: US 60/082,614
; PRIOR FILING DATE: EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11680
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..21
; OTHER INFORMATION: downstream amplification primer 99-22404 for SEQ 3815, in complement
US-10-349-143-11680
```

```
Query Match          0.7%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1643 TCTCTTCTTCTCCCTTCTCT 1659
Db      1 TCTCTTCTTCTCCCTTCTCT 17
```

```
RESULT 323
US-09-733-294A-40/c
; Sequence 40, Application US/09733294A
; Patent No. US20020045588A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: William Gaarde
; APPLICANT: Susan W. Freiler
; APPLICANT: Edward V. Manciewicz
; TITLE OF INVENTION: ANTISENSE MODULATION OF TERT EXPRESSION
; FILE REFERENCE: ISPH-0527
; CURRENT APPLICATION NUMBER: US/09/733,294A
; PRIOR FILING DATE: 2000-12-07
; PRIOR APPLICATION NUMBER: 09/572,423
; PRIOR FILING DATE: 2000-05-16
; NUMBER OF SEQ ID NOS: 108
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-733-294A-40
```

```
Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      139 GCGGAGAGCCCTGGCCCCGG 158
Db      20 GTGGAGAGCCCTGGCCCCGG 1
```

```
RESULT 324
US-10-174-175-15/c
```

```
; Sequence 15, Application US/10174175
; Publication No. US20030232440A1
; GENERAL INFORMATION:
; APPLICANT: James Karraas
; APPLICANT: Sue Freiler
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STAT1 EXPRESSION
; FILE REFERENCE: PTS-0032
; CURRENT APPLICATION NUMBER: US/10/174,175
; PRIOR FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 73
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-174-175-15
```

```
Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      588 GGTGCGAGAGTGTCTCAGTG 607
Db      20 GGTGCGAGAGTGTCTCAGTG 1
```

```
RESULT 325
US-10-174-175-52
; Sequence 52, Application US/10174175
; Publication No. US20030232440A1
; GENERAL INFORMATION:
; APPLICANT: James Karraas
; APPLICANT: Sue Freiler
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF STAT1 EXPRESSION
; FILE REFERENCE: PTS-0032
; CURRENT APPLICATION NUMBER: US/10/174,175
; PRIOR FILING DATE: 2002-06-17
; NUMBER OF SEQ ID NOS: 73
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
; OTHER INFORMATION:
US-10-174-175-52
```

```
Query Match          0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 2.5e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      588 GGTGCGAGAGTGTCTCAGTG 607
Db      1 GGTGCGAGAGTGTCTCAGTG 20
```

```
RESULT 326
US-10-818-939-27
; Sequence 27, Application US/10818939
; Publication No. US20050020527A1
; GENERAL INFORMATION:
; APPLICANT: Peters, Thomas
; APPLICANT: Grose, Johannes
; APPLICANT: Schluter, Volker
; APPLICANT: Schauer, Helke
; APPLICANT: Margardt, Andreas
; TITLE OF INVENTION: Spindler-like protein genes, expression
; TITLE OF INVENTION: products, non-human animal model: uses in human metabolic
; FILE REFERENCE: 14851-005001
; CURRENT APPLICATION NUMBER: US/10/818,939
; CURRENT FILING DATE: 2004-04-05
```

```
; PRIOR APPLICATION NUMBER: US 60/550,192
; PRIOR FILING DATE: 2004-03-04
; PRIOR APPLICATION NUMBER: US 60/460,110
; PRIOR FILING DATE: 2003-04-04
; PRIOR APPLICATION NUMBER: US 60/550,800
; PRIOR FILING DATE: 2004-03-05
; PRIOR APPLICATION NUMBER: US 60/538,831
; PRIOR FILING DATE: 2004-01-23
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-10-818-939-27

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1933 CCCCTACCTGACCCCTAGTC 1952
DB 1 CCTCTACCCACCCCTAGTC 20

RESULT 327
US-10-643-801-106/c
; Sequence 106, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 106
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-106

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 427 AGCAGCTACAGCTCATCTCA 446
DB 20 AACAGCTGAGGCTCATCTCA 1

RESULT 328
US-10-643-801-109/c
; Sequence 109, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 109
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-109

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 610 TCCGAACCTGAGGCTGTGG 629
DB 20 TCCGAACCTGAGGCTGTGG 1

RESULT 329
US-10-643-801-113/c
; Sequence 113, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 113
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-113

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1030 TGCCTCATGAGCTGACCTG 1049
DB 20 TGCCTCATGAGCTGACCTG 1

RESULT 330
US-10-643-801-114/c
; Sequence 114, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 114
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-114

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1075 ATGAAGTGTACAGCAGGTG 1094
DB 20 ATGAAGTGTACAGCAGGTG 1

RESULT 331
US-10-643-801-122/c
; Sequence 122, Application US/10643801
```

```
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 122
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-122

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1542 TTTAGAGGAGGAGGAGTCTAGT 1561
DB 20 TTTAGAGGAGGAGGAGTCTAGT 1

RESULT 332
US-10-643-801-215
; Sequence 215, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 215
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
; OTHER INFORMATION:
US-10-643-801-215

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 610 TCGGAACCTGGCGCTGCTGG 629
DB 1 TCGGAACCTGGCGCTGCTGG 20

RESULT 333
US-10-643-801-216
; Sequence 216, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 216
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
; OTHER INFORMATION:
US-10-643-801-216
```

```
Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1075 ATGAGCTGTACAGCAGGTG 1094
DB 1 ATGAGCTGTACAGCAGGTG 20

RESULT 334
US-10-643-801-220
; Sequence 220, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; CURRENT FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 220
; LENGTH: 20
; TYPE: DNA
; ORGANISM: M. musculus
; FEATURE:
; OTHER INFORMATION:
US-10-643-801-220

Query Match
Best Local Similarity 90.0%; Score 16.8; DB 1; Length 20;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1542 TTTAGAGGAGGAGGAGTCTAGT 1561
DB 1 TTTAGAGGAGGAGGAGTCTAGT 20

RESULT 335
US-09-005-243-16
; Sequence 16, Application US/09005243
; Patent No. US20020018763A1
; GENERAL INFORMATION:
; APPLICANT: Zeebo, Kristina M.
; APPLICANT: Boeselman, Robert A.
; APPLICANT: Snuggs, Sidney V.
; APPLICANT: Martin, Francis H.
; TITLE OF INVENTION: Stem Cell Factor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Marshall, O'Toole, Garstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/005,243
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/449,653
; FILING DATE: 24-MAY-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/982,255
; FILING DATE: 25-NOV-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/589,701
```

FILING DATE: 01-OCT-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/34465
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-005-243-16

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAAGTGAGATCC 2421
DB 2 ATTAATGCAAGTGATATCC 21

RESULT 336
US-09-224-683-16
Sequence 16, Application US/09224683
Patent No. US20020031491A1
GENERAL INFORMATION:
APPLICANT: Zeebo, Kristina M.
APPLICANT: Bosseiman, Robert A.
APPLICANT: Suggs, Sidney V.
APPLICANT: Martin, Francis H.
TITLE OF INVENTION: Stem Cell Factor: Composition Claims
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/224,683
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/005,893
FILING DATE: 12-JAN-1998
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/449,653
FILING DATE: 24-MAY-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/982,255

FILING DATE: 25-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/589,701
FILING DATE: 01-OCT-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/35136
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-224-683-16

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAAGTGAGATCC 2421
DB 2 ATTAATGCAAGTGATATCC 21

RESULT 337
US-10-113-916-13
Sequence 13, Application US/10113916
Publication No. US20030186251A1
GENERAL INFORMATION:
APPLICANT: Brookhaven Science Associates
APPLICANT: Dunn, John J.
TITLE OF INVENTION: Genome Sequence Tags
FILE REFERENCE: BSA 02-03
CURRENT APPLICATION NUMBER: US/10/113,916
CURRENT FILING DATE: 2002-04-01
NUMBER OF SEQ ID NOS: 61
SOFTWARE: Patentin version 3.1
SEQ ID NO 13
LENGTH: 21
TYPE: DNA
ORGANISM: Yersinia pestis
FEATURES:
NAME/KEY: misc feature
OTHER INFORMATION: Y. pestis-specific primer
US-10-113-916-13

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 487 CCTGCAGTGCATCTCATG 506
DB 1 CATGCAGTGCATCTCATG 20

RESULT 338
US-10-175-608-16
Sequence 16, Application US/10175608

```
/ Publication No. US20040181044A1
/ GENERAL INFORMATION:
/ APPLICANT: Zeebo, Kristztina M.
/ Boseelman, Robert A.
/ Suggs, Sidney V.
/ Martin, Francis H.
/ TITLE OF INVENTION: Stem Cell Factor
/ NUMBER OF SEQUENCES: 104
/ CORRESPONDENCE ADDRESS:
/ ADDRESS: Marshall, O'Toole, Gerstein, Murray & Bornun
/ STREET: 6300 Sears Tower, 233 South Wacker Drive
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: United States of America
/ ZIP: 60606-6402
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/10/175,608
/ FILING DATE: 16-Oct-2002
/ CLASSIFICATION: <Unknown>
/ PRIORITY APPLICATION DATA:
/ APPLICATION NUMBER: 09/635,249
/ FILING DATE: 07-AUG-2000
/ APPLICATION NUMBER: 09/486,546
/ FILING DATE: 24-MAY-1995
/ APPLICATION NUMBER: 08/172,329
/ FILING DATE: 21-DEC-1993
/ APPLICATION NUMBER: 07/982,255
/ FILING DATE: 25-NOV-1992
/ APPLICATION NUMBER: 07/684,535
/ FILING DATE: 10-APR-1991
/ APPLICATION NUMBER: 09/589,701
/ FILING DATE: 10-OCT-1991
/ APPLICATION NUMBER: 07/573,616
/ FILING DATE: 24-AUG-1990
/ APPLICATION NUMBER: 07/537,198
/ FILING DATE: 11-JUN-1990
/ APPLICATION NUMBER: 07/422,383
/ FILING DATE: 16-OCT-1989
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Clough, David W.
/ REGISTRATION NUMBER: 36,107
/ REFERENCE/DOCKET NUMBER: 01017/35199
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 312/474-6300
/ TELEFAX: 312/474-0448
/ TELEX: <Unknown>
/ INFORMATION FOR SEQ ID NO: 16:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 21 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
/ SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-10-175-608-16

Query Match      0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      2402 ATAAATGAAGTGAATCC 2421
DB      2 ATAAATGACAGTATATTC 21
```

```
RESULT 339
US-10-791-074-13
/ Sequence 13, Application US/10791074
```

```
/ Publication No. US20040219580A1
/ GENERAL INFORMATION:
/ APPLICANT: DUNN, JOHN J.
/ APPLICANT: LELIE, DANIEL VANDER
/ APPLICANT: KRAUSE, MAUREN K.
/ APPLICANT: MCCORMICK, SEAN R.
/ TITLE OF INVENTION: GENOME SEQUENCE TAGS
/ FILE REFERENCE: BSA 02-16
/ CURRENT APPLICATION NUMBER: US/10/791,074
/ PRIOR FILING DATE: 2004-03-02
/ PRIOR APPLICATION NUMBER: 10/113,916
/ PRIOR FILING DATE: 2002-04-01
/ NUMBER OF SEQ ID NOS: 95
/ SOFTWARE: Patent Ver. 3.2
/ SEQ ID NO 13
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-791-074-13

Query Match      0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 2.7e+02;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      487 CCTGCAGTGCCTCTCAGT 506
DB      1 CATGCAGTGCCTCTCAGC 20
```

```
RESULT 340
US-10-620-642-16
/ Sequence 16, Application US/10620642
/ Publication No. US20050080250A1
/ GENERAL INFORMATION:
/ APPLICANT: Zeebo, Kristztina M.
/ Boseelman, Robert A.
/ Suggs, Sidney V.
/ Martin, Francis H.
/ TITLE OF INVENTION: Stem Cell Factor
/ NUMBER OF SEQUENCES: 104
/ CORRESPONDENCE ADDRESS:
/ ADDRESS: Marshall, O'Toole, Gerstein, Murray & Bornun
/ STREET: 6300 Sears Tower, 233 South Wacker Drive
/ CITY: Chicago
/ STATE: Illinois
/ COUNTRY: United States of America
/ ZIP: 60606-6402
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/10/620,642
/ FILING DATE: 16-Jul-2003
/ CLASSIFICATION: <Unknown>
/ PRIORITY APPLICATION DATA:
/ APPLICATION NUMBER: US/10/175,608
/ FILING DATE: 16-Oct-2002
/ APPLICATION NUMBER: 09/635,249
/ FILING DATE: 07-AUG-2000
/ APPLICATION NUMBER: 09/486,546
/ FILING DATE: 24-MAY-1995
/ APPLICATION NUMBER: 08/172,329
/ FILING DATE: 21-DEC-1993
/ APPLICATION NUMBER: 07/982,255
/ FILING DATE: 25-NOV-1992
/ APPLICATION NUMBER: 07/684,535
/ FILING DATE: 10-APR-1991
/ APPLICATION NUMBER: 09/589,701
/ FILING DATE: 10-OCT-1991
```


ORGANISM: RNAi-sense strand
US-10-786-720-2516

Query Match
Best Local Similarity 61.1%; Score 16.4; DB 1; Length 21;
Matches 11; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

2177 AGATCTAGATCTGAT 2194
|||:|||||:|
Db 3 AGAUAUAGAUUCUGAU 20

RESULT 345
US-10-751-736-41385
; Sequence 41385, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 41385
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-41385

Query Match
Best Local Similarity 50.0%; Score 16.4; DB 1; Length 21;
Matches 9; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

Qy 1523 TTACATGTTAGTCTTT 1540
::|::|::|::|::|::|::|
Db 2 UUAUAGUUGAGCCUUU 19

RESULT 346
US-10-751-736-42150
; Sequence 42150, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42150
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-42150

Query Match
Best Local Similarity 50.0%; Score 16.4; DB 1; Length 21;
Matches 9; Conservative 8; Mismatches 1; Indels 0; Gaps 0;

Qy 1523 TTACATGTTAGTCTTT 1540
::|::|::|::|::|::|::|
Db 2 UUAUAGUUGAGCCUUU 19

RESULT 347
US-10-799-369-36
; Sequence 36, Application US/10799369
; Publication No. US20050042629A1
; GENERAL INFORMATION:
; APPLICANT: Applied Biosystems
; APPLICANT: Bolchakova, Elena V.
; APPLICANT: Rozelle, James E.
; TITLE OF INVENTION: A Novel DNA Polymerase from the Thermophilic Thermus scotoductus
; FILE REFERENCE: 1560.002W01
; CURRENT APPLICATION NUMBER: US/10/799,369
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/334489
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 60/322218
; PRIOR FILING DATE: 2000-09-14
; NUMBER OF SEQ ID NOS: 50
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 36
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Thermus scotoductus
US-10-799-369-36

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1322 GGCCCTGGTGAAGCTCTT 1339
|||||:|||||:|
Db 3 GGCCATGATGAAGCTCTT 20

RESULT 348
US-10-800-350-359
; Sequence 359, Application US/10800350
; Publication No. US20050084873A1
; GENERAL INFORMATION:
; APPLICANT: Krasnoperov, Valery
; APPLICANT: Zozulya, Sergey
; APPLICANT: Kertesz, Nathalie
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parakash
; TITLE OF INVENTION: POLYPEPTIDE COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-002
; CURRENT APPLICATION NUMBER: US/10/800,350
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; PRIOR FILING DATE: 2003-03-12
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 359
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-350-359

Query Match
Best Local Similarity 94.4%; Score 16.4; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 227 ACCCATGAAGACCTCAT 244
|||||:|||||:|

Db 4 AGCCATGAAGATCTCAT 21

RESULT 349

US-10-800-077-359
; Sequence 359, Application US/10800077
; Publication No. US20050164965A1
; GENERAL INFORMATION:
; APPLICANT: Reddy, Ramachandra
; APPLICANT: Gill, Parkash
; TITLE OF INVENTION: NUCLEIC ACID COMPOUNDS FOR INHIBITING
; FILE REFERENCE: VASG-P01-001
; CURRENT APPLICATION NUMBER: US/10/800,077
; PRIOR FILING DATE: 2004-03-12
; PRIOR APPLICATION NUMBER: US 60/454,432
; PRIOR FILING DATE: 2003-03-12
; PRIOR APPLICATION NUMBER: US 60/454,300
; NUMBER OF SEQ ID NOS: 396
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 359
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: Oligonucleotide
US-10-800-077-359

Query Match

Best Local Similarity 0.7%; Score 16.4; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 227 AGCCATGAAGATCTCAT 244

Db 4 AGCCATGAAGATCTCAT 21

RESULT 350

US-10-625-152-4
; Sequence 4, Application US/10625152
; Publication No. US20040132776A1
; GENERAL INFORMATION:
; APPLICANT: Agus, David B.
; TITLE OF INVENTION: Use of Benzothienopyridines to Treat and Prevent Prostate Cancer
; FILE REFERENCE: 81476-294295
; CURRENT APPLICATION NUMBER: US/10/625,152
; PRIOR FILING DATE: 2003-07-23
; PRIOR APPLICATION NUMBER: US 10/412,087
; PRIOR FILING DATE: 2002-05-09
; PRIOR APPLICATION NUMBER: US 60/290,307
; PRIOR FILING DATE: 2001-05-10
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-625-152-4

Query Match

Best Local Similarity 0.7%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1327 TGGTGAAGCTCTTCGACGAC 1347

Db 1 TGGTGAAGCTCTTCGACGAC 21

RESULT 351

US-10-786-720-20417

; Sequence 20417, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM101331L)
; CURRENT APPLICATION NUMBER: US/10/786,720
; PRIOR FILING DATE: 2004-02-26
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20417
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-sense strand
US-10-786-720-20417

Query Match

Best Local Similarity 0.7%; Score 16.2; DB 1; Length 21;
Matches 13; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 1716 GGACCAAGTATGATGATCACT 1736

Db 1 GGACCAAGTATGATGATCACT 21

RESULT 352

US-10-751-736-14616/c
; Sequence 14616, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; PRIOR FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 14616
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-14616

Query Match

Best Local Similarity 0.7%; Score 16.2; DB 1; Length 21;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1125 GTCCGAGAGAGTTCAGAAA 1145

Db 21 GTCCGAGAGAGTTCAGAAA 1

RESULT 353

US-10-751-736-15119
; Sequence 15119, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)

```
; CURRENT APPLICATION NUMBER: US/10/751.736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 15119
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-15119

Query Match
Best Local Similarity 71.4%; Pred. No. 2.9e+02;
Matches 15; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 995 CTTGGGAGACCGCAGGCGCTT 1015
DB 1 CCUGCUGAGACCCUACUGGCUU 21

RESULT 354
US-10-751-736-19221/c
; Sequence 19221, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751.736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19221
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-19221

Query Match
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 768 GAAGTGAGCAAGACTCCCA 788
DB 21 GAAGTGAGCAAGAGGTCCAA 1

RESULT 355
US-10-751-736-42616
; Sequence 42616, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751.736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 42616
```

```
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-42616

Query Match
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1130 GAGAGACTCCGGAATACAT 1150
DB 1 GAGAGACTCCGGAATACAT 21

RESULT 356
US-10-751-736-43132
; Sequence 43132, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43132
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-43132

Query Match
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1692 AAGAGATTGCCATTAGTGA 1712
DB 1 AAGAGATTGCCATTAGTGA 21

RESULT 357
US-10-751-736-43411
; Sequence 43411, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751.736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43411
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-43411

Query Match
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1692 AAGAGATTGCCATTAGTGA 1712
DB 1 AAGAGATTGCCATTAGTGA 21

RESULT 357
US-10-751-736-43411
; Sequence 43411, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US/10/751.736
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 43411
; LENGTH: 21
; TYPE: DNA
; ORGANISM: homo sapiens
US-10-751-736-43411

Query Match
Best Local Similarity 85.7%; Pred. No. 2.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1691 GAAGAAGATTGCATTAGTG 1711

Db 1 GAAGAAAGCTTGCAATTAGTG 21

RESULT 358

US-10-712-672-391
; Sequence 391, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Chowitra, Bharat
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH00-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 391
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-391

Query Match 0.7%; Score 16; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 2.5e+02;
Matches 15; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 143 GAAGCCCTGGCCCCGG 158

Db 2 GAAGCCCTGGCCCCGG 17

RESULT 359

US-10-483-289A-25/c
; Sequence 25, Application US/10483289A
; Publication No. US20050048466A1
; GENERAL INFORMATION:
; APPLICANT: Qian, Qijun
; TITLE OF INVENTION: A specific proliferation in tumour cell which can express
; FILE REFERENCE: IEC020038PUS
; CURRENT APPLICATION NUMBER: US/10/483,289A
; CURRENT FILING DATE: 2004-01-09
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 25
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: oligonucleotide
US-10-483-289A-25

Query Match 0.7%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 143 GAAGCCCTGGCCCCGG 158

Db 19 GAAGCCCTGGCCCCGG 4

RESULT 360
US-10-180-781-80/c

; Sequence 80, Application US/10180781

; Publication No. US2003018080A1

; GENERAL INFORMATION:

; APPLICANT: Tanzi, Rudolph E.

; Masco, Wilma

; Schellenberg, Gerard D.

; Levy-Lahad, Ephrat

; Bird, Thomas D.

; Galae, David J.

; TITLE OF INVENTION: CHROMOSOME 1 GENE AND GENE PRODUCTS RELATED TO

ALZHEIMER'S DISEASE

NUMBER OF SEQUENCES: 88

CORRESPONDENCE ADDRESS:

ADDRESSES: Seed Intellectual Property Law Group PLLC

STREET: 701 Fifth Ave, Suite 6300

CITY: Seattle

STATE: Washington

COUNTRY: USA

ZIP: 98104-7092

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/10/180,781

FILING DATE: 24-Jun-2002

CLASSIFICATION: <Unknown>

ATTORNEY/AGENT INFORMATION:

NAME: Potter, Jane E. R.

REGISTRATION NUMBER: 33,332

REFERENCE/DOCKET NUMBER: 920010.571C2

TELECOMMUNICATION INFORMATION:

TELEPHONE: (206) 622-4900

TELEFAX: (206) 682-6031

INFORMATION FOR SEQ ID NO: 80:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 80:

US-10-180-781-80

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.9e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1842 CCAAGGAGAGGAGCTGAG 1860

Db 19 CCAAGGAGAGGAGCTGAG 1

RESULT 361

US-08-771-737-8/c
; Sequence 8, Application US/08771737
; Publication No. US20010006796A1
; GENERAL INFORMATION:
; APPLICANT: Briggs, Clark A.
; APPLICANT: Gopalakrishnan, Murali
; APPLICANT: McKenna, David G.
; APPLICANT: Monteggia, Lisa M.
; APPLICANT: Roch, Jean-Marie
; APPLICANT: Sullivan, James P.
; APPLICANT: Touma, Edward
; APPLICANT: Abbott Laboratories
; TITLE OF INVENTION: A VARIANT HUMAN ALPHA 7 ACETYLCHOLINE
; FILE REFERENCE: 6017.US.01
; CURRENT APPLICATION NUMBER: US/08/771,737
; CURRENT FILING DATE: 1996-12-20

; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapien
US-08-771-737-8

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 GGCACCTTCGAAATGCCTG 837
DB 20 GGCACCTTCGAAATGCCTG 2

RESULT 362
US-09-954-936-8/c
; Sequence 8, Application US/09954936
; Publication No. US20030073161A1
; GENERAL INFORMATION:
; APPLICANT: Briggs, Clark A.
; APPLICANT: Gopalakrishnan, Murali
; APPLICANT: McKenna, David G.
; APPLICANT: Monteggia, Lisa M.
; APPLICANT: Roch, Jean-Marc
; APPLICANT: Sullivan, James P.
; APPLICANT: Touma, Edward
; APPLICANT: Abbott Laboratories
; TITLE OF INVENTION: A VARIANT HUMAN ALPHA 7 ACETYLCHOLINE
; TITLE OF INVENTION: RECEPTOR SUBUNIT, AND METHODS OF PRODUCTION AND USES THEREOF
; FILE REFERENCE: 6017 US. 01
; CURRENT APPLICATION NUMBER: US/09/954,936
; CURRENT FILING DATE: 2001-09-18
; PRIOR APPLICATION NUMBER: 08/771,737
; PRIOR FILING DATE: 1996-12-20
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapien
US-09-954-936-8

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 819 GGCACCTTCGAAATGCCTG 837
DB 20 GGCACCTTCGAAATGCCTG 2

RESULT 363
US-09-972-607-12
; Sequence 12, Application US/09972607
; Publication No. US20030105037A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/09/972,607
; CURRENT FILING DATE: 2001-10-06
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-972-607-12

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2278 CCTCACTTCTGTGTCCTT 2296
DB 1 CCTCACTTCTGTGTCCTT 19

RESULT 364
US-10-376-566-63
; Sequence 63, Application US/10376566
; Publication No. US20030158144A1
; GENERAL INFORMATION:
; APPLICANT: Kenneth W. Doble
; APPLICANT: Mark P. Roach
; APPLICANT: Erich Koeller
; TITLE OF INVENTION: ANTISENSE MODULATION OF ESTROGEN RECEPTOR BETA EXPRESSION
; FILE REFERENCE: RTS-0347
; CURRENT APPLICATION NUMBER: US/10/376,566
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: US/10/005,058
; PRIOR FILING DATE: 2001-12-07
; NUMBER OF SEQ ID NOS: 96
; SEQ ID NO 63
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-376-566-63

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1316 CATGAGGCGCTGTGTAAG 1334
DB 1 CATGAGGCGCTGTGTAAG 19

RESULT 365
US-10-455-229-22
; Sequence 22, Application US/10455229
; Publication No. US20040016030A1
; GENERAL INFORMATION:
; APPLICANT: LOME, BRENDA A.
; APPLICANT: CHOMET, PAUL
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR PRODUCTION OF MAIZE LINES
; FILE REFERENCE: DEM:195US
; CURRENT APPLICATION NUMBER: US/10/455,229
; CURRENT FILING DATE: 2003-06-05
; PRIOR APPLICATION NUMBER: 60/386,522
; PRIOR FILING DATE: 2002-06-06
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-10-455-229-22

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1641 CCTCTCTCTCTCCCTTCCCT 1659
|||||

Db 1 CCTCTCTGACCCCTTCCT 19

RESULT 366
US-10-628-841-12
; Sequence 12, Application US/10628841
; Publication No. US20040023918A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Jacqueline Wyatt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INHIBITOR-KAPPA B KINASE-GAMMA EXPRESSION
; FILE REFERENCE: RTS-0191
; CURRENT APPLICATION NUMBER: US/10/628,841
; PRIOR FILING DATE: 2003-07-28
; PRIOR APPLICATION NUMBER: US/09/972,607
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-628-841-12

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2;

Qy 2278 CCTCACTTCTCTGTGCGCTT 2296
Db 1 CCTCACTTCTCTGTGCGCTT 19

RESULT 367
US-10-749-075-8/c
; Sequence 8, Application US/10749075
; Publication No. US2004020303A1
; GENERAL INFORMATION:
; APPLICANT: Briggs, Clark A.
; APPLICANT: Gopalakrishnan, Murali
; APPLICANT: McKenna, David G.
; APPLICANT: Monteggia, Lisa M.
; APPLICANT: Roch, Jean-Marc
; APPLICANT: Sullivan, James P.
; APPLICANT: Touma, Edward
; APPLICANT: Abbott Laboratories
; TITLE OF INVENTION: A VARIANT HUMAN ALPHA 7 ACETYLCHOLINE
; FILE REFERENCE: 6017, US. 01
; CURRENT APPLICATION NUMBER: US/10/749,075
; PRIOR FILING DATE: 2003-12-30
; PRIOR APPLICATION NUMBER: US/08/771,737
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapien
US-10-749-075-8

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2;

Qy 819 GCGCACTTCGAATGCGCTG 837
Db 20 GCGAGCTCGAATGCGCTG 2

RESULT 368
US-10-643-801-111/c

; Sequence 111, Application US/10643801
; Publication No. US20050043524A1
; GENERAL INFORMATION:
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
; FILE REFERENCE: RTS-0678US
; CURRENT APPLICATION NUMBER: US/10/643,801
; PRIOR FILING DATE: 2003-08-18
; NUMBER OF SEQ ID NOS: 230
; SEQ ID NO 111
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-111

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2;

Qy 865 GTATCTGCCCTGTCAACCG 883
Db 20 GCATCTGCCCTGTCAACCG 2

RESULT 369
US-10-257-158A-6237/c
; Sequence 6237, Application US/10257158A
; Publication No. US20050142543A1
; GENERAL INFORMATION:
; APPLICANT: Barany, Francis
; APPLICANT: Zilvi, Monib
; APPLICANT: Gerry, Norman P.
; APPLICANT: Favis, Reyna
; APPLICANT: Kliman, Richard
; TITLE OF INVENTION: METHOD OF DESIGNING ADDRESSABLE ARRAY FOR DETECTION OF NUCLEIC AC
; FILE REFERENCE: 19603/2834
; CURRENT APPLICATION NUMBER: US/10/257,158A
; PRIOR FILING DATE: 2002-10-07
; PRIOR APPLICATION NUMBER: PCT/US01/10958
; PRIOR FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: US 60/197,271
; NUMBER OF SEQ ID NOS: 9544
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6237
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Hypothetical Probe Sequence
US-10-257-158A-6237

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 3e+02; 2; Indels 0; Gaps 0;
Matches 17; Conservative 0; Mismatches 2;

Qy 1113 TGGGGCGATGCTCCAGA 1131
Db 19 TGGGGCTGATGCTCCAGA 1

RESULT 370
US-10-432-422-20/c
; Sequence 20, Application US/10432422
; Publication No. US20040076981A1
; GENERAL INFORMATION:
; APPLICANT: Syngenta Participations AG
; APPLICANT: Corneil Research Foundation, Inc.
; APPLICANT: Yoder, Olen

```
/ APPLICANT: Turgeon, Barbara G.
/ APPLICANT: Lu, Shen-wen
/ TITLE OF INVENTION: Fungal Iron Reductase Gene
/ FILE REFERENCE: 1360.017M01
/ CURRENT APPLICATION NUMBER: US/10/432,422
/ PRIOR FILING DATE: 2003-05-21
/ PRIOR APPLICATION NUMBER: US 60/252,732
/ PRIOR FILING DATE: 2000-11-22
/ PRIOR APPLICATION NUMBER: US 60/252,649
/ PRIOR FILING DATE: 2000-11-22
/ NUMBER OF SEQ ID NOS: 210
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 20
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Primer
US-10-432-422-20

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      510 ATATCTGCACTGATGCT 528
Db      20 ATGCTCTGCACTGATGCT 2

RESULT 371
US-10-786-720-12520
/ Sequence 12520, Application US/10786720
/ Publication No. US20040191818A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: O'Toole, Margot
/ APPLICANT: Liu, Wei
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
/ FILE REFERENCE: 031896-023000 (AM101331L)
/ CURRENT APPLICATION NUMBER: US/10/786,720
/ CURRENT FILING DATE: 2004-02-26
/ NUMBER OF SEQ ID NOS: 21135
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 12520
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-786-720-12520

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2343 TTCTGTATCTCTTGATGA 2361
Db      3 TTCTGTAACTCTTGAGA 21

RESULT 372
US-10-786-720-12521
/ Sequence 12521, Application US/10786720
/ Publication No. US20040191818A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: O'Toole, Margot
/ APPLICANT: Liu, Wei
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
/ FILE REFERENCE: 031896-023000 (AM101331L)
/ CURRENT APPLICATION NUMBER: US/10/786,720
/ CURRENT FILING DATE: 2004-02-26
/ NUMBER OF SEQ ID NOS: 21135
```

```
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 12521
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: RNAi-sense strand
US-10-786-720-12521

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 47.4%; Pred. No. 3.1e+02;
Matches 9; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

QY      2343 TTCTGTATCTCTTGATGA 2361
Db      1 UUCUGUAAUCUCUGAGA 19

RESULT 373
US-10-786-720-12522/c
/ Sequence 12522, Application US/10786720
/ Publication No. US20040191818A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: O'Toole, Margot
/ APPLICANT: Liu, Wei
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
/ FILE REFERENCE: 031896-023000 (AM101331L)
/ CURRENT APPLICATION NUMBER: US/10/786,720
/ CURRENT FILING DATE: 2004-02-26
/ NUMBER OF SEQ ID NOS: 21135
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 12522
/ LENGTH: 21
/ TYPE: RNA
/ ORGANISM: RNAi-antisense strand
US-10-786-720-12522

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2343 TTCTGTATCTCTTGATGA 2361
Db      19 TTCTGTAACTCTTGAGA 1

RESULT 374
US-10-786-720-20416
/ Sequence 20416, Application US/10786720
/ Publication No. US20040191818A1
/ GENERAL INFORMATION:
/ APPLICANT: Wyeth
/ APPLICANT: O'Toole, Margot
/ APPLICANT: Liu, Wei
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
/ FILE REFERENCE: 031896-023000 (AM101331L)
/ CURRENT APPLICATION NUMBER: US/10/786,720
/ CURRENT FILING DATE: 2004-02-26
/ NUMBER OF SEQ ID NOS: 21135
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 20416
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-786-720-20416

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1716 GGACGAGTAGATGATTC 1734
Db      1716 GGACGAGTAGATGATTC 1734
```

```
Db          3  GGATCAGTGAGATGATTCA 21

RESULT 375
US-10-786-720-20418/c
; Sequence 20418, Application US/10786720
; Publication No. US20040191818A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: O'Toole, Margot
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE
; FILE REFERENCE: 031896-023000 (AM1013311)
; CURRENT APPLICATION NUMBER: US/10/786,720
; CURRENT FILING DATE: 2004-02-26
; NUMBER OF SEQ ID NOS: 21135
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 20418
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi-antisense strand
US-10-786-720-20418

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY          1716  GGACCACTTAGATGATTCA 1734
Db          19  GGATCAGTGAGATGATTCA 1

RESULT 376
US-10-751-736-18485/c
; Sequence 18485, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 18485
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-18485

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 3.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY          2127  AGCCTTGCCCTGGAGACCA 2145
Db          20  AGCCTTGCCCTGGATCACA 2

RESULT 377
US-10-751-736-40402
; Sequence 40402, Application US/10751736
; Publication No. US20040265230A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Martinez, Robert
; APPLICANT: Brown, Eugene
; APPLICANT: Liu, Wei
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
; FILE REFERENCE: AM100927 (031896-002000)
; CURRENT APPLICATION NUMBER: US/10/751,736
; CURRENT FILING DATE: 2003-01-06
; PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
; PRIOR FILING DATE: 2003-01-06
; NUMBER OF SEQ ID NOS: 54873
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 42617
; LENGTH: 21
; TYPE: RNA
; ORGANISM: RNAi
US-10-751-736-42617

Query Match          0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 68.4%; Pred. No. 3.1e+02;
Matches 13; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY          1133  GAAGTCCGAAATACATT 1151
Db          2  GAAGTCCGGAATACATU 20

RESULT 379
US-10-847-918-12719
; Sequence 12719, Application US/10847918
; Publication No. US20050119210A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Be, Xiaobing
; APPLICANT: Liu, Wei
; APPLICANT: Slonim, Donna
; APPLICANT: Howes, Steve
; TITLE OF INVENTION: Compositions and Methods for Diagnosing and Treating Cancers
; FILE REFERENCE: 031896-026000 (AM101264)
; CURRENT APPLICATION NUMBER: US/10/847,918
; CURRENT FILING DATE: 2004-05-19
```


PRIOR APPLICATION NUMBER: US 60/471,729
PRIOR FILING DATE: 2003-05-20
NUMBER OF SEQ ID NOS: 14937
SOFTWARE: PatentIn version 3.2
SEQ ID NO 12719
LENGTH: 21
TYPE: RNA
ORGANISM: RNAI-sense strand
US-10-847-918-12719

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 57.9%; Pred. No. 3.1e+02;
Matches 11; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1185 CTCTTCTCCCTCCGACCT 1203
DB 2 CUCUCUCUCUCUCUCUCU 20

RESULT 380

US-09-866-108-2021
Sequence 2021, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 2021
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2021

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 731 CCGGCTGCTCTGCA 747
DB 1 CCGGCTGCTCTGCA 17

RESULT 381

US-09-866-108-2842
Sequence 2842, Application US/09866108
Patent No. US20020048800A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOMICA-7
CURRENT APPLICATION NUMBER: US/09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00662
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00661
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00670
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: US 60/234,687
PRIOR FILING DATE: 2000-09-21
PRIOR APPLICATION NUMBER: US 60/266,860
PRIOR FILING DATE: 2001-02-05
NUMBER OF SEQ ID NOS: 15752
SOFTWARE: Aeomica Sequence Listing Engine
SEQ ID NO 2842
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108-2842

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1974 GGCCTCAGATAGGA 1990
DB 1 GGCCTCAGATAGGA 17

RESULT 382

```
US-10-238-700-2/c
; Sequence 2, Application US/10238700
; Publication No. US20030153521A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwigen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/057 (MH801-1158-A)
; CURRENT APPLICATION NUMBER: US/10/238,700
; CURRENT FILING DATE: 2002-09-18
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2
```

```
Query Match      0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      16 CGCGCGCGCTGCGCGCT 32
      |||||
Db      17 CGCGCGCGCGCGCGCT 1
```

```
RESULT 383
US-10-712-672-390
; Sequence 390, Application US/10712672
; Publication No. US20040102413A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Chowrita, Bharat
; APPLICANT: MCSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme
; FILE REFERENCE: MBH800-882-C (400/019)
; CURRENT APPLICATION NUMBER: US/10/712,672
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US/09/653,225
; PRIOR FILING DATE: 2000-08-31
; PRIOR APPLICATION NUMBER: 60/197,769
; PRIOR FILING DATE: 2000-04-14
; PRIOR APPLICATION NUMBER: 60/150,713
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 5586
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 390
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-712-672-390
```

```
Query Match      0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 2.8e+02;
Matches 15; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      141 GCGAGCCTGCGCCCG 157
      |||||
Db      1 GGGAGCCCGGCCCG 17
```

```
RESULT 384
US-10-723-361-2021
; Sequence 2021, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```

```
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AT
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 2021
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-2021
```

```
Query Match      0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.8e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      731 CCTGCTGCTTCTGCA 747
      |||||
Db      1 CCTGCTGCTTCTGCA 17
```

```
RESULT 385
US-10-723-361-2842
; Sequence 2842, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AT
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; SEQ ID NO 2842
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-723-361-2842

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1974 GGCCTCGAGGATGAGCA 1990
Db 1 GGCCTCGAGGATGAGCA 17

RESULT 386
US-10-498-462-1757
; Sequence 1757, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; PRIOR FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecmca Sequence Listing Engine
; SEQ ID NO 1757
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-498-462-1757

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

725 CATTGGGCTGGGTCCT 741
Db 1 CATTGGGCTGGGTCCT 17

RESULT 387
US-10-498-462-1759
; Sequence 1759, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; PRIOR FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
```

```
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecmca Sequence Listing Engine
; SEQ ID NO 1759
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-498-462-1759

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

727 TGGCGCTGGGTCCTTC 743
Db 1 TGGCGCTGGGTCCTTC 17

RESULT 388
US-10-724-270-2/c
; Sequence 2, Application US/10724270
; Publication No. US20050080031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MBHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-10-724-270-2

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

16 CGCGCGGCTGCCGCT 32
Db 17 CGCGCGGCTGCCGCT 1

RESULT 389
US-10-353-461-2
; Sequence 2, Application US/10353461
; Publication No. US20030176682A1
; GENERAL INFORMATION:
```

```
/ APPLICANT: Vlaams Internationaal Instituut voor Biotechnol
/ TITLE OF INVENTION: Molecular characterization of chromosome translocation
/ TITLE OF INVENTION: t(11;18) (q21;q21) and its correlation to
/ TITLE OF INVENTION: carcinogenesis
/ FILE REFERENCE: PMA/MALT/V043
/ CURRENT APPLICATION NUMBER: US/10/353,461
/ CURRENT FILING DATE: 2003-01-26
/ PRIOR APPLICATION NUMBER: US/09/579,692
/ PRIOR FILING DATE: 2000-05-26
/ PRIOR APPLICATION NUMBER: 60/138,834
/ PRIOR FILING DATE: 1999-06-09
/ NUMBER OF SEQ ID NOS: 56
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 2
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: primer MLTr1
US-10-353-461-2

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 20;
Pred. No. 3.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 739 CCTTGTGCACTTCAGC 755
DB 1 CCTTGTGCACTTCATC 17

RESULT 390
US-10-303-266-15
/ Sequence 15, Application US/10303266
/ Publication No. US20040101848A1
/ GENERAL INFORMATION:
/ APPLICANT: Donna T. Ward
/ APPLICANT: Alexander H. Borchers
/ APPLICANT: Kenneth W. Doble
/ TITLE OF INVENTION: MODULATION OF GLUCOSE TRANSPORTER-4 EXPRESSION
/ FILE REFERENCE: RTS-0426
/ CURRENT APPLICATION NUMBER: US/10/303,266
/ CURRENT FILING DATE: 2002-11-23
/ NUMBER OF SEQ ID NOS: 157
/ SEQ ID NO 15
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-303-266-15

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 20;
Pred. No. 3.2e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1219 ACTCCAGCCCATCACC 1235
DB 2 ACTCCAGCCCATCACC 18

RESULT 391
US-10-874-242-13/C
/ Sequence 13, Application US/10874242
/ Publication No. US20050026252A1
/ GENERAL INFORMATION:
/ APPLICANT: ESTES, SCOTT
/ APPLICANT: ZHANG, WEIQION
/ TITLE OF INVENTION: NOVEL PROMOTERS AND USES THEREOF
/ FILE REFERENCE: 07680.0027-00000
/ CURRENT APPLICATION NUMBER: US/10/874,242
/ CURRENT FILING DATE: 2004-06-24
/ PRIOR APPLICATION NUMBER: 60/480,768
/ PRIOR FILING DATE: 2003-06-24
```

```
/ NUMBER OF SEQ ID NOS: 41
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 13
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: reverse primer for rps21
US-10-874-242-13

Query Match
Best Local Similarity 0.6%; Score 15.4; DB 1; Length 20;
Pred. No. 3.2e+02;
Matches 16; Conservative 1; Indels 0; Gaps 0;

QY 2402 ATTAATGAAGTGAGAA 2418
DB 17 ATTAATGAAGTGAGAA 1

RESULT 392
US-09-373-938-10
/ Sequence 10, Application US/09373938
/ Publication No. US20020115202A1
/ GENERAL INFORMATION:
/ APPLICANT: Hallenbeck, Paul
/ APPLICANT: Chen, Cheayun Theresa
/ TITLE OF INVENTION: ADENO VIRAL VECTORS INCLUDING DNA SEQUENCES ENCODING ANGIOGENIC IN
/ FILE REFERENCE: 4-30899P1
/ CURRENT APPLICATION NUMBER: US/09/373,938
/ CURRENT FILING DATE: 1999-08-13
/ NUMBER OF SEQ ID NOS: 17
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 10
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Primer
US-09-373-938-10

Query Match
Best Local Similarity 0.6%; Score 15.2; DB 1; Length 20;
Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 518 CACTGATTGCTGGCTCATCG 537
DB 1 CACTGTTACTGGCTTATCG 20

RESULT 393
US-09-784-674-552/C
/ Sequence 552, Application US/09784674
/ Publication No. US20030054346A1
/ GENERAL INFORMATION:
/ APPLICANT: Shannon, Karen W.
/ APPLICANT: Wolber, Paul K.
/ APPLICANT: Delenstater, Glenda C.
/ APPLICANT: Webb, Peter G.
/ APPLICANT: Kincaid, Robert H.
/ TITLE OF INVENTION: Methods for evaluating oligonucleotide
/ probe sequences
/ NUMBER OF SEQUENCES: 1165
/ CORRESPONDENCE ADDRESS:
/ ADDRESS: Records Manager, Legal Department, Hewlett-Packard
/ STREET: 3000 Hanover Street
/ CITY: Palo Alto
/ STATE: CA
/ COUNTRY: USA
/ ZIP: 94304
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
```

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/784,674
FILING DATE: 15-Feb-2001
CLASSIFICATION: No. US20030054346A1 available
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/021,701
FILING DATE: 10-FEB-1998
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 552:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 552:
US-09-784-674-552

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1543 TAAAGAGAAAGTCACTA 1562
DB 20 TAAAAAGAAAAATCAGTA 1

RESULT 394
US-09-784-674-553/c
Sequence 553, Application US/09784674
Publication No. US20030054346A1
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
Molber, Paul K.
Delensfair, Glenda C.
Webb, Peter G.
Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
probe sequences
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
Company M/S 2080
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/784,674
FILING DATE: 15-Feb-2001
CLASSIFICATION: No. US20030054346A1 available
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/021,701
FILING DATE: 10-FEB-1998
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697

REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 553:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 553:
US-09-784-674-553

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1542 TTAAGAGAAAGTCACT 1561
DB 20 TAAAAAGAAAAATCAGT 1

RESULT 395
US-10-080-797-8
Sequence 8, Application US/10080797
Publication No. US20020183253A1
GENERAL INFORMATION:
APPLICANT: Dixon, Katherine H.
Applicant: Brazzell, Romulus K.
TITLE OF INVENTION: METHOD FOR TREATING OCULAR
FILE REFERENCE: 4-31881A
CURRENT APPLICATION NUMBER: US/10/080,797
CURRENT FILING DATE: 2002-02-21
NUMBER OF SEQ ID NOS: 21
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 8
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PCR Primer
US-10-080-797-8

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 518 CACTGATTCGTGCTATCG 537
DB 1 CACTGCTACTGCTATCG 20

RESULT 396
US-10-057-550-80/c
Sequence 80, Application US/10057550
Publication No. US20030032607A1
GENERAL INFORMATION:
APPLICANT: Monla, Brett P.
TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
FILE REFERENCES:
CURRENT APPLICATION NUMBER: US/10/057,550
CURRENT FILING DATE: 2002-01-25
PRIOR APPLICATION NUMBER: 09/506,073
PRIOR FILING DATE: 2000-02-18
PRIOR APPLICATION NUMBER: US 09/143,214
PRIOR FILING DATE: 1998-08-28
PRIOR APPLICATION NUMBER: PCT/US98/13961
PRIOR FILING DATE: 1998-07-06

```
; PRIOR APPLICATION NUMBER: US 08/888,982
; PRIOR FILING DATE: 1997-07-07
; PRIOR APPLICATION NUMBER: US 08/756,806
; PRIOR FILING DATE: 1996-11-26
; PRIOR APPLICATION NUMBER: PCT/US95/07111
; PRIOR FILING DATE: 1995-05-31
; PRIOR APPLICATION NUMBER: US 08/250,856
; PRIOR FILING DATE: 1994-05-31
; NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-10-057-550-80
```

```
Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1873 CCGTGTGTGAGGCGCAGTAG 1892
Db      20  CAGTGTGTGAGGCGCAGCAG 1
```

```
RESULT 397
US-10-037-182-22/c
; Sequence 22, Application US/10037182
; Publication No. US20030044899A1
; GENERAL INFORMATION:
; APPLICANT: Trygsvason, Karl
; APPLICANT: Doi, Masayuki
; APPLICANT: Thyboll, Jilil
; TITLE OF INVENTION: Recombinant Laminin 10
; FILE REFERENCE: 99-274-F
; CURRENT APPLICATION NUMBER: US/10/037,182
; CURRENT FILING DATE: 2001-12-21
; PRIOR APPLICATION NUMBER: 60/257,449
; PRIOR FILING DATE: 2000-12-21
; PRIOR FILING DATE: 2001-03-28
; PRIOR APPLICATION NUMBER: 60/279,282
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Primer Bact
US-10-037-182-22
```

```
Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      450 CTCGAGTGGTCTCTGCTT 469
Db      20  CCCGAGTGATCTCTGCCCTT 1
```

```
RESULT 398
US-10-045-360-16
; Sequence 16, Application US/10045360
; Publication No. US20030138781A1
; GENERAL INFORMATION:
; APPLICANT: Whitehead, Alexander Steven
; TITLE OF INVENTION: METHODS FOR DETERMINING STEROID RESPONSIVENESS
; FILE REFERENCE: UPA-008
; CURRENT APPLICATION NUMBER: US/10/045,360
; CURRENT FILING DATE: 2002-01-22
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR mutagenesis primer GREIF
US-10-045-360-16
```

```
Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1634 CAGCTAACCCTCTCTTCC 1653
Db      1  CAGCAAACTCTCTGTCCC 20
```

```
RESULT 399
US-10-176-277-16/c
; Sequence 16, Application US/10176277
; Publication No. US2003023243A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CENTROMERE PROTEIN B EXPRESSION
; FILE REFERENCE: HTS-0022
; CURRENT APPLICATION NUMBER: US/10/176,277
; CURRENT FILING DATE: 2002-06-18
; NUMBER OF SEQ ID NOS: 77
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-176-277-16
```

```
Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      1121 ATGGGTCGAGAAGATTCC 1140
Db      20  AGGCTCCAGAAAGATGCC 1
```

```
RESULT 400
US-10-176-277-20/c
; Sequence 20, Application US/10176277
; Publication No. US2003023243A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CENTROMERE PROTEIN B EXPRESSION
; FILE REFERENCE: HTS-0022
; CURRENT APPLICATION NUMBER: US/10/176,277
; CURRENT FILING DATE: 2002-06-18
; NUMBER OF SEQ ID NOS: 77
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-10-176-277-20
```

```
Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
QY      308 TCACGAGGACCTGGCTGT 327
Db      20  TCACGAGGACCTGCACCTT 1
```

RESULT 401
US-10-176-277-53
; Sequence 53, Application US/10176277
; Publication No. US20030232443A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CENTROMERE PROTEIN B EXPRESSION
; FILE REFERENCE: HTS-0022
; CURRENT APPLICATION NUMBER: US/10/176,277
; CURRENT FILING DATE: 2002-06-18
; NUMBER OF SEQ ID NOS: 77
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-176-277-53
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1121 ATGGGTCAGAGAGATTCC 1140
DB 1 AGGCTTCAGAGAGGCTTC 20
RESULT 402
US-10-176-277-56
; Sequence 56, Application US/10176277
; Publication No. US20030232443A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Kenneth W. Dobie
; TITLE OF INVENTION: ANTISENSE MODULATION OF CENTROMERE PROTEIN B EXPRESSION
; FILE REFERENCE: HTS-0022
; CURRENT APPLICATION NUMBER: US/10/176,277
; CURRENT FILING DATE: 2002-06-18
; NUMBER OF SEQ ID NOS: 77
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-176-277-56
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 308 TCACGAGAGACTGCGCTGT 327
DB 1 TCACGAGAGCGCCCTGCACCTT 20
RESULT 403
US-10-186-157-76
; Sequence 76, Application US/10186157
; Publication No. US20040002151A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Walt
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF SILENPHOSPHATE SYNTHETASE 2 EXPRESSION
; FILE REFERENCE: RTS-0193
; CURRENT APPLICATION NUMBER: US/10/186,157
; CURRENT FILING DATE: 2002-06-28
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 76
; LENGTH: 20
; TYPE: DNA

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-186-157-76
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1548 AGGAAAGTCATATTTC 1567
DB 1 AGGAAAGCGCACTACTTCA 20
RESULT 404
US-10-289-762-3356
; Sequence 3356, Application US/10289762
; Publication No. US20040006218A1
; GENERAL INFORMATION:
; APPLICANT: Griffiths, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragment thereof and uses thereof, in particular for the diagnosis, prev.
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/10/289,762
; CURRENT FILING DATE: 2003-03-27
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3356
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-10-289-762-3356
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 386 CCTCTCTCTGTCACCTGCG 405
DB 1 CCTCTCTCTATCAGCTTC 20
RESULT 405
US-10-210-838-36
; Sequence 36, Application US/10210838
; Publication No. US20040023905A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Dobie
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF LAR EXPRESSION
; FILE REFERENCE: PTS-0013
; CURRENT APPLICATION NUMBER: US/10/210,838
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 198
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-210-838-36
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1986 GAGATGGGGGTGGCAATGA 2005
DB 1 GAGATGGCGCATGACATGA 20

RESULT 406
US-10-210-838-141/c
; Sequence 141, Application US/10210838
; Publication No. US20040023905A1
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Sanjay Bhanot
; APPLICANT: Kenneth W. Doble
; APPLICANT: Susan M. Freiler
; TITLE OF INVENTION: ANTISENSE MODULATION OF LAR EXPRESSION
; FILE REFERENCE: PTS-0013
; CURRENT APPLICATION NUMBER: US/10/210,838
; CURRENT FILING DATE: 2002-07-31
; NUMBER OF SEQ ID NOS: 198
; SEQ ID NO 141
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-210-838-141

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1986 GAGGATGGGGTGGCAATGA 2005
DB 20 GAGGATGGCGATGACATGA 1

RESULT 407
US-10-348-346-16
; Sequence 16, Application US/10348346
; Publication No. US20040072181A1
; GENERAL INFORMATION:
; APPLICANT: Whitehead, Alexander Steven
; APPLICANT: Chailberg, Sharon S.
; APPLICANT: Lazar, James G.
; TITLE OF INVENTION: METHODS FOR DETERMINING DRUG RESPONSIVENESS
; FILE REFERENCE: UPA-009
; CURRENT APPLICATION NUMBER: US/10/348,346
; CURRENT FILING DATE: 2003-04-22
; PRIOR APPLICATION NUMBER: US 10/045,360
; PRIOR FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: US 60/370,008
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR mutagenesis primer GREIF
US-10-348-346-16

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1634 CAGCTAAGCTCTCTTCTTCC 1653
DB 1 CAGCAAACTCTCTTGTCCC 20

RESULT 408
US-10-273-826-24/c
; Sequence 24, Application US/10273826
; Publication No. US20040077083A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF HISTONE DEACETYLASE 4 EXPRESSION
; FILE REFERENCE: RTS-0161

; CURRENT APPLICATION NUMBER: US/10/273,826
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-273-826-24

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 764 CACAGAAGTGACGAAGAGT 783
DB 20 CACAGAAGTGAAAGATGAAGT 1

RESULT 409
US-10-274-347-24/c
; Sequence 24, Application US/10274347
; Publication No. US20040077084A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; APPLICANT: Steven Davidlsen
; APPLICANT: Tunling Li
; APPLICANT: Keith Glaser
; TITLE OF INVENTION: ANTISENSE MODULATION OF HISTONE DEACETYLASE 4 EXPRESSION
; FILE REFERENCE: RTS-0264
; CURRENT APPLICATION NUMBER: US/10/274,347
; CURRENT FILING DATE: 2002-10-17
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-274-347-24

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 764 CACAGAAGTGACGAAGAGT 783
DB 20 CACAGAAGTGAAAGATGAAGT 1

RESULT 410
US-10-280-183A-459/c
; Sequence 459, Application US/10280183A
; Publication No. US20040081964A1
; GENERAL INFORMATION:
; APPLICANT: Pfizer Inc.
; APPLICANT: Bachmanov, Alexander A
; APPLICANT: Beauchamp, Gary K.
; APPLICANT: Charterjee, Anubindo
; APPLICANT: De Jong, Pieter J.
; APPLICANT: Li, Shantu
; APPLICANT: Li, Xia
; APPLICANT: Ohmen, Jeffrey D
; APPLICANT: Reed, Danielle R.
; APPLICANT: Ross, David
; APPLICANT: Tordoff, Michael G.
; TITLE OF INVENTION: GENE AND SEQUENCE VARIATION ASSOCIATED WITH SENSING
; FILE REFERENCE: PCI8106A
; CURRENT APPLICATION NUMBER: US/10/280,183A
; CURRENT FILING DATE: 2002-10-25
; PRIOR APPLICATION NUMBER: 60/200,794

PRIOR FILING DATE: 2000-04-28
NUMBER OF SEQ ID NOS: 652
SOFTWARE: PatentIn Ver. 3.1
SEQ ID NO 459
LENGTH: 20
TYPE: DNA
ORGANISM: Mouse
US-10-280-183A-459

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1991 TGGGGTGGCAATGACACCC 2010
DB 20 TCGAGGTGACATGATACCC 1

RESULT 411
US-10-300-424-77/c
Sequence 77, Application US/10300424
Publication No. US20040096835A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF TNFSF14 EXPRESSION
FILE REFERENCE: RTS-0437
CURRENT APPLICATION NUMBER: US/10/300,424
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 129
SEQ ID NO 77
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-424-77

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 988 CAGTCACCTGCGGACCGC 1007
DB 20 CAGTCACCTGCGGACCGC 1

RESULT 412
US-10-300-424-124
Sequence 124, Application US/10300424
Publication No. US20040096835A1
GENERAL INFORMATION:
APPLICANT: Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF TNFSF14 EXPRESSION
FILE REFERENCE: RTS-0437
CURRENT APPLICATION NUMBER: US/10/300,424
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 129
SEQ ID NO 124
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-300-424-124

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 988 CAGTCACCTGCGGACCGC 1007
DB 1 CAGTCACCTGCGGACCGC 20

RESULT 413
US-10-300-399-28
Sequence 28, Application US/10300399
Publication No. US20040097450A1
GENERAL INFORMATION:
APPLICANT: Andrew T. Wate
TITLE OF INVENTION: MODULATION OF TDP-1 EXPRESSION
FILE REFERENCE: RTS-0173
CURRENT APPLICATION NUMBER: US/10/300,399
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 158
SEQ ID NO 28
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-300-399-28

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 ATCACCATCCCAAGCTGA 1273
DB 1 ATCACCATCCCAAGCAGA 20

RESULT 414
US-10-300-399-105/c
Sequence 105, Application US/10300399
Publication No. US20040097450A1
GENERAL INFORMATION:
APPLICANT: Andrew T. Wate
TITLE OF INVENTION: MODULATION OF TDP-1 EXPRESSION
FILE REFERENCE: RTS-0173
CURRENT APPLICATION NUMBER: US/10/300,399
CURRENT FILING DATE: 2002-11-19
NUMBER OF SEQ ID NOS: 158
SEQ ID NO 105
LENGTH: 20
TYPE: DNA
ORGANISM: H. sapiens
FEATURE:
US-10-300-399-105

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 ATCACCATCCCAAGCTGA 1273
DB 20 ATCACCATCCCAAGCAGA 1

RESULT 415
US-10-688-706-316/c
Sequence 316, Application US/10688706
Publication No. US20040102412A1
GENERAL INFORMATION:
APPLICANT: Broechar, Kay
TITLE OF INVENTION: ANTISENSE MODULATION OF GRP EXPRESSION
FILE REFERENCE: 01393/1
CURRENT APPLICATION NUMBER: US/10/688,706
CURRENT FILING DATE: 2003-10-17
PRIOR APPLICATION NUMBER: 60/419,268
PRIOR FILING DATE: 2002-10-17
NUMBER OF SEQ ID NOS: 3071
SEQ ID NO 316
SOFTWARE: PatentIn version 3.2
LENGTH: 20
TYPE: DNA

```

; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GPAT antisense
US-10-688-706-316

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 147 CCTGGCCCCGGGGCCGGG 166
DB 20 CCTGGCCTCGCGGCGCTG 1

RESULT 416
US-10-688-706-2458
; Sequence 2458, Application US/10688706
; Publication No. US20040102412A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Broscat, Kay
; TITLE OF INVENTION: ANTISENSE MODULATION OF GPAT EXPRESSION
; FILE REFERENCE: 01393/1
; CURRENT APPLICATION NUMBER: US/10/688,706
; PRIOR FILING DATE: 2003-10-17
; PRIOR APPLICATION NUMBER: 60/419,268
; NUMBER OF SEQ ID NOS: 1071
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2458
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: human GPAT antisense
US-10-688-706-2458

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 416 CAAGGTGAAAGCAGCTAC 435
DB 1 CAAGGTGAAAGCAGCTAC 20

RESULT 417
US-10-316-459-16/c
; Sequence 16, Application US/10316459
; Publication No. US20040110149A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Ravi Jain
; TITLE OF INVENTION: MODULATION OF BUB1-BETA EXPRESSION
; FILE REFERENCE: RTS-0461
; CURRENT APPLICATION NUMBER: US/10/316,459
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 169
; SEQ ID NO 16
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-316-459-16

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 132 GTGCTCTGCGGAGCCCTG 151
DB 20 GTGCTCTGAGTGAGCCATG 1
```

```

RESULT 418
US-10-316-459-94
; Sequence 94, Application US/10316459
; Publication No. US20040110149A1
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Ravi Jain
; TITLE OF INVENTION: MODULATION OF BUB1-BETA EXPRESSION
; FILE REFERENCE: RTS-0461
; CURRENT APPLICATION NUMBER: US/10/316,459
; CURRENT FILING DATE: 2002-12-10
; NUMBER OF SEQ ID NOS: 169
; SEQ ID NO 94
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-316-459-94

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 132 GTGCTCTGCGGAGCCCTG 151
DB 1 GTGCTCTGAGTGAGCCATG 20

RESULT 419
US-10-671-395-1546/c
; Sequence 1546, Application US/10671395
; Publication No. US20040132063A1
; GENERAL INFORMATION:
; APPLICANT: Pharmacia Corp.
; APPLICANT: Gierse, James K
; TITLE OF INVENTION: ANTISENSE MODULATION OF MICROSOAM PROSTAGLANDIN E2 SYNTHASE
; FILE REFERENCE: 1179/1/US
; CURRENT APPLICATION NUMBER: US/10/671,395
; CURRENT FILING DATE: 2003-09-25
; PRIOR APPLICATION NUMBER: 60/413,549
; PRIOR FILING DATE: 2002-09-25
; NUMBER OF SEQ ID NOS: 1809
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1546
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: Human pGR2 antisense
US-10-671-395-1546

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1667 CAAGGAAACTGACTTCTT 1686
DB 20 CACAGGAGCTCAGCCTTCT 1

RESULT 420
US-10-666-909-14/c
; Sequence 14, Application US/10666909
; Publication No. US20040137623A1
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Kathleen Myers
; APPLICANT: Joshua Finger
; TITLE OF INVENTION: DELIVERY OF OLIGONUCLEOTIDE COMPOUNDS INTO OSTEOCLASTS AND MODULA
; TITLE OF INVENTION: OSTEOCLAST DIFFERENTIATION
```

FILE REFERENCE: 23546-07993/RTSP-0313US.P1
CURRENT APPLICATION NUMBER: US/10/666,909
CURRENT FILING DATE: 2003-09-17
PRIOR APPLICATION NUMBER: 10/111,868
PRIOR FILING DATE: 2002-08-06
PRIOR APPLICATION NUMBER: PCT/US00/29828
PRIOR FILING DATE: 2000-10-30
PRIOR APPLICATION NUMBER: 09/435,296
PRIOR FILING DATE: 1999-11-05
NUMBER OF SEQ ID NOS: 110
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 14
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: antisense oligonucleotide
US-10-666-909-14

Query Match 0.64; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.04; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 11 GCCAGCGCGCGGCTGCGCG 30
DB 20 GCCCGCGCGCGCTGCGCG 1

RESULT 421
US-10-666-909-62
Sequence 62, Application US/10666909
Publication No. US20040137623A1
GENERAL INFORMATION:
APPLICANT: Brenda F. Baker
APPLICANT: Kathleen Myers
APPLICANT: Joshua Finger
TITLE OF INVENTION: DELIVERY OF OLIGONUCLEOTIDE COMPOUNDS INTO OSTEOCLASTS AND MODULA
FILE REFERENCE: 23546-07993/RTSP-0313US.P1
CURRENT APPLICATION NUMBER: US/10/666,909
CURRENT FILING DATE: 2003-09-17
PRIOR APPLICATION NUMBER: 10/111,868
PRIOR FILING DATE: 2002-08-06
PRIOR APPLICATION NUMBER: PCT/US00/29828
PRIOR FILING DATE: 2000-10-30
PRIOR APPLICATION NUMBER: 09/435,296
PRIOR FILING DATE: 1999-11-05
NUMBER OF SEQ ID NOS: 110
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 62
LENGTH: 20
TYPE: DNA
ORGANISM: M. musculus
FEATURE:
US-10-666-909-62

Query Match 0.64; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.04; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 11 GCCAGCGCGCGGCTGCGCG 30
DB 1 GCCCGCGCGCGCTGCGCG 20

RESULT 422
US-10-744-055-16
Sequence 16, Application US/10744055
Publication No. US20040203031A1
GENERAL INFORMATION:
APPLICANT: Whitehead, Alexander Steven
APPLICANT: Chailberg, Sharon S.
APPLICANT: Lazar, James G.

TITLE OF INVENTION: METHODS FOR DETERMINING DRUG RESPONSIVENESS
FILE REFERENCE: UPA-009
CURRENT APPLICATION NUMBER: US/10/744,055
CURRENT FILING DATE: 2003-12-22
PRIOR APPLICATION NUMBER: US/10/348,346
PRIOR FILING DATE: 2003-04-22
PRIOR APPLICATION NUMBER: US 10/045,360
PRIOR FILING DATE: 2002-01-22
PRIOR APPLICATION NUMBER: US 60/370,008
PRIOR FILING DATE: 2002-04-03
NUMBER OF SEQ ID NOS: 29
SOFTWARE: PatentIn version 3.1
SEQ ID NO 16
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: PCR mutagenesis primer GREIF
US-10-744-055-16

Query Match 0.64; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.04; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1634 CAGCTAACCTCTTCTTCC 1653
DB 1 CAGCAACCTCTTCTTCCC 20

RESULT 423
US-10-877-231-552/c
Sequence 552, Application US/10877231
Publication No. US20050027461A1
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
APPLICANT: Wolber, Paul K.
APPLICANT: Delenstarr, Glenda C.
APPLICANT: Webb, Peter G.
APPLICANT: Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSER: Records Manager, Legal Department, Hewlett-Packard
COMPANY: M/S 2050
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/877,231
FILING DATE: 24-Jun-2004
CLASSIFICATION: Not available
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/784,674
FILING DATE: 15-Feb-2001
APPLICATION NUMBER: 09/021,701
FILING DATE: 10-FEB-1998
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 552:
SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 552:
US-10-877-231-552

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1543 TAAGAGGAAAAGTCAGTA 1562
DB 20 TTAAGAGGAAAAGTCAGTA 1

RESULT 424

US-10-877-231-553/c
Sequence 553, Application US/10877231
Publication No. US20050027461A1

GENERAL INFORMATION:

APPLICANT: Shannon, Karen W.
Wolber, Paul K.
Delestar, Glenda C.
Webb, Peter G.
Kincaid, Robert H.

TITLE OF INVENTION: Methods for evaluating oligonucleotide
probe sequences

NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:

ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard
Company M/S 2050
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/877,231
FILING DATE: 24-Jun-2004
CLASSIFICATION: Not available
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/784,674
FILING DATE: 15-Feb-2001
APPLICATION NUMBER: 09/021,701
FILING DATE: 10-Feb-1998

ATTORNEY/AGENT INFORMATION:

NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 553:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 553:
US-10-877-231-553

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1542 TTAAGAGGAAAAGTCAGT 1561
DB 20 TTAAGAGGAAAAGTCAGT 1

RESULT 425

US-10-643-801-107/c
Sequence 107, Application US/10643801
Publication No. US20050043524A1

GENERAL INFORMATION:

APPLICANT: Sanjay Bhanot
Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 107
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-107

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 471 CTTGACTGGAGAGTGCCCTG 490
DB 20 CTGGGCTAGGAGTGCCCTG 1

RESULT 426

US-10-643-801-116/c
Sequence 116, Application US/10643801
Publication No. US20050043524A1

GENERAL INFORMATION:

APPLICANT: Sanjay Bhanot
Kenneth W. Dobie
TITLE OF INVENTION: MODULATION OF DIACYLGLYCEROL ACYLTRANSFERASE 2 EXPRESSION
FILE REFERENCE: RTS-0678US
CURRENT APPLICATION NUMBER: US/10/643,801
CURRENT FILING DATE: 2003-08-18
NUMBER OF SEQ ID NOS: 230
SEQ ID NO 116
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-10-643-801-116

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1233 ACCACTGTGTGGGAGGCC 1252
DB 20 ACCACCGTGTGGGAGGCC 1

RESULT 427

US-10-831-901A-1717/c
Sequence 1717, Application US/10831901A
Publication No. US20050100885A1

GENERAL INFORMATION:

APPLICANT: Crooke, Stanley T.

```

; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIO0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1717
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1717

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No.3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1775 TACAGCCCTTATTGCCA 1794
DB      20 TACAGTGCCTTATTGACA 1

RESULT 428
US-10-831-901A-1718/C
; Sequence 1718, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIO0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1719
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1719
```

```

; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1718
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1718

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No.3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1776 ACAGCCCTTATTGCCAC 1795
DB      20 ACAGTGCCTTATTGACAC 1

RESULT 429
US-10-831-901A-1719/C
; Sequence 1719, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampath, Rangarajan
; APPLICANT: Freier, Susan M.
; APPLICANT: Massire, Christian
; APPLICANT: Hofstadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swayze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIO0008US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1719
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1719

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No.3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1777 CAAGCCCTTATTGCCACT 1796
DB      20 CAAGTGCCTTATTGACACT 1
```

```
RESULT 430
US-10-831-901A-1720/C
; Sequence 1720, Application US/10831901A
; Publication No. US20050100885A1
; GENERAL INFORMATION:
; APPLICANT: Crooke, Stanley T.
; APPLICANT: Ecker, David J.
; APPLICANT: Sampach, Rangarajan
; APPLICANT: Freiler, Susan M.
; APPLICANT: Messire, Christian
; APPLICANT: Hostadler, Steven A.
; APPLICANT: Lowery, Kristin Sannes
; APPLICANT: Swaze, Eric
; APPLICANT: Baker, Brenda F.
; APPLICANT: Bennett, C. Frank
; TITLE OF INVENTION: Compositions And Methods For The Treatment Of Severe
; FILE REFERENCE: ISIS0083-100 (BIOL00080US)
; CURRENT APPLICATION NUMBER: US/10/831,901A
; PRIOR FILING DATE: 2004-04-26
; PRIOR APPLICATION NUMBER: 60/466,426
; PRIOR FILING DATE: 2003-04-28
; PRIOR APPLICATION NUMBER: 60/468,562
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/467,770
; PRIOR FILING DATE: 2003-04-30
; PRIOR APPLICATION NUMBER: 60/468,627
; PRIOR FILING DATE: 2003-05-06
; PRIOR APPLICATION NUMBER: 60/477,637
; PRIOR FILING DATE: 2003-06-10
; PRIOR APPLICATION NUMBER: 60/483,579
; PRIOR FILING DATE: 2003-06-27
; NUMBER OF SEQ ID NOS: 30063
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1720
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense compound
US-10-831-901A-1720

Query Match      0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1778 AAGCCCTTATGACACTA 1797
DB      20 AAGTGCCTTATGACACTA 1

RESULT 431
US-10-018-320A-13
; Sequence 13, Application US/10018320A
; Publication No. US20050130116A1
; GENERAL INFORMATION:
; APPLICANT: Dohmer, Johannes
; APPLICANT: Krebsfanger, Niels
; APPLICANT: Eichelbaum, Michel
; APPLICANT: Zanger, Ulrich M.
; TITLE OF INVENTION: Stable Expression of Polymorphic Forms of Human Cytochrome
; FILE REFERENCE: 01-1637
; CURRENT APPLICATION NUMBER: P450 2D5 as an Analytical Tool in Preclinical Drug Development
; CURRENT FILING DATE: 2001-11-12
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
```

```
; OTHER INFORMATION: Synthetic oligonucleotide
US-10-018-320A-13

Query Match      0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 3.3e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      518 CACTGATTCGCTGCTATCG 537
DB      1 CACTGCTTACTGCTTATCG 20

RESULT 432
US-09-961-077-153
; Sequence 153, Application US/09961077
; Publication No. US20030014775A1
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; Edington, Brent E.
; McSwiggen, James A.
; Merlo, Patricia Ann Owens
; Guo, Lining
; Skokul, Thomas A.
; Young, Scott A.
; Folkerts, Otto
; Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; MODULATION OF GENE EXPRESSION
; IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/961,077
; FILING DATE: 21-Sep-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/679,645
; FILING DATE: July 12, 1996
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELE: 67-3510
; INFORMATION FOR SEQ ID NO: 153:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 153:
US-09-961-077-153

Query Match      0.6%; Score 15; DB 1; Length 17;
```

Best Local Similarity 86.7%; Pred. No. 3e+02;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 778 AGAAGTCCAGCA 792
DB 3 AGAAGUCCAGCA 17

RESULT 433

US-09-961-077-155

; Sequence 155, Application US/09961077
; Publication No. US20030014775A1

GENERAL INFORMATION:

APPLICANT: Zwick, Michael G.

Edington, Brent E.

McSwiggen, James A.

Merlo, Patricia Ann Owens

Guo, Lining

Skokut, Thomas A.

Young, Scott A.

Folkerts, Otto

Merlo, Donald J.

TITLE OF INVENTION: COMPOSITION AND METHODS FOR

MODULATION OF GENE EXPRESSION

IN PLANTS

NUMBER OF SEQUENCES: 1263

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 MB

storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/961.077

FILING DATE: 21-Sep-2001

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/679,645

FILING DATE: July 12, 1996

APPLICATION NUMBER: 60/001,135

FILING DATE: July 13, 1995

APPLICATION NUMBER: 08/300,726

FILING DATE: September 2, 1994

ATTORNEY/AGENT INFORMATION:

NAME: Wardburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 219/247

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

INFORMATION FOR SEQ ID NO: 155:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

STRANDEDNESS: single

TOPOLOGY: linear

SEQUENCE DESCRIPTION: SEQ ID NO: 155:

US-09-961-077-155

QY 778 AGAAGTCCAGCA 792

DB 2 AGAAGUCCAGCA 16

QY 1184 CCTCTTCTCCTCCGA 1198
DB 15 CCTCTTCTCCTCCGA 1

RESULT 434

US-10-156-306-6949/c

; Sequence 6949, Application US/10156306
; Publication No. US20030119017A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

McSwiggen, James

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat

FILE REFERENCE: MHB01-664-A (400/050)

CURRENT APPLICATION NUMBER: US/10/156,306

CURRENT FILING DATE: 2002-05-28

NUMBER OF SEQ ID NOS: 8013

SOFTWARE: PatentIn version 3.0

SEQ ID NO 6949

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-10-156-306-6949

QY 1184 CCTCTTCTCCTCCGA 1198

DB 17 CCTCTTCTCCTCCGA 3

RESULT 435

US-10-156-306-6950/c

; Sequence 6950, Application US/10156306
; Publication No. US20030119017A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

McSwiggen, James

TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relat

FILE REFERENCE: MHB01-664-A (400/050)

CURRENT APPLICATION NUMBER: US/10/156,306

CURRENT FILING DATE: 2002-05-28

NUMBER OF SEQ ID NOS: 8013

SOFTWARE: PatentIn version 3.0

SEQ ID NO 6950

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-10-156-306-6950

Query Match

0.6%; Score 15; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 3e+02;

Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1184 CCTCTTCTCCTCCGA 1198
DB 15 CCTCTTCTCCTCCGA 1

RESULT 436

US-10-238-700-2764

; Sequence 2764, Application US/10238700
; Publication No. US20030153521A1

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

McSwiggen, James

TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Leve

FILE REFERENCE: 400/057 (MHB01-1158-A)

CURRENT APPLICATION NUMBER: US/10/238,700

CURRENT FILING DATE: 2002-09-18

QY 778 AGAAGTCCAGCA 792

```
; PRIOR APPLICATION NUMBER: PCT/US 02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; NUMBER OF SEQ ID NOS: 4666
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2764
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-238-700-2764

Query Match          0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      146 GCCCTGGCCCCGGGG 160
DB      3 GCCCTGGCCCCGGGG 17

RESULT 437
US-10-498-462-1758
; Sequence 1758, Application US/10498462
; Publication No. US20040259175A1
; GENERAL INFORMATION:
; APPLICANT: Guo, Jinjiao
; TITLE OF INVENTION: HUMAN PROSTATE CANCER CANDIDATE PROTEIN 1
; FILE REFERENCE: PB01102
; CURRENT APPLICATION NUMBER: US/10/498,462
; CURRENT FILING DATE: 2004-06-10
; PRIOR APPLICATION NUMBER: US 60/339,764
; PRIOR FILING DATE: 2001-12-10
; PRIOR APPLICATION NUMBER: PCT/US02/37506
; PRIOR FILING DATE: 2002-11-22
; NUMBER OF SEQ ID NOS: 3320
; SOFTWARE: Aecmica Sequence Listing Engine
; SEQ ID NO 1758
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-498-462-1758

Query Match          0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      727 TGGGCTGGGTGCT 741
DB      2 TGGGCTGGGTGCT 16

RESULT 438
US-10-724-270-1443
; Sequence 1443, Application US/10724270
; Publication No. US2005008031A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: MGSwigen, James
; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
; FILE REFERENCE: 400/046-US (MEHB02-326-A)
; CURRENT APPLICATION NUMBER: US/10/724,270
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: PCT/US02/16840
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/318,471
; PRIOR FILING DATE: 2001-09-10
; PRIOR APPLICATION NUMBER: US 60/296,249
; PRIOR FILING DATE: 2001-06-06
; PRIOR APPLICATION NUMBER: US 60/294,140
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 10/238,700
```

```
; PRIOR FILING DATE: 2002-09-10
; PRIOR APPLICATION NUMBER: US 10/163,552
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 10/157,580
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2002-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: US 10/417,012
; PRIOR FILING DATE: 2003-04-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 6810
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1443
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-724-270-1443

Query Match          0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 3e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY      146 GCCCTGGCCCCGGGG 160
DB      3 GCCCTGGCCCCGGGG 17

RESULT 439
US-09-938-689-14/c
; Sequence 14, Application US/09938689
; Publication No. US20030028911A1
; GENERAL INFORMATION:
; APPLICANT: Huang, Manley
; APPLICANT: Harding, Fiona
; TITLE OF INVENTION: TRANSGENIC MAMMAL CAPABLE OF FACILITATING PRODUCTION OF
; FILE REFERENCE: 9342-028
; CURRENT APPLICATION NUMBER: US/09/938,689
; CURRENT FILING DATE: 2001-08-23
; PRIOR APPLICATION NUMBER: 09/651,361
; PRIOR FILING DATE: 2000-08-30
; PRIOR APPLICATION NUMBER: 60/151,688
; PRIOR FILING DATE: 1999-08-31
; NUMBER OF SEQ ID NOS: 72
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: PCR Primer
US-09-938-689-14

Query Match          0.6%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1423 GAGGACCAGCTGCA 1437
DB      15 GAGGACCAGCTGCA 1

RESULT 440
US-08-887-505-145/c
; Sequence 145, Application US/08887505
; Publication No. US20020081577A1
; GENERAL INFORMATION:
; APPLICANT: Kilukskje, Robert E.
; APPLICANT: Frank, Bruce L.
; APPLICANT: Goodchild, John
; APPLICANT: Wolfe, Jia L.
```



```

; APPLICANT: Roberts, Peter C.
; APPLICANT: Hamlin, Jr., Henry A.
; APPLICANT: Roberts, No. US2002008157A11 A.
; APPLICANT: Walther, Debra M.
; TITLE OF INVENTION: OIGONUCLEOTIDES SPECIFIC FOR
; NUMBER OF SEQUENCES: 172
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Hale and Dorr LLP
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/887,505
; FILING DATE:
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/471,968
; FILING DATE: 06-JUN-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Kerner, Ann-Louise
; REGISTRATION NUMBER: 33,523
; REFERENCE/DOCKET NUMBER: HY2-040CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 526-6000
; TELEFAX: (617) 526-5000
; INFORMATION FOR SEQ ID NO: 145:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA/RNA
; HYPOTHEICAL: NO
; ANTI-SENSE: YES
; US-08-887-505-145

Query Match          0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      372 TCCGCCCTCCAGACCTC 389
DB      18 TCAGCCTCCAGACCTC 1

RESULT 441
; Sequence 352, Application US/10297068
; Publication No. US20030228585A1
; GENERAL INFORMATION:
; APPLICANT: INOKO, Hidetoshi
; APPLICANT: KAGIYA, Taeko
; APPLICANT: ICHIHARA, Tatsuo
; APPLICANT: Matsumura, Yoshiyuki
; APPLICANT: MORIYA, Shogo
; APPLICANT: NISHIDA, Michio
; TITLE OF INVENTION: KIT AND METHOD FOR DETERMINING HLA TYPES
; FILE REFERENCE: 1314OP1174
; CURRENT APPLICATION NUMBER: US/10/297,068
; CURRENT FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: JP 2000-164798
; PRIOR FILING DATE: 2000-06-01
; NUMBER OF SEQ ID NOS: 1298
; SOFTWARE: Patent In Ver. 2.1
; SEQ ID NO 352

```

```

; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: capture
; US-10-297-068-352

Query Match          0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1071 GAGATGAAGTGTACAG 1088
DB      1 GAGATTAAGTGTACAG 18

RESULT 442
; US-10-813-203-1
; Sequence 1, Application US/10813203
; Publication No. US20050037495A1
; GENERAL INFORMATION:
; APPLICANT: SIGNAL PHARMACEUTICALS LLC.
; APPLICANT: SAH, Dinah W. Y.
; APPLICANT: GAGE, Fred H.
; APPLICANT: RAY, Jasodhara
; TITLE OF INVENTION: HUMAN CNS CELL LINES AND METHODS OF USE THEREFOR
; FILE REFERENCE: REG1610-1
; CURRENT APPLICATION NUMBER: US/10/813,203
; CURRENT FILING DATE: 2004-03-29
; PRIOR APPLICATION NUMBER: US 08/711,628
; PRIOR FILING DATE: 1996-09-03
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: Patent In version 3.1
; SEQ ID NO 1
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
; US-10-813-203-1

Query Match          0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 3.2e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      993 ACCTCGCGAACCAG 1010
DB      1 AACCTGCAGACCGCAG 18

RESULT 443
; US-08-983-605-55/c
; Sequence 55, Application US/08983605A
; Publication No. US2002006118A1
; GENERAL INFORMATION:
; APPLICANT: Roder, Marion
; TITLE OF INVENTION: Microsatellite Markers for Plants of the Species
; TITLE OF INVENTION: Triticum aestivum and Triticum spelta and the Use of
; FILE REFERENCE: 2936.10400
; CURRENT APPLICATION NUMBER: US/08/983,605A
; CURRENT FILING DATE: 1998-05-01
; EARLIER APPLICATION NUMBER: DE 195 25 284.5
; EARLIER FILING DATE: 1995-06-28
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 55
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Triticum aestivum
; US-08-983-605-55

Query Match          0.6%; Score 14.8; DB 1; Length 19;

```

Best Local Similarity 88.9%; Pred. No. 3,4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 ATCTCCCTTCTCCACCC 1935

Db 18 ATCTCCTTCTCCACCC 1

RESULT 444

US-09-901-484A-476
Sequence 476, Application US/09901484A
Patent No. US20020119460A1
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
APPLICANT: Bougueleret, Lydie
TITLE OF INVENTION: Prostate Cancer Gene
FILE REFERENCE: GEN-T11XC3D2
CURRENT APPLICATION NUMBER: US/09/901,484A
CURRENT FILING DATE: 2001-07-09
PRIOR APPLICATION NUMBER: US 08/996,306
PRIOR FILING DATE: 1997-12-22
PRIOR APPLICATION NUMBER: US 60/099,658
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: US 09/218,207
PRIOR FILING DATE: 1998-12-22
PRIOR APPLICATION NUMBER: US 09/338,907
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: US 09/853,526
PRIOR FILING DATE: 2001-05-11
NUMBER OF SEQ ID NOS: 578
SOFTWARE: PatentIn version 3.1
SEQ ID NO 476
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
LOCATION: (1)-(19)
OTHER INFORMATION: microsequencing oligo for 99-140-130.misl
US-09-901-484A-476

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3,4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 424 AAAAGCAGCTACGAGTCA 441

Db 2 AAAAGCAGCTACGAGTCA 19

RESULT 445

US-09-966-147-22/C
Sequence 22, Application US/09966147
Patent No. US20020146416A1
GENERAL INFORMATION:
APPLICANT: Presta, Leonard G.
APPLICANT: Shelton, David L.
TITLE OF INVENTION: HUMAN TRK RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson & Bear, LLP
STREET: 620 Newport Center Drive, 16th Floor
CITY: Newport Beach
STATE: California
COUNTRY: USA
ZIP: 92660

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: WinPatIn (Genentech)

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/966,147

FILING DATE: 27-Sep-2000

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/446172

FILING DATE: 19-MAY-1995

APPLICATION NUMBER: 08/286846

FILING DATE: 05-AUG-1994

APPLICATION NUMBER: 08/215139

FILING DATE: 18-MAR-1994

ATTORNEY/AGENT INFORMATION:

NAME: Dreger, Ginger

REGISTRATION NUMBER: 33,055

REFERENCE/DOCKET NUMBER: GENENT.33CPC4C

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 954-4114

TELEFAX: (415) 954-4111

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs

TYPE: Nucleic Acid

STRANDEDNESS: Single

TOPOLOGY: Linear

SEQUENCE DESCRIPTION: SEQ ID NO: 22:

US-09-966-147-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 3,4e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCACCTTGCGCTGCG 2141

Db 19 CTCACCTTGCGCTGCG 2

RESULT 446

US-09-853-526-476
Sequence 476, Application US/09853526
Patent No. US20020165345A1
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Ilya, Chumakov
APPLICANT: Bougueleret, Lydie
TITLE OF INVENTION: PROSTATE CANCER GENE
FILE REFERENCE: GENSET.18CPICP
CURRENT APPLICATION NUMBER: US/09/853,526
CURRENT FILING DATE: 2001-05-11
PRIOR APPLICATION NUMBER: 09/338,907
PRIOR FILING DATE: 1999-06-23
PRIOR APPLICATION NUMBER: 08/996,306
PRIOR FILING DATE: 1997-12-22
PRIOR APPLICATION NUMBER: 60/099,658
PRIOR FILING DATE: 1998-09-09
PRIOR APPLICATION NUMBER: 09/218,207
PRIOR FILING DATE: 1998-12-22
NUMBER OF SEQ ID NOS: 578
SOFTWARE: Patent.pm
SEQ ID NO 476
LENGTH: 19
TYPE: DNA
ORGANISM: Homo sapiens
FEATURE:
NAME/KEY: misc_feature
LOCATION: 1..19
OTHER INFORMATION: microsequencing oligo for 99-140-130.misl
US-09-853-526-476

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3,4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 424 AAAAGCAGTACAGTCA 441
|||||
Db 2 AAAAGCAGTACAGACCA 19

RESULT 447
US-09-864-954D-8/c
; Sequence 8, Application US/09864954D
; Publication No. US20030118993A1
; GENERAL INFORMATION:
; APPLICANT: Sepp Kaul
; APPLICANT: Josef Preiherr (Deceased)
; APPLICANT: Ulrich Weidle
; TITLE OF INVENTION: A nucleic acid which is upregulated in human tumor
; TITLE OF INVENTION: cells, a protein encoded thereby and a process for
; TITLE OF INVENTION: tumor diagnosis
; FILE REFERENCE: Case 20678
; CURRENT APPLICATION NUMBER: US/09/864,954D
; PRIOR FILING DATE: 2001-05-24
; PRIOR APPLICATION NUMBER: EP00110953.7
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: EP00115369.1
; PRIOR FILING DATE: 2000-07-15
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer RTR-5
US-09-864-954D-8

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2395 CTGGAATTAATGAAG 2412
|||||
Db 19 CTGGAATGAATGAAG 2

RESULT 448
US-10-045-360-17/c
; Sequence 17, Application US/10045360
; Publication No. US20030138781A1
; GENERAL INFORMATION:
; APPLICANT: Whitehead, Alexander Steven
; TITLE OF INVENTION: METHODS FOR DETERMINING STEROID RESPONSIVENESS
; FILE REFERENCE: USA-008
; CURRENT APPLICATION NUMBER: US/10/045,360
; CURRENT FILING DATE: 2002-01-22
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR mutagenesis primer GREIR
US-10-045-360-17

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1630 GGCTCAGCTAACCTCTCT 1647
|||||
Db 18 GGCTCAGCTAACCTCTCT 1

RESULT 449

US-10-374-469-22/c
; Sequence 22, Application US/10374469
; Publication No. US20030157099A1
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; APPLICANT: Shelton, David L.
; APPLICANT: Ufer, Roman

TITLE OF INVENTION: HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobe, Martens, Olson & Bear, LLP
STREET: 620 Newport Center Drive, 16th Floor
CITY: Newport Beach
STATE: California
COUNTRY: USA
ZIP: 92660

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Mapatin (Genentech)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/10/374,469
FILING DATE: 24-Feb-2003
CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/09/966,147
FILING DATE: 27-Sep-2000
APPLICATION NUMBER: 08/46172
FILING DATE: 19-MAY-1995
APPLICATION NUMBER: 08/286846
FILING DATE: 05-AUG-1994
APPLICATION NUMBER: 08/215139
FILING DATE: 18-MAR-1994

ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: GENENT-33CPC4C
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 954-4114
TELEFAX: (415) 954-4111
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-374-469-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2124 CTCAGCCTGGCCTGAG 2141
|||||
Db 19 CTCAGCCTGGCCTGAG 2

RESULT 450
US-10-698-597-22/c
; Sequence 22, Application US/10698597
; Publication No. US20040058416A1
; GENERAL INFORMATION:
; APPLICANT: Presta, Leonard G.
; APPLICANT: Shelton, David L.
; APPLICANT: Ufer, Roman

TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobe, Martens, Olson & Bear
STREET: 620 Newport Center Drive 16th Floor

US-10-698-597-22

```

; CITY: Newport Beach
; STATE: California
; COUNTRY: USA
; ZIP: 92660
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Winpatin (Genentech)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/698,597
; FILING DATE: 31-Oct-2003
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/724,524
; FILING DATE: 27-No. US20040058416a1-2000
; APPLICATION NUMBER: 09/156,923
; FILING DATE: 18-SEP-1998
; APPLICATION NUMBER: 08/359,705
; FILING DATE: 20-DEC-1994
; APPLICATION NUMBER: 08/268846
; FILING DATE: 10-AUG-1994
; APPLICATION NUMBER: 08/215139
; FILING DATE: 18-MAR-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Dreger, Ginger
; REGISTRATION NUMBER: 33,055
; REFERENCE/DOCKET NUMBER: GENENT.33CP2C2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 949/760-0404
; TELEFAX: 949/760-9502
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 22:
US-10-698-597-22

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2124 CTCAGCCTTGCTGAG 2141
Db      19 CTCACCTTGCTGAGC 2

RESULT 451
US-10-348-346-17/c
; Sequence 17, Application US/10348346
; Publication No. US20040072181A1
; GENERAL INFORMATION:
; APPLICANT: Whitehead, Alexander Steven
; APPLICANT: Chailberg, Sharon S.
; TITLE OF INVENTION: METHODS FOR DETERMINING DRUG RESPONSIVENESS
; FILE REFERENCE: UPA-009
; CURRENT APPLICATION NUMBER: US/10/348,346
; CURRENT FILING DATE: 2003-04-22
; PRIOR APPLICATION NUMBER: US 10/045,360
; PRIOR FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: US 60/370,008
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR mutagenesis primer GREIR
```

```

US-10-348-346-17

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1630 GGCTAGCTACCTCTCT 1647
Db      18 GGCACAGCAACCTCTCT 1

RESULT 452
US-10-683-990-57/c
; Sequence 57, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 57
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r

US-10-683-990-57

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      451 TTCAGTGGTCTGTCTCT 468
Db      18 TTCGAGGCTCTGTCTCT 1

RESULT 453
US-10-683-990-154
; Sequence 154, Application US/10683990
; Publication No. US20040198682A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Usman, Nassim
```

```

; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Placental Growth Factor
; FILE REFERENCE: 400/134 (02-742-H)
; CURRENT APPLICATION NUMBER: US/10/683,990
; CURRENT FILING DATE: 2003-10-10
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/366,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 256
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 154
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-683-990-154

Query Match          0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 61.1%; Pred. No. 3.4e+02;
Matches 11; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY      451 TCCAGTGGCTCTGCTCT 468
      :|||:|||:|||:
Db       2 UCCGAGGCGUCCTGUCU 19

RESULT 454
; Sequence 17, Application US/10744055
; Publication No. US20040203031A1
; GENERAL INFORMATION:
; APPLICANT: Whitehead, Alexander Steven
; APPLICANT: Chalibery, Sharon S.
; APPLICANT: Lazar, James G.
; FILE REFERENCE: UPA-009
; TITLE OF INVENTION: METHODS FOR DETERMINING DRUG RESPONSIVENESS
; CURRENT APPLICATION NUMBER: US/10/744,055
; CURRENT FILING DATE: 2003-12-22
; PRIOR APPLICATION NUMBER: US/10/348,346
; PRIOR FILING DATE: 2003-04-22
; PRIOR APPLICATION NUMBER: US 10/045,360
; PRIOR FILING DATE: 2002-01-22
; PRIOR APPLICATION NUMBER: US 60/370,008
; PRIOR FILING DATE: 2002-04-03
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR mutagenesis primer GREIR
US-10-744-055-17
```

```

Query Match          0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1630 GGCTACGCTAACCTCTCT 1647
      |||||
Db       18 GGCACGCAACCTCTCT 1

RESULT 455
; Sequence 3, Application US/10923115
; Publication No. US20050079610A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Polisky, Barry
; APPLICANT: McSwigen, James
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of FOS Gene Expression
; FILE REFERENCE: 400/193 (MBHB03-194-A)
; CURRENT APPLICATION NUMBER: US/10/923,115
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05162
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-923-115-3

Query Match          0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      15 GCGCGCGGCTCCGCGCT 32
      |||||
Db       18 GCGCGCGGCGCGCGCT 1

RESULT 456
; Sequence 119, Application US/10923115
; Publication No. US20050079610A1
; GENERAL INFORMATION:
; APPLICANT: Sigma Therapeutics, Inc.
; APPLICANT: Polisky, Barry
; APPLICANT: McSwigen, James
; APPLICANT: Beigelman, Leonid
```

```

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of FOS Gene Expression
; FILE REFERENCE: 400/193 (MHB03-194-A)
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05162
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 358
; SOFTWARE: Patentin version 3.2
; SEQ ID NO 119
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-923-115-119

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 3.4e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      15 GCGCCGCGGCTGCGGCT 32
Db      2 GCGCCGCGGCGGCGGCU 19

RESULT 457
US-10-888-226-288/C
; Sequence 288, Application US/10888226
; Publication No. US20050124568A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Mswigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase
; FILE REFERENCE: 400-199 (MHB03-710-A)
; CURRENT APPLICATION NUMBER: US/10/888,226
; CURRENT FILING DATE: 2004-07-09
; PRIOR APPLICATION NUMBER: US 60/486,729
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
```

```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 955
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 288
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-888-226-288

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      213 GGCCTGAGCAGATCCTT 2150
Db      19 GGCCTGAGCAGATCCTT 2

RESULT 458
US-10-888-226-702
; Sequence 702, Application US/10888226
; Publication No. US20050124568A1
; GENERAL INFORMATION:
; APPLICANT: Sitna Therapeutics, Inc.
; APPLICANT: Mswigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase
; FILE REFERENCE: 400-199 (MHB03-710-A)
; CURRENT APPLICATION NUMBER: US/10/888,226
; CURRENT FILING DATE: 2004-07-09
; PRIOR APPLICATION NUMBER: US 60/486,729
; PRIOR FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT/US03/05028
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/358580
; PRIOR FILING DATE: 2002-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 955
; SOFTWARE: Patentin version 3.3
; SEQ ID NO 702
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-888-226-702

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
```

QY 2133 GGCCTGGAGCAGATGCTT 2150
|||:|||||:|:|:
Db 1 GGCCTGGAGCAGATGCTT 18

RESULT 459
US-10-505-030-4/c
Sequence 4, Application US/10505030
Publication No. US20050142128A1
GENERAL INFORMATION:
APPLICANT: SCHRAEMER, ULRICH
TITLE OF INVENTION: THERAPY OF DISEASES OF THE EYE, THE INNER EAR AND THE
FILE REFERENCE: DEB:041US
CURRENT APPLICATION NUMBER: US/10/505,030
CURRENT FILING DATE: 2004-08-16
PRIOR APPLICATION NUMBER: PCT/DE 03/00415
PRIOR FILING DATE: 2003-02-12
PRIOR APPLICATION NUMBER: 102 06 723.6
PRIOR FILING DATE: 2002-02-18
NUMBER OF SEQ ID NOS: 4
SOFTWARE: Patentin version 3.1
SEQ ID NO 4
LENGTH: 19
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Primer
US-10-505-030-4

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3,4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1273 AGCACCACCCAGCAAG 1290
|||:|||||:|:|:
Db 19 ACCACCACCCAGCAAG 2

RESULT 460
US-10-697-527-55/c
Sequence 55, Application US/10697527
Publication No. US20040146898A1
GENERAL INFORMATION:
APPLICANT: Roder, Marion
TITLE OF INVENTION: MICROSATELLITE MARKERS FOR PLANTS OF THE SPECIES TRITICUM AESTIVUM
FILE REFERENCE: US 08/983,605
CURRENT APPLICATION NUMBER: US/10/697,527
CURRENT FILING DATE: 2003-10-30
PRIOR APPLICATION NUMBER: PCT/DE96/01185
PRIOR FILING DATE: 1996-06-27
PRIOR APPLICATION NUMBER: DE 195 25 284.5
PRIOR FILING DATE: 1995-06-28
NUMBER OF SEQ ID NOS: 466
SOFTWARE: Patentin version 3.1
SEQ ID NO 55
LENGTH: 19
TYPE: DNA
ORGANISM: Triticum sp.
US-10-697-527-55

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3,4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 ATCTCCTTCTCCACCC 1935
|||:|||||:|:|:
Db 18 ATCTCCTTCTCCACCC 1

RESULT 461
US-10-923-522-6/c

Sequence 6, Application US/10923522
Publication No. US20050159381A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwigen, James
APPLICANT: Chowrira, Bharat
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
FILE REFERENCE: 400/192 (MBH03-026-B)
CURRENT APPLICATION NUMBER: US/10/923,522
CURRENT FILING DATE: 2004-08-20
PRIOR APPLICATION NUMBER: PCT/US 03/05234
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/439,922
PRIOR FILING DATE: 2003-01-14
PRIOR APPLICATION NUMBER: US 60/404,039
PRIOR FILING DATE: 2002-08-15
PRIOR APPLICATION NUMBER: PCT/US 04/16390
PRIOR FILING DATE: 2004-05-24
PRIOR APPLICATION NUMBER: US 10/826,966
PRIOR FILING DATE: 2004-04-16
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/444,853
PRIOR FILING DATE: 2003-05-23
PRIOR APPLICATION NUMBER: PCT/US03/05346
PRIOR FILING DATE: 2003-02-20
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 1779
SOFTWARE: Patentin version 3.3
SEQ ID NO 6
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense
US-10-923-522-6

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3,4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 16 CCGCGCGCTGCCGCTC 33
|||:|||||:|:|:
Db 18 CCGCGCGCTGCCGCTC 1

RESULT 462
US-10-923-522-269
Sequence 269, Application US/10923522
Publication No. US20050159381A1
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwigen, James
APPLICANT: Chowrira, Bharat
APPLICANT: Beigelman, Leonid
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
FILE REFERENCE: 400/192 (MBH03-026-B)
CURRENT APPLICATION NUMBER: US/10/923,522
CURRENT FILING DATE: 2004-08-20
PRIOR APPLICATION NUMBER: PCT/US 03/05234
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/439,922
PRIOR FILING DATE: 2003-01-14
PRIOR APPLICATION NUMBER: US 60/404,039
PRIOR FILING DATE: 2002-08-15
PRIOR APPLICATION NUMBER: PCT/US 04/16390

```

; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1779
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 269
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-923-522-269

Query Match          0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 3.4e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      16 CGCGCGCGCTGCCGCTC 33
DB      2 CGCGCGCGCGCGCGCTC 19

RESULT 463
US-10-923-522-568
; Sequence 568, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Chowrira, Bharat
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
; FILE REFERENCE: 400/192 (MBH03-026-B)
; CURRENT APPLICATION NUMBER: US/10/923,522
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05234
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/439,922
; PRIOR FILING DATE: 2003-01-14
; PRIOR APPLICATION NUMBER: US 60/404,039
; PRIOR FILING DATE: 2002-08-15
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1779
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 568
; LENGTH: 19
; TYPE: RNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense r
US-10-923-522-568

Query Match          0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 3.4e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY      717 CATGATATCATGGGCTG 734
DB      1 CCUGGUACCAUGGCTUG 18

RESULT 464
US-10-923-522-887/c
; Sequence 887, Application US/10923522
; Publication No. US20050159381A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Chowrira, Bharat
; APPLICANT: Beigelman, Leonid
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Chromosome Translocation
; FILE REFERENCE: 400/192 (MBH03-026-B)
; CURRENT APPLICATION NUMBER: US/10/923,522
; CURRENT FILING DATE: 2004-08-20
; PRIOR APPLICATION NUMBER: PCT/US 03/05234
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/439,922
; PRIOR FILING DATE: 2003-01-14
; PRIOR APPLICATION NUMBER: US 60/404,039
; PRIOR FILING DATE: 2002-08-15
; PRIOR APPLICATION NUMBER: PCT/US 04/16390
; PRIOR FILING DATE: 2004-05-24
; PRIOR APPLICATION NUMBER: US 10/826,966
; PRIOR FILING DATE: 2004-04-16
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT/US03/05346
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1779
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 887
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-923-522-887

Query Match          0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 3.4e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      717 CATGATATCATGGGCTG 734
DB      19 CCTGGTACCATGGGCTG 2
```

Search completed: August 8, 2005, 10:01:30
Job time : 15 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 8, 2005, 09:56:45 ; Search time 8 Seconds
(without alignments)
3.700 Million cell updates/sec

Title: US-10-643-801-4
Perfect score: 2421
Sequence: 1 ccccggaagccagcgccg.....ataatgaagtgcagatcc 2421

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 0.5

Searched: 287 seqs, 6113 residues

Total number of hits satisfying chosen parameters: 574

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 287 summaries

Database : fetch4mg.seq:*

Prod. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	60	2.5	60	1	ABN43866 Human spliced ctran
2	60	2.5	65	1	ADD27789 Human psoriasis re
3	57	2.4	65	1	AAT20778 Human gene oligonuc
4	40.5	1.7	51	1	AAL32434 Human 86606 DGAT2
5	28	1.2	28	1	AAD56898 Human 86606 DGAT2
6	27.6	1.1	31	1	AAK06395 Human biallelic po
7	27	1.1	27	1	ADO42529 Human NOVX probe #
8	24	1.0	24	1	AAA37275 Human PRO1433 reve
9	24	1.0	24	1	AAA37274 Human PRO1433 forw
10	24	1.0	24	1	AAFS4410 Human encoding prote
11	24	1.0	24	1	AAFS4411 Novel human secret
12	24	1.0	24	1	ACD68450 Novel human secret
13	24	1.0	24	1	ACD68449 Novel human secret
14	24	1.0	24	1	ACH04511 Human secreted/tra
15	24	1.0	24	1	ACH04512 Human secreted/tra
16	24	1.0	24	1	ACD68095 Novel human secret
17	24	1.0	24	1	ACD68095 Novel human secret
18	24	1.0	24	1	ADC18163 Human PRO PCR prim
19	24	1.0	24	1	ADC18162 Human secreted/tra
20	24	1.0	24	1	ADD70809 Human secreted/tra
21	24	1.0	24	1	ADD70808 Human secreted/tra
22	24	1.0	24	1	ADD39886 Human secreted/tra
23	24	1.0	24	1	ADD39885 Human secreted/tra
24	24	1.0	24	1	ADD70331 Human secreted/tra
25	24	1.0	24	1	ADD70332 Human secreted/tra
26	24	1.0	24	1	ADD38452 Human secreted/tra
27	24	1.0	24	1	ADD38453 Human secreted/tra
28	24	1.0	24	1	ADD39408 Human secreted/tra
29	24	1.0	24	1	ADD39409 Human secreted/tra
30	24	1.0	24	1	ADD38931 Human secreted/tra
31	24	1.0	24	1	ADD38932 Human secreted/tra
32	24	1.0	24	1	ADD40362 Human secreted/tra
33	24	1.0	24	1	ADD40363 Human secreted/tra

107	16.4	0.7	21	1	AAZ30148	PCR primer pnf12 u
108	16.4	0.7	21	1	ADA50411	Thermus scotoductu
109	16.4	0.7	21	1	ADR87061	Human EphrinB2 sho
110	16.4	0.7	21	1	ADR82616	Human EphrinB2 ant
111	16.2	0.7	21	1	AAO63503	NANBV primer 77R,
112	16.2	0.7	21	1	AAZ26556	Human polymorphic
113	16.2	0.7	21	1	AAQ96288	Human gene single
114	16.2	0.7	21	1	ADQ93958	Human oestrogen re
115	16.2	0.7	19	1	AA155455	Specific tumour ce
116	16	0.7	19	1	ABQ76085	Anticancer gene-as
117	16	0.7	20	1	AAZ03129	PCR primer used to
118	16	0.7	20	1	ABZ88088	Human oligonucleot
119	16	0.7	21	1	ABD24318	AI095013-derived o
120	16	0.7	21	1	ADQ90611	Mouse Sca-2 target
121	16	0.7	21	1	ADQ90612	Sca-2 siRNA duplex
122	16	0.7	19	1	AA185565	Human STM2 exon 10
123	15.8	0.7	19	1	AAV43852	APC mutant gene ev
124	15.8	0.7	19	1	AB189068	HIV-1 related bind
125	15.8	0.7	19	1	AB189073	Real-time PCR forw
126	15.8	0.7	19	1	ACH66843	V274T variant huma
127	15.8	0.7	19	1	AAV44694	E. coli SecA antis
128	15.8	0.7	20	1	AAAX38463	Human jun N-termi
129	15.8	0.7	20	1	AAAX29835	Human jun N-termi
130	15.8	0.7	20	1	AAAX38463	Capture oligonucle
131	15.8	0.7	20	1	AB194517	Antisense oligonuc
132	15.8	0.7	20	1	AB194517	Chimeric antisense
133	15.8	0.7	20	1	AB194517	Novel mutant prote
134	15.8	0.7	20	1	ADN61692	Human CCR-2 promot
135	15.8	0.7	20	1	AA232695	Human gene single
136	15.8	0.7	21	1	AAAF5623	CPS1/TRS1 genomic
137	15.8	0.7	21	1	AAAF5623	Sequencing primer
138	15.8	0.7	21	1	ABSE6426	Human GDMLP-1 17-m
139	15.8	0.7	21	1	ABSE6426	Human GDMLP-1 17-m
140	15.4	0.6	17	1	ABNO2850	Human ERG DNzyme
141	15.4	0.6	17	1	ABK18894	Human MD23 scanlin
142	15.4	0.6	17	1	ABD00305	Human K-Ras DNzyme
143	15.4	0.6	17	1	ABZ59890	Human PCP1 DNA fr
144	15.4	0.6	17	1	ABZ59890	Human PCP1 DNA fr
145	15.4	0.6	17	1	ADFE6855	Human GMMLP-1 prob
146	15.4	0.6	17	1	ADFE6855	Human GMMLP-1 prob
147	15.4	0.6	17	1	ACN65119	Rat astrocyte kohl
148	15.4	0.6	17	1	ACN65940	Single nucleotide
149	15.4	0.6	17	1	ADAI9158	Anti-AKT3 bRNA re
150	15.4	0.6	18	1	ADFE8173	Human apolipoprote
151	15.4	0.6	19	1	ADFE8173	Human apolipoprote
152	15.4	0.6	19	1	ADQ60774	PCR primer used to
153	15.4	0.6	19	1	ADR80551	Human APT2-WT chi
154	15.4	0.6	19	1	ADR80551	Human nucleolin ph
155	15.4	0.6	19	1	ADR75724	Human oligonucleot
156	15.4	0.6	19	1	ADR75724	Human APT2-WT pri
157	15.4	0.6	20	1	AAZ05177	Phosphorothioate C
158	15.4	0.6	20	1	AAZ05177	Cpdl/du ODN 1962 u
159	15.4	0.6	20	1	AAZ05177	Immunostimulatory
160	15.4	0.6	20	1	ADL93361	DNA oligo #1 usefu
161	15.4	0.6	20	1	ADL93361	AI092623-derived o
162	15.4	0.6	20	1	ADL93361	PCR primer MLT1 f
163	15.4	0.6	20	1	ADL93361	Human glucose tran
164	15.4	0.6	20	1	ADL93361	Beta-S globin gene
165	15.4	0.6	20	1	ADL93361	Chromosome 11 (loc
166	15.4	0.6	20	1	ADL93361	VEGF-B167 exon 6B1
167	15.4	0.6	20	1	ADL93361	primer #1 to ampli
168	15.4	0.6	20	1	ADL93361	PCR primer used to
169	15.2	0.6	20	1	AAZ03193	Human telomerase a
170	15.2	0.6	20	1	AAZ03193	primer 2L for a hu
171	15.2	0.6	20	1	AAZ03193	Primer 2L for a hu
172	15.2	0.6	20	1	AAZ03193	S. pneumoniae groE
173	15.2	0.6	20	1	AAZ03193	Nucleotide sequenc
174	15.2	0.6	20	1	AAZ03193	Human cytochrome p
175	15.2	0.6	20	1	AAZ03193	
176	15.2	0.6	20	1	AAZ03193	
177	15.2	0.6	20	1	AAZ03193	
178	15.2	0.6	20	1	AAZ03193	
179	15.2	0.6	20	1	AAZ03193	

180	15.2	0.6	20	1	AAZ03193	Mouse Ig-kappa Iea
181	15.2	0.6	20	1	AAZ03193	Oligonucleotide hy
182	15.2	0.6	20	1	AAZ03193	Oligonucleotide hy
183	15.2	0.6	20	1	AAZ03193	VEGF receptor Flt-
184	15.2	0.6	20	1	AAZ03193	Mouse immunoglobul
185	15.2	0.6	20	1	AAZ03193	Murine SACL gene-g
186	15.2	0.6	20	1	AAZ03193	Human lysophosphol
187	15.2	0.6	20	1	AAZ03193	Laminin 5 expressi
188	15.2	0.6	20	1	AAZ03193	Human TSP1 domain
189	15.2	0.6	20	1	AAZ03193	Human hiber44BP an
190	15.2	0.6	20	1	AAZ03193	Human raf kinase p
191	15.2	0.6	20	1	AAZ03193	Human C/EBP beta p
192	15.2	0.6	20	1	AAZ03193	Human ADAMTS prote
193	15.2	0.6	20	1	AAZ03193	PCR primer 3 relat
194	15.2	0.6	20	1	AAZ03193	Serum amyloid A1 m
195	15.2	0.6	20	1	AAZ03193	HIV PRT antisense
196	15.2	0.6	20	1	AAZ03193	Human oligonucleot
197	15.2	0.6	20	1	AAZ03193	Human oligonucleot
198	15.2	0.6	20	1	AAZ03193	Human oligonucleot
199	15.2	0.6	20	1	AAZ03193	Human oligonucleot
200	15.2	0.6	20	1	AAZ03193	Human oligonucleot
201	15.2	0.6	20	1	AAZ03193	Human oligonucleot
202	15.2	0.6	20	1	AAZ03193	Human oligonucleot
203	15.2	0.6	20	1	AAZ03193	Human oligonucleot
204	15.2	0.6	20	1	AAZ03193	Human oligonucleot
205	15.2	0.6	20	1	AAZ03193	Human oligonucleot
206	15.2	0.6	20	1	AAZ03193	Human oligonucleot
207	15.2	0.6	20	1	AAZ03193	Human oligonucleot
208	15.2	0.6	20	1	AAZ03193	Human oligonucleot
209	15.2	0.6	20	1	AAZ03193	Human oligonucleot
210	15.2	0.6	20	1	AAZ03193	Human oligonucleot
211	15.2	0.6	20	1	AAZ03193	Human oligonucleot
212	15.2	0.6	20	1	AAZ03193	Human oligonucleot
213	15.2	0.6	20	1	AAZ03193	Human oligonucleot
214	15.2	0.6	20	1	AAZ03193	Human oligonucleot
215	15.2	0.6	20	1	AAZ03193	Human oligonucleot
216	15.2	0.6	20	1	AAZ03193	Human oligonucleot
217	15.2	0.6	20	1	AAZ03193	Human oligonucleot
218	15.2	0.6	20	1	AAZ03193	Human oligonucleot
219	15.2	0.6	20	1	AAZ03193	Human oligonucleot
220	15.2	0.6	20	1	AAZ03193	Human oligonucleot
221	15.2	0.6	20	1	AAZ03193	Human oligonucleot
222	15.2	0.6	20	1	AAZ03193	Human oligonucleot
223	15.2	0.6	20	1	AAZ03193	Human oligonucleot
224	15.2	0.6	20	1	AAZ03193	Human oligonucleot
225	15.2	0.6	20	1	AAZ03193	Human oligonucleot
226	15.2	0.6	20	1	AAZ03193	Human oligonucleot
227	15.2	0.6	20	1	AAZ03193	Human oligonucleot
228	15.2	0.6	20	1	AAZ03193	Human oligonucleot
229	15.2	0.6	20	1	AAZ03193	Human oligonucleot
230	15.2	0.6	20	1	AAZ03193	Human oligonucleot
231	15.2	0.6	20	1	AAZ03193	Human oligonucleot
232	15.2	0.6	20	1	AAZ03193	Human oligonucleot
233	15.2	0.6	20	1	AAZ03193	Human oligonucleot
234	15.2	0.6	20	1	AAZ03193	Human oligonucleot
235	15.2	0.6	20	1	AAZ03193	Human oligonucleot
236	15.2	0.6	20	1	AAZ03193	Human oligonucleot
237	15.2	0.6	20	1	AAZ03193	Human oligonucleot
238	15.2	0.6	20	1	AAZ03193	Human oligonucleot
239	15.2	0.6	20	1	AAZ03193	Human oligonucleot
240	15.2	0.6	20	1	AAZ03193	Human oligonucleot
241	15.2	0.6	20	1	AAZ03193	Human oligonucleot
242	15.2	0.6	20	1	AAZ03193	Human oligonucleot
243	15.2	0.6	20	1	AAZ03193	Human oligonucleot
244	15.2	0.6	20	1	AAZ03193	Human oligonucleot
245	15.2	0.6	20	1	AAZ03193	Human oligonucleot
246	15.2	0.6	20	1	AAZ03193	Human oligonucleot
247	15.2	0.6	20	1	AAZ03193	Human oligonucleot
248	15.2	0.6	20	1	AAZ03193	Human oligonucleot
249	15.2	0.6	20	1	AAZ03193	Human oligonucleot
250	15.2	0.6	20	1	AAZ03193	Human oligonucleot
251	15.2	0.6	20	1	AAZ03193	Human oligonucleot
252	15.2	0.6	20	1	AAZ03193	Human oligonucleot

Mouse Ig-kappa Iea	Human C/EBP beta p	Human CD44 antisense	Human multiple tan
Oligonucleotide hy	Human ADAMTS prote	Human CD44 antisense	Human multiple tan
Oligonucleotide hy	PCR primer 3 relat	Human CD44 antisense	Human multiple tan
VEGF receptor Flt-1	Serum amyloid A1 m	Human CD44 antisense	Human multiple tan
Mouse immunoglobul	HIV PRT antisense	Human CD44 antisense	Human multiple tan
Murine SACL gene-s	Human oligonucleot	Human CD44 antisense	Human multiple tan
Human lysophosphol	Human oligonucleot	Human CD44 antisense	Human multiple tan
Laminin 5 expressi	Human rat-associat	Human CD44 antisense	Human multiple tan
Human TSP1 domain	AA156940-derived o	Human CD44 antisense	Human multiple tan
Human hiber44BP an	AI16833-derived oli	Human CD44 antisense	Human multiple tan
Human raf kinase p	AA644211-derived o	Human CD44 antisense	Human multiple tan
Human C/EBP beta p	PCR primer used in	Human CD44 antisense	Human multiple tan
Human ADAMTS prote	Primer of the live	Human CD44 antisense	Human multiple tan
PCR primer 3 relat	Primer of the live	Human CD44 antisense	Human multiple tan
Serum amyloid A1 m	Human Centromere p	Human CD44 antisense	Human multiple tan
HIV PRT antisense	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD44 antisense	Human multiple tan
Human oligonucleot	Human Centromere p	Human CD	

253	14.8	0.6	18	1	AAF21465	Human multiple tar
C 254	14.8	0.6	18	1	AAS05704	Polypyrrolidone reg
255	14.8	0.6	18	1	ABL30663	Human HLA genotypi
C 256	14.8	0.6	18	1	ABSG65939	Inhibitory oligonu
257	14.8	0.6	18	1	ABZ96456	Human nucleic acid
258	14.8	0.6	18	1	ABZ97159	Human MTA oligonuc
259	14.8	0.6	18	1	ABD20418	Human pulmonary ar
260	14.8	0.6	18	1	ABD32442	Human MTA oligo SE
C 261	14.8	0.6	18	1	ADH08326	Mutant gene fragme
C 262	14.8	0.6	18	1	ADM69504	Plant gene polymor
C 263	14.8	0.6	18	1	ADM76423	Human myeloid leuk
C 264	14.8	0.6	18	1	ADR27625	Monoclonal antibod
C 265	14.8	0.6	19	1	AAT0705	Human trkC recepto
C 266	14.8	0.6	19	1	AAT77561	Wheat microselli
C 267	14.8	0.6	19	1	AAZ01319	PCR primer for Pci
C 268	14.8	0.6	19	1	AAZ88855	Human trkC recepto
C 269	14.8	0.6	19	1	AAA46217	Primer IPM14F for
C 270	14.8	0.6	19	1	AAA84585	Cyclin E ribozyme
C 271	14.8	0.6	19	1	AAH59747	Cyclin E ribozyme
C 272	14.8	0.6	19	1	ABL57139	Human PKM gene spe
C 273	14.8	0.6	19	1	ADB25800	Human CYP2D6-relat
C 274	14.8	0.6	19	1	ACR79453	Serum amyloid A1 m
C 275	14.8	0.6	19	1	ADB65548	Human c-fos transc
C 276	14.8	0.6	19	1	ADB65664	Human c-fos siNA 1
C 277	14.8	0.6	19	1	ADB29461	Microgen activated
C 278	14.8	0.6	19	1	ADB29624	Microgen activated
C 279	14.8	0.6	19	1	ADB29711	Microgen activated
C 280	14.8	0.6	19	1	ADB29816	Microgen activated
C 281	14.8	0.6	19	1	ACH00745	Albino and pigment
C 282	14.8	0.6	19	1	ADP83712	Human breakpoint c
C 283	14.8	0.6	19	1	ADP84593	Human ABL1-targete
C 284	14.8	0.6	19	1	ADP84374	Human ABL1-targete
285	14.8	0.6	19	1	ADP83575	Human breakpoint c
286	14.8	0.6	19	1	ADG34885	Human TNF receptor
C 287	14.8	0.6	19	1	ADG35008	Human TNF receptor

ALIGNMENTS

RESULT 1
ABN43866/C
ID ABN43866 standard; DNA; 60 BP.
XX
AC ABN43866;
XX
DT 15-JUN-2002 (first entry)
XX
DE Human spliced transcript detection oligonucleotide SEQ ID NO:16614.
XX
KW Human; mouse; rat; splice transcript; detection; RNA transcript;
KW splice variant; transcriptome; oligonucleotide library; ss.
XX
OS Homo sapiens.
XX
PN WO200210449-A2.
XX
PD 07-FEB-2002.
XX
PF 20-JUL-2001; 2001WO-IB001903.
XX
PR 28-JUL-2000; 2000US-0221607P.
PR 02-MAY-2001; 2001US-0287724P.
XX
PA (COMP-) COMPUGEN INC.
XX
PI Shoshan A, Wasserman A, Mintz E, Mintz L, Feigler S;
XX
DR WPI; 2002-257383/30.
XX
PT New oligonucleotide libraries comprising oligonucleotides which
PT selectively hybridize to mRNAs transcribed from a transcription unit of a
PT genome, useful for detecting tissue-, pathology-, and developmental-

PT specific genes.
XX
BS Example 1; SEQ ID NO 16614; 47bp; English.
XX
CC The present invention describes oligonucleotide libraries for detecting
CC messenger RNAs that populate a (sub-)transcriptome, where the (sub-
CC)transcriptome comprises messenger RNAs transcribed from multiple
CC transcription units that populate a genome. The library comprises several
CC oligonucleotides, each capable of hybridising selectively to a set of
CC messenger RNAs transcribed from a given transcription unit of the genome,
CC which encodes one or more messenger RNA splice variants. The
CC oligonucleotide libraries are useful for detecting mRNAs from a
CC biological sample, in expression profiling studies, in qualitatively or
CC quantitatively characterising the corresponding transcriptome, and in
CC detecting RNA transcripts and splice variants of human or animal
CC transcriptomes. The libraries may also be used as specialised mini
CC libraries to detect transcripts of a sub-transcriptome under a particular
CC biological or pathological state, and so allowing the detection of tissue
CC - and pathology-specific genes such as those genes only expressed in
CC specific tissue under a specific pathological condition; to detect
CC developmental specific genes; and to detect RNA transcripts and splice
CC variants of a transcriptome of a patient suffering from a particular
CC disorder. ABR27253 to ABR59589 represent oligonucleotide sequences from
CC rats, humans and mice, which are used in the exemplification of the
CC present invention. N.B. The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 60 BP; 16 A; 7 C; 23 G; 14 T; 0 U; 0 Other;
XX
Query Match 2.5%; Score 60; DB 1; Length 60;
Best Local Similarity 100.0%; Pred. No. 6.3e-05;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1767 ACTTCTATACAGCCCTTATTGCGCACTACCCACGCTGTAGTCTGGAACGTGCA 1826
DB 60 ACTTCTATACAGCCCTTATTGCGCACTACCCACGCTGTAGTCTGGAACGTGCA 1
XX
RESULT 2
ADD27789
ID ADD27789 standard; cDNA; 65 BP.
XX
AC ADD27789;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human psoriasis related genes EST #1.
XX
KW Human; ss; psoriasis; Psoriasis-related gene; body map; EST;
KW expressed sequence tag.
XX
OS Homo sapiens.
XX
PN JP2002330770-A.
XX
PD 19-NOV-2002.
XX
PF 25-MAY-2001; 2001JP-00156529.
XX
PR 30-AUG-2000; 2000JP-00260818.
PR 01-NOV-2000; 2000JP-00334042.
XX
PA (TANA) TANABE SEIYAKU CO.
XX
PI WPI; 2003-460750/44.
XX
DR Gene of which expression changes in psoriasis and examination directed to
XX said gene, a recombinant vector, a host cell.
PT Claim 7; SEQ ID NO 4; 27bp; Japanese.
XX
XX The invention relates to detection of psoriasis by determining the

expression level of a Psoriasis-related gene in a biosample collected from a human or nonhuman animal individual. The gene consisting of one of 5 538-2713 nucleotide sequences, given in the specification, or a DNA hybridizing with it under stringent conditions are disclosed. The method is used for the detection of Psoriasis. The Psoriasis-related gene was detected by the body map method. The present sequence is an EST (expressed sequence tag) from one of the psoriasis-related genes.

XX Sequence 65 BP; 24 A; 11 C; 11 G; 19 T; 0 U; 0 Other;

XX Query Match 2.5%; Score 60; DB 1; Length 65;
Best Local Similarity 100.0%; Pred. No. 6e-05;
Matches 60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2362 GATCATTGACCAATGACACTTTGTATATGCTTGAATAATGAAGTGAATCC 2421
1 GATCATTGACCAATGACACTTTGTATATGCTTGAATAATGAAGTGAATCC 60

DB 1 GATCATTGACCAATGACACTTTGTATATGCTTGAATAATGAAGTGAATCC 60

RESULT 3
AAT20778
ID AAT20778 standard; cDNA to mRNA; 65 BP.
AC AAT20778;
XX 26-JUL-1996 (first entry)
XX Human gene signature HUMGS01999.
XX
XX Human gene signature; messenger RNA; mRNA; relative abundance; frequency;
KW human; cloning; mapping; non-biased library; diagnosis; detection;
KW cell typing; abnormal cell function; ss.
XX
XX Homo sapiens.
OS
XX W09514772-A1.
EN
XX 01-JUN-1995.
PD
XX 11-NOV-1994; 94MO-JP001916.
PF
XX 12-NOV-1993; 93JP-00355504.
PR
XX (MATS/) MATSUBARA K.
PA (OKUBO/) OKUBO K.
XX Matsubara K, Okubo K;
PI
XX WPI; 1995-206931/27.
DR
XX Single-stranded DNA for identifying gene signatures - isolated from 3'-
PT directed human cDNA library that reflects relative abundance of corresp.
PT mRNA in specific human tissues.
XX
XX Claim 1; Page 721; 2245pp; Japanese.

XX A single-stranded DNA (or its complementary strand or the corresp. double
CC -stranded DNA) which comprises one of the 7837 "GS" sequences given in
CC AAT19001-126637 and which is able to hybridize to part of human genomic
CC DNA, cDNA or mRNA is claimed. The GS (Gene Signature) sequences were
CC obtained from 3'-directed cDNA libraries prepared from various human
CC tissues; synthesis of cDNA was initiated from the 3'-end of mRNA by using
CC poly(I) as the sole primer. Since the 3'- untranslated sequence is unique
CC to a particular mRNA species, almost all the 3'-oriented cDNAs hybridize
CC with specific mRNAs. Each library is constructed so as to reflect
CC accurately the relative abundance of different mRNAs in the particular
CC tissue from which it was derived. The appearance frequency of a given GS
CC in a cDNA library can be determined (esp. using primers and probes
CC derived from the GS sequences) as a means of diagnosing abnormal cell
CC function or for recognising different cell types

XX Sequence 65 BP; 24 A; 10 C; 9 G; 19 T; 0 U; 3 Other;

Query Match 2.4%; Score 57; DB 1; Length 65;
Best Local Similarity 96.6%; Pred. No. 0.00015;
Matches 57; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2362 GATCATTGACCAATGACACTTTGTATATGCTTGAATAATGAAGTGAATCC 2420
1 GATCATTGACCAATGACACTTTGTATATGCTTGAATAATGAAGTGAATCC 59

DB 1 GATCATTGACCAATGACACTTTGTATATGCTTGAATAATGAAGTGAATCC 59

RESULT 4
AAL32434/c
ID AAL32434 standard; DNA; 51 BP.
AC AAL32434;
XX 24-JAN-2002 (first entry)
XX
XX Human SNP oligonucleotide #5642.
XX
XX Immunosuppressive; immunostimulatory; antiinflammatory; cytostatic;
KW neuroprotective; antimicrobial; gene therapy; vaccine; amylose; cancer;
KW amyloid protein; angiotensin; apoptosis related protein; cadherin;
KW cyclin; polymerase; oncogene; histone; kinase; colony stimulating factor;
KW complement related protein; cytochrome; kinase; cytokine; interferon;
KW interleukin; G-protein coupled receptor; thioesterase; inflammation;
KW multifactorial disease; autoimmune disease; infection;
KW nervous system disease; ss.
XX
XX Homo sapiens.
OS
XX W0200147944-A2.
EN
XX 05-JUL-2001.
PD
XX 28-DEC-2000; 2000MO-US035498.
PF
XX 28-DEC-1999; 99US-0173419P.
PR 27-DEC-2000; 2000US-00173419.
XX
XX (CURA-) CURAGEN CORP.
PA
XX Shinketsu RA, Leach M;
PI
XX WPI; 2001-465210/50.
DR
XX Polymorphic nucleic acids encoding e.g. amyloses, cyclins, polymerases,
PT oncogenes and histones, useful for diagnosing and treating, e.g. cancer,
PT autoimmune diseases and infections.
XX
XX Claim 1; Page 3012; 4143pp; English.

XX The present invention relates to oligonucleotides encoding polymorphic
CC variants of proteins related to amyloses, amyloid proteins, angiotensin,
CC apoptosis related proteins, cadherin, cyclin, polymerase, oncogenes,
CC histones, kinases, colony stimulating factors, complement related
CC protein coupled receptors and thioesterases. The present sequence is one
CC such oligonucleotide. The oligonucleotides and the peptides encoded by
CC them may be used in the prevention, diagnosis and treatment of diseases
CC associated with inappropriate expression of the proteins listed above.
CC Disorders that may be prevented, diagnosed and/or treated include
CC multifactorial diseases with a genetic component, such as autoimmune
CC diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes,
CC systemic lupus erythematosus and Grave's disease), inflammation, cancer
CC (e.g. cancers of the bladder, brain, breast, colon and kidney,
CC leukemia), diseases of the nervous system and an infection of pathogenic
CC organisms

XX Sequence 51 BP; 8 A; 14 C; 16 G; 13 T; 0 U; 0 Other;

XX Query Match 1.7%; Score 40.5; DB 1; Length 51;
Best Local Similarity 98.1%; Pred. No. 0.031;
Matches 51; Conservative 0; Mismatches 0; Indels 1; Gaps 1;

OY 1390 TGAAGTGAAGCCGCTTGGGGGCAACTGCTGAGAACCAAGCTCAATC 1441
|||||
DB 51 TGAAGTGAAGCCAG-CTTGGGGGCAACTGCTGAGAACCAAGCTCAATC 1

RESULT 5
AAS56898
ID AAS56898 standard; DNA; 28 BP.

AC AAS56898;

DT 06-NOV-2003 (first entry)

DE Human 86606 DGAT2 gene specific PCR probe.

XX Human; diacylglycerol acyltransferase 2; DGAT2; obesity; arrhythmia;
KW coronary artery disease; hypertension; heart failure; tissue typing;
KW aberrant lipogenesis; cardiovascular disorder; atherosclerosis; angina;
KW atrial fibrillation; dilated cardiomyopathy; idiopathic cardiomyopathy;
KW diabetes; chromosome mapping; forensic biology; PCR; probe; ss.

OS Homo sapiens.

PN WO200305363-A2.

PD 03-JUL-2003.

PF 19-DEC-2002; 2002WO-US040974.

XX 19-DEC-2001; 2001US-0341947P.

PR 19-SEP-2002; 2002US-0411859P.

XX (MILL-) MILLENNIUM PHARM INC.

PI Gimeno RE, Wu Z, Kapeller-Lidemann R, Hubbard BK;

XX WPI; 2003-559092/52.

DR New human diacylglycerol acyltransferase 2 (DGAT2) family member
XX polypeptide and nucleic acid molecules, useful for diagnosing and
PT treating obesity, diabetes, atherosclerosis, aberrant lipogenesis or
PT triglyceride synthesis.

PS Example 3; Page 100; 154pp; English.

XX The invention relates to human diacylglycerol acyltransferase 2 (DGAT2)
CC family members and their uses. DGAT2 family member sequences or their
CC modulators are useful for diagnosing and treating a subject with a
CC disorder associated with the aberrant DGAT family member polypeptide
CC activity or nucleic acid expression, such as a disorder associated with
CC obesity, diabetes, aberrant lipogenesis or triglyceride synthesis, or
CC cardiovascular disorder (e.g. atherosclerosis, coronary artery disease,
CC hypertension, heart failure, atrial fibrillation, arrhythmias, dilated
CC cardiomyopathy, idiopathic cardiomyopathy or angina). The invention is
CC also useful in screening assays (e.g. tissue typing, chromosome mapping,
CC or in forensic biology), in predictive medicine (e.g. diagnostic assays,
CC prognostic assays, monitoring clinical trials or pharmacogenetics), or as
CC surrogate markers (e.g. markers of disease states or markers of drug
CC activity). The present sequence is human DGAT2 gene specific PCR probe.
CC This sequence is used in the exemplification of the invention

XX Sequence 28 BP; 6 A; 10 C; 6 G; 6 T; 0 U; 0 Other;

SO Query Match 1.2%; Score 28; DB 1; Length 28;

Best Local Similarity 100.0%; Pred. No. 2.3;

OY 1800 CCAGCTGCTCTAGTCTGAACTGACG 1827
|||||
DB 1 CCAGCTGCTCTAGTCTGAACTGACG 28

RESULT 6
AAX06395/cf
ID AAX06395 standard; DNA; 31 BP.

XX AAX06395;

DT 31-MAR-1999 (first entry)

DE Human biallelic polymorphic DNA fragment SGC33608.

XX Polymorphism; biallelic; paternity testing; forensic; genetic mapping;
KW phenotypic typing; medicament; disease; marker; human; ss.

OS Homo sapiens.

PN WO9858529-A2.

PD 30-DEC-1998.

PF 22-JUN-1998; 98WO-US012930.

XX 24-JUN-1997; 97US-0050594P.

XX (AFFY-) AFFYMETRIX INC.

PI Lipshutz RJ, Chee M, Fan J, Bero A;

XX WPI; 1999-080963/07.

DR New nucleic acid segments containing polymorphic sites - used for, e.g.
XX detecting a disease phenotype, in forensics, paternity testing or genetic
PT mapping of phenotypic traits.

PS Claim 1; Page 25; 61pp; English.

XX Sequences AAX06101-X06558 represent human DNA fragments which contain
CC biallelic polymorphic markers. The base occupying the polymorphic site is
CC indicated by the appropriate IUPAC-IUB ambiguity code. These fragments
CC can be used in a method for determining polymorphic forms in an
CC individual. The invention further provides computer-readable storage
CC medium for storing data for access by an application programme being
CC executed on a data processing system. Such a method comprises a data
CC structure stored in the computer-readable storage medium, the data
CC structure including information resident in a database used by the
CC application programme and including records, each record comprising
CC information identifying a polymorphism shown in the above sequences. The
CC products and methods can be used for analysing polymorphic sites in
CC individuals for testing for the presence of a disease phenotype or in
CC forensics, paternity testing or genetic mapping of phenotypic traits.
CC They can also be used for the production of polypeptides expressed by
CC variant genes and for the production of transgenic animals. The nucleic
CC acid segments can also be used in the manufacture of medicaments for the
CC treatment or prophylaxis of diseases

XX Sequence 31 BP; 4 A; 9 C; 10 G; 7 T; 0 U; 1 Other;

SO Query Match 1.1%; Score 27.6; DB 1; Length 31;

Best Local Similarity 96.4%; Pred. No. 2.4;

OY 1404 CTTGGGGGCAACTGCTGAGAACCA 1431
|||||
DB 28 CTTGGGGGCAACTGCTGAGAACCA 1

XX CTTGGGGGCAACTGCTGAGAACCA 1

RESULT 7

ID ADO42529 standard; DNA; 27 BP.

XX ADO42529;

DT 15-JUL-2004 (first entry)

DE Human NOVX probe #1.
XX
KW Human; NOVX; ss; cancer; atherosclerosis; diabetes; Alzheimer's disease;
KW Parkinson's disease; graft-versus-host disease; scleroderma;
KW hypertension; haemophilia; idiopathic thrombocytopenic purpura;
KW immunodeficiency; AIDS; dyslipidemia; obesity; Crohn's disease;
KW bronchial asthma; anorexia; cancer-associated cachexia;
KW multiple sclerosis; fertility; probe.
OS Homo sapiens.
XX
PN US2004058338-A1.
PD 25-MAR-2004.
XX
PF 02-DEC-2002; 2002US-00307817.
XX
PR 03-DEC-2001; 2001US-0336881P.
PR 05-DEC-2001; 2001US-0336820P.
PR 07-DEC-2001; 2001US-0338285P.
PR 07-DEC-2001; 2001US-0338318P.
PR 10-DEC-2001; 2001US-0338989P.
PR 10-DEC-2001; 2001US-0339022P.
PR 11-DEC-2001; 2001US-0339314P.
PR 11-DEC-2001; 2001US-0339516P.
PR 11-DEC-2001; 2001US-0339517P.
PR 11-DEC-2001; 2001US-0339611P.
PR 12-DEC-2001; 2001US-0340981P.
PR 12-DEC-2001; 2001US-0341346P.
PR 14-DEC-2001; 2001US-0340390P.
PR 14-DEC-2001; 2001US-0340440P.
PR 14-DEC-2001; 2001US-0340565P.
PR 14-DEC-2001; 2001US-0340608P.
PR 14-DEC-2001; 2001US-0341144P.
PR 17-DEC-2001; 2001US-0341477P.
PR 17-DEC-2001; 2001US-0341540P.
PR 18-DEC-2001; 2001US-0341768P.
PR 20-DEC-2001; 2001US-0344592P.
PR 31-DEC-2001; 2001US-0344903P.
PR 01-FEB-2002; 2002US-0353286P.
PR 01-FEB-2002; 2002US-0353288P.
PR 26-FEB-2002; 2002US-0355999P.
PR 26-FEB-2002; 2002US-0359626P.
PR 26-FEB-2002; 2002US-0359671P.
PR 27-FEB-2002; 2002US-0359914P.
PR 27-FEB-2002; 2002US-0359956P.
PR 28-FEB-2002; 2002US-0360924P.
PR 28-FEB-2002; 2002US-0360964P.
PR 28-FEB-2002; 2002US-0361028P.
PR 28-FEB-2002; 2002US-0361256P.
PR 28-FEB-2002; 2002US-0361264P.
PR 05-MAR-2002; 2002US-0361770P.
PR 05-MAR-2002; 2002US-0362230P.
PR 13-MAR-2002; 2002US-0364181P.
PR 13-MAR-2002; 2002US-0364238P.
PR 15-MAR-2002; 2002US-0365025P.
PR 17-APR-2002; 2002US-0372888P.
PR 15-MAY-2002; 2002US-0380981P.
PR 16-MAY-2002; 2002US-0381004P.
PR 17-MAY-2002; 2002US-0381495P.
PR 28-MAY-2002; 2002US-0383534P.
PR 28-MAY-2002; 2002US-0383744P.
PR 29-MAY-2002; 2002US-0383829P.
PR 29-MAY-2002; 2002US-0384024P.
PR 02-JUL-2002; 2002US-0393332P.
PR 06-AUG-2002; 2002US-0401315P.
PR 07-AUG-2002; 2002US-0401788P.
PR 20-AUG-2002; 2002US-0404675P.
PR 23-AUG-2002; 2002US-0405400P.
PR 23-AUG-2002; 2002US-0405684P.
PR 23-AUG-2002; 2002US-0405687P.
PR 23-AUG-2002; 2002US-0405698P.

PR 26-AUG-2002; 2002US-0406353P.
XX
PA (AGEE/) AGEE M. L.
PA (AUSO/) ALSOBROOK J P.
PA (ANDE/) ANDERSON D W.
PA (BERG/) BERGHS C.
PA (BOLD/) BOLDOS F L.
PA (BURG/) BURGESS C E.
PA (CATT/) CATTERTON E.
PA (DIFT/) DIFTIPO V A.
PA (EDIN/) EDINGER S R.
PA (EISE/) EISEN A.
PA (ELLE/) ELLERMAN K.
PA (GANG/) GANGOLLI E A.
PA (GERL/) GERLACH V.
PA (GORM/) GORMAN L.
PA (ROTH/) ROTHBERG B G.
PA (GUOX/) GUO X S.
PA (HERR/) HERRMANN J L.
PA (HALV/) HALVORSEN Y.
PA (JTWI/) JI W.
PA (KERU/) KERUDA R.
PA (KHRA/) KHRAMTSOV N V.
PA (LARO/) LAROCHELLE W J.
PA (LEPL/) LEPLLEY D M.
PA (LILL/) LI L.
PA (MACD/) MACDOUGALL J R.
PA (MILL/) MILLER C E.
PA (ORTT/) ORT T.
PA (PADI/) PADIGARU M.
PA (PATT/) PATTURAJAN M.
PA (PENNA/) PENNA C E A.
PA (PEYM/) PEYMAN J A.
PA (RIEG/) RIEGER D K.
PA (ROTH/) ROTHENBERG M E.
PA (SHEN/) SHENOY S G.
PA (SMIT/) SMITHSON G.
PA (SPAD/) SPADERNA S K.
PA (SPYT/) SPYTEK K A.
PA (STON/) STONE D J.
PA (TAUP/) TAUPIER R J.
PA (VERN/) VERNET C A M.
PA (VOSS/) VOSS E Z.
PA (ZHON/) ZHONG M.
XX
PI Agee ML, Alsobrook JP, Anderson DM, Berghs C, Boldos FL;
PI Buggess CE, Catterton E, Diftipo VA, Edinger SR, Eisen A;
PI Ellerman K, Gangolli EA, Gerlach V, Gorman L, Rothberg BG, Guo XS;
PI Herrmann JL, Halvorsen Y, Ji W, Kekuda R, Khrantsov NV;
PI Larochele WJ, Lepley DM, Li L, Macdougall JR, Miller CE, Ort T;
PI Padigar M, Paturajan M, Penna CE, Peyman JA, Rieger DK;
PI Rothenberg ME, Shenoy SG, Smithson G, Spaderna SK, Spytek KA;
PI Stone DJ, Taupier RJ, Vernet CM, Voss EZ, Zhong M;
XX
DR WPI; 2004-268786/25.
XX
PT New human NOVX polypeptides and nucleic acid molecules, useful for
PT diagnosing, preventing or treating NOVX-associated disorder, e.g. cancer,
PT atherosclerosis, diabetes, Alzheimer's disease, Parkinson's disease or
PT scleroderma.
XX
PS Example D; SEQ ID NO 378; 610bp; English.
XX
CC The invention relates to human NOVX polypeptides and the polynucleotides
CC encoding them. The invention also relates to antibodies specific to the
CC NOVX polypeptides. The polypeptides, polynucleotides and antibodies are
CC useful for manufacturing a medicament for treating a syndrome associated
CC with a human disease, such as a pathology associated with the NOVX
CC polypeptide. The sequences are useful for diagnosing, treating or
CC preventing a NOVX-associated disorder, e.g., cancer, atherosclerosis,
CC diabetes, Alzheimer's disease, Parkinson's disease, graft-versus-host
CC disease, scleroderma, hypertension, haemophilia, idiopathic
CC thrombocytopenic purpura, immunodeficiencies, AIDS, dyslipidemia,

CC obesity, Crohn's disease, bronchial asthma, anorexia, cancer-associated
CC cachexia, multiple sclerosis or fertility. The nucleic acids may be used
CC as hybridisation probes, in chromosome mapping, in tissue typing, in
CC preventive medicine or in pharmacogenomics. This sequence represents a
CC probe used in analysis of expression of a human NOVX polynucleotide of
CC the invention.

XX Sequence 27 BP; 3 A; 10 C; 5 G; 9 T; 0 U; 0 Other;

Query Match 1.1%; Score 27; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 3.2;
Matches 27; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1167 ATCTTCATGTCGAGGCTCTTCTCC 1193
Db 1 ATCTTCATGTCGAGGCTCTTCTCC 27

RESULT 8
AAA37275/C
ID AAA37275 standard; DNA; 24 BP.

XX AAA37275;

DT 08-AUG-2000 (first entry)

XX Human PRO1433 reverse PCR primer SEQ ID NO:294.

KW Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
KW transmembrane; secretion; immunoadhesion; pharmaceutical; screening;
KW PCR primer; hybridisation; probe; ss.

XX Homo sapiens.

XX MO200012708-A2.

PD 09-MAR-2000.

PF 01-SEP-1999; 99WO-US020111.

XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100644P.
PR 16-SEP-1998; 98US-0100646P.
PR 16-SEP-1998; 98US-0100647P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100663P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.

PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102966P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106033P.
PR 27-OCT-1998; 98US-0106034P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106385P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 30-OCT-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106933P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.

PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108825P.
PR 17-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PA (GETH) GENENTECH INC.
XX Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
PI WPI; 2000-237871/20.
XX
XX WPI; 2000-237871/20.
XX
XX New mammalian DNA sequences encoding transmembrane, receptor or secreted
PT PRO polypeptides, useful for screening of potential peptide or small
PT molecule inhibitors of the relevant receptor/ligand interactions.
XX
XX Example 85; Page 445; 773pp; English.
XX
XX AAA37022 to AAA37144 encode the new isolated human transmembrane,
CC receptor or secreted PRO polypeptides given in AA99340 to AA99462. The
CC transmembrane and receptor PRO proteins can be used for screening of
CC potential peptide or small molecule inhibitors of the relevant
CC receptor/ligand interactions. The polypeptides and nucleotide sequences
CC encoding them have various industrial applications, including uses as
CC pharmaceutical and diagnostic agents. AAA37145 to AAA37350 represent PCR
CC primers and hybridisation probes used in the isolation of the PRO
XX polypeptides from the present invention
XX
XX Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1463 GGAGTGTATGCGGTCTGTGG 1486
Db 24 GGAGTGTATGCGGTCTGTGG 1
RESULT 9
ID AAA37274 standard; DNA; 24 BP.
XX AAA37274;
AC
XX
XX 08-AUG-2000 (first entry)
DT
XX
DE Human PRO1433 forward PCR primer SEQ ID NO:293.
XX
XX Human; PRO polypeptide; membrane bound protein; receptor; diagnosis;
KW transmembrane; secretion; immunoadhesion; pharmaceutical; screening;
KW PCR primer; hybridisation; probe; ss.
XX
XX Homo sapiens.
XX
XX WO200012708-A2.
XX
XX 09-MAR-2000.
PD
XX 01-SEP-1999; 99WO-US020111.
PF
XX 01-SEP-1998; 98US-0098716P.
PR

PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101473P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102547P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103335P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.

PR 08-OCT-1998; 98US-0103711P.
 PR 14-OCT-1998; 98US-0104257P.
 PR 20-OCT-1998; 98US-0104987P.
 PR 20-OCT-1998; 98US-0105000P.
 PR 20-OCT-1998; 98US-0105002P.
 PR 21-OCT-1998; 98US-0105104P.
 PR 22-OCT-1998; 98US-0105169P.
 PR 22-OCT-1998; 98US-0105266P.
 PR 26-OCT-1998; 98US-0105693P.
 PR 26-OCT-1998; 98US-0105694P.
 PR 27-OCT-1998; 98US-0105807P.
 PR 27-OCT-1998; 98US-0105881P.
 PR 27-OCT-1998; 98US-0105882P.
 PR 27-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106029P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.
 PR 28-OCT-1998; 98US-0106178P.
 PR 29-OCT-1998; 98US-0106248P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 29-OCT-1998; 98US-0106500P.
 PR 30-OCT-1998; 98US-0106464P.
 PR 03-NOV-1998; 98US-0106856P.
 PR 03-NOV-1998; 98US-0106902P.
 PR 03-NOV-1998; 98US-0106905P.
 PR 03-NOV-1998; 98US-0106919P.
 PR 03-NOV-1998; 98US-0106932P.
 PR 03-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.
 PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108867P.
 PR 17-NOV-1998; 98US-0108925P.
 PR 18-NOV-1998; 98US-0108848P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108850P.
 PR 18-NOV-1998; 98US-0108851P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;
 XX
 DR WPI; 2000-237871/20.
 XX
 XX New mammalian DNA sequences encoding transmembrane, receptor or secreted
 PT PRO polypeptides, useful for screening of potential peptide or small
 PT molecule inhibitors of the relevant receptor/ligand interactions.
 XX
 PS Example 85; Page 445; 773pp; English.
 XX
 CC AAA37022 to AAA37144 encode the new isolated human transmembrane,
 CC receptor or secreted PRO polypeptides given in AA959340 to AA959462. The
 CC transmembrane and receptor PRO proteins can be used for screening of
 CC potential peptide or small molecule inhibitors of the relevant
 CC receptor/ligand interactions. The polypeptides and nucleotide sequences
 CC encoding then have various industrial applications, including uses as
 CC pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent PCR
 CC primers and hybridisation probes used in the isolation of the PRO
 CC polypeptides from the present invention
 XX
 SQ Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 24; DB 1; Length 24;
 Beat Local Similarity 100.0%; Pred. No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1041 GCTGACCTGTTCCCATCTACTCC 1064
 Db 1 GCTGACCTGTTCCCATCTACTCC 24
 RESULT 10
 AAF54410
 ID AAF54410 standard; DNA; 24 BP.
 XX
 AC AAF54410;
 XX
 DT 02-APR-2001 (first entry)
 XX
 DE Probe #43 used in the identification of proteins.
 XX
 KW Secreted; transmembrane; gene therapy; ss.
 XX
 OS Unidentified.
 XX
 PN WO200078961-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 18-FEB-2000; 2000WO-US004342.
 XX
 XX 23-JUN-1999; 99US-0141037P.
 XX 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US030095.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 XX
 XX (GETH) GENENTECH INC.
 PA
 PI Baker KP, Botstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S;
 PI Gao W, Goddard A, Godowski PJ, Grimaldi CJ, Gurney AL, Hillan KJ;
 PI Pan J, Paoletti NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
 PI Williams PM, Wood WI;
 XX
 DR WPI; 2001-071395/08.
 XX
 PT Secreted and transmembrane proteins and nucleic acids designated PRO,
 PT useful as hybridization probes, in chromosome and gene mapping and gene
 PT therapy.
 XX
 PS Example 84; Page 458; 787pp; English.
 XX
 CC The present invention relates to secreted and transmembrane proteins.
 CC These proteins and the DNA encoding them may be used as hybridization
 CC probes, in chromosome and gene mapping and in the generation of anti-
 CC sense RNA and DNA. They may also be used used to generate either
 CC transgenic animals or knockout animals which are in turn useful for
 CC development and screening of therapeutically useful reagents. The nucleic
 CC acids may also be used in gene therapy
 XX
 SQ Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;
 XX
 Oy Query Match 1.0%; Score 24; DB 1; Length 24;
 Beat Local Similarity 100.0%; Pred. No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1041 GCTGACCTGTTCCCATCTACTCC 1064
 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 11
ID AAF54411 standard; DNA; 24 BP.
XX
XX AAF54411;
XX
DT 02-APR-2001 (first entry)
XX
DE DNA encoding protein of the invention #82.
XX
XX Secreted; transmembrane; gene therapy; ss.
XX
XX Unidentified.
XX
XX WO200078961-A1.
XX
XX PD 28-DEC-2000.
XX
XX PF 18-FEB-2000; 2000WO-US004342.
XX
XX PR 23-JUN-1999; 99US-0141037P.
XX PR 20-JUL-1999; 99US-0144758P.
XX PR 26-JUL-1999; 99US-0145698P.
XX PR 01-SEP-1999; 99WO-US020111.
XX PR 29-OCT-1999; 99US-0162506P.
XX PR 30-NOV-1999; 99WO-US028313.
XX PR 02-DEC-1999; 99WO-US028551.
XX PR 16-DEC-1999; 99WO-US020095.
XX PR 05-JAN-2000; 2000WO-US000219.
XX PR 06-JAN-2000; 2000WO-US000376.
XX
XX PA (GETH) GENENTECH INC.
XX
XX PI Baker KP, Bostein D, Deenoyers I, Eaton DL, Ferrara N, Fong S;
XX PI Gao W, Goddard A, Godowski P, Grimaldi CJ, Gurney AL, Hillan KJ,
XX PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
XX PI Williams PM, Wood WI;
XX
XX DR WPI, 2001-071395/08.
XX
XX PT Secreted and transmembrane proteins and nucleic acids designated PRO,
XX PT useful as hybridization probes, in chromosome and gene mapping and gene
XX PT therapy.
XX
XX PS Claim 2; Fig 163; 787pp; English.
XX
XX CC The present invention relates to secreted and transmembrane proteins.
XX CC These proteins and the DNA encoding them may be used as hybridization
XX CC probes, in chromosome and gene mapping and in the generation of anti-
XX CC sense RNA and DNA. They may also be used to generate either
XX CC transgenic animals or knockout animals which are in turn useful for
XX CC development and screening of therapeutically useful reagents. The nucleic
XX CC acids may also be used in gene therapy
XX
XX SQ Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred. No. 8.7;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1463 GGAAGTGCATGGCTGTCTGTGGG 1486
XX ||||||||||||||||||||
XX Db 24 GGAAGTGCATGGCTGTCTGTGGG 1

XX
DE Novel human secreted and transmembrane protein related primer #86.
XX
XX Human; secreted and transmembrane protein; PRO; angiogenesis;
XX endotheial cell proliferation; wound healing; immune response;
XX T-lymphocytes proliferation; neonatal heart hypertrophy; tumour;
XX cardiac insufficiency disorder; calcium flux; inflammation;
XX vascular endothelial growth factor-stimulated proliferation;
XX mammalian kidney mesangial cell proliferation; Berger disease;
XX nephropathy; Schanlein-Henoch purpura; celiac disease; Crohn's disease;
XX dermatitis herpetiformis; diabetes; haemoglobin Swich; insulinemia;
XX pancreatic beta-cell precursor cell differentiation; thalassemias;
XX obesity; auditory hair cell regeneration; hearing loss; bone disorder;
XX cartilage disorder; sports injury; arthritis; PCR; primer; ss.
XX
XX OS Homo sapiens.
XX
XX PN US2003073130-A1.
XX
XX PD 17-APR-2003.
XX
XX PF 11-DEC-2001; 2001US-00015869.
XX
XX PR 01-SEP-1998; 98US-0098716P.
XX PR 01-SEP-1998; 98US-0098723P.
XX PR 01-SEP-1998; 98US-0098749P.
XX PR 01-SEP-1998; 98US-0098750P.
XX PR 02-SEP-1998; 98US-0098801P.
XX PR 02-SEP-1998; 98US-0098821P.
XX PR 02-SEP-1998; 98US-0098831P.
XX PR 09-SEP-1998; 98US-0099536P.
XX PR 09-SEP-1998; 98US-0099596P.
XX PR 09-SEP-1998; 98US-0099598P.
XX PR 09-SEP-1998; 98US-0099602P.
XX PR 09-SEP-1998; 98US-0099642P.
XX PR 10-SEP-1998; 98US-0099741P.
XX PR 10-SEP-1998; 98US-0099754P.
XX PR 10-SEP-1998; 98US-0099763P.
XX PR 10-SEP-1998; 98US-0099792P.
XX PR 10-SEP-1998; 98US-0099808P.
XX PR 10-SEP-1998; 98US-0099812P.
XX PR 10-SEP-1998; 98US-0099815P.
XX PR 10-SEP-1998; 98US-0099816P.
XX PR 15-SEP-1998; 98US-0100385P.
XX PR 15-SEP-1998; 98US-0100388P.
XX PR 15-SEP-1998; 98US-0100390P.
XX PR 16-SEP-1998; 98US-0100584P.
XX PR 16-SEP-1998; 98US-0100627P.
XX PR 16-SEP-1998; 98US-0100661P.
XX PR 16-SEP-1998; 98US-0100662P.
XX PR 16-SEP-1998; 98US-0100664P.
XX PR 17-SEP-1998; 98US-0100683P.
XX PR 17-SEP-1998; 98US-0100684P.
XX PR 17-SEP-1998; 98US-0100710P.
XX PR 17-SEP-1998; 98US-0100711P.
XX PR 17-SEP-1998; 98US-0100919P.
XX PR 17-SEP-1998; 98US-0100930P.
XX PR 18-SEP-1998; 98US-0100848P.
XX PR 18-SEP-1998; 98US-0100849P.
XX PR 18-SEP-1998; 98US-0101014P.
XX PR 18-SEP-1998; 98US-0101068P.
XX PR 18-SEP-1998; 98US-0101071P.
XX PR 22-SEP-1998; 98US-0101279P.
XX PR 23-SEP-1998; 98US-0101471P.
XX PR 23-SEP-1998; 98US-0101472P.
XX PR 23-SEP-1998; 98US-0101474P.
XX PR 23-SEP-1998; 98US-0101475P.
XX PR 23-SEP-1998; 98US-0101476P.
XX PR 23-SEP-1998; 98US-0101477P.
XX PR 23-SEP-1998; 98US-0101479P.
XX PR 24-SEP-1998; 98US-0101738P.
XX PR 24-SEP-1998; 98US-0101741P.
XX PR 24-SEP-1998; 98US-0101915P.

PR	24-SEP-1998;	98US-0101916P.
PR	29-SEP-1998;	98US-0102207P.
PR	29-SEP-1998;	98US-0102240P.
PR	29-SEP-1998;	98US-0102307P.
PR	29-SEP-1998;	98US-0102330P.
PR	30-SEP-1998;	98US-0102331P.
PR	30-SEP-1998;	98US-0102444P.
PR	30-SEP-1998;	98US-0102487P.
PR	30-SEP-1998;	98US-0102570P.
PR	30-SEP-1998;	98US-0102571P.
PR	01-OCT-1998;	98US-0102684P.
PR	01-OCT-1998;	98US-0102687P.
PR	02-OCT-1998;	98US-0102965P.
PR	06-OCT-1998;	98US-0103258P.
PR	06-OCT-1998;	98US-0103449P.
PR	07-OCT-1998;	98US-0103314P.
PR	07-OCT-1998;	98US-0103315P.
PR	07-OCT-1998;	98US-0103388P.
PR	07-OCT-1998;	98US-0103395P.
PR	07-OCT-1998;	98US-0103396P.
PR	07-OCT-1998;	98US-0103401P.
PR	08-OCT-1998;	98US-0103633P.
PR	08-OCT-1998;	98US-0103678P.
PR	08-OCT-1998;	98US-0103679P.
PR	08-OCT-1998;	98US-0103711P.
PR	14-OCT-1998;	98US-0104257P.
PR	20-OCT-1998;	98US-0104987P.
PR	20-OCT-1998;	98US-0105000P.
PR	20-OCT-1998;	98US-0105002P.
PR	21-OCT-1998;	98US-0105149P.
PR	22-OCT-1998;	98US-0105169P.
PR	22-OCT-1998;	98US-0105266P.
PR	26-OCT-1998;	98US-0105693P.
PR	26-OCT-1998;	98US-0105694P.
PR	27-OCT-1998;	98US-0105807P.
PR	27-OCT-1998;	98US-0105881P.
PR	27-OCT-1998;	98US-0105882P.
PR	27-OCT-1998;	98US-0106062P.
PR	28-OCT-1998;	98US-0106023P.
PR	28-OCT-1998;	98US-0106029P.
PR	28-OCT-1998;	98US-0106030P.
PR	28-OCT-1998;	98US-0106032P.
PR	28-OCT-1998;	98US-0106033P.
PR	28-OCT-1998;	98US-0106178P.
PR	29-OCT-1998;	98US-0106248P.
PR	29-OCT-1998;	98US-0106384P.
PR	29-OCT-1998;	98US-0106500P.
PR	30-OCT-1998;	98US-0106464P.
PR	03-NOV-1998;	98US-0106856P.
PR	03-NOV-1998;	98US-0106902P.
PR	03-NOV-1998;	98US-0106905P.
PR	03-NOV-1998;	98US-0106919P.
PR	03-NOV-1998;	98US-0106932P.
PR	03-NOV-1998;	98US-0106934P.
PR	10-NOV-1998;	98US-0107783P.
PR	17-NOV-1998;	98US-0108775P.
PR	17-NOV-1998;	98US-0108779P.
PR	17-NOV-1998;	98US-0108787P.
PR	17-NOV-1998;	98US-0108788P.
PR	17-NOV-1998;	98US-0108801P.
PR	17-NOV-1998;	98US-0108802P.
PR	17-NOV-1998;	98US-0108806P.
PR	17-NOV-1998;	98US-0108807P.
PR	17-NOV-1998;	98US-0108867P.
PR	17-NOV-1998;	98US-0108925P.
PR	18-NOV-1998;	98US-0108848P.
PR	18-NOV-1998;	98US-0108849P.
PR	18-NOV-1998;	98US-0108850P.
PR	18-NOV-1998;	98US-0108851P.
PR	18-NOV-1998;	98US-0108852P.
PR	18-NOV-1998;	98US-0108858P.
PR	18-NOV-1998;	98US-0108904P.
PR	22-DEC-1998;	98US-0113296P.
PR	30-DEC-1998;	98US-0114223P.
PR	05-JAN-1999;	99MO-US000106.
PR	16-APR-1999;	99US-0129674P.
PR	23-JUN-1999;	99US-0141037P.
PR	20-JUL-1999;	99US-0144758P.
PR	26-JUL-1999;	99US-0145698P.
PR	01-SEP-1999;	99MO-US020111.
PR	15-SEP-1999;	99MO-US02119P.
PR	29-OCT-1999;	99US-0162506P.
PR	30-NOV-1999;	99MO-US028313.
PR	02-DEC-1999;	99MO-US028551.
PR	16-DEC-1999;	99MO-US030095.
PR	05-JAN-2000;	2000MO-US000219.
PR	06-JAN-2000;	2000MO-US000376.
PR	11-FEB-2000;	2000MO-US003565.
PR	18-FEB-2000;	2000MO-US004342.
PR	24-FEB-2000;	2000MO-US005004.
PR	02-MAR-2000;	2000MO-US005841.
PR	15-MAR-2000;	2000MO-US006884.
PR	17-MAY-2000;	2000MO-US013705.
PR	22-MAY-2000;	2000MO-US014042.
PR	30-MAY-2000;	2000MO-US014941.
PR	02-JUN-2000;	2000MO-US015264.
PR	23-AUG-2000;	2000MO-US023522.
PR	24-AUG-2000;	2000MO-US023328.
PR	08-NOV-2000;	2000MO-US030952.
PR	10-NOV-2000	

KW vascular endothelial growth factor-stimulated proliferation;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW nephropathy; Schnitzlein-Henoch purpura; celiac disease; Crohn's disease;
KW dermatitis herpetiformis; diabetes; hemoglobin electrophoresis;
KW pancreatic beta-cell precursor cell differentiation; thalassemias;
KW obesity; auditory hair cell regeneration; hearing loss; bone disorder;
KW cartilage disorder; sports injury; arthritis; PCR; primer; ss.
XX Homo sapiens.
XX US2003073130-A1.
XX 17-APR-2003.
PF 11-DEC-2001; 2001US-00015869.
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105002P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105163P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 30-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108825P.
PR 18-NOV-1998; 98US-0108846P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.

PR 15-SEP-1999; 99WO-US021194.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US030095.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US019941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 04-SEP-2001; 2001US-00946374.
 XX
 PA (GENTH) GENENTECH INC.
 XX
 PI Baker KP, Boretstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillen KJ;
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
 PI Williams PM, Wood WI,
 XX
 XX WPI; 2003-585293/55.
 XX
 PT Novel isolated PRO polypeptides e.g. PRO1130, PRO1275, PRO1418, PRO1555,
 PT PRO1787 that modulate glucose or free fatty acid uptake by skeletal
 PT muscle cells, and are useful for treating diabetes, hyper- or hypo-
 PT insulinemia.
 PT

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred.No.8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1041 GCTGACCTGTTCCCATCTACTCC 1064
 DB 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 14
 ACH04551
 ID ACH04551 standard; DNA; 24 BP.
 XX ACH04551;
 AC
 XX
 DT 01-OCT-2003 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
 XX
 KW Human; ss; PCR; secreted protein; transmembrane protein; PRO; vulnary;
 KW cardiant; antidiabetic; anorectic; antiarthritis; angiogenesis; cancer;
 KW adrenal cortical capillary; endothelial cell growth; wound healing;
 KW stimulated T-lymphocyte proliferation; immune response suppression;
 KW neonatal heart hypertrophy; cardiac insufficiency disorder;
 KW vascular endothelial growth factor; inflammation; mononuclear cell;
 KW eosinophil; diabetes; obesity; or hyper-insulinemia; hypo-insulinemia;
 KW chondrocyte redifferentiation; bone disorder; cartilage disorder;
 KW sports injury; arthritis; primer.
 XX
 OS Homo sapiens.

XX
 PN US2003044841-A1.
 XX
 PD 06-MAR-2003.
 XX
 PF 06-DEC-2001; 2001US-00006856.
 XX
 PR 01-SEP-1998; 98US-0098716P.
 PR 01-SEP-1998; 98US-0098723P.
 PR 01-SEP-1998; 98US-0098749P.
 PR 01-SEP-1998; 98US-0098750P.
 PR 02-SEP-1998; 98US-0098803P.
 PR 02-SEP-1998; 98US-0098821P.
 PR 02-SEP-1998; 98US-0098843P.
 PR 09-SEP-1998; 98US-0098536P.
 PR 09-SEP-1998; 98US-0098596P.
 PR 09-SEP-1998; 98US-0098598P.
 PR 09-SEP-1998; 98US-0098602P.
 PR 09-SEP-1998; 98US-0098642P.
 PR 10-SEP-1998; 98US-0098741P.
 PR 10-SEP-1998; 98US-0098754P.
 PR 10-SEP-1998; 98US-0098763P.
 PR 10-SEP-1998; 98US-0098792P.
 PR 10-SEP-1998; 98US-0098808P.
 PR 10-SEP-1998; 98US-0098812P.
 PR 10-SEP-1998; 98US-0098815P.
 PR 10-SEP-1998; 98US-0098816P.
 PR 15-SEP-1998; 98US-0100385P.
 PR 15-SEP-1998; 98US-0100388P.
 PR 15-SEP-1998; 98US-0100390P.
 PR 15-SEP-1998; 98US-0100584P.
 PR 16-SEP-1998; 98US-0100627P.
 PR 16-SEP-1998; 98US-0100661P.
 PR 16-SEP-1998; 98US-0100662P.
 PR 16-SEP-1998; 98US-0100664P.
 PR 17-SEP-1998; 98US-0100683P.
 PR 17-SEP-1998; 98US-0100684P.
 PR 17-SEP-1998; 98US-0100710P.
 PR 17-SEP-1998; 98US-0100711P.
 PR 17-SEP-1998; 98US-0100919P.
 PR 17-SEP-1998; 98US-0100930P.
 PR 18-SEP-1998; 98US-0100848P.
 PR 18-SEP-1998; 98US-0100849P.
 PR 18-SEP-1998; 98US-0101014P.
 PR 18-SEP-1998; 98US-0101068P.
 PR 18-SEP-1998; 98US-0101069P.
 PR 22-SEP-1998; 98US-0101071P.
 PR 23-SEP-1998; 98US-0101471P.
 PR 23-SEP-1998; 98US-0101472P.
 PR 23-SEP-1998; 98US-0101474P.
 PR 23-SEP-1998; 98US-0101475P.
 PR 23-SEP-1998; 98US-0101476P.
 PR 23-SEP-1998; 98US-0101477P.
 PR 23-SEP-1998; 98US-0101479P.
 PR 24-SEP-1998; 98US-0101743P.
 PR 24-SEP-1998; 98US-0101744P.
 PR 24-SEP-1998; 98US-0101915P.
 PR 24-SEP-1998; 98US-0102016P.
 PR 29-SEP-1998; 98US-0102207P.
 PR 29-SEP-1998; 98US-0102240P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102330P.
 PR 29-SEP-1998; 98US-0102331P.
 PR 30-SEP-1998; 98US-0102484P.
 PR 30-SEP-1998; 98US-0102487P.
 PR 30-SEP-1998; 98US-0102570P.
 PR 30-SEP-1998; 98US-0102571P.
 PR 01-OCT-1998; 98US-0102684P.
 PR 01-OCT-1998; 98US-0102687P.
 PR 02-OCT-1998; 98US-0102965P.
 PR 06-OCT-1998; 98US-0103258P.
 PR 06-OCT-1998; 98US-0103449P.

[illegible]

PR	18-FEB-2000;	200OWO-US004342.
PR	24-FEB-2000;	200OWO-US005004.
PR	02-MAR-2000;	200OWO-US005841.
PR	15-MAR-2000;	200OWO-US006884.
PR	17-MAY-2000;	200OWO-US013705.
PR	22-MAY-2000;	200OWO-US014042.
PR	30-MAY-2000;	200OWO-US014941.
PR	02-JUN-2000;	200OWO-US015264.
PR	23-AUG-2000;	200OWO-US023328.
PR	24-AUG-2000;	200OWO-US023328.
PR	08-NOV-2000;	200OWO-US030952.
PR	10-NOV-2000;	200OWO-US030873.
PR	01-DEC-2000;	200OWO-US032678.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	01-JUN-2001;	2001WO-US017800.
PR	20-JUN-2001;	2001WO-US019692.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	04-SEP-2001;	2001US-00946374.
XX		
PA	(GETH) GENENTECH INC.	
XX		
P1	Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,	
P1	Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gueney AL, Hillan KJ,	
P1	Pan J, Pooni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK,	
P1	Williams PM, Wood WI;	
XX		
DR	WPI; 2003-492259/46.	
XX		
PT	Novel secreted and transmembrane polypeptides and polynucleotides	
PT	encoding them useful for treating various cardiac insufficiency	
PT	disorders, bone and/or cartilage disorders such as sports injuries and	
PT	arthritis.	
XX		
Query Match:	1.0%; Score 24; DB 1; Length 24;	
Best Local Similarity	100.0%; Pred. No. 8.7;	
Matches	24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
OY	1041 GCTGACTCGGTTCATCTACTCC 1064	
Db	1 GCTGACCTGGTTCATCTACTCC 24	
RESULT 15		
ACH04552/c		
ID	ACH04552 standard; DNA; 24 BP.	
XX		
AC	ACH04552;	
XX		
DT	01-OCT-2003 (first entry)	
XX		
DE	Human secreted/transmembrane protein PRO1433 PCR primer #2.	
XX		
KM	Human; ss; PCR; secreted protein; transmembrane protein; PRO; vulnary;	
KM	cardiant; antidiabetic; anorectic; antiarthritic; angiogenesis; cancer;	
KM	adrenal cortical capillary; endothelial cell growth; wound healing;	
KM	stimulated T-lymphocyte proliferation; immune response suppression;	
KM	neonatal heart hypertrophy; cardiac insufficiency disorder;	
KM	vascular endothelial growth factor; inflammation; mononuclear cell;	
KM	eosinophil; diabetes; obesity; or hyper-insulinaemia; hypo-insulinaemia;	
KM	chondrocyte redifferentiation; bone disorder; cartilage disorder;	
KM	sports injury; arthritis; primer.	
XX		
OS	Homo sapiens.	
XX		
PN	US2003044841-A1.	
XX		
PD	06-MAR-2003.	
XX		
PF	06-DEC-2001; 2001US-00006856.	
XX		

PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GENTH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX MPI; 2003-492259/46.
XX
XX Novel secreted and transmembrane polypeptides and polynucleotides
PT encoding them useful for treating various cardiac insufficiency
PT disorders, bone and/or cartilage disorders such as sports injuries and
PT arthritis.
XX
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1463 GGAAGTCATGCGGTCTGTCGCG 1466
Db 24 GGAAGTCATGCGGTCTGTCGCG 1
RESULT 16
ACD68096/C
ID ACD68096 standard; DNA; 24 BP.
XX
AC ACD68096;
XX
DT 17-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein related primer #86.
XX
KW Human; secreted and transmembrane protein; PRO; gene therapy; vaccine;
KW tissue typing; chromosome identification; vaccine; PCR; primer; ss.
XX
XX Homo sapiens.
XX
XX US2003073129-A1.
XX
XX 17-APR-2003.
XX
XX 04-SEP-2001; 2001US-00946374.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099643P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.

PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 15-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100384P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 24-SEP-1998; 98US-0101917P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102242P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0104371P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105861P.

PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-APR-1999; 99US-00284291.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US036278.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001US-0087053.
PR 14-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001WO-US019692.

PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
XX
PA (GENTH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-585292/55.
XX
PT Novel isolated PRO polypeptides e.g. PRO1491 and PRO1571, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Example 85; Page 260; 561pp; English.
XX
CC The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (I), having at least 80% sequence identity to a sequence
CC selected from any one of the 123 amino acid sequences given in

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCAAGGCGTCTGTGGG 1486
DB 24 GGAAGTGTCAAGGCGTCTGTGGG 1
|||||

RESULT 17
ACD68095
ID ACD68095 standard; DNA; 24 BP.
XX
AC ACD68095;
XX
DT 17-SEP-2003 (first entry)
XX
DE Novel human secreted and transmembrane protein related primer #85.
XX
KW Human; secreted and transmembrane protein; PRO; gene therapy; vaccine;
XX tissue typing; chromosome identification; vaccine; PCR; primer; ss.
OS Homo sapiens.
XX
PN US2003073129-A1.
XX
PD 17-APR-2003.
XX
PF 04-SEP-2001; 2001US-00946374.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-00989536P.
PR 02-SEP-1998; 98US-0098956P.
PR 09-SEP-1998; 98US-00989598P.
PR 09-SEP-1998; 98US-0098602P.
PR 09-SEP-1998; 98US-0098642P.
PR 10-SEP-1998; 98US-0098741P.
PR 10-SEP-1998; 98US-0098754P.
PR 10-SEP-1998; 98US-0098763P.
PR 10-SEP-1998; 98US-0098792P.
PR 10-SEP-1998; 98US-0098808P.
PR 10-SEP-1998; 98US-0098812P.
PR 10-SEP-1998; 98US-0098815P.
PR 10-SEP-1998; 98US-0098816P.
PR 15-SEP-1998; 98US-0100385P.

PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105883P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0105882P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.

PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108847P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-APR-1999; 99US-00284291.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 18-OCT-1999; 99US-00403297.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US030055.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US0000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006684.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00882636.
PR 20-JUN-2001; 2001WO-US019592.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
(GETH) GENENTECH INC.
XX Baker KP, Botstein D, Desnovers I, Eaton DI, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KO;

PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX WPI; 2003-585292/55.
XX Novel isolated PRO polypeptides e.g. PRO1491 and PRO1571, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX Example 85; Page 260; 561pp; English.
XX The invention describes an isolated PRO (secreted and transmembrane)
CC polypeptide (1), having at least 80% sequence identity to a sequence
CC selected from any one of the 123 amino acid sequences given in

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GGTGACCTGGTCCATCTACTCC 1064
DB 1 GGTGACCTGGTCCATCTACTCC 24

RESULT 18
ID ADC18163/C
XX ADC18163 standard; DNA; 24 BP.
AC ADC18163;
XX 18-DEC-2003 (first entry)
DT 18-DEC-2003 (first entry)
XX Human PRO PCR primer #86.
DE Human PRO; PCR; ss; protein electrophoresis; chromosome mapping;
KW Human; PRO; PCR; ss; protein electrophoresis; chromosome mapping;
KW gene mapping; genetic disorder; primer.
XX Homo sapiens.
OS US2003064925-A1.
FN US2003064925-A1.
XX 03-APR-2003.
PD 03-APR-2003.
XX 10-DEC-2001; 2001US-00013907.
PF 10-DEC-2001; 2001US-00013907.
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.

PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101473P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 07-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0106082P.
PR 27-OCT-1998; 98US-0106083P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106346P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.

```
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-010783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-0129674P.
PR 16-APR-1999; 99US-0141037P.
PR 23-JUN-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-0145698P.
PR 15-SEP-1999; 99US-0145698P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-0162506P.
PR 02-DEC-1999; 99US-0162506P.
PR 16-DEC-1999; 99US-0162506P.
PR 05-JAN-2000; 2000US-0000219P.
PR 06-JAN-2000; 2000US-0000376P.
PR 11-FEB-2000; 2000US-0000376P.
PR 18-FEB-2000; 2000US-0000376P.
PR 24-FEB-2000; 2000US-0000376P.
PR 02-MAR-2000; 2000US-0000376P.
PR 15-MAR-2000; 2000US-0000376P.
PR 17-MAY-2000; 2000US-0000376P.
PR 22-MAY-2000; 2000US-0000376P.
PR 30-MAY-2000; 2000US-0000376P.
PR 02-JUN-2000; 2000US-0000376P.
PR 23-AUG-2000; 2000US-0000376P.
PR 24-AUG-2000; 2000US-0000376P.
PR 08-NOV-2000; 2000US-0000376P.
PR 10-NOV-2000; 2000US-0000376P.
PR 01-DEC-2000; 2000US-0000376P.
PR 28-FEB-2001; 2001US-0000376P.
PR 01-MAR-2001; 2001US-0000376P.
PR 01-JUN-2001; 2001US-0000376P.
PR 20-JUN-2001; 2001US-0000376P.
PR 29-JUN-2001; 2001US-0000376P.
PR 09-JUL-2001; 2001US-0000376P.
PR 04-SEP-2001; 2001US-0000376P.
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK,
XX Williams PM, Wood WI;
XX WPI; 2003-555602/52.
XX
XX Novel isolated PRO polypeptides e.g. PRO1491 and PRO1571, useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide, and as therapeutic agents e.g. vaccines.
XX
PS Example 85; SEQ ID NO 294; 555BP; English.
```

```
XX The invention relates to human PRO polypeptides and the polynucleotides
CC encoding them. The sequences are useful in the preparation of a
CC medicament for treating a condition responsive to a PRO polypeptide. The
CC polypeptides are useful in a number of functional biological assays, as
CC molecular weight markers for protein electrophoresis and as therapeutic
CC agents. The polynucleotides are useful as hybridisation probes for a cDNA
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAAGTCATGATGCTGTGGG 1486
Db 24 GGAAGTCATGATGCTGTGGG 1
RESULT 19
ADCl8162
ID ADCl8162 standard; DNA; 24 BP.
XX
AC ADCl8162;
XX
DT 18-DEC-2003 (first entry)
XX
DE Human PRO PCR primer #85.
XX
KM Human; PRO; PCR; ss; protein electrophoresis; chromosome mapping;
KW gene mapping; genetic disorder; primer.
XX
OS Homo sapiens.
XX
PN US2003064925-A1.
XX
PD 03-APR-2003.
XX
PF 10-DEC-2001; 2001US-00013907.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098936P.
PR 09-SEP-1998; 98US-0099356P.
PR 09-SEP-1998; 98US-0099588P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
```

PR	18-SEP-1998	98US-01008499
PR	18-SEP-1998	98US-0101014P
PR	18-SEP-1998	98US-0101068P
PR	18-SEP-1998	98US-0101077P
PR	22-SEP-1998	98US-0101271P
PR	23-SEP-1998	98US-0101472P
PR	23-SEP-1998	98US-0101477P
PR	23-SEP-1998	98US-0101474P
PR	23-SEP-1998	98US-0101475P
PR	23-SEP-1998	98US-0101476P
PR	23-SEP-1998	98US-0101477P
PR	23-SEP-1998	98US-0101479P
PR	24-SEP-1998	98US-0101738P
PR	24-SEP-1998	98US-0101741P
PR	24-SEP-1998	98US-0101743P
PR	24-SEP-1998	98US-0101915P
PR	24-SEP-1998	98US-0101916P
PR	29-SEP-1998	98US-0102240P
PR	29-SEP-1998	98US-0102307P
PR	29-SEP-1998	98US-0102331P
PR	29-SEP-1998	98US-0102333P
PR	30-SEP-1998	98US-0102484P
PR	30-SEP-1998	98US-0102487P
PR	30-SEP-1998	98US-0102570P
PR	30-SEP-1998	98US-0102571P
PR	30-SEP-1998	98US-0102624P
PR	01-OCT-1998	98US-0102631P
PR	01-OCT-1998	98US-0102687P
PR	02-OCT-1998	98US-0102965P
PR	06-OCT-1998	98US-0103258P
PR	06-OCT-1998	98US-0103449P
PR	07-OCT-1998	98US-0103314P
PR	07-OCT-1998	98US-0103315P
PR	07-OCT-1998	98US-0103328P
PR	07-OCT-1998	98US-0103329P
PR	07-OCT-1998	98US-0103396P
PR	07-OCT-1998	98US-0103401P
PR	08-OCT-1998	98US-0103633P
PR	08-OCT-1998	98US-0103678P
PR	08-OCT-1998	98US-0103679P
PR	08-OCT-1998	98US-0103711P
PR	14-OCT-1998	98US-0104257P
PR	20-OCT-1998	98US-0104987P
PR	20-OCT-1998	98US-0105000P
PR	20-OCT-1998	98US-0105002P
PR	21-OCT-1998	98US-0105104P
PR	22-OCT-1998	98US-0105169P
PR	22-OCT-1998	98US-0105266P
PR	26-OCT-1998	98US-0105563P
PR	26-OCT-1998	98US-0105564P
PR	27-OCT-1998	98US-0105607P
PR	27-OCT-1998	98US-0105818P
PR	27-OCT-1998	98US-0105882P
PR	27-OCT-1998	98US-0106062P
PR	28-OCT-1998	98US-0106023P
PR	28-OCT-1998	98US-0106029P
PR	28-OCT-1998	98US-0106030P
PR	28-OCT-1998	98US-0106032P
PR	28-OCT-1998	98US-0106033P
PR	28-OCT-1998	98US-0106178P
PR	29-OCT-1998	98US-0106248P
PR	29-OCT-1998	98US-0106384P
PR	29-OCT-1998	98US-0106580P
PR	30-OCT-1998	98US-0106464P
PR	03-NOV-1998	98US-0106562P
PR	03-NOV-1998	98US-0106563P
PR	03-NOV-1998	98US-0106590P
PR	03-NOV-1998	98US-0106615P
PR	03-NOV-1998	98US-0106332P
PR	03-NOV-1998	98US-0106334P
PR	10-NOV-1998	98US-0107783P
PR	17-NOV-1998	98US-0108775P
PR	17-NOV-1998	98US-0108779P

PR	17-NOV-1998;	98US-0108787P.
PR	17-NOV-1998;	98US-0108788P.
PR	17-NOV-1998;	98US-0108801P.
PR	17-NOV-1998;	98US-0108802P.
PR	17-NOV-1998;	98US-0108806P.
PR	17-NOV-1998;	98US-0108807P.
PR	17-NOV-1998;	98US-0108867P.
PR	17-NOV-1998;	98US-0108925P.
PR	18-NOV-1998;	98US-0108848P.
PR	18-NOV-1998;	98US-0108849P.
PR	18-NOV-1998;	98US-0108850P.
PR	18-NOV-1998;	98US-0108851P.
PR	18-NOV-1998;	98US-0108852P.
PR	18-NOV-1998;	98US-0108858P.
PR	22-DEC-1998;	98US-0108904P.
PR	30-DEC-1998;	98US-0114236P.
PR	05-JAN-1999;	99WC-US000106.
PR	16-APR-1999;	99US-0129674P.
PR	23-JUN-1999;	99US-0141037P.
PR	26-JUL-1999;	99US-0144758P.
PR	26-JUL-1999;	99US-0145698P.
PR	01-SEP-1999;	99WC-US020111.
PR	15-SEP-1999;	99WC-US021194.
PR	29-OCT-1999;	99US-0162506P.
PR	30-NOV-1999;	99WC-US028313.
PR	02-DEC-1999;	99WC-US028551.
PR	16-DEC-1999;	99WC-US030095.
PR	05-JAN-2000;	2000WC-US000219.
PR	06-JAN-2000;	2000WC-US000376.
PR	11-FEB-2000;	2000WC-US003565.
PR	18-FEB-2000;	2000WC-US004342.
PR	24-FEB-2000;	2000WC-US005004.
PR	02-MAR-2000;	2000WC-US005841.
PR	15-MAR-2000;	2000WC-US006884.
PR	17-MAY-2000;	2000WC-US013705.
PR	22-MAY-2000;	2000WC-US014042.
PR	30-MAY-2000;	2000WC-US014941.
PR	02-JUN-2000;	2000WC-US015264.
PR	23-AUG-2000;	2000WC-US023522.
PR	24-AUG-2000;	2000WC-US023328.
PR	08-NOV-2000;	2000WC-US030952.
PR	10-NOV-2000;	2000WC-US030873.
PR	01-DEC-2000;	2000WC-US032678.
PR	28-FEB-2001;	2001WC-US006520.
PR	01-MAR-2001;	2001WC-US006666.
PR	01-JUN-2001;	2001WC-US017800.
PR	20-JUN-2001;	2001WC-US019692.
PR	29-JUN-2001;	2001WC-US021066.
PR	09-JUL-2001;	2001WC-US021735.
PR	04-SEP-2001;	2001US-00946374.
XX		
PA	(GERTH) GENENTECH INC.	
XX		
PI	Baker KP, Botstein D, Desnoyers L, Eaton DU, Ferrara N, Fong S,	
PI	Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,	
PI	Par J, Paonli NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,	
PI	Williams PM, Wood WT;	
XX		
DR	WPI; 2003-555602/52.	
XX		
PT	Novel isolated PRO polypeptides e.g. PRO1491 and PRO1571, useful in the	
PT	preparation of a medicament for treating a condition responsive to PRO	
PT	polypeptide, and as therapeutic agents e.g. vaccines.	
XX		
PS	Example 85; SEQ ID NO 293; 555bp; English.	
XX		
CC	The invention relates to human PRO polypeptides and the polynucleotides	
CC	encoding them. The sequences are useful in the preparation of a	
CC	medicament for treating a condition responsive to a PRO polypeptide. The	
CC	polypeptides are useful in a number of functional biological assays, as	
CC	molecular weight markers for protein electrophoresis and as therapeutic	
CC	agents. The polynucleotides are useful as hybridisation probes for a cDNA	

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred.No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
1041 GCTGACCTGTTCCATCTACTCC 1064
1 GCTGACCTGTTCCATCTACTCC 24
Db

RESULT 20
ADD70809/c
ID ADD70809 standard; DNA; 24 BP.
XX
AC ADD70809;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; neuropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003099625-A1.
XX
PD 29-MAY-2003.
XX
PF 12-DEC-2001; 2001US-00015386.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.

PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 21-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106344P.
PR 29-OCT-1998; 98US-0106345P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.

PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-05000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-05020111.
PR 15-SEP-1999; 99US-05021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-05028313.
PR 02-DEC-1999; 99US-05028551.
PR 16-DEC-1999; 99US-05030095.
PR 05-JAN-2000; 2000US-05000219.
PR 06-JAN-2000; 2000US-05000376.
PR 11-FEB-2000; 2000US-05003565.
PR 18-FEB-2000; 2000US-05004342.
PR 24-FEB-2000; 2000US-05005004.
PR 02-MAR-2000; 2000US-05005841.
PR 15-MAR-2000; 2000US-05006884.
PR 17-MAY-2000; 2000US-05013705.
PR 22-MAY-2000; 2000US-05014042.
PR 30-MAY-2000; 2000US-05019411.
PR 02-JUN-2000; 2000US-05015264.
PR 23-AUG-2000; 2000US-05023522.
PR 24-AUG-2000; 2000US-05023328.
PR 08-NOV-2000; 2000US-05030952.
PR 10-NOV-2000; 2000US-05030873.
PR 01-DEC-2000; 2000US-05035678.
PR 28-FEB-2001; 2001US-05006520.
PR 01-MAR-2001; 2001US-05006666.
PR 01-JUN-2001; 2001US-05017800.
PR 20-JUN-2001; 2001US-05019692.
PR 29-JUN-2001; 2001US-05021066.
PR 09-JUL-2001; 2001US-05021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurevsky AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI,
XX
XX WPI, 2003-874602/81.
XX
XX Novel isolated PRO polypeptides e.g., PRO1130, PRO1275, PRO1418, PRO1555,
PT PRO1787 affect glucose or free fatty acid (FFA) uptake by skeletal muscle
PT cells and are useful for treating diabetes or hyper- or hypo-insulinemia.
XX
XX Example 85; SEQ ID NO 294; 553bp, English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred.No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

1463 GGAAGTGTATGAGGTCTGTGGG 1486
|||||

DB 24 GGAAGTGTATGAGGTCTGTGGG 1
1463
RESULT 21
ADD70808
ID ADD70808 standard; DNA; 24 BP.
XX
XX ADD70808;
XX
XX 15-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
DE
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; colliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003099625-A1.
XX
XX 29-MAY-2003.
XX
XX 12-DEC-2001; 2001US-00015386.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 02-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099603P.
XX 09-SEP-1998; 98US-0099642P.
XX 09-SEP-1998; 98US-0099741P.
XX 10-SEP-1998; 98US-0099754P.
XX 10-SEP-1998; 98US-0099763P.
XX 10-SEP-1998; 98US-0099793P.
XX 10-SEP-1998; 98US-0099808P.
XX 10-SEP-1998; 98US-0099812P.
XX 10-SEP-1998; 98US-0099815P.
XX 10-SEP-1998; 98US-0099816P.
XX 15-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100390P.
XX 16-SEP-1998; 98US-0100584P.
XX 16-SEP-1998; 98US-0100627P.
XX 16-SEP-1998; 98US-0100661P.
XX 16-SEP-1998; 98US-0100662P.
XX 16-SEP-1998; 98US-0100664P.
XX 17-SEP-1998; 98US-0100683P.
XX 17-SEP-1998; 98US-0100684P.
XX 17-SEP-1998; 98US-0100710P.
XX 17-SEP-1998; 98US-0100711P.
XX 17-SEP-1998; 98US-0100919P.
XX 17-SEP-1998; 98US-0100930P.
XX 18-SEP-1998; 98US-0100848P.
XX 18-SEP-1998; 98US-0100849P.
XX 18-SEP-1998; 98US-0101014P.
XX 18-SEP-1998; 98US-0101068P.
XX 18-SEP-1998; 98US-0101071P.
XX 22-SEP-1998; 98US-0101279P.
XX 23-SEP-1998; 98US-0101471P.
XX 23-SEP-1998; 98US-0101472P.
XX 23-SEP-1998; 98US-0101475P.
XX 23-SEP-1998; 98US-0101476P.

PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102865P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103439P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104357P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105933P.
PR 26-OCT-1998; 98US-0105944P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.

PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 98US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX PA (GETH) GENENTECH INC.
XX
XX Baker KP, Borstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godswami RJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2003-874602/81.
XX
XX
XX Novel isolated PRO polypeptides e.g., PRO1130, PRO1275, PRO1418, PRO1555,
PT PRO1787 affect glucose or free fatty acid (FFA) uptake by skeletal muscle
PT cells and are useful for treating diabetes or hyper- or hypo-insulinemia.
XX
XX Example 85; SEQ ID NO 293; 553bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GCTGACCTGGTTCATCTACTCC 1064
|||||
DB 1 GCTGACCTGGTTCATCTACTCC 24
|||||
RESULT 22
ADD39886/C
ID ADD39886 standard; DNA; 24 BP.
XX

AC ADD39886;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
 XX
 KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
 KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003083462-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 10-DEC-2001; 2001US-00013913.
 XX
 XX 05-JAN-1999; 99WO-US000106.
 PR 01-SEP-1999; 99WO-US020111.
 PR 15-SEP-1999; 99WO-US021194.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US030095.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023528.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 04-SEP-2001; 2001US-00946374.
 XX
 XX (GENTH) GENENTECH INC.
 XX
 PA Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tunes D, Watanabe CK,
 PI Williams PM, Wood WI;
 XX
 DR WPI: 2003-755122/71.
 XX
 PT New secreted and transmembrane PRO polypeptides useful for treating
 PT cancers, kidney disorders, Crohn's disease, diabetes mellitus, hyper- or
 PT hypo-insulinemia, sports injuries and arthritis.
 XX
 PS Example 85; SEQ ID NO 294; 557bp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 123 fully defined sequences as
 CC given in the specification (including their extracellular domains either
 CC or without their associated signal peptides. Also include are the
 CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
 CC host cell comprising the vector, producing PRO, a chimeric molecule

CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
 CC PRO antibody. Pro is useful as molecular weight markers for protein
 CC electrophoresis and also for chromosome identification. PRO is also
 CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
 CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
 CC useful for generating transgenic animals or knock-out animals which are
 CC useful in development and screening useful reagents. PRO NA is also
 CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
 CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
 CC polypeptides are useful for suppressing immune response. PRO1246
 CC polypeptide is useful for treating cardiac insufficiency disorders.
 CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
 CC PRO1561 polypeptide are useful for stimulating calcium flux in human
 CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
 CC polypeptides are useful for treating bone and/or cartilage disorders
 CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
 CC polypeptides are useful for treating diabetes in skeletal muscle cells
 CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
 CC treating Berger disease or other nephropathies associated with Schonlein-
 CC Henoch purpura, coeliac disease, dermatitis, herpiformis or Crohn's
 CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
 CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
 CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
 CC the invention.
 XX
 SQ Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;
 XX
 Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 QY 1463 GGAAGTGCATGCGGTCTGTGCGG 1486
 DB 24 GGAAGTGCATGCGGTCTGTGCGG 1
 XX
 RESULT 23
 ADD39885
 ID ADD39885 standard; DNA; 24 BP.
 XX
 XX ADD39885;
 AC
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
 XX
 KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
 KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003083462-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 10-DEC-2001; 2001US-00013913.
 XX
 XX 05-JAN-1999; 99WO-US000106.
 PR 01-SEP-1999; 99WO-US020111.
 PR 15-SEP-1999; 99WO-US021194.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US030095.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR


```
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 08-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0103711P.
PR 20-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105593P.
PR 26-OCT-1998; 98US-0105594P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105811P.
PR 27-OCT-1998; 98US-0105822P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106802P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106912P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.

PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 98US-0108801P.
PR 16-APR-1999; 98US-0129674P.
PR 23-JUN-1999; 98US-0141037P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 98US-0145698P.
PR 01-SEP-1999; 98US-0102011P.
PR 15-SEP-1999; 98US-0102119P.
PR 29-OCT-1999; 98US-0162506P.
PR 30-NOV-1999; 98US-0102831P.
PR 02-DEC-1999; 98US-0102855P.
PR 16-DEC-1999; 98US-0102855P.
PR 05-JAN-2000; 98US-0102855P.
PR 06-JAN-2000; 98US-0102855P.
PR 11-FEB-2000; 98US-0102855P.
PR 18-FEB-2000; 98US-0102855P.
PR 24-FEB-2000; 98US-0102855P.
PR 02-MAR-2000; 98US-0102855P.
PR 15-MAR-2000; 98US-0102855P.
PR 17-MAY-2000; 98US-0103370P.
PR 22-MAY-2000; 98US-0104042P.
PR 30-MAY-2000; 98US-0104941P.
PR 02-JUN-2000; 98US-0105264P.
PR 23-AUG-2000; 98US-0105322P.
PR 24-AUG-2000; 98US-0105328P.
PR 08-NOV-2000; 98US-0105328P.
PR 10-NOV-2000; 98US-0105328P.
PR 01-DEC-2000; 98US-0105328P.
PR 28-FEB-2001; 98US-0105328P.
PR 01-MAR-2001; 98US-0105328P.
PR 01-JUN-2001; 98US-0105328P.
PR 20-JUN-2001; 98US-0105328P.
PR 29-JUN-2001; 98US-0105328P.
PR 09-JUL-2001; 98US-0105328P.
PR 04-SEP-2001; 98US-0105328P.

PR PA (GETH ) GENENTECH INC.
XX
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PW, Wood WI,
XX
XX WPI, 2003-708344/67.
XX
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis, tumor.
XX
XX Example 85; SEQ ID NO 293; 549pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC

Query Match 100.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGTTCCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 25
ADD70332/c
ID ADD70332 standard; DNA; 24 BP.
XX
```

AC ADD70332;
XX 15-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
KW Human; PCR: primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
XX US2003054406-A1.
PD 20-MAR-2003.
XX
XX 06-DEC-2001; 2001US-00066818.
PF
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.

PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105841P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106388P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106931P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114233P.

```
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GERTH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnovers I, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2003-706344/67.
XX
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis, tumor.
XX
XX Example 85; SEQ ID NO 294; 549pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAAGTGTATGGGTGTCTGTGG 1486
Db 24 GGAAGTGTATGGGTGTCTGTGG 1
XX
XX
RESULT 26
ADD38452
ID ADD38452 standard; DNA; 24 BP.
XX
XX ADD38452;
XX AC
XX 15-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
DE Human secreted/transmembrane protein; transmembrane protein; PRO; tumour;
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
```

```
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003096955-A1.
XX
XX 22-MAY-2003.
XX
XX 07-DEC-2001; 2001US-00012755.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099602P.
XX 09-SEP-1998; 98US-0099642P.
XX 10-SEP-1998; 98US-0099741P.
XX 10-SEP-1998; 98US-0099754P.
XX 10-SEP-1998; 98US-0099763P.
XX 10-SEP-1998; 98US-0099792P.
XX 10-SEP-1998; 98US-0099812P.
XX 10-SEP-1998; 98US-0099815P.
XX 10-SEP-1998; 98US-0099816P.
XX 15-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100390P.
XX 16-SEP-1998; 98US-0100647P.
XX 16-SEP-1998; 98US-0100647P.
XX 16-SEP-1998; 98US-0100662P.
XX 16-SEP-1998; 98US-0100662P.
XX 17-SEP-1998; 98US-0100663P.
XX 17-SEP-1998; 98US-0100664P.
XX 17-SEP-1998; 98US-0100710P.
XX 17-SEP-1998; 98US-0100711P.
XX 17-SEP-1998; 98US-0100919P.
XX 17-SEP-1998; 98US-0100930P.
XX 18-SEP-1998; 98US-0100848P.
XX 18-SEP-1998; 98US-0100849P.
XX 18-SEP-1998; 98US-0101014P.
XX 18-SEP-1998; 98US-0101068P.
XX 18-SEP-1998; 98US-0101071P.
XX 22-SEP-1998; 98US-0101279P.
XX 23-SEP-1998; 98US-0101471P.
XX 23-SEP-1998; 98US-0101472P.
XX 23-SEP-1998; 98US-0101474P.
XX 23-SEP-1998; 98US-0101475P.
XX 23-SEP-1998; 98US-0101476P.
XX 23-SEP-1998; 98US-0101477P.
XX 23-SEP-1998; 98US-0101479P.
XX 24-SEP-1998; 98US-0101738P.
XX 24-SEP-1998; 98US-0101741P.
XX 24-SEP-1998; 98US-0101741P.
XX 24-SEP-1998; 98US-0101915P.
XX 24-SEP-1998; 98US-0101916P.
XX 29-SEP-1998; 98US-0102207P.
XX 29-SEP-1998; 98US-0102240P.
XX 29-SEP-1998; 98US-0102307P.
XX 29-SEP-1998; 98US-0102330P.
XX 29-SEP-1998; 98US-0102331P.
XX 30-SEP-1998; 98US-0102484P.
XX 30-SEP-1998; 98US-0102487P.
XX 30-SEP-1998; 98US-0102570P.
```

```
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106912P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108854P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-011296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-US020111.
PR 15-SEP-1999; 99US-US021194.
PR 29-OCT-1999; 99US-0162506P.

PR 30-NOV-1999; 99US-US028313.
PR 02-DEC-1999; 99US-US028551.
PR 16-DEC-1999; 99US-US030095.
PR 05-JAN-2000; 2000US-US000219.
PR 06-JAN-2000; 2000US-US000376.
PR 11-FEB-2000; 2000US-US003565.
PR 18-FEB-2000; 2000US-US004342.
PR 24-FEB-2000; 2000US-US005004.
PR 02-MAR-2000; 2000US-US005841.
PR 15-MAR-2000; 2000US-US006884.
PR 17-MAR-2000; 2000US-US013705.
PR 22-MAY-2000; 2000US-US014042.
PR 30-MAY-2000; 2000US-US014941.
PR 02-JUN-2000; 2000US-US015264.
PR 23-AUG-2000; 2000US-US023522.
PR 24-AUG-2000; 2000US-US023328.
PR 08-NOV-2000; 2000US-US030952.
PR 10-NOV-2000; 2000US-US030873.
PR 01-DEC-2000; 2000US-US032678.
PR 28-FEB-2001; 2001US-US006520.
PR 01-MAR-2001; 2001US-US006666.
PR 01-JUN-2001; 2001US-US017800.
PR 20-JUN-2001; 2001US-US019692.
PR 29-JUN-2001; 2001US-US021066.
PR 09-JUL-2001; 2001US-US021735.
PR 04-SEP-2001; 2001US-00946374.

PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI,
XX WPI, 2003-787000/74.
XX
XX Novel isolated PRO polypeptide, useful for treating cancerous tumors,
PT cardiac insufficiency disorders, wound healing, diabetes mellitus,
PT thalassemias.
XX
XX Example 85; SEQ ID NO 293; 556bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCGTCCATCTACTCC 1064
DB 1 GCTGACCGTCCATCTACTCC 24

RESULT 27
ADD38453/C
ID ADD38453 standard; DNA; 24 BP.
XX
XX ADD38453;
AC
XX
XX 15-JAN-2004 (first entry)
DT
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
DE
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
```


PR 24-FEB-2000; 2000MO-US005004.
PR 02-MAR-2000; 2000MO-US005841.
PR 15-MAR-2000; 2000MO-US006884.
PR 17-MAY-2000; 2000MO-US013705.
PR 22-MAY-2000; 2000MO-US014042.
PR 30-MAY-2000; 2000MO-US014941.
PR 02-JUN-2000; 2000MO-US015264.
PR 23-AUG-2000; 2000MO-US023522.
PR 24-AUG-2000; 2000MO-US023328.
PR 08-NOV-2000; 2000MO-US030952.
PR 10-NOV-2000; 2000MO-US030873.
PR 01-DEC-2000; 2000MO-US032678.
PR 28-FEB-2001; 2001MO-US006520.
PR 01-MAR-2001; 2001MO-US006666.
PR 01-JUN-2001; 2001MO-US017800.
PR 20-JUN-2001; 2001MO-US019692.
PR 29-JUN-2001; 2001MO-US021066.
PR 09-JUL-2001; 2001MO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
PA (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI,
XX
XX WPI; 2003-787000/74.
XX
XX Novel isolated PRO polypeptide, useful for treating cancerous tumors,
PT cardiac insufficiency disorders, wound healing, diabetes mellitus,
PT thalassemias.
XX
XX Example 85; SEQ ID NO 294; 556pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 GGAAGTGTATGGTGTGTGTGCG 1486
Db 24 GGAAGTGTATGGTGTGTGTGCG 1

RESULT 28
ADD39408
ID ADD39408 standard; DNA; 24 BP.
XX
XX ADD39408;
XX
XX 15-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
DE
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
XX US2003096954-A1.
XX
XX 22-MAY-2003.
XX
XX 07-DEC-2001; 2001US-00011671.
XX

PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100386P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 16-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100939P.
PR 17-SEP-1998; 98US-0100939P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101473P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-010207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102448P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103355P.
PR 07-OCT-1998; 98US-0103356P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.


```
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106646P.
PR 03-NOV-1998; 98US-0106656P.
PR 03-NOV-1998; 98US-0106802P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107875P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114233P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 11-FEB-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US003565.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014044.
PR 30-MAY-2000; 2000WO-US014941.

PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023128.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US030873.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001WO-US046374.

XX
XX (GENTECH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
XX Williams PM, Wood WI,
XX
XX WPI; 2003-786999/74.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
XX biological activity of cell, as molecular weight markers in protein
XX electrophoresis, for treating arthritis, tumor.
XX
XX Example 85; SEQ ID NO 293; 550pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGTTCCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 29
ADD39409/C
ID ADD39409 standard; DNA; 24 BP.
XX
XX ADD39409;
XX
XX 15-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schönlein-Henoch purpura; celiac disease;
XX dermatitis; herpetiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003096954-A1.
XX
XX 22-MAY-2003.
XX
XX
XX 07-DEC-2001; 2001US-00011671.
XX
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
```

PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101799P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102956P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103318P.
PR 07-OCT-1998; 98US-0103338P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.

PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105159P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 28-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0106464P.
PR 30-OCT-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108807P.
PR 18-NOV-1998; 98US-0108847P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114233P.
PR 05-JAN-1999; 99WMO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WMO-US020111.
PR 15-SEP-1999; 99WMO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WMO-US028313.
PR 02-DEC-1999; 99WMO-US028551.
PR 16-DEC-1999; 99WMO-US030095.
PR 05-JAN-2000; 2000WMO-US000219.
PR 06-JAN-2000; 2000WMO-US003376.
PR 11-FEB-2000; 2000WMO-US003565.
PR 18-FEB-2000; 2000WMO-US004342.
PR 24-FEB-2000; 2000WMO-US005004.
PR 02-MAR-2000; 2000WMO-US005841.
PR 15-MAR-2000; 2000WMO-US006884.
PR 17-MAY-2000; 2000WMO-US013705.
PR 22-MAY-2000; 2000WMO-US014042.
PR 30-MAY-2000; 2000WMO-US014941.
PR 02-JUN-2000; 2000WMO-US015264.
PR 23-AUG-2000; 2000WMO-US023522.
PR 24-AUG-2000; 2000WMO-US023328.
PR 08-NOV-2000; 2000WMO-US030952.
PR 10-NOV-2000; 2000WMO-US030873.
PR 01-DEC-2000; 2000WMO-US032678.
PR 28-FEB-2001; 2001WMO-US006520.

PR 01-MAR-2001; 2001MO-US006666.
PR 01-JUN-2001; 2001MO-US017800.
PR 20-JUN-2001; 2001MO-US019692.
PR 29-JUN-2001; 2001MO-US021066.
PR 09-JUL-2001; 2001MO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MB, Smith V, Stewart RA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
DR MPI; 2003-786999/74.
XX
PT Novel isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis, tumor.
XX
PS Example 85; SEQ ID NO 294; 550bp; English.
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred.No.8.7; 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0;

QY 1463 GGAGTGTCTATGGTCTCTGTGGG 1486
Db 24 GGAGTGTCTATGGTCTCTGTGGG 1

RESULT 30
ADD38931
ID ADD38931 standard; DNA; 24 BP.
XX
AC ADD38931:
XX
DT 15-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW Immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003092061-A1.
XX
PD 15-MAY-2003.
XX
PF 06-DEC-2001; 2001US-00007194.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099588P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.

PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100394P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 18-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101473P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101745P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.

PR 27-OCT-1998; 98US-0105882P.
 PR 27-OCT-1998; 98US-0106062P.
 PR 28-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106029P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.
 PR 28-OCT-1998; 98US-0106178P.
 PR 29-OCT-1998; 98US-0106248P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 30-OCT-1998; 98US-0106500P.
 PR 30-OCT-1998; 98US-0106646P.
 PR 03-NOV-1998; 98US-0106856P.
 PR 03-NOV-1998; 98US-0106902P.
 PR 03-NOV-1998; 98US-0106905P.
 PR 03-NOV-1998; 98US-0106919P.
 PR 03-NOV-1998; 98US-0106932P.
 PR 03-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.
 PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108867P.
 PR 17-NOV-1998; 98US-0108925P.
 PR 18-NOV-1998; 98US-0108848P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108850P.
 PR 18-NOV-1998; 98US-0108851P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 30-DEC-1998; 98US-0114323P.
 PR 05-JAN-1999; 99MO-US000106.
 PR 16-JAN-1999; 99US-0129674P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 01-SEP-1999; 99MO-US020111.
 PR 15-SEP-1999; 99MO-US021194.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99MO-US028313.
 PR 02-DEC-1999; 99MO-US028551.
 PR 16-DEC-1999; 99MO-US030095.
 PR 05-JAN-2000; 2000MO-US000219.
 PR 06-JAN-2000; 2000MO-US000376.
 PR 11-FEB-2000; 2000MO-US000365.
 PR 18-FEB-2000; 2000MO-US004342.
 PR 24-FEB-2000; 2000MO-US005004.
 PR 02-MAR-2000; 2000MO-US005841.
 PR 15-MAR-2000; 2000MO-US006884.
 PR 17-MAY-2000; 2000MO-US013705.
 PR 22-MAY-2000; 2000MO-US014941.
 PR 30-MAY-2000; 2000MO-US015264.
 PR 02-JUN-2000; 2000MO-US023522.
 PR 23-AUG-2000; 2000MO-US023522.
 PR 24-AUG-2000; 2000MO-US023128.
 PR 08-NOV-2000; 2000MO-US030952.
 PR 10-NOV-2000; 2000MO-US030873.
 PR 01-DEC-2000; 2000MO-US032678.
 PR 28-FEB-2001; 2001MO-US005620.
 PR 01-MAR-2001; 2001MO-US006666.
 PR 01-JUN-2001; 2001MO-US017800.
 PR 20-JUN-2001; 2001MO-US019992.
 PR 29-JUN-2001; 2001MO-US021066.
 PR 09-JUL-2001; 2001MO-US021735.
 PR 04-SEP-2001; 2001US-00946374.
 XX

PA (GETH) GENENTECH INC.
 XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
 PI Gao W, Goddard A, Godowski FJ, Grimaldi JC, Gurney AL, Hillan KJ,
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
 PI Williams PM, Wood WI;
 XX WPI, 2003-765477/72.
 XX
 PT New isolated PRO polypeptide such as PRO1560, PRO444, PRO1018, PRO1773,
 PT PRO1244, PRO1246, useful for treating cancerous tumors, cardiac
 PT insufficiency disorders, wound healing, Crohn's disease, celiac disease.
 XX
 PS Example 85; SEQ ID NO 293; 555bp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 8,7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1041 GCTGACCTGTTCCCATCTACTCC 1064
 Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 31
 ADD38932/c
 ID ADD38932 standard; DNA; 24 BP.
 XX
 AC ADD38932;
 XX
 DT 15-JAN-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
 XX
 KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schonlein-Henoch purpura; celiac disease;
 KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003092061-A1.
 XX
 PD 15-MAY-2003.
 XX
 PF 06-DEC-2001; 2001US-00007194.
 XX
 PR 01-SEP-1998; 98US-0098716P.
 PR 01-SEP-1998; 98US-0098723P.
 PR 01-SEP-1998; 98US-0098749P.
 PR 01-SEP-1998; 98US-0098750P.
 PR 02-SEP-1998; 98US-0098803P.
 PR 02-SEP-1998; 98US-0098821P.
 PR 02-SEP-1998; 98US-0098843P.
 PR 02-SEP-1998; 98US-0099536P.
 PR 09-SEP-1998; 98US-0099598P.
 PR 09-SEP-1998; 98US-0099602P.
 PR 09-SEP-1998; 98US-0099602P.
 PR 09-SEP-1998; 98US-0099642P.
 PR 10-SEP-1998; 98US-0099741P.
 PR 10-SEP-1998; 98US-0099754P.
 PR 10-SEP-1998; 98US-0099763P.
 PR 10-SEP-1998; 98US-0099792P.
 PR 10-SEP-1998; 98US-0099808P.
 PR 10-SEP-1998; 98US-0099812P.
 PR 10-SEP-1998; 98US-0099815P.
 PR 10-SEP-1998; 98US-0099816P.
 PR 15-SEP-1998; 98US-0100385P.
 PR

PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 22-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-010138P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 30-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103459P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 21-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.

PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108852P.
PR 17-NOV-1998; 98US-0108853P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0112968P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030973.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

XX
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Borstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ,
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
XX Williams PM, Wood WI,
XX

DR WPI; 2003-765477/72.
XX New isolated PRO polypeptide such as PRO1560, PRO444, PRO1018, PRO1773,
PT PRO1244, PRO1246, useful for treating cancerous tumors, cardiac
PT insufficiency disorders, wound healing, Crohn's disease, celiac disease.
XX
PS Example 85; SEQ ID NO 294; 555pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAGGTCATGGGCTCTGTGGG 1486
DB 24 GGAGGTCATGGGCTCTGTGGG 1
RESULT 32
ADD40362
ID ADD40362 standard; DNA; 24 BP.
XX
AC ADD40362;
XX
DT 15-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schomlein-Henoch purpura; celiac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003082627-A1.
XX
PD 01-MAY-2003.
XX
PF 06-DEC-2001; 2001US-0006117.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.

PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102072P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106461P.
PR 30-OCT-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.

PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108852P.
PR 17-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-0129674P.
PR 16-APR-1999; 99US-0141037P.
PR 23-JUN-1999; 99US-0144758P.
PR 20-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-0202011P.
PR 15-SEP-1999; 99US-0202119P.
PR 29-OCT-1999; 99US-0202831P.
PR 30-NOV-1999; 99US-0202831P.
PR 02-DEC-1999; 99US-0202851P.
PR 16-DEC-1999; 99US-0203095P.
PR 05-JAN-2000; 2000US-0200021P.
PR 11-FEB-2000; 2000US-0200376P.
PR 18-FEB-2000; 2000US-0200356P.
PR 24-FEB-2000; 2000US-0200342P.
PR 02-MAR-2000; 2000US-0200504P.
PR 15-MAR-2000; 2000US-0200584P.
PR 17-MAY-2000; 2000US-0201370P.
PR 22-MAY-2000; 2000US-0201404P.
PR 30-MAY-2000; 2000US-0201494P.
PR 02-JUN-2000; 2000US-0201526P.
PR 23-AUG-2000; 2000US-0203522P.
PR 24-AUG-2000; 2000US-0203522P.
PR 08-NOV-2000; 2000US-0203952P.
PR 10-NOV-2000; 2000US-0203952P.
PR 01-DEC-2000; 2000US-0203952P.
PR 28-FEB-2001; 2001US-0200652P.
PR 01-MAR-2001; 2001US-0200666P.
PR 01-JUN-2001; 2001US-0201780P.
PR 20-JUN-2001; 2001US-0201969P.
PR 29-JUN-2001; 2001US-0201969P.
PR 09-JUL-2001; 2001US-0201735P.
PR 04-SEP-2001; 2001US-0094637P.
XX
XX
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski FJ, Grimaldi JC, Gutney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WJ;
XX
XX WPI; 2003-755104/71.
XX
PT New isolated PRO polypeptides such as PRO1560, PRO444, PRO1018, PRO1773,
PT PRO1244, PRO1246, are useful for treating cancerous tumors and cardiac
PT insufficiency disorders.
XX
XX Example 85; SEQ ID NO 293; 550bp; English.

XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC with the PRO polypeptide.
XX
XX Query Match 1.0%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred. No. 8.7;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1041 GGTGACCTGCTTCCATCTACTCC 1064
DB 1 GGTGACCTGCTTCCATCTACTCC 24
XX
XX RESULT 33
XX ID ADD40363 standard; DNA, 24 BP.
XX
XX ADD40363;
XX
XX 15-JAN-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schönlein-Henoch purpura; celliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003082627-A1.
XX
XX 01-MAY-2003.
XX
XX 06-DEC-2001; 2001US-00006117.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098802P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099603P.
XX 09-SEP-1998; 98US-0099642P.
XX 10-SEP-1998; 98US-0099741P.
XX 10-SEP-1998; 98US-0099754P.
XX 10-SEP-1998; 98US-0099763P.
XX 10-SEP-1998; 98US-0099792P.
XX 10-SEP-1998; 98US-0099808P.
XX 10-SEP-1998; 98US-0099812P.
XX 10-SEP-1998; 98US-0099815P.
XX 10-SEP-1998; 98US-0099816P.
XX 15-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100390P.
XX 16-SEP-1998; 98US-0100584P.
XX 16-SEP-1998; 98US-0100627P.
XX 16-SEP-1998; 98US-0100661P.
XX 16-SEP-1998; 98US-0100662P.
XX 16-SEP-1998; 98US-0100664P.
XX 17-SEP-1998; 98US-0100683P.
XX 17-SEP-1998; 98US-0100684P.
XX 17-SEP-1998; 98US-0100710P.
XX 17-SEP-1998; 98US-0100711P.
XX 17-SEP-1998; 98US-0100930P.
XX 18-SEP-1998; 98US-0100848P.

PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101388P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102310P.
PR 29-SEP-1998; 98US-0102311P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.
PR 07-OCT-1998; 98US-0103491P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0104257P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 22-OCT-1998; 98US-0105693P.
PR 25-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.

PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005841.
PR 02-MAR-2000; 2000WO-US006884.
PR 15-MAR-2000; 2000WO-US013705.
PR 17-MAY-2000; 2000WO-US014042.
PR 22-MAY-2000; 2000WO-US014941.
PR 30-MAY-2000; 2000WO-US015264.
PR 02-JUN-2000; 2000WO-US023522.
PR 23-AUG-2000; 2000WO-US023328.
PR 24-AUG-2000; 2000WO-US030952.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

(GETH) GENENTECH INC.

XX Baker KP, Botstein D, Desnovers L, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX WPI, 2003-755104/71.

XX New isolated PRO polypeptides such as PRO1560, PRO444, PRO1018, PRO1773,
PT PRO1244, PRO1246, are useful for treating cancerous tumors and cardiac
PT insufficiency disorders.

XX Example 85; SEQ ID NO 294; 550bp; English.

XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGGTCATGGGTCGTCTGGG 1486
DB 24 GGAGGTCATGGGTCGTCTGGG 1
RESULT 34
ADE50584/C
ID ADE50584 standard; DNA; 24 BP.
XX
AC ADE50584;
XX
DT 29-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritic; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003069179-A1.
XX
PD 10-APR-2003.
XX
PF 11-DEC-2001; 2001US-00015393.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-0098536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 09-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100611P.
PR 16-SEP-1998; 98US-0100622P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.

PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101478P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105104P.
PR 21-OCT-1998; 98US-0105102P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105933P.
PR 26-OCT-1998; 98US-0105949P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0105883P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106284P.
PR 29-OCT-1998; 98US-0106300P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.

PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
PA (GENTH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK,
PI Williams PM, Wood WT;
XX
XX WPI; 2003-708395/67.
XX
XX Novel secreted and transmembrane PRO polypeptides useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide and as therapeutic agents e.g. vaccines.
XX
XX Example 85; SEQ ID NO 294; 555bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1463 GGAAGTGCATGGGTCTGTGGG 1486
DB 24 GGAAGTGCATGGGTCTGTGGG 1
RESULT 35

ADE50583
ID ADE50583 standard; DNA; 24 BP.
XX
XX ADE50583;
AC
XX
XX 29-JAN-2004 (first entry)
DT
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
DE
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
OS
XX
XX US2003069179-A1.
PN
XX
XX 10-APR-2003.
PD
XX
XX 11-DEC-2001; 2001US-00015393.
PF
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.

PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-010349P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-010656P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-010875P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.

PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 26-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GENTH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX WPI; 2003-708395/67.
XX
XX Novel secreted and transmembrane PRO polypeptides useful in the
PT preparation of a medicament for treating a condition responsive to PRO
PT polypeptide and as therapeutic agents e.g. vaccines.
XX
XX Example 85; SEQ ID NO 293; 555pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GCTGACCTGGTTCACATCACTCC 1064
DB 1 GCTGACCTGGTTCACATCACTCC 24
RESULT 36
ADE20196/c
ID ADE20196 standard; DNA; 24 BP.
XX
XX ADE20196;
AC
XX
XX
DT 29-JAN-2004 (first entry)
XX

DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
PN US2003092883-A1.
PD 15-MAY-2003.
XX
PF 10-DEC-2001; 2001US-00013430.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.

PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 28-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 29-OCT-1998; 98US-0108504P.
PR 30-OCT-1998; 98US-0108656P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108804P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114423P.
PR 05-JAN-1999; 99WC-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.

PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US0201194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028310.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030872.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006566.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Botsstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX WPI; 2003-765493/72.
XX
XX
XX New isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis and tumors.
XX
XX Example 85; SEQ ID NO 294; 555pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC

Query Match 1 0%; Score 24; DB 1; Length 24;
Beer Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 GGAAGTGCATGCGTCTGTGCGG 1486
Db 24 GGAAGTGCATGCGTCTGTGCGG 1

RESULT 37
ADE20195
ID ADE20195 standard; DNA; 24 BP.
XX
XX
AC ADE20195;
XX
XX 29-JAN-2004 (first entry)
DT
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
DE
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;

KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX HomS*Eapiens.
OS
XX
XX US2003092883-A1.
PN
XX
XX 15-MAY-2003.
PD
XX
XX 10-DEC-2001; 2001US-00013430.
PF
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 02-SEP-1998; 98US-0098936P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099598P.
XX 09-SEP-1998; 98US-0099603P.
XX 09-SEP-1998; 98US-0099642P.
XX 10-SEP-1998; 98US-0099741P.
XX 10-SEP-1998; 98US-0099754P.
XX 10-SEP-1998; 98US-0099763P.
XX 10-SEP-1998; 98US-0099792P.
XX 10-SEP-1998; 98US-0099808P.
XX 10-SEP-1998; 98US-0099812P.
XX 10-SEP-1998; 98US-0099815P.
XX 10-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100392P.
XX 16-SEP-1998; 98US-0100584P.
XX 16-SEP-1998; 98US-0100627P.
XX 16-SEP-1998; 98US-0100662P.
XX 16-SEP-1998; 98US-0100664P.
XX 16-SEP-1998; 98US-0100683P.
XX 17-SEP-1998; 98US-0100684P.
XX 17-SEP-1998; 98US-0100710P.
XX 17-SEP-1998; 98US-0100711P.
XX 17-SEP-1998; 98US-0100919P.
XX 17-SEP-1998; 98US-0100930P.
XX 18-SEP-1998; 98US-0100848P.
XX 18-SEP-1998; 98US-0100849P.
XX 18-SEP-1998; 98US-0101014P.
XX 18-SEP-1998; 98US-0101068P.
XX 18-SEP-1998; 98US-0101071P.
XX 22-SEP-1998; 98US-0101279P.
XX 23-SEP-1998; 98US-0101471P.
XX 23-SEP-1998; 98US-0101472P.
XX 23-SEP-1998; 98US-0101474P.
XX 23-SEP-1998; 98US-0101475P.
XX 23-SEP-1998; 98US-0101476P.
XX 23-SEP-1998; 98US-0101477P.
XX 23-SEP-1998; 98US-0101479P.
XX 24-SEP-1998; 98US-0101741P.
XX 24-SEP-1998; 98US-0101743P.
XX 24-SEP-1998; 98US-0101744P.
XX 24-SEP-1998; 98US-0101915P.
XX 24-SEP-1998; 98US-0101916P.
XX 29-SEP-1998; 98US-0102207P.
XX 29-SEP-1998; 98US-0102240P.
XX 29-SEP-1998; 98US-0102307P.
XX 29-SEP-1998; 98US-0102330P.
XX 29-SEP-1998; 98US-0102331P.
XX 30-SEP-1998; 98US-0102487P.
XX 30-SEP-1998; 98US-0102487P.
XX 30-SEP-1998; 98US-0102570P.
XX 30-SEP-1998; 98US-0102571P.
XX 01-OCT-1998; 98US-0102684P.
XX 01-OCT-1998; 98US-0102687P.

PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103966P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-010379P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-010504P.
PR 21-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 22-OCT-1998; 98US-0105633P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106466P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.

PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023328.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030973.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

(GETH) GENENTECH INC.

XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Goddard RJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Thomas D, Watanabe CK;
PI Williams PM, Wood WI;
XX MPI; 2003-765493/72.

PT New isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis and tumors.

XX Example 85; SEQ ID NO 293; 555pp; English.

CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTCCCATCTACTCC 1064

Db 1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 38

ADBS0106
ID ADE50106 standard; DNA; 24 BP.

AC ADE50106;
XX

DT 29-JAN-2004 (first entry)

DE Human secreted/transmembrane protein PRO1433 PCR primer #1.

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritic; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassaemia; ss.

XX Homo sapiens.

OS US2003082626-A1.

PN 01-MAY-2003.
XX
PD

XX 06-DEC-2001; 2001US-00006116.
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101071P.
PR 23-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-010138P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-010349P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.

PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0105883P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106912P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108804P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-00218517.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 12-APR-1999; 99US-00284291.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 18-OCT-1999; 99US-00403297.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028513.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.

PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023522.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 01-JUN-2001; 2001US-00872035.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 14-JUN-2001; 2001US-00882636.
 PR 20-JUN-2001; 2001WO-US015692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 04-SEP-2001; 2001US-00946374.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S;
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
 PI Williams PM, Wood WI;
 XX WPI; 2003-765413/72.
 XX Novel isolated PRO polypeptides useful for tissue typing, modulating
 PT biological activity of cell, as molecular weight markers in protein
 PT electrophoresis, for treating arthritis and tumors.
 Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 8.7; Indels 0; Gaps 0;
 Matches 24; Conservative 0; Mismatches 0;
 Oy 1041 GCTGACCTGGTCCATCTACTCC 1064
 Db 1 GCTGACCTGGTCCATCTACTCC 24
 RESULT 39
 ADE50107/C
 ID ADE50107 standard; DNA; 24 BP.
 XX
 AC ADE50107;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
 XX
 KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schonlein-Henoch purpura; celiac disease;
 KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003082626-A1.
 XX
 PD 01-MAY-2003.
 XX
 PF 06-DEC-2001; 2001US-00006116.
 XX
 PR 01-SEP-1998; 98US-0098716P.
 PR 01-SEP-1998; 98US-0098723P.
 PR 01-SEP-1998; 98US-0098749P.
 PR 01-SEP-1998; 98US-0098750P.

PR 02-SEP-1998; 98US-0098803P.
 PR 02-SEP-1998; 98US-0098821P.
 PR 02-SEP-1998; 98US-0098843P.
 PR 09-SEP-1998; 98US-0099556P.
 PR 09-SEP-1998; 98US-0099596P.
 PR 09-SEP-1998; 98US-0099598P.
 PR 09-SEP-1998; 98US-0099602P.
 PR 09-SEP-1998; 98US-0099642P.
 PR 10-SEP-1998; 98US-0099741P.
 PR 10-SEP-1998; 98US-0099754P.
 PR 10-SEP-1998; 98US-0099763P.
 PR 10-SEP-1998; 98US-0099792P.
 PR 10-SEP-1998; 98US-0099808P.
 PR 10-SEP-1998; 98US-0099812P.
 PR 10-SEP-1998; 98US-0099815P.
 PR 10-SEP-1998; 98US-0099816P.
 PR 15-SEP-1998; 98US-0100385P.
 PR 15-SEP-1998; 98US-0100388P.
 PR 15-SEP-1998; 98US-0100390P.
 PR 16-SEP-1998; 98US-0100584P.
 PR 16-SEP-1998; 98US-0100627P.
 PR 16-SEP-1998; 98US-0100641P.
 PR 16-SEP-1998; 98US-0100662P.
 PR 16-SEP-1998; 98US-0100664P.
 PR 17-SEP-1998; 98US-0100683P.
 PR 17-SEP-1998; 98US-0100710P.
 PR 17-SEP-1998; 98US-0100711P.
 PR 17-SEP-1998; 98US-0100919P.
 PR 17-SEP-1998; 98US-0100930P.
 PR 17-SEP-1998; 98US-0100848P.
 PR 18-SEP-1998; 98US-0100849P.
 PR 18-SEP-1998; 98US-0101014P.
 PR 18-SEP-1998; 98US-0101068P.
 PR 18-SEP-1998; 98US-0101071P.
 PR 22-SEP-1998; 98US-0101471P.
 PR 23-SEP-1998; 98US-0101472P.
 PR 23-SEP-1998; 98US-0101474P.
 PR 23-SEP-1998; 98US-0101475P.
 PR 23-SEP-1998; 98US-0101476P.
 PR 23-SEP-1998; 98US-0101477P.
 PR 23-SEP-1998; 98US-0101479P.
 PR 24-SEP-1998; 98US-0101738P.
 PR 24-SEP-1998; 98US-0101741P.
 PR 24-SEP-1998; 98US-0101743P.
 PR 24-SEP-1998; 98US-0101915P.
 PR 24-SEP-1998; 98US-0101916P.
 PR 29-SEP-1998; 98US-0102076P.
 PR 29-SEP-1998; 98US-0102240P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102310P.
 PR 29-SEP-1998; 98US-0102331P.
 PR 30-SEP-1998; 98US-0102487P.
 PR 30-SEP-1998; 98US-0102570P.
 PR 30-SEP-1998; 98US-0102571P.
 PR 30-SEP-1998; 98US-0102684P.
 PR 01-OCT-1998; 98US-0102687P.
 PR 02-OCT-1998; 98US-0102965P.
 PR 06-OCT-1998; 98US-0103258P.
 PR 06-OCT-1998; 98US-0103449P.
 PR 07-OCT-1998; 98US-0103314P.
 PR 07-OCT-1998; 98US-0103315P.
 PR 07-OCT-1998; 98US-0103328P.
 PR 07-OCT-1998; 98US-0103395P.
 PR 07-OCT-1998; 98US-0103396P.
 PR 07-OCT-1998; 98US-0103401P.
 PR 08-OCT-1998; 98US-0103633P.
 PR 08-OCT-1998; 98US-0103678P.
 PR 08-OCT-1998; 98US-0103679P.
 PR 08-OCT-1998; 98US-0103711P.
 PR 14-OCT-1998; 98US-0104257P.


```
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0108464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108825P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0021851P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-0028429P.
PR 12-APR-1999; 99US-0028429P.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-0020111P.
PR 15-SEP-1999; 99US-0020114P.
PR 18-OCT-1999; 99US-0040329P.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99US-0028313P.
PR 02-DEC-1999; 99US-0028551P.
PR 16-DEC-1999; 99US-0030095P.
PR 05-JAN-2000; 2000US-0000219P.
PR 06-JAN-2000; 2000US-0000376P.
PR 11-FEB-2000; 2000US-0003565P.
PR 18-FEB-2000; 2000US-0004342P.
PR 24-FEB-2000; 2000US-0005804P.
PR 02-MAR-2000; 2000US-0005841P.
PR 15-MAR-2000; 2000US-0006884P.
PR 17-MAY-2000; 2000US-0013705P.
PR 22-MAY-2000; 2000US-0014042P.
PR 30-MAY-2000; 2000US-0014941P.
PR 02-JUN-2000; 2000US-0015264P.

PR 23-AUG-2000; 2000US-0023522P.
PR 24-AUG-2000; 2000US-0023328P.
PR 08-NOV-2000; 2000US-0003952P.
PR 10-NOV-2000; 2000US-0003087P.
PR 01-DEC-2000; 2000US-0003267P.
PR 28-FEB-2001; 2001US-0006520P.
PR 01-MAR-2001; 2001US-0006666P.
PR 01-JUN-2001; 2001US-0087203P.
PR 01-JUN-2001; 2001US-0017800P.
PR 14-JUN-2001; 2001US-0088263P.
PR 20-JUN-2001; 2001US-0019692P.
PR 29-JUN-2001; 2001US-0021066P.
PR 09-JUL-2001; 2001US-0021735P.
PR 04-SEP-2001; 2001US-00946374P.

XX (GENTH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX WPI/ 2003-765413/72.
XX
XX Novel isolated PRO polypeptides useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis and tumors.

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTCAATGCGGTCTCTGTCGG 1486
DB 24 GGAAGTGTCAATGCGGTCTCTGTCGG 1

RESULT 40
ID ADE21665 standard; DNA, 24 BP.
AC ADE21665;
XX
XX 29-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; celliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
XX US2003082628-A1.
EN
PD 01-MAY-2003.
XX
XX 13-DEC-2001; 2001US-00017527.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 09-SEP-1998; 98US-0099536P.
XX 09-SEP-1998; 98US-0099596P.
XX 09-SEP-1998; 98US-0099602P.
```

PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103799P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.

PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108825P.
PR 17-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108859P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 98US-0129674P.
PR 16-APR-1999; 99US-0141037P.
PR 23-JUN-1999; 99US-0144758P.
PR 20-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-0145698P.
PR 15-SEP-1999; 99US-0145698P.
PR 29-OCT-1999; 99US-0145698P.
PR 30-NOV-1999; 99US-0145698P.
PR 02-DEC-1999; 99US-0145698P.
PR 16-DEC-1999; 99US-0145698P.
PR 05-JAN-2000; 99US-0145698P.
PR 06-JAN-2000; 99US-0145698P.
PR 11-FEB-2000; 99US-0145698P.
PR 18-FEB-2000; 99US-0145698P.
PR 24-FEB-2000; 99US-0145698P.
PR 02-MAR-2000; 99US-0145698P.
PR 15-MAR-2000; 99US-0145698P.
PR 17-MAY-2000; 99US-0145698P.
PR 22-MAY-2000; 99US-0145698P.
PR 30-MAY-2000; 99US-0145698P.
PR 02-JUN-2000; 99US-0145698P.
PR 23-AUG-2000; 99US-0145698P.
PR 24-AUG-2000; 99US-0145698P.
PR 08-NOV-2000; 99US-0145698P.
PR 10-NOV-2000; 99US-0145698P.
PR 01-DEC-2000; 99US-0145698P.
PR 28-FEB-2001; 99US-0145698P.
PR 01-MAR-2001; 99US-0145698P.
PR 10-JUN-2001; 99US-0145698P.
PR 20-JUN-2001; 99US-0145698P.
PR 29-JUN-2001; 99US-0145698P.

PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
PA (GETH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WT;
XX
XX MPI; 2003-755105/71.
XX
PT Novel secreted and transmembrane PRO polypeptides useful for treating
PT cancers, kidney disorders, Crohn's disease, diabetes mellitus, hyper- or
PT hypo-inulinemia, sports injuries and arthritis.
XX
XX Example 85; SEQ ID NO 294; 548bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGGTCATGGGTCGTCTGGG 1486
DB 24 GGAGGTCATGGGTCGTCTGGG 1

RESULT 41
ADE21664
ID ADE21664 standard; DNA; 24 BP.
XX
XX ADE21664;
AC
XX
DT 29-JAN-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2003082628-A1.
XX
XX 01-MAY-2003.
XX
XX 13-DEC-2001; 2001US-00017527.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-0099536P.
PR 02-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 09-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.

PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105897P.
PR 27-OCT-1998; 98US-0105898P.
PR 27-OCT-1998; 98US-0105882P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.

PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106931P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 17-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99MO-US000106.
PR 16-APR-1999; 99US-0129667P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99MO-US020111.
PR 15-SEP-1999; 99MO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99MO-US028313.
PR 02-DEC-1999; 99MO-US028551.
PR 16-DEC-1999; 99MO-US030095.
PR 05-JAN-2000; 2000MO-US000219.
PR 06-JAN-2000; 2000MO-US000376.
PR 11-FEB-2000; 2000MO-US003565.
PR 18-FEB-2000; 2000MO-US004342.
PR 24-FEB-2000; 2000MO-US005004.
PR 02-MAR-2000; 2000MO-US005841.
PR 15-MAR-2000; 2000MO-US006884.
PR 17-MAY-2000; 2000MO-US013705.
PR 22-MAY-2000; 2000MO-US014042.
PR 30-MAY-2000; 2000MO-US014941.
PR 02-JUN-2000; 2000MO-US025264.
PR 23-AUG-2000; 2000MO-US025522.
PR 24-AUG-2000; 2000MO-US023328.
PR 08-NOV-2000; 2000MO-US030952.
PR 10-NOV-2000; 2000MO-US030873.
PR 01-DEC-2000; 2000MO-US032678.
PR 28-FEB-2001; 2001MO-US006520.
PR 01-MAR-2001; 2001MO-US006666.
PR 01-JUN-2001; 2001MO-US017800.
PR 20-JUN-2001; 2001MO-US019692.
PR 29-JUN-2001; 2001MO-US021066.
PR 09-JUL-2001; 2001MO-US021735.
PR 04-SEP-2001; 2001US-00946374.

(GETH) GENENTECH INC.
PA Baker KP, Botstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;

PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
DR WPI; 2003-755105/71.
XX
PT Novel secreted and transmembrane PRO polypeptides useful for treating
PT cancers, kidney disorders, Crohn's disease, diabetes mellitus, hyper- or
PT hypo-insulinemia, sports injuries and arthritis.
XX
PS Example 85; SEQ ID NO 293; 548bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTTCCTCACTCTCC 1064
Db 1 GCTGACCTGGTTCCTCACTCTCTCC 24

RESULT 42
ADF30089
XX ID ADF30089 standard; DNA; 24 BP.
XX AC ADF30089;
XX DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
KW dermatitis; herpeticiformis; Cronn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003204053-A1.
XX
PD 30-OCT-2003.
XX
PF 10-DEC-2001; 2001US-00013915.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.

```

PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102309P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103459P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103318P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106622P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.

PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-011296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAR-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030973.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Borstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S,
XX Gao W, Goddard A, Godowski PV, Grimaldi JC, Gurney AL, Hillan KJ,
XX Pan J, Paci NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
XX Williams PW, Wood WI;
XX
XX MPI; 2003-900674/82.
XX
XX New PRO nucleic acid, useful for the manufacture of a medicament for
XX diagnosing or treating tumor or for tissue typing.
XX
XX Example 85; SEQ ID NO 293; 558pp; English.
XX

```

XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred No. 8.7; 0; Indels 0; Gaps 0;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCCATCTACTTC 1064
|||
Db 1 GCTGACCTGTTCCCATCTACTTC 24

RESULT 43
ADFF30090/C
ID ADF30090 standard; DNA; 24 BP.

XX ADF30090;

XX 12-FEB-2004 (first entry)

DE Human secreted/transmembrane protein PRO1433 PCR primer #2.

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthralgia; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

OS Homo sapiens.

XX US2003204053-A1.

XX 30-OCT-2003.

XX 10-DEC-2001; 2001US-00013915.

XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098936P.
PR 09-SEP-1998; 98US-0098959P.
PR 09-SEP-1998; 98US-0098960P.
PR 09-SEP-1998; 98US-0098642P.
PR 10-SEP-1998; 98US-0098741P.
PR 10-SEP-1998; 98US-0098754P.
PR 10-SEP-1998; 98US-0098763P.
PR 10-SEP-1998; 98US-0098792P.
PR 10-SEP-1998; 98US-0098808P.
PR 10-SEP-1998; 98US-0098812P.
PR 10-SEP-1998; 98US-0098815P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.

PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105164P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106857P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106931P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.

PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.
 PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108867P.
 PR 17-NOV-1998; 98US-0108925P.
 PR 18-NOV-1998; 98US-0108848P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108850P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 30-DEC-1998; 98US-0114223P.
 PR 05-JAN-1999; 99US-US000106.
 PR 16-APR-1999; 99US-0129674P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 01-SEP-1999; 99US-US020111.
 PR 15-SEP-1999; 99US-US021194.
 PR 30-NOV-1999; 99US-US028313.
 PR 02-DEC-1999; 99US-US028551.
 PR 16-DEC-1999; 99US-US030095.
 PR 05-JAN-2000; 2000US-US000219.
 PR 06-JAN-2000; 2000US-US003376.
 PR 11-FEB-2000; 2000US-US003565.
 PR 18-FEB-2000; 2000US-US004342.
 PR 24-FEB-2000; 2000US-US005004.
 PR 02-MAR-2000; 2000US-US005841.
 PR 15-MAR-2000; 2000US-US006884.
 PR 17-MAY-2000; 2000US-US013705.
 PR 22-MAY-2000; 2000US-US014042.
 PR 30-MAY-2000; 2000US-US014941.
 PR 02-JUN-2000; 2000US-US015264.
 PR 23-AUG-2000; 2000US-US023522.
 PR 24-AUG-2000; 2000US-US023328.
 PR 08-NOV-2000; 2000US-US030952.
 PR 10-NOV-2000; 2000US-US030873.
 PR 01-DEC-2000; 2000US-US032678.
 PR 28-FEB-2001; 2001US-US006520.
 PR 01-MAR-2001; 2001US-US006666.
 PR 01-JUN-2001; 2001US-US017800.
 PR 20-JUN-2001; 2001US-US019692.
 PR 29-JUN-2001; 2001US-US021065.
 PR 09-JUL-2001; 2001US-US021735.
 PR 04-SEP-2001; 2001US-US0246374.
 PR XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
 PI Williams PM, Wood WI;
 XX
 XX WPI; 2003-900674/82.
 DR
 XX
 PT New PRO nucleic acid, useful for the manufacture of a medicament for
 PT diagnosing or treating tumor or for tissue typing.
 PS
 PS Example 85; SEQ ID NO 294; 558bp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 123 fully defined sequences as
 CC given in the specification (including their extracellular domains either
 CC or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 8.7;
 Matches: 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Oy 1463
 24 GGAGTGTATGCGGTCTGTGGG 1486
 Db 24 GGAGTGTATGCGGTCTGTGGG 1
 RESULT 44
 ADF55982
 ID ADF55982 standard; DNA; 24 BP.
 XX
 AC ADF55982;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
 XX
 KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
 KW immune response; cardiac insufficiency disorder; calcium flux;
 KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
 KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
 KW Berger disease; nephropathy; Schönlein-Henoch purpura; colliac disease;
 KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
 XX
 OS Homo sapiens.
 XX
 PN US2003204054-A1.
 XX
 PD 30-OCT-2003.
 XX
 PF 11-DEC-2001; 2001US-00015394.
 XX
 PR 17-NOV-1998; 98US-0108787P.
 PR 01-SEP-1999; 99US-US020111.
 PR 18-OCT-1999; 99US-US0403297.
 PR 18-FEB-2000; 2000US-US004342.
 PR 04-SEP-2001; 2001US-00946374.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
 PI Williams PM, Wood WI;
 XX
 XX WPI; 2003-900675/82.
 DR
 XX
 PT New PRO nucleic acid, useful for the manufacture of a medicament for
 PT diagnosing or treating tumor or for tissue typing.
 PS
 PS Example 85; SEQ ID NO 293; 558bp; English.
 XX
 CC The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 123 fully defined sequences as
 CC given in the specification (including their extracellular domains either
 CC or without their associated signal peptides. Also include are the
 CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
 CC host cell comprising the vector, producing PRO, a chimaeric molecule
 CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
 CC PRO antibody. PRO is useful as molecular weight markers for protein
 CC electrophoresis and also for chromosome identification. PRO is also
 CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
 CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
 CC useful in development and screening animals or knock-out animals which are
 CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
 CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
 CC polypeptides are useful for suppressing immune response. PRO1246
 CC polypeptide is useful for treating cardiac insufficiency disorders.
 CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and

CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schönlein-
CC Henoch purpura, coeliac disease, dermatitis, herpiformis or Crohn's
CC disease. PRO178, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.

SQ Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTCCCATCTACTCC 1064
Db 1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 45
ADFS5983/C
ID ADFS5983 standard; DNA; 24 BP.

AC ADFS5983;
XX
XX
XX
DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
XX
PN US200324054-A1.
XX
PD 30-OCT-2003.
XX
XX
PF 11-DEC-2001; 2001US-00015394.
XX
XX
PR 17-NOV-1998; 98US-0108787P.
PR 01-SEP-1998; 98WO-US020111.
PR 18-OCT-1998; 98US-00403297.
PR 18-FEB-2000; 2000WO-US004342.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
PA (GENTH) GENENTECH INC.
XX
XX Baker KP, Botsstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy WA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX WPI, 2003-900675/82.
XX
XX New PRO nucleic acid, useful for the manufacture of a medicament for
PT diagnosing or treating tumor or for tissue typing.
XX
XX
PS Example 85; SEQ ID NO 294; 558bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either

CC or without their associated signal peptides. Also include are the
CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimaeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. Pro is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours PRO1246 and
CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schönlein-
CC Henoch purpura, coeliac disease, dermatitis, herpiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.

SQ Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTATGGTGTGTGTGGG 1486
Db 24 GGAAGTGTATGGTGTGTGTGGG 1

RESULT 46
ADH99486
ID ADH99486 standard; DNA; 24 BP.

AC ADH99486;
XX
XX
XX
DT 15-APR-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
XX
XX
OS Homo sapiens.
XX
XX
PN US2003065142-A1.
XX
PD 03-APR-2003.
XX
XX
PF 11-DEC-2001; 2001US-00015499.
XX
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.

PR 09-SEP-1998;	98US-0099598P.	PR 22-OCT-1998;	98US-0105266P.
PR 09-SEP-1998;	98US-0099602P.	PR 26-OCT-1998;	98US-0105693P.
PR 09-SEP-1998;	98US-0099642P.	PR 26-OCT-1998;	98US-0105694P.
PR 10-SEP-1998;	98US-0099741P.	PR 27-OCT-1998;	98US-0105807P.
PR 10-SEP-1998;	98US-0099754P.	PR 27-OCT-1998;	98US-0105811P.
PR 10-SEP-1998;	98US-0099763P.	PR 27-OCT-1998;	98US-0105882P.
PR 10-SEP-1998;	98US-0099792P.	PR 27-OCT-1998;	98US-0106023P.
PR 10-SEP-1998;	98US-0099808P.	PR 28-OCT-1998;	98US-0106029P.
PR 10-SEP-1998;	98US-0099812P.	PR 28-OCT-1998;	98US-0106030P.
PR 10-SEP-1998;	98US-0099815P.	PR 28-OCT-1998;	98US-0106032P.
PR 10-SEP-1998;	98US-0099816P.	PR 28-OCT-1998;	98US-0106033P.
PR 15-SEP-1998;	98US-0100385P.	PR 28-OCT-1998;	98US-0106178P.
PR 15-SEP-1998;	98US-0100388P.	PR 29-OCT-1998;	98US-0106248P.
PR 15-SEP-1998;	98US-0100390P.	PR 29-OCT-1998;	98US-0106384P.
PR 15-SEP-1998;	98US-0100584P.	PR 29-OCT-1998;	98US-0106500P.
PR 16-SEP-1998;	98US-0100627P.	PR 29-OCT-1998;	98US-0106505P.
PR 16-SEP-1998;	98US-0100661P.	PR 30-OCT-1998;	98US-0106646P.
PR 16-SEP-1998;	98US-0100662P.	PR 03-NOV-1998;	98US-0106856P.
PR 17-SEP-1998;	98US-0100683P.	PR 03-NOV-1998;	98US-0106902P.
PR 17-SEP-1998;	98US-0100684P.	PR 03-NOV-1998;	98US-0106905P.
PR 17-SEP-1998;	98US-0100710P.	PR 03-NOV-1998;	98US-0106919P.
PR 17-SEP-1998;	98US-0100711P.	PR 03-NOV-1998;	98US-0106932P.
PR 17-SEP-1998;	98US-0100930P.	PR 10-NOV-1998;	98US-0106934P.
PR 17-SEP-1998;	98US-0100930P.	PR 17-NOV-1998;	98US-0107783P.
PR 18-SEP-1998;	98US-0100848P.	PR 17-NOV-1998;	98US-0108775P.
PR 18-SEP-1998;	98US-0100849P.	PR 17-NOV-1998;	98US-0108779P.
PR 18-SEP-1998;	98US-0101014P.	PR 17-NOV-1998;	98US-0108787P.
PR 18-SEP-1998;	98US-0101068P.	PR 17-NOV-1998;	98US-0108801P.
PR 18-SEP-1998;	98US-0101071P.	PR 17-NOV-1998;	98US-0108802P.
PR 22-SEP-1998;	98US-0101279P.	PR 17-NOV-1998;	98US-0108806P.
PR 23-SEP-1998;	98US-0101471P.	PR 17-NOV-1998;	98US-0108807P.
PR 23-SEP-1998;	98US-0101472P.	PR 17-NOV-1998;	98US-0108867P.
PR 23-SEP-1998;	98US-0101474P.	PR 17-NOV-1998;	98US-0108925P.
PR 23-SEP-1998;	98US-0101475P.	PR 18-NOV-1998;	98US-0108848P.
PR 23-SEP-1998;	98US-0101476P.	PR 18-NOV-1998;	98US-0108849P.
PR 23-SEP-1998;	98US-0101477P.	PR 18-NOV-1998;	98US-0108850P.
PR 23-SEP-1998;	98US-0101479P.	PR 18-NOV-1998;	98US-0108851P.
PR 24-SEP-1998;	98US-0101738P.	PR 18-NOV-1998;	98US-0108852P.
PR 24-SEP-1998;	98US-0101741P.	PR 18-NOV-1998;	98US-0108858P.
PR 24-SEP-1998;	98US-0101743P.	PR 18-NOV-1998;	98US-0108904P.
PR 24-SEP-1998;	98US-0101915P.	PR 22-DEC-1998;	98US-0113296P.
PR 24-SEP-1998;	98US-0101916P.	PR 30-DEC-1998;	98US-0114232P.
PR 29-SEP-1998;	98US-0102207P.	PR 05-JAN-1999;	99US-0129674P.
PR 29-SEP-1998;	98US-0102240P.	PR 16-APR-1999;	99US-0129674P.
PR 29-SEP-1998;	98US-0102307P.	PR 23-JUN-1999;	99US-0141037P.
PR 29-SEP-1998;	98US-0102330P.	PR 20-JUL-1999;	99US-0144758P.
PR 30-SEP-1998;	98US-0102484P.	PR 26-JUL-1999;	99US-0145698P.
PR 30-SEP-1998;	98US-0102510P.	PR 01-SEP-1999;	99US-0202011P.
PR 30-SEP-1998;	98US-0102517P.	PR 15-SEP-1999;	99US-0202119P.
PR 01-OCT-1998;	98US-0102684P.	PR 29-SEP-1999;	99US-0162506P.
PR 01-OCT-1998;	98US-0102687P.	PR 30-NOV-1999;	99US-0502831P.
PR 02-OCT-1998;	98US-0102965P.	PR 16-DEC-1999;	99US-0502855P.
PR 06-OCT-1998;	98US-0103258P.	PR 05-JAN-2000;	2000US-0000219
PR 06-OCT-1998;	98US-0103449P.	PR 06-JAN-2000;	2000US-0000375
PR 07-OCT-1998;	98US-0103314P.	PR 11-FEB-2000;	2000US-0000365
PR 07-OCT-1998;	98US-0103315P.	PR 18-FEB-2000;	2000US-0000434P.
PR 07-OCT-1998;	98US-0103328P.	PR 24-FEB-2000;	2000US-0000500P.
PR 07-OCT-1998;	98US-0103395P.	PR 02-MAR-2000;	2000US-0000584P.
PR 07-OCT-1998;	98US-0103396P.	PR 15-MAR-2000;	2000US-0000684P.
PR 08-OCT-1998;	98US-0103401P.	PR 17-MAY-2000;	2000US-0001370P.
PR 08-OCT-1998;	98US-0103633P.	PR 22-MAY-2000;	2000US-0001404P.
PR 08-OCT-1998;	98US-0103678P.	PR 30-MAY-2000;	2000US-0001494P.
PR 08-OCT-1998;	98US-0103679P.	PR 02-JUN-2000;	2000US-0001526P.
PR 14-OCT-1998;	98US-0103711P.	PR 23-AUG-2000;	2000US-0002352P.
PR 20-OCT-1998;	98US-0104257P.	PR 24-AUG-2000;	2000US-0002332P.
PR 20-OCT-1998;	98US-0104987P.	PR 08-NOV-2000;	2000US-0003095P.
PR 20-OCT-1998;	98US-0105000P.	PR 10-NOV-2000;	2000US-0003087P.
PR 20-OCT-1998;	98US-0105002P.	PR 01-DEC-2000;	2000US-0003267P.
PR 21-OCT-1998;	98US-0105104P.	PR 28-FEB-2001;	2001US-0000652P.
PR 22-OCT-1998;	98US-0105169P.	PR 01-MAR-2001;	2001US-0000666P.
		PR 01-JUN-2001;	2001US-0001780P.

PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GENTH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Baton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX WPI; 2003-567191/53.
XX
XX PT Novel secreted and transmembrane polypeptide useful identifying agonists
PT or antagonists of polypeptide, as molecular weight markers, and in tissue
XX typing.
XX
XX PS Example 85; SEQ ID NO 293; 553pp; English.
XX
XX CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GCTGACCTGGTTCCTACTCTCC 1064
DB 1 GCTGACCTGGTTCCTACTCTCC 24
RESULT 47
ADH99487/c
ID ADH99487 standard; DNA; 24 BP.
XX
AC ADH99487;
XX
DT 15-APR-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO133 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; Coeliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
OS Homo sapiens.
XX
XX PN US2003065142-A1.
XX
XX PD 03-APR-2003.
XX
XX PF 11-DEC-2001; 2001US-00015499.
XX
XX PR 01-SEP-1998; 98US-0098716P.
XX PR 01-SEP-1998; 98US-0098723P.
XX PR 01-SEP-1998; 98US-0098749P.
XX PR 01-SEP-1998; 98US-0098750P.
XX PR 02-SEP-1998; 98US-0098803P.
XX PR 02-SEP-1998; 98US-0098821P.
XX PR 02-SEP-1998; 98US-0098843P.
XX PR 02-SEP-1998; 98US-0099536P.
XX PR 02-SEP-1998; 98US-0099596P.
XX PR 02-SEP-1998; 98US-0099598P.
XX PR 02-SEP-1998; 98US-0099602P.
XX PR 02-SEP-1998; 98US-0099642P.
XX PR 02-SEP-1998; 98US-0099741P.
XX PR 02-SEP-1998; 98US-0099754P.
XX PR 10-SEP-1998; 98US-0099763P.
XX PR 10-SEP-1998; 98US-0099792P.

PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 15-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100663P.
PR 16-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105811P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.

PR	16-SEP-1998,	9805-0100554P
PR	16-SEP-1998,	9805-0100627P
PR	16-SEP-1998,	9805-0100661P
PR	16-SEP-1998,	9805-0100662P
PR	16-SEP-1998,	9805-0100664P
PR	17-SEP-1998,	9805-0100663P
PR	17-SEP-1998,	9805-0100684P
PR	17-SEP-1998,	9805-0100710P
PR	17-SEP-1998,	9805-0100711P
PR	17-SEP-1998,	9805-0100919P
PR	17-SEP-1998,	9805-0100930P
PR	18-SEP-1998,	9805-0100848P
PR	18-SEP-1998,	9805-0100849P
PR	18-SEP-1998,	9805-0101014P
PR	18-SEP-1998,	9805-0101068P
PR	18-SEP-1998,	9805-0101071P
PR	22-SEP-1998,	9805-0101279P
PR	23-SEP-1998,	9805-0101471P
PR	23-SEP-1998,	9805-0101472P
PR	23-SEP-1998,	9805-0101474P
PR	23-SEP-1998,	9805-0101475P
PR	23-SEP-1998,	9805-0101476P
PR	24-SEP-1998,	9805-0101478P
PR	24-SEP-1998,	9805-0101741P
PR	24-SEP-1998,	9805-0101743P
PR	24-SEP-1998,	9805-0101915P
PR	24-SEP-1998,	9805-0101916P
PR	29-SEP-1998,	9805-0102207P
PR	29-SEP-1998,	9805-0102240P
PR	29-SEP-1998,	9805-0102307P
PR	29-SEP-1998,	9805-0102309P
PR	29-SEP-1998,	9805-0102331P
PR	29-SEP-1998,	9805-0102365P
PR	30-SEP-1998,	9805-0102484P
PR	30-SEP-1998,	9805-0102487P
PR	30-SEP-1998,	9805-0102510P
PR	30-SEP-1998,	9805-0102571P
PR	01-OCT-1998,	9805-0102684P
PR	01-OCT-1998,	9805-0102687P
PR	01-OCT-1998,	9805-0102965P
PR	01-OCT-1998,	9805-0103258P
PR	06-OCT-1998,	9805-0103449P
PR	07-OCT-1998,	9805-0103314P
PR	07-OCT-1998,	9805-0103315P
PR	07-OCT-1998,	9805-0103328P
PR	07-OCT-1998,	9805-0103395P
PR	07-OCT-1998,	9805-0103396P
PR	08-OCT-1998,	9805-0103401P
PR	08-OCT-1998,	9805-0103653P
PR	08-OCT-1998,	9805-0103678P
PR	08-OCT-1998,	9805-0103679P
PR	08-OCT-1998,	9805-0103711P
PR	14-OCT-1998,	9805-0104257P
PR	20-OCT-1998,	9805-0104987P
PR	20-OCT-1998,	9805-0105000P
PR	21-OCT-1998,	9805-0105002P
PR	21-OCT-1998,	9805-0105104P
PR	22-OCT-1998,	9805-0105169P
PR	22-OCT-1998,	9805-0105266P
PR	26-OCT-1998,	9805-0105639P
PR	26-OCT-1998,	9805-0105643P
PR	27-OCT-1998,	9805-0105607P
PR	27-OCT-1998,	9805-0105882P
PR	27-OCT-1998,	9805-0105888P
PR	27-OCT-1998,	9805-0106062P
PR	28-OCT-1998,	9805-0106023P
PR	28-OCT-1998,	9805-0106029P
PR	28-OCT-1998,	9805-0106030P
PR	28-OCT-1998,	9805-0106032P
PR	28-OCT-1998,	9805-0106033P
PR	28-OCT-1998,	9805-0106178P
PR	29-OCT-1998,	9805-0106248P
PR	29-OCT-1998,	9805-0106384P

PT DNA, in various diagnostic assays and in gene therapy.
XX
PS Example 85; SEQ ID NO 294; 552bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1463 GGAGGTCATGGCTCTGTGGG 1486
DB 24 GGAGGTCATGGCTCTGTGGG 1
RESULT 49
ADE96666
ID ADE96666 standard; DNA; 24 BP.
XX
AC ADE96666;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
immune response; cardiac insufficiency disorder; calcium flux;
umbilical vein endothelial cell; bone disorder; cartilage disorder;
arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003195347-A1.
XX
PD 16-OCT-2003.
XX
PF 12-DEC-2001; 2001US-00015385.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100611P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.

PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105002P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 21-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 22-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 26-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106023P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.

PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-US020111.
PR 15-SEP-1999; 99US-US021194.
PR 30-NOV-1999; 99US-US028313.
PR 02-DEC-1999; 99US-US028551.
PR 16-DEC-1999; 99US-US030095.
PR 05-JAN-2000; 2000US-US000219.
PR 06-JAN-2000; 2000US-US003376.
PR 11-FEB-2000; 2000US-US003565.
PR 18-FEB-2000; 2000US-US004342.
PR 24-FEB-2000; 2000US-US005004.
PR 02-MAR-2000; 2000US-US005841.
PR 15-MAR-2000; 2000US-US006884.
PR 17-MAY-2000; 2000US-US013705.
PR 22-MAY-2000; 2000US-US014042.
PR 30-MAY-2000; 2000US-US014941.
PR 02-JUN-2000; 2000US-US015264.
PR 23-AUG-2000; 2000US-US023322.
PR 24-AUG-2000; 2000US-US023328.
PR 08-NOV-2000; 2000US-US030952.
PR 10-NOV-2000; 2000US-US030873.
PR 01-DEC-2000; 2000US-US032678.
PR 28-FEB-2001; 2001US-US006520.
PR 01-MAR-2001; 2001US-US006666.
PR 01-JUN-2001; 2001US-US017800.
PR 20-JUN-2001; 2001US-US019692.
PR 29-JUN-2001; 2001US-US021066.
PR 09-JUL-2001; 2001US-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
XX (GETH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Deamoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart RA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;
XX
XX WPI; 2004-021098/02.
XX
XX
XX New secreted and transmembrane PRO nucleic acid, for use in molecular
PT biology, chromosome and gene mapping, in generating antisense RNA and
PT DNA, in various diagnostic assays and in gene therapy.
XX
XX Example 85; SEQ ID NO 293; 552bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC

CC given in the specification (including their extracellular domains either
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GCTGACCTGGTTCATCTACTCC 1064
DB 1 GCTGACCTGGTTCATCTACTCC 24
RESULT 50
ADP25977
ID ADP25977 standard; DNA; 24 BP.
XX
XX ADP25977;
XX
XX 12-FEB-2004 (first entry)
XX
XX DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human, PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
KW dermatitis; herpiformis; Crohn's disease; thalassemia; se.
XX
XX Homo sapiens.
XX
XX US2003199675-A1.
XX
XX 23-OCT-2003.
XX
XX PF 11-DEC-2001; 2001US-00015389.
XX
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100549P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100651P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.

PR 18-SEP-1998; 98US-0101068P.
 PR 18-SEP-1998; 98US-0101071P.
 PR 22-SEP-1998; 98US-0101279P.
 PR 23-SEP-1998; 98US-010171P.
 PR 23-SEP-1998; 98US-0101472P.
 PR 23-SEP-1998; 98US-0101474P.
 PR 23-SEP-1998; 98US-0101475P.
 PR 23-SEP-1998; 98US-0101476P.
 PR 23-SEP-1998; 98US-0101477P.
 PR 23-SEP-1998; 98US-0101479P.
 PR 24-SEP-1998; 98US-0101738P.
 PR 24-SEP-1998; 98US-0101741P.
 PR 24-SEP-1998; 98US-0101743P.
 PR 24-SEP-1998; 98US-0101915P.
 PR 24-SEP-1998; 98US-0101916P.
 PR 29-SEP-1998; 98US-0102207P.
 PR 29-SEP-1998; 98US-0102240P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102310P.
 PR 29-SEP-1998; 98US-0102331P.
 PR 30-SEP-1998; 98US-0102484P.
 PR 30-SEP-1998; 98US-0102487P.
 PR 30-SEP-1998; 98US-0102570P.
 PR 30-SEP-1998; 98US-0102571P.
 PR 01-OCT-1998; 98US-0102684P.
 PR 01-OCT-1998; 98US-0102687P.
 PR 02-OCT-1998; 98US-0102965P.
 PR 06-OCT-1998; 98US-0103258P.
 PR 06-OCT-1998; 98US-0103499P.
 PR 07-OCT-1998; 98US-0103149P.
 PR 07-OCT-1998; 98US-0103115P.
 PR 07-OCT-1998; 98US-0103128P.
 PR 07-OCT-1998; 98US-0103395P.
 PR 07-OCT-1998; 98US-0103966P.
 PR 07-OCT-1998; 98US-0103401P.
 PR 08-OCT-1998; 98US-0103633P.
 PR 08-OCT-1998; 98US-0103678P.
 PR 08-OCT-1998; 98US-0103679P.
 PR 08-OCT-1998; 98US-0103711P.
 PR 14-OCT-1998; 98US-0104257P.
 PR 20-OCT-1998; 98US-0104987P.
 PR 20-OCT-1998; 98US-0105000P.
 PR 20-OCT-1998; 98US-0105002P.
 PR 21-OCT-1998; 98US-0105104P.
 PR 22-OCT-1998; 98US-0105169P.
 PR 22-OCT-1998; 98US-0105266P.
 PR 26-OCT-1998; 98US-0105693P.
 PR 26-OCT-1998; 98US-0105694P.
 PR 27-OCT-1998; 98US-0105807P.
 PR 27-OCT-1998; 98US-0105881P.
 PR 27-OCT-1998; 98US-0105882P.
 PR 27-OCT-1998; 98US-0106062P.
 PR 28-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106029P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.
 PR 28-OCT-1998; 98US-0106178P.
 PR 29-OCT-1998; 98US-0106248P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 29-OCT-1998; 98US-0106380P.
 PR 30-OCT-1998; 98US-0106464P.
 PR 03-NOV-1998; 98US-0106566P.
 PR 03-NOV-1998; 98US-0106502P.
 PR 03-NOV-1998; 98US-0106905P.
 PR 03-NOV-1998; 98US-0106919P.
 PR 03-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.

PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108867P.
 PR 17-NOV-1998; 98US-0108925P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108850P.
 PR 18-NOV-1998; 98US-0108851P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 22-DEC-1998; 98US-0114223P.
 PR 05-JAN-1999; 99WO-US000106.
 PR 16-APR-1999; 99US-0129674P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 26-JUL-1999; 99US-0145698P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 15-SEP-1999; 99WO-US021194.
 PR 29-OCT-1999; 99US-0162506P.
 PR 30-NOV-1999; 99WO-US028313.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US030095.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023528.
 PR 24-AUG-2000; 2000WO-US033282.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030873.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 01-JUN-2001; 2001WO-US017800.
 PR 20-JUN-2001; 2001WO-US019692.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 04-SEP-2001; 2001US-00946374.
 PA (GETH) GENENTECH INC.
 XX Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S,
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
 PI Williams EM, Wood WI;
 XX WPI; 2004-041394/04.
 DR Novel isolated PRO polypeptide useful for tissue typing, modulating
 XX biological activity of cell, as molecular weight markers in protein
 PT electrophoresis, for treating arthritis, tumor.
 PT
 XX Example 85; SEQ ID NO 293; 552pp; English.
 PS The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC
 Query Match 1.0%; Score 24; DB 1; Length 24;
 Beat Local Similarity 100.0%; Pred. No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1041 GGTGACCTGGTCCATCTACTCC 1064

Db 1 ||||| 1 GCTGACCTGATCCATCTACTCC 24

RESULT 51
ID ADF25978/c
ID ADF25978 standard; DNA; 24 BP.

AC ADF25978;
XX
XX
DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

OS Homo sapiens.
XX
XX US200319675-A1.
PN
XX
XX
XX 23-OCT-2003.
PD
XX
XX 11-DEC-2001; 2001US-00015389.
PF
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.

PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104258P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105639P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105811P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.

PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108853P.
PR 18-NOV-1998; 98US-0108854P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GERTH) GENENTECH INC.
XX
PI Baker KP, Botestein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart RA, Tumas D, Watanabe CK;
PI Williams PM, Wood WT;
XX
DR WPI; 2004-041394/04.
XX
XX
PT Novel isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis, tumor.
XX
PS Example 85; SEQ ID NO 294; 552pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1463 GGAGGTCTATGGGTCTGTGTGG 1486
|||
Db 24 GGAGGTCTATGGGTCTGTGTGG 1

RESULT 52
ADF24877/c
ID ADF24877 standard; DNA; 24 BP.

XX
AC ADF24877;
XX
DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
KW dermatitis; herpiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003198993-A1.
XX
XX 23-OCT-2003.
XX
PD 06-DEC-2001; 2001US-00007236.
PF
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099534P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100719P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 22-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.

PR	29-SEP-1998;	98US-0101916;
PR	29-SEP-1998;	98US-0102207;
PR	29-SEP-1998;	98US-0102240;
PR	29-SEP-1998;	98US-0102307;
PR	29-SEP-1998;	98US-0102330;
PR	29-SEP-1998;	98US-0102331;
PR	30-SEP-1998;	98US-0102444;
PR	30-SEP-1998;	98US-0102487;
PR	30-SEP-1998;	98US-0102570;
PR	30-SEP-1998;	98US-0102571;
PR	01-OCT-1998;	98US-0102664;
PR	01-OCT-1998;	98US-0102667;
PR	02-OCT-1998;	98US-0102965;
PR	06-OCT-1998;	98US-0103258;
PR	06-OCT-1998;	98US-0103449;
PR	07-OCT-1998;	98US-0103314;
PR	07-OCT-1998;	98US-0103315;
PR	07-OCT-1998;	98US-0103328;
PR	07-OCT-1998;	98US-0103359;
PR	07-OCT-1998;	98US-0103366;
PR	08-OCT-1998;	98US-0103401;
PR	08-OCT-1998;	98US-0103633;
PR	08-OCT-1998;	98US-0103678;
PR	08-OCT-1998;	98US-0103679;
PR	08-OCT-1998;	98US-0103711;
PR	14-OCT-1998;	98US-0104257;
PR	20-OCT-1998;	98US-0104967;
PR	20-OCT-1998;	98US-0105000;
PR	20-OCT-1998;	98US-0105002;
PR	21-OCT-1998;	98US-0105104;
PR	22-OCT-1998;	98US-0105169;
PR	22-OCT-1998;	98US-0105263;
PR	26-OCT-1998;	98US-0105629;
PR	26-OCT-1998;	98US-0105644;
PR	27-OCT-1998;	98US-0105807;
PR	27-OCT-1998;	98US-0105811;
PR	27-OCT-1998;	98US-0105862;
PR	27-OCT-1998;	98US-0105882;
PR	28-OCT-1998;	98US-0106023;
PR	28-OCT-1998;	98US-0106030;
PR	28-OCT-1998;	98US-0106032;
PR	28-OCT-1998;	98US-0106033;
PR	28-OCT-1998;	98US-0106178;
PR	29-OCT-1998;	98US-0106248;
PR	29-OCT-1998;	98US-0106384;
PR	29-OCT-1998;	98US-0106500;
PR	30-OCT-1998;	98US-0106534;
PR	30-OCT-1998;	98US-0106464;
PR	30-NOV-1998;	98US-0106565;
PR	03-NOV-1998;	98US-0106502;
PR	03-NOV-1998;	98US-0106509;
PR	03-NOV-1998;	98US-0106519;
PR	03-NOV-1998;	98US-0106532P;
PR	03-NOV-1998;	98US-0106534P;
PR	10-NOV-1998;	98US-0107783;
PR	17-NOV-1998;	98US-0107755;
PR	17-NOV-1998;	98US-0108779;
PR	17-NOV-1998;	98US-0108787;
PR	17-NOV-1998;	98US-0108788P;
PR	17-NOV-1998;	98US-0108801P;
PR	17-NOV-1998;	98US-0108802P;
PR	17-NOV-1998;	98US-0108805P;
PR	17-NOV-1998;	98US-0108807P;
PR	17-NOV-1998;	98US-0108867P;
PR	17-NOV-1998;	98US-0108925P;
PR	18-NOV-1998;	98US-0108848P;
PR	18-NOV-1998;	98US-0108849P;
PR	18-NOV-1998;	98US-0108850P;
PR	18-NOV-1998;	98US-0108851P;
PR	18-NOV-1998;	98US-0108852P;
PR	18-NOV-1998;	98US-0108858P;
PR	18-NOV-1998;	98US-0108904P;
PR	22-DEC-1998;	98US-0101396P;

PR	30-DEC-1998;	98US-0114223P.
PR	05-JAN-1999;	98WO-US000106.
PR	16-APR-1999;	99US-0129674P.
PR	23-JUN-1999;	99US-0141037P.
PR	20-JUL-1999;	99US-0144758P.
PR	26-JUL-1999;	99US-0145698P.
PR	01-SEP-1999;	99WO-US020111.
PR	15-SEP-1999;	99WO-US021194.
PR	29-OCT-1999;	99US-0162506P.
PR	30-NOV-1999;	99WO-US028313.
PR	02-DEC-1999;	99WO-US028551.
PR	16-DEC-1999;	99WO-US030095.
PR	05-JAN-2000;	2000WO-US000212.
PR	06-JAN-2000;	2000WO-US000376.
PR	11-FEB-2000;	2000WO-US003565.
PR	18-FEB-2000;	2000WO-US004342.
PR	24-FEB-2000;	2000WO-US005004.
PR	02-MAR-2000;	2000WO-US005841.
PR	15-MAR-2000;	2000WO-US006844.
PR	17-MAY-2000;	2000WO-US013705.
PR	22-MAY-2000;	2000WO-US014042.
PR	30-MAY-2000;	2000WO-US014941.
PR	02-JUN-2000;	2000WO-US015264.
PR	23-JUN-2000;	2000WO-US023522.
PR	24-AUG-2000;	2000WO-US023328.
PR	08-NOV-2000;	2000WO-US030952.
PR	10-NOV-2000;	2000WO-US030873.
PR	01-DEC-2000;	2000WO-US032678.
PR	28-FEB-2001;	2001WO-US006520.
PR	01-MAR-2001;	2001WO-US006666.
PR	01-JUN-2001;	2001WO-US017800.
PR	20-JUN-2001;	2001WO-US019692.
PR	29-JUN-2001;	2001WO-US021066.
PR	09-JUL-2001;	2001WO-US021735.
PR	04-SEP-2001;	2001US-00946374.
XX		
PA	(GETH) GENENTECH INC.	
XX		
PI	Baker KP, Borstein D, Deanyers L, Eaton DL, Ferrara N, Fong S,	
PI	Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,	
PI	Pan Y, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;	
PI	Williams PM, Wood WI;	
XX		
DR	WPI; 2004-041347/04.	
XX		
PT	Novel isolated PRO polypeptides e.g. PRO1130, PRO1275, PRO1418, PRO1555,	
PT	PRO1787 affect glucose or free fatty acid (FFA) uptake by skeletal muscle	
PT	cells and are useful for treating diabetes or hyper- or hypo-insulinemia.	
XX		
PS	Example 85; SEQ ID NO 294; 553bp; English.	
XX		
CC	The invention relates to an isolated PRO polypeptide (secreted or	
CC	transmembrane protein) having at least 80% amino acid sequence identity	
CC		
QY	Query Match 1.0%; Score 24; DB 1; Length 24;	
	Best Local Similarity 100.0%; Pred. No. 8.7;	
	Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
	1463 GGAAGTCATGGAGGCTGTGGG 1486	
Db	24 GGAAGTCATGGAGGCTGTGGG 1	
XX		
RESULT 53		
ID	ADF24876	
AD	ADF24876 standard; DNA; 24 BP.	
XX		
AC	ADF24876;	
XX		
DT	12-FEB-2004 (first entry)	
XX		
DE	Human secreted/transmembrane protein PRO1433 PCR primer #1.	
XX		

KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
OS Homo sapiens.
XX
XX US2003198993-A1.
PN
XX 23-OCT-2003.
PD
XX
PF 06-DEC-2001; 2001US-00007236.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 15-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101388P.
PR 24-SEP-1998; 98US-0101411P.
PR 24-SEP-1998; 98US-0101433P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.

PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103799P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108856P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0128674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.

PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028511.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US000365.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023528.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US016992.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX
XX (GENTH) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX WPI; 2004-041347/04.
XX
XX
XX Novel isolated PRO polypeptides e.g. PRO1130, PRO1275, PRO1418, PRO1555,
PT PRO1787 affect glucose or free fatty acid (FFA) uptake by skeletal muscle
PT cells and are useful for treating diabetes or hyper- or hypo-insulinemia.
XX
XX
XX Example 85; SEQ ID NO 293; 553bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GCTGACCTGTTCCCATCTACTCC 1064
DB 1 GCTGACCTGTTCCCATCTACTCC 24
RESULT 54
ADP29612
ID ADF29612 standard; DNA; 24 BP.
XX
XX ADF29612;
XX
XX 12-FEB-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX

OS Homo sapiens.
XX
XX US2003203401-A1.
XX
XX 30-OCT-2003.
PD
XX
PF 11-DEC-2001; 2001US-00015519.
XX
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101068P.
PR 23-SEP-1998; 98US-0101271P.
PR 23-SEP-1998; 98US-0101271P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101477P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 24-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102584P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.

PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108825P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114232P.
PR 05-JAN-1999; 99MO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99MO-US020111.
PR 15-SEP-1999; 99MO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99MO-US028313.
PR 02-DEC-1999; 99MO-US028551.
PR 16-DEC-1999; 99MO-US030095.
PR 05-JAN-2000; 2000MO-US000219.
PR 06-JAN-2000; 2000MO-US000376.

PR 11-FEB-2000; 2000MO-US003565.
PR 18-FEB-2000; 2000MO-US004342.
PR 24-FEB-2000; 2000MO-US005004.
PR 02-MAR-2000; 2000MO-US005841.
PR 15-MAR-2000; 2000MO-US006884.
PR 17-MAY-2000; 2000MO-US013705.
PR 22-MAY-2000; 2000MO-US014941.
PR 30-MAY-2000; 2000MO-US015264.
PR 02-JUN-2000; 2000MO-US015264.
PR 23-AUG-2000; 2000MO-US023522.
PR 24-AUG-2000; 2000MO-US023328.
PR 08-NOV-2000; 2000MO-US030952.
PR 10-NOV-2000; 2000MO-US030873.
PR 01-DEC-2000; 2000MO-US032678.
PR 28-FEB-2001; 2001MO-US006520.
PR 01-MAR-2001; 2001MO-US006666.
PR 01-JUN-2001; 2001MO-US017800.
PR 20-JUN-2001; 2001MO-US019692.
PR 29-JUN-2001; 2001MO-US021066.
PR 09-JUL-2001; 2001MO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
PA
XX Baker KP, Bocstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
PI Williams PM, Wood WO;
XX
XX WPI; 2004-041478/04.
XX
XX
PT New isolated PRO polypeptide useful for tissue typing, modulating the
PT biological activity of a cell, as molecular weight markers in protein
PT electrophoresis, and for treating e.g. arthritis, or tumor.
XX
XX Example 85; SEQ ID NO 293; 551bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC
Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1041 GCTGACCTGGTCCCATCTACTCC 1064
DB 1 GCTGACCTGGTCCCATCTACTCC 24
RESULT 55
ID ADF29613/c
XX ADF29613; standard; DNA, 24 BP.
AC
XX ADF29613;
DT 12-FEB-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; colliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
XX US2003203401-A1.
PN
XX
XX 30-OCT-2003.
PD
XX
XX 11-DEC-2001; 2001US-00015519.
PF

```

XX 01-SEP-1998; 98US-0098716P
PR 01-SEP-1998; 98US-0098723P
PR 01-SEP-1998; 98US-0098749P
PR 01-SEP-1998; 98US-0098750P
PR 02-SEP-1998; 98US-0098803P
PR 02-SEP-1998; 98US-0098821P
PR 02-SEP-1998; 98US-0098843P
PR 09-SEP-1998; 98US-0099536P
PR 09-SEP-1998; 98US-0099596P
PR 09-SEP-1998; 98US-0099598P
PR 09-SEP-1998; 98US-0099602P
PR 10-SEP-1998; 98US-0099642P
PR 10-SEP-1998; 98US-0099741P
PR 10-SEP-1998; 98US-0099754P
PR 10-SEP-1998; 98US-0099763P
PR 10-SEP-1998; 98US-0099792P
PR 10-SEP-1998; 98US-0099808P
PR 10-SEP-1998; 98US-0099812P
PR 10-SEP-1998; 98US-0099815P
PR 15-SEP-1998; 98US-0100385P
PR 15-SEP-1998; 98US-0100388P
PR 15-SEP-1998; 98US-0100390P
PR 16-SEP-1998; 98US-0100584P
PR 16-SEP-1998; 98US-0100627P
PR 16-SEP-1998; 98US-0100661P
PR 16-SEP-1998; 98US-0100662P
PR 16-SEP-1998; 98US-0100664P
PR 17-SEP-1998; 98US-0100683P
PR 17-SEP-1998; 98US-0100684P
PR 17-SEP-1998; 98US-0100710P
PR 17-SEP-1998; 98US-0100711P
PR 17-SEP-1998; 98US-0100919P
PR 17-SEP-1998; 98US-0100930P
PR 18-SEP-1998; 98US-0100848P
PR 18-SEP-1998; 98US-0100849P
PR 18-SEP-1998; 98US-0101014P
PR 18-SEP-1998; 98US-0101068P
PR 18-SEP-1998; 98US-0101071P
PR 22-SEP-1998; 98US-0101279P
PR 23-SEP-1998; 98US-0101471P
PR 23-SEP-1998; 98US-0101472P
PR 23-SEP-1998; 98US-0101474P
PR 23-SEP-1998; 98US-0101475P
PR 23-SEP-1998; 98US-0101476P
PR 23-SEP-1998; 98US-0101477P
PR 23-SEP-1998; 98US-0101479P
PR 24-SEP-1998; 98US-0101738P
PR 24-SEP-1998; 98US-0101741P
PR 24-SEP-1998; 98US-0101743P
PR 24-SEP-1998; 98US-0101915P
PR 24-SEP-1998; 98US-0101916P
PR 29-SEP-1998; 98US-0102207P
PR 29-SEP-1998; 98US-0102240P
PR 29-SEP-1998; 98US-0102307P
PR 29-SEP-1998; 98US-0102330P
PR 29-SEP-1998; 98US-0102331P
PR 30-SEP-1998; 98US-0102484P
PR 30-SEP-1998; 98US-0102487P
PR 30-SEP-1998; 98US-0102570P
PR 30-SEP-1998; 98US-0102571P
PR 01-OCT-1998; 98US-0102684P
PR 01-OCT-1998; 98US-0102687P
PR 02-OCT-1998; 98US-0102965P
PR 06-OCT-1998; 98US-0103258P
PR 06-OCT-1998; 98US-0103149P
PR 07-OCT-1998; 98US-0103314P
PR 07-OCT-1998; 98US-0103315P
PR 07-OCT-1998; 98US-0103328P
PR 07-OCT-1998; 98US-0103395P
PR 07-OCT-1998; 98US-0103396P
PR 07-OCT-1998; 98US-0103401P

PR 08-OCT-1998; 98US-0103633P
PR 08-OCT-1998; 98US-0103678P
PR 08-OCT-1998; 98US-0103711P
PR 14-OCT-1998; 98US-0104257P
PR 20-OCT-1998; 98US-0104987P
PR 20-OCT-1998; 98US-0105000P
PR 20-OCT-1998; 98US-0105002P
PR 21-OCT-1998; 98US-0105104P
PR 22-OCT-1998; 98US-0105169P
PR 22-OCT-1998; 98US-0105266P
PR 26-OCT-1998; 98US-0105693P
PR 26-OCT-1998; 98US-0105694P
PR 27-OCT-1998; 98US-0105807P
PR 27-OCT-1998; 98US-0105881P
PR 27-OCT-1998; 98US-0105882P
PR 27-OCT-1998; 98US-0106023P
PR 28-OCT-1998; 98US-0106029P
PR 28-OCT-1998; 98US-0106030P
PR 28-OCT-1998; 98US-0106032P
PR 28-OCT-1998; 98US-0106033P
PR 28-OCT-1998; 98US-0106178P
PR 29-OCT-1998; 98US-0106248P
PR 29-OCT-1998; 98US-0106384P
PR 30-OCT-1998; 98US-0106500P
PR 30-OCT-1998; 98US-0106464P
PR 30-NOV-1998; 98US-0106856P
PR 03-NOV-1998; 98US-0106902P
PR 03-NOV-1998; 98US-0106905P
PR 03-NOV-1998; 98US-0106919P
PR 03-NOV-1998; 98US-0106932P
PR 10-NOV-1998; 98US-0107783P
PR 17-NOV-1998; 98US-0108775P
PR 17-NOV-1998; 98US-0108779P
PR 17-NOV-1998; 98US-0108787P
PR 17-NOV-1998; 98US-0108788P
PR 17-NOV-1998; 98US-0108801P
PR 17-NOV-1998; 98US-0108802P
PR 17-NOV-1998; 98US-0108806P
PR 17-NOV-1998; 98US-0108807P
PR 17-NOV-1998; 98US-0108825P
PR 18-NOV-1998; 98US-0108925P
PR 18-NOV-1998; 98US-0108848P
PR 18-NOV-1998; 98US-0108849P
PR 18-NOV-1998; 98US-0108850P
PR 18-NOV-1998; 98US-0108851P
PR 18-NOV-1998; 98US-0108852P
PR 18-NOV-1998; 98US-0108858P
PR 18-NOV-1998; 98US-0108904P
PR 22-DEC-1998; 98US-0113296P
PR 30-DEC-1998; 98US-0114223P
PR 05-JAN-1999; 99WO-US000106
PR 16-APR-1999; 99US-0129674P
PR 23-JUN-1999; 99US-0141037P
PR 26-JUL-1999; 99US-0144758P
PR 26-JUL-1999; 99US-0145698P
PR 01-SEP-1999; 99WO-US020111
PR 15-SEP-1999; 99WO-US021194
PR 29-OCT-1999; 99US-0162506P
PR 30-NOV-1999; 99WO-US028513
PR 02-DEC-1999; 99WO-US028551
PR 16-DEC-1999; 99WO-US030095
PR 05-JAN-2000; 2000WO-US000219
PR 06-JAN-2000; 2000WO-US000376
PR 11-FEB-2000; 2000WO-US003565
PR 18-FEB-2000; 2000WO-US004342
PR 24-FEB-2000; 2000WO-US005004
PR 02-MAR-2000; 2000WO-US005841
PR 15-MAR-2000; 2000WO-US006884
PR 17-MAY-2000; 2000WO-US013705
PR 22-MAY-2000; 2000WO-US014042

```



```
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 23-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 29-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0108500P.
PR 03-NOV-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 17-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108825P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-JUN-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.

PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
PA (GENTH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WJ,
XX
DR WPI; 2004-041280/04.
XX
PT New isolated PRO polypeptides useful for treating diseases such as cancer
PT and diabetes.
XX
PS Example 85; SEQ ID NO 293; 551bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1041 GCTGACCTGTTCCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCCATCTACTCC 24

RESULT 57
ADE97144/C
ID ADE97144 standard; DNA; 24 BP.
XX
XX ADE97144;
AC
XX
XX 12-FEB-2004 (first entry)
DT
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW Immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003195334-A1.
XX
PD 16-OCT-2003.
XX
PF 07-DEC-2001; 2001US-00012753.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-00989536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
```


PR 10-SEP-1998; 98US-009754P.
 PR 10-SEP-1998; 98US-009763P.
 PR 10-SEP-1998; 98US-009792P.
 PR 10-SEP-1998; 98US-0099808P.
 PR 10-SEP-1998; 98US-0099812P.
 PR 10-SEP-1998; 98US-0099815P.
 PR 10-SEP-1998; 98US-0099816P.
 PR 15-SEP-1998; 98US-0100385P.
 PR 15-SEP-1998; 98US-0100388P.
 PR 15-SEP-1998; 98US-0100390P.
 PR 16-SEP-1998; 98US-0100584P.
 PR 16-SEP-1998; 98US-0100627P.
 PR 16-SEP-1998; 98US-0100661P.
 PR 16-SEP-1998; 98US-0100662P.
 PR 16-SEP-1998; 98US-0100664P.
 PR 17-SEP-1998; 98US-0100683P.
 PR 17-SEP-1998; 98US-0100684P.
 PR 17-SEP-1998; 98US-0100710P.
 PR 17-SEP-1998; 98US-0100711P.
 PR 17-SEP-1998; 98US-0100919P.
 PR 17-SEP-1998; 98US-0100930P.
 PR 18-SEP-1998; 98US-0100848P.
 PR 18-SEP-1998; 98US-0100849P.
 PR 18-SEP-1998; 98US-0101014P.
 PR 18-SEP-1998; 98US-0101068P.
 PR 18-SEP-1998; 98US-0101071P.
 PR 22-SEP-1998; 98US-0101279P.
 PR 23-SEP-1998; 98US-0101471P.
 PR 23-SEP-1998; 98US-0101472P.
 PR 23-SEP-1998; 98US-0101474P.
 PR 23-SEP-1998; 98US-0101475P.
 PR 23-SEP-1998; 98US-0101476P.
 PR 23-SEP-1998; 98US-0101479P.
 PR 24-SEP-1998; 98US-0101388P.
 PR 24-SEP-1998; 98US-0101741P.
 PR 24-SEP-1998; 98US-0101743P.
 PR 24-SEP-1998; 98US-0101915P.
 PR 24-SEP-1998; 98US-0101916P.
 PR 29-SEP-1998; 98US-0102207P.
 PR 29-SEP-1998; 98US-0102240P.
 PR 29-SEP-1998; 98US-0102307P.
 PR 29-SEP-1998; 98US-0102330P.
 PR 29-SEP-1998; 98US-0102331P.
 PR 30-SEP-1998; 98US-0102484P.
 PR 30-SEP-1998; 98US-0102487P.
 PR 30-SEP-1998; 98US-0102570P.
 PR 30-SEP-1998; 98US-0102571P.
 PR 01-OCT-1998; 98US-0102684P.
 PR 01-OCT-1998; 98US-0102687P.
 PR 02-OCT-1998; 98US-0102965P.
 PR 06-OCT-1998; 98US-0103258P.
 PR 06-OCT-1998; 98US-0103449P.
 PR 07-OCT-1998; 98US-0103314P.
 PR 07-OCT-1998; 98US-0103315P.
 PR 07-OCT-1998; 98US-0103328P.
 PR 07-OCT-1998; 98US-0103395P.
 PR 07-OCT-1998; 98US-0103396P.
 PR 07-OCT-1998; 98US-0103401P.
 PR 08-OCT-1998; 98US-0103633P.
 PR 08-OCT-1998; 98US-0103678P.
 PR 08-OCT-1998; 98US-0103679P.
 PR 08-OCT-1998; 98US-0103711P.
 PR 14-OCT-1998; 98US-0104257P.
 PR 20-OCT-1998; 98US-0104987P.
 PR 20-OCT-1998; 98US-0105000P.
 PR 20-OCT-1998; 98US-0105002P.
 PR 21-OCT-1998; 98US-0105104P.
 PR 22-OCT-1998; 98US-0105169P.
 PR 22-OCT-1998; 98US-0105266P.
 PR 26-OCT-1998; 98US-0105693P.
 PR 26-OCT-1998; 98US-0105694P.
 PR 27-OCT-1998; 98US-0105807P.
 PR 27-OCT-1998; 98US-0105811P.

PR 27-OCT-1998; 98US-0105882P.
 PR 27-OCT-1998; 98US-0106022P.
 PR 28-OCT-1998; 98US-0106023P.
 PR 28-OCT-1998; 98US-0106029P.
 PR 28-OCT-1998; 98US-0106030P.
 PR 28-OCT-1998; 98US-0106032P.
 PR 28-OCT-1998; 98US-0106033P.
 PR 28-OCT-1998; 98US-0106178P.
 PR 29-OCT-1998; 98US-0106248P.
 PR 29-OCT-1998; 98US-0106384P.
 PR 29-OCT-1998; 98US-0106500P.
 PR 30-OCT-1998; 98US-0106464P.
 PR 03-NOV-1998; 98US-0106856P.
 PR 03-NOV-1998; 98US-0106902P.
 PR 03-NOV-1998; 98US-0106905P.
 PR 03-NOV-1998; 98US-0106919P.
 PR 03-NOV-1998; 98US-0106932P.
 PR 03-NOV-1998; 98US-0106934P.
 PR 10-NOV-1998; 98US-0107783P.
 PR 17-NOV-1998; 98US-0108775P.
 PR 17-NOV-1998; 98US-0108779P.
 PR 17-NOV-1998; 98US-0108787P.
 PR 17-NOV-1998; 98US-0108788P.
 PR 17-NOV-1998; 98US-0108789P.
 PR 17-NOV-1998; 98US-0108801P.
 PR 17-NOV-1998; 98US-0108802P.
 PR 17-NOV-1998; 98US-0108806P.
 PR 17-NOV-1998; 98US-0108807P.
 PR 17-NOV-1998; 98US-0108867P.
 PR 17-NOV-1998; 98US-0108925P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108849P.
 PR 18-NOV-1998; 98US-0108851P.
 PR 18-NOV-1998; 98US-0108852P.
 PR 18-NOV-1998; 98US-0108858P.
 PR 18-NOV-1998; 98US-0108904P.
 PR 22-DEC-1998; 98US-0113296P.
 PR 30-DEC-1998; 98US-0114223P.
 PR 05-JAN-1999; 99WO-US000106.
 PR 16-APR-1999; 99US-0129674P.
 PR 23-JUN-1999; 99US-0141037P.
 PR 26-JUL-1999; 99US-0144758P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 01-SEP-1999; 99WO-US021199.
 PR 15-SEP-1999; 99WO-US028313.
 PR 30-NOV-1999; 99WO-US028551.
 PR 02-DEC-1999; 99WO-US028551.
 PR 16-DEC-1999; 99WO-US030095.
 PR 05-JAN-2000; 2000WO-US000219.
 PR 06-JAN-2000; 2000WO-US000376.
 PR 11-FEB-2000; 2000WO-US003565.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 24-FEB-2000; 2000WO-US005004.
 PR 02-MAR-2000; 2000WO-US005841.
 PR 15-MAR-2000; 2000WO-US006884.
 PR 17-MAY-2000; 2000WO-US013705.
 PR 22-MAY-2000; 2000WO-US014042.
 PR 30-MAY-2000; 2000WO-US014941.
 PR 02-JUN-2000; 2000WO-US015264.
 PR 23-AUG-2000; 2000WO-US023322.
 PR 24-AUG-2000; 2000WO-US023328.
 PR 08-NOV-2000; 2000WO-US030952.
 PR 10-NOV-2000; 2000WO-US030878.
 PR 01-DEC-2000; 2000WO-US032678.
 PR 28-FEB-2001; 2001WO-US006520.
 PR 01-MAR-2001; 2001WO-US006666.
 PR 20-JUN-2001; 2001WO-US017800.
 PR 29-JUN-2001; 2001WO-US021066.
 PR 09-JUL-2001; 2001WO-US021735.
 PR 04-SEP-2001; 2001US-00946374.
 XX
 XX
 (GETH) GENENTECH INC.

XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX WPI; 2004-041280/04.
XX
PT New isolated PRO polypeptides useful for treating diseases such as cancer
and diabetes.
XX
PS Example 85; SEQ ID NO 294; 551bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides). Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred.No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAGGTCTCATGGGTCTCTGTGGG 1486
DB 24 GGAGGTCTCATGGGTCTCTGTGGG 1

RESULT 58
ADH03181
ID ADH03181 standard; DNA; 24 BP.
AC
XX ADH03181;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
KW Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW Immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; neuropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
OS Homo sapiens.
XX
PN US2003216562-A1.
XX
PD 20-NOV-2003.
PF 12-DEC-2001; 2001US-00015390.
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 02-SEP-1998; 98US-0098856P.
PR 02-SEP-1998; 98US-0098956P.
PR 02-SEP-1998; 98US-0098958P.
PR 02-SEP-1998; 98US-0098962P.
PR 02-SEP-1998; 98US-0098964P.
PR 02-SEP-1998; 98US-0098974P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099753P.
PR 10-SEP-1998; 98US-0099752P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.

PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0104257P.
PR 14-OCT-1998; 98US-0104371P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106022P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.

PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106646P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99US-05000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99US-02020111.
PR 15-SEP-1999; 99US-02021194.
PR 30-NOV-1999; 99US-02028313.
PR 02-DEC-1999; 99US-02028551.
PR 16-DEC-1999; 99US-02030095.
PR 05-JAN-2000; 2000US-05000219.
PR 06-JAN-2000; 2000US-05000376.
PR 11-FEB-2000; 2000US-05003565.
PR 18-FEB-2000; 2000US-05004342.
PR 24-FEB-2000; 2000US-05005004.
PR 02-MAR-2000; 2000US-05005841.
PR 15-MAR-2000; 2000US-05006884.
PR 17-MAY-2000; 2000US-0501705.
PR 22-MAY-2000; 2000US-0501842.
PR 30-MAY-2000; 2000US-0501941.
PR 02-JUN-2000; 2000US-05015264.
PR 23-AUG-2000; 2000US-05023522.
PR 24-AUG-2000; 2000US-05023328.
PR 08-NOV-2000; 2000US-05039552.
PR 10-NOV-2000; 2000US-05038773.
PR 01-DEC-2000; 2000US-0503678.
PR 28-FEB-2001; 2001US-05006520.
PR 01-MAR-2001; 2001US-05006666.
PR 01-JUN-2001; 2001US-05017800.
PR 20-JUN-2001; 2001US-05019692.
PR 29-JUN-2001; 2001US-05021066.
PR 09-JUL-2001; 2001US-05021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurrey AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI,
XX
XX WPI; 2004-021867/02.
DR

XX
PT Novel isolated PRO polypeptide useful for treating tumor, kidney
XX disorders, diabetes mellitus, thalassemias.
XX
XX Example 85; SEQ ID NO 293; 552pp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCATCTACTCC 1064
DB 1 GCTGACCTGTTCCATCTACTCC 24

RESULT 59
ADH03182/C
ID ADH03182 standard; DNA; 24 BP.
XX
AC ADH03182;
XX
DT 11-MAR-2004 (first entry)
XX
DE Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX Immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritic; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
OS Homo sapiens.
XX
XX US2003216562-A1.
XX
XX 20-NOV-2003.
XX
XX 12-DEC-2001; 2001US-00015390.
XX
XX 01-SEP-1998; 98US-0098716P.
XX 01-SEP-1998; 98US-0098723P.
XX 01-SEP-1998; 98US-0098749P.
XX 01-SEP-1998; 98US-0098750P.
XX 02-SEP-1998; 98US-0098803P.
XX 02-SEP-1998; 98US-0098821P.
XX 02-SEP-1998; 98US-0098843P.
XX 02-SEP-1998; 98US-00989536P.
XX 09-SEP-1998; 98US-0098956P.
XX 09-SEP-1998; 98US-0098958P.
XX 09-SEP-1998; 98US-00989602P.
XX 09-SEP-1998; 98US-00989642P.
XX 10-SEP-1998; 98US-00989741P.
XX 10-SEP-1998; 98US-00989754P.
XX 10-SEP-1998; 98US-00989763P.
XX 10-SEP-1998; 98US-00989792P.
XX 10-SEP-1998; 98US-00989808P.
XX 10-SEP-1998; 98US-00989812P.
XX 10-SEP-1998; 98US-00989815P.
XX 10-SEP-1998; 98US-00989816P.
XX 15-SEP-1998; 98US-0100385P.
XX 15-SEP-1998; 98US-0100388P.
XX 15-SEP-1998; 98US-0100390P.
XX 16-SEP-1998; 98US-0100584P.
XX 16-SEP-1998; 98US-0100627P.
XX 16-SEP-1998; 98US-0100661P.
XX 16-SEP-1998; 98US-0100662P.

PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101747P.
PR 23-SEP-1998; 98US-0101755P.
PR 23-SEP-1998; 98US-0101476P.
PR 24-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102655P.
PR 06-OCT-1998; 98US-0103258P.
PR 07-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103114P.
PR 07-OCT-1998; 98US-0103115P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 14-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106035P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106454P.
PR 03-NOV-1998; 98US-0106456P.
PR 03-NOV-1998; 98US-0106902P.

PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 17-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108845P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 98US-0129674P.
PR 23-JUN-1999; 98US-0141037P.
PR 20-JUL-1999; 98US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014942.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 01-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

(GETH) GENENTECH INC.
XX Baker KP, Botstein D, Desnoyers L, Baton DL, Ferrara N, Fong S;
XX Pi Pan J, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
XX Pi Gao W, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
XX Williams PM, Wood WI;
XX WPI; 2004-021867/02.
XX
XX Novel isolated PRO polypeptide useful for treating tumor, kidney
XX disorders, diabetes mellitus, thalassemias.
XX
XX Example 85; SEQ ID NO 294; 552pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX CC

CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1463 GGAAGTGTATGGGTCTGTCTGG 1486

DB 24 GGAAGTGTATGGGTCTGTCTGG 1

RESULT 60

ADH04135

ID ADH04135 standard; DNA; 24 BP.

AC ADH04135;

XX 11-MAR-2004 (first entry)

DE Human secreted/transmembrane protein PRO1433 PCR primer #1.

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;

KW immune response; cardiac insufficiency disorder; calcium flux;

KW umbilical vein endothelial cell; bone disorder; cartilage disorder;

KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;

KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;

XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

OS Homo sapiens.

XX US2003220471-A1.

XX 27-NOV-2003.

PD 06-DEC-2001; 2001US-0006746.

XX 04-SEP-2001; 2001US-00946374.

PR (GENTH) GENENTECH INC.

XX Baker KP, Borstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;

PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ;

PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;

PI Williams PM, Wood WI;

XX MPI; 2004-010888/01.

DR New PRO polypeptides and nucleic acids encoding the polypeptides, useful

XX in gene therapy, chromosome identification, tissue typing, or as

PT hybridization probes in chromosome and gene mapping.

XX Example 85; SEQ ID NO 293; 554pp; English.

XX The invention relates to an isolated PRO polypeptide (secreted or

CC transmembrane protein) having at least 80% amino acid sequence identity

CC to an amino acid sequence chosen from 123 fully defined sequences as

CC given in the specification (including their extracellular domains either

CC or without their associated signal peptides. Also include are the

CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC PRO1561 polypeptides are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schönlein-
CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.

SQ Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 1.0%; Score 24; DB 1; Length 24;

Best Local Similarity 100.0%; Pred. No. 8.7;

Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGGTCCCATCTACTCC 1064

DB 1 GCTGACCTGGTCCCATCTACTCC 24

RESULT 61

ADH04136/C

ID ADH04136 standard; DNA; 24 BP.

AC ADH04136;

XX 11-MAR-2004 (first entry)

DE Human secreted/transmembrane protein PRO1433 PCR primer #2.

XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;

KW immune response; cardiac insufficiency disorder; calcium flux;

KW umbilical vein endothelial cell; bone disorder; cartilage disorder;

KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;

KW Berger disease; nephropathy; Schönlein-Henoch purpura; coeliac disease;

XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

OS Homo sapiens.

XX US2003220471-A1.

XX 27-NOV-2003.

PD 06-DEC-2001; 2001US-0006746.

XX 04-SEP-2001; 2001US-00946374.

PR (GENTH) GENENTECH INC.

XX Baker KP, Borstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;

PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ;

PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;

PI Williams PM, Wood WI;

XX MPI; 2004-010888/01.

DR New PRO polypeptides and nucleic acids encoding the polypeptides, useful

XX in gene therapy, chromosome identification, tissue typing, or as

PT hybridization probes in chromosome and gene mapping.

XX Example 85; SEQ ID NO 294; 554pp; English.

XX The invention relates to an isolated PRO polypeptide (secreted or

CC transmembrane protein) having at least 80% amino acid sequence identity

CC to an amino acid sequence chosen from 123 fully defined sequences as

CC given in the specification (including their extracellular domains either

CC or without their associated signal peptides. Also include are the

CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. Pro is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC PRO1561 polypeptide are useful for treating tumours. PRO1246 and
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schonlein-
CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.

SO Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1463 GGAAGTGCATGGGTCTGTGCG 1486
|||
24 GGAAGTGCATGGGTCTGTGCG 1

RESULT 62
ADH03659/C
ID ADH03659 standard; DNA; 24 BP.

AC ADH03659;

DT 11-MAR-2004 (first entry)

DE Human secreted/transmembrane protein PRO1433 PCR primer #2.

KM Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KM immune response; cardiac insufficiency disorder; calcium flux;
KM umbilical vein endothelial cell; bone disorder; cartilage disorder;
KM arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KM Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KM dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

OS Homo sapiens.

PN US2003224478-A1.

BD 04-DEC-2003.

PF 21-AUG-2002; 2002US-00226254.

PR 29-OCT-1999; 99US-0162506P.

PR 18-FEB-2000; 2000MO-US004342.

PR 04-SEP-2001; 2001US-00946374.

PA (GETH) GENENTECH INC.

XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoi NF, Roy MA, Smith V, Stewart RA, Tumas D, Watanabe CK;
PI Williams PM, Wood WI;

XX WPI, 2004-022072/02.

DR New secreted and transmembrane PRO polypeptides and nucleic acid
XX molecules, useful in gene therapy, or preparing a medicament for treating
PT a condition that is responsive to the PRO polypeptide or anti-PRO
PT antibody, e.g. cancer.

PS Example 85; SEQ ID NO 294; 557bp; English.

XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the
CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. Pro is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schonlein-
CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1304, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.

SO Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1463 GGAAGTGCATGGGTCTGTGCG 1486
|||
24 GGAAGTGCATGGGTCTGTGCG 1

RESULT 63
ADH03658
ID ADH03658 standard; DNA; 24 BP.

AC ADH03658;

DT 11-MAR-2004 (first entry)

DE Human secreted/transmembrane protein PRO1433 PCR primer #1.

KM Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KM immune response; cardiac insufficiency disorder; calcium flux;
KM umbilical vein endothelial cell; bone disorder; cartilage disorder;
KM arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KM Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KM dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.

OS Homo sapiens.

PN US2003224478-A1.

XX 04-DEC-2003.
PD
XX
PF 21-AUG-2002; 2002US-00226254.
XX
XX 29-OCT-1999; 99US-0162506P.
PR 18-FEB-2000; 2000WO-US004342.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S;
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ;
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumes D, Watanabe CK;
PI Williams PM, Wood WT;
XX
XX MPI; 2004-022072/02.
XX
XX New secreted and transmembrane PRO polypeptides and nucleic acid
PT molecules, useful in gene therapy, or preparing a medicament for treating
PT a condition that is responsive to the PRO polypeptide or anti-PRO
PT antibody, e.g. cancer.
XX
XX Example 85; SEQ ID NO 293; 557bp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC to an amino acid sequence chosen from 123 fully defined sequences as
CC transmembrane protein) having at least 80% amino acid sequence identity
CC given in the specification (including their extracellular domains either
CC or without their associated signal peptides. Also include are the
CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
CC host cell comprising the vector, producing PRO, a chimeric molecule
CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
CC PRO antibody. PRO is useful as molecular weight markers for protein
CC electrophoresis and also for chromosome identification. PRO is also
CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
CC useful for generating transgenic animals or knock-out animals which are
CC useful in development and screening useful reagents. PRO NA is also
CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
CC polypeptides are useful for suppressing immune response. PRO1246
CC polypeptide is useful for treating cardiac insufficiency disorders.
CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
CC PRO1561 polypeptide are useful for stimulating calcium flux in human
CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
CC polypeptides are useful for treating bone and/or cartilage disorders
CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
CC polypeptides are useful for treating diabetes in skeletal muscle cells
CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
CC treating Berger disease or other nephropathies associated with Schonlein-
CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
CC disease. PRO1478, PRO1265, PRO1312, PRO1279, PRO1306, PRO1418,
CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
CC the invention.
XX
XX Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;
SQ

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1041 GCTGACCTGGTCCATCTACTCC 1064
Db 1 GCTGACCTGGTCCATCTACTCC 24

RESULT 64
ADH04613/c
ID ADH04613 standard; DNA; 24 BP.
XX
AC ADH04613;

XX 25-MAR-2004 (first entry)
DT
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
DE
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
OS
XX
XX US2004005626-A1.
PN
XX
XX 08-JAN-2004.
PD
XX
XX 07-DEC-2001; 2001US-00011795.
PF
XX
XX 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 01-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 09-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 10-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101743P.
PR 24-SEP-1998; 98US-0101745P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.

```
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103799P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0106500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106565P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 03-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108805P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.

PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028511.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US003376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015284.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US032678.
PR 01-DEC-2000; 2000WO-US006520.
PR 28-FEB-2001; 2001WO-US006666.
PR 01-MAR-2001; 2001WO-US017800.
PR 01-JUN-2001; 2001WO-US019692.
PR 20-JUN-2001; 2001WO-US021066.
PR 29-JUN-2001; 2001WO-US021735.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

XX PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Deenoyers L, Eaton DL, Ferrara N, Fong S;
XX PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK;
XX PI Williams PM, Wood WI;
XX
XX WPI; 2004-081719/08.
XX
XX Novel isolated PRO polypeptide, useful for treating diabetes mellitus,
XX PT cancerous tumors, cardiac insufficiency disorders, thalassemia,
XX PT architis.
XX PS Example 85; SEQ ID NO 294; 563pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX CC transmembrane protein) having at least 80% amino acid sequence identity
XX
XX Query Match 1.0%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred. No. 8.7;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
OY 1463 GAAGTGTCAATGGGTGCTGTGGG 1486
DB 24 GAAGTGTCAATGGGTGCTGTGGG 1

RESULT 65
ADH04612
ID ADH04612 standard; DNA; 24 BP.
XX
XX ADH04612;
XX
XX 25-MAR-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX DE Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX KW immune response; cardiac insufficiency disorder; calcium flux;
XX KW
```


PR 30-NOV-1999; 99W0-US028313.
PR 02-DEC-1999; 99W0-US028551.
PR 16-DEC-1999; 99W0-US030095.
PR 05-JAN-2000; 2000W0-US000219.
PR 06-JAN-2000; 2000W0-US000376.
PR 11-FEB-2000; 2000W0-US003565.
PR 18-FEB-2000; 2000W0-US004342.
PR 24-FEB-2000; 2000W0-US005004.
PR 02-MAR-2000; 2000W0-US005841.
PR 15-MAR-2000; 2000W0-US006884.
PR 17-MAY-2000; 2000W0-US013705.
PR 22-MAY-2000; 2000W0-US014042.
PR 30-MAY-2000; 2000W0-US014941.
PR 02-JUN-2000; 2000W0-US015264.
PR 23-AUG-2000; 2000W0-US023522.
PR 24-AUG-2000; 2000W0-US023328.
PR 08-NOV-2000; 2000W0-US030952.
PR 10-NOV-2000; 2000W0-US030873.
PR 01-DEC-2000; 2000W0-US032678.
PR 28-FEB-2001; 2001W0-US006520.
PR 01-MAR-2001; 2001W0-US006666.
PR 01-JUN-2001; 2001W0-US017800.
PR 20-JUN-2001; 2001W0-US019692.
PR 29-JUN-2001; 2001W0-US021066.
PR 09-JUL-2001; 2001W0-US021735.
PR 04-SEP-2001; 2001US-00946374.
XX
XX (GETH) GENENTECH INC.
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gunney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tamas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
DR WPI; 2004-081719/08.
XX
XX Novel isolated PRO polypeptide, useful for treating diabetes mellitus,
PT cancerous tumors, cardiac insufficiency disorders, thalassemia,
PT arthritis.
XX
XX Example 85; SEQ ID NO 293; 563bp; English.
XX
CC The invention relates to an isolated PRO polypeptide (secreted or
transmembrane protein) having at least 80% amino acid sequence identity
to the sequence of the PRO polypeptide of Example 85.

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGCTCCATCTACTCC 1064
DB 1 GCTGACCTGCTCCATCTACTCC 24

RESULT 66
ADH61613
ID ADH61613 standard; DNA; 24 BP.
XX
AC ADH61613;
XX
DT 22-APR-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; colliac disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX

PN US2004014130-A1.
XX
XX 22-JAN-2004.
XX
XX 07-DEC-2001; 2001US-00012231.
XX
PR 01-SEP-1998; 98US-0098716P.
PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 09-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0098935P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 15-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 18-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102448P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.

```
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103678P.
PR 08-OCT-1998; 98US-0103679P.
PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105593P.
PR 26-OCT-1998; 98US-0105594P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105811P.
PR 27-OCT-1998; 98US-0105822P.
PR 28-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106344P.
PR 29-OCT-1998; 98US-0108500P.
PR 30-OCT-1998; 98US-0106464P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 17-NOV-1998; 98US-0107783P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 17-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113966P.
PR 30-DEC-1998; 98US-0114232P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.

PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023328.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 20-JUN-2001; 2001WO-US017800.
PR 20-JUN-2001; 2001WO-US019692.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 04-SEP-2001; 2001US-00946374.

PA (GETH ) GENENTECH INC.
XX
XX Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI;
XX
XX WPI; 2004-108212/11.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
PT biological activity of cell, as molecular weight markers in protein
PT electrophoresis, for treating arthritis, tumor.
XX
XX Example 85; SEQ ID NO 293; 562pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
CC transmembrane protein) having at least 80% amino acid sequence identity
CC to an amino acid sequence chosen from 123 fully defined sequences as

Query Match 10%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 8.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1041 GCTGACCTGTTCCATCTACTCC 1064
Db 1 GCTGACCTGTTCCATCTACTCC 24

RESULT 67
ADH61614/C
ID ADH61614 standard; DNA; 24 BP.
XX
XX ADH61614;
AC
XX
XX 22-APR-2004 (first entry)
DT
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
DE
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
KW immune response; cardiac insufficiency disorder; calcium flux;
KW umbilical vein endothelial cell; bone disorder; cartilage disorder;
KW arthritic; wound healing; diabetes; skeletal muscle cells; obesity;
KW Berger disease; nephropathy; Schonlein-Henoch purpura; coeliac disease;
KW dermatitis; herpeticiformis; Cronin's disease; thalassemia; ss.
XX
XX Homo sapiens.
OS
XX
XX US2004014130-A1.
PN
XX
XX 22-JAN-2004.
PD
XX
XX 07-DEC-2001; 2001US-00012231.
PF
XX
XX 01-SEP-1998; 98US-0098716P.
```

PR 01-SEP-1998; 98US-0098723P.
PR 01-SEP-1998; 98US-0098749P.
PR 01-SEP-1998; 98US-0098750P.
PR 02-SEP-1998; 98US-0098803P.
PR 02-SEP-1998; 98US-0098821P.
PR 02-SEP-1998; 98US-0098843P.
PR 09-SEP-1998; 98US-0099536P.
PR 09-SEP-1998; 98US-0099596P.
PR 09-SEP-1998; 98US-0099598P.
PR 09-SEP-1998; 98US-0099602P.
PR 10-SEP-1998; 98US-0099642P.
PR 10-SEP-1998; 98US-0099741P.
PR 10-SEP-1998; 98US-0099754P.
PR 10-SEP-1998; 98US-0099763P.
PR 10-SEP-1998; 98US-0099792P.
PR 10-SEP-1998; 98US-0099808P.
PR 10-SEP-1998; 98US-0099812P.
PR 10-SEP-1998; 98US-0099815P.
PR 15-SEP-1998; 98US-0099816P.
PR 15-SEP-1998; 98US-0100385P.
PR 15-SEP-1998; 98US-0100388P.
PR 15-SEP-1998; 98US-0100390P.
PR 16-SEP-1998; 98US-0100584P.
PR 16-SEP-1998; 98US-0100627P.
PR 16-SEP-1998; 98US-0100661P.
PR 16-SEP-1998; 98US-0100662P.
PR 16-SEP-1998; 98US-0100664P.
PR 17-SEP-1998; 98US-0100683P.
PR 17-SEP-1998; 98US-0100684P.
PR 17-SEP-1998; 98US-0100710P.
PR 17-SEP-1998; 98US-0100711P.
PR 17-SEP-1998; 98US-0100919P.
PR 17-SEP-1998; 98US-0100930P.
PR 18-SEP-1998; 98US-0100848P.
PR 18-SEP-1998; 98US-0100849P.
PR 18-SEP-1998; 98US-0101014P.
PR 18-SEP-1998; 98US-0101068P.
PR 22-SEP-1998; 98US-0101071P.
PR 22-SEP-1998; 98US-0101279P.
PR 23-SEP-1998; 98US-0101471P.
PR 23-SEP-1998; 98US-0101472P.
PR 23-SEP-1998; 98US-0101474P.
PR 23-SEP-1998; 98US-0101475P.
PR 23-SEP-1998; 98US-0101476P.
PR 23-SEP-1998; 98US-0101477P.
PR 23-SEP-1998; 98US-0101479P.
PR 24-SEP-1998; 98US-0101738P.
PR 24-SEP-1998; 98US-0101741P.
PR 24-SEP-1998; 98US-0101915P.
PR 24-SEP-1998; 98US-0101916P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102207P.
PR 29-SEP-1998; 98US-0102240P.
PR 29-SEP-1998; 98US-0102307P.
PR 29-SEP-1998; 98US-0102330P.
PR 29-SEP-1998; 98US-0102331P.
PR 30-SEP-1998; 98US-0102484P.
PR 30-SEP-1998; 98US-0102487P.
PR 30-SEP-1998; 98US-0102570P.
PR 30-SEP-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102571P.
PR 01-OCT-1998; 98US-0102684P.
PR 01-OCT-1998; 98US-0102687P.
PR 02-OCT-1998; 98US-0102965P.
PR 06-OCT-1998; 98US-0103258P.
PR 06-OCT-1998; 98US-0103449P.
PR 07-OCT-1998; 98US-0103314P.
PR 07-OCT-1998; 98US-0103315P.
PR 07-OCT-1998; 98US-0103328P.
PR 07-OCT-1998; 98US-0103395P.
PR 07-OCT-1998; 98US-0103396P.
PR 07-OCT-1998; 98US-0103401P.
PR 08-OCT-1998; 98US-0103633P.
PR 08-OCT-1998; 98US-0103673P.
PR 08-OCT-1998; 98US-0103679P.

PR 08-OCT-1998; 98US-0103711P.
PR 14-OCT-1998; 98US-0104257P.
PR 20-OCT-1998; 98US-0104987P.
PR 20-OCT-1998; 98US-0105000P.
PR 20-OCT-1998; 98US-0105002P.
PR 21-OCT-1998; 98US-0105104P.
PR 22-OCT-1998; 98US-0105169P.
PR 22-OCT-1998; 98US-0105266P.
PR 26-OCT-1998; 98US-0105693P.
PR 26-OCT-1998; 98US-0105694P.
PR 27-OCT-1998; 98US-0105807P.
PR 27-OCT-1998; 98US-0105881P.
PR 27-OCT-1998; 98US-0105882P.
PR 27-OCT-1998; 98US-0106062P.
PR 28-OCT-1998; 98US-0106023P.
PR 28-OCT-1998; 98US-0106029P.
PR 28-OCT-1998; 98US-0106030P.
PR 28-OCT-1998; 98US-0106032P.
PR 28-OCT-1998; 98US-0106033P.
PR 28-OCT-1998; 98US-0106178P.
PR 29-OCT-1998; 98US-0106248P.
PR 29-OCT-1998; 98US-0106384P.
PR 29-OCT-1998; 98US-0106384P.
PR 30-OCT-1998; 98US-0108500P.
PR 03-NOV-1998; 98US-0106856P.
PR 03-NOV-1998; 98US-0106902P.
PR 03-NOV-1998; 98US-0106905P.
PR 03-NOV-1998; 98US-0106919P.
PR 03-NOV-1998; 98US-0106932P.
PR 10-NOV-1998; 98US-0106934P.
PR 10-NOV-1998; 98US-0107833P.
PR 17-NOV-1998; 98US-0108775P.
PR 17-NOV-1998; 98US-0108779P.
PR 17-NOV-1998; 98US-0108787P.
PR 17-NOV-1998; 98US-0108788P.
PR 17-NOV-1998; 98US-0108801P.
PR 17-NOV-1998; 98US-0108802P.
PR 17-NOV-1998; 98US-0108806P.
PR 17-NOV-1998; 98US-0108807P.
PR 17-NOV-1998; 98US-0108867P.
PR 18-NOV-1998; 98US-0108925P.
PR 18-NOV-1998; 98US-0108848P.
PR 18-NOV-1998; 98US-0108849P.
PR 18-NOV-1998; 98US-0108850P.
PR 18-NOV-1998; 98US-0108851P.
PR 18-NOV-1998; 98US-0108852P.
PR 18-NOV-1998; 98US-0108858P.
PR 18-NOV-1998; 98US-0108904P.
PR 22-DEC-1998; 98US-0113296P.
PR 30-DEC-1998; 98US-0114223P.
PR 05-JAN-1999; 99WO-US000106.
PR 16-APR-1999; 99US-0129674P.
PR 23-JUN-1999; 99US-0141037P.
PR 20-JUL-1999; 99US-0144758P.
PR 26-JUL-1999; 99US-0145698P.
PR 01-SEP-1999; 99WO-US020111.
PR 15-SEP-1999; 99WO-US021194.
PR 29-OCT-1999; 99US-0162506P.
PR 30-NOV-1999; 99WO-US028313.
PR 02-DEC-1999; 99WO-US028551.
PR 16-DEC-1999; 99WO-US030095.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004342.
PR 24-FEB-2000; 2000WO-US005004.
PR 02-MAR-2000; 2000WO-US005841.
PR 15-MAR-2000; 2000WO-US006884.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 23-AUG-2000; 2000WO-US023522.

```

PR 24-AUG-2000; 2000WO-US023328-
PR 08-NOV-2000; 2000WO-US030952-
PR 10-NOV-2000; 2000WO-US030873-
PR 01-DEC-2000; 2000WO-US032678-
PR 28-FEB-2001; 2001WO-US006520-
PR 01-MAR-2001; 2001WO-US006666-
PR 01-JUN-2001; 2001WO-US017800-
PR 20-JUN-2001; 2001WO-US019692-
PR 29-JUN-2001; 2001WO-US021066-
PR 09-JUL-2001; 2001WO-US021735-
PR 04-SEP-2001; 2001US-00946374-
XX
XX (GETH ) GENENTECH INC.
XX
PI Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S,
PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
PI Williams PM, Wood WI,
XX
XX WPI; 2004-108212/11.
XX
XX Novel isolated PRO polypeptide useful for tissue typing, modulating
XX biological activity of cell, as molecular weight markers in protein
XX electrophoresis, for treating arthritis, tumor.
XX
XX Example 85; SEQ ID NO 294; 562pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 123 fully defined sequences as
XX
XX Query Match 1.0%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred.No. 8.7;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1463 GGAGTGTCTATGGTCTGTGGG 1486
XX |||||
XX 24 GGAGTGTCTATGGTCTGTGGG 1
XX
XX RESULT 68
XX ADL94813/c
XX ID ADL94813 standard; DNA; 24 BP.
XX
XX ADL94813;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #2.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; collagen disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX
XX Homo sapiens.
XX
XX US2004073015-A1.
XX
XX 15-APR-2004.
XX
XX 12-DEC-2001; 2001US-00015395.
XX
XX 23-SEP-1998; 98US-0101477P-
XX 20-JUL-1999; 99US-0144758P-
XX 01-SEP-1999; 99WO-US020111-
XX 18-OCT-1999; 99US-00403297-
XX 18-FEB-2000; 2000WO-US004342-
XX 04-SEP-2001; 2001US-00946374-
XX
XX (GETH ) GENENTECH INC.

```

```

XX Baker KP, Botstein D, Desnovers L, Eaton DL, Ferrara N, Fong S,
XX Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
XX Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
XX Williams PM, Wood WI,
XX
XX WPI; 2004-115422/29.
XX
XX New PRO polynucleotides and polypeptides, useful in promoting wound
XX healing and in diagnosing and treating cancer, neurodegenerative
XX diseases, stroke, hypertension or diabetes mellitus.
XX
XX Example 85; SEQ ID NO 294; 550pp; English.
XX
XX The invention relates to an isolated PRO polypeptide (secreted or
XX transmembrane protein) having at least 80% amino acid sequence identity
XX to an amino acid sequence chosen from 123 fully defined sequences as
XX given in the specification (including their extracellular domains either
XX or without their associated signal peptides. Also include are the
XX nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
XX host cell comprising the vector, producing PRO, a chimeric molecule
XX comprising PRO fused to a heterologous amino acid sequence, and an anti-
XX PRO antibody. Pro is useful as molecular weight markers for protein
XX electrophoresis and also for chromosome identification. PRO is also
XX useful for tissue typing. PRO and PRO NA are useful as hybridisation
XX probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
XX useful for generating transgenic animals or knock-out animals which are
XX useful in development and screening useful reagents. PRO NA is also
XX useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
XX useful for treating cancerous tumours. PRO1250, PRO1438 and PRO1410
XX polypeptides are useful for suppressing immune response. PRO1246
XX polypeptide is useful for treating cardiac insufficiency disorders.
XX PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
XX PRO1361 polypeptide are useful for stimulating calcium flux in human
XX umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
XX polypeptides are useful for treating bone and/or cartilage disorders
XX (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
XX polypeptides are useful for treating diabetes in skeletal muscle cells
XX and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
XX treating Berger disease or other nephropathies associated with Schonlein-
XX Henoch purpura, collagen disease, dermatitis, herpeticiformis or Crohn's
XX disease. PRO1478, PRO1265, PRO1412, PRO1279, PRO1306, PRO1418,
XX PRO1410 and PRO1575 are useful in treating thalassemias. The present
XX sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
XX the invention.
XX
XX Sequence 24 BP; 7 A; 12 C; 2 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 1.0%; Score 24; DB 1; Length 24;
XX Best Local Similarity 100.0%; Pred.No. 8.7;
XX Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1463 GGAGTGTCTATGGTCTGTGGG 1486
XX |||||
XX 24 GGAGTGTCTATGGTCTGTGGG 1
XX
XX RESULT 69
XX ADL94812
XX ID ADL94812 standard; DNA; 24 BP.
XX
XX ADL94812;
XX
XX 01-JUL-2004 (first entry)
XX
XX Human secreted/transmembrane protein PRO1433 PCR primer #1.
XX
XX Human; PCR; primer; secreted protein; transmembrane protein; PRO; tumour;
XX immune response; cardiac insufficiency disorder; calcium flux;
XX umbilical vein endothelial cell; bone disorder; cartilage disorder;
XX arthritis; wound healing; diabetes; skeletal muscle cells; obesity;
XX Berger disease; nephropathy; Schonlein-Henoch purpura; collagen disease;
XX dermatitis; herpeticiformis; Crohn's disease; thalassemia; ss.
XX

```

XX OS Homo sapiens.
 XX XX US2004073015-A1.
 XX PD 15-APR-2004.
 XX PF 12-DEC-2001; 2001US-00015395.
 XX PR 23-SEP-1998; 98US-0101477P.
 PR 20-JUL-1999; 99US-0144758P.
 PR 01-SEP-1999; 99WO-US020111.
 PR 18-OCT-1999; 99US-00403297.
 PR 18-FEB-2000; 2000WO-US004342.
 PR 04-SEP-2001; 2001US-00946374.
 XX XX (GENTH) GENENTECH INC.
 XX PA Baker KP, Botstein D, Desnoyers L, Eaton DL, Ferrara N, Fong S,
 PI Gao W, Goddard A, Godowski PJ, Grimaldi JC, Gurney AL, Hillan KJ,
 PI Pan J, Paoni NF, Roy MA, Smith V, Stewart TA, Tumas D, Watanabe CK,
 PI Williams PM, Wood WT;
 XX DR WPI; 2004-315422/29.
 XX XX New PRO polynucleotides and polypeptides, useful in promoting wound
 PT healing and in diagnosing and treating cancer, neurodegenerative
 PT diseases, stroke, hypertension or diabetes mellitus.
 XX XX Example 85; SEQ ID NO 293; 550bp; English.
 XX XX The invention relates to an isolated PRO polypeptide (secreted or
 CC transmembrane protein) having at least 80% amino acid sequence identity
 CC to an amino acid sequence chosen from 123 fully defined sequences as
 CC given in the specification (including their extracellular domains either
 CC or without their associated signal peptides. Also include are the
 CC nucleotide (NA) sequences encoding PRO, a vector comprising the PRO NA, a
 CC host cell comprising the vector, producing PRO, a chimeric molecule
 CC comprising PRO fused to a heterologous amino acid sequence, and an anti-
 CC PRO antibody. Pro is useful as molecular weight markers for protein
 CC electrophoresis and also for chromosome identification. PRO is also
 CC useful for tissue typing. PRO and PRO NA are useful as hybridisation
 CC probes for a cDNA library to isolate the full-length PRO cDNA. PRO NA is
 CC useful for generating transgenic animals or knock-out animals which are
 CC useful in development and screening useful reagents. PRO NA is also
 CC useful in gene therapy. PRO1244, PRO1286 and PRO1303 polypeptides are
 CC useful for treating cancerous tumours. PRO1250, PRO1418 and PRO1410
 CC polypeptides are useful for suppressing immune response. PRO1246
 CC polypeptide is useful for treating cardiac insufficiency disorders.
 CC PRO1246 polypeptide is also useful for treating tumours. PRO1246 and
 CC PRO1561 polypeptide are useful for stimulating calcium flux in human
 CC umbilical vein endothelial cells. PRO1265, PRO1250 and PRO1474
 CC polypeptides are useful for treating bone and/or cartilage disorders
 CC (e.g., arthritis) and wound healing. PRO1130, PRO1275 and PRO1418
 CC polypeptides are useful for treating diabetes in skeletal muscle cells
 CC and obesity. PRO1265, PRO1244 and PRO1382 polypeptides are useful for
 CC treating Berger disease or other nephropathies associated with Schöten-
 CC Henoch purpura, coeliac disease, dermatitis, herpeticiformis or Crohn's
 CC disease. PRO1478, PRO1265, PRO1279, PRO1304, PRO1306, PRO1418,
 CC PRO1410 and PRO1575 are useful in treating thalassemias. The present
 CC sequence is a PCR primer used to isolate a cDNA encoding a PRO protein of
 CC the invention.
 XX XX
 SQ Sequence 24 BP; 3 A; 10 C; 4 G; 7 T; 0 U; 0 Other;
 Query Match 1 0%; Score 24; DB 1; Length 24;
 Best Local Similarity 100.0%; Pred. No. 8.7;
 Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1041 GCTGACCTGTTCCATCTACTCC 1064
 DB 1 GCTGACCTGTTCCATCTACTCC 24

RESULT 70
 ID ADO42528
 ID ADO42528 standard; DNA; 23 BP.
 XX AC ADO42528;
 XX XX
 DT 15-JUL-2004 (first entry)
 XX XX
 DE Human NOVX PCR primer #1.
 XX XX
 KW Human; NOVX; PCR; sv; cancer; atherosclerosis; diabetes;
 KW Alzheimer's disease; Parkinson's disease; graft-versus-host disease;
 KW scleroderma; hypertension; haemophilia;
 KW idiopathic thrombocytopenic purpura; immunodeficiency; AIDS;
 KW dyslipidemia; obesity; Crohn's disease; bronchial asthma; anorexia;
 KW cancer-associated cachexia; multiple sclerosis; fertility; primer.
 XX XX
 OS Homo sapiens.
 XX XX US2004058338-A1.
 XX PD 25-MAR-2004.
 XX PF 02-DEC-2002; 2002US-00307817.
 XX PR 03-DEC-2001; 2001US-0336881P.
 PR 05-DEC-2001; 2001US-0336820P.
 PR 07-DEC-2001; 2001US-0338285P.
 PR 10-DEC-2001; 2001US-0338318P.
 PR 10-DEC-2001; 2001US-0338989P.
 PR 11-DEC-2001; 2001US-0339022P.
 PR 11-DEC-2001; 2001US-0339314P.
 PR 11-DEC-2001; 2001US-0339516P.
 PR 11-DEC-2001; 2001US-0339517P.
 PR 12-DEC-2001; 2001US-0339611P.
 PR 12-DEC-2001; 2001US-0340981P.
 PR 14-DEC-2001; 2001US-0340390P.
 PR 14-DEC-2001; 2001US-0340440P.
 PR 14-DEC-2001; 2001US-0340565P.
 PR 14-DEC-2001; 2001US-0340608P.
 PR 14-DEC-2001; 2001US-0341144P.
 PR 17-DEC-2001; 2001US-0341477P.
 PR 17-DEC-2001; 2001US-0341540P.
 PR 18-DEC-2001; 2001US-0341768P.
 PR 20-DEC-2001; 2001US-0342592P.
 PR 31-DEC-2001; 2001US-0344903P.
 PR 01-FEB-2002; 2002US-0353286P.
 PR 01-FEB-2002; 2002US-0353288P.
 PR 26-FEB-2002; 2002US-0359599P.
 PR 26-FEB-2002; 2002US-0359626P.
 PR 26-FEB-2002; 2002US-0359671P.
 PR 27-FEB-2002; 2002US-0359914P.
 PR 27-FEB-2002; 2002US-0359956P.
 PR 28-FEB-2002; 2002US-0360924P.
 PR 28-FEB-2002; 2002US-0360964P.
 PR 28-FEB-2002; 2002US-0361028P.
 PR 28-FEB-2002; 2002US-0361256P.
 PR 28-FEB-2002; 2002US-0361264P.
 PR 05-MAR-2002; 2002US-0361770P.
 PR 05-MAR-2002; 2002US-0362230P.
 PR 13-MAR-2002; 2002US-0364238P.
 PR 13-MAR-2002; 2002US-0364978P.
 PR 15-MAR-2002; 2002US-0365025P.
 PR 17-APR-2002; 2002US-0373288P.
 PR 15-MAY-2002; 2002US-0380981P.
 PR 16-MAY-2002; 2002US-0381004P.
 PR 17-MAY-2002; 2002US-0381485P.
 PR 28-MAY-2002; 2002US-0383534P.
 PR 28-MAY-2002; 2002US-0383744P.
 PR 29-MAY-2002; 2002US-0383829P.

29-MAY-2002; 2002US-0384024P.
PR 02-JUL-2002; 2002US-0393332P.
PR 06-AUG-2002; 2002US-0401315P.
PR 07-AUG-2002; 2002US-0401788P.
PR 20-AUG-2002; 2002US-0404676P.
PR 23-AUG-2002; 2002US-0405400P.
PR 23-AUG-2002; 2002US-0405684P.
PR 23-AUG-2002; 2002US-0405687P.
PR 23-AUG-2002; 2002US-0405698P.
PR 26-AUG-2002; 2002US-0406353P.
XX
PA (AGEE/) AGEE M L.
PA (ALSO/) ALSOBROOK J P.
PA (ANDE/) ANDERSON D W.
PA (BERG/) BERGHS C.
PA (BOLD/) BOLDOG F L.
PA (BURG/) BURGESS C E.
PA (CAT/) CATTERTON E.
PA (DIP/) DIPPEO V A.
PA (EDIN/) EDINGER S R.
PA (EISE/) EISEN A.
PA (ELLE/) ELLERMAN K.
PA (GANG/) GANGOLLI E A.
PA (GERL/) GERLACH V.
PA (GORM/) GORMAN L.
PA (ROTH/) ROTHBERG B G.
PA (GUOX/) GUO X S.
PA (HERR/) HERRMANN J L.
PA (HALV/) HALVORSEN Y.
PA (JIMW/) JI W.
PA (KEKU/) KERUDA R.
PA (KIRA/) KHRAMTSOV N V.
PA (LARO/) LAROCHELLE W J.
PA (LEPL/) LEPELEY D M.
PA (LILL/) LI L.
PA (MACD/) MACDOUGALL J R.
PA (MILL/) MILLER C E.
PA (ORTT/) ORT T.
PA (PAD/) PADIGARU M.
PA (PAT/) PATTURAJAN M.
PA (PENB/) PENNA C E A.
PA (PEYM/) PEYMAN J A.
PA (RIEG/) RIEGER D K.
PA (ROTH/) ROTHENBERG M E.
PA (SHEN/) SHENOY S G.
PA (SMIT/) SMITHSON G.
PA (SPAD/) SPADERNA S K.
PA (SPYT/) SPYTEK K A.
PA (STON/) STONE D J.
PA (TAUP/) TAUPIER R J.
PA (VERN/) VERNET C A M.
PA (VOSS/) VOSS E Z.
PA (ZHON/) ZHONG M.
XX
PI Agee ML, Alsobrook JP, Anderson DW, Berghs C, Boldog FL;
PI Burgess CE, Catterton E, Dippeo VA, Edinger SR, Eisen A;
PI Ellerman K, Gangolli EA, Gerlach V, Gorman L, Rothberg BG, Guo XS;
PI Hermann JL, Halvorsen Y, Ji W, Kekuda R, Khrantsov NV;
PI Larochelle WJ, Lepeley DM, Li L, MacDougall JR, Miller CE, Ort T;
PI Padigar M, Patturajan M, Penna CE, Peyman JA, Rieger DK;
PI Rothberg ME, Shenoj SG, Smithson G, Spaderna SK, Spytek KA;
PI Stone DJ, Taupier RJ, Vernet CM, Voss EZ, Zhong M;
XX
DR WPI; 2004-268786/25.
XX
XX New human NOVX polypeptides and nucleic acid molecules, useful for
PT diagnosing, preventing or treating NOVX-associated disorder, e.g. cancer,
PT atherosclerosis, diabetes, Alzheimer's disease, Parkinson's disease or
PT scleroderma.
XX
XX Example D; SEQ ID NO 377; 610bp; English.
XX
CC The invention relates to human NOVX polypeptides and the polynucleotides

CC encoding them. The invention also relates to antibodies specific to the
CC NOVX polypeptides. The polypeptides, polynucleotides and antibodies are
CC useful for manufacturing a medicament for treating a syndrome associated
CC with a human disease, such as a pathology associated with the NOVX
CC polypeptide. The sequences are useful for diagnosing, treating or
CC preventing a NOVX-associated disorder, e.g., cancer, atherosclerosis,
CC diabetes, Alzheimer's disease, Parkinson's disease, graft-versus-host
CC disease, scleroderma, hypertension, haemophilia, idiopathic
CC thrombocytopenic purpura, immunodeficiencies, AIDS, dyslipidemia,
CC obesity, Crohn's disease, bronchial asthma, anorexia, cancer-associated
CC cachexia, multiple sclerosis or fertility. The nucleic acids may be used
CC as hybridisation probes, in chromosome mapping, in tissue typing, in
CC preventive medicine or in pharmacogenomics. This sequence represents a
CC PCR primer used in analysis of expression of a human NOVX polynucleotide
CC of the invention.
XX
SQ Sequence 23 BP; 11 A; 5 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 1.0%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1127 CCAGAGGAAGTTCAGAAATACA 1149
Db 1 CCAGAGGAAGTTCAGAAATACA 23
XX
RESULT 71
AADS6896
ID AADS6896 standard; DNA; 22 BP.
XX
AC AADS6896;
XX
DT 06-NOV-2003 (first entry)
XX
DE Human 86606 DGAT2 gene specific forward PCR primer.
XX
XX Human; diacylglycerol acyltransferase 2; DGAT2; obesity; arrhythmia;
XX coronary artery disease; hypertension; heart failure; tissue typing;
XX aberrant lipogenesis; cardiovascular disorder; atherosclerosis; angina;
XX atrial fibrillation; dilated cardiomyopathy; idiopathic cardiomyopathy;
XX diabetes; chromosome mapping; forensic biology; PCR; primer; ss.
XX
OS Homo sapiens.
XX
XX WO200305363-A2.
XX
XX 03-JUL-2003.
XX
XX 19-DEC-2002; 2002WO-US040974.
XX
XX 19-DEC-2001; 2001US-0341947P.
XX
XX 19-SEP-2002; 2002US-0411859P.
XX
XX (MILL-) MILLENNIUM PHARM INC.
XX
XX Gimeno RE, Wu Z, Kapeller-Libermann R, Hubbard BK;
XX
XX WPI; 2003-559092/52.
XX
XX New human diacylglycerol acyltransferase 2 (DGAT2) family member
PT polypeptide and nucleic acid molecules, useful for diagnosing and
PT treating obesity, diabetes, atherosclerosis, aberrant lipogenesis or
PT triglyceride synthesis.
XX
XX Example 3; Page 100; 154bp; English.
XX
XX The invention relates to human diacylglycerol acyltransferase 2 (DGAT2)
CC family members and their uses. DGAT2 family member sequences or their
CC modulators are useful for diagnosing and treating a subject with a
CC disorder associated with the aberrant DGAT family member polypeptide
CC activity or nucleic acid expression, such as a disorder associated with
CC obesity, diabetes, aberrant lipogenesis or triglyceride synthesis, or

CC cardiovascular disorder (e.g. atherosclerosis, coronary artery disease,
CC hypertension, heart failure, atrial fibrillation, arrhythmias, dilated
CC cardiomyopathy, idiopathic cardiomyopathy or angina). The invention is
CC also useful in screening assays (e.g. tissue typing, chromosome mapping,
CC or in forensic biology), in predictive medicine (e.g. diagnostic assays,
CC prognostic assays, monitoring clinical trials or pharmacogenetics), or as
CC surrogate markers (e.g. markers of disease states or markers of drug
CC activity). The present sequence is human DGAT2 gene specific PCR primer.
CC This sequence is used in the exemplification of the invention
XX

Sequence 22 BP; 5 A; 9 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1777 CAAAGCCCTTTATTGCCACTAC 1798
DB 1 CAAAGCCCTTTATTGCCACTAC 22

RESULT 72
ADD27798/C

ID ADD27798 standard; DNA; 22 BP.

AC ADD27798;

DT 15-JAN-2004 (first entry)

DE Human psoriasis related genes PCR primer #7.

KW ss; psoriasis; Psoriasis-related gene; body map; PCR; primer; human.

OS Homo sapiens.

PN JP2002330770-A.

PD 19-NOV-2002.

PF 25-MAY-2001; 2001JP-00156529.

PR 30-AUG-2000; 2000JP-00260818.

PR 01-NOV-2000; 2000JP-00334042.

PA (TANA) TANABE SEIYAKU CO.

DR WPI; 2003-460750/44.

PT Gene of which expression changes in Psoriasis and examination directed to
PT said gene, a recombinant vector, a host cell.

PS Example 3; SEQ ID NO 13; 27bp; Japanese.

CC The invention relates to detection of psoriasis by determining the
CC expression level of a Psoriasis-related gene in a biosample collected
CC from a human or nonhuman animal individual. The gene consisting of one of
CC 5 538-2713 nucleotide sequences, given in the specification, or a DNA
CC hybridising with it under stringent conditions are disclosed. The method
CC is used for the detection of Psoriasis. The Psoriasis-related gene was
CC detected by the body map method. The present sequence is a PCR primer
CC used in the isolation of the psoriasis-related genes.
XX

Sequence 22 BP; 6 A; 5 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 17;

Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2357 GATGAGATCATTCACCATGTC 2378

DB 22 GATGAGATCATTCACCATGTC 1

RESULT 73
ADD27797
ID ADD27797 standard; DNA; 22 BP.

AC ADD27797;

DT 15-JAN-2004 (first entry)

DE Human psoriasis related genes PCR primer #6.

KW ss; psoriasis; Psoriasis-related gene; body map; PCR; primer; human.

OS Homo sapiens.

PN JP2002330770-A.

PD 19-NOV-2002.

PF 25-MAY-2001; 2001JP-00156529.

PR 30-AUG-2000; 2000JP-00260818.

PR 01-NOV-2000; 2000JP-00334042.

PA (TANA) TANABE SEIYAKU CO.

DR WPI; 2003-460750/44.

PT Gene of which expression changes in Psoriasis and examination directed to
PT said gene, a recombinant vector, a host cell.

PS Example 3; SEQ ID NO 12; 27bp; Japanese.

CC The invention relates to detection of psoriasis by determining the
CC expression level of a Psoriasis-related gene in a biosample collected
CC from a human or nonhuman animal individual. The gene consisting of one of
CC 5 538-2713 nucleotide sequences, given in the specification, or a DNA
CC hybridising with it under stringent conditions are disclosed. The method
CC is used for the detection of Psoriasis. The Psoriasis-related gene was
CC detected by the body map method. The present sequence is a PCR primer
CC used in the isolation of the psoriasis-related genes.
XX

Sequence 22 BP; 5 A; 6 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2057 CGCCACCATGAGCTAGGTGGAG 2078

DB 1 CGCCACCATGAGCTAGGTGGAG 22

RESULT 74
AAD56897/C

ID AAD56897 standard; DNA; 20 BP.

AC AAD56897;

DT 06-NOV-2003 (first entry)

DE Human 86606 DGAT2 gene specific reverse PCR primer.

KW Human; diacylglycerol acyltransferase 2; DGAT2; obesity; arrhythmia;
KW coronary artery disease; hypertension; heart failure; tissue typing;
KW aberrant lipogenesis; cardiovascular disorder; atherosclerosis; angina;
KW atrial fibrillation; dilated cardiomyopathy; idiopathic cardiomyopathy;
KW diabetes; chromosome mapping; forensic biology; PCR; primer; ss.

OS Homo sapiens.

PN WO2003053363-A2.

DR 03-JUL-2003.

PT

PS

XX 19-DEC-2002; 2002MO-US040974.
XX 19-DEC-2001; 2001US-0341947P.
PR 19-SEP-2002; 2002US-0411859P.
XX (MILL-) MILLENNIUM PHARM INC.
XX
PI GJmeno RE, Wu Z, Kapeller-Libermann R, Hubbard BK;
XX WPI; 2003-559092/52.
XX
XX New human diacylglycerol acyltransferase 2 (DGAT2) family member
PT polypeptide and nucleic acid molecules, useful for diagnosing and
PT treating obesity, diabetes, atherosclerosis, aberrant lipogenesis or
PT triglyceride synthesis.
XX
XX Example 3; Page 100; 154pp; English.
XX
XX The invention relates to human diacylglycerol acyltransferase 2 (DGAT2)
CC family members and their uses. DGAT2 family member sequences or their
CC modulators are useful for diagnosing and treating a subject with a
CC disorder associated with the aberrant DGAT family member polypeptide
CC activity or nucleic acid expression, such as a disorder associated with
CC obesity, diabetes, aberrant lipogenesis or triglyceride synthesis, or
CC cardiovascular disorder (e.g. atherosclerosis, coronary artery disease,
CC hypertension, heart failure, atrial fibrillation, arrhythmias, dilated
CC cardiomyopathy, idiopathic cardiomyopathy or angina). The invention is
CC also useful in screening assays (e.g. tissue typing, chromosome mapping,
CC or in forensic biology), in predictive medicine (e.g. diagnostic assays,
CC prognostic assays, monitoring clinical trials or pharmacogenetics), or as
CC surrogate markers (e.g. markers of disease states or markers of drug
CC activity). The present sequence is human DGAT2 gene specific PCR primer.
XX This sequence is used in the exemplification of the invention
XX
SQ Sequence 20 BP; 5 A; 6 C; 5 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.84; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 34;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY 1831 CAGTTTCTGCGCAGGCGA 1850
Db 20 CAGTTTCTGCGCAGGCGA 1
XX
RESULT 75
ADO42530/c
ID ADO42530 standard; DNA; 20 BP.
XX
AC ADO42530;
XX
DT 15-JUL-2004 (first entry)
XX
DE Human NOVX PCR primer #2.
XX
XX Human; NOVX, PCR; ss; cancer; atherosclerosis; diabetes;
XX Alzheimer's disease; Parkinson's disease; graft-versus-host disease;
XX scleroderma; hypertension; haemophilia;
XX idiopathic thrombocytopenic purpura; immunodeficiency; AIDS;
XX dyslipidemia; obesity; Crohn's disease; bronchial asthma; anorexia;
XX cancer-associated cachexia; multiple sclerosis; fertility; primer.
XX
OS Homo sapiens.
XX
PN US2004058338-A1.
XX
PD 25-MAR-2004.
XX
XX 02-DEC-2002; 2002US-00307817.
XX
XX 03-DEC-2001; 2001US-0336881P.
XX
PR 05-DEC-2001; 2001US-0336820P.

PR 07-DEC-2001; 2001US-0338285P.
PR 07-DEC-2001; 2001US-0338318P.
PR 10-DEC-2001; 2001US-0338989P.
PR 10-DEC-2001; 2001US-0339022P.
PR 11-DEC-2001; 2001US-0339314P.
PR 11-DEC-2001; 2001US-0339516P.
PR 11-DEC-2001; 2001US-0339517P.
PR 11-DEC-2001; 2001US-0339611P.
PR 12-DEC-2001; 2001US-0340981P.
PR 12-DEC-2001; 2001US-0341346P.
PR 14-DEC-2001; 2001US-0340390P.
PR 14-DEC-2001; 2001US-0340440P.
PR 14-DEC-2001; 2001US-0340565P.
PR 14-DEC-2001; 2001US-0340608P.
PR 14-DEC-2001; 2001US-0341144P.
PR 17-DEC-2001; 2001US-0341777P.
PR 17-DEC-2001; 2001US-0341540P.
PR 18-DEC-2001; 2001US-0341768P.
PR 20-DEC-2001; 2001US-0342592P.
PR 31-DEC-2001; 2001US-0344903P.
PR 01-FEB-2002; 2002US-0353286P.
PR 01-FEB-2002; 2002US-0353288P.
PR 26-FEB-2002; 2002US-0359599P.
PR 26-FEB-2002; 2002US-0359626P.
PR 26-FEB-2002; 2002US-0359671P.
PR 27-FEB-2002; 2002US-0359914P.
PR 27-FEB-2002; 2002US-0359956P.
PR 28-FEB-2002; 2002US-0360924P.
PR 28-FEB-2002; 2002US-0360964P.
PR 28-FEB-2002; 2002US-0361028P.
PR 28-FEB-2002; 2002US-0361256P.
PR 28-FEB-2002; 2002US-0361264P.
PR 05-MAR-2002; 2002US-0361770P.
PR 05-MAR-2002; 2002US-0362230P.
PR 13-MAR-2002; 2002US-0364181P.
PR 13-MAR-2002; 2002US-0364238P.
PR 15-MAR-2002; 2002US-0364978P.
PR 15-MAR-2002; 2002US-0365025P.
PR 17-APR-2002; 2002US-0373288P.
PR 15-MAY-2002; 2002US-0380981P.
PR 16-MAY-2002; 2002US-0381004P.
PR 17-MAY-2002; 2002US-0381495P.
PR 28-MAY-2002; 2002US-0383534P.
PR 28-MAY-2002; 2002US-0383744P.
PR 29-MAY-2002; 2002US-0383829P.
PR 29-MAY-2002; 2002US-0384024P.
PR 02-JUL-2002; 2002US-0393332P.
PR 06-AUG-2002; 2002US-0401315P.
PR 07-AUG-2002; 2002US-0401788P.
PR 20-AUG-2002; 2002US-0404676P.
PR 23-AUG-2002; 2002US-0405400P.
PR 23-AUG-2002; 2002US-0405684P.
PR 23-AUG-2002; 2002US-0405687P.
PR 23-AUG-2002; 2002US-0405698P.
PR 26-AUG-2002; 2002US-0406353P.
XX
XX (AGEE/) AGE E M L.
XX (ALSO/) ALSOBROOK J P.
XX (ANDE/) ANDERSON D W.
XX (BERG/) BERGHS C.
XX (BOLD/) BOLDOG F L.
XX (BURG/) BURGESS C E.
XX (CATT/) CATTERTON E.
XX (DIP/) DIPIPPO V A.
XX (EDIN/) EDINGER S R.
XX (EISE/) EISEN A.
XX (EILE/) EILERMAN K.
XX (GANG/) GANGOLI E A.
XX (GERL/) GERLACH V.
XX (GORN/) GORMAN L.
XX (ROTH/) ROTHBERG B G.
XX (GUOX/) GUO X S.
XX (HERR/) HERRMANN J L.


```
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 23-MAY-2001; 2001US-00864761.
PR 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
XX acids encoding the protein, useful for treating subjects having defects
XX in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
XX e.g., liver or bone.
XX
XX Example 2; Page 348; 418bp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the
XX invention has cytostatic activity. The nucleotide may have a use in gene
XX therapy. The KTOM1 nucleic acid may be used to diagnose, treat or
XX monitor a disease caused by altered expression of human KTOM1.
XX Compositions comprising the nucleic acids, proteins or antibodies may be
XX used to treat subjects having defects in KTOM1 which can manifest as
XX cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX function. The sequence represents a probe used in the invention to scan
XX the nt 1-1001 portion of human KTOM1a (AB063232)
XX
XX Sequence 25 BP; 5 A; 7 C; 8 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 19.2; DB 1; Length 25;
XX Best Local Similarity 87.5%; Pred. No. 37;
XX Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX 1419 CCTGGAGAACGCTGCAATCA 1442
XX ||||| ||||| ||||| |||||
XX 25 CCTGGAGCTCTGCTGCAATCA 2
XX
XX RESULT 78
XX AB064741/c
XX ID AB064741 standard; DNA; 25 BP.
XX
XX AC AB064741;
XX
XX 20-AUG-2002 (first entry)
XX
XX Human KTOM1a portion (AB063232) probe # 1454.
XX
XX Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;
XX gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
XX kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX
XX Homo sapiens.
XX
XX OS
XX PN WO200224750-A2.
XX
XX 28-MAR-2002.
XX
XX 21-SEP-2001; 2001WO-US029656.
```

```
XX
XX 21-SEP-2000; 2000US-0234687P.
XX 27-SEP-2000; 2000US-0236359P.
XX 04-OCT-2000; 2000GB-00024263.
XX 30-JAN-2001; 2001WO-US000661.
XX 30-JAN-2001; 2001WO-US000662.
XX 30-JAN-2001; 2001WO-US000663.
XX 30-JAN-2001; 2001WO-US000664.
XX 30-JAN-2001; 2001WO-US000665.
XX 30-JAN-2001; 2001WO-US000666.
XX 30-JAN-2001; 2001WO-US000667.
XX 30-JAN-2001; 2001WO-US000668.
XX 30-JAN-2001; 2001WO-US000669.
XX 30-JAN-2001; 2001WO-US000670.
XX 23-MAY-2001; 2001US-00864761.
XX 28-AUG-2001; 2001US-0315676P.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Zhang J;
XX
XX WPI; 2002-479509/51.
XX
XX
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic
XX acids encoding the protein, useful for treating subjects having defects
XX in KTOM1 which can manifest as cancer of the kidney, or as a disorder of
XX e.g., liver or bone.
XX
XX Example 2; Page 348; 418bp; English.
XX
XX The invention relates to a novel isolated nucleic acid encoding human
XX KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the
XX invention has cytostatic activity. The nucleotide may have a use in gene
XX therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
XX monitor a disease caused by altered expression of human KTOM1.
XX Compositions comprising the nucleic acids, proteins or antibodies may be
XX used to treat subjects having defects in KTOM1 which can manifest as
XX cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
XX heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
XX function. The sequence represents a probe used in the invention to scan
XX the nt 1-1001 portion of human KTOM1a (AB063232)
XX
XX Sequence 25 BP; 5 A; 7 C; 8 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 19.2; DB 1; Length 25;
XX Best Local Similarity 87.5%; Pred. No. 37;
XX Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX 1419 CCTGGAGAACGCTGCAATCA 1442
XX ||||| ||||| ||||| |||||
XX 24 CCTGGAGCTCTGCTGCAATCA 1
XX
XX RESULT 79
XX AAH48071/c
XX ID AAH48071 standard; DNA; 24 BP.
XX
XX AC AAH48071;
XX
XX 19-SEP-2001 (first entry)
XX
XX Dihydropyrimidinase synthase 9 PCR primer #2.
XX
XX Dihydropyrimidinase synthase 9; cytostatic; haemostatic; virucide;
XX immunomodulatory; antiinflammatory; gene therapy; malignant tumour;
XX haemopathy; HIV infection; immunological disease; inflammation;
XX PCR primer; ss.
XX
XX Unidentified.
XX
XX OS
XX PN WO200147980-A1.
XX
XX 05-JUL-2001.
```

XX 25-DEC-2000; 2000MO-CN000715.
 XX PF
 XX 27-DEC-1999; 99CN-00125792.
 XX PR
 XX (SHAN-) SHANGHAI BIOWINDOM GENE DEV INC.
 XX PA
 XX Mao Y, Xie Y;
 XX PI
 XX WPI, 2001-418229/44.
 XX DR
 XX Dihydrodipicolinate synthase 9 and encoded polynucleotide, used in
 XX PT
 XX diagnosis and treatment of malignant tumors, hemopathy, human
 XX PT immunodeficiency virus infection, immunological diseases and
 XX PT inflammation.
 XX PS
 XX Example 3; Page 16; 39pp; Chinese.
 XX CC
 XX The present invention relates to dihydrodipicolinate synthase 9 and its
 XX CC coding sequence (see AAH48069 and AAG64225). Dihydrodipicolinate synthase
 XX CC 9 and its coding sequence are useful in the diagnosis and treatment of
 XX CC malignant tumor, haemopathy, human immunodeficiency virus (HIV)
 XX CC infection, immunological diseases and various inflammations. The present
 XX CC sequence is a PCR primer, which was used in an example from the present
 XX CC invention
 XX CC
 XX SQ Sequence 24 BP; 9 A; 2 C; 1 G; 12 T; 0 U; 0 Other;
 XX
 XX Query Match 0.8%; Score 18.8; DB 1; Length 24;
 XX Best Local Similarity 90.9%; Pred. No. 43;
 XX Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1498 AAATTATACAAATTTGCTTAA 1519
 Db 23 AAATTATACAAATTTGTTTAA 2
 RESULT 80
 ADF72789
 ID ADF72789 standard; DNA; 23 BP.
 XX AC
 XX ADF72789;
 XX DT
 XX 26-FEB-2004 (first entry)
 XX DE
 XX Detection probe #1.
 XX KW
 XX detection; triplet expansion disease; fragile X syndrome;
 XX KW Huntington's disease; bulbar muscular dystrophy;
 XX KW spinocerebral ataxia type I; myotonic dystrophy; Friedrich ataxia; ss;
 XX KW probe.
 XX OS
 XX Synthetic.
 XX PN
 XX WO200307654-A2.
 XX PD
 XX 18-SEP-2003.
 XX PF
 XX 04-MAR-2003; 2003WO-EP002202.
 XX PR
 XX 08-MAR-2002; 2002DE-01010100.
 XX PR 17-JUN-2002; 2002DE-01027042.
 XX XX
 XX (NOVE-) NOVEMBER GES MOLEKULARE MED AG.
 XX PA
 XX Palecek E, Kosak H;
 XX PI
 XX WPI, 2003-756830/71.
 XX DR
 XX WPI, 2003-756830/71.
 XX PT
 XX Detection, quantification and characterization of analyte, useful for
 XX PT diagnosing diseases associated with triplet extensions, using probes with
 XX PT electrochemical labels.

PS Disclosure; SEQ ID NO 3; 50bp; German.
 XX
 XX This invention describes a novel method for detection, quantification
 XX CC and/or characterisation of an analyte using two affinity probes, each
 XX CC having an electrochemically detectable marker. The analyte is bound,
 XX CC preferably specifically to a capture molecule which may be immobilised on
 XX CC a surface. Especially the capture molecule is a nucleic acid or its
 XX CC analogue, particularly peptide nucleic acid (PNA), antibody or receptor,
 XX CC and may also include an affinity molecule, particularly (strept)avidin,
 XX CC biotin or a biotinylated oligonucleotide. One of the probes or analyte
 XX CC contains an affinity component, especially streptavidin or biotin.
 XX CC Particularly the analyte is a nucleic acid having a polyT or polyA tail,
 XX CC most particularly a DNA fragment associated with a triplet-expansion
 XX CC disease. Both probes are nucleic acid or analogues, particularly PNA and
 XX CC especially have a linear primary structure with the marker attached at
 XX CC one end. The markers are reversibly oxidisable or reducible, e.g. osmium
 XX CC complexes, nanogold particles, ferrocenyl, anthraquinone groups or dyes,
 XX CC particularly of the indophenol, thiazine or phenazine types. The method
 XX CC is specifically used to detect DNA fragments that include repetitive
 XX CC sequences, particularly triplet expansions associated with fragile X
 XX CC syndrome, Huntington's disease, bulbar muscular dystrophy,
 XX CC spinocerebral ataxia type I, myotonic dystrophy, or Friedrich ataxia, but
 XX CC may also be used to detect proteins or other biomolecules. The method is
 XX CC simple, rapid (particularly when compared with the known PCR/Southern
 XX CC blotting method for diagnosis of triplet-expansion diseases) and very
 XX CC sensitive.
 XX CC
 XX SQ Sequence 23 BP; 8 A; 0 C; 5 G; 10 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 17.8; DB 1; Length 23;
 XX Best Local Similarity 90.5%; Pred. No. 59;
 XX Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1536 TCTTTTAAAGAGAAAG 1556
 Db 3 TTTTAAAGAGAAAG 23
 RESULT 81
 AAH26588/C
 ID AAH26588 standard; DNA; 22 BP.
 XX AC
 XX AAH26588;
 XX DT
 XX 12-NOV-2001 (first entry)
 XX DE
 XX Mouse GLUT4 3' PCR primer.
 XX KW
 XX Glucose transporter-4; GLUT4; FOXC2; adipose tissue; mouse;
 XX KW transgenic animal; obesity; malnutrition; hyperlipidaemia; diabetes;
 XX KW hypertension; antidiabetic; anorectic; hypolipemic; hypotensive;
 XX KW gene therapy; insulin; PCR primer; ss.
 XX OS
 XX Mus sp.
 XX PN
 XX WO200160853-A1.
 XX PD
 XX 23-AUG-2001.
 XX PF
 XX 16-FEB-2001; 2001WO-SE000339.
 XX PR
 XX 18-FEB-2000; 2000SE-00000531.
 XX PR 26-MAY-2000; 2000SE-00001982.
 XX PR 06-JUN-2000; 2000US-00587945.
 XX PR 14-DEC-2000; 2000SE-00004629.
 XX XX
 XX (PHAA) PHARMACIA AB.
 XX PA
 XX Enerbaeck S, Carlsson P;
 XX PI
 XX WPI, 2001-557641/62.
 XX DR
 XX WPI, 2001-557641/62.
 XX PT
 XX New construct comprising a human FOXC2 gene, useful in gene therapy for

PT treating obesity- or malnutrition-related diseases (e.g. obesity or
PT hyperlipidemia), as well as for identifying compounds useful in treating
PT these diseases.
XX
XX Example 1; Page 32; 92pp; English.
XX
CC The present sequence is that of a 3' primer, used with the 5' primer
CC given in AAH26567, for the PCR amplification of mouse insulin-responsive
CC glucose transporter-4 (GLUT-4) cDNA. cDNA probes for mouse FOXO2, ap2,
CC ADL1/SREBP1, cytochrome c-oxidase subunit II, adiponin, beta-1-3
CC adrenergic receptors, GLUT4, insulin receptor and insulin receptor
CC substrate IRS1 and IRS2 were prepared by RT-PCR using mouse epididymal
CC fat poly(A)+ RNA and the primers given in AAH26571-94. The probes were
CC used in Northern blots to examine gene expression in the brown and white
CC adipose tissue (WAT) of wild-type mice and 3 transgenic mice expressing
CC the human FOXO2 gene (see AAH26570). Upregulation of GLUT4 was observed
CC in transgenic mice. This was most evident in WAT. FOXO2 is expressed
CC exclusively in adult adipose tissue and plays a major role in regulating
CC energy balance and adiposity. The invention provides methods for
CC identifying compounds capable of increasing or decreasing FOXO2 protein
CC activity or gene expression, and for using such compounds to treat
CC medical conditions related to obesity, such as obesity, non-insulin
CC dependent diabetes mellitus, hypertension and hyperlipidaemia (claimed),
CC or medical conditions related to malnutrition, such as anorexia (claimed)
XX
XX Sequence 22 BP; 5 A; 6 C; 8 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 73;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 239 CCTCATAGCGCGCTACTCGGG 260
DB 22 CCTCATAGCGCGCTACTCGGG 1
RESULT 82
ADF08228
ID ADF08228 standard; DNA; 22 BP.
XX
XX ADF08228;
XX
XX 12-FEB-2004 (first entry)
XX
XX Transgenic APOAV mouse genotyping primer #2.
XX
XX ss; PCR; primer; mouse; apolipoprotein A-V; APOAV; triglyceride;
XX lipid-related; diabetic disease; cardiovascular disease;
XX plasma triglyceride; diabetes; obesity; metabolic disease; gene therapy;
XX single nucleotide polymorphism; apoA5; human.
XX
XX Mus musculus.
XX OS
XX Homo sapiens.
XX
XX US2003150003-A1.
XX
XX 07-AUG-2003.
XX
XX 27-AUG-2002; 2002US-00229834.
XX
XX 07-SEP-2001; 2001US-0318219P.
XX
XX (RUBI/) RUBIN E.
XX (PENN/) PENNACCHIO L A.
XX
XX Rubin E, Pennacchio LA;
XX
XX MPI; 2003-897618/82.
XX
XX New human apolipoprotein A-V (APOAV) polynucleotides and polypeptides,
XX useful for identifying or screening of drugs that treat lipid-related or
XX diabetic diseases, for lowering plasma triglycerides, or in gene therapy.
XX

PS Disclosure; SEQ ID NO 11; 192pp; English.
XX
XX The invention relates to an isolated polynucleotide homologous to the
XX cDNA apolipoprotein A-V (APOAV) sequence. The human apolipoprotein A-V
XX (APOAV) gene, polynucleotides and polypeptides are useful for determining
XX predisposition towards elevated triglyceride levels, for identifying or
XX screening of drugs that treat lipid-related or diabetic diseases, or in
XX genetic analysis of cardiovascular diseases. The APOAV polypeptide is
XX useful for lowering plasma triglycerides or treating diabetes, obesity or
XX other metabolic diseases. The APOAV gene and vector are useful in gene
XX therapy. The single nucleotide polymorphisms are useful for determining
XX the genetic status of individuals or for studying individual risk
XX factors. The transgenic non-human animals are useful for further animal
XX studies of human or mouse apoA5. The present sequence represents a
XX transgenic APOAV mouse genotyping primer.
XX
XX Sequence 22 BP; 2 A; 6 C; 8 G; 6 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 73;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1173 CATGTCGAGCGCTTCTCTCT 1194
DB 1 CAGGTCGAGCGCTTCTCTCT 22
RESULT 83
AAZ77324
ID AAZ77324 standard; DNA; 21 BP.
XX
XX AAZ77324;
XX
XX 10-SEP-2001 (first entry)
XX
XX Human biallelic marker downstream amplification primer SEQ ID NO:11680.
XX
XX Human genome; biallelic marker; high density disequilibrium map;
XX genomic map; haplotype; phenotype; polymorphic base; genotyping;
XX haplotyping; hybridisation; identification; characterisation;
XX amplification; single nucleotide polymorphism; SNP; PCR primer;
XX diagnosis; ss.
XX
XX Homo sapiens.
XX OS
XX WO954500-A2.
XX
XX 28-OCT-1999.
XX
XX 21-APR-1999; 99WO-1B000822.
XX
XX 21-APR-1998; 98US-0082614P.
XX PR
XX 23-NOV-1998; 98US-0109732P.
XX
XX (GEST) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I;
XX
XX MPI; 2000-013267/01.
XX
XX Novel biallelic markers used to construct a high density disequilibrium
XX map of the human genome.
XX
XX Claim 9; Page 2720; 2745pp; English.
XX
XX AAZ6564 to AAZ69578 represent human biallelic markers from the present
XX invention, which contain a polymorphic base at position 24 of their
XX nucleotide sequences. AAZ65579 to AAZ77440 represent amplification
XX primers for the biallelic markers. The biallelic markers of the invention
XX have a variety of uses: they can be used for high density mapping of the
XX human genome, and in complex association studies and haplotyping studies
XX which are useful in determining the genetic basis for disease states.
XX
XX Compositions and methods of the invention can also be useful for the

CC identification of the targets for the development of pharmaceutical
CC agents and diagnostic methods, as well as the characterisation of the
CC differential efficacious responses to and side effects from
CC pharmaceutical agents acting on a disease as well as other treatment.
CC N.B. The SEQ ID Nos 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297 and
CC 3367, are not actually given a sequence in the Sequence Listing from the
CC present invention
XX
SQ Sequence 21 BP; 0 A; 11 C; 0 G; 10 T; 0 U; 0 Other;
Query Match 0.7%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1643 TCTCTTCTTCTCCTTCTTCT 1659
DB 1 TCTCTTCTTCTCCTTCTTCT 17
RESULT 84
AAS96617/c
ID AAS96617 standard; DNA; 20 BP.
XX
AC AAS96617;
XX
DT 09-APR-2002 (first entry)
XX
DE Telomerase reverse transcriptase, antisense oligonucleotide #27.
XX
KM Telomerase reverse transcriptase; TERT; cytosolic; apoptosis;
KM cell growth inhibitor; antisense oligonucleotide; antisense technology;
KM ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN MO200188198-A1.
XX
PD 22-NOV-2001.
XX
PF 15-MAY-2001; 2001MO-US015774.
XX
PR 16-MAY-2000; 2000US-00572423.
PR 07-DEC-2000; 2000US-00733294.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Gaarde WA, Freier SM, Wanciewicz E;
XX
DR WPI; 2002-075321/10.
XX
PT New compound targeted to nucleic acid molecule encoding telomerase
PT transcriptase (TERT), which specifically hybridizes with and inhibits
PT expression of TERT, useful for modulating apoptosis and inhibiting cell
PT growth.
XX
PS Claim 26; Page 90; 154pp; English.
XX
CC The invention describes a compound, 8-50 nucleobases in length targeted
CC to a nucleic acid molecule encoding human TERT (telomerase reverse
CC transcriptase), where the compound specifically hybridizes with and
CC inhibits the expression of TERT. A series of oligonucleotides were
CC designed to target different regions of the human TERT RNA. These were 20
CC nucleotides in length and composed of a central gap region consisting of
CC ten 2'-deoxynucleotides, flanked on both sides (5' and 3' directions) by
CC five-nucleotide wings. The wings were composed of 2'-methoxyethyl (2'-
CC MOE) nucleotides. The compounds were analysed for their effect on human
CC TERT mRNA levels by reverse transcriptase (RT)-polymerase chain reaction
CC (PCR). The compound is useful for inhibiting the expression of TERT in
CC cells or tissues, for treating a human having disease or condition
CC associated with TERT, for modulating apoptosis, for inhibiting cell
CC growth (preferably, cancer cell growth), in antisense therapy and for
CC diagnostics and therapeutics. This sequence is an antisense

CC oligonucleotide used to modulate the activity of nucleic acid molecules
CC encoding TERT, described in the method of the invention
XX
SQ Sequence 20 BP; 2 A; 9 C; 7 G; 2 T; 0 U; 0 Other;
Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 87;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 139 GCGGAGACCTTGCGCCCGG 158
DB 20 GTGGAGACCTTGCGCCCGG 1
RESULT 85
ADJ32329
ID ADJ32329 standard; DNA; 20 BP.
XX
AC ADJ32329;
XX
DT 22-APR-2004 (first entry)
XX
DE Human STAT1 target DNA fragment #3.
XX
KM Human; signal transducer and activator of transcription; STAT1;
KM hyperproliferative disorder; cancer; infection; immune response;
KM gene therapy; ds.
XX
OS Homo sapiens.
XX
PN US2003232440-A1.
XX
PD 18-DEC-2003.
XX
PF 17-JUN-2002; 2002US-00174175.
XX
PR 17-JUN-2002; 2002US-00174175.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Karraas J, Freier SM, Dobie KM;
XX
DR WPI; 2004-052173/05.
XX
PT New antisense oligonucleotide targeted to a nucleic acid encoding signal
PT transducers and activators of transcription 1, useful for treating
PT cancer, or viral or bacterial infections.
XX
PS Example 15; SEQ ID NO 52; 72pp; English.
XX
CC The invention relates to novel antisense compounds targeted to a nucleic
CC acid molecule encoding signal transducers and activators of transcription
CC 1 (STAT1) to inhibit its expression. Compounds, compositions and methods
CC of the invention are useful for treating diseases or conditions
CC associated with STAT1 such as hyperproliferative disorders e.g. cancer,
CC viral or bacterial infections and diseases or conditions involving
CC hyperactivation of immune response. They are also useful in research and
CC diagnostic for modulating the expression of STAT1. The invention is also
CC useful in gene therapy. The present sequence is human STAT1 target DNA
CC fragment used in the exemplification of the invention.
XX
SQ Sequence 20 BP; 3 A; 3 C; 9 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 87;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 588 GGTGCGAGGAGTCAAGTG 607
DB 1 GGTGCGAGGAGTCAAGTG 20
RESULT 86

ADJ32292/c
ID ADJ32292 standard; DNA; 20 BP.
XX
AC ADJ32292;
XX
DT 22-APR-2004 (first entry)
XX
DE Human STAT1 antisense oligonucleotide, ISIS 204461.
XX
KW Human; signal transducer and activator of transcription; STAT1;
KW antisense; hyperproliferative disorder; cancer; infection;
KW immune response; gene therapy; phosphorothioate; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT 1..20
FT modified_base /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone where all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT modified_base /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN US2003232440-A1.
XX
PD 18-DEC-2003.
XX
PF 17-JUN-2002; 2002US-00174175.
XX
PR 17-JUN-2002; 2002US-00174175.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Karas J, Freter SM, Dobie KW;
XX WPI; 2004-052173/05.
XX
DR WPI; 2004-052173/05.
XX
XX
PT New antisense oligonucleotide targeted to a nucleic acid encoding signal
PT transducers and activators of transcription 1, useful for treating
PT cancer, or viral or bacterial infections.
XX
XX
PS Example 15; SEQ ID NO 15; 72bp; English.
XX
XX
CC The invention relates to novel antisense compounds targeted to a nucleic
CC acid molecule encoding signal transducers and activators of transcription
CC 1 (STAT1) to inhibit its expression. Compounds, compositions and methods
CC of the invention are useful for treating diseases or conditions
CC associated with STAT1 such as hyperproliferative disorders e.g. cancer,
CC viral or bacterial infections and diseases or conditions involving
CC hyperactivation of immune response. They are also useful in research and
CC diagnostic for modulating the expression of STAT1. The invention is also
CC useful in gene therapy. The present sequence is an antisense
CC oligonucleotide targeted to human STAT1 DNA. This sequence is used in
CC the exemplification of the invention.
XX
SQ Sequence 20 BP; 5 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
XX
XX
Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 87;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 588 GGTGGCAGAGGTCTCAGTG 607
DB 20 GGTGGCAGAGGTCTCAGTG 1

RESULT 87
ADK98410 standard; DNA; 20 BP.
ID ADK98410
XX
AC ADK98410;
XX
DT 06-MAY-2004 (first entry)
XX
DE Primer of the invention #4130.
XX
KW human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS Synthetic.
OS JP2003259875-A.
XX
PN JP2003259875-A.
XX
PD 16-SEP-2003.
XX
PF 08-MAR-2002; 2002JP-00064373.
XX
PR 08-MAR-2002; 2002JP-00064373.
XX
PA (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX
DR WPI; 2004-093977/10.
XX
PT Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.
XX
PS Claim 2; SEQ ID NO 7439; 267bp; Japanese.
XX
XX
CC The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.
XX
SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;
XX
XX
Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 87;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 757 CAGAGCCACAGACTGAGC 776
DB 1 CAGAGCCCTCAGAGGTGAGC 20
XX
XX
RESULT 88
AAQ11523
ID AAQ11523 standard; DNA; 21 BP.
XX
AC AAQ11523;
XX
DT 20-JUN-1991 (first entry)
XX
DE Rat Stem Cell Factor probe/primer 228-30.
XX
KW Stem cell factor; SCF; leukopenia; AIDS; haematopoiesis; primer; probe;
KW ss.
XX
OS Synthetic.
OS EP423980-A.
XX
PN EP423980-A.
XX
PD 24-APR-1991.
XX
PF 04-OCT-1990; 90EP-00310899.
XX
PR 16-OCT-1989; 89US-00422383.
XX
PR 11-JUN-1990; 90US-00537198.

```

PR 24-AUG-1990; 90US-00573616.
PR 28-SEP-1990; 90MO-US005548.
PR 01-OCT-1990; 90US-00589701.
XX
XX (AMGE-) AMGEN.
XX
XX Zeebo KM, Suggs SV, Bosselman RA, Martin FH;
XX WPI, 1991-119233/17.
XX
XX New naturally-occurring polypeptide stem cell factor analogues - have
XX haematopoietic biological activity of stem cell factor and are used to
XX treat e.g. leukaemia, AIDS, nerve damage and infertility.
XX
XX Disclosure; Fig 12A; 127pp; English.
XX
XX Determination of the amino acid sequence of fragments of the rat SCF
XX protein (see AAK11708) made it possible to design mixed sequence
XX oligonucleotides (see AAQ1509-526) specific for rat SCF (see AAQ1538
XX for the genomic and AAQ11539 for the cDNA sequence). The location of this
XX sequence is 45-65. The SCF has the ability to stimulate growth of
XX primitive progenitors including early hematopoietic progenitor cells and
XX non-hematopoietic stem cells such as neural stem cells and primordial
XX germ stem cells. The product may be used in a pharmaceutical compen. for
XX treating, in a mammal, leukaemia, thrombocytopenia, anaemia, AIDS,
XX neoplasia, nerve damage, infertility and intestinal damage
XX
XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 16.8; DB 1; Length 21;
XX Best Local Similarity 90.0%; Pred. No. 84;
XX Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2402 ATAAATGAAGTGAATCC 2421
XX ||||| ||||| |||||
XX 2 ATAAATGCAGTATATCC 21
XX
XX RESULT 89
XX AAT04911
XX ID AAT04911 standard; cDNA; 21 BP.
XX
XX AC AAT04911;
XX
XX DT 25-MAR-2003 (revised)
XX DT 15-MAY-1996 (first entry)
XX
XX DE Rat stem cell factor (SCF) cDNA oligonucleotide primer 228-30.
XX
XX KM Stem cell factor; progenitor; haematopoiesis; SCF; anaemia;
XX KM thrombocytopenia; leucopenia; AIDS; immunodeficiency; bone graft;
XX KM transplant; neoplasia; myelosuppression; bone marrow; ss.
XX
XX OS Synthetic.
XX
XX PN EP676470-A1.
XX
XX PD 11-OCT-1995.
XX
XX PF 04-OCT-1990; 9SEP-00105391.
XX
XX PR 16-OCT-1989; 89US-00422383.
XX PR 11-JUN-1990; 90US-00537198.
XX PR 24-AUG-1990; 90US-00573616.
XX PR 28-SEP-1990; 90MO-US005548.
XX PR 01-OCT-1990; 90US-00589701.
XX
XX (AMGE-) AMGEN INC.
XX
XX Zeebo KM, Suggs SV, Bosselman RA, Martin FH;
XX WPI, 1995-346090/45.
XX

```

```

PT New stem cell factor polypeptide(s) - for stimulating the growth of
PT primitive progenitor cells, esp. for treating disorders involving blood
PT cells.
XX
XX Example 3; Fig 12A; 127pp; English.
XX
XX AAT04897-T04914 are oligonucleotide primers and probes used for the
XX amplification and sequencing of rat stem cell factor (SCF). Non-naturally
XX occurring SCF and C-terminally truncated polypeptides, having amino acid
XX sequences sufficiently duplicative of naturally occurring SCF, stimulate
XX growth of primitive progenitors such as haematopoietic progenitor cells,
XX neural stem cells and primordial germ stem cells. The peptides can be
XX used in a composition for treating leucopenia, anaemia or
XX thrombocytopenia, for enhancing engraftment of bone marrow during
XX transplantation or for bone marrow recovery after chemotherapy or
XX radiation-induced bone marrow aplasia or myelosuppression. They can also
XX be used for treating neoplasia, nerve damage, infertility, intestinal
XX damage or myeloproliferative disorders. Antibodies may be raised against
XX the peptides for use in detection or neutralisation of SCF in serum. SCF
XX may be useful for the treatment of AIDS and severe combined
XX immunodeficiency (SCID) states alone or in combination with other factors
XX such as IL-7. (Updated on 25-MAR-2003 to correct PF field.)
XX
XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 16.8; DB 1; Length 21;
XX Best Local Similarity 90.0%; Pred. No. 84;
XX Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX 2402 ATAAATGAAGTGAATCC 2421
XX ||||| ||||| |||||
XX 2 ATAAATGCAGTATATCC 21
XX
XX Db
XX
XX RESULT 90
XX AAA13736
XX ID AAA13736 standard; DNA; 21 BP.
XX
XX AC AAA13736;
XX
XX DT 27-JUN-2000 (first entry)
XX
XX DE Rat stem cell factor oligonucleotide 228-30.
XX
XX KM Stem cell factor; SCF; haematopoietic progenitor cell; blood forming;
XX KM primitive progenitor cell; haematopoietic disorder; syngeneic;
XX KM allogeneic; autologous bone marrow transplant; gene therapy;
XX KM transfection; haematopoietic stem cell; acute blood loss; neoplasia;
XX KM cancer; ss.
XX
XX OS Rattus sp.
XX
XX PN EP992579-A1.
XX
XX PD 12-APR-2000.
XX
XX PF 04-OCT-1990; 99EP-00122861.
XX
XX PR 16-OCT-1989; 89US-00422383.
XX PR 11-JUN-1990; 90US-00537198.
XX PR 24-AUG-1990; 90US-00573616.
XX PR 28-SEP-1990; 90MO-US005548.
XX PR 01-OCT-1990; 90US-00589701.
XX PR 04-OCT-1990; 90EP-00310899.
XX
XX (AMGE-) AMGEN INC.
XX
XX Zeebo KM, Suggs SV, Bosselmann RA, Martin FH;
XX WPI, 2000-259135/23.
XX
XX Production of hematopoietic cells suitable for administration to a
XX subject using progenitor cells and expanding the cells using stem cell
XX

```



```
PT Factor.
XX
PS Example 3; Fig 12A, 123pp; English.
XX
CC A method has been developed of making haematopoietic cells suitable for
CC administration to a subject. The method comprises: (a) obtaining
CC haematopoietic progenitor cells from a donor; and (b) expanding the cells
CC by adding to the cells a haematopoietically effective dose of a
CC polypeptide product having at least part of the primary structural
CC confirmation and one or more of the biological properties of naturally
CC occurring stem cell factor (SCF). The method is useful for stimulating
CC primitive progenitor cells including early haematopoietic progenitor
CC cells which are capable of maturing to erythroid, megakaryocyte,
CC granulocyte, lymphocyte and macrophage cells. SCF results in absolute
CC increases in haematopoietic cells of both myeloid and lymphoid lineages.
CC SCF is useful for treating haematopoietic disorders. The method is useful
CC for expanding early haematopoietic progenitors in syngeneic, allogeneic
CC or autologous bone marrow transplant. SCF is useful for enhancing the
CC efficiency of gene therapy based on transfecting haematopoietic stem
CC cells. SCF is also useful for combating the myelosuppressive effects of
CC anti-HIV drugs such as AZT and for enhancing haematopoietic recovery
CC after acute blood loss and as a boost to the immune system for fighting
CC neoplasia (cancer). The present sequence represents an oligonucleotide
CC for rat SCF cDNA which is used in an example from the present invention
XX
SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2402 ATTAATGCAAGTGAGATCC 2421
DB 2 ATTAATGCAAGTGATATATCC 21
RESULT 91
AAH41315
ID AAH41315 standard; DNA; 21 BP.
AC AAH41315;
XX
DT 21-AUG-2001 (first entry)
XX
DE Rat stem cell factor (SCF) related oligonucleotide SEQ ID NO:16.
XX
KM Stem cell factor; SCF; stem cell factor receptor; blood cell disorder;
XX Gene therapy; PCR primer; mutagenesis; probe; ss.
XX
OS Rattus sp.
XX
PN US6207454-B1.
XX
PD 27-MAR-2001.
XX
PF 31-DEC-1998; 98US-00224681.
XX
XX 16-OCT-1989; 89US-00422383.
XX 11-JUN-1990; 90US-00537198.
XX 24-AUG-1990; 90US-00573616.
XX 01-OCT-1990; 90US-00589701.
XX 25-NOV-1992; 92US-00982255.
XX 21-DEC-1993; 93US-00172329.
XX 24-MAY-1995; 95US-00449653.
XX 12-JAN-1998; 98US-00005893.
XX
PA (AMGE-) AMGEN INC.
XX
PI Zeebo KM, Bosseelman RA, Suggs SV, Martin FH;
XX
DR WPI; 2001-366062/38.
XX
PT Enhancing efficiency of transfer of polynucleotide into a target
```

```
PT mammalian cell in vitro, involves exposing cell that expresses a stem
PT cell factor receptor to stem cell factor, and introducing polynucleotide
PT into cell in vitro.
XX
XX Example 3; Fig 12A; 210pp; English.
XX
CC The present invention describes a method for enhancing (B) the efficiency
CC of transfer of a polynucleotide (I) into a target mammalian cell (II) in
CC vitro, comprising exposing (II) that expresses a stem cell factor (SCF)
CC receptor to a biologically active SCF, its analogue or fragment, which
CC induces cell proliferation, and introducing (I) to (II) in vitro.
CC Exposure of SCF to (II) results in increased uptake of (I) into the cell.
CC The method is useful for enhancing the efficiency of the transfer of a
CC polynucleotide into a target mammalian cell in vitro. The method is
CC useful in gene therapy techniques. AAH41301 to AAH41364 and AAB98351 to
CC AAB98390 represent sequences used in the exemplification of the present
XX
SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2402 ATTAATGCAAGTGAGATCC 2421
DB 2 ATTAATGCAAGTGATATATCC 21
RESULT 92
AAS04095
ID AAS04095 standard; DNA; 21 BP.
AC AAS04095;
XX
DT 29-AUG-2001 (first entry)
XX
DE Rat SCF (stem cell factor) cDNA PCR primer 228-30.
XX
KM Rat, stem cell factor; SCF, early haematopoietic progenitor cell;
XX blood disorder; Leukemia; Hodgkin's disease; lymphoma; splenomegaly;
XX anaemia; Kala azar; septicemia; malaria; hypopigmentation disorder;
XX PCR primer; ss.
XX
OS Rattus sp.
XX
PN US6207417-B1.
XX
PD 27-MAR-2001.
XX
PF 07-JUN-1995; 95US-00482918.
XX
XX 16-OCT-1989; 89US-00422383.
XX 11-JUN-1990; 90US-00537198.
XX 24-AUG-1990; 90US-00573616.
XX 01-OCT-1990; 90US-00589701.
XX 21-DEC-1993; 93US-00172329.
XX
XX (ZSEB/) ZSEBO K M.
XX (BOSS/) BOSSELMAN R A.
XX (SUGS/) SUGGS S V.
XX (MART/) MARTIN F H.
XX
PI Zeebo KM, Bosseelman RA, Suggs SV, Martin FH;
XX
DR WPI; 2001-298941/31.
XX
PT Novel nucleic acids encoding stem cell factor useful for treating
PT disorders involving blood cells, e.g. leukemia, splenomegaly, Hodgkin's
PT disease, Kala azar, anemia and septicemia.
XX
XX Example 3; Fig 12A; 209pp; English.
```

```
CC The present sequence for PCR primer 228-30 is 1 of 18 oligonucleotides
CC (AA504081-AA504098) used to isolate the rat SCF (stem cell factor) cDNA
CC sequence. The present invention relates to novel stem cell factors
CC (AAU02453-AAU02458, AAU02460, AAU02461) and the polynucleotides encoding
CC them. SCF stimulate primitive progenitor cells including early
CC haematopoietic progenitor cells. The invention also describes SCF
CC peptides (AAU02462-AAU02481) and the oligonucleotides (AA504099-AA504117)
CC used in the isolation of human SCF sequences. The polynucleotide encoding
CC SCF is useful for producing SCF and useful in gene therapy. It is useful
CC for treating disorders involving blood cells such as myelofibrosis,
CC metastatic carcinoma, acute leukaemia, multiple myeloma, Hodgkin's
CC disease, lymphoma, Gaucher's disease, anaemia, congestive splenomegaly,
CC Kala azar, sarcoidosis, military tuberculosis, disseminated fungus
CC disease, fulminating septicemia, malaria, vitamin B12 and folic acid
CC deficiency, pyridoxine deficiency, and hypopigmentation disorders such as
CC piebaldism and vitiligo
XX
SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2402 ATTAATGAAAGTGAGATCC 2421
DB 2 ATTAATGCAAGTGATATCC 21
XX
RESULT 93
AAF89075
ID AAF89075 standard; DNA; 21 BP.
XX
AC AAF89075;
XX
DT 13-JUL-2001 (first entry)
XX
DE Rat stem cell factor PCR primer SEQ ID NO: 16.
XX
XX Human; rat; mammal; stem cell factor; SCF; cell growth stimulation;
XX gene therapy; haematopoietic disorder; aplastic anaemia; leukaemia;
XX neurological damage; intestinal damage; infertility; AIDS; SCID;
XX severe combined immunodeficiency; PCR primer; ss.
OS Rattus sp.
XX
PN US6207802-B1.
XX
PD 27-MAR-2001.
XX
PF 09-NOV-1994; 94US-00336728.
XX
PR 16-OCT-1989; 89US-00422383.
XX 11-JUN-1990; 90US-00537198.
XX 24-AUG-1990; 90US-00573616.
XX 01-OCT-1990; 90US-00589701.
XX 25-NOV-1992; 92US-00982255.
XX
PA (AMGE-) AMGEN INC.
XX
PI Zsebo KM, Bosselman RA, Suggs SV, Martin FH;
XX
XX WPI; 2001-353108/37.
XX
DR WPI; 2001-353108/37.
XX
PT Novel isolated non-human mammalian stem cell factor polypeptide
XX stimulating growth of early hematopoietic progenitor cells, useful for
XX treating aplastic anemia, lymphoma, Letterer-Siwe disease, Kala azar,
XX sarcoïdosis.
XX
PS Example 3; Fig 12A; 209pp; English.
XX
CC The present invention provides the protein and coding sequences of
XX mammalian stem cell factors (SCFs). These are capable of stimulating the
XX growth of early haematopoietic progenitor cells, neural stem cells and
```

```
CC primordial germ stem cells. The sequences are useful in the treatment of
CC leukaemias, haematopoietic disorders, aplastic anaemia, paroxysmal
CC nocturnal haemoglobinuria, malaria, pigmentation disorders, neurological
CC and intestinal damage, infertility, AIDS and severe combined
CC immunodeficiency (SCID). The present sequence is primer used to amplify
XX an SCF in the exemplification of the invention
XX
SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2402 ATTAATGAAAGTGAGATCC 2421
DB 2 ATTAATGCAAGTGATATCC 21
XX
RESULT 94
AAH23873
ID AAH23873 standard; DNA; 21 BP.
XX
AC AAH23873;
XX
DT 07-AUG-2001 (first entry)
XX
DE Rat SCF (stem cell factor) cDNA PCR primer 228-30.
XX
XX Rat; stem cell factor; SCF; early haematopoietic progenitor cell;
XX blood disorder; leukaemia; Hodgkin's disease; lymphoma; splenomegaly;
XX anaemia; Kala azar; septicemia; malaria; hypopigmentation disorder;
XX PCR primer; ss.
OS Rattus sp.
XX
PN US6204363-B1.
XX
PD 20-MAR-2001.
XX
PF 25-NOV-1992; 92US-00982255.
XX
PR 16-OCT-1989; 89US-00422383.
XX 11-JUN-1990; 90US-00537198.
XX 24-AUG-1990; 90US-00573616.
XX 01-OCT-1990; 90US-00589701.
XX 10-APR-1991; 91US-00684535.
XX
PA (AMGE-) AMGEN INC.
XX
PI Zsebo KM, Bosselman RA, Suggs SV, Martin FH;
XX
XX WPI; 2001-256683/26.
XX
DR WPI; 2001-256683/26.
XX
PT New stem cell factor polypeptides and their analogs which stimulate
XX growth of early hematopoietic progenitors, useful for treating aplastic
XX anemia, carcinoma, multiple myeloma, vitiligo, Kala azar, Hodgkin's
XX disease.
XX
PS Example 3; Fig 12A; 166pp; English.
XX
CC The present sequence for PCR primer 228-30 is 1 of 18 oligonucleotides
XX (AAH23859-AAH23876) used to isolate the rat SCF (stem cell factor) cDNA
XX sequence. The present invention relates to novel stem cell factors
XX (AAH73561-AAH73568, AAH73571-AAH73576) and the polynucleotides encoding
XX them. SCF stimulate primitive progenitor cells including early
XX haematopoietic progenitor cells. The invention also describes SCF
XX peptides (AAH73578-AAH73597) and the oligonucleotides (AAH23877-AAH23895)
XX used in the isolation of human SCF sequences. The polynucleotide encoding
XX SCF is useful for producing SCF and useful in gene therapy. It is useful
XX for treating disorders involving blood cells such as myelofibrosis,
XX metastatic carcinoma, acute leukaemia, multiple myeloma, Hodgkin's
XX disease, lymphoma, Gaucher's disease, anaemia, congestive splenomegaly,
XX Kala azar, sarcoidosis, military tuberculosis, disseminated fungus
```

CC disease, fulminating septicæmia, malaria, vitamin B12 and folic acid
 CC deficiency, pyridoxine deficiency, and hypopigmentation disorders such as
 CC piebaldism and vitiligo

Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
 Best local Similarity 90.0%; Pred. No. 84;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATAAATGAAAGTGAGATCC 2421
 Db 2 ATAAATGCAAGTGATATCC 21

RESULT 95
 AAS04196
 ID AAS04196 standard; DNA; 21 BP.

XX AAS04196;

XX 29-AUG-2001 (first entry)

DE Rat SCF (stem cell factor) cDNA PCR primer 228-30.

KM Rat; stem cell factor; SCF; early haematopoietic progenitor cell;
 KM blood disorder; leukaemia; Hodgkin's disease; lymphoma; splenomegaly;
 KM anaemia; Kala azar; septicæmia; malaria; hypopigmentation disorder;
 KM PCR primer; ss.

OS Rattus sp.

PN US6218148-B1.

PD 17-APR-2001.

PF 21-DEC-1993; 93US-00172329.

PR 16-OCT-1989; 89US-00422383.

PR 11-JUN-1990; 90US-00537198.

PR 24-AUG-1990; 90US-00573616.

PR 01-OCT-1990; 90US-00589701.

PR 25-NOV-1992; 92US-00982255.

PA (AMGE-) AMGEN INC.

PI Zeebo KM, Bosselman RA, Suggs SV, Martin FH;

DR WPI; 2001-281051/29.

XX Isolated DNA sequence, encoding polypeptide product useful for

PT stimulating growth of early hematopoietic progenitor cells.

PS Example 3; Fig 12A; 167pp; English.

XX

CC The present sequence for PCR primer 228-30 is 1 of 18 oligonucleotides

CC (AAS04192-AAS04195) used to isolate the rat SCF (stem cell factor) cDNA

CC sequence. The present invention relates to novel stem cell factors

CC (AAU02761-AAU02767, AAU02770-AAU02775, AAU02797) and the polynucleotides

CC encoding them. SCF stimulate primitive progenitor cells including early

CC haematopoietic progenitor cells. The invention also describes SCF

CC peptides (AAU02777-AAU02794) and the oligonucleotides (AAS04200-AAS04218)

CC used in the isolation of human SCF sequences. The polynucleotide encoding

CC SCF is useful for producing SCF and useful in gene therapy. It is useful

CC for treating disorders involving blood cells such as myelofibrosis,

CC metastatic carcinoma, acute leukaemia, multiple myeloma, Hodgkin's

CC disease, lymphoma, Gaucher's disease, anaemia, congestive splenomegaly,

CC Kala azar, sarcoidosis, military tuberculosis, disseminated fungus

CC disease, fulminating septicæmia, malaria, vitamin B12 and folic acid

CC deficiency, pyridoxine deficiency, and hypopigmentation disorders such as

CC piebaldism and vitiligo

XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
 Best local Similarity 90.0%; Pred. No. 84;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATAAATGAAAGTGAGATCC 2421
 Db 2 ATAAATGCAAGTGATATCC 21

RESULT 96
 AAS10431
 ID AAS10431 standard; DNA; 21 BP.

XX AAS10431;

XX 24-OCT-2001 (first entry)

DE Rat stem cell factor (SCF) cDNA PCR primer 228-30.

KM Rat; stem cell factor; SCF; haematopoietic progenitor cell;
 KM blood disorder; Hodgkin's disease; vitamin B12; folic acid deficiency;
 KM hypopigmentation disorder; viral disorder; AIDS; PCR primer; ss.

OS Rattus sp.

PN US6248319-B1.

PD 19-JUN-2001.

PF 24-MAY-1995; 95US-00449653.

PR 16-OCT-1989; 89US-00422383.

PR 11-JUN-1990; 90US-00537198.

PR 24-AUG-1990; 90US-00573616.

PR 01-OCT-1990; 90US-00589701.

PR 10-APR-1991; 91US-00684535.

PR 25-NOV-1992; 92US-00982255.

PR 21-DEC-1993; 93US-00172329.

XX (ZSEB/) ZSEBO K M.

PA (BOSS/) BOSSSELMAN R A.

PA (SUGS/) SUGGS S V.

PA (MART/) MARTIN F H.

PI Zeebo KM, Bosselman RA, Suggs SV, Martin FH;

DR WPI; 2001-407312/43.

XX Increasing the number of early hematopoietic progenitor cells in the

PT peripheral blood useful for the treatment of blood disorders including

PT Hodgkin's disease comprises the administration of human stem cell factor.

PS Example 3; Fig 12A; 210pp; English.

XX

CC The present sequence for rat stem cell factor (SCF) cDNA PCR primer 228-

CC 30 is 1 of 18 primers (AAS10417-AAS10434) used to amplify various

CC portions of the rat SCF cDNA sequence. The sequence is described in an

CC invention relating to novel stem cell factors, the polynucleotides

CC encoding them and methods for producing the stem cell factors. The

CC methods involve increasing the number of early haematopoietic progenitor

CC cells in human peripheral blood by administering a haematopoietically

CC effective human stem cell factor polypeptide. The methods are useful for

CC the treatment of blood disorders, including myelofibrosis,

CC myeloid leukaemia, osteopetrosis, metastatic carcinoma, acute leukaemia,

CC multiple myeloma, Hodgkin's disease, lymphoma, Gaucher's disease, Niemann

CC -Pick disease, refractory anaemia, malaria, vitamin B12 and folic acid

CC deficiency, hypopigmentation disorders i.e. piebaldism and viral induced

CC disorders, including AIDS

XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAAGTGAGATCC 2421
|||||
DB 2 ATTAATGCAAGTATATCC 21

RESULT 97

AAD35448
ID AAD35448 standard; DNA, 21 BP.

AC AAD35448;

DT 25-JUL-2002 (first entry)

DE Rat SCF cDNA amplifying PCR primer, 228-30.

KM Rat; stem cell factor; SCF protein; leucopaenia; thrombocytopaenia;
KM anaemia; myelosuppression; nerve damage; myeloproliferative disorder;
KM infertility; neoplasia; myelofibrosis; myelosclerosis; osteopetrosis;
KM metastatic carcinoma; acute leukaemia; multiple myeloma; sarcoidosis;
KM Hodgkin's disease; lymphoma; Gaucher's disease; Niemann-Pick disease;
KM Letterer-Siwe disease; refractory erythroidlastic anaemia; Kala azar;
KM Di Guglielmo syndrome; congestive splenomegaly; splenic pancyopaenia;
KM disseminated fungus disease; fulminating septicaemia; plebaldism; AIDS;
KM acquired immune deficiency syndrome; malaria; military tuberculosis;
KM pyridoxine deficiency; vitamin B12 deficiency; folic acid deficiency;
KM Diamond Blackfan anaemia; hypopigmentation disorder; vitiligo; PCR;
KM primer; ss.

XX Rattus sp.

XX US2002018763-A1.

XX 14-FEB-2002.

XX 12-JUN-1998; 98US-00005243.

XX 24-MAY-1995; 95US-0049653.

XX (ZSEB/) ZSEBO K M.

XX (BOSS/) BOSSELMAN R A.

XX (SUGS/) SUGGS S V.

XX (MART) MARTIN F H.

XX Zsebo KM, Bosseلمان RA, Suggs SV, Martin FH;

XX WPI; 2002-350789/38.

XX Novel non-naturally-occurring stem cell factor polypeptide, useful for

XX treating leucopenia, thrombocytopenia, anemia and for enhancing

XX engraftment of bone marrow during transplantation in a mammal.

XX Example 3; Fig 12A; 217pp; English.

XX The present invention relates to novel non-naturally-occurring stem cell
XX factor (SCF) polypeptides having an amino acid sequence sufficiently
XX duplicative of that of naturally-occurring SCF to allow possession of
XX haematopoietic biological activity of naturally occurring SCF. Sequences
XX of the invention are useful for treating leucopenia, thrombocytopaenia,
XX anaemia and for enhancing bone marrow recovery in treatment of radiation,
XX engraftment of bone marrow during transplantation in mammals and chemical
XX or chemotherapeutic induced bone marrow aplasia or myelosuppression. They
XX are also useful for treating acquired immune deficiency in a human, nerve
XX damage in a mammal. SCF sequences are useful for preparing biologically
XX active polymer polypeptide adduct, for enhancing transfection of early
XX haematopoietic progenitor cells with a gene, and transfer of a gene into
XX a mammal. They are useful for treating myelofibrosis, myelosclerosis,
XX osteopetrosis, metastatic carcinoma, acute leukaemia, multiple myeloma,
XX Hodgkin's disease, lymphoma, Gaucher's disease, Niemann-Pick disease,
XX Letterer-Siwe disease, refractory erythroidlastic anaemia, Di Guglielmo

CC syndrome, congestive splenomegaly, Kala azar, sarcoidosis, primary
CC splenic pancytopaenia, disseminated fungus disease, malaria, military
CC tuberculous, fulminating septicaemia, pyridoxine deficiency, vitamin B12
CC and folic acid deficiency, Diamond Blackfan anaemia, hypopigmentation
CC disorders such as plebaldism, AIDS (acquired immune deficiency syndrome)
CC and vitiligo. The present sequence is a PCR primer which is used for
CC amplifying rat SCF cDNA. This sequence is also used as a probe
XX

SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 84;

Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATTAATGAAAGTGAGATCC 2421
|||||
DB 2 ATTAATGCAAGTATATCC 21

RESULT 98

AB573832
ID AB573832 standard; DNA, 21 BP.

XX AB573832;

XX 05-DEC-2002 (first entry)

DE Rat SCF cDNA oligonucleotide 228-30.

XX Stem cell factor; SCF; blood-forming system; blood cell disorder;
XX haematopoietic system; metastatic carcinoma; acute leukaemia;
XX multiple myeloma; Hodgkin's disease; lymphoma; malaria; vitiligo;
XX refractory erythroidlastic anaemia; military tuberculosis; cytostatic;
XX disseminated fungus disease; haematopoietic; tuberculous; atic;
XX anti-naeemic; antifungal; antimalarial; dermatological; rat; ss.

XX Rattus norvegicus.

XX EP1241258-A2.

XX 18-SEP-2002.

XX 04-OCT-1990; 2002EP-00008587.

XX 16-OCT-1989; 89US-00422383.

XX 11-JUN-1990; 90US-00537198.

XX 24-AUG-1990; 90US-00573616.

XX 28-SEP-1990; 90WO-US005548.

XX 01-OCT-1990; 90US-00589701.

XX 04-OCT-1990; 90EP-00310899.

XX 04-OCT-1990; 95EP-00105391.

XX (AMGE-) AMGEN INC.

XX Zsebo KM, Suggs SV, Bosseلمان RA, Martin FH;

XX WPI; 2002-684093/74.

XX Production of a human stem cell factor (SCF) polypeptide for treating

XX disorders involving blood cells, such as leukemia, comprises culturing

XX mammalian cells comprising non-human SCF promoter DNA linked to DNA

XX encoding the human SCF.

XX Example 3; Fig 12A; 120pp; English.

XX The present invention relates to novel stem cell factors (SCFs),
XX polynucleotide sequences encoding the SCFs, and methods of producing
XX them. SCFs are involved in the blood-forming (haematopoietic) system in
XX mammals, particularly humans. The method of the invention is useful for
XX the production of human SCF. The stem cell factors are useful to treat
XX disorders involving blood cells e.g. metastatic carcinoma, acute
XX leukaemia, multiple myeloma, Hodgkin's disease, lymphoma, refractory
XX erythroidlastic anaemia, military tuberculosis, disseminated fungus

CC disease, malaria, and vitiligo. The present sequence representing an
CC oligonucleotide for rat SCF cDNA is used in the examples of the present
CC invention
XX
SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2402 ATAAATGAAAGTGAGATCC 2421
DB 2 ATAAATGCAAGTGATATCC 21

RESULT 99
ADE35984
ID ADE35984 standard; DNA; 21 BP.

XX ADE35984;

XX 29-JAN-2004 (first entry)

XX Y. pestis specific PCR primer #5.

XX PCR; primer; ss; genome signature tag; library;

XX genome signature tag library.

XX Yersinia pestis.

XX US2003186251-A1.

XX 02-OCT-2003.

XX 01-APR-2002; 2002US-00113916.

XX 01-APR-2002; 2002US-00113916.

XX (BROO-) BROOKHAVEN SCI ASSOC LLC.

XX Dunn JF, Van Der Lelje D, Krause MK;

XX WPI; 2003-844149/78.

XX Generating a genome signature tag library useful for genetic analysis.

XX Example; Page 7; 12pp; English.

XX The invention relates to a method of generating a genome signature tag

XX library. The method is used for generating a genome signature tag

XX library. The present sequence represents a Y. pestis specific PCR primer.

XX Sequence 21 BP; 4 A; 8 C; 5 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 487 CCTGCAGTGCCTCTCANG 506
DB 1 CATGCAGTGCCTCTCANG 20

RESULT 100
ADE52444
ID ADE52444 standard; DNA; 21 BP.

XX ADE52444;

XX 29-JAN-2004 (first entry)

XX Stem cell factor (SCF) related DNA #15.

KW Stem cell factor; SCF; haematopoietic activity; infertility;
KW intestinal damage; myeloproliferative disorder; leucopenia;
KW thrombocytopenia; anaemia; bone marrow transplant; immune deficiency;
KW neoplasia; nerve damage; osteoporosis; metastatic carcinoma; leukaemia;
KW military tuberculosis; haematopoietic progenitor cell; ss.

OS Synthetic.
XX
XX US2002031491-A1.
XX
XX 14-MAR-2002.
XX
XX 31-DEC-1998; 98US-00224683.

XX 16-OCT-1989; 89US-00422383.
XX 11-JUN-1990; 90US-00537198.
XX 24-AUG-1990; 90US-00573616.
XX 01-OCT-1990; 90US-00589701.
XX 10-APR-1991; 91US-00684535.
XX 25-NOV-1992; 92US-00982255.
XX 21-DEC-1993; 93US-00172329.
XX 24-MAY-1995; 95US-00449653.
XX 12-JAN-1998; 98US-00005893.

XX (ZSEB/) ZSEBO K M.
XX (BOSS/) BOSSSELMAN R A.
XX (SUGG/) SUGGS S V.
XX (MART/) MARTIN F H.

XX Zsebo KM, Bosselman RA, Suggs SV, Martin FH;
XX WPI; 2003-851459/79.

XX New non-natural stem cell factor, useful for treating e.g. leucopenia or
XX immune deficiency, also related nucleic acid and antibodies.
XX
XX Disclosure; SEQ ID NO 16; 217pp; English.

XX The invention relates to stem cell factor (SCF) polypeptides with
XX haematopoietic activity and the polynucleotides encoding them. The
XX polypeptides are used for treating infertility, intestinal damage,
XX myeloproliferative disorders, leucopenia, thrombocytopenia or anaemia,
XX for improving engraftment of bone marrow transplants, for enhancing bone
XX marrow recovery after radiotherapy or chemotherapy and in treatment of
XX immune deficiency, neoplasia, nerve damage, osteoporosis, metastatic
XX carcinoma, leukaemia and military tuberculosis. The SCF polypeptides are
XX also used to expand haematopoietic progenitor cells for transplantation
XX and to prepare such cells for transfection with a gene. The SCF
XX polynucleotides can be used for recombinant expression of the
XX polypeptides and also as probes for mapping of the SCF gene, for
XX identifying SCF-related diseases and as a marker for neighbouring genes.
XX Antibodies raised against the polypeptides are useful in diagnosis and to
XX remove SCF from blood. This sequence represents SCF related DNA of the
XX invention.

XX Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 84;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2402 ATAAATGAAAGTGAGATCC 2421
DB 2 ATAAATGCAAGTGATATCC 21

RESULT 101
ADP99286
ID ADP99286 standard; DNA; 21 BP.

XX ADP99286;

XX 23-SEP-2004 (first entry)

XX Rat stem cell factor, SCF, PCR primer #15.
 XX
 DE Rat; SCF; stem cell factor; gene therapy; hematopoietic progenitor cell;
 XX aplastic anaemia; paroxysmal nocturnal haemoglobinuria; myelofibrosis;
 KW myelocystic leukaemia; osteopetrosis; metastatic carcinoma; acute leukaemia;
 KW multiple myeloma; Hodgkin's disease; lymphoma; Gaucher's disease;
 KW Niemann-Pick disease; Letterer-Siwe disease;
 KW refractory erythroidlastic anaemia; Di Guglielmo syndrome;
 KW congestive splenomegaly; Kala awar; sarcoidosis;
 KW primary splenic pancytopenia; miliary tuberculosis;
 KW disseminated fungus disease; Fulminating septicemia; malaria;
 KW vitamin B12 deficiency; folic acid deficiency; pyridoxine deficiency;
 KW Diamond Blackfan anaemia; hypopigmentation disorder; piebaldism;
 KW vitiligo; neurological damage; infertility; intestinal damage;
 KW irradiation; chemotherapy; AIDS; hematopoietic recovery;
 KW acute blood loss; neoplasm; cancer; ss; PCR; primer.
 XX
 OS Rattus norvegicus.
 XX Synthetic.
 XX
 PN US6759215-B1.
 XX
 PD 06-JUL-2004.
 XX
 PF 07-AUG-2000; 2000US-00635251.
 XX
 PR 16-OCT-1989; 89US-00422383.
 XX
 PR 11-JUN-1990; 90US-00537198.
 XX
 PR 24-AUG-1990; 90US-00573616.
 XX
 PR 01-OCT-1990; 90US-00589701.
 XX
 PR 10-APR-1991; 91US-00684535.
 XX
 PR 25-NOV-1992; 92US-00982255.
 XX
 PR 21-DEC-1993; 93US-00172329.
 XX
 PR 24-MAY-1995; 95US-00449182.
 XX
 PA (AMGE-) AMGEN INC.
 XX
 PI Zeebo KM, Boeselman RA, Suggs SV, Martin FH;
 XX
 DR WPI; 2004-497128/47.
 XX
 PT Preparing a human stem cell factor (SCF) polypeptide, useful for treating
 PT hematopoietic disorders, e.g., aplastic anemia, comprises growing host
 PT cells transfected or transfected with DNA encoding a human SCF.
 XX
 PS Example 3; SEQ ID NO 16; 210pp; English.
 XX
 XX The invention relates to preparing a (vertebrate) human stem cell factor
 CC (SCF) polypeptide comprising growing host cells transfected or
 CC transfected with DNA encoding a human SCF that stimulates growth of
 CC hematopoietic progenitor cells under nutrient conditions, the DNA being
 CC operatively linked to an expression control sequence, and isolating the
 CC polypeptide produced. Also included is a recombinant host cell
 CC transformed or transfected with an expression construct comprising a
 CC vertebrate SCF polypeptide-encoding DNA operatively linked to a
 CC heterologous expression regulatory sequence, permitting the expression of
 CC the vertebrate SCF polypeptide in the host cell. Disclosed as new are rat
 CC and human nucleic acids encoding SCF, SCF proteins from a number of other
 CC mammals and recombinantly expressed SCF protein fragments. The DNA
 CC sequences are useful for effecting the large scale synthesis of SCF by a
 CC variety of recombinant techniques or for generating new and useful viral
 CC and circular plasmid DNA vectors, new and useful transformed and
 CC transfected prokaryotic and eukaryotic host cells, and new and useful
 CC methods for cultured growth of such host cells capable of expression of
 CC SCF and its related products. The DNA sequences are also useful as
 CC labeled probes in isolating human genomic DNA encoding SCF, in methods
 CC of protein synthesis, in genetic therapy in humans and other mammals, and
 CC in developing transgenic mammalian species which may serve as eukaryotic
 CC hosts for production of SCF and SCF products in quantity. The SCF is
 CC useful for treating hematopoietic disorders, e.g., aplastic anaemia,
 CC paroxysmal nocturnal haemoglobinuria, myelofibrosis, myelocystic leukaemia,
 CC osteopetrosis, metastatic carcinoma, acute leukaemia, multiple myeloma,

CC Hodgkin's disease, lymphoma, Gaucher's disease, Niemann-Pick disease,
 CC Letterer-Siwe disease, refractory erythroidlastic anaemia, Di Guglielmo
 CC syndrome, congestive splenomegaly, Kala awar, sarcoidosis, primary
 CC splenic pancytopenia, miliary tuberculosis, disseminated fungus disease,
 CC fulminating septicemia, malaria, vitamin B 12 and folic acid deficiency,
 CC pyridoxine deficiency, Diamond Blackfan anaemia, and hypopigmentation
 CC disorders such as piebaldism and vitiligo. The SCF are also useful for
 CC treating neurological damage, infertility states, intestinal damage
 CC resulting from irradiation or chemotherapy, acute blood loss and as a
 CC boost to the immune system for fighting neoplasia (cancer). The present
 CC sequence is a rat SCF PCR primer used in the isolation of SCF DNA.
 XX
 SQ Sequence 21 BP; 9 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
 XX
 Query Match 0.7%; Score 16.8; DB 1; Length 21;
 Best Local Similarity 90.0%; Pred. No. 84;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 2402 ATTAATGAAAGTGAATCC 2421
 DB 2 ATTAATGCAAGTGAATATCC 21
 RESULT 102
 ADD01326/C
 ID ADD01326 standard; DNA; 22 BP.
 XX
 AC ADD01326;
 XX
 DT 01-JAN-2004 (first entry)
 XX
 DE Human STAT-1 inhibitor oligonucleotide SEQ ID 41.
 XX
 KW ss; inhibitor; STAT-1; signal transducer and activator of transcription;
 KW cardiovascular; restenosis; percutaneous angioplasty; stenosis;
 KW graft versus host reaction; ischaemic injury; reperfusion injury;
 KW organ transplantation; immunological hypersensitivity; allergic rhinitis;
 KW food; urticaria; celiac disease; contact dermatitis;
 KW immune complex disease; alveolitis; arthritis; bone disease;
 KW glomerulonephritis; allergic vasculitis; gout; osteitis; osteomyelitis;
 KW polynueritis; bronchitis; endocarditis; hepatitis; myocarditis;
 KW nephritis; pericarditis; peritonitis; pancreatitis; septic shock;
 KW vasculitic; immunosuppressive; antiallergic; antiinflammatory;
 KW dermatological; antiarthritic; nephrotropic; antigen; osteopathic;
 KW hepatotropic; virucide; cardiac; antibacterial; human.
 XX
 XX Homo sapiens.
 OS
 XX
 PN WO2003030944-A2.
 XX
 PD 17-APR-2003.
 XX
 PF 02-OCT-2002; 2002WO-DE003748.
 XX
 PR 04-OCT-2001; 2001DE-01048886.
 XX
 PA (AVON-) AVONTEC GMBH.
 XX
 PI Hecker M, Wagner AH;
 XX
 DR WPI; 2003-381684/36.
 XX
 PT Use of inhibitor of STAT-1 activity, for treating or preventing e.g.
 PT cardiovascular complications, graft versus host reactions or
 PT immunological hypersensitivity.
 XX
 PS Disclosure, SEQ ID NO 41; 53pp; German.
 XX
 CC This invention describes the novel use of an inhibitor of STAT-1 (signal
 CC transducer and activator of transcription) for prevention or treatment of
 CC cardiovascular complications and other diseases e.g. restenosis after
 CC percutaneous angioplasty or stenosis in venous by-passes; graft versus

CC host reactions; ischemic/reperfusion injury in surgical operations or
CC organ transplantation, immunological hypersensitivity reactions,
CC especially allergic rhinitis, food and medicine allergies (particularly
CC urticaria and celiac disease), contact dermatitis, immune complex
CC diseases, especially alveolitis, arthritis, glomerulonephritis and
CC allergic vasculitis, inflammatory cartilage and bone diseases (especially
CC arthritis, gout, osteitis and osteomyelitis), polyneuropathy, also
CC (sub)acute infection-related, particularly post-infection, inflammatory
CC conditions, particularly bronchitis, endocarditis, hepatitis,
CC myocarditis, nephritis, pericarditis, peritonitis and pancreatitis,
CC including septic shock. The inhibitor is a double-stranded (ds) DNA
CC oligonucleotide which acts as a decoy, a single-stranded antisense
CC oligonucleotide, an antisense expression vector or ds RNA-interference
CC (RNAi) oligonucleotide. The products of the invention have vasotropic,
CC immunosuppressive, anti-allergic, anti-inflammatory, dermatological,
CC anti-arthritic, nephrotropic, anti-gout, osteopathic, hepatotropic,
CC virucide, cardiant and antibacterial activity. ADD01286-ADD01346
CC represent the STAT-1 decoy oligonucleotides used in the method of the
CC invention.

SO Sequence 22 BP; 6 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 589 GTGGCAGAGTCTCAGTGG 608

DB 22 GTGGCAGAGTCTCAGTGG 3

RESULT 103
ADC79529/C

ID ADC79529 standard; DNA; 22 BP.

AC ADC79529;

DT 01-JAN-2004 (first entry)

DE Human STAT-1 decoy oligonucleotide #41.

XX vasotropic; anti-allergic; neuroprotective; immunosuppressive;
XX anti-rheumatic; anti-inflammatory; dermatological; anti-arthritic;
XX anti-asthmatic; anti-diabetic; antiparasitic; antibacterial; STAT-1;
XX proinflammatory; leucocyte; endothelial cell; smooth muscle cell; CD40;
XX E-selectin; inducible nitric oxide synthase; iNOS; interleukin-12;
XX interferon-gamma; cardiovascular; restenosis; percutaneous angioplasty;
XX transplant rejection; graft versus host disease; reperfusion;
XX hypersensitivity reaction; autoimmune disease; diabetes mellitus;
XX multiple sclerosis; rheumatoid arthritis; chronic inflammatory disease;
XX arthritis; asthma; bronchitis; psoriasis; neurodermatitis;
XX ulcerative colitis; Crohn's disease; primer; ss.

OS Homo sapiens.

PN WO2003031459-A2.

PD 17-APR-2003.

PF 02-OCT-2002; 2002WO-DE003747.

PR 04-OCT-2001; 2001DE-01048828.

PA (AVON-) AVONTEC GMBH.

PI Hecker M, Wagner AH;

DR WPI; 2003-363361/34.

PT New decoy oligonucleotides, useful for treating and preventing e.g.
PT cardiovascular complications or transplant rejection, by neutralization
XX of STAT-1.

PS Claim 3; SEQ ID NO 41; 52pp; German.

XX This invention describes novel decoy oligonucleotides which have
XX vasotropic, anti-allergic, neuroprotective, immunosuppressive,
XX anti-rheumatic, anti-inflammatory, dermatological, anti-arthritic,
XX anti-asthmatic, anti-diabetic, antiparasitic and antibacterial activity.
XX The oligonucleotides neutralise or inhibit expression of STAT-1 and thus
XX of a range of potentially proinflammatory gene products in leucocytes,
XX endothelial and smooth muscle cells. Genes that have a STAT-1 binding
XX site in their promoters include those for CD40, E-selectin, inducible
XX nitric oxide synthase (iNOS), interleukin-12 and interferon-gamma. Also
XX the oligonucleotides of the invention may lift inhibition of gene
XX expression where this is blocked by transcription factors, e.g. the gene
XX for endothelial NOS which is down regulated by interferon-gamma. The
XX decoy oligonucleotide and new antisense oligonucleotides, are used to
XX treat or prevent cardiovascular complications, especially restenosis
XX after percutaneous angioplasty and stenosis in venous by-passes,
XX transplant rejection, graft versus host disease, ischemic/reperfusion
XX injuries of surgery, immunological hypersensitivity reactions (types I-
XX V), autoimmune diseases (especially diabetes mellitus, multiple sclerosis
XX and rheumatoid arthritis), all forms of (sub)acute or chronic
XX inflammatory diseases, especially of the joints (arthritis), respiratory
XX organs (bronchial asthma and chronic bronchitis), skin (psoriasis and
XX neurodermatitis) or gastrointestinal tract (ulcerative colitis or Crohn's
XX disease). ADC79489-ADC79549 represent the decoy oligonucleotides
XX described in the disclosure of the invention.

SO Sequence 22 BP; 6 A; 9 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 82;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 589 GTGGCAGAGTCTCAGTGG 608

DB 22 GTGGCAGAGTCTCAGTGG 3

RESULT 104

ID ADR77478 standard; DNA; 19 BP.

AC ADR77478;

DT 16-DEC-2004 (first entry)

DE Human apolipoprotein B (ApoB) oligonucleotide seqid 1963.

XX antilipemic; cardiant; vasotropic; antiarteriosclerotic; antidiabetic;
XX cytoprotective; anticonvulsant; nootropic; muscular; anti-HIV;
XX RNA interference; iRNA; antisense technology; lipid metabolism;
XX cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
XX coronary artery disease; CAD; coronary heart disease; CHD;
XX atherosclerosis; hepatic glucose production;
XX glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
XX colon cancer; lung cancer; neurological disease; Huntington disease;
XX spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apoB; ss.

OS Homo sapiens.

PN WO2004080406-A2.

PD 23-SEP-2004.

PF 08-MAR-2004; 2004WO-US007070.

PR 07-MAR-2003; 2003US-0452682P.

PR 12-MAR-2003; 2003US-0454265P.

PR 13-MAR-2003; 2003US-0454982P.

PR 13-MAR-2003; 2003US-0455050P.

PR 14-APR-2003; 2003US-0462894P.

PR 17-APR-2003; 2003US-0463772P.

PR 25-APR-2003; 2003US-0465665P.

Seq	Sequence	19 BP; 2 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
Query Match	0.7%; Score 16.4; DB 1; Length 19;	
Best Local Similarity	94.4%; Pred. No. 1e+02;	
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
QY	215 TGGGCGGCGCTTCAGCCAT 232	
DB	1 TGGCGTGGCTTCAGCCAT 18	
RESULT 106		
AAD09637/C		
ID	AAD09637 standard; DNA; 20 BP.	
XX		
AC	AAD09637;	
XX		
DT	10-SEP-2001 (first entry)	
XX		
DE	Human PKA C-alpha chimeric antisense oligonucleotide (ISIS# 102594).	
XX		
KW	Human; protein kinase A; PKA catalytic subunit C-alpha inhibitor;	
KW	therapy; infection; inflammation; tumour; prophylaxis; antisense;	
KW	phosphorothioate backbone; chimeric; ss.	
XX		
OS	Homo sapiens.	
OS	Synthetic.	
OS	Chimeric.	
XX		
Key	Location/Qualifiers	
FT	modified_base	
FT	1..20	
FT	/*tag= a	
FT	/mod_base= OTHER	
FT	/note= "Phosphorothioate backbone"	
FT	1..5	
FT	/*tag= b	
FT	/mod_base= OTHER	
FT	/note= "Methoxyethyl residues"	
FT	4	
FT	/*tag= c	
FT	/mod_base= m5c	
FT	6..15	
FT	/*tag= d	
FT	/note= "Central gap region"	
FT	16..20	
FT	/*tag= e	
FT	/mod_base= OTHER	
FT	/note= "Methoxyethyl residues"	
FT	17..19	
FT	/*tag= f	
FT	/mod_base= m5c	
XX		
PN	US6248586-B1.	
XX		
PD	19-JUN-2001.	
XX		
PF	17-DEC-1999; 99US-00467082.	
XX		
PR	17-DEC-1999; 99US-00467082.	
XX		
PA	(ISIS-) ISIS PHARM INC.	
XX		
PI	Monia BP, Cowser LM;	
XX		
DR	WPI; 2001-407321/43.	
XX		
PT	Antisense oligonucleotides for inhibiting the expression of the human	
PT	protein kinase A catalytic subunit C-alpha, particularly useful for	
PT	preventing, delaying or treating infection, inflammation or tumor	
PT	formation.	
XX		
DS	Claim 1; Col 44; 35pp; English.	
XX		

CC	The invention is directed to antisense compounds, particularly
CC	oligonucleotides which are targeted to a DNA encoding human protein
CC	kinase A (PKA) catalytic subunit C-alpha to modulate (inhibit) its
CC	expression. The antisense compounds are useful for diagnostics,
CC	therapeutic, prophylaxis and as research reagents or kits. The antisense
CC	oligonucleotides are useful for treating human, suspected of having or
CC	being prone to a disease or condition associated with the expression of
CC	PKA catalytic subunit C-alpha. In particular, the antisense
CC	oligonucleotides are useful for preventing, delaying or treating
CC	infection, inflammation and tumour formation. They are also useful in
CC	cancer therapy. The present sequence is a chimeric antisense
CC	oligonucleotide with a phosphorothioate backbone. This oligo is targeted
CC	to the 5' untranslated region (UTR) of human PKA catalytic subunit C-
CC	alpha to inhibit its expression
XX	
SQ	Sequence 20 BP; 0 A; 8 C; 10 G; 2 T; 0 U; 0 Other;
XX	
Query Match	0.7%; Score 16.4; DB 1; Length 20;
Best Local Similarity	94.4%; Pred. No. 98;
Matches 17; Conservative	0; Mismatches 1; Indels 0; Gaps 0
Dn	68 CTGCGCCGCCGCCGCAGC 85 20 CGGGCCCCGCCGCAGC 3
XX	
RESULT 107	
AAZ30148	
ID	AAZ30148 standard; DNA; 21 BP.
AC	AAZ30148;
XX	
DT	26-JAN-2000 (first entry)
DE	
PCR primer pnf12 used to amplify DNA encoding 3' end of P44-12 protein.	
KM	Human granulocytic ehrlichiosis; HGE; HGB agent; P44 protein; P44-12;
KW	outer membrane protein; hypervariable region; HVR; CR1; CR2; vaccine;
KM	Ehrlichia chaffeensis; Borrelia burgdorferi; PCR primer; ss.
OS	Synthetic.
OS	Ehrlichia sp.
PN	WC9952370-A1.
PD	21-OCT-1999.
Pf	08-APR-1999; 99WO-US007759.
PR	09-APR-1998; 98US-0081192P.
PR	07-APR-1999; 99US-0128087P.
XX	(OHIS) OHIO STATE RES FOUND.
PI	Rikhisa Y, Zhi N, Ohashi N;
PI	WPI; 1999-620249/53.
DR	
New outer membrane proteins from the agent that causes human granulocytic	
ehrlichiosis, used for diagnosis, treatment and prevention.	
Example 2; Page 24; 52pp; English.	
XX	
CC	PCR primers AAZ30148-49 were used to amplify DNA encoding P44-12 protein
CC	of the agent that causes human granulocytic ehrlichiosis (HGE). P44
CC	proteins are outer membrane proteins, which comprise a hypervariable
CC	region (HVR), and two conserved regions (CR1 and CR2), linked, directly
CC	or indirectly through a linker to the N-terminus and C-terminus,
CC	respectively, of HVR. The proteins are used to diagnose HGE, by binding to
CC	antibodies present in infected subjects and as immunogens or vaccines for
CC	treatment/prevention of HGE. Antibodies against Ab are used for
CC	immunoblotting of isolates of the HGB agent, for detecting HGB in
CC	biological samples, for affinity purification of P44 proteins and for

identifying P44-expressing cells. P44 nucleic acids are used for recombinant production of the protein, and as a source of primers or probes (for isolating and identifying cDNA or genomic clones, their allelic variants or transcripts, or for amplification) or as antisense reagents. The P44 proteins can be used to differentiate between infection by the HGE agent and infection by *Escherichia chaffeensis* or *Borrelia burgdorferi*.

Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;

Query Match
Best Local Similarity 94.4%; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

563 GTTTGACTGGAACACACC 580
4 GTTTGACTGGAACACTCC 21

RESULT 108
ADA50411
ID ADA50411 standard; DNA; 21 BP.
AC ADA50411;
XX
XX
XX 20-NOV-2003 (first entry)
XX
XX
XX Thermus scotoductus nucleic acid polymerase PCR primer SEQ ID NO:36.
DE
XX
XX nucleic acid polymerase; enzyme; Thermus scotoductus; DNA polymerase;
KW salt tolerance; thermostability; PCR primer; ss.
XX
XX Synthetic.
OS Thermus scotoductus.
XX
XX WO2003066804-A2.
XX
XX 14-AUG-2003.
XX
XX 13-SEP-2002; 2002WO-US029102.
XX
XX 14-SEP-2001; 2001US-0322218P.
XX
XX 30-NOV-2001; 2001US-0334489P.
XX
XX (APPL-) APPLERA CORP.
XX (BOLC/) BOLCHAKOVA E V.
XX (ROZZ/) ROZZELLE J E.
XX
XX Bolchakova EV, Rozzelle JE;
PI
XX
XX WPI; 2003-663590/62.
XX
XX
XX New nucleic acid encoding a Thermus scotoductus strain X-1, ATCC Deposit
PT No. 27978 nucleic acid polymerase, useful for producing nucleic acid
PT polymerases having e.g., improved sequence discrimination or better salt
PT tolerance.
XX
XX Example 1; Page 81; 179pp; English.

The present invention describes isolated nucleic acids encoding nucleic acid polymerases from Thermus scotoductus. Also described: (1) an isolated nucleic acid (I) encoding a nucleic acid polymerase from Thermus scotoductus strain X-1, ATCC Deposit No. 27978; (2) an isolated DNA polymerase polypeptide from Thermus scotoductus strain X-1, ATCC Deposit No. 27978; (3) an isolated nucleic acid (II) comprising any of a set of 12 nucleic acid sequences (S1, see ADA50425 to ADA50436) which encodes a nucleic acid polymerase; (4) an isolated nucleic acid (III) encoding a nucleic acid polymerase comprising any of a set of 16 amino acid sequences (S2, see ADA50389 to ADA50404); (5) isolated nucleic acid polymerases comprising any of amino acid sequences S2; (6) vectors comprising (I), (II), or (III), and especially expression vectors in which the nucleic acid polymerase gene is operably linked to a promoter; (7) a host cell comprising an isolated nucleic acid molecule encoding a

nucleic acid polymerase from Thermus scotoductus strain X-1, ATCC Deposit No. 27978; (8) a host cell comprising (I) or (II); (9) a kit comprising a container containing a nucleic acid polymerase comprising any of amino acid sequences S2; (10) preparing (M1) a nucleic acid polymerase comprising any of amino acid sequences S2 by incubating a host cell comprising an encoding nucleic acid under conditions sufficient for RNA transcription and translation; (11) a nucleic acid polymerase prepared by M1; (12) synthesizing DNA (M2) comprising contacting a polypeptide comprising any of amino acid sequences S2 with a DNA under conditions sufficient to permit DNA polymerisation; (13) a method (M3) for thermocyclic amplification of nucleic acid; and (14) a method (M4) of primer extension. The nucleic acid is useful for producing nucleic acid polymerases having improved sequence discrimination, better salt tolerance or varying degrees of thermostability with applications e.g. in PCR and DNA sequencing. The present sequence represents a PCR primer for Thermus scotoductus nucleic acid polymerase, which is used in an example from the present invention.

Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match
Best Local Similarity 94.4%; DB 1; Length 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

1322 GACCCTGGTGAAGCTCTT 1339
3 GACCCTGGTGAAGCTCTT 20

RESULT 109
ADR87061
ID ADR87061 standard; DNA; 21 BP.
XX
XX
XX ADR87061;
XX
XX 16-DEC-2004 (first entry)
XX
XX
XX Human ephrinB2 short interference RNA seqid 366.
DE
XX
XX
XX Cytostatic; antiinflammatory; antirheumatic; antipruritic;
KW dermatological; ophthalmological; gene therapy; EphB4; Ephrin B2;
KW pharmaceutical; cosmetic; diagnostic; Ephrin B2/EphB4 pathway; tumour;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; human; ephrin B2; short interference RNA; siRNA;
KW RNA interference; gene silencing; ss.
XX
XX
XX Homo sapiens.
OS
XX
XX WO2004080425-A2.
XX
XX 23-SEP-2004.
XX
XX 12-MAR-2004; 2004WO-US007755.
XX
XX 12-MAR-2003; 2003US-0454300P.
XX
XX 12-MAR-2003; 2003US-0454432P.
XX
XX (VASG-) VASGENE THERAPEUTICS INC.
XX
XX Krasnoperov V, Zozulya S, Kerebesz N, Reddy R, Gail P;
PI WPI; 2004-668883/65.
XX
XX
XX New soluble polypeptides comprising an extracellular domain of EphB4 or
PT Ephrin B2 protein for diagnosing or treating cancer or angiogenesis-
PT associated diseases, such as inflammatory disorders, psoriasis or
PT scleroderma.
XX
XX Example 9; Page 98; 198pp; English.

The invention describes an isolated soluble polypeptide comprising an amino acid sequence of an extracellular domain of an EphB4 or Ephrin B2

CC protein. The EphB4 or Ephrin B2 polypeptide is a monomer, the EphB4
CC polypeptide binds specifically to the Ephrin B2 polypeptide, and the
CC Ephrin B2 polypeptide binds specifically to the EphB4 polypeptide. Also
CC described are: an antagonist antibody that binds to an extracellular
CC domain of the EphB4 or Ephrin B2 protein and inhibits an activity of the
CC EphB4 or Ephrin B2; a pharmaceutical or cosmetic composition, or a
CC diagnostic kit, comprising the above soluble polypeptide or antagonist
CC antibody, and a pharmaceutical carrier; methods of inhibiting
CC angiogenesis or inhibiting signaling through Ephrin B2/EphB4 pathway in a
CC cell; a method of reducing the growth rate of a tumour; methods for
CC treating a patient suffering from a cancer or an angiogenesis-associated
CC disease; and a method for identifying a tumor that is suitable for
CC treatment with an EphrinB2 or EphB4 antagonist. The polypeptide or
CC antibody is useful for manufacturing a medicament for the treatment of
CC cancer or an angiogenesis-associated disease. The composition and methods
CC are useful for diagnosing or treating cancer or angiogenesis-associated
CC diseases, such as inflammatory disorders, chronic articular rheumatism,
CC psoriasis, ocular angiogenic diseases or scleroderma. This sequence
CC represents a human ephrin B2 siRNA that can be used to control EphB2
CC expression.

SO Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 227 AGCCATGAAGACCTCAT 244
DB 4 AGCCATGAAGATCCTCAT 21
|||||
|||||

RESULT 110

ID ADR82616 standard; DNA; 21 BP.

AC ADR82616;

DT 16-DEC-2004 (first entry)

DE Human EphrinB2 antisense RNAi probe #18.

human; ss; antisense; EphB4; EphrinB2; cancer;
KW angiogenesis-associated disease; inflammatory disorder;
KW chronic articular rheumatism; psoriasis; ocular angiogenic disease;
KW scleroderma; cytotoxic; antiinflammatory; antirheumatic; antiproliferative;
KW dermatological; ophthalmological; angiogenesis inhibitor; probe; RNAi.
XX
XX Homo sapiens.
XX
XX WO2004080418-A2.
XX
XX 23-SEP-2004.

PD 12-MAR-2004; 2004WO-US007491.

PF 12-MAR-2003; 2003US-0454300P.

PR 12-MAR-2003; 2003US-0454432P.

PA (VASC-) VASGENE THERAPEUTICS INC.

PI Reddy R, Gill P;

DR WPI; 2004-668879/65.

PT New isolated nucleic acid compounds that hybridize to EphB4 or EphrinB2
PT transcripts or decrease the expression of EphB4 or EphrinB2 in cells,
PT useful for diagnosing or treating cancer or angiogenesis-associated
PT diseases.

PS Example 9; Page 105; 206BP; English.

XX The invention relates to an isolated nucleic acid compound comprising at

CC least a portion that hybridises to an EphB4 or EphrinB2 transcript under
CC physiological conditions and decreases the expression of EphB4 or
CC EphrinB2 in a cell. The nucleic acid is useful for manufacturing a
CC medicament for the treatment of cancer or angiogenesis-associated
CC diseases. The composition and methods are useful for diagnosing or
CC treating cancer or angiogenesis-associated diseases, such as inflammatory
CC disorders, chronic articular rheumatism, psoriasis, ocular angiogenic
CC diseases or scleroderma. The present sequence represents a human EphrinB2
CC antisense RNAi probe.

SO Sequence 21 BP; 8 A; 5 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 94;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 227 AGCCATGAAGACCTCAT 244
DB 4 AGCCATGAAGATCCTCAT 21
|||||
|||||

RESULT 111

ID AA063503 standard; DNA; 21 BP.

AC AA063503;

DT 17-JAN-1995 (first entry)

DE NANBH primer 77R, binding position 2535-2554.

KW polymerase chain reaction; PCR; amplify; primer; non-A, non-B hepatitis;
KW NANBH; virus; blood transmissible; detection; hepatitis virus; RT-PCR;
KW C100 antibody; HCV RNA; NS5 region; ss.

OS Synthetic.

PN JP06105690-A.

PD 19-APR-1994.

PF 10-MAR-1992; 92JP-00051885.

PR 10-MAR-1992; 92JP-00051885.

PA (KAEN/) KAENNO K.

DR WPI; 1994-163130/20.

PT Blood-transmissible non-A non-B hepatitis virus DNA - used for detection
PT of hepatitis virus.

PS Example 1; Page 3; 22pp; Japanese.

CC The sequences given in AA063500-35 are primers which were used in the
CC amplification of regions of the non-A, non-B hepatitis (NANBH) virus
CC genome. The pref. virus is blood transmissible and the amplified
CC fragments are used in the detection of hepatitis virus. The target DNA
CC was isolated from serum of chronically infected NANBH patients who were
CC C100 antibody-positive and HCV RNA (NS5 region) positive. Reverse
CC transcription-PCR and PCR were performed on cDNA and the total human
CC NANBH DNA was constructed from 23 clones (see also AA063499)

SO Sequence 21 BP; 8 A; 7 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.7%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1256 CACCATCCCAAGCTGAGCA 1276
DB 1 CATCATCCACAGCAGAGCA 21
|||||
|||||

```
RESULT 112
AAZ26556
ID AAZ26556 standard; DNA; 21 BP.
XX
AC AAZ26556;
XX
DT 30-NOV-1999 (first entry)
XX
DE Human polymorphic region 745.
XX
KW Polymorphism; human; inhibitor; cancer; treatment; cell growth; LOH;
KW cell viability; loss of heterozygosity; precancerous condition; ASI;
KW allele specific inhibitor; somatic cell; diagnosis; prevention;
KW atherosclerotic plaque; premalignant metaplastic lesion; endometriosis;
KW dysplastic lesion; benign tumour; polycystic kidney disease; transplant;
KW graft versus host disease; malignant cell removal; bone marrow; ss.
XX
OS Homo sapiens.
XX
PN WO9841648-A2.
XX
PD 24-SEP-1998.
XX
PF 19-MAR-1998; 98WO-US005419.
XX
PR 20-MAR-1997; 97US-0041057P.
XX
PA (VAR1-) VARIAGENICS INC.
XX
PI Houseman D, Ledley FD, Stanton VP;
XX
DR WPI; 1998-521232/44.
XX
PT Identifying target genes for allele-specific drugs - used for diagnosis,
PT prevention and treatment of, e.g. cancer; atherosclerotic plaque,
PT dysplastic lesions, endometriosis or graft versus host disease.
XX
PS Disclosure; Fig 7; 605pp; English.
XX
CC This invention describes a novel method for identifying an inhibitor
CC potentially useful for treatment of cancer, where the inhibitor is active
CC on a gene vital for cell growth or viability, and where the gene is
CC subject to loss of heterozygosity (LOH) in a cancer. The inhibitor is
CC used for preventing the development of cancer in a patient having a
CC precancerous condition, by administering to the patient a first allele
CC specific inhibitor (ASI) targeted to an allele of a first essential gene
CC present in cells of the precancerous condition, where the normal somatic
CC cells of the patient are heterozygous for the first gene, the inhibitor
CC is active on at least one but less than all allelic forms of the gene
CC present in a population and targets only one allelic form present in the
CC normal somatic cells, and the first gene. The products and methods can be
CC used in the diagnosis, prevention and treatment of LOH disorders, e.g.
CC cancers, benign tumours, endometriosis, polycystic kidney disease, and
CC great vessels host disease. The method can also be used to remove
CC malignant cells from bone marrow transplants. AAZ25812-226825 represent
CC human polymorphic sites described in the method of the invention
XX
SQ Sequence 21 BP; 6 A; 4 C; 6 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 822 AACTTCGAATGCGCTGTGTTG 842
DB 1 AACTTCAGAGGCCAGTGTG 21
```

```
RESULT 113
AAF96288
ID AAF96288 standard; DNA; 21 BP.
```

```
XX
AC AAF96288;
XX
DT 18-NOV-2004 (revised)
DT 06-JUN-2001 (first entry)
XX
DE Human gene single nucleotide polymorphism #1049.
XX
KW Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX
OS Homo sapiens.
XX
OS Unidentified.
XX
FH Key Location/Qualifiers
FH variation 11
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism"
XX
PN WO200118250-A2.
XX
PD 15-MAR-2001.
XX
PF 07-SEP-2000; 2000WO-US024503.
XX
PR 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
PA (MHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JJ;
XX
DR WPI; 2001-226749/23.
XX
PT Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
PS Example; Page 123; 242pp; English.
XX
CC The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
XX
CC Revised record issued on 18-NOV-2004 : The variation feature was
CC incorrectly given a capital V
XX
SQ Sequence 21 BP; 8 A; 6 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 16.2; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 745 GCAACTTCAGCAGAGGCCA 765
DB 1 GTAACCTTCAGCAAAAGGCCA 21
```

```
RESULT 114
ADQ93958
```

```

ID ADQ93958 standard; DNA; 21 BP.
XX
XX ADQ93958;
AC
XX
DT 23-SEP-2004 (first entry)
XX
DE Human oestrogen receptor (ER)-alpha DNA amplifying forward RT-PCR primer.
XX
XX Androgen-independent prostate cancer; hormone refractory prostate cancer;
KM benzoethophene; therapy; human; ER; oestrogen receptor; RT;
KW reverse transcription; PCR; primer; ss.
XX
XX Homo sapiens.
OS
XX US2004132776-A1.
PN
XX 08-JUL-2004.
PD
XX 23-JUL-2003; 2003US-00625152.
PF
XX 09-MAY-2002; 2002US-00142087.
PR
XX (CEDA-) CEDARS SINAI MEDICAL CENT.
PA
XX Agus DB;
XX
XX WPI; 2004-517037/49.
DR
XX Use of benzoethophene derivatives for preventing and/or treating androgen
PT -independent prostate cancer in mammals.
XX
XX Example 6; SEQ ID NO 4; 21bp; English.
XX
XX The present invention relates to a method for treating and preventing
CC androgen-independent prostate cancer (also called hormone refractory
CC prostate cancer) in mammal. The method involves administration of a
CC benzoethophene derivative to a mammal. The present sequence is human
CC oestrogen receptor (ER)-alpha DNA amplifying reverse transcription (RT)-
CC PCR primer. This sequence is used to illustrate the method of the
CC invention.
XX
XX Sequence 21 BP; 4 A; 4 C; 7 G; 6 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.7%; Score 16.2; DB 1; Length 21;
XX Best Local Similarity 85.7%; Pred. No. 1e+02;
XX Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1327 TGGTGAAGCTCTTCGACAAGC 1347
DB 1 TGGTGAAGCTCTTCGACAAGC 21
XX
XX RESULT 115
XX AAL55455/c
XX ID AAL55455 standard; DNA; 19 BP.
XX
XX AAL55455;
AC
XX
XX 22-MAY-2003 (first entry)
DT
XX
XX Specific tumour cell proliferation related PCR primer, SEQ ID No 25.
DE
XX
XX Recombination virus; proliferation; tumour cell; anti-oncogene;
KM proliferation; telomerase promoter; therapy; tumour; PCR; primer; ss.
XX
XX Unidentified.
OS
XX
XX WO2003006640-A1.
PN
XX
XX 23-JAN-2003.
PD
XX
XX 12-JUL-2002; 2002WO-CN000493.
PF
XX
XX

```

```

PR 12-JUL-2001; 2001CN-00126113.
XX
XX (QIAN/) QIAN Q.
PA
XX
XX Qian Q, Wu M, Shan S;
PI
XX
XX WPI; 2002-464081/22.
DR
XX
XX Telomerase promoter-controlled recombinant viruses proliferating
PT specifically in tumor cells to highly express anti-oncogene to kill tumor
PT cells by synergism, applicable in treating tumor.
XX
XX Example 6; Page 30; 56pp; Chinese.
XX
XX The invention relates to a recombination virus proliferating in a tumour
CC cell, which can express an anti-oncogene with high efficiency. The
CC invention also relates to the method of its proliferation. A telomerase
CC promoter controlling the transcription of at least one necessary gene for
CC a recombination virus proliferating, can make the virus optionally
CC proliferate in a tumour cell, which has the activity of telomerase and
CC basically does not proliferate in a normal cell without the activity of a
CC telomerase. The recombination virus can be used in therapy of many kinds
CC of tumours. This polynucleotide sequence represents a PCR primer relating
CC to the specific proliferation in a tumour cell of the invention
XX
XX Sequence 19 BP; 1 A; 6 C; 9 G; 3 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.7%; Score 16; DB 1; Length 19;
XX Best Local Similarity 100.0%; Pred. No. 1.1e+02;
XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 143 GAAGCCCTGGCCCGG 158
DB 19 GAAGCCCTGGCCCGG 4
XX
XX RESULT 116
XX ABQ76085/c
XX ID ABQ76085 standard; DNA; 19 BP.
XX
XX ABQ76085;
AC
XX
XX 30-SEP-2002 (first entry)
DT
XX
XX Anticancer gene-associated PCR primer #16.
DE
XX Proliferation; anticancer gene; tumour cell; telomerase; promoter;
KM early virus gene; PCR; primer; ss.
XX
XX Unidentified.
OS
XX
XX CN139584-A.
PN
XX
XX 13-MAR-2002.
PD
XX
XX 12-JUL-2001; 2001CN-00126113.
PF
XX
XX 12-JUL-2001; 2001CN-00126113.
PR
XX
XX (QIAN/) QIAN Q.
PA
XX
XX Qian Q, Wu M, Cen X;
PI
XX
XX WPI; 2002-464081/50.
DR
XX
XX Telomerase promoter-controlled recombinant viruses proliferating
PT specifically in tumor cells to highly express anti-oncogene to kill tumor
PT cells by synergism, applicable in treating tumor.
XX
XX Example 5; Page 16; 25pp; Chinese.
XX
XX This invention describes a novel recombinant virus for specific
CC proliferation and efficient expression of an anticancer gene in tumour
CC

```

CC cells. By inserting a telomerase promoter in the upstream area of an
CC early virus gene, the recombinant virus is made to proliferate
CC selectively in tumour cells with telomerase activity rather than in
CC normal cells without telomerase activity. This recombinant virus may be
CC used to treat several kinds of tumours. This sequence represents a PCR
CC primer used to illustrate the method described in the disclosure of the
CC invention

XX
SQ Sequence 19 BP; 1 A; 6 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 143 GAAGCCTGGCCCGG 158
DB 19 GAAGCCTGGCCCGG 4

RESULT 117
AAZ03129/c
ID AAZ03129 standard; DNA; 20 BP.
XX AAZ03129;
AC
XX
AC AAZ03129;
XX
XX 07-OCT-1999 (first entry)
XX
XX PCR primer used to amplify an ORF of Chlamydia trachomatis.
DE
XX
XX Vaccine; eye disease; conventional trachoma; nongendemic trachoma;
KW paratrachoma; inclusion conjunctivitis; genital disease; perithenitis;
KW nongonococcal urethritis; epididymitis; cervicitis; salpingitis; PCR primer;
KW bartolinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
XX Synthetic.
OS Chlamydia trachomatis.
XX
XX WO928475-A2.
XX
XX 10-JUN-1999.
XX
XX 27-NOV-1998; 98WO-IB001939.
XX
XX 28-NOV-1997; 97FR-00015041.
PR 17-DEC-1997; 97FR-00016034.
PR 04-NOV-1998; 98US-0107077P.
XX
XX (GSET) GENSET.
XX
XX Griffiths R;
PI
XX
XX WPI; 1999-371125/31.
XX
XX Genome sequence of Chlamydia trachomatis.
XX
XX Disclosure; Page 1581; 1755pp; English.
XX
XX PCR primers AAZ01426-206209 were used to amplify open reading frames
CC (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC encode polypeptides (see AAY36754-Y37949) which can be used as vaccines
CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC be used to control growth of the microorganism. Chlamydia trachomatis is
CC responsible for a large number of diseases, e.g. eye diseases such as
CC conjunctivitis; genital diseases such as nongonococcal urethritis;
CC epilymritis, cervicitis, salpingitis, perithenitis, bartolinitis;
CC pneumonia in breast feeding infants, and venereal lymphogranulomatosis.
CC The polypeptides of the invention may be of use in treating these
CC diseases
XX
SQ Sequence 20 BP; 4 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.7%; Score 16; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2206 ATCCCTCTTCAGAGG 2221
DB 19 ATCCCTCTTCAGAGG 4

RESULT 118
ABZ808/c
ID ABZ808 standard; DNA; 20 BP.
XX
XX ABZ80808;
AC
XX
XX 17-OCT-2003 (first entry)
XX
XX Human oligonucleotide sequence.
XX
XX Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiasthmatic; hypotensive; immunosuppressive; cytoskeletal; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
XX Homo sapiens.
OS
XX
XX WO200285308-A2.
XX
XX 31-OCT-2002.
XX
XX 23-APR-2002; 2002WO-US013135.
XX
XX 24-APR-2001; 2001US-0286137P.
XX
XX (EPIC-) EPIGENESIS PHARM INC.
XX
XX Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
XX WPI; 2003-229219/22.
XX
XX Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
XX Disclosure; SEQ ID NO 3330; 872pp; English.
XX
XX The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,
CC immunosuppressive, and cytoskeletal activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 0.7%; Score 16; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1677 TCAGTCTTCTGGCGA 1692
DB 20 TCAGTCTTCTGGCGA 5
RESULT 119
ABD24318/C
ID ABD24318 standard; DNA; 20 BP.
XX
AC ABD24318;
XX
DT 29-JUL-2004 (first entry)
XX
DE A1095013-derived oligonucleotide DNA SEQ ID 3330.
XX
KM Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KM respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KM surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KM analgesic; hypotensive; immunosuppressive; cytostatic; cyclic fibrosis;
KM beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KM respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KM emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KM pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR MPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 3330; 763bp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the target. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory

CC distress syndrome, pain, cyclic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc. tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 6 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1677 TCAGTCTTCTGGCGA 1692
DB 20 TCAGTCTTCTGGCGA 5
RESULT 120
ADG90647
ID ADG90647 standard; mRNA; 21 BP.
XX
AC ADG90647;
XX
DT 21-OCT-2004 (first entry)
XX
DE Mouse Sca-2 target oligonucleotide SEQ ID NO:44.
XX
KM lentiviral vector; small interference RNA; siRNA; cytostatic; virocidic;
KM gene therapy; Sca-2; ss.
XX
OS Mus musculus.
XX
OS Synthetic.
XX
PN WO2004065549-A2.
XX
PD 05-AUG-2004.
XX
PF 15-JAN-2004; 2004WO-US001320.
XX
PR 17-JAN-2003; 2003US-0440987P.
XX
PA (UyFL) UNIV FLORIDA.
XX
PI Chang L, He J;
XX
DR MPI; 2004-562155/54.
XX
PT New lentiviral vector comprising a nucleotide sequence encoding a small
PT interference RNA, useful for reducing expression of a target gene in a
PT cell.
XX
PS Example 1; SEQ ID NO 44; 51bp; English.
XX
CC The present invention describes a lentiviral vector comprising a
CC nucleotide sequence encoding a small interference RNA (siRNA). Also
CC described is a method of reducing expression of a target gene in a cell
CC comprising: (a) introducing into the cell a lentiviral vector encoding a
CC siRNA specific for the gene; and (b) placing the cell under conditions,
CC where the siRNA specific for the gene is expressed to cause a detectable
CC decrease in expression of the gene. The siRNA has cytostatic and virocidic
CC activities, and can be used in gene therapy. The vector is useful for
CC reducing expression of a target gene in a cell. The present sequence
CC represents a mouse Sca-2 target oligonucleotide, which is used in an
CC example from the present invention.
XX
SQ Sequence 21 BP; 5 A; 7 C; 3 G; 0 T; 6 U; 0 Other;
XX
Query Match 0.7%; Score 16; DB 1; Length 21;
Best Local Similarity 68.8%; Pred. No. 1.1e+02;
Matches 11; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

```
QY      739 CCTTCTGCACTTCAG 754
XX      ||:::||:::||::||
KM      6 CCUUCUCCACACUUCAG 21
XX

RESULT 121
ADQ90611
ID      ADQ90611 standard; DNA; 21 BP.
XX
AC      ADQ90611;
XX
DT      21-OCT-2004 (first entry)
XX
DE      Sca-2 siRNA duplex sense oligonucleotide SEQ ID NO:8.
XX
KM      lentiviral vector; small interference RNA; siRNA; cytosstatic; virucide;
KW      gene therapy; Sca-2; ss.
XX
OS      Mus musculus.
OS      Synthetic.
XX
PN      MO2004065549-A2.
XX
PD      05-AUG-2004.
XX
PF      15-JAN-2004; 2004MO-US001320.
XX
PR      17-JAN-2003; 2003US-0440987P.
XX
(UYFL ) UNIV FLORIDA.
XX
PI      Chang L, He J;
XX
DR      WPI; 2004-562155/54.
XX
PT      New lentiviral vector comprising a nucleotide sequence encoding a small
PT      interference RNA, useful for reducing expression of a target gene in a
PT      cell.
XX
PS      Example 1; SEQ ID NO 8; 51pp; English.
XX
CC      The present invention describes a lentiviral vector comprising a
CC      nucleotide sequence encoding a small interference RNA (siRNA). Also
CC      described is a method of reducing expression of a target gene in a cell
CC      comprising: (a) introducing into the cell a lentiviral vector encoding a
CC      siRNA specific for the gene; and (b) placing the cell under conditions
CC      where the siRNA specific for the gene is expressed to cause a detectable
CC      decrease in expression of the gene. The siRNA has cytosstatic and virucide
CC      activities, and can be used in gene therapy. The vector is useful for
CC      reducing expression of a target gene in a cell. The present sequence
CC      represents a Sca-2 siRNA duplex oligonucleotide, which is used in an
CC      example from the present invention.
XX
SQ      Sequence 21 BP; 3 A; 7 C; 3 G; 8 T; 0 U; 0 Other;
XX
Query Match      0.7%; Score 16; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY      739 CCTTCTGCACTTCAG 754
XX      ||:::||:::||::||
DB      4 CCTTCTGCACTTCAG 19
XX

RESULT 122
ADQ90612/C
ID      ADQ90612 standard; DNA; 21 BP.
XX
AC      ADQ90612;
XX
DT      21-OCT-2004 (first entry)
XX
```

```
DE      Sca-2 siRNA duplex antisense oligonucleotide SEQ ID NO:9.
XX
XX      lentiviral vector; small interference RNA; siRNA; cytosstatic; virucide;
KM      gene therapy; Sca-2; ss.
XX
XX
OS      Mus musculus.
OS      Synthetic.
XX
PN      MO2004065549-A2.
XX
PD      05-AUG-2004.
XX
PF      15-JAN-2004; 2004MO-US001320.
XX
PR      17-JAN-2003; 2003US-0440987P.
XX
(UYFL ) UNIV FLORIDA.
XX
PI      Chang L, He J;
XX
DR      WPI; 2004-562155/54.
XX
PT      New lentiviral vector comprising a nucleotide sequence encoding a small
PT      interference RNA, useful for reducing expression of a target gene in a
PT      cell.
XX
PS      Example 1; SEQ ID NO 9; 51pp; English.
XX
CC      The present invention describes a lentiviral vector comprising a
CC      nucleotide sequence encoding a small interference RNA (siRNA). Also
CC      described is a method of reducing expression of a target gene in a cell
CC      comprising: (a) introducing into the cell a lentiviral vector encoding a
CC      siRNA specific for the gene; and (b) placing the cell under conditions
CC      where the siRNA specific for the gene is expressed to cause a detectable
CC      decrease in expression of the gene. The siRNA has cytosstatic and virucide
CC      activities, and can be used in gene therapy. The vector is useful for
CC      reducing expression of a target gene in a cell. The present sequence
CC      represents a Sca-2 siRNA duplex oligonucleotide, which is used in an
CC      example from the present invention.
XX
SQ      Sequence 21 BP; 6 A; 3 C; 7 G; 5 T; 0 U; 0 Other;
XX
Query Match      0.7%; Score 16; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
QY      739 CCTTCTGCACTTCAG 754
XX      ||:::||:::||::||
DB      16 CCTTCTGCACTTCAG 1
XX

RESULT 123
AAT85565/C
ID      AAT85565 standard; DNA; 19 BP.
XX
AC      AAT85565;
XX
DT      11-NOV-1997 (first entry)
XX
DE      Human STM2 exon 10 RT-PCR primer EX102R.
XX
XX      Autosomal dominant early-onset Alzheimer's Disease; AD4 gene; STM2;
KM      neurodegeneration; senile dementia; human chromosome 1;
KM      Voilga German kindred; VG; reverse transcription; PCR primer;
KM      polymerase chain reaction; Homo sapiens; diagnosis; detection;
KM      polymorphism; alternative splicing; ss.
XX
OS      Synthetic.
XX
PN      MO9703192-A2.
XX
XX      30-JAN-1997.
XX
```


PF 05-JUL-1996; 96WO-US011386.
XX
PR 07-JUL-1995; 95US-0000956P.
PR 28-JUL-1995; 95US-0001673P.
PR 11-AUG-1995; 95US-0002174P.
PR 14-AUG-1995; 95US-0002328P.
XX
PA (DARW-) DARWIN MOLECULAR CORP.
PA (VAME-) VA MEDICAL CENT.
PA (GEHO) GEN HOSPITAL CORP.
XX
PI Levy-Lahad E, Tanzi RE, Schellenberg GD, Wasco W, Bird TD;
PI Mulligan J, Galae DJ;
XX WPI; 1997-119048/11.
XX
PT New Alzheimer's disease related gene, AD4 - used to develop prode. for
PT detecting pre-disposition to or for diagnosis, prevention or treatment of
PT Alzheimer's disease.
XX
PS Example 9; Page 55; 83pp; English.
XX
CC A genetically isolated group of families with autosomal dominant early-
CC onset Alzheimer's Disease (AD) has been studied and initial mapping
CC analyses have predicted the AD4 locus (also known as STM2) resides on
CC chromosome 1. The group of families has been designated the Volga German
CC (VG) kindreds. The entire gene has been amplified from VG individuals and
CC unaffected individuals (from VG and unrelated lineages). Sequence
CC analysis has shown that affected individuals have a nucleotide change at
CC codon 141 resulting in an amino acid alteration from Asn to Ile. In a
CC study of the expression pattern of STM2, two alternative sequences were
CC identified which resulted from alternative splicing of exon 10. Both
CC transcripts were present in RT-PCR products from a lymphoblastoid cell
CC line using primers EX10JL and EX102R (see AAT85564 and AAT85565) from
CC exons 9 and 10, respectively. Both transcripts were also found in
CC leukocytes and skeletal muscle. One foetal brain library contained both
CC transcripts with the longer being the more abundant, while a second
CC library contained only the longer transcript. A foreskin fibroblast
CC library contained only the shorter transcript
XX
SQ Sequence 19 BP; 1 A; 10 C; 4 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1842 CCAAGCGAGAGCTTGAG 1860
DB 19 CCCAGCGAGAGCTTGAG 1
XX
RESULT 124
AAV43852
ID AAV43852 standard; DNA; 19 BP.
XX
AC AAV43852;
XX
DT 26-OCT-1998 (first entry)
XX
DE APC mutant gene evaluating primer 1.
XX
KM APC; human; colorectal cancer; CRC; missense mutation; Ashkenazi Jew;
XX PCR primer; ss.
XX
OS Synthetic.
XX Homo sapiens.
XX
PN MO9833940-A1.
XX
PD 06-AUG-1998.
XX
PF 21-JAN-1998; 98WO-US000961.
XX

PR 31-JAN-1997; 97US-00791883.
XX
PA (UXJO) UNIV JOHNS HOPKINS.
XX
PI Laken S, Gruber S, Petersen G, Kinzler K, Vogelstein B;
XX
DR WPI; 1998-437490/37.
XX
PT Detection of mutation in APC gene - comprising T to A transversion at
PT nucleotide 3920, useful for predicting predisposition to colorectal
PT cancer.
XX
PS Example 2; Page 8; 23pp; English.
XX
CC This primer is used for evaluating the stability of the (A)8 repeat
CC embodying the 1130K mutation of the APC gene by PCR amplification. This
CC is used for exemplifying the method of the invention of detecting a
CC mutation in APC gene. The method uses an allele-specific nucleic acid
CC probe which comprises a nucleic acid sequence of a region of a human
CC mutant APC or its ribonucleotide equivalent, where the region contains a
CC T to A transversion at nucleotide 3920. The method is used for
CC determining the presence in a proband of a mutation in APC which is
CC associated with a family history of colorectal cancer (CRC) especially
CC among Ashkenazi Jews
XX
SQ Sequence 19 BP; 5 A; 6 C; 3 G; 5 T; 0 U; 0 Other;
XX
Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1040 AGCTGACCTGCTCCATC 1058
DB 1 AGCTGACCTGCTCCATC 19
XX
RESULT 125
ABL89068
ID ABL89068 standard; DNA; 19 BP.
XX
AC ABL89068;
XX
DT 22-MAY-2002 (first entry)
XX
DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:290.
XX
KM Binding molecule; HIV-1; human immunodeficiency virus type 1;
XX reverse transcriptase; binding group; ss.
XX
OS Human immunodeficiency virus 1.
XX Synthetic.
XX
PN EP1174518-A1.
XX
PD 23-JAN-2002.
XX
PF 20-JUL-2000; 2000EP-00202611.
XX
PR 20-JUL-2000; 2000EP-00202611.
XX
PA (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
XX
PI Loukachov VV, Van Gemen B, Goudamit J;
XX
DR WPI; 2002-156696/21.
XX
PT Collection of binding groups for determining or typing samples,
PT especially clinical samples, has groups capable to identify essentially
PT all members of the family of nucleic acids of relatively high
PT significance.
XX
PS Disclosure; Page 77; 166pp; English.
XX

CC The present invention describes a collection of binding groups for a
CC family of nucleic acids comprising members of relative high and relative
CC low significance, where the binding groups are selected to be capable to
CC identify, alone or in combination, essentially all members of the family
CC of nucleic acids of relatively high significance. The collection of
CC binding groups is useful for typing of nucleic acid in a clinical sample,
CC by contacting the nucleic acid with the collection and determining
CC whether one or more binding groups bound to the nucleic acid of the
CC sample. This method is useful for determining whether the sample
CC comprises at least a part of a member of relatively high significance of
CC a family of nucleic acids. The collection of binding groups is useful for
CC diagnosing the severity of a disease caused by a pathogen containing a
CC member of a family of nucleic acids. ABL88779 to ABL89321 represent
CC oligonucleotide sequences used in the exemplification of the present
CC invention

XX SQ Sequence 19 BP; 12 A; 1 C; 3 G; 3 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 15.8; DB 1; Length 19;
XX Best Local Similarity 89.5%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1543 TAAGAGGAAAAAGTCAGT 1561
DB 1 TAAAAAGAAAAAGTCAGT 19

RESULT 126
ABL89073
ID ABL89073 standard; DNA; 19 BP.
XX ABL89073;
XX ABL89073;
XX 22-MAY-2002 (first entry)
XX
XX HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:295.
XX
XX Binding molecule; HIV-1; human immunodeficiency virus type 1;
XX reverse transcriptase; binding group; ss.
XX
XX Human immunodeficiency virus 1.
XX Synthetic.
XX
XX EPI174518-A1.
XX
XX 23-JAN-2002.
XX
XX 20-JUL-2000; 2000EP-00202611.
XX
XX 20-JUL-2000; 2000EP-00202611.
XX
XX 20-JUL-2000; 2000EP-00202611.
XX
XX (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
XX
XX Loukachov VV, Van Gemen B, Goudemits J;
XX
XX WPI; 2002-156696/21.
XX
XX Collection of binding groups for determining or typing samples,
XX especially clinical samples, has groups capable to identify essentially
XX all members of the family of nucleic acids of relatively high
XX significance.
XX
XX Disclosure; Page 78; 166pp; English.
XX
XX The present invention describes a collection of binding groups for a
XX family of nucleic acids comprising members of relative high and relative
XX low significance, where the binding groups are selected to be capable to
XX identify, alone or in combination, essentially all members of the family
XX of nucleic acids of relatively high significance. The collection of
XX binding groups is useful for typing of nucleic acid in a clinical sample,
XX by contacting the nucleic acid with the collection and determining
XX whether one or more binding groups bound to the nucleic acid of the
XX sample. This method is useful for determining whether the sample

CC comprises at least a part of a member of relatively high significance of
CC a family of nucleic acids. The collection of binding groups is useful for
CC diagnosing the severity of a disease caused by a pathogen containing a
CC member of a family of nucleic acids. ABL88779 to ABL89321 represent
CC oligonucleotide sequences used in the exemplification of the present
CC invention

XX SQ Sequence 19 BP; 12 A; 1 C; 3 G; 3 T; 0 U; 0 Other;

XX Query Match 0.7%; Score 15.8; DB 1; Length 19;
XX Best Local Similarity 89.5%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1543 TAAGAGGAAAAAGTCAGT 1561
DB 1 TAAAAAGAAAAAGTCAGT 19

RESULT 127
ACH66643/C
ID ACH66643 standard; DNA; 19 BP.
XX ACH66643;
XX ACH66643;
XX 06-NOV-2003 (first entry)
XX
XX Real-time PCR forward primer used to detect mouse CD40 expression.
XX
XX Mouse; ss; PCR; primer; real-time PCR; costimulatory molecule; CD40;
XX major histocompatibility complex; MHC; class II; antigen;
XX tumour; deacetylase inhibitor; DAI; tumourogenesis; immune system;
XX T lymphocyte; T cell activation; immunogenicity; antigen presentation;
XX cell lysis; trichostatin A; TSA; sodium butyrate; cyclostatic; CD40.
XX
XX Mus sp.
XX
XX US6518012-B1.
XX
XX 11-FEB-2003.
XX
XX 31-MAR-2000; 2000US-00540257.
XX
XX 02-APR-1999; 99US-0127591P.
XX
XX 29-JUL-1999; 99US-0146275P.
XX
XX (HEAL-) HEALTH RES INC.
XX
XX Tomasi TB;
XX
XX WPI; 2003-575859/54.
XX
XX Increasing expression of gene in tumor cells in vitro comprises
XX contacting tumor cells with deacetylase inhibitor.
XX
XX Example 1; Fig 9; 20pp; English.
XX
XX The invention discloses a method for increasing the expression of
XX costimulatory molecules, such as CD40, and major histocompatibility
XX complex (MHC) class I and class II antigens in tumour cells in vitro. The
XX method comprises contacting the tumour cells with deacetylase inhibitor
XX (DAI). Tumourogenesis is related, in part, to the failure of the immune
XX system to reject spontaneously arising tumours by responding
XX appropriately to tumour antigens. Induction of T lymphocytes is
XX considered to be a critical initial step and T cell activation requires
XX an antigen specific signal, which involves the antigenic peptide and the
XX MHC class I and II proteins. The increased expression of these molecules
XX increases the immunogenicity of tumours and their susceptibility to
XX lysis. The inhibitors of deacetylation, at low concentrations, produce
XX little or no apoptosis and maintain a normal cell cycle. The expression
XX of MHC genes, and other molecules of immunologic importance, in antigen
XX presentation and cell lysis is induced. The DAI are preferably
XX trichostatin A (TSA) or sodium butyrate. The sequence presented is a real
XX time PCR primer used to detect expression levels of the mouse CD40 gene

XX Sequence 19 BP; 1 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1999 GCAATGACACCTCGCAGG 2017
DB 19 GCAAGACACCATGACAGG 1
RESULT 128
AAV44694/C
ID AAV44694 standard; DNA; 20 BP.
XX AAV44694;
XX 09-OCT-1998 (first entry)
XX
XX V274T variant human alpha7 nAChR antisense sequence.
XX
XX Alpha7 nAChR; alpha7 nicotinic acetylcholine receptor subunit; cancer;
KW neurodegeneration; enzyme dysfunction; affective disorder; therapy;
KW immune dysfunction; diabetic neuropathy; Alzheimer's disease;
KW schizophrenia; ss.
XX
XX Synthetic.
OS Homo sapiens.
XX
XX WO9828331-A2.
XX
XX 02-JUL-1998.
XX
XX 22-DEC-1997; 97WO-US023405.
XX
XX 20-DEC-1996; 96US-00771737.
XX
XX (ABBO) ABBOTT LAB.
XX
XX Briggs CA, Gopalakrishnan M, McKenna DG, Monteggia LM, Roch J;
PI Sullivan JF, Touma E;
XX
XX MPI; 1998-37593/32.
XX
XX Nucleic acid encoding variant of human alpha 7 nicotinic acetylcholine
PT receptor sub-unit - used to identify modulators of the receptor,
PT potentially useful for treating neuro-degeneration, cancer etc.
XX
XX Example-7; Page 30; 44pp; English.
XX
XX This sequence is an antisense inhibitor of the DNA encoding the V247T
CC variant of human alpha7 nicotinic acetylcholine receptor (nAChR) subunit
CC of the invention. Cells containing the DNA are used to express the
CC protein and to identify modulators of alpha7 nAChR activity or
CC cytoprotective agents, e.g. antisense compounds or antagonists that are
CC potentially useful for treating neurodegeneration, enzyme dysfunction,
CC affective disorders and immune dysfunction, such as cancer, post-herpetic
CC neuralgia, diabetic neuropathy, osteoarthritis, Alzheimer's or
CC Parkinson's disease, kuru, psychosis and schizophrenia. Probes based on
CC the DNA are used to detect the DNA in usual hybridisation or
CC amplification tests, while monoclonal antibodies are used to detect the
CC protein for diagnosis (in vitro or by in situ immuno-fluorescent assay).
CC Compared with wild-type alpha7 nAChR, the protein has about 100-fold
CC greater sensitivity to cholinergic receptor agonists (nicotine or
CC acetylcholine) and response to these agonists decays more slowly, but the
CC wild-type inward rectification is retained
XX
XX Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 819 GGCACTTCGAATGCTG 837
DB 20 GGCAAGCTCGAATGCTG 2
RESULT 129
AAK38483
ID AAK38483 standard; DNA; 20 BP.
XX AAK38483;
XX 16-JUN-1999 (first entry)
XX
XX E. coli SecA antisense oligonucleotide 39.
XX
XX Microorganism inhibitor; antisense; nuclease resistant; treatment;
KW ribonucleotide reductase; secA gene; pathological condition; R1 subunit;
KW antimicrobial agent; crop protection; primer; R2 subunit; ss.
XX
XX Synthetic.
OS Escherichia coli.
XX
XX WO9902673-A2.
XX
XX 21-JAN-1999.
XX
XX 10-JUL-1998; 98WO-CA000666.
XX
XX 10-JUL-1997; 97US-0052160P.
XX
XX (GENE-) GENESENSE TECHNOLOGIES INC.
XX
XX Wright JA, Young AH, Dugourd D;
PI
DR MPI; 1999-120874/10.
XX
XX New oligonucleotides complementary to RR or SecA genes - useful to
PT inhibit growth of microorganisms.
PT
XX
XX Disclosure; Page 24; 103pp; English.
XX
XX This invention describes novel antisense oligonucleotides (AAK38301-
CC X38552) which are nuclease resistant, and comprises about 3-50
CC nucleotides complementary to the ribonucleotide reductase gene or the
CC secA gene of a microorganism. The antisense oligonucleotides are used to
CC treat mammalian pathological conditions mediated by microorganisms. The
CC oligonucleotides are particularly useful as antimicrobial agents in crop
CC protection
XX
XX Sequence 20 BP; 5 A; 8 C; 5 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 1345 AGCACAAGCCAGTTCGG 1363
DB 2 AGCACCAGACCACTTCGG 20
RESULT 130
AAA29835
ID AAA29835 standard; DNA; 20 BP.
XX AAA29835;
XX
XX 25-AUG-2000 (first entry)
XX
XX Human jun N-terminal kinase kinase-2 antisense oligonucleotide #20.
DE Human jun N-terminal kinase kinase-2; JNK-2; modulation; tumour;
KW Human; jun N-terminal kinase kinase-2; JNK-2; modulation; tumour;
KW antiinflammatory; cytosolic; antiinfectious; infection; inflammation;

```
KM detection; antisense therapy; phosphorothioate; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /note= "Phosphorothioate linkages"
XX
XX US6054440-A.
XX
XX 25-APR-2000.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Cowsett LM;
XX
XX WPI; 2000-338506/29.
XX
XX Antisense compound specifically hybridizing and inhibiting the expression
PT of human Jun N-terminal Kinase Kinase-2 is useful for treating infection,
PT inflammation and tumor.
XX
XX Claim 3; Col 40; 31pp; English.
XX
XX The present invention describes an antisense compound (I) of 8-30
CC nucleobases, specifically hybridizing to, and inhibiting expression of,
CC human Jun N-terminal Kinase Kinase-2 (JNK-2). Also described is a method
CC of inhibiting the expression of human JNK-2 in human cells or tissues,
CC comprising contacting the cells or tissues, with (I), in vitro. (I) has
CC antiinflammatory, cyostatic and antiinfectious activities. (I) is useful
CC for inhibiting the expression of JNK-2 in human cells or tissues and
CC prevents or delays infection, inflammation or tumour formation associated
CC with altered expression of JNK-2. (I) is also useful for detecting the
CC levels of JNK-2 in a sample. The present sequence represents a
CC phosphorothioate antisense oligonucleotide for human JNK-2, from the
CC present invention
XX
XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other:
SQ
XX
XX Query Match 0.7%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2043 TGCAGGAGGATGCCGCCA 2061
DB 1 TCCAGGAGGAGCGCCGCCA 19
XX
XX RESULT 131
XX ID AAA29834 standard; DNA; 20 BP.
XX
XX AAA29834;
XX
XX 25-AUG-2000 (first entry)
XX
XX Human Jun N-terminal Kinase Kinase-2 antisense oligonucleotide #19.
XX
XX Human; Jun N-terminal Kinase Kinase-2; JNK-2; modulation; tumour;
XX antiinflammatory; cyostatic; antiinfectious; infection; inflammation;
XX detection; antisense therapy; phosphorothioate; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /note= "Phosphorothioate linkages"
XX
XX
```

```
XX
XX US6054440-A.
XX
XX 25-APR-2000.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX 24-JUN-1999; 99US-00344001.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Cowsett LM;
XX
XX WPI; 2000-338506/29.
XX
XX Antisense compound specifically hybridizing and inhibiting the expression
PT of human Jun N-terminal Kinase Kinase-2 is useful for treating infection,
PT inflammation and tumor.
XX
XX Claim 3; Col 40; 31pp; English.
XX
XX The present invention describes an antisense compound (I) of 8-30
CC nucleobases, specifically hybridizing to, and inhibiting expression of,
CC human Jun N-terminal Kinase Kinase-2 (JNK-2). Also described is a method
CC of inhibiting the expression of human JNK-2 in human cells or tissues,
CC comprising contacting the cells or tissues, with (I), in vitro. (I) has
CC antiinflammatory, cyostatic and antiinfectious activities. (I) is useful
CC for inhibiting the expression of JNK-2 in human cells or tissues and
CC prevents or delays infection, inflammation or tumour formation associated
CC with altered expression of JNK-2. (I) is also useful for detecting the
CC levels of JNK-2 in a sample. The present sequence represents a
CC phosphorothioate antisense oligonucleotide for human JNK-2, from the
CC present invention
XX
XX Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other:
SQ
XX
XX Query Match 0.7%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2045 CAGGAGGATGCCGCCAC 2063
DB 1 CAGGAGGAGGAGCGCCGCATC 19
XX
XX RESULT 132
XX ID AB194517 standard; DNA; 20 BP.
XX
XX AB194517;
XX
XX 16-FEB-2002 (first entry)
XX
XX Capture oligonucleotide zip ID#1604 oligo #9.
XX
XX Human; K-ras; PCR primer; probe; capture probe; mutation detection;
XX ligase detection reaction; LDR; p53; BRCA1; BRCA2; infectious disease;
XX infection; 21 hydroxylase deficiency; Turner Syndrome; obesity; cancer;
XX oncogene; tumour suppressor; human papillomavirus; forensic;
XX environmental monitoring; food industry; feed industry; ss.
XX
XX Synthetic.
XX
XX WO200179548-A2.
XX
XX 25-OCT-2001.
XX
XX 04-APR-2001; 2001WO-US010958.
XX
XX 14-APR-2000; 2000US-0197271P.
XX
XX (CORR ) CORNELL RES FOUND INC.
XX
```

```
PI Barany F, Zivvi M, Gerry NP, Favis R, Kliman R;
XX WPI, 2002-034366/04.
XX
XX Designing capture oligonucleotide probes for use on a support to which
PT complementary oligonucleotides hybridize with little mismatch.
XX
XX Example 5, Fig 29; 300pp; English.
XX
XX The present invention describes a method (M1) for designing capture
CC oligonucleotide probes (I) for use on a support to which complementary
CC oligonucleotide probes (II) will hybridize with little mismatch, where
CC (I) have melting temperatures within a narrow range. The method is useful
CC for detecting infectious diseases caused by bacterial infectious agents
CC e.g. Salmonella, listeria monocytogenes and Haemophilus influenza, fungal
CC infectious agents e.g. Cryptococcus neoformans, Candida albicans and
CC Aspergillus fumigatus, viruses e.g. T-cell lymphocytophils virus,
CC Epstein-Barr virus and polio virus, and parasitic infectious agents
CC selected from Onchocerca volvulus, Brugia malayi, Leishmania and Dracunculus
CC medicines. The method is also useful for detecting genetic diseases such
CC as 21 hydroxylase deficiency, Turner Syndrome and obesity defects.
CC Detecting cancer involving oncogenes, tumour suppressor genes, or genes
CC involved in DNA amplification, replication, recombination or repair, the
CC cancer is specifically associated with a gene selected from BRCA1 gene,
CC p53 gene, human papillomavirus types 16 and 18 and liver cancers. The
CC method is also used for environmental monitoring, forensics and the food
CC and feed industry, detecting comprises scanning (using e.g. a scanning
CC electron microscope and infrared microscope) the support at the
CC particular sites and identifying if ligation of the oligonucleotide probe
CC sets occurred and correlating (using a computer) identified ligation to a
CC presence or absence of the target nucleotide sequences. AB182074 to
CC AB197546 represent oligonucleotide sequences used in the exemplification
CC of the present invention
XX
XX Sequence 20 BP; 5 A; 8 C; 3 G; 4 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1113 TGGGGCCGATGCTGCAGA 1131
DB 19 TGGGGCTGATTGCTCCAGA 1
RESULT 133
ADA44714
ID ADA44714 standard; DNA; 20 BP.
XX
XX ADA44714;
AC
XX
XX 20-NOV-2003 (first entry)
DT
XX
XX Antisense oligonucleotide #ISIS 115386 #SEQ ID 12.
DE
XX
XX Antisense oligonucleotide; cytosstatic; immunosuppressive;
KW antiinflammatory; gene therapy; hyperproliferative disorder; cancer;
KW autoimmune; inflammatory disorder; inhibitor-kappa B kinase-gamma; ss;
KW human.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate linkages, all cytosines are 5-
FT methylycytosine"
FT 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT 16..20
FT modified_base
```

```
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
XX WO2003031576-A2.
XX
XX 17-APR-2003.
XX
XX 03-OCT-2002; 2002WO-US031809.
XX
XX 06-OCT-2001; 2001US-00972607.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Wyatt JR;
XX WPI; 2003-457242/3.
XX
XX New compound having sequence targeted to nucleic acid encoding inhibitor-
PT kappa B kinase-gamma, useful for preparing composition for treating e.g.,
PT cancer, or inflammatory or autoimmune disorder.
XX
XX Example 15; Page 76; 106pp; English.
XX
XX The invention relates to an antisense compound that is targeted to a
CC nucleic acid encoding inhibitor-kappa B kinase-gamma, specifically
CC hybridizing to the nucleic acid encoding inhibitor-kappa B kinase-gamma
CC and inhibiting its expression. Compounds of the invention are antisense
CC oligonucleotides comprising at least one modified internucleoside
CC linkage, which is a phosphorothioate linkage, at least one modified sugar
CC moiety, which is a 2'-O-methoxyethyl sugar moiety, or at least one
CC modified nucleobase, which is a 5-methylcytosine. Preferably, the
CC antisense oligonucleotide is a chimeric oligonucleotide. The compound of
CC the invention is useful for preparing a composition for treating a
CC hyperproliferative disorder e.g., cancer, or an autoimmune or
CC inflammatory disorder. The methods are useful for inhibiting the
CC expression of inhibitor-kappa B kinase-gamma in cells or tissues, and
CC treating an animal having a disease or condition associated with
CC inhibitor-kappa B kinase-gamma. Sequences given in ADA44713-ADA44790
CC represent antisense oligonucleotides for the inhibition of human
CC inhibitor-kappa B kinase-gamma mRNA levels.
XX
XX Sequence 20 BP; 2 A; 8 C; 3 G; 7 T; 0 U; 0 Other;
SQ
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2278 CCTCACTTCTCTGCGCTT 2296
DB 1 CCTCACTTCTCTGCGCTT 19
RESULT 134
ABT44412
ID ABT44412 standard; DNA; 20 BP.
XX
XX ABT44412;
AC
XX
XX 06-NOV-2003 (first entry)
DT
XX
XX Chimeric antisense oligonucleotide ISIS 192387 to inhibit human ESRB.
DE
XX
XX Oestrogen receptor beta; ESRB; steroid hormone; female sexual maturation;
KW bone maintenance; cardiovascular system; ER beta; oestrogen receptor 2;
KW ESR2; Alzheimer's; uterine leiomyomata; cytosstatic; kidney neoplasm; ss;
KW cellular proliferation; cancer; human; antisense; chimeric.
XX
XX Chimeric - Homo sapiens.
OS
XX
XX WO2003050133-A1.
XX
XX 19-JUN-2003.
XX
```

```
XX 06-DEC-2002; 2002WO-US039200.
XX
XX 07-DEC-2001; 2001US-00005058.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Double KW, Roach MP, Koller E;
XX WPI; 2003-577284/54.
XX
XX New antisense oligonucleotides for modulating estrogen receptor beta gene
XX expression, particularly useful for treating cancers, specifically
XX leiomyoma, pancreatic cancer, prostate cancer, breast cancer, bone cancer
XX or lymphoma.
XX
XX Claim 3; Page 81; 160pp; English.
XX
XX This invention relates to a novel antisense compounds that modulate the
XX expression of oestrogen receptor beta (ERSB). Oestrogen is a steroid
XX hormone that exerts a wide range of effects throughout the human body
XX being primarily involved in female sexual maturation. Additionally,
XX however, oestrogen targets male reproductive tissues, is known to be
XX important in bone maintenance and plays a protective role in the
XX cardiovascular system. This hormone receptor, ERSB (also known as ER
XX beta, oestrogen receptor 2 and ERS2) has been mapped to chromosome 14q22-
XX q24, a region known to be associated with early onset of Alzheimer's
XX disease, uterine leiomyoma and neoplasms of the kidney. Furthermore,
XX ERSB has been localised to metastatic cells indicating an involvement in
XX cellular proliferation. Accordingly, the selective inhibition of ERSB by
XX the cytostatic antisense oligonucleotides of this invention could provide
XX a therapeutic target for the treatment of cancer, as well as other ERSB-
XX related disorders. This oligonucleotide sequence is the chimeric human
XX antisense oligo used to inhibit expression of human ERSB, the aim of the
XX invention. Note that it has two terminal five nucleotide 2'-methoxyethyl
XX (2'-MOE) wings separated by a ten deoxynucleotide gap. The
XX oligonucleotide backbone is phosphorothioate throughout
XX
XX Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1316 CATGAGGCCCTGTGAG 1334
XX ||||| |||||
XX 1 CATGAGGCCCTGTGAG 19
XX
XX RESULT 135
XX ADN61692
XX ID ADN61692 standard; DNA; 20 BP.
XX
XX AC ADN61692;
XX
XX DT 01-JUN-2004 (first entry)
XX
XX DE Corn chromosome 6 SSR marker nc009.6.03 PCR primer 2 SEQ ID:22.
XX
XX KW Corn; plant; transformable; introgression; chromosomal locus;
XX bin 6.02-6.04; bin 10.04-10.06; bin 1.03-1.06; bin 1.08-1.11;
XX bin 3.05-3.07; corn seed; plant breeding; transgenic plant; chromosome 6;
XX SSR marker; marker assisted breeding; PCR; primer; ss.
XX
XX Zea mays.
XX
XX OS
XX
XX PN WO2003103377-A2.
XX
XX PD 18-DEC-2003.
XX
XX PF 05-JUN-2003; 2003WO-US017626.
XX
XX PR 06-JUN-2002; 2002US-0386522P.
XX
```

```
XX (MONS ) MONSANTO TECHNOLOGY LLC.
XX
XX Lowe BA, Chomet P;
XX
XX WPI; 2004-062179/06.
XX
XX Producing a transformable corn line comprises introgressing at least one
XX chromosomal locus mapping to bin 6.02-6.04 or 10.04-10.06, where the
XX locus is introgressed from a more transformable corn line into a less
XX transformable corn line.
XX
XX Example 3; SEQ ID NO 22; 77bp; English.
XX
XX The invention relates to a method of producing a transformable corn line
XX by introgressing at least one chromosomal locus mapping to bin 6.02-6.04
XX or bin 10.04-10.06, where the locus is introgressed from a more
XX transformable corn line into a less transformable corn line. The
XX invention also relates to corn variety 178-187-20 seed (ATCC accession
XX no. PTA-5183) and corn variety 178-74-25 seed (ATCC accession no. PTA-
XX 5182); progeny of a plant grown from the seed cited above, where the
XX progeny comprises loci mapping to chromosomal bins 1.03-1.06, 1.08-1.11,
XX 3.05-3.07, and 6.02-6.04; a transgenic corn plant produced by
XX transforming the progeny cited above; and hybrid corn seed and plants
XX produced by crossing a corn line with the progeny cited above. Because
XX more transformable lines are typically agronomically poor, while lines
XX with superior or desired agronomic traits tend to be less transformable,
XX the methods of the invention provide a means of testing for the effects
XX of an introduced gene on traits such as yield, kernel quality and plant
XX phenotype in earlier plant generations in a breeding programme. Sequences
XX ADN61671-ADN61702 represent PCR primers used in an example of the
XX invention to amplify corn SSR markers useful in marker assisted breeding.
XX
XX SQ Sequence 20 BP; 1 A; 11 C; 0 G; 8 T; 0 U; 0 Other;
XX
XX Query Match 0.7%; Score 15.8; DB 1; Length 20;
XX Best Local Similarity 89.5%; Pred. No. 1.2e+02;
XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1641 CCTCTCTTCTCCCTCTCT 1659
XX ||||| |||||
XX 1 CCTCTCTTCTCCCTCTCT 19
XX
XX RESULT 136
XX ADT00517
XX ID ADT00517 standard; DNA; 20 BP.
XX
XX AC ADT00517;
XX
XX DT 16-DEC-2004 (first entry)
XX
XX DE Novel mutant protein tyrosine kinase-related oligonucleotide SeqID505.
XX
XX KW tyrosine kinase; cancer; anti-cancer agent; signalling molecule;
XX tumorigenesis; somatic alteration; colorectal cancer; NTRK3; FES;
XX GUCY2F; MCKK; MLK4; kinase domain; cytoskeletal; tyrosine kinase inhibitor;
XX guanlylate cyclase stimulator; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO2004082458-A2.
XX
XX PD 30-SEP-2004.
XX
XX PF 18-FEB-2004; 2004WO-US004452.
XX
XX PR 21-FEB-2003; 2003US-0448537P.
XX
XX PR 29-MAY-2003; 2003US-0473895P.
XX
XX (UJJO ) UNIV JOHNS HOPKINS.
XX
XX Bardeili A, Parsons W, Velculescu V, Kinzler KW, Vogelstein B;
XX
```

```
XX DR WPI; 2004-718702/70.
XX XX
PT Activated mutant protein tyrosine kinases (e.g. NTRK3, FES and MCKK) and
PT associated methods for diagnosing cancer and screening for anti-cancer
PT agents.
XX XX
PS Disclosure; SEQ ID NO 505; 363pp; English.
XX XX
CC This invention relates to a novel activated mutant protein tyrosine
CC kinases and associated methods for diagnosing cancer and screening for
CC anti-cancer agents. Protein kinases are signalling molecules involved in
CC tumorigenesis. Mutational analysis of the human tyrosine kinase gene
CC family identified somatic alterations sin 1 in 5 colorectal cancers, with
CC the majority of mutations occurring in the NTRK3, FES, GUCY2F and
CC MCKK/MLK4 genes. Most were identified in the kinase domain. The invention
CC may be useful for the production of compounds with a cytostatic activity
CC acting as protein tyrosine kinase inhibitors or guanylate cyclase
CC stimulators. The invention may be useful for developing methods for
CC detecting mutations involved in cancer or screening for anti-cancer
CC agents. The present sequence is that of a human-derived oligonucleotide
CC which is related to the invention.
XX XX
SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;
XX XX
Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 1.2e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX XX
QY 221 GGCTCAGCATGAGACC 239
    |||||
Db 2 GGCTGAGCATTAAGACC 20
    |||||
RESULT 137
AA292695/c
ID AA292695 standard; DNA; 21 BP.
XX XX
AC AA292695;
XX XX
DT 05-JUN-2000 (first entry)
XX XX
DE Human CCR-2 promoter SNP (position 41768) constant PCR primer.
XX XX
KM CCR2; C-C chemokine receptor-2; human; promoter; SNP;
KM single nucleotide polymorphism; detection; diagnostic;
KM disease susceptibility; cardiovascular disease; inflammatory disease;
KM rheumatoid arthritis; PCR primer; ss.
XX XX
OS Homo sapiens.
XX XX
PN WO200006769-A2.
XX XX
PD 10-FEB-2000.
XX XX
PF 20-JUL-1999; 99WO-GB002341.
XX XX
PR 25-JUL-1998; 98GB-00016193.
XX XX
PR 28-JAN-1999; 99GB-00001844.
XX XX
PA (ZENE ) ZENECA LTD.
XX XX
PI Smith JC, Anand R, Morten JEN;
XX XX
DR WPI; 2000-205470/18.
XX XX
PT diagnosing chemokine receptor allele-2 polymorphisms for diagnosing
PT rheumatoid arthritis and cardiovascular disease comprises determining the
PT sequence of the allele or its promoter at specified positions.
XX XX
PS Example 2; Page 24; 35pp; English.
XX XX
CC The invention relates to a novel method of diagnosing a single nucleotide
```

```
CC polymorphism (SNP) in the human C-C chemokine receptor-2 gene (CCR-2).
CC The method of the invention comprises determining the nucleic acid
CC sequence at at least 1 of 13 specific positions in the coding region of
CC the CCR-2 gene and/or its promoter sequence. In the coding region of the
CC CCR-2 gene (EMBL U80924) polymorphisms at positions 2385 and 2649 are
CC detected, while in the CCR-2 promoter sequence (EMBL U95626) the
CC polymorphisms that can be detected are at positions 40915, 41047, 41058,
CC 41507, 41768, 42401, 42598, 42673, 42874 and 43018. The invention
CC also relates to allele-specific primers and probes for detecting these
CC SNPs, diagnostic kits comprising the diagnostic primers and probes, and
CC methods of treating a patient by administering a CCR-2 ligand antagonist
CC drug after diagnosing a SNP in the CCR-2 gene. The method is useful for
CC diagnosing SNPs in the CCR-2 gene and is therefore useful in assessing
CC the predisposition and/or susceptibility of an individual to conditions
CC such as rheumatoid arthritis and cardiovascular diseases which are
CC mediated by CCR-2 ligands. CCR-2 ligand antagonist drugs are useful for
CC treating CCR-2 ligand mediated diseases in humans such as rheumatoid
CC arthritis and other inflammatory diseases. The SNP identification method
CC is also useful for assessing the efficacy of therapeutic compounds in the
CC treatment of CCR-2 ligand mediator diseases and developing new drugs
CC therapies targeting allelic variants of the CCR-2 gene. Computer readable
CC mediums comprising polymorphism-containing nucleic acids are useful in
CC homology searching, mapping, haplotyping, genotyping, pharmacogenetic
CC analysis and other bioinformatic analysis. Polymorphism-containing
CC nucleic acids are useful in characterising individuals in terms of
CC haplotype and other sub-groupings; this information may be used to
CC determine the patient's susceptibility to treatment with particular
CC drugs. SNPs of the CCR-2 gene are useful as genetic markers in linkage
CC studies. Processes such as characterising individuals in terms of
CC haplotype and other sub-groupings are made easier by storing the sequence
CC information in a computer readable medium. Sequences 292694-292695
CC represent a set of PCR primers for detecting an SNP (A to T mutation) at
CC position 41768 of the CCR-2 promoter (EMBL U95626). Primer 292694 is the
CC diagnostic allele-specific primer, while primer 292695 is a constant
CC primer
XX XX
SQ Sequence 21 BP; 7 A; 6 C; 6 G; 2 T; 0 U; 0 Other;
XX XX
Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 1.1e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX XX
QY 1208 GCTGGGCGCTACTCCAG 1226
    |||||
Db 20 GCTGTGCTCTCTCCAG 2
    |||||
RESULT 138
AAF95623/c
ID AAF95623 standard; DNA; 21 BP.
XX XX
AC AAF95623;
XX XX
DT 18-NOV-2004 (revised)
XX XX
DT 06-JUN-2001 (first entry)
XX XX
DE Human gene single nucleotide polymorphism #384.
XX XX
KM Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KM polymorphism; vascular disease; coronary artery disease; forensics;
KM myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KM pulmonary embolism; paternity test; ds.
XX XX
OS Homo sapiens.
XX XX
OS Unidentified.
XX XX
FH Key location/Qualifiers
FT variation 11
FT /tag= a
FT /standard_name= "single nucleotide polymorphism"
XX XX
PN WO200118250-A2.
XX XX
```

PD 15-MAR-2001.
 XX
 PF 07-SEP-2000; 2000MO-US024503.
 XX
 PR 10-SEP-1999; 99US-0153357P.
 XX 26-JUL-2000; 2000US-0220947P.
 PR 16-AUG-2000; 2000US-0225724P.
 XX
 PA (MHED) WHITEHEAD INST BIOMEDICAL RES.
 PA (MILL-) MILENNIUM PHARM INC.
 XX
 PI Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, McCarthy JU;
 XX
 DR WPI; 2001-226749/23.
 XX
 PT Nucleic acids comprising single nucleotide polymorphisms, useful in
 PT applications such as forensics, paternity testing, medicine, genetic
 PT analysis and phenotype correlations to diseases such as diabetes and
 PT atherosclerosis.
 XX
 PS Example; Page 75; 242pp; English.
 XX
 CC The present invention provides a method of diagnosing a vascular disease
 CC in an individual, involving determining the sequence at various
 CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
 CC genes. The sequences at a number of polymorphic sites are also provided
 CC in the specification. In particular, the method can be used in the
 CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
 CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
 CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
 CC useful in forensics, paternity testing, genetic analysis and phenotype
 CC correlations to diseases. The present sequence is an example of one of
 CC the human gene SNPs shown in the specification
 CC
 CC Revised record issued on 18-NOV-2004 : The variation feature was
 CC incorrectly given a capital V
 CC
 SQ Sequence 21 BP; 5 A; 5 C; 9 G; 2 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 15.8; DB 1; Length 21;
 XX Best Local Similarity 89.5%; Pred. No. 1.1e+02;
 XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 1187 CTTCTCTCCGACACCTGG 1205
 Db |||||
 19 CTTCTCTCGGGACCTGG 1
 RESULT 139
 AAS07302/C
 ID AAS07302 standard; DNA; 21 BP.
 XX
 AC AAS07302;
 XX
 DT 12-SEP-2001 (first entry)
 XX
 DE CPS1/TES1 genomic DNA sequencing primer FPS.
 XX
 XX CPS1; peptide synthetase; peptide toxin; fungal pathogen;
 KW corn crop infection; ss; sequencing primer; FPS.
 KW
 XX Cochliobolus heterostrophus.
 OS
 PN WO200138489-A2.
 XX
 PD 31-MAY-2001.
 XX
 PF 22-NOV-2000; 2000WO-US032227.
 XX
 PR 23-NOV-1999; 99US-00448215.
 XX
 PA (CORR) CORNELL RES FOUND INC.
 XX

PI Yoder OC, Turgeon BC, Lu S;
 XX
 DR WPI; 2001-367672/38.
 XX
 PT New isolated nucleic acid molecule from a plant pathogen useful in
 PT preventing plant pathogenic infections.
 XX
 PS Example 1; Page 54; 132pp; English.
 XX
 CC The sequence represents a sequencing primer used to sequence a genomic
 CC clone from Cochliobolus heterostrophus which contains the CPS1 and TES1
 CC peptide synthetase genes. CPS1 is an enzyme thought to be involved in the
 CC production of peptide toxins, which are involved in the pathogenic
 CC infection of corn crops. The nucleic acids and proteins can be used as
 CC targets for anti-fungal compounds to prevent fungal corn infection and
 CC the nucleic acids can be used in gene therapy to alter the biosynthetic
 CC pathway for the peptide toxins to lower the pathogenicity of the fungi
 CC
 XX
 SQ Sequence 21 BP; 7 A; 4 C; 6 G; 4 T; 0 U; 0 Other;
 XX
 XX Query Match 0.7%; Score 15.8; DB 1; Length 21;
 XX Best Local Similarity 89.5%; Pred. No. 1.1e+02;
 XX Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 510 ATATCTGCACCTGATGCT 528
 Db |||||
 20 ATGTTCTGCACCTGATGCT 2
 RESULT 140
 ABS68426/C
 ID ABS68426 standard; DNA; 21 BP.
 XX
 AC ABS68426;
 XX
 DT 19-NOV-2002 (first entry)
 XX
 DE Sequencing primer #17 for fungal DNA flanking REM1 insertion site.
 XX
 XX Fungal pathogen; peptide synthetase gene cluster; iron reductase;
 KW permease; major facilitator superfamily transporter; MFS transporter;
 KW anti-fungal agent; fungicide; pathogenic fungi; plant pathogen; CPS1;
 KW animal pathogen; fungal infection; wild grass; cereal; corn; mycoides;
 KW leaf spot maize; immunocompromised vertebrate; pneumonia; arthritis;
 KW military disease; bone infection; joint infection; skin disease;
 KW aesophagitis; vaginitis; onychomycosis; inflammation; urinary tract;
 KW kidney; liver; brain; gastrointestinal tract; lung; fungicidal;
 KW mycoides; antiarthritic; antiinflammatory; dermatological; CoA ligase;
 KW sequencing; primer; ss.
 KW
 XX Cochliobolus heterostrophus.
 OS
 OS Synthetic.
 XX
 PN WO200242444-A2.
 XX
 PD 30-MAY-2002.
 XX
 PF 21-NOV-2001; 2001WO-US043381.
 XX
 PR 22-NOV-2000; 2000US-0252649P.
 XX
 PR 22-NOV-2000; 2000US-0252732P.
 XX
 XX (SYGN) SYNGENTA PARTICIPATIONS AG.
 PA (CORR) CORNELL RES FOUND INC.
 PA (YODE/) YODER O.
 PA (TURG/) TURGEON B G.
 PA (LUS/) LU S.
 XX
 PI Yoder O, Turgeon BG, Lu S;
 XX
 DR WPI; 2002-666824/71.
 XX
 PT Nucleic acid molecules comprising fungal, e.g. Cochliobolus

XX		26-MAY-2000; 2000US-0207456P.
PR	21-SEP-2000; 2000US-0234687P.	
PR	27-SEP-2000; 2000US-0236359P.	
PR	04-OCT-2000; 2000GB-00024263.	
PR	30-JAN-2001; 2001MO-US000661.	
PR	30-JAN-2001; 2001MO-US000662.	
PR	30-JAN-2001; 2001MO-US000663.	
PR	30-JAN-2001; 2001MO-US000664.	
PR	30-JAN-2001; 2001MO-US000665.	
PR	30-JAN-2001; 2001MO-US000666.	
PR	30-JAN-2001; 2001MO-US000667.	
PR	30-JAN-2001; 2001MO-US000668.	
PR	30-JAN-2001; 2001MO-US000669.	
PR	30-FEB-2001; 2001MO-US000670.	
PR	05-FEB-2001; 2001US-0266860P.	
XX		(AECOM-) AECOMICA INC.
PA		
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME,	
XX		
XX	WPI; 2002-179446/23.	
DR		
PT	New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,	
PT	or as specific biomolecule capture probes for surface-enhanced laser	
PT	desorption ionization, comprises human myosin-like protein hGDMLP-1.	
PS		
XX	Disclosure; SEQ ID NO 2842; 214bp; English.	
XX		
CC	The present invention describes a human genome-derived myosin-like	
CC	protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-	
CC	1 can be used in gene therapy and vaccine production. The hGDMLP-1	
CC	nucleic acids can be used as probes to detect, characterise and quantify	
CC	hGDMLP-1 nucleic acids in samples, as amplification substrates, to	
CC	provide initial substrates for the recombinant engineering of hGDMLP-1	
CC	protein variants having desired phenotypic improvements, and for	
CC	expressing the proteins. The hGDMLP-1 proteins or polypeptides may be	
CC	used as immunogens to raise antibodies that specifically recognise hGDMLP	
CC	-1 proteins, as standards in assays used to determine the concentration	
CC	and/or amount specifically of hGDMLP proteins, as specific biomolecule	
CC	capture probes for surface-enhanced laser desorption/ionisation, as	
CC	therapeutic supplement in patients having specific deficiency in hGDMLP-1	
CC	production, and in vaccines or for replacement therapy. The	
CC	polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a	
CC	disorder associated with the expression of hGDMLP-1, in particular heart	
CC	and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.	
CC	The present sequence represents an oligomer used in the screening of the	
CC	hGDMLP-1 sequence in the exemplification of the present invention. N.B.	
CC	The sequence data for this patent did not form part of the printed	
CC	specification, but was obtained in electronic format directly from WIPO	
CC	at ftp.wipo.int/pub/published_pct_sequence	
XX		
SQ	Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;	
QY	Query Match	0.6%; Score 15.4; DB 1; Length 17;
Db	Best Local Similarity 94.1%; Pred.No.1.5e-02;	
	Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
QY	1974 GGCGTCGAGATGACGA 1990	
	1 GGCGTCGAGATGACGA 17	
RESULT 143		
ID	ABK18894	
XX	ABK18894 standard; RNA; 17 BP.	
AC	ABK18894;	
DT	09-APR-2002 (first entry)	
XX		
DE	Human ERG DNAzyme target sequence Seq ID No 1541.	

KM		Human; hammerhead ribozyme; cytosolic; antitumor; antidiabetic;
KM		ophthalmological; antiarthritis; antisporadic; virucide; osteopathic;
KW		vulnerary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
KW		tumour angiogenesis; diabetic retinopathy; macular degeneration;
KW		neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
KW		angioidiforma of tubercous sclerosis; port-wine stain; wound healing;
KW		Sturge Weber syndrome; Kippel-Trennaway-Weber syndrome; leukaemia; ss;
KM		Oeler-Weber-rendu syndrome, leukaemia, osteoporosis; DNAzyme; inozyme;
XX		ambrzyme.
OS	Homo sapiens.	
PN	WO200186124-A2.	
PD	22-NOV-2001.	
PX	16-MAY-2001; 2001WO-USO15866.	
PX	16-MAY-2000; 2000US-00572021.	
PA	(RIBO-) RIBOZYME PHARM INC. (GLAX) GLAXO GROUP LTD.	
PI	Jarvis T, Von Carlowitz I, Mewiggen JA, McLaughlin F, Randi AM; MPI; 2002-082995/11.	
PT	Novel polynucleotide which down regulates expression of Ets-related gene, useful for treating cancer, diabetic retinopathy, macular degeneration, psoriasis, psoriasis, verruca vulgaris and Sturge Weber syndrome.	
PS	Claim 4; Page 94; 149pp; English.	
CC	The invention relates to a nucleic acid molecule (I) which down regulates expression of an Ets-related gene (ERG). (I) is useful for treating conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma, tumour angiogenesis, diabetic retinopathy, macular degeneration, neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca vulgaris, angioidiforma of tuberous sclerosis, port-wine stains, Sturge Weber syndrome, Kippel-Trennaway-Weber syndrome, Oeler-Weber-rendu syndrome, leukaemia, osteoporosis and wound healing. (II) is useful for treating a patient having a condition associated with the level of ERG, by contacting cells of the patient with (I) under conditions suitable for the treatment. The method comprises the use of one or more therapies under conditions suitable for the treatment. Leukemia or tumour angiogenesis is treated by administering (I) to the patient in conjunction with one or more of other therapies such as radiation or chemotherapy treatment. (I) is useful for reducing ERG activity in a cell, by contacting the cell with (I). (I) is useful for cleaving RNA of ERG gene, by contacting (I) with RNA, in the presence of a divalent cation such as Mg ²⁺ . (I) is useful for diagnosis of conditions and diseases related to the expression of ERG, and as diagnostic tool to examine genetic drift and mutations within diseased cells or to detect the presence of ERG RNA in a cell. (I) is useful for specifically targeting genes that share homology with ERG gene or ERG fusion genes. ABRL17344-BKX22719 represent nuclic acids, including antisense and enzymatic nucleic acid molecules which regulate expression of ERG, and related PCR primers of the invention	
SQ	Sequence 17 BP, 9 A; 1 C; 4 G; 0 T; 3 U; 0 Other;	
Query Match	0.6%; Score 15.4; DB 1; Length 17;	
Best Local Similarity	76.5%; Pred.No.1.5e+02;	
Matches 13; Conservative 3; Mismatches 1; Indels 0; Gaps 0;		
Dy	1072 AGAATGAAGTGTAACAG 1088	
Db	1 AGAAUCAAUAUACAAG 17	
RESULT 144		
ID	ADB00305	
ID	ADB00305 standard; DNA; 17 BP.	

```

XX AC ADB00305;
XX XX
XX 20-NOV-2003 (first entry)
XX DT
XX DE Human MD23 scanning oligonucleotide SEQ ID 1291.
XX
XX KW Cytostatic; immunostimulant; gene therapy; vaccine; human;
XX KM zinc finger protein; MD23; MD24; MD27; chromosome 7q22.1;
XX KW chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;
XX KM developmental disorder; ss.
XX
XX OS Homo sapiens.
XX
XX PN EPI281758-A2.
XX
XX PD 05-FEB-2003.
XX
XX PF 30-JUL-2002; 2002EP-00016874.
XX
XX PR 02-AUG-2001; 2001US-00922181.
XX
XX PA (ABOM-) ABOMICA INC.
XX
XX PI Shannon M, Gu Y, Nguyen C;
XX
XX DR WPI; 2003-423107/40.
XX
XX PT New zinc finger-containing proteins and nucleic acids, useful in
XX PT manufacturing a medicament for treating or preventing a disorder
XX PT associated with decreased or increased expression or activity of MD23,
XX PT MD24, MD27 or MD212, e.g. cancer.
XX
XX PS Example 8; SEQ ID NO 1291; 103bp; English.
XX
XX CC The present invention relates to novel human zinc finger-containing
XX CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is
XX CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,
XX CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome
XX CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,
XX CC or in manufacturing a medicament for treating or preventing a disorder,
XX CC associated with decreased or increased expression or activity of MD23,
XX CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic
XX CC acids and proteins are also useful for diagnosing or monitoring a disease
XX CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic
XX CC acids can also be used as probes to detect and characterize gross
XX CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are
XX CC useful in constructing microarrays for measuring gene expression. The
XX CC proteins are useful as therapeutic agents for gene therapy or as
XX CC vaccines. The present sequence was used to illustrate the invention.
XX
XX SQ Sequence 17 BP; 5 A; 2 C; 6 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 1.5e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 841 TGAGGAGTACTGATG 857
XX DB 1 TGAGAGAGTACTGATG 17
XX
XX RESULT 145
XX ID AB259890 standard; RNA; 17 BP.
XX
XX AC AB259890;
XX
XX XX
XX DT 21-MAR-2003 (first entry)
XX
XX DE Human K-Ras DNAzyme substrate #2.
XX
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;

```

```

KW KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosolic; anti-HIV;
KW KM anti-rheumatic; cancer; AIDS; ss.
XX KM
XX OS Homo sapiens.
XX
XX PN WO200297114-A2.
XX
XX PD 05-DEC-2002.
XX
XX PF 29-MAY-2002; 2002WO-US016840.
XX
XX PR 29-MAY-2001; 2001US-0294140P.
XX PR 06-JUN-2001; 2001US-0296249P.
XX PR 10-SEP-2001; 2001US-0318471P.
XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX
XX PI Mcswiggen J;
XX
XX DR WPI; 2003-140484/13.
XX
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.
XX
XX PS Claim 58; Page 85; 185bp; English.
XX
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytosolic, anti-HIV, and anti-
XX CC rheumatic activity. The nucleic acid molecules are useful for reducing
XX CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are
XX CC also useful for treating breast, ovarian, colorectal, lung, prostate,
XX CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences
XX CC shown in AB259889 - AB262216, AB264544 - AB265531, AB266520 - AB266524,
XX CC AB266530 - AB266585 represent substrate/target sequences for the human
XX CC ribozymes of the invention
XX
XX SQ Sequence 17 BP; 1 A; 6 C; 10 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.6%; Score 15.4; DB 1; Length 17;
XX Best Local Similarity 94.1%; Pred. No. 1.5e+02;
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 16 CGCCGCGGCTGCGGCT 32
XX DB 17 CGCCGCGGCTGCGGCT 1
XX
XX RESULT 146
XX ID ADF63855 standard; DNA; 17 BP.
XX
XX AC ADF63855;
XX
XX XX
XX DT 12-FEB-2004 (first entry)
XX
XX DE Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1759.
XX
XX KW chromatin organization modifier; CHROMO domain; cytosolic; PCCP1;
XX KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;
XX KW human; ss; probe.
XX
XX OS Homo sapiens.
XX
XX PN WO2003050284-A1.
XX
XX PD 19-JUN-2003.
XX
XX PF 22-NOV-2002; 2002WO-US037506.
XX

```


XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX
PS Disclosure; SEQ ID NO 2021; 0pp; English.
XX
CC The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMRP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMRP-1, or as an inhibitor of hGDMRP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMRP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63102
XX
SO Sequence 17 BP; 1 A; 7 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 731 CCTGGTGCTCTTCTGCA 747
DB 1 CCTGGTGCTCTTCTGCA 17
RESULT 149
ACN65940
ID ACN65940 standard; DNA; 17 BP.
XX
XX ACN65940;
AC
XX
DT 02-DEC-2004 (first entry)
XX
DE Human GDMRP-1 probe SEQ ID NO:2842.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMRP-1;
KM hGDMRP-1 agonist hGDMRP antagonist; hGDMRP inhibitor; heart disorder;
KM skeletal muscle function.
XX
XX Homo sapiens.
OS
XX
XX US2004137589-A1.
PN
XX
PD 15-JUL-2004.
XX
XX
PF 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0266860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX
XX (GVYV/) GU Y.
PA (JIVV/) JI Y.
PA (PENN/) PENN S G.

PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX
PT Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX
PS Disclosure; SEQ ID NO 2842; 0pp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMRP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 95% deviation from (S1) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMRP-1, or as an inhibitor of hGDMRP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMRP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63102
XX
SO Sequence 17 BP; 4 A; 3 C; 8 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1974 GGCTTCAGATGAGCA 1990
DB 1 GGCTTCAGATGAGCA 17
RESULT 150
ADA19158/c
ID ADA19158 standard; DNA; 18 BP.
XX
XX ADA19158;
AC
XX
XX 20-NOV-2003 (first entry)
XX
XX
XX Rat astrocyte konjirin 5' RACE primer SEQ ID NO:4.
DE
XX
XX rat; astrocyte; konjirin; osteogenic protein binding region; neurotropic;
KM neuroprotective; antiparkinsonian; cerebroprotective;
KM bone morphogenic protein antagonist; BMP antagonist; gene therapy;
KM brain disorder; Alzheimer's disease; Parkinson's disease;
KM cerebral ischaemia; external brain trauma; primer; ss.
XX
XX
XX Synthetic.
OS
XX Rattus sp.
XX
XX WO2003070937-A1.
PN
XX
XX 28-AUG-2003.
XX
XX
XX 20-FEB-2003; 2003WO-JP001850.
PF
XX
XX 20-FEB-2002; 2002JP-00042984.
PR
XX
XX (TAIS/) TAISHO PHARM CO LTD.
PA (SATO/) SATO K.
PA
XX
XX Sato K, Ueki T;
PI
XX
XX WPI; 2003-671811/63.
DR
XX

PR 08-AUG-2003; 2003US-0493986P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALANY-) ALNYLTM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
XX
PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 209; 378bp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and
CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
CC is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of apob-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a human apolipoprotein B (apob) antisense oligonucleotide that
CC can be used to control apob gene expression.
XX
XX Sequence 19 BP; 0 A; 6 C; 5 G; 8 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 2330 CCTCTCCTGTGTCTTCT 2346
Db 3 CCTCTCCTGTGTCTTCT 19
RESULT 155
ADRT7893/C
ID ADR77893 standard; DNA; 19 BP.
XX
XX ADR77893;
AC
XX
XX 16-DEC-2004 (first entry)
DT
XX
XX Human apolipoprotein B (Apob) oligonucleotide seqid 2378.
DE
XX
XX antilipemic; cardiac; vasotropic; antiarteriosclerotic; antidiabetic;
XX cytostatic; anticonvulsant; nootropic; muscular; anti-HIV;
XX RNA interference; iRNA; antisense technology; lipid metabolism;
XX cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KW

KW coronary artery disease; CAD; coronary heart disease; CHD;
KW atherosclerosis; hepatic glucose production;
KW glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KW colon cancer; lung cancer; neurological disease; Huntington disease;
KW spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; apob; ss.
XX
OS Homo sapiens.
XX
XX WO2004080406-A2.
XX
XX 23-SEP-2004.
XX
XX
XX 08-MAR-2004; 2004WO-US007070.
XX
XX
XX 07-MAR-2003; 2003US-0452682P.
XX 12-MAR-2003; 2003US-0454265P.
XX 13-MAR-2003; 2003US-0454962P.
XX 14-MAR-2003; 2003US-0455050P.
XX 17-APR-2003; 2003US-0462894P.
XX 25-APR-2003; 2003US-0463772P.
XX 25-APR-2003; 2003US-0465665P.
XX 25-APR-2003; 2003US-0465802P.
XX 09-MAY-2003; 2003US-0469612P.
XX 08-AUG-2003; 2003US-0493986P.
XX 11-AUG-2003; 2003US-0494597P.
XX 26-SEP-2003; 2003US-0506341P.
XX 09-OCT-2003; 2003US-0510246P.
XX 10-OCT-2003; 2003US-0510318P.
XX 07-NOV-2003; 2003US-0518453P.
XX
XX (ALANY-) ALNYLTM PHARM.
XX
XX Manoharan M, Bumcrot D;
XX WPI; 2004-677362/66.
XX
XX
XX Interference RNA agent useful for treating dyslipidemias, coronary artery
XX disease, diabetes, cancer or neurological disease, comprises sense
XX sequence and antisense sequence which has specific modifications.
XX
XX Example 5; SEQ ID NO 2378; 378bp; English.
XX
XX The invention describes a RNA interference (iRNA) agent (I) comprising a
XX sense sequence and an antisense sequence, where the sense sequences have
XX one or more asymmetrical 2'-O alkyl modifications, the antisense
XX sequences have one or more asymmetrical phosphorothioate modifications
XX and the antisense sequence targets a human gene sequence. Also described
XX are: a pharmaceutical preparation comprising (I); reducing (M1) apob-100
XX levels or glucose-6-phosphatase levels in a subject; producing (I);
XX stabilising (I), involves selecting a sequence with activity and
XX introducing one or more asymmetrical modification in the sequence, where
XX the modification decreases nuclease sensitivity while not decreasing its
XX activity; a kit comprising (I) and instruction for its use; and a device
XX that can be dispense or administer a composition comprising (I). (I) is
XX useful for reducing apob-100 levels or glucose-6-phosphatase levels. (M1)
XX is useful for reducing apob-100 levels or glucose-6-phosphatase levels.
XX The subject is suffering from a disorder characterised by elevated or
XX otherwise unwanted expression of apob-100, elevated or otherwise unwanted
XX levels of cholesterol, and/or dysregulation of lipid metabolism. The
XX disorder is chosen from the HDL/LDL cholesterol imbalance,
XX dyslipidaemias, hypercholesterolaemia, statin-resistant
XX hypercholesterolaemia, coronary artery disease (CAD), coronary heart
XX disease (CHD) and atherosclerosis. (I) is administered to a subject to
XX inhibit hepatic glucose production or for treating glucose-metabolism-
XX related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
XX treating the diseases as mentioned above, cancer (e.g. breast, colon or
XX lung cancer), neurological disease (e.g., Huntington disease or
XX spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
XX represents a human apolipoprotein B (Apob) antisense oligonucleotide that
XX can be used to control apob gene expression.
XX
XX Sequence 19 BP; 7 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
SQ

Query Match 0.6%; Score 15.4; DB 1; Length 19;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 507 TACATATTGCACTGA 523
| | | | | | | | | | | | | | | | | | | | |
19 TTCATATTGCACTGA 3

Db

RESULT 156
ADR78342
ID ADR78342 standard; DNA; 19 BP.
XX
AC ADR78342;
DT 16-DEC-2004 (first entry)
XX
DE Human apolipoprotein B (ApoB) oligonucleotide seqid 2827.
XX
KM antilipemic; cardiatic; vasotropic; antiarteriosclerotic; antidiabetic;
KM cytostatic; anticonvulsant; nootropic; muscular; anti-HIV;
KM RNA interference; IRNA; antisense technology; lipid metabolism;
KM cholesterol imbalance; dyslipidaemia hypercholesterolaemia;
KM coronary artery disease; CAD; coronary heart disease; CHD;
KM atherosclerosis; hepatic glucose production;
KM glucose-metabolism-related disorder; diabetes; cancer; breast cancer;
KM colon cancer; lung cancer; neurological disease; Huntington disease;
KM spinocerebellar ataxia; viral disease; AIDS; apolipoprotein B; ApoB; ss.
XX
OS Homo sapiens.
XX
PN WO2004080406-A2.
XX
PD 23-SEP-2004.
XX
PF 08-MAR-2004; 2004WO-US007070.
XX
PR 07-MAR-2003; 2003US-0452682P.
PR 12-MAR-2003; 2003US-0454285P.
PR 13-MAR-2003; 2003US-0454962P.
PR 14-MAR-2003; 2003US-0455050P.
PR 17-APR-2003; 2003US-0462894P.
PR 25-APR-2003; 2003US-0463772P.
PR 25-APR-2003; 2003US-0465665P.
PR 09-MAY-2003; 2003US-0465802P.
PR 08-AUG-2003; 2003US-0469612P.
PR 11-AUG-2003; 2003US-0494597P.
PR 26-SEP-2003; 2003US-0506341P.
PR 09-OCT-2003; 2003US-0510246P.
PR 10-OCT-2003; 2003US-0510318P.
PR 07-NOV-2003; 2003US-0518453P.
XX
PA (ALANY-) ALANYLAM PHARM.
XX
PI Manoharan M, Bumcrot D;
XX
DR MPI; 2004-677362/66.
XX
PT Interference RNA agent useful for treating dyslipidemias, coronary artery
PT disease, diabetes, cancer or neurological disease, comprises sense
PT sequence and antisense sequence which has specific modifications.
XX
PS Example 5; SEQ ID NO 2827; 378bp; English.
XX
CC The invention describes a RNA interference (iRNA) agent (I) comprising a
CC sense sequence and an antisense sequence, where the sense sequences have
CC one or more asymmetrical 2'-O alkyl modifications, the antisense
CC sequences have one or more asymmetrical phosphorothioate modifications
CC and the antisense sequence targets a human gene sequence. Also described
CC are: a pharmaceutical preparation comprising (I); reducing (MI) ApoB-100
CC levels or glucose-6-phosphatase levels in a subject; producing (I);
CC stabilising (I), involves selecting a sequence with activity and

CC introducing one or more asymmetrical modification in the sequence, where
CC the modification decreases nuclease sensitivity while not decreasing its
CC activity; a kit comprising (I) and instruction for its use; and a device
CC that can be dispense or administer a composition comprising (I). (I) is
CC useful for reducing ApoB-100 levels or glucose-6-phosphatase levels. (MI)
CC is useful for reducing ApoB-100 levels or glucose-6-phosphatase levels.
CC The subject is suffering from a disorder characterised by elevated or
CC otherwise unwanted expression of ApoB-100, elevated or otherwise unwanted
CC levels of cholesterol, and/or dysregulation of lipid metabolism. The
CC disorder is chosen from the HDL/LDL cholesterol imbalance,
CC dyslipidaemias, hypercholesterolaemia, statin-resistant
CC hypercholesterolaemia, coronary artery disease (CAD), coronary heart
CC disease (CHD) and atherosclerosis. (I) is administered to a subject to
CC inhibit hepatic glucose production or for treating glucose-metabolism-
CC related disorder e.g. diabetes or type-2 diabetes. (I) is useful for
CC treating the diseases as mentioned above, cancer (e.g. breast, colon or
CC lung cancer), neurological disease (e.g., Huntington disease or
CC spinocerebellar ataxia) or viral disease (e.g., AIDS). This sequence
CC represents a human apolipoprotein B (ApoB) antisense oligonucleotide that
CC can be used to control ApoB gene expression.

QY 2330 CCTCTCTGTGTGTCT 2346
| | | | | | | | | | | | | | | | | | | | |
3 CCTCTCTGTGTGTCT 19

Db

RESULT 157
AAZ05177/C
ID AAZ05177 standard; DNA; 20 BP.
XX
AC AAZ05177;
XX
DT 07-OCT-1999 (first entry)
XX
DE PCR primer used to amplify an ORF of Chlamydia trachomatis.
XX
KM Vaccine; eye disease; conventional trachoma; nongonococcal urethritis; genital disease; peritrophic;
KM paratrachoma; inclusion conjunctivitis; epidermal; ceratitis; salpingitis; PCR primer;
KM bartolinitis; pneumopathy; venereal lymphogranulomatosis; ss.
XX
OS Synthetic.
OS Chlamydia trachomatis.
XX
PN WO9928475-A2.
XX
PD 10-JUN-1999.
XX
PF 27-NOV-1998; 98WO-IB001939.
XX
PR 28-NOV-1997; 97FR-00015041.
PR 17-DEC-1997; 97FR-00016034.
PR 04-NOV-1998; 98US-0107077P.
XX
PA (GENT) GENSET.
XX
PI Griffiths R;
XX
DR MPI; 1999-371125/31.
XX
PT Genome sequence of Chlamydia trachomatis.
XX
PS Disclosure; Page 1749; 1755pp; English.
XX
CC PCR primers AAZ01426-206209 were used to amplify open reading frames
CC (ORFs) of the genome of Chlamydia trachomatis (see AAZ01425). These ORFs
CC encode polypeptides (see AAZ06754-Y37949) which can be used as vaccines

CC against Chlamydia trachomatis. Antisense and ribozyme sequences can also
CC be used to control growth of the microorganism. Chlamydia trachomatis is
CC responsible for a large number of diseases, e.g. eye diseases such as
CC conventional trachoma, nonendemic trachoma, paratrachoma, and inclusion
CC conjunctivitis; genital diseases such as nongonococcal urethritis,
CC epididymitis, cervicitis, salpingitis, perihepatitis, bartolinitis;
CC pneumonia in breast feeding infants; and venereal lymphogranulomatosis.
CC The polypeptides of the invention may be of use in treating these
CC diseases
CC
SQ Sequence 20 BP; 4 A; 5 C; 5 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1123 GGGTCCAGAGAGTTC 1139
DB 20 GAGTCCAGAGAGTTC 4
RESULT 158
AAC90974
ID AAC90974 standard; DNA; 20 BP.
XX
AC AAC90974;
XX
DT 19-MAR-2001 (first entry)
XX
DE Human API2-MLT chimeric cDNA construction PCR primer #2.
XX
KW Human; API2-MLT chimera; chimeric; apoptosis inhibitor 2; MLT; API2;
KW mucosa-associated lymphoid tissue lymphoma associated translocation;
KW chromosome 11 region q21-22.3; chromosome 18 region q21.1-22;
KW molecular characterisation; chromosome translocation; carcinogenesis;
KW fusion protein; malignancy; PCR primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
OS Chimeric.
XX
PN WC200073500-A1.
XX
PD 07-DEC-2000.
XX
PF 26-MAY-2000; 2000MO-EP004796.
XX
PR 27-MAY-1999; 99EP-00201683.
XX
PA (VLAAM-) VLAAMS INTERUNIVERSITAIR INST BIOTECHNOG.
XX
PI Baens M, Marynen P, Dierlamm J;
XX
DR WPI; 2001-061556/07.
XX
PT Determining if a tissue sample has a chromosome (11:18) translocation
PT associated with malignancies by amplifying a nucleic acid sample using
PT primers complementary to chromosome 11 region q21-22.3 and chromosome 18
PT region q21.1-22.
XX
PS Example 1; Page 11; 47pp; English.
XX
CC The present invention describes a method for determining if a tissue
CC sample comprises a cell with a chromosome (11:18) translocation
CC associated with malignancies such as mucosa-associated lymphoid tissue
CC (MALT) lymphomas. The method comprises subjecting a sample nucleic acid
CC to amplification using primers complementary to sequences which are on
CC chromosome 11 region q21-22.3 and on chromosome 18 region q21.1-22. The
CC method can be used for determining if a tissue sample or analogue
CC comprises a chromosome (11:18) translocation associated with malignancies
CC such as mucosa-associated lymphoid tissue lymphomas. The nucleic acid or
CC the antibody may be used as a probe for detection, for hybridisation to
CC southern blot cell DNAs or for in situ hybridisation of cells, or for

CC determining the presence of complementary DNA. The present sequence
CC represents a PCR primer used in the construction of the specifically
CC claimed chimeric human apoptosis inhibitor 2 (API2)/MALT-lymphoma
CC associated translocation (MLT) protein
XX
SQ Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 739 CCTTCGCACTTCACG 755
DB 1 CCTTCGCACTTCATC 17
RESULT 159
AAC92562
ID AAC92562 standard; DNA; 20 BP.
XX
AC AAC92562;
XX
DT 27-MAR-2001 (first entry)
XX
DE Human nucleolin phosphorothioate antisense oligonucleotide, SEQ ID NO:12.
XX
KW Human nucleolin; P92; C23; phosphoprotein; ribosome biogenesis;
KW ribosome transport; cytokinesis; nucleogenesis; cell proliferation;
KW cell growth; transcriptional repression; replication;
KW signal transduction; chromatin decondensation; Ag-NOR family;
KW nucleolin antibody; systemic connective tissue disease; SLE;
KW systemic lupus erythematosus;
KW scleroderma-like chronic graft versus host disease;
KW expression inhibition; tumour formation; cancer; inflammation;
KW immune disorder; phosphorothioate; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN US6165786-A.
XX
PD 26-DEC-2000.
XX
PF 03-NOV-1999; 99US-00433699.
XX
PR 03-NOV-1999; 99US-00433699.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Cowseart LM;
XX
DR WPI, 2001-079846/09.
XX
PT Novel antisense compound targeted to human nucleolin which specifically
PT hybridizes with and inhibits the expression of human nucleolin, useful
PT for modulating the expression of nucleolin in cells.
XX
PS Claim 14; Col 41-42; 41pp; English.
XX
CC Sequences AAC92560-C92639 represent antisense oligonucleotides targeted
CC to the human nucleolin gene, which inhibit its expression. The antisense
CC oligonucleotides were designed to target different regions of the human
CC nucleolin mRNA, and were analysed for their effect on nucleolin mRNA
CC levels by quantitative real-time PCR. Nucleolin (also known as P92 or
CC C23) is the most abundant nucleolar phosphoprotein in actively growing
CC cells. Nucleolin primarily participates in ribosome biogenesis and
CC transport of ribosomal components, being able to transiently bind to pre-
CC ribosomes in the nucleolus via a ribonucleoprotein consensus sequence.
CC However, it has also been shown to be involved in cytokinesis.
CC Nucleogenesis, cell proliferation and growth, transcriptional repression,
CC replication, signal transduction, and chromatin decondensation. Nucleolin
CC is a member of the Ag-NOR (active ribosomal gene located in the nucleolar
CC organiser region) family of proteins which are markers of active
CC ribosomal genes, and whose expression is associated with the prediction

CC of tumour growth rate. The presence of antibodies against nucleolin are
CC associated with systemic connective tissue diseases such as systemic
CC lupus erythematosus (SLE) and scleroderma-like chronic graft versus host
CC disease. The oligonucleotides of the invention are useful for diagnosis,
CC prevention and treatment of conditions associated with nucleolin
CC expression, such as tumour formation, immune disorders and inflammation
XX
SQ Sequence 20 BP; 8 A; 4 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1120 GATGGTCGAGAGAG 1136
Db 2 GATGAGTCGAGAGAG 18
RESULT 160
AB288613
ID AB288613 standard; DNA; 20 BP.
XX
AC AB288613;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiseptic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN MO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002MO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPICGENESIS PHARM INC.
XX
PI Myce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
XX
PS ubiquinone.
XX
PS Disclosure; SEQ ID NO 3855; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiseptic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine

CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1106 GGCGTCCTGGGCGCGAT 1122
Db 4 GGCGTCCTGGGCGCGAT 20
RESULT 161
ADL93361
ID ADL93361 standard; DNA; 20 BP.
XX
AC ADL93361;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human API2-MLT primer #2.
XX
KW chromosome (11:18) translocation; cancer;
KW mucosa-associated lymphoid tissue; MALT lymphoma; API2-MLT; human; ss;
KW primer.
XX
OS Homo sapiens.
XX
PN US2003176682-A1.
XX
PD 18-SEP-2003.
XX
PF 28-JAN-2003; 2003US-00353461.
XX
PR 09-JUN-1999; 99US-0138834P.
XX
PR 26-MAY-2000; 2000US-00579692.
XX
PA (DIER/) DIERLAWM J.
PA (BAEN/) BAENS M.
PA (MARI/) MARIJEN P.
XX
PI Dierlamm J, Baens M, Marijen P;
XX
DR WPI; 2003-052143/79.
XX
PT Nucleic acids derived from a chromosome (11:18) translocation associated
PT with malignancies such as mucosa-associated lymphoid tissue (MALT)
PT lymphomas, useful for diagnosing low grade lymphomas.
XX
PS Example; SEQ ID NO 2; 39pp; English.
XX
XX
CC The invention relates to nucleic acids derived from a chromosome (11:18)
CC translocation associated with malignancies such as mucosa-associated
CC lymphoid tissue (MALT) lymphomas. The nucleic acids are useful in the
CC diagnosis of low grade lymphomas. The present sequence represents a human
CC API2-MLT primer.
XX
SQ Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 739 CCTTGCACACTTCAGC 755
Db 1 CCTTGCACACTTCATC 17

```

RESULT 162
ADM35952
ID ADM35952 standard; DNA, 20 BP.
XX
AC ADM35952;
XX
XX 03-JUN-2004 (first entry)
XX
DE Phosphorothioate Cpdl/du DNA oligo #3 useful for induction of NK LU.
XX
XX phosphorothioate; natural killer lytic activity; NK LU; ss;
XX immunostimulatory; deoxyinosine; deoxyuridine; antigenic;
XX immune system deficiency; autoimmune disorder;
XX systemic lupus erythematosus; SLE; myasthenia gravis;
XX immunodeficiency disorder; AIDS; malignant tumour; gastric cancer;
XX skin cancer; leukaemia; lymphoma; infectious disease; dermatological;
XX immunosuppressive; antineoplastic; antineoplastic; virucide;
XX antiparasitic; cytostatic; antineoplastic; antineoplastic; neuroprotective;
XX antimicrobial; antiallergic; immunopharmacological.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "OTHER= Any n represents deoxyuridine or
XX deoxyinosine"
XX
XX WO2003047602-A1.
XX
XX 12-JUN-2003.
XX
XX 05-DEC-2002; 2002WO-EP013791.
XX
XX 07-DEC-2001; 2001AT-00001924.
XX
XX (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.
XX
XX Schmidt W, Schellack C, Egyed A, Lingnau K;
XX WPI; 2003-569024/53.
XX
XX Use of an immunostimulatory oligodeoxynucleic acid molecule in the
XX preparation of pharmaceutical composition for treating e.g. systemic
XX lupus erythematosus, sepsis or viral infections.
XX
XX Example 14; Page 107; 139pp; English.
XX
XX This invention relates to a novel use of immunostimulatory
XX oligodeoxynucleic acid molecules (ODNs) that contain deoxyinosine (di) or
XX deoxyuridine (du). Specifically, it refers to ODN molecules that encode
XX antigenic proteins, yet do not induce the systemic production of pro-
XX inflammatory cytokines such as TNF-alpha and interleukin-6 (IL-6), thus
XX reducing the induction of potential harmful side effects. The present
XX invention describes compositions that are useful for preparing a
XX pharmaceutical composition that can activate dendritic cells, B cells,
XX natural killer cells and hence treat an immune system deficiency.
XX Furthermore, they can be used to treat various diseases including
XX autoimmune disorders such as systemic lupus erythematosus (SLE) and
XX myasthenia gravis, immunodeficiency disorders such as AIDS, malignant
XX tumours that cause gastric and skin cancer as well as leukaemia and
XX lymphoma, and various infectious diseases for example from bacteria,
XX viruses and protozoa. Accordingly, such compositions exhibit
XX dermatological, immunosuppressive, antineoplastic, antineoplastic,
XX virucide, antiparasitic, cytostatic, antineoplastic, antineoplastic,
XX neuroprotective, antineoplastic, antineoplastic, antineoplastic. These
XX oligodeoxynucleotides have immunopharmacological activity and induce a
XX synergistic antigen specific immune response of an immunopotentiating
XX cytokine. This oligonucleotide sequence is an immunostimulatory di/du
XX containing ODN with a phosphorothioate backbone of the invention.

```

```

SQ Sequence 20 BP; 0 A; 6 C; 2 G; 10 T; 0 U; 2 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 460 TCGTGCCTCTGTGAC 478
DB 1 TCGTGCCTCTGTGAC 19
RESULT 163
ADM35976
ID ADM35976 standard; DNA, 20 BP.
XX
AC ADM35976;
XX
XX 03-JUN-2004 (first entry)
XX
DE Cpdl/du ODN 1962 useful for B cell proliferation & IL-12 secretion.
XX
XX phosphorothioate; IL-12; B cell proliferation; ss; immunostimulatory;
XX deoxyinosine; deoxyuridine; antigenic; immune system deficiency;
XX autoimmune disorder; systemic lupus erythematosus; SLE;
XX myasthenia gravis; immunodeficiency disorder; AIDS; malignant tumour;
XX gastric cancer; skin cancer; leukaemia; lymphoma; infectious disease;
XX dermatological; immunosuppressive; antineoplastic; antineoplastic;
XX virucide; antiparasitic; cytostatic; antineoplastic; antineoplastic;
XX neuroprotective; antimicrobial; antiallergic; immunopharmacological.
XX
OS Synthetic.
XX
XX Key Location/Qualifiers
XX modified_base 1..20
XX /*tag= a
XX /mod_base= OTHER
XX /note= "OTHER= Any n represents deoxyuridine or
XX deoxyinosine"
XX
XX WO2003047602-A1.
XX
XX 12-JUN-2003.
XX
XX 05-DEC-2002; 2002WO-EP013791.
XX
XX 07-DEC-2001; 2001AT-00001924.
XX
XX (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.
XX
XX Schmidt W, Schellack C, Egyed A, Lingnau K;
XX WPI; 2003-569024/53.
XX
XX Use of an immunostimulatory oligodeoxynucleic acid molecule in the
XX preparation of pharmaceutical composition for treating e.g. systemic
XX lupus erythematosus, sepsis or viral infections.
XX
XX Example 14; Page 108; 139pp; English.
XX
XX This invention relates to a novel use of immunostimulatory
XX oligodeoxynucleic acid molecules (ODNs) that contain deoxyinosine (di) or
XX deoxyuridine (du). Specifically, it refers to ODN molecules that encode
XX antigenic proteins, yet do not induce the systemic production of pro-
XX inflammatory cytokines such as TNF-alpha and interleukin-6 (IL-6), thus
XX reducing the induction of potential harmful side effects. The present
XX invention describes compositions that are useful for preparing a
XX pharmaceutical composition that can activate dendritic cells, B cells,
XX natural killer cells and hence treat an immune system deficiency.
XX Furthermore, they can be used to treat various diseases including
XX autoimmune disorders such as systemic lupus erythematosus (SLE) and
XX myasthenia gravis, immunodeficiency disorders such as AIDS, malignant
XX tumours that cause gastric and skin cancer as well as leukaemia and
XX lymphoma, and various infectious diseases for example from bacteria,

```

CC viruses and protozoa. Accordingly, such compositions exhibit
 CC dermatological, immunosuppressive, antiinflammatory, antibacterial,
 CC virucide, antiparasitic, cytostatic, antineoplastic, antiaerthetic,
 CC neuroprotective, antimicrobial and antiallergic activities. These
 CC oligodeoxynucleotides have immunopharmacological activity and induce a
 CC synergistic antigen specific immune response of an immunopotentiating
 CC cytokine. This oligonucleotide sequence is an immunostimulatory di/dU
 CC containing ODN with a phosphorothioate backbone of the invention.
 XX

SQ Sequence 20 BP; 0 A; 6 C; 2 G; 10 T; 0 U; 2 Other;

Query Match 0.6%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 460 TCCTGTCCTTCCTGACT 478
 Db 1 TCCTGTCCTTCCTGTCNT 19

RESULT 164
 ADM36056 standard; DNA; 20 BP.

XX ADM36056;
 XX 03-JUN-2004 (first entry)

DE Immunostimulatory Cpdi/dU DNA oligonucleotide #59.

XX ss; immunostimulatory; deoxyinosine; deoxyuridine; antigenic;
 KM immune system deficiency; autoimmune disorder;
 KM systemic lupus erythematosus; SLE; myasthenia gravis;
 KM immunodeficiency disorder; AIDS; malignant tumour; gastric cancer;
 KM skin cancer; leukaemia; lymphoma; infectious disease; dermatological;
 KM immunosuppressive; antineoplastic; antineoplastic; virucide;
 KM antiparasitic; cytostatic; antineoplastic; antiaerthetic; neuroprotective;
 KM antimicrobial; antiallergic; immunopharmacological.

XX Synthetic.

OS Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= Any n represents deoxyuridine or
 deoxyinosine"

XX WO2003047602-A1.
 XX 12-JUN-2003.
 XX 05-DEC-2002; 2002WO-EP013791.
 XX 07-DEC-2001; 2001AT-00001924.
 XX (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.
 XX Schmidt W, Schellack C, Eyed A, Lingnau K;
 XX WPI; 2003-569024/53.
 XX

PT Use of an immunostimulatory oligodeoxynucleic acid molecule in the
 PT preparation of pharmaceutical composition for treating e.g. systemic
 PT lupus erythematosus, sepsis or viral infections.
 XX

PS Example 14; Page 112; 139pp; English.

CC This invention relates to a novel use of immunostimulatory
 CC oligodeoxynucleic acid molecules (ODNs) that contain deoxyinosine (di) or
 CC deoxyuridine (du). Specifically, it refers to ODN molecules that encode
 CC antigenic proteins, yet do not induce the systemic production of pro-
 CC inflammatory cytokines such as TNF-alpha and interleukin-6 (Il-6), thus

CC reducing the induction of potential harmful side effects. The present
 CC invention describes compositions that are useful for preparing a
 CC pharmaceutical composition that can activate dendritic cells, B cells,
 CC natural killer cells and hence treat an immune system deficiency.
 CC Furthermore, they can be used to treat various diseases including
 CC autoimmune disorders such as systemic lupus erythematosus (SLE) and
 CC myasthenia gravis, immunodeficiency disorders such as AIDS, malignant
 CC tumours that cause gastric and skin cancer as well as leukaemia and
 CC lymphoma, and various infectious diseases for example from bacteria,
 CC viruses and protozoa. Accordingly, such compositions exhibit
 CC dermatological, immunosuppressive, antiinflammatory, antibacterial,
 CC virucide, antiparasitic, cytostatic, antineoplastic, antiaerthetic,
 CC neuroprotective, antimicrobial and antiallergic activities. These
 CC oligodeoxynucleotides have immunopharmacological activity and induce a
 CC synergistic antigen specific immune response of an immunopotentiating
 CC cytokine. This oligonucleotide sequence is an immunostimulatory di/dU
 CC containing ODN taken from table 1 of the invention.
 XX

SQ Sequence 20 BP; 0 A; 6 C; 2 G; 10 T; 0 U; 2 Other;

Query Match 0.6%; Score 15.4; DB 1; Length 20;
 Best Local Similarity 84.2%; Pred. No. 1.3e+02;
 Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 460 TCCTGTCCTTCCTGACT 478
 Db 1 TCCTGTCCTTCCTGTCNT 19

RESULT 165
 ADM35921 standard; DNA; 20 BP.

XX ADM35921;
 XX 03-JUN-2004 (first entry)

DE DNA oligo #1 useful for stimulating B cell proliferation in humans.

XX ss; immunostimulatory; deoxyinosine; deoxyuridine; antigenic;
 KM immune system deficiency; autoimmune disorder;
 KM systemic lupus erythematosus; SLE; myasthenia gravis;
 KM immunodeficiency disorder; AIDS; malignant tumour; gastric cancer;
 KM skin cancer; leukaemia; lymphoma; infectious disease; dermatological;
 KM immunosuppressive; antineoplastic; antineoplastic; virucide;
 KM antiparasitic; cytostatic; antineoplastic; antiaerthetic; neuroprotective;
 KM antimicrobial; antiallergic; immunopharmacological.

XX Synthetic.

OS Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= Any n represents deoxyuridine or
 deoxyinosine"

XX WO2003047602-A1.
 XX 12-JUN-2003.
 XX 05-DEC-2002; 2002WO-EP013791.
 XX 07-DEC-2001; 2001AT-00001924.
 XX (INTE-) INTERCELL BIOMEDIZINISCHE FORSCHUNGS.
 XX Schmidt W, Schellack C, Eyed A, Lingnau K;
 XX WPI; 2003-569024/53.
 XX

PT Use of an immunostimulatory oligodeoxynucleic acid molecule in the
 PT preparation of pharmaceutical composition for treating e.g. systemic

PT lupus erythematosus, sepsis or viral infections.
XX
XX
PS Example 14; Page 106; 139pp; English.
XX
CC This invention relates to a novel use of immunostimulatory
CC oligodeoxynucleic acid molecules (ODNs) that contain deoxyinosine (di) or
CC deoxyuridine (du). Specifically, it refers to ODN molecules that encode
CC antigenic proteins, yet do not induce the systemic production of pro-
CC inflammatory cytokines such as TNF-alpha and interleukin-6 (IL-6), thus
CC reducing the induction of potential harmful side effects. The present
CC invention describes compositions that are useful for preparing a
CC pharmaceutical composition that can activate dendritic cells, B cells,
CC natural killer cells and hence treat an immune system deficiency.
CC Furthermore, they can be used to treat various diseases including
CC autoimmune disorders such as systemic lupus erythematosus (SLE) and
CC myasthenia gravis, immunodeficiency disorders such as AIDS, malignant
CC tumours that cause gastric and skin cancer as well as leukemia and
CC lymphoma, and various infectious diseases for example from bacteria,
CC viruses and protozoa. Accordingly, such compositions exhibit
CC dermatological, immunosuppressive, anti-inflammatory, antibacterial,
CC virocidic, antiparasitic, cytostatic, antineoplastic, antiasthmatic,
CC neuroprotective, antimicrobial and antiallergic activities. These
CC oligodeoxynucleotides have immunopharmacological activity and induce a
CC synergistic antigen specific immune response of an immunopotentiating
CC cytokine. This oligonucleotide sequence is an immunostimulatory di/du
CC containing ODN of the invention.
XX
SQ Sequence 20 BP; 0 A; 6 C; 2 G; 10 T; 0 U; 2 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
Qy 460 TCCTGCTCTCTCTGACT 478
Db 1 TCCTGCTCTCTCTGACT 19
RESULT 166
ID ABD24843
AC ABD24843; standard; DNA; 20 BP.
XX
DT 29-JUL-2004 (first entry)
XX
DE AI092623-derived oligonucleotide SEQ ID 3855.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenovirus sensitivity; lung; cancer;
KW surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN MO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Myce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI, 2003-093058/08.

XX
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 3855; 763pp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity. Levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiallergic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 3 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 1.3e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1106 GGCTCTCTGGGCGCAT 1122
Db 4 GGCTCTCTGGGCGCAT 20
RESULT 167
ID ADO26536 standard; DNA; 20 BP.
XX
AC ADO26536;
XX
DT 01-JUL-2004 (first entry)
XX
DE PCR primer MLT1 for human MLT cDNA.
XX
KW Chromosome translocation; malignancy;
KW mucosa-associated lymphoid tissue-lymphoma associated translocation;
KW MLT1; MLT; primary cell transformation; apoptosis inhibitor 2; APl2;
KW tumour; cytostatic; human; PCR; primer; ss.
XX
OS Homo sapiens.
XX
PN US6689875-B1.
XX
PD 10-FEB-2004.
XX
PF 26-MAY-2000; 2000US-00579692.
XX

PR	09-JUN-1999;	99US-0138834P.
XX		
PA	(VLA-A)	VLAAMS INTERNUNIVERSITAIR INST BIOTECHNOS.
XX		
PI	Dierlamm J, Baens M, Marijnen P;	
XX		
DR	WPI; 2004-141430/14.	
XX		
PT	New mucosa-associated lymphoid tissue-lymphoma associated translocation	
XX	protein, useful in diagnosing and treating tumors.	
PS	Example; SEQ ID NO 2; 88pp; English.	
XX		
CC	The present invention relates to a method for characterisation of	
CC	chromosome translocation T (11;18) (q21;q21) and its association with	
CC	malignancies such as mucosa-associated lymphoid tissue (MALT)-lymphomas.	
CC	Also disclosed are: the polynucleotide and polypeptide sequences for	
CC	human mucosa-associated lymphoid tissue (MALT)-lymphoma associated	
CC	translocation (MALT), and a novel mechanism of primary cell transformation	
CC	by expression of a fusion protein comprising at least apoptosis inhibitor	
CC	2 (API2) fused to another protein such as MTR. The MTR polynucleotide and	
CC	polypeptide sequences, and the method of the invention are useful in	
CC	diagnosing and treating tumours. The present invention represents a PCR	
CC	primer used in the examples of the present invention.	
SO	Sequence 20 BP; 4 A; 8 C; 2 G; 6 T; 0 U; 0 Other;	
XX		
Query Match	0.6%; Score 15.4; DB 1; Length 20;	
Best Local Similarity	94.1%; Pred. No. 1.3e+02;	
Matches 16; Conservative	0; Mismatches 1; Indels 0; Gaps 0;	
OY	739 CCTTCTGCACTTCAGC 755	
Db	1 CCTTCTGCACTTCATC 17	
RESULT 168		
ADN71962		
ID	ADN71962 standard; DNA; 20 BP.	
XX		
AC	ADN71962;	
XX		
DT	12-AUG-2004 (first entry)	
XX		
DE	Human glucose transporter-4 antisense oligonucleotide #3.	
XX		
KW	as; human; antisense therapy; glucose transporter-4;	
KW	hyperproliferative disorder; probe.	
XX		
OS	Homo sapiens.	
XX		
FH	Key	Location/Qualifiers
FT	modified_base	1..20
FT		/*tag= b
FT		/mod_base= Other
FT		/note= "Phosphorothioate backbone. All cytidines are 5-
FT	modified_base	methylcytidines"
FT		1..5
FT		/*tag= a
FT		/mod_base= Other
FT	modified_base	/note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT		16..20
FT		/*tag= C
FT		/mod_base= Other
FT		/note= "2'-methoxyethyl (2'-MOE) nucleotides"
PV	US2004101848-A1.	
XX		
PD	27-MAY-2004.	
XX		
XX	23-NOV-2002; 2002US-00303266.	
XX		
XX	23-NOV-2002; 2002US-00303266.	
XX		
XX		

[illegible]

CC The sequences given in AAQ91921-26 are primers which were used in an
CC example to illustrate the method of the invention. These primers were
CC used in the correction of the human beta-S globin gene. The method
CC comprises transforming the target cell with a linear DNA construct
CC containing a sequence with at least 50 bp homology with an indigenous
CC region (IR) of the target locus (TL), but different from the TL, and a
CC marker gene. The construct is an omega-(replacement) or O-(insertional)
CC targeting vector, where a non-homologous sequence forms an internal or
CC external loop, respectively. The cells are then grown and selected for
CC marker-containing cells. Cells containing the construct in the IR were
CC isolated by identifying the presence of the construct sequence at the
CC locus. (Updated on 25-MAR-2003 to correct PN field.)
XX

SO Sequence 20 BP; 5 A; 7 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. NO. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 870 TGCCCTGTGACGGGACAC 889
Db 1 TGCGCTGACAGCCGGAACAC 20

RESULT 170
AAQ82543/c
ID AAQ82543 standard; DNA; 20 BP.

AC AAQ82543;

DT 25-MAR-2003 (revised)

DT 13-SEP-1995 (first entry)

DE Chromosome 11 (locus CD44) SRS primer CD44-A.

KM sequence sampled mapping; genomic analysis; complex genome mapping;
KW cosmid library; chromosome 11; sequence tagged site; SRS analysis; ss.

OS Synthetic.

PN WO9429486-A1.

PD 22-DEC-1994.

PF 15-JUN-1994; 94MO-US006810.

PR 15-JUN-1993; 93US-00078471.

PR 07-SEP-1993; 93US-00117952.

PA (SALK) SALK INST BIOLOGICAL STUDIES.

PI Evans GA, Smith MW;

PI MPI; 1995-036508/05.

PT Sequencing complex genomes, present as fragments in a cosmid library - by
PT sequencing end-specific nucleotides of each clone then correlating with
PT spatial relationship of cosmid, esp. for mammalian chromosomes.

XX Example 4; Page 86; 128bp; English.

CC Sequences were determined from the ends of chromosome 11-specific cosmids
CC by automated sequencing without intermediate subcloning. A sample of 371
CC DNA sequence fragments were determined and of these, 277 were suitable
CC for SRS primer prediction by computer analysis (using the "primer"
CC program available from E. Lander, MIT). The SRSs and cosmids were mapped
CC by in situ hybridisation, somatic cell hybrid analysis or both. Using
CC this method, 370 SRSs specific for human chromosome 11 were generated and
CC most of them were regionally mapped. This procedure illustrates a novel
CC method for sequencing complex genomes, designated "sequence sampled
CC mapping". The sequence sampled mapping method is useful for the
CC completion of high density sequence-based maps, and ultimately, for the
CC complete sequencing of genomic DNA directly from cosmid clones. See

CC AAQ82001-Q82706 for SRS primers. (Also see AAQ91325-58). (Updated on 25-
CC MAR-2003 to correct PN field.)
XX

SO Sequence 20 BP; 8 A; 2 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. NO. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 499 TCCCTGATGACATATTCGC 518
Db 20 TCTTATGTCACATTCTGC 1

RESULT 171
AAT37932/c
ID AAT37932 standard; cDNA; 20 BP.

AC AAT37932;

DT 30-APR-1997 (first entry)

DE VEGF-B167 exon 6B1 boundary 2.

KM Endothelial cell; proliferation; vascular endothelial growth factor; VPF;
KW VEGF; endothelium; mesodermal cell; cationic dimer; tissue regeneration;
KW vascular permeability factor; cell mitogen; angiogenesis; cell growth;
KW embryonic development; wound healing; tissue reorganisation; antibody;
KW cancer; metastatic risk; tumour cell; mouse; ss.

OS Mus musculus.

PN WO9626736-A1.

PD 06-SEP-1996.

PF 01-MAR-1996; 96MO-US002957.

PR 01-MAR-1995; 95US-00397651.

PR 06-JUN-1995; 95US-00469427.

PR 06-DEC-1995; 95US-00569063.

PA (LUDWIG) LUDWIG INST CANCER RES.

PI (UWHE-) UNIV HELSINKI LICENSING LTD OY.

PI Eriksson U, Olofsson B, Alitalo K, Pajusola K;

PI MPI; 1996-412582/41.

PT Vascular endothelial growth factor VEGF-B proteins - useful to accelerate
PT angiogenesis in wound healing, also related nucleic acid and antibodies
PT for cancer diagnosis.

XX Example 7; Page 28; 107bp; English.

CC AAT37919-T37932 represent the intron/exon boundaries for the murine
CC vascular endothelial growth factor (VEGF) proteins of the invention (see
CC AAQ84824-W04828, and AAQ84830), which promote endothelial or mesodermal
CC cell proliferation. VEGF is also a glycosylated cationic dimer, and is
CC sometimes referred to as vascular permeability factor (VPF). VEGF has
CC diverse effects, depending on the specific biological context in which it
CC is found. VEGF is a potent endothelial cell mitogen, and directly
CC contributes to induction of angiogenesis in vivo by promoting endothelial
CC cell growth during normal embryonic development, wound healing, and
CC tissue regeneration/reorganisation. The VEGF proteins of the invention
CC share the angiogenic and other properties of VEGF, but are distributed
CC and expressed in tissues differently to VEGF. The proteins can therefore
CC be used to accelerate angiogenesis in wound healing. Antibodies against
CC the proteins can be used for inhibiting angiogenesis. The antibodies can
CC also be used diagnostically to quantitatively detect VEGF-B. Primers
CC complementary to the coding sequences for the proteins of the invention
CC can also be used to detect VEGF-B coding sequences. Quantification of
CC VEGF-B in cancer biopsy specimens may be useful as an indicator of

CC metastatic risk. VEGF-B expression in a cell can be retarded using
 CC antisense sequences direct against the VEGF coding sequences, this is
 CC especially useful in retarding VEGF expression in tumour cells
 XX

Sequence 20 BP, 3 A; 8 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1192 CCTCCGACACCTGGGAGTG 1211

Db 20 CCTCCGACACCTGGGAGTG 1

RESULT 172
 AAT65908
 AAT65908 standard; DNA; 20 BP.

AC AAT65908;
 XX
 DT 25-MAR-2003 (revised)
 DT 18-JUN-1997 (first entry)
 DE Primer #1 to amplify repeat sequence marker Mfd56.

XX Polymorphism; repeat sequence; genetic marker; primer; amplification;
 KM PCR; polymerase chain reaction; paternity; maternity; human; pedigree;
 KM linkage analysis; genetic disease; animal; plant; breeding; locus;
 KM hybridisation; chromosome; ds.

OS Synthetic.

PN US5582979-A.

PD 10-DEC-1996.

PF 04-APR-1994; 94US-00222177.

PR 21-APR-1989; 89US-00341562.

PR 05-SEP-1991; 91US-00754351.

PA (MARS-) MARSHFIELD CLINIC.

PI Weber JL;

XX WPI; 1997-042299/04.

PT Detection of polymorphic genetic markers of the form (dc-da)n(dg-dt)n -
 XX using novel nucleic acid moles. as primers.

PS Disclosure; Col 11-12; 186pp; English.

XX The invention relates to the isolation of polymorphic repeat sequences
 CC having the sequence (dc-da)n.(dg-dt)n which can be used as genetic
 CC markers. Primers based on these sequences can be used to detect these
 CC repeats, especially for use in e.g. paternity or maternity testing, human
 CC genetic analysis such as linkage analysis of genetic disease, commercial
 CC animal or plant breeding or pedigree analysis. Clones containing the
 CC repeat sequences were isolated by hybridisation of chromosome-specific
 CC phase libraries with a synthetic poly(dc-da).(dg-dt) probe. Over 100
 CC repeat blocks were isolated. The primers AAT65798-T66047 were used to PCR
 CC amplify the inserts from the isolated clones containing the repeat
 CC sequences. The primers AAT65908-9 were used to amplify the repeat
 CC sequence marker clone Mfd56. (Updated on 25-MAR-2003 to correct PF
 CC field.)

XX Sequence 20 BP; 7 A; 5 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 660 CTGTGAGACACACACCT 679
 DB CTGTGATTCACACACCT 20

RESULT 173

AAK94030
 ID AAK94030 standard; DNA; 20 BP.

AC AAK94030;

XX 13-SEP-1999 (first entry)

DE PCR primer used to amplify an ORF of Chlamydia pneumoniae.

XX Respiratory disease; pneumonia; bronchitis; heart disease; sarcoidosis;
 KM sinusitis; purulent otitis media; erythema nodosum; pharyngitis; vaccine;
 KM neutralising epitope; PCR primer; ss.

OS Synthetic.

OS Chlamydia pneumoniae.

PN WO927105-A2.

PD 03-JUN-1999.

PF 20-NOV-1998; 98WO-1B001890.

PR 21-NOV-1997; 97FR-00014673.

PR 04-NOV-1998; 98US-0107078P.

PA (GEST) GENSET.

PI Griffiths R;

DR WPI; 1999-357842/30.

PT Genome sequence of Chlamydia pneumoniae.

PS Page 1638; Disclosure; 1912pp; English.

XX AAK91991-X97517 represent PCR primers used to amplify open reading frames
 CC and other nucleic acid sequences from the genome of Chlamydia pneumoniae
 CC (see AAK91990). C. pneumoniae causes respiratory disease such as
 CC pneumonia and bronchitis and is thought to be a contributing factor in
 CC heart disease, sarcoidosis, sinusitis, purulent otitis media, erythema
 CC nodosum or pharyngitis. The polypeptides encoded by the open reading
 CC frames of the C. pneumoniae genome (see AAK91584- AAK91587) can be used
 CC in immunogenic compositions as vaccines. Vectors containing C. pneumoniae
 CC nucleotide sequences can also be used as immunogenic compositions,
 CC especially where the vector directs the expression of a neutralising
 CC epitope of C. pneumoniae

XX Sequence 20 BP; 2 A; 8 C; 2 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 386 CCTTCTCTGACCTGAC 405
 DB 1 CCTTCTCTACAGTGC 20

RESULT 174

AAK60404/C
 ID AAK60404 standard; DNA; 20 BP.

AC AAK60404;

XX 06-OCT-2000 (first entry)

DE Human telomerase antisense oligonucleotide hEST23 SEQ ID NO.5.

```
XX Human; telomerase; antisense oligonucleotide; inhibition; hEST2;  
KW malignant tumour; cytostatic; telomerase inhibitor; liver cancer;  
KM lung cancer; breast cancer; brain glioma; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200027858-A1.  
XX  
PD 18-MAY-2000.  
XX  
PF 29-OCT-1999; 99WO-CN000173.  
XX  
PR 09-NOV-1998; 98CN-00124461.  
XX  
PA (RADI-) INST RADIATION MEDICINE ACAD MILITARY ME.  
XX  
PI Wang S, Zheng X, Zhu B, Xing R, Guan W, Sun Z;  
XX  
DR WPI; 2000-376478/32.  
XX  
PT Antisense oligonucleotides which inhibit human telomerase activity useful  
PT in the inhibition of malignant tumor growth, used to treat e.g. liver,  
PT lung and breast cancers and brain glioma.  
XX  
PS Claim 2; Page 4; 32pp; Chinese.  
XX  
CC AAA60400 to AAA60428 represent specifically claimed antisense  
CC oligonucleotides (1) complementary to a part of the gene encoding a  
CC protein subunit hEST2 of human telomerase that has reverse transcriptase  
CC activity, or its transcriptional mRNA. Also described are: (1) a  
CC pharmaceutical composition comprising (1); (2) a reagent kit for  
CC detecting telomerase hEST2 RNA component or DNA encoding telomerase hEST2  
CC containing (1); and (3) preparing a drug for treating a tumour,  
CC comprising the use of (1). The antisense oligonucleotides can inhibit  
CC telomerase activity, applicable in inhibiting the growth of malignant  
CC tumours e.g. for treatment of liver, lung and breast cancers and brain  
CC glioma  
XX  
SQ Sequence 20 BP; 1 A; 5 C; 11 G; 3 T; 0 U; 0 Other;  
XX  
Query Match 0.6%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.4e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
XX  
QY 144 AGCCCTGGCCCCGGCGGCC 163  
DB 20 AAGCCCTGGCCCCGGCGCACCC 1  
XX  
RESULT 175  
AAZ61526  
ID AAZ61526 standard; DNA; 20 BP.  
XX  
AC AAZ61526;  
XX  
DT 19-JUN-2000 (first entry)  
XX  
DE Primer 2L for a human 5'-OT EST (oxytloxin expressed sequence tag).  
XX  
KM Oxytloxin expressed sequence tag; 5'-OT EST; obesity; fertility; male;  
KM transgenic animal; human late onset obesity; late onset visceral obesity;  
KM male infertility; wasting; anorexia; cachexia; malabsorptive state;  
KM catabolic state; inflammatory condition; Crohn's disease; AIDS wasting;  
KM burn; cancer; bone disease; PCR primer; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200009686-A1.  
XX  
PD 24-FEB-2000.  
XX  
PF 12-AUG-1999; 99WO-GB002658.  
XX
```

```
XX  
PR 12-AUG-1998; 98GB-00017566.  
PR 06-MAY-1999; 99GB-00010522.  
XX  
PA (MEDI-) MEDICAL RES COUNCIL.  
XX  
PI Robinson ICAF, Stoye JP, Flavell D, Welle SE, Le Tissier P;  
XX  
DR WPI; 2000-224331/19.  
XX  
PT New anti-obesity polypeptide useful for treating obesity or infertility  
PT in mammals.  
XX  
PS Disclosure; Page 26; 162pp; English.  
XX  
CC PCR primers and probes AAZ61525-26 are used to amplify and identify human  
CC 5'-OT-EST (oxytloxin expressed sequence tag) cDNA sequences. The 5'-OT EST  
CC gene is involved in the control of obesity and fertility in males. 5'-OT  
CC EST nucleic acids are useful for producing transgenic animals. The  
CC transgenic animals created serve as a model for human late onset obesity  
CC and other related disorders and are also used for identifying the genetic  
CC cause of obesity. Compounds which modulate 5'-OT EST expression or  
CC activity are useful in the treatment or modulation of late onset visceral  
CC obesity or male infertility particularly in the disorders related to  
CC these conditions such as wasting, or anorexia, or cachexia associated  
CC with prolonged illness, or malabsorptive states or catabolic states  
CC associated with other diseases such as inflammatory conditions, Crohn's  
CC disease or AIDS wasting, or burns, or cancer, or bone disease  
XX  
SQ Sequence 20 BP; 4 A; 10 C; 3 G; 3 T; 0 U; 0 Other;  
XX  
Query Match 0.6%; Score 15.2; DB 1; Length 20;  
Best Local Similarity 85.0%; Pred. No. 1.4e+02;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
XX  
QY 358 GATCCAGCATCCTCTCCGCC 377  
DB 1 GAATCAGCACCTCTCCGCC 20  
XX  
RESULT 176  
AAA55723  
ID AAA55723 standard; DNA; 20 BP.  
XX  
AC AAA55723;  
XX  
DT 30-AUG-2000 (first entry)  
XX  
DE TRAF1 antisense oligonucleotide ISIS# 101874.  
XX  
KM Tumour necrosis factor receptor-associated factor; TRAF; human;  
KM antisense oligonucleotide; phosphorochiater; antiproliferative;  
KM anti-inflammatory; E-selectin; jun kinase; ss.  
XX  
OS Synthetic.  
XX  
PN WO2000020435-A1.  
XX  
PD 13-APR-2000.  
XX  
PF 05-OCT-1999; 99WO-US023171.  
XX  
PR 06-OCT-1998; 98US-00167109.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Baker BF, Cowser LM, Monia BP, Xu XS;  
XX  
DR WPI; 2000-303732/26.  
XX  
PT Antisense oligonucleotides targeted to nucleic acids encoding human tumor  
PT necrosis factor receptor-associated factor (TRAF), useful for treating  
PT diseases associated with TRAF expression such as inflammatory diseases.  
XX
```

XX Example 33; Page 99; 170pp; English.

XX CC The present invention relates to antisense oligonucleotides (see AA55496

CC -A55757) which are targeted to nucleic acids encoding a human tumour

CC necrosis factor receptor-associated factor (TRAF). The antisense

CC sequences comprise at least one modified internucleotide linkage, which

CC is a phosphorothioate linkage. The oligonucleotides also include at least

CC one modified sugar moiety such as a 2'-O-methoxyethyl sugar moiety.

CC Sequences AA55490-A55495 represent nucleotide sequences encoding human

CC TRAF-6. Included in the invention is a method for treating a human

CC having a disease associated with the expression of TRAF comprising

CC administering an antisense oligonucleotide. The reduction of Jun kinase

CC activation in cells comprises contacting the cells with an antisense

CC oligonucleotide targeted to TRAF-6. A method for the reduction of E-

CC selectin expression in cells or tissues comprises contacting the cells or

CC tissues with an antisense oligonucleotide targeted to TRAF-2 or TRAF-6.

CC The antisense oligonucleotides have antiproliferative and anti-

CC inflammatory activity and are useful for treating disorders associated

CC with cell proliferation and inflammation. The antisense oligonucleotides

CC may also be used as a diagnostic probe for studying gene function

SQ Sequence 20 BP; 4 A; 6 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 436 AGGTCATCTCAGTCTCCAG 455

|||||

1 AGGCCATCTCAGGCTCCAG 20

Db

RESULT 177

AAH56532/c

ID AAH56532 standard; DNA; 20 BP.

XX AAH56532;

AC 06-SEP-2001 (first entry)

DT

DE S. pneumoniae groE operon antisense oligonucleotide SEQ ID NO:180.

XX

XX Antisense oligonucleotide; groE; groEL; groES; inhibitor; growth;

KW microorganism; Escherichia coli; Streptococcus pneumoniae; diagnosis;

KW Streptococcus pyogenes; Staphylococcus aureus; Pseudomonas aeruginosa;

KW antibacterial; antiviral; antiproliferative; antisense therapy;

XX microbial infection; ss.

XX

OS Streptococcus pneumoniae.

XX

PN WO200136625-A2.

XX

PD 25-MAY-2001.

XX

PF 20-NOV-2000; 2000WO-CN001347.

XX

PR 18-NOV-1999; 99US-0166249P.

XX

PA (GENE-) GENSENSE TECHNOLOGIES INC.

XX

PI Wright JA, Young AH, Dugourd D;

XX

DR WPI; 2001-355633/37.

XX

PT Novel antisense compounds targeting nucleic acid encoding groEL or groES

PT gene of microorganism, which hybridize with and inhibit expression of the

XX gene, useful to inhibit growth of microorganism having the gene.

XX

PS Claim 3; Page 45; 110pp; English.

XX

CC The present invention specifically claims AAH56368 to AAH56832 which are

CC antisense oligonucleotides to nucleotide sequences encoding groE. More

CC generally, antisense compounds (I) comprising antisense oligonucleotides

CC of 5-50 bases targeted to a nucleotide sequence encoding groEL (heat

CC shock protein (HSP)60) (GL) and groES (HSP10) (GS) gene from a

CC microorganism, where the antisense compound is complementary to GL or GS

CC of a microorganism and specifically hybridises with and inhibits the

CC expression of GL or GS, is claimed. (I) have antibacterial, antiviral and

CC antiproliferative activities, and can be used in antisense therapy and

CC for inhibition of expression of groES or groEL. (I) are useful for

CC inhibiting expression of GL or GS in cells or tissues in vitro. (I) are

CC also useful for inhibiting the growth of a microorganism, or inhibiting

CC the expression of GL or GS gene in a microorganism (a bacterial cell or a

CC virus) having a GL or GS gene which involves administering to the

CC microorganism or to a cell infected with the microorganism, (I). (I) are

CC also useful for treating a mammalian pathological condition mediated by

CC the microorganisms which involves identifying a eukaryotic organism

CC having a pathological condition mediated by microorganisms having a GL or

CC GS gene and administering (I) such that the growth of microorganism is

CC inhibited. The antisense compounds are utilised for diagnostics,

CC therapeutics, prophylaxis and as research reagents and kits, e.g., to

CC prevent or delay microbial infections in humans. They are also useful as

CC molecular weight markers. AAH56362 to AAH56367 and AAH56833 to AAH56854

CC represent PCR primers for groE sequences which are used in the

CC exemplification of the present invention. AAH56855 to AAH56870 represent

CC groE nucleotide sequence given in the present invention

SQ Sequence 20 BP; 4 A; 6 C; 1 G; 9 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1548 AGCAAAAAGTCACTATTCA 1567

|||||

20 AGCAAGAAAGTCACTATTCA 1

Db

RESULT 178

AAH47273

ID AAH47273 standard; DNA; 20 BP.

XX AAH47273;

AC 30-NOV-2001 (first entry)

DT

DE Nucleotide sequence of PCR primer pCDNA-S1.

XX

XX Serine protease-like protein; C-PLACB100992; Alzheimer's disease;

KW pharmaceutical; nootropic; neuroprotective; gene therapy; PCR primer; ss.

XX

OS Synthetic.

XX

PN WO200109349-A1.

XX

PD 08-FEB-2001.

XX

PF 28-JUL-2000; 2000WO-JP005062.

XX

PR 29-JUL-1999; 99JP-00248036.

XX

PR 27-AUG-1999; 99JP-00300253.

XX

PR 18-OCT-1999; 99US-0159590P.

XX

PR 11-JAN-2000; 2000JP-00118776.

XX

PR 17-FEB-2000; 2000US-0183322P.

XX

PR 02-MAY-2000; 2000JP-00183767.

XX

PA (HELI-) HELIX RES INST.

XX

PI Ota T, Isegaki T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;

PI Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T, Yano K;

PI Murakami K, Kanazaki K, Inoue Y, Hashimoto E, Kashiwa A;

XX

DR WPI; 2001-564738/63.

XX

PT New genes encoding serine protease-like protein, useful for diagnosis and

```
PT treatment of Alzheimer's disease.
XX
PS Example 12; Page 33; 110pp; Japanese.
XX
CC The invention relates to genes encoding serine protease-like proteins.
CC The genes are human and murine C-PLACE100992. The proteins can be
CC expressed by standard recombinant methodology. The genes and proteins are
CC useful in the diagnosis of Alzheimer's disease, or developing
CC pharmaceuticals for treating the disease, and gene therapy. The present
CC sequence represents a PCR primer used during the course of the invention
XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 518 CACTGATTGCTGCTCATCG 537
DB 1 CACTGCTTACTGGCTTATCG 20

RESULT 179
AA168544
ID AA168544 standard; DNA; 20 BP.
XX
AC AA168544;
XX
DT 21-DEC-2001 (first entry)
XX
DE Human cytochrome p4502D6 associated primer SEQ ID 13.
XX
KW Cytochrome P450; human; metabolite toxicity; primer; ss.
XX
OS Homo sapiens.
XX
PN DE10012220-A1.
XX
PD 20-SEP-2001.
XX
PF 14-MAR-2000; 2000DE-01012220.
XX
PR 14-MAR-2000; 2000DE-01012220.
XX
PA (DOEH/) DOEHMER J.
XX
PI DoeHmer J, Krebsfaenger N, Eichelbaum M, Zanger UM;
XX
DR WPI; 2001-626902/73.
XX
PT Test system comprising cells expressing different cytochrome P450 2D6
PT alleles used to investigate genetically caused metabolite toxicity and to
PT determine toxic, mutagenic or carcinogenic effect of compounds.
XX
PS Example 1; Page 45; 72pp; German.
XX
CC This invention describes a novel test system comprising cells expressing
CC a cytochrome P450 2D6 (MCP2D6) allele heterolog, and at least three P450
CC 2D6 alleles are expressed in the system. The test system is used to
CC investigate genetically caused toxicity of metabolites, particularly
CC medicaments and to determine the toxic, mutagenic or carcinogenic effect of
CC compounds. This sequence represents a primer used to illustrate the
CC method of the invention
XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 518 CACTGATTGCTGCTCATCG 537
DB 1 CACTGCTTACTGGCTTATCG 20
```

```
RESULT 180
AAAF60328
ID AAFA60328 standard; DNA; 20 BP.
XX
AC AAFA60328;
XX
DT 10-MAY-2001 (first entry)
XX
DE Mouse Ig-kappa leader PCR primer #1.
XX
KW Mouse; endostatin; antitumour; cytostatic; antiarthritic; antipsoriatic;
KW antidiabetic; ophthalmological; gene therapy; angiogenic inhibitor;
KW adenoviral vector; diabetic retinopathy; cardiovascular disease;
KW arthritis; psoriasis; cerebral oedema; intravascular coagulopathy;
KW lymphoma; leukaemia; immunoglobulin; Ig; Ig-kappa; PCR primer; ss.
XX
OS Mus sp.
XX
PN WO200112830-A1.
XX
PD 22-FEB-2001.
XX
PF 11-AUG-2000; 2000MO-EP007865.
XX
PR 13-AUG-1999; 99US-00373938.
XX
PA (NOVS ) NOVARTIS AG.
XX
PA (NOVS ) NOVARTIS-ERFINDUNGEN VERW GES MBH.
XX
PI Hallenbeck PL, Chen CT;
XX
DR WPI; 2001-202871/20.
XX
PT Adenoviral vector for treating tumors and disorders associated with
PT angiogenesis, such as cancer, arthritis, and psoriasis, comprises a DNA
PT sequence encoding an angiogenic inhibitor, particularly endostatin.
XX
PS Example 1; Page 17; 59pp; English.
XX
CC The present sequence was used in the construction of an adenoviral vector
CC which includes a DNA sequence encoding endostatin. The adenoviral vector
CC is useful for expressing endostatin in a mammalian cell such as an A549
CC or Hep3B cell. It is useful for treating other diseases and disorders
CC associated with angiogenesis, such as neovascular diseases of the eye,
CC including diabetic retinopathy, cardiovascular disease, arthritis,
CC psoriasis, cerebral oedema and intravascular coagulopathy (Kasabach-
CC Merritt syndrome). The vector inhibits, prevents or destroys the growth
CC of tumours by preventing the formation of blood vessels in tumours, such
CC as lymphoma and leukaemia
XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 518 CACTGATTGCTGCTCATCG 537
DB 1 CACTGCTTACTGGCTTATCG 20

RESULT 181
AAH80588/c
ID AAH80588 standard; cDNA; 20 BP.
XX
AC AAH80588;
XX
DT 11-SEP-2003 (revised)
DT 19-SEP-2001 (first entry)
XX
DE Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 552.
```

```
XX Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
KM disease diagnosis; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN US6251588-B1.
XX
PD 26-JUN-2001.
XX
PF 10-FEB-1998; 98US-00021701.
XX
PR 10-FEB-1998; 98US-00021701.
XX
PA (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI Shannon KM, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
XX
DR WPI; 2001-424456/45.
XX
PT Predicting the potential of an oligonucleotide to hybridize to a target
PT nucleotide sequence, useful for evaluating oligonucleotide probe
PT sequences, by identifying a oligonucleotides based on the evaluation of
PT parameters.
XX
PS Example 2; Col 65; 342pp; English.
XX
CC The present invention describes a method for predicting the potential of
CC an oligonucleotide to hybridize to a (complementary) target nucleotide
CC sequence, involving identifying a subset of oligonucleotides within the
CC predetermined number of unique oligonucleotides based on the evaluation
CC of the parameter. Oligonucleotides in the subset are identified that are
CC clustered along a region of the nucleotide sequence that is hybridisable
CC to the target nucleotide sequence. This is useful for evaluating
CC oligonucleotide probe sequences. The present sequence is an
CC oligonucleotide described in the exemplification of the invention.
CC (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ Sequence 20 BP; 3 A; 2 C; 1 G; 14 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1543 TTAAGAGGAAAAAGTCAGTA 1562
DB 20 TTAAGAGGAAAAAGTCAGTA 1
XX
RESULT 182
AAH80589/C
ID AAH80589 standard; cDNA; 20 BP.
XX
AC AAH80589;
XX
DT 11-SEP-2003 (revised)
DT 19-SEP-2001 (first entry)
XX
DE Oligonucleotide hybridisation potential related cDNA SEQ ID NO: 553.
XX
KW Nucleic acid hybridisation; probe; primer; human; rabbit; HIV-1;
KW disease diagnosis; ss.
XX
OS Human immunodeficiency virus 1.
XX
PN US6251588-B1.
XX
PD 26-JUN-2001.
XX
PF 10-FEB-1998; 98US-00021701.
XX
PR 10-FEB-1998; 98US-00021701.
XX
XX
```

```
PA (AGIL-) AGILENT TECHNOLOGIES INC.
XX
PI Shannon KM, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
XX
DR WPI; 2001-424456/45.
XX
PT Predicting the potential of an oligonucleotide to hybridize to a target
PT nucleotide sequence, useful for evaluating oligonucleotide probe
PT sequences, by identifying a oligonucleotides based on the evaluation of
PT parameters.
XX
PS Example 2; Col 65; 342pp; English.
XX
CC The present invention describes a method for predicting the potential of
CC an oligonucleotide to hybridize to a (complementary) target nucleotide
CC sequence, involving identifying a subset of oligonucleotides within the
CC predetermined number of unique oligonucleotides based on the evaluation
CC of the parameter. Oligonucleotides in the subset are identified that are
CC clustered along a region of the nucleotide sequence that is hybridisable
CC to the target nucleotide sequence. This is useful for evaluating
CC oligonucleotide probe sequences. The present sequence is an
CC oligonucleotide described in the exemplification of the invention.
CC (Updated on 11-SEP-2003 to standardise OS field)
XX
SQ Sequence 20 BP; 4 A; 2 C; 1 G; 13 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1542 TTAAGAGGAAAAAGTCAGT 1561
DB 20 TTAAGAGGAAAAAGTCAGT 1
XX
RESULT 183
AAH26100/C
ID AAH26100 standard; DNA; 20 BP.
XX
AC AAH26100;
XX
DT 17-SEP-2001 (first entry)
XX
DE VEGF receptor Flt-1 internal reverse PCR primer.
XX
KW Flt-1; vascular endothelial growth factor; VEGF; receptor; VEGF148;
KW human; cancer; tumour; antitumour; vascular disease; kidney disease;
KW arthritis; antiarthritis; therapy; PCR primer; ss.
XX
OS Homo sapiens.
XX
PN WO200153345-A1.
XX
PD 26-JUL-2001.
XX
PR 20-JAN-2000; 2000WO-GB000134.
XX
PR 20-JAN-2000; 2000WO-GB000134.
XX
PA (NBRI-) NORTH BRISTOL NHS TRUST.
XX
PI Harper SJ;
XX
DR WPI; 2001-465370/50.
XX
PT Treating or preventing e.g. tumor growth and metastasis, arthritis,
PT psoriasis, comprises inducing vascular endothelial growth factor (VEGF)
PT heterodimer formation in vivo, or administering a pre-formed VEGF
PT heterodimer.
XX
PS Example 1; Page 22; 37pp; English.
XX
CC The present sequence is that of an internal reverse PCR primer for human
```


CC which is then detected. The sequences represent cDNA encoding human and
XX mouse SACL polypeptides and PCR primers specific for the SACL genes
SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1991 TGGGGGTGGCATGACACCC 2010
DB 20 TGGAGGTGACATGATATACC 1

RESULT 186
ABK37128/c
ID ABK37128 standard; DNA; 20 BP.

XX ABK37128;

XX 08-MAY-2002 (first entry)

XX Human lysophospholipase I gene, antisense oligonucleotide #80.

XX Human; mouse; antiinflammatory; antiarteriosclerotic; vasotropic;

XX antilipemic; cardiant; lysophospholipase I; inflammation; ischaemia;

XX hyperlipidaemia; cardiovascular disorder; atherosclerosis;

XX antisense gene therapy; primer; ss.

XX Homo sapiens.

XX Synthetic.

XX WO200210185-A1.

XX 07-FEB-2002.

XX 20-JUL-2001; 2001WO-US022975.

XX 31-JUL-2000; 2000US-00629645.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Wyatt JR;

XX WPI, 2002-188720/24.

XX Novel antisense compound useful for treating inflammation,

XX hyperlipidemia, and cardiovascular disorders such as atherosclerosis and

XX myocardial ischemia, inhibits lysophospholipase I.

XX Claim 3; Page 82; 131pp; English.

XX The invention relates to an antisense compound (I) 8-30 nucleobases in

XX length targeted to a nucleic acid molecule encoding lysophospholipase I

XX (II), where (I) specifically hybridizes with and inhibits the expression

XX of (II). (I) is useful for inhibiting the expression of (II) in cells or

XX tissues, and for treating a human having a disease or condition

XX associated with lysophospholipase I e.g. inflammation, hyperlipidaemia,

XX and cardiovascular disorders such as atherosclerosis and myocardial

XX ischemia. (I) is useful as research reagent and diagnostics. (I) is also

XX useful for distinguishing functions of various members of a biological

XX pathway. (I) is useful in antisense gene therapy. ABK37028-ABK37191

XX represent lysophospholipase I coding sequences, antisense

XX oligonucleotides and related PCR primers of the invention. Note:

XX CC 2'-methoxyethyl (2'-MOE) nucleotides are modified such that bases 1-5 and 16-20 are

XX linkages, and all cytidines are 5-methyl cytidines

XX Sequence 20 BP; 0 A; 8 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 4 CCGGAACGCCAGCGCCGG 23
DB 20 CCGGAAGCCACCGCCGG 1

RESULT 187
ABQ72917/c
ID ABQ72917 standard; DNA; 20 BP.

XX ABQ72917;

XX 19-SEP-2002 (first entry)

XX Laminin 5 expression construct preparation primer SEQ ID NO:22.

XX Laminin alpha 5; laminin 10; vulnery; cell growth; differentiation;

XX tissue repair development; laminin; healing; vascular tissue;

XX re-endothelialisation; vascular injury; cell attachment; cell stasis;

XX proliferation; migration; primer; ss.

XX Homo sapiens.

XX Synthetic.

XX WO200250111-A2.

XX 27-JUN-2002.

XX 21-DEC-2001; 2001WO-US051035.

XX 21-DEC-2000; 2000US-0257449P.

XX 28-MAR-2001; 2001US-0279282P.

XX 13-NOV-2001; 2001US-00279282.

XX (BIOS-) BIOSTRATUM INC.

XX Trygsvaeson K, Doi M, Thyboll J;

XX WPI, 2002-557650/59.

XX New human laminin-10 proteins, useful for accelerating the healing of

XX vascular tissue, improving the biocompatibility of grafts, or for

XX promoting re-endothelialization at the site of vascular injuries.

XX Disclosure; Page 9; 231pp; English.

XX The present invention describes human laminin alpha 5. Also described is

XX an isolated laminin 10. Laminin 10 has vulnery activity. Laminins are

XX useful in maintaining cell/tissue phenotype as well as promoting cell

XX growth and differentiation in tissue repair development. Specifically,

XX laminin 10 can be used for accelerating the healing injuries of vascular

XX tissue, improving the biocompatibility of grafts useful for treating such

XX injuries, for promoting re-endothelialisation at the site of vascular

XX injuries, and promoting cell attachment and subsequent cell stasis,

XX proliferation, differentiation, and/or migration. The present sequence

XX represents a primer used in the preparation of a laminin 5 expression

XX construct, which is used in the exemplification of the present invention

XX Sequence 20 BP; 5 A; 4 C; 9 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 450 CTCGAGTGGTCTGTCCTT 469
DB 20 CCCGAGTGATCTGCTCTT 1

RESULT 188
ABK70817
ID ABK70817 standard; DNA; 20 BP.

```
AC ABK70817;
XX
XX 15-JUL-2002 (first entry)
XX
XX Human TSPI domain containing gene PCR primer pCDNA-S1.
DE
XX TSPI; thrombospondin domain; PCR; primer; ss; FG06969; FG01896;
KM angiogenesis; vasculogenesis.
XX
XX Homo sapiens.
OS
XX JF2002085059-A.
PN
XX
XX 26-MAR-2002.
PD
XX
XX 08-SEP-2000; 2000JP-00273778.
PF
XX
XX 08-SEP-2000; 2000JP-00273778.
PR
XX
XX (KAZU-) 2H KAZUSA DNA KENKYUSHO.
PA
XX (YOSH ) YOSHITOMI PHARM IND KK.
XX
XX WPI; 2002-378268/41.
DR
XX
XX TSPI domain-containing polypeptide useful for drug compositions.
PT
XX
XX Example 6; Page 20; 51pp; Japanese.
PS
XX
XX The invention relates to a TSPI (thrombospondin 1) domain-containing
CC polypeptide comprising the proteins appearing as AA080188 and AA080189,
CC encoded by cDNAs designated FG06969 and FG01896. Also included are
CC proteins that are 50% homologous to the proteins and a polypeptide having
CC at least one deletion, replacement, addition or insertion of amino acid
CC in the proteins and having at least 8 repetitions of the TSPI domain. The
CC polypeptide can be used in drug compositions particularly for disorders
CC associated with angiogenesis and vasculogenesis. The present sequence is
CC a PCR primer for the TSPI domain containing DNA sequences
XX
XX Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.6%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 1.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY
XX 518 CACTGATGCTGCCTCATCG 537
XX ||||| ||||| ||||| |||||
DB 1 CACTGCTACTGCTTATCG 20
XX
XX RESULT 189
XX AAD35752/c
XX ID AAD35752 standard; DNA; 20 BP.
XX
XX AAD35752;
AC
XX
XX 26-JUL-2002 (first entry)
DT
XX
XX Human h1beta4BP antisense oligonucleotide, ISIS #129477.
DE
XX
XX Antisense; human Integrin beta 4 binding protein; h1beta4BP; cytostatic;
KM cell proliferation; cancer; gene therapy; phosphorothioate backbone; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
```

```
FT modified_base 14
FT /tag= d
FT /mod_base= m5c
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 17
FT /tag= e
FT /mod_base= m5c
FT modified_base 19
FT /tag= f
FT /mod_base= m5c
XX
XX US6355482-B1.
PN
XX
XX 12-MAR-2002.
PD
XX
XX 17-NOV-2000; 2000US-00716161.
PF
XX
XX 17-NOV-2000; 2000US-00716161.
PR
XX
XX 17-NOV-2000; 2000US-00716161.
XX
XX (ISIS-) ISIS PHARM INC.
PA
XX
XX Bennett CF, Freiler SM;
PI
XX
XX WPI; 2002-370579/40.
DR
XX
XX Claim 3; Col 45-46; 40pp; English.
PS
XX
XX The invention relates to antisense compounds targeted to a nucleic acid
CC encoding human Integrin beta 4 binding protein (h1beta4BP), which
CC specifically hybridises with the nucleic acid and inhibits its
CC expression. The antisense compounds are useful to prevent or treat
CC diseases associated with h1beta4BP expression, particularly conditions
CC involving aberrant or deregulated cell proliferation (e.g. cancer). The
CC h1beta4BP polynucleotide is used in gene therapy. The present sequence is
CC an antisense oligonucleotide targeted to h1beta4BP
XX
XX Sequence 20 BP; 9 A; 3 C; 7 G; 1 T; 0 U; 0 Other;
SQ
XX
XX Query Match 0.6%; Score 15.2; DB 1; Length 20;
XX Best Local Similarity 85.0%; Pred. No. 1.4e+02;
XX Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY
XX 1633 TCAGCTAACCTCTCTTTC 1652
XX ||||| ||||| ||||| |||||
DB 20 TCAGCTGTCCTCTCTTTC 1
XX
XX RESULT 190
XX AAD44835/c
XX ID AAD44835 standard; DNA; 20 BP.
XX
XX AAD44835;
AC
XX
XX 13-DEC-2002 (first entry)
DT
XX
XX Human raf kinase related antisense oligonucleotide #14.
DE
XX
XX Raf kinase; hyperproliferation; neovascularisation; ocular angiogenesis;
KM therapy; cancer; cytostatic; anti-angiogenic; vascular; ophthalmological;
KM antisense; ss.
XX
XX Unidentified.
OS
XX
XX US6410518-B1.
PN
XX
XX 25-JUN-2002.
PD
```


XX 18-FEB-2000; 2000US-00506073.
PF 31-MAY-1994; 94US-00250856.
XX 31-MAY-1995; 95WO-US007111.
PR 26-NOV-1996; 96US-00756806.
XX 07-JUL-1997; 97US-00888982.
PR 06-JUL-1998; 98WO-US013961.
XX 28-AUG-1998; 98US-00143214.
PA (ISIS-) ISIS PHARM INC.
XX Monia BP;
XX MPI; 2002-597918/64.
DR Treating cancer, angiogenesis or neovascularization by administering
XX antisense oligonucleotides targeted to human raf sequences.
XX PS Disclosure; Col 59; 41pp; English.
XX The present invention relates to novel antisense oligonucleotides which
CC are targeted to nucleic acids encoding human raf proteins and capable of
CC inhibiting raf expression. The invention also relates to methods of
CC inhibiting hyperproliferation of cells which involves contacting the
CC hyperproliferating cells with a therapeutically effective amount of an
CC oligonucleotide of the invention. The method is useful for treating
CC cancer, angiogenesis or neovascularisation, especially ocular
CC angiogenesis or neovascularisation. The present DNA sequence is human raf
CC kinase related antisense oligonucleotide
XX
SQ Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1873 CGGTGTCGAGGGCAGTAG 1892
DB 20 CAGTGTGTGAGGGCAGCAG 1
RESULT 191
ABK94252
ID ABL94252 standard; DNA; 20 BP.
XX
AC ABL94252;
XX
DT 29-JUL-2002 (first entry)
XX
DE Human C/EBP beta phosphorothioate antisense oligonucleotide, SEQ ID:18.
XX
XX Human; C/EBP beta; CCAAT/enhancer-binding protein beta; C/EBP2; LAP;
KW TCF5; CRP2; NFIL6; IL6DB; NF-M; AGP/EBP; Apc/EBP; transcription factor;
KW tissue development; cellular function; proliferation; differentiation;
KW hormone responsiveness; oxidative stress response;
KW IL-6 signalling mediator; interleukin-6; carbohydrate metabolism;
KW immunity; Th1 response; female fertility; gluconeogenesis; ovarian;
KW cancer; tumour formation; type II; diabetes; infection; inflammation;
KW expression inhibition; phosphorothioate; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
XX Key Location/Qualifiers
FH modified_base 1..20
FT /*tag= a
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages"
FT modified_base 1..5
FT /*tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
FT cytosines are 5-methylcytosine"

FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides. All 2' MOE
FT cytosines are 5-methylcytosine"
US6271030-B1.
PD 07-AUG-2001.
XX
PF 14-JUN-2000; 2000US-00593711.
XX
XX 14-JUN-2000; 2000US-00593711.
XX
XX 14-JUN-2000; 2000US-00593711.
XX
XX (ISIS-) ISIS PHARM INC.
XX Monia BP, Butler MM, Wyatt J;
XX MPI; 2002-214451/27.
DR Novel antisense compound targeted to nucleic acids encoding human or
XX inhibiting expression of human or mouse C/EBP beta in cells/tissues.
XX
PS Claim 1; Col 42; 69pp; English.
XX
CC Sequences ABL94252-ABL94476 represent antisense oligonucleotides targeted
CC to the human or mouse CCAAT/enhancer-binding protein alpha (C/EBP alpha)
CC gene, which inhibit its expression. The antisense oligonucleotides were
CC designed to target different regions of the human and/or mouse C/EBP
CC alpha RNA, and were analysed for their effect on C/EBP alpha mRNA levels
CC by quantitative real-time PCR. The C/EBP family of proteins are a family
CC of transcription factors which regulate the expression of a wide range of
CC genes that control normal tissue development, cellular function, cellular
CC proliferation and functional differentiation. C/EBP beta (also known as
CC C/EBP2, LAP, TCF5, CRP2, NFIL6, IL6DB, NF-M, AGP/EBP and Apc/EBP)
CC primarily regulates hormone responsiveness and oxidative stress responses
CC and is a mediator of IL-6 (interleukin-6) signalling. C/EBP beta is
CC thought to be involved in carbohydrate metabolism, immunity, the Th1
CC response, female fertility and gluconeogenic pathways. C/EBP beta is
CC expressed in the liver, lung, spleen, kidney, brain, and testis, with the
CC highest expression found in the lung. It is also expressed at a higher
CC level in malignant ovarian tissue compared with normal ovarian tissue,
CC and its expression in pancreas is upregulated in response to chronically
CC elevated levels of glucose, indicating that it is involved in the
CC impairment of insulin secretion in type II diabetes. The oligonucleotides
CC of the invention are useful for diagnosis, prevention and treatment of
CC conditions associated with C/EBP beta expression, such as cancer
CC (particularly ovarian cancer), tumour formation, diabetes (particularly
CC type II diabetes), infection, or inflammation
XX
SQ Sequence 20 BP; 0 A; 9 C; 3 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 21 CGCTGCCGCCCTCTGCTGGG 40
DB 1 CTGCTGCCGCCCTGCTGGG 20
RESULT 192
ABK49833
ID ABL49833 standard; DNA; 20 BP.
XX
AC ABL49833;
XX
DT 15-JUL-2002 (first entry)
XX
DE Human ADAMTS protein sequencing primer pcDNA-S1.
XX
XX Human; ss; ADAMTS; cytostatic; antidiabetic; antirheumatic;

PD 31-JUL-2003.
XX
XX 22-JAN-2003; 2003WC-US001651.
PF
XX 22-JAN-2002; 2002US-00045360.
XX
PR 03-APR-2002; 2002US-0370008P.
XX
XX (UYPE-) UNIV PENNSYLVANIA.
PA
XX Whitehead AS, Challberg SS, Lazar JG;
PI WPI; 2003-748014/70.
DR
XX
XX Determining steroid responsiveness, useful e.g. for monitoring, or
PT assessing likely success of therapy, comprises measuring relative
PT expression of responsive and non-responsive genes.
XX
XX Example 1; Page 29; 0pp; English.
PS
XX The present sequence is that of primer GREIF, which was used in the PCR
CC mutagenesis of the human serum amyloid A1 (SAA1) gene promoter to produce
CC construct GREI (see ACF79439). GREI was used to confirm that a putative
CC glucocorticoid responsive element of SAA1 is functional. A method for
CC determining steroid responsiveness involves determining, in a tissue, of
CC body fluid or cell sample from a subject being treated with steroids, the
CC RNA expression levels of genes that are known to be, or suspected of
CC being, respectively, responsive and non-responsive to steroids. The first
CC gene is preferably the SAA1 gene controlled by a GRE, and the second gene
CC is the SAA2 gene; the responses of only the SAA1 gene are augmented by
CC glucocorticoid administration. The method is applied to subjects being
CC treated with steroids for a very wide range of diseases (e.g.
CC inflammation, cancer, autoimmune disease, arthritic diseases, coronary
CC artery disease, endocrine disease, stroke etc.), e.g. for monitoring to
CC detect loss of responsiveness, to detect response when a combination of
CC stimuli or drugs is administered and to assess side effects, to evaluate
CC subjects for transplantation or steroid therapy, and to determine
CC suitable doses of steroids
XX
XX Sequence 20 BP; 4 A; 9 C; 2 G; 5 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1634 CAGCTAACCTCTTCTCTCC 1653
DB 1 CAGCAAACTCTTGTCTCC 20
RESULT 195
ADD81480/C
ID ADD81480 standard; DNA; 20 BP.
XX
XX ADD81480;
AC
XX
XX 29-JAN-2004 (first entry)
DT
XX
XX HIV PRT antisense derived probe #409.
DE
XX
XX ss; oligonucleotide hybridisation potential; efficient hybridisation;
KM large array; minimum oligonucleotide synthesis; probe.
XX
XX Human immunodeficiency virus.
OS
XX
XX US2003054346-A1.
PN
XX
XX 20-MAR-2003.
PD
XX
XX 15-FEB-2001; 2001US-00784674.
PF
XX
XX 10-FEB-1998; 98US-00021701.
PR
XX
XX (SHAN/) SHANNON K W.

PA (WOLB/) WOLBER P K.
PA (DELE/) DELENSTARR G C.
PA (WEBB/) WEBB P G.
PA (KINC/) KINCAID R H.
PI Shannon KW, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
PI WPI; 2003-743746/70.
DR
XX
XX Predicting potential of oligonucleotides to hybridize to target
PT nucleotide sequence comprises determining and evaluating for each
PT oligonucleotide a parameter predictive of the oligonucleotides ability to
PT hybridize with target.
XX
XX Example 2; SEQ ID NO 553; 423pp; English.
PS
XX The invention relates to a method of predicting the potential of
CC oligonucleotides to hybridise to target nucleotide sequences. The method
CC is useful for predicting the potential of an oligonucleotide to hybridise
CC to a target nucleotide sequence, e.g. RNA or DNA or a sequence that
CC contains chemically modified nucleotides. The method is also useful for
CC predicting the potential of the oligonucleotides to hybridise to a
CC complementary target nucleotide sequence. The method is useful to predict
CC efficient hybridisation oligonucleotides for each of multiple target
CC sequences therefore very large arrays may be constructed and tested with
CC minimum synthesis of oligonucleotides. The present sequence represents a
CC HIV PRT antisense derived probe.
XX
XX Sequence 20 BP; 4 A; 2 C; 1 G; 13 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1542 TTAAGACGAAAGACTCACT 1561
DB 20 TTAAGAAAGAAAAAATCACT 1
RESULT 196
ADD81479/C
ID ADD81479 standard; DNA; 20 BP.
XX
XX ADD81479;
AC
XX
XX 29-JAN-2004 (first entry)
DT
XX
XX HIV PRT antisense derived probe #408.
DE
XX
XX ss; oligonucleotide hybridisation potential; efficient hybridisation;
KM large array; minimum oligonucleotide synthesis; probe.
XX
XX Human immunodeficiency virus.
OS
XX
XX US2003054346-A1.
PN
XX
XX 20-MAR-2003.
PD
XX
XX 15-FEB-2001; 2001US-00784674.
PF
XX
XX 10-FEB-1998; 98US-00021701.
PR
XX
XX (SHAN/) SHANNON K W.
PA (WOLB/) WOLBER P K.
PA (DELE/) DELENSTARR G C.
PA (WEBB/) WEBB P G.
PA (KINC/) KINCAID R H.
PI Shannon KW, Wolber PK, Delenstarr GC, Webb PG, Kincaid RH;
PI WPI; 2003-743746/70.
DR
XX
XX Predicting potential of oligonucleotides to hybridize to target

PT nucleotide sequence comprises determining and evaluating for each
PT oligonucleotide a parameter predictive of the oligonucleotide's ability to
XX hybridize with target.
PS Example 2; SEQ ID NO 552; 423bp; English.
XX
CC The invention relates to a method of predicting the potential of
CC oligonucleotides to hybridize to target nucleotide sequences. The method
CC is useful for predicting the potential of an oligonucleotide to hybridize
CC to a target nucleotide sequence, e.g., RNA or DNA or a sequence that
CC contains chemically modified nucleotides. The method is also useful for
CC predicting the potential of the oligonucleotides to hybridize to a
CC complementary target nucleotide sequence. The method is useful to predict
CC efficient hybridization oligonucleotides for each of multiple target
CC sequences therefore very large arrays may be constructed and tested with
CC minimum synthesis of oligonucleotides. The present sequence represents a
CC HIV PRT antisense derived probe.
XX
SQ Sequence 20 BP; 3 A; 2 C; 1 G; 14 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1543 TAAGAGGAAAAAGTCAGTA 1562
Db 20 TAAAGAAAGAAAAATCAGTA 1
RESULT 197
AB293072
ID AB293072 standard; DNA; 20 BP.
XX
AC AB293072;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiaesthetic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002MO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 8314; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiaesthetic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 12 A; 1 C; 3 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1543 TAAGAGGAAAAAGTCAGTA 1562
Db 1 TAAAGAAAGAAAAATGTCATTA 20
RESULT 198
AB291914
ID AB291914 standard; DNA; 20 BP.
XX
AC AB291914;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KW Human; antisense; lung dysfunction; nasal airway dysfunction;
KW antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KW antiaesthetic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KW lung inflammation; respiratory disease; ds.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002MO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 7156; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiaesthetic, hypotensive,
CC immunosuppressive, and cyostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 9 A; 2 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.64; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2388 TATATGCTTGAATAATAT 2407
Db 1 TATATGCTTTAAAAAAT 20

RESULT 199
AB293016
ID AB293016 standard; DNA; 20 BP.
XX
AC AB293016;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human oligonucleotide sequence.
XX
KM Human; antisense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antiaesthetic; hypotensive; immunosuppressive; cyostatic; gene therapy;
KM antisense gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; de.
XX
OS Homo sapiens.
XX
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
RA (EPIC-) EPIGENESIS PHARM INC.
XX
PI Myce JW, Li Y, Sandrasegura A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S,
XX
DR MPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antisense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ubiquinone.
XX
PS Disclosure; SEQ ID NO 8258; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antisense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,

CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ubiquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antiaesthetic, hypotensive,
CC immunosuppressive, and cyostatic activity. The composition may have a
CC use in antisense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences

XX SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 0.64; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1554 AAGTCAGATTTCAAGTCT 1573
Db 1 AGCTCAGATTTCAAGTCT 20

RESULT 200
ACD42151/c
ID ACD42151 standard; DNA; 20 BP.
XX
AC ACD42151;
XX
DT 05-SEP-2003 (first entry)
XX
DE Human raf-associated antisense oligonucleotide #13.
XX
KM Antisense; c-raf; a-raf; b-raf; protein kinase; cancer; ss;
KM signal transduction; cell proliferation; lung carcinoma; cyostatic;
KM antisense gene therapy; chemotherapeutic agent; angiogenesis;
KM hyperproliferative condition; neovascularisation; ocular angiogenesis.
XX
OS Unidentified.
XX
PN US2003032607-A1.
XX
PD 13-FEB-2003.
XX
PF 25-JAN-2002; 2002US-00057550.
XX
PR 31-MAY-1994; 94US-00250856.
PR 31-MAY-1995; 95WO-US007111.
PR 26-NOV-1996; 96US-00756806.
PR 07-JUL-1997; 97US-00889882.
PR 06-JUL-1998; 98WO-US013961.
PR 28-AUG-1998; 98US-00143214.
PR 18-FEB-2000; 2000US-00506073.
XX
PA (MONT/) MONIA B P.
XX
PI Monia BP,
XX
DR MPI; 2003-503332/47.
XX
PT Novel antisense oligonucleotide which is targeted to mRNA encoding human
PT raf and which is capable of inhibiting raf expression, useful for
PT treating or preventing hyperproliferative conditions such as cancer.
XX
PS Disclosure; Page 31; 42pp; English.
XX
CC The invention relates to an oligonucleotide 8-50 nucleotides in length

CC which is targeted to mRNA encoding human c-raf, a-raf or b-raf (raf is a
CC protein kinase playing a regulatory role in signal transduction,
CC regulating cell proliferation and has been implicated in lung carcinoma),
CC and which is capable of inhibiting raf expression. Also included is a
CC composition comprising the oligonucleotide and a pharmaceutically
CC acceptable carrier. The antisense oligonucleotide is useful for
CC inhibiting the expression of human raf in human cells or tissues, by
CC contacting the human cells or tissues with the oligo. The oligo, is also
CC is useful for treating or preventing a disease or condition associated
CC with the expression of raf by administering it in combination with a
CC chemotherapeutic agent to a human or cells of the human, where the
CC expression of raf is abnormal expression, and the condition is a
CC hyperproliferative condition such as cancer, angiogenesis or
CC neovascularisation (preferably ocular angiogenesis or
CC neovascularisation). The oligo, is also useful for inhibiting
CC hyperproliferation of cells. The oligos, are also useful as tools, for
CC example for detecting and determining the role of raf expression in
CC various cell functions and physiological processes and conditions and for
CC diagnosing conditions associated with raf expression and for research
CC purposes. The present sequence is an antisense oligonucleotide included
CC in the sequence listing but not mentioned elsewhere in the specification
XX

SQ Sequence 20 BP; 3 A; 10 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1873 CCCTTGTGAGGCGAGTAG 1892
|||
20 CAGTGGTGTGAGGCGAGTAG 1

RESULT 201

ID ABD28144 standard; DNA; 20 BP.

AC ABD28144;

DT 29-JUL-2004 (first entry)

DE AA156940-derived oligonucleotide SEQ ID 7156.

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiasthmatic; antiinflammatory; antiallergic;
KW analgesic; hypotensive; immunosuppressive; cytoskeletal; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

PN WO200265309-A2.

XX 31-OCT-2002.

PF 23-APR-2002; 2002WO-US013143.

PR 24-APR-2001; 2001US-0286036P.

PA (EPIC-) EPIGENESIS PHARM INC.

PI Nyce JM, Li Y, Sandraagra A, Katz E, Pabalan J, Aguilar D;

PI Miller S, Tang L, Shahabuddin S;

DR WPI; 2003-093058/08.

PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.

XX Claim 15; SEQ ID NO 7156; 763bp; English.

XX This invention describes a novel composition (a) a first active agent,
XX comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiasthmatic, antiinflammatory, antiallergic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or surfactant hypoproduction and/or lung
CC inflammation, allergies and/or bronchoconstriction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, cancer,
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it

SQ Sequence 20 BP; 9 A; 2 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2388 TATATGCTTGAATAAAT 2407
|||
1 TATATGCTTGAATAAAT 20

RESULT 202

ID ABD29246 standard; DNA; 20 BP.

AC ABD29246;

DT 29-JUL-2004 (first entry)

DE H16833-derived oligonucleotide SEQ ID 8258.

KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiasthmatic; antiinflammatory; antiallergic;
KW analgesic; hypotensive; immunosuppressive; cytoskeletal; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.

OS Homo sapiens.

PN WO200265309-A2.

XX 31-OCT-2002.

PF 23-APR-2002; 2002WO-US013143.

PR 24-APR-2001; 2001US-0286036P.

XX (EPiG-) EPIGENESIS PHARM INC.
PA
XX
PI Nyce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 8258; 763bp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC inflammation, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hyperextension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1554 AAGTCAGTATTCACAGTCT 1573
| | | | | | | | | | | | | | | | | | | | | |
1 AGGTCAGAAATTCACAGCTCT 20
DB
RESULT 203
ABD29302
ID ABD29302 standard; DNA; 20 BP.
XX
AC ABD29302;
XX
DT 29-JUL-2004 (first entry)
XX
DE AA644211-derived oligonucleotide SEQ ID 8314.
XX
XX Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KM respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KM surfactant depletion; anti-allergic; anti-inflammatory; antiasthmatic;
KM analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;
KM beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KM respiratory distress syndrome; allergic rhinitis; pulmonary hyperextension;

KM emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KM pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN WO200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US011143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPiG-) EPIGENESIS PHARM INC.
XX
PI Nyce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 8314; 763bp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has anti-allergic, anti-inflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a
CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC inflammation, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hyperextension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 12 A; 1 C; 3 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1543 TAAGAAGAAAAGTCAGTA 1562
| | | | | | | | | | | | | | | | | | | | | |
1 TAAGAAGAAAAGTCAGTA 20
DB
RESULT 204
ADK71763/c
ID ADK71763 standard; DNA; 20 BP.
XX


```

AC ADX71763;
XX
DT 06-MAY-2004 (first entry)
XX
DE PCR primer used in a three prime end amplification.
XX
KM AKIP1; RNA-binding protein; ABA; abscisic acid;
XX ABA-activated protein kinase; AAPK; plant protectant; plant; transgenic;
XX PCR; primer; SE.
XX
OS Synthetic.
XX
PN WO2004013295-A2.
XX
PD 12-FEB-2004.
XX
PF 01-AUG-2003; 2003WO-US024197.
XX
PR 01-AUG-2002; 2002US-0400549P.
XX
PA (PENN-) PENN STATE RES FOUND.
XX
PI Asmann SM, Mansfield JL, Kinoshita T, Shimazaki K, Ng CKY;
XX WPI; 2004-157117/15.
XX
DR New AKIP1 nucleic acids and proteins, useful in producing plants with
XX improved response to stresses including cold, heat, salinity, synthetic
XX and natural chemical agents, viral, fungal and bacterial pathogens and
XX drought.
XX
PS Example; Page 38; 106pp; English.
XX
CC The invention relates to plant RNA-binding proteins and encoding
XX polynucleotides. The polynucleotide encodes an ABA (abscisic acid) -
XX mediated phosphorylation-regulated RNA binding protein, AKIP1. The
XX encoded protein is a substrate for phosphorylation by an ABA-activated
XX protein kinase or AAPK. The protein's ability to interact with RNA is
XX altered upon phosphorylation. The binding affinity for RNA increases upon
XX phosphorylation. The nucleic acid molecule and the encoded protein is
XX useful in producing plants with improved response to stresses including
XX cold, heat, salinity, synthetic and natural chemical agents, viral,
XX fungal and bacterial pathogens and drought. The present sequence
XX represents a PCR primer used in a three prime end amplification method.
XX
SQ Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1576 CACTTCCAGCTTGCCCTGTT 1595
DB 20 CACTTCCAGCTTGCCCTGTT 1
RESULT 205
ADK97267
ID ADK97267 standard; DNA; 20 BP.
AC ADK97267;
XX
DT 06-MAY-2004 (first entry)
XX
DE Primer of the invention #2987.
XX
KM human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS Synthetic.
XX
PN JP2003259875-A.
XX
PD 16-SEP-2003.

```

```

XX
XX 08-MAR-2002; 2002JP-00064373.
XX
XX 08-MAR-2002; 2002JP-00064373.
XX
XX (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
XX
XX WPI; 2004-093977/10.
XX
XX Novel polynucleotide useful for PCR amplification along with two DNA
XX fragment from another set of sequences, or for detecting single
XX nucleotide polymorphism in human gene.
XX
PS Claim 2; SEQ ID NO 6296; 2627pp; Japanese.
XX
CC The present invention relates to a polynucleotide isolated from a human
XX gene and is useful for detecting a single nucleotide polymorphism in a
XX human gene or for diagnosing of disease. The invention enables the
XX detection of a single nucleotide polymorphism in a human gene. The
XX present sequence represents a primer of the invention.
XX
SQ Sequence 20 BP; 6 A; 3 C; 9 G; 2 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 754 GCACGAGGCCACAGAGTG 773
DB 1 GCACGAGTGCCACAGAGAGTG 20
RESULT 206
ADK95115
ID ADK95115 standard; DNA; 20 BP.
AC ADK95115;
XX
DT 06-MAY-2004 (first entry)
XX
DE Primer of the invention #835.
XX
KM human; single nucleotide polymorphism; SNP; ss; primer.
XX
OS Synthetic.
XX
PN JP2003259875-A.
XX
PD 16-SEP-2003.
XX
PF 08-MAR-2002; 2002JP-00064373.
XX
PR 08-MAR-2002; 2002JP-00064373.
XX
PA (KAGA-) KAGAKU GIUTSU SHINKO JIGYODAN.
XX
XX WPI; 2004-093977/10.
XX
XX Novel polynucleotide useful for PCR amplification along with two DNA
XX fragment from another set of sequences, or for detecting single
XX nucleotide polymorphism in human gene.
XX
PS Claim 2; SEQ ID NO 4144; 2627pp; Japanese.
XX
CC The present invention relates to a polynucleotide isolated from a human
XX gene and is useful for detecting a single nucleotide polymorphism in a
XX human gene or for diagnosing of disease. The invention enables the
XX detection of a single nucleotide polymorphism in a human gene. The
XX present sequence represents a primer of the invention.
XX
SQ Sequence 20 BP; 4 A; 8 C; 3 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;

```


Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 355 CTGGATCCAGCAGCTCTCC 374
DB 1 CTGGATCCAGCAGCTCTGCC 20

RESULT 207

ADJ26887
ID ADJ26887 standard; DNA; 20 BP.

AC ADJ26887;

DT 20-MAY-2004 (first entry)

XX Human Centromere protein B target DNA fragment #9.

XX Centromere protein B; hyperproliferative disorder; cancer;

KW autoimmune disorder; rheumatoid arthritis; scleroderma;

KM Raynaud's syndrome; systemic lupus erythematosus; gene therapy;

KW cytostatic; immunosuppressive; dermatological; antiinflammatory; human;

OS Homo sapiens.

PN US2003232443-A1.

PD 18-DEC-2003.

PF 18-JUN-2002; 2002US-00176277.

PR 18-JUN-2002; 2002US-00176277.

PA (ISIS-) ISIS PHARM INC.

PI Bennett CF, Dobie KW;

XX WPI; 2004-052175/05.

XX New antisense oligonucleotide targeted to a nucleic acid encoding

PT Centromere protein B, useful for treating a disease, e.g. cancer,

PT rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus

PT erythematosus.

PS Example 15; SEQ ID NO 56; 47bp; English.

XX The present invention relates to antisense compounds, compositions and

CC methods for modulating the expression of Centromere protein B. The

CC compound, composition and methods are useful for treating diseases or

CC conditions associated with Centromere protein B, such as

CC hyperproliferative disorders (e.g. cancer), autoimmune disorders e.g.

CC rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus

CC erythematosus. The invention is also useful in gene therapy. The present

CC sequence is human Centromere protein B target DNA fragment used in the

CC exemplification of the invention.

XX Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

SO Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

XX 20-MAY-2004 (first entry)

DT Human Centromere protein B antisense oligonucleotide, ISIS #156868.

DE Centromere protein B; hyperproliferative disorder; cancer;

XX autoimmune disorder; rheumatoid arthritis; scleroderma;

KW Raynaud's syndrome; systemic lupus erythematosus; gene therapy;

KM cytostatic; immunosuppressive; dermatological; antiinflammatory; human;

XX antisense; phosphorochioate backbone; ss.

OS Homo sapiens.

PN Synthetic.

FT Key

FT modified_base

FT 1..20

FT /tag= b

FT /mod_base= OTHER

FT /note= "Phosphorochioate backbone where all cytidines are

FT 5-methylcytidines"

FT modified_base

FT 1..5

FT /tag= a

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified_base

FT 16..20

FT /tag= c

FT /mod_base= OTHER

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX US2003232443-A1.

XX 18-DEC-2003.

XX 18-JUN-2002; 2002US-00176277.

XX 18-JUN-2002; 2002US-00176277.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Dobie KW;

XX WPI; 2004-052175/05.

XX New antisense oligonucleotide targeted to a nucleic acid encoding

PT Centromere protein B, useful for treating a disease, e.g. cancer,

PT rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus

PT erythematosus.

PS Example 15; SEQ ID NO 16; 47bp; English.

XX The present invention relates to antisense compounds, compositions and

XX methods for modulating the expression of Centromere protein B. The

XX compound, composition and methods are useful for treating diseases or

XX conditions associated with Centromere protein B, such as

XX hyperproliferative disorders (e.g. cancer), autoimmune disorders e.g.

XX rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus

XX erythematosus. The invention is also useful in gene therapy. The present

XX sequence is human Centromere protein B antisense oligonucleotide used in

XX the exemplification of the invention.

XX Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

SO Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1121 ATGGCTCCAGGAAGTTC 1140

DB 20 AGGCTCCAGGAAGTTC 1

RESULT 209

ADJ26884

```

ID ADJ26884 standard; DNA; 20 BP.
XX
AC ADJ26884;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human Centromere protein B target DNA fragment #6.
XX
KW Centromere protein B; hyperproliferative disorder; cancer;
KW autoimmune disorder; rheumatoid arthritis; scleroderma;
KW Raynaud's syndrome; systemic lupus erythematosus; gene therapy;
KW cytostatic; immunosuppressive; dermatological; antiinflammatory; human;
KW ds.
XX
OS Homo sapiens.
XX
PN US2003232443-A1.
XX
PD 18-DEC-2003.
XX
PF 18-JUN-2002; 2002US-00176277.
XX
PR 18-JUN-2002; 2002US-00176277.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Dobie KW;
XX
PI MPI; 2004-052175/05.
XX
DR
XX
PT New antisense oligonucleotide targeted to a nucleic acid encoding
PT Centromere protein B, useful for treating a disease, e.g. cancer.
PT Rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus
PT erythematosus.
XX
PS Example 15; SEQ ID NO 53; 47bp; English.
XX
CC The present invention relates to antisense compounds, compositions and
CC methods for modulating the expression of Centromere protein B. The
CC compound, composition and methods are useful for treating diseases or
CC conditions associated with Centromere protein B, such as
CC hyperproliferative disorders (e.g. cancer), autoimmune disorders e.g.
CC rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus
CC erythematosus. The invention is also useful in gene therapy. The present
CC sequence is human Centromere protein B target DNA fragment used in the
CC exemplification of the invention.
XX
SQ Sequence 20 BP; 6 A; 5 C; 7 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 1121 ATGGGTCGAGAGAGATTCC 1140
1 |||||
1 AGGGCTCCAGAGAGGTCC 20
Db
XX
RESULT 210
ADJ26851/c
ID ADJ26851 standard; DNA; 20 BP.
XX
AC ADJ26851;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human Centromere protein B antisense oligonucleotide, ISIS #156872.
XX
KW Centromere protein B; hyperproliferative disorder; cancer;
KW autoimmune disorder; rheumatoid arthritis; scleroderma;
KW Raynaud's syndrome; systemic lupus erythematosus; gene therapy;
KW cytostatic; immunosuppressive; dermatological; antiinflammatory; human;
KW antisense; phosphorothioate backbone; ss.

```

```

XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone where all cytidines are
FT 5-methylcytidines"
FT 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
FT modified_base 16..20
FT /tag= C
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"
XX
PN US2003232443-A1.
XX
PD 18-DEC-2003.
XX
PF 18-JUN-2002; 2002US-00176277.
XX
PR 18-JUN-2002; 2002US-00176277.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Dobie KW;
XX
PI MPI; 2004-052175/05.
XX
DR
XX
PT New antisense oligonucleotide targeted to a nucleic acid encoding
PT Centromere protein B, useful for treating a disease, e.g. cancer.
PT Rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus
PT erythematosus.
XX
PS Example 15; SEQ ID NO 20; 47bp; English.
XX
CC The present invention relates to antisense compounds, compositions and
CC methods for modulating the expression of Centromere protein B. The
CC compound, composition and methods are useful for treating diseases or
CC conditions associated with Centromere protein B, such as
CC hyperproliferative disorders (e.g. cancer), autoimmune disorders e.g.
CC rheumatoid arthritis, scleroderma, Raynaud's syndrome or systemic lupus
CC erythematosus. The invention is also useful in gene therapy. The present
CC sequence is human Centromere protein B antisense oligonucleotide used in
CC the exemplification of the invention.
XX
SQ Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
QY 308 TCACGAGGACCTGCCTGT 327
20 TCACGAGGACCTGCACATT 1
Db
XX
RESULT 211
ADJ18833
ID ADJ18833 standard; DNA; 20 BP.
XX
AC ADJ18833;
XX
DT 20-MAY-2004 (first entry)
XX
DE Antisense DNA oligo used to modulate human LRH1 expression Segid 3383.
XX
KW human; ss; liver related homologue-1, LRH1, NR5A2; antisense;
KW phosphorothioate; 2' MOE; breast cancer; dyslipidaemia; atherosclerosis;

```

OS	Homo sapiens.
XX	Synthetic.
FT	Key
FT	Location/Qualifiers
FT	modified_base
FT	1..20
FT	/tag= b
FT	/mod_base= OTHER
FT	/label= OTHER= phosphorochioate backbone
FT	1..5
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT	cytidine nucleobases are 5-methylcytidine."
FT	16..20
FT	/tag= c
FT	/mod_base= OTHER
FT	/note= "OTHER= 2' methoxyethyl (2' MOE) nucleotides. All
FT	cytidine nucleobases are 5-methylcytidine."
XX	
PN	WO2004003201-A2.
PD	08-JAN-2004.
XX	
PF	01-JUL-2003; 2003WO-US020865.
XX	
PR	01-JUL-2002; 2002US-0392813P.
PA	(PRNA) PHARMACIA CORP.
XX	
P1	Kane CD;
DR	WPI; 2004-083058/08.
XX	
PT	New antisense oligonucleotides targeted to a nucleic acid encoding liver
PT	related homologue-1 (LRH1), useful for treating breast cancer,
PT	dyslipidemia, atherosclerosis, hypercholesterolemia, or hepatitis.
XX	
PS	Example 15; SEQ ID NO 3383; 909bp; English.
XX	
CC	This invention relates to novel antisense compounds useful for modulating
CC	the expression of liver related homologue-1 (LRH1) and splice variants
CC	thereof. Specifically, it refers to compositions 8-30 nucleobases in
CC	length that target a portion of an active site on the nucleic acid
CC	molecule encoding LRH1 (also known as NR5A2). LRH1 is a monomeric orphan
CC	nuclear receptor protein that functions as a tissue specific
CC	transcription factor. The present invention describes antisense
CC	oligonucleotides that comprise at least one modified internucleoside
CC	linkage, a phosphorochioate linkage; at least one modified sugar moiety,
CC	a 2'-O-methoxyethyl (2' MOE) and at least one modified nucleobase, a 5-
CC	methylcytidine. These antisense compounds are useful for treating or
CC	diagnosing a disease associated with LRH1, such as breast cancer,
CC	dyslipidemia, atherosclerosis, low HDL (high density lipoprotein), high
CC	LDL (low density lipoprotein), hypercholesterolaemia, gall stones,
CC	cirriglyceridaemia, obesity, hepatitis B virus-mediated acute or chronic
CC	hepatitis, as well as hepatocellular carcinoma or a condition associated
CC	with aromatase activity. Accordingly, these compositions exhibit
CC	cytostatic, antilipemic, antarteriosclerotic, anorectic, hepatotropic,
CC	litholytic, antiinflammatory and virucidal activities. This
CC	oligonucleotide sequence is an antisense DNA oligo used to modulate the
CC	expression of the human LRH1 protein of the invention.
XX	
SQ	Sequence 20 BP; 4 A; 4 C; 4 G; 8 T; 0 U; 0 Other;
Query Match	0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pred. No. 1,4e-02;
Matches 17; Conservative	0; Mismatches 3; Indels 0; Gaps 0

RESULT 212
 ADJ24083 standard; DNA; 20 BP.
 ID ADJ24083
 AC ADJ24083;
 DT 20-MAY-2004 (first entry)
 XX Human endothelial lipase antisense oligonucleotide, SEQ ID 2481.
 XX Antihypertensive; Cardiovascular; Analgesic; Antianginal; Antisense therapy;
 XX Human; Endothelial lipase; dyslipidaemia; high density lipoprotein; HDL;
 XX cardiovascular disorder; metabolic syndrome X; ss.
 OS Homo sapiens.
 OS Synthetic.
 FH Key
 FT modified_base 1-20
 FT Location/Qualifiers
 FT 1-20
 FT /tag=a
 FT /mod_base=OTHER
 FT /note="This oligonucleotide has a phosphorothioate
 FT backbone and 2'-methoxyethyl (2'-MOE) wings at the 5'
 FT and 3' ends, which are 4 nucleotides in length. Also all
 FT cytidine residues are 5-methylcytidines"
 MN MO2004009541-A2.
 PD 29-JAN-2004.
 PE 18-JUL-2003; 2003MO-US022410.
 PR 19-JUL-2002; 2002US-0397106P.
 PA (PHAA) PHARMACIA CORP.
 PI Bhat BG;
 PT WP1; 2004-132912/13.
 PT New antisense oligonucleotide for modulating endothelial lipase
 PT expression, for diagnosing, preventing or treating e.g. dyslipidaemia, low
 PT high density lipoprotein or cardiovascular disorders.
 PS Claim 3; SEQ ID NO 2481; 1007bp; English.
 CC The present invention relates to antisense oligonucleotides (ADJ21603-
 CC ADJ25510) targeted to human Endothelial Lipase (EL) coding sequence
 CC (ADJ25517), where the antisense oligonucleotide specifically hybridises
 CC with and inhibits the expression of EL. The antisense oligonucleotides
 CC are useful for modulating the expression of endothelial lipase in cells
 CC or tissues to treat diseases associated with EL expression, such as
 CC dyslipidaemia, low high density lipoprotein (HDL), cardiovascular
 CC disorder or metabolic syndrome X. In addition, the oligonucleotides are
 CC used for diagnostics, prophylaxis, or as research reagents or kits.
 SQ Sequence 20 BP; 6 A; 4 C; 4 G; 6 T; 0 U; 0 Other;
 Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0.
 Oy 2242 AGATTAGTCCAAAGCAGGT 2261
 |||||
 Db 1 AGATTGCTCCAAAGCAGTT 20
 |||||

```
ADN06232
ID ADN06232 standard; DNA; 20 BP.
XX
AC ADN06232;
XX
DT 17-JUN-2004 (first entry)
XX
DE Human SPS2 specific antisense oligonucleotide, ISIS 138303.
XX
KW Selenophosphate synthetase 2; SPS2; rheumatoid arthritis; infection;
KW inflammation; tumour; antisense therapy; human; antisense;
KW phosphorothioate backbone; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate backbone in which all cytidines
FT are 5-methylcytidines"
FT modified_base 1..5
FT /tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
XX
PN US2004002151-A1.
XX
PD 01-JAN-2004.
XX
PF 28-JUN-2002; 2002US-00186157.
XX
PR 28-JUN-2002; 2002US-00186157.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Watt AT, Freiler SM;
XX
DR WPI; 2004-070740/07.
XX
PT New antisense oligonucleotides for modulating selenophosphate synthetase
PT 2 (SPS2) expression, useful for diagnosing, preventing or treating
PT conditions associated with SPS2, e.g. rheumatoid arthritis, inflammation
PT or tumors.
XX
PS Claim 1; SEQ ID NO 76; 47pp; English.
XX
CC The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of selenophosphate synthetase 2 (SPS2). The
CC composition comprises antisense oligonucleotides targeted to SPS2 gene.
CC The antisense oligonucleotide is useful for modulating the expression of
CC SPS2 in cells or tissues to treat diseases associated with their
CC expression, e.g. rheumatoid arthritis, infections, inflammation or
CC tumours. It is also used for diagnostics, prophylaxis, or as research
CC reagents or kits. The antisense oligonucleotide is useful in antisense
CC therapy. The present sequence is an antisense oligonucleotide targeted to
CC human SPS2 DNA. This sequence is used in the exemplification of the
CC invention.
XX
SQ Sequence 20 BP; 8 A; 4 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1548 AGGAAAGTCAGTATTTC A 1567
DB 1 AGGAAAGCCAGTACTTCA 20
```

```
RESULT 214
ADN0607
ID ADN0607 standard; DNA; 20 BP.
XX
AC ADN0607;
XX
DT 17-JUN-2004 (first entry)
XX
DE Mouse Ig kappa leader sequence PCR primer, SEQ ID 8.
XX
KW Retinal detachment; retinal edema; endostatin; ocular tissue;
KW ophthalmological; gene therapy; murine; PCR; primer; ss;
KW Ig kappa leader sequence.
XX
OS Mus sp.
OS WO2004020469-A2.
XX
PN WO2004020469-A2.
XX
PD 11-MAR-2004.
XX
PF 27-AUG-2003; 2003WO-EP009497.
XX
PR 28-AUG-2002; 2002US-0406470P.
XX
PA (NOVS ) NOVARTIS AG.
XX PA (NOVS ) NOVARTIS PHARMA GMBH.
XX PI Campochiaro PA, Kaleko M;
XX
DR WPI; 2004-239158/22.
XX
PT Treating retinal detachment or retinal edema in an individual comprises
PT increasing the amount of an endostatin in the ocular tissues of the
PT individual to a retinal detachment- or retinal edema-inhibiting amount.
XX
PS Example 1; SEQ ID NO 8; 48pp; English.
XX
CC The present invention relates to a method for treating retinal detachment
CC or retinal edema in an individual. The method comprises effecting an
CC increase in the amount of an endostatin (ADN0607 or ADN0602) in ocular
CC tissues of the individual to a retinal detachment- or retinal edema-
CC inhibiting amount. The endostatin is used in manufacturing a medicament
CC for the treatment of retinal detachment or retinal edema in an
CC individual. The present sequence is a PCR primer, used in an example from
CC the invention.
XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 3; Indels 0; Gaps 0;

QY 518 CACTGATTGCTGGCTCATCG 537
DB 1 CACTGCTTACTGCTTATCG 20

RESULT 215
ADN15359/C
ID ADN15359 standard; DNA; 20 BP.
XX
AC ADN15359;
XX
DT 01-JUL-2004 (first entry)
XX
DE Human mPGES-1 chimeric antisense oligonucleotide SEQ ID NO:1546.
XX
KW chimeric; antisense oligonucleotide; phosphorothioate; human;
KW microsomal prostaglandin E2 synthase; mPGES-1; mPGES-1 inhibitor;
KW microsomal prostaglandin E2 synthase inhibitor; cyclooxygenase; antidiabetic;
KW immunomodulator; cardiant; neuroprotective; antiinflammatory;
```

KM neuroprotective; nootropic; antiarthritic; vasotropic; ophthalmological;
KM immunomodulatory; cardiovascular; gene therapy; inflammation;
KM Alzheimer's disease; arthritis; diabetes; cancer; ischaemia;
KM reperfusion injury; ophthalmic disorder; immunological disorder;
KM cardiovascular disorder; neurological disorder; ss.
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "phosphorothioate linkages and all cytidine
FT residues are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-O-methoxyethyls"
XX
PN WO2004028458-A2.
XX
PD 08-APR-2004.
XX
PF 25-SEP-2003; 2003WO-US030374.
XX
PR 25-SEP-2002; 2002US-0413549P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Gierse JK;
XX
DR WPI; 2004-305094/28.
XX
PT New antisense compound, having a sequence targeted to a nucleic acid
PT encoding mPES-1, useful for preparing a composition for treating e.g.,
PT inflammation, Alzheimer's disease, arthritis, diabetes, cancer or
PT ischemia.
XX
PS Claim 4; SEQ ID NO 1546; 132bp; English.
XX
CC The present sequence represents a chimeric antisense oligonucleotide
CC targeted to human microsomal prostaglandin E2 synthase (mPES-1). The
CC human mPES-1 gene is located on chromosome 9, more specifically to
CC 9q34.3. The present invention also describes: (1) antisense compounds,
CC having a sequence comprising 8-30 bp targeted to a nucleic acid encoding
CC mPES-1, which specifically hybridise with the nucleic acid mPES-1 and
CC inhibit its expression; (2) a method of inhibiting the expression of
CC mPES-1 in cells or tissues; and (3) a method of treating an animal
CC having a disease or condition associated with mPES-1. mPES-1 chimeric
CC antisense oligonucleotides and antisense compounds have cytosratic,
CC antiinflammatory, immunomodulatory, cardiac, neuroprotective,
CC antiinflammatory, neuroprotective, nootropic, antiarthritic, vasotropic,
CC ophthalmological, immunomodulatory, and cardiovascular activities, and can
CC be used as mPES-1 inhibitors and in gene therapy. The antisense compound
CC can be used for preparing a composition for treating a disease or
CC condition associated with mPES-1 e.g., inflammation, Alzheimer's
CC disease, arthritis, diabetes, cancer, ischaemia or reperfusion injury, or
CC ophthalmic, immunological, cardiovascular or neurological disorder.
XX
SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1667 CAAGGAACCTGCTTCT 1686
DB 20 CACAGAGCTCAGCTCT 1

RESULT 216.4
ADN49263/C
ID ADN49263 standard; DNA; 20 BP.
XX
XX ADN49263;
AC
XX
XX
DT 15-JUL-2004 (first entry)
XX
XX Human HDAC4 specific antisense oligo, ISIS 130854.
XX
XX Histone deacetylase 4; HDAC4; hyperproliferative disorder; cancer;
KM antisense therapy; human; myeloid leukaemia; phosphorothioate backbone;
KM antisense; ss; HDAC-A.
XX
XX Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..20
FT /*tag= b
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone in which all cytidines
FT are 5-methylcytidines"
FT modified_base 1..5
FT /*tag= a
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl bases"
FT modified_base 16..20
FT /*tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl bases"
XX
PN US2004077083-A1.
XX
PD 22-APR-2004.
XX
PF 17-OCT-2002; 2002US-00273826.
XX
PR 17-OCT-2002; 2002US-00273826.
XX
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Watt AT;
XX
DR WPI; 2004-340008/31.
XX
XX
PT New antisense oligonucleotides for modulating Histone deacetylase 4
PT expression, useful for diagnosing, preventing or treating diseases or
PT conditions associated with Histone deacetylase 4, such as cancer (i.e.
PT myeloid leukemia).
XX
PS Example 15; SEQ ID NO 24; 45bp; English.
XX
CC The invention relates to antisense compounds, compositions and methods
CC for modulating the expression of histone deacetylase 4 (HDAC4). HDAC4 is
CC also known as HDAC-A. The composition comprises antisense compounds that
CC can be targeted towards HDAC4. The antisense oligonucleotide is useful
CC for inhibiting the expression of HDAC4 in cells or tissues. It is also
CC useful for treating an animal having a disease or condition associated
CC with HDAC4, such as a hyperproliferative disorder, particularly cancer
CC (i.e. myeloid leukaemia). The compound is used for diagnostics, in
CC prophylaxis, or as research reagents or kits. It is also useful in
CC antisense therapy. The present sequence is an antisense oligonucleotide
CC targeted towards human HDAC4 DNA.
XX
SQ Sequence 20 BP; 3 A; 6 C; 2 G; 9 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 764 CACAGAGTGCACAGAGT 783
 |||||
 DB 20 CACAGAGTGAAGATGAGT 1

RESULT 217
 ADM10436/C
 ID ADM10436 standard; DNA; 20 BP.
 XX
 XX ADM10436;
 AC
 XX
 DT 15-JUL-2004 (first entry)
 DE Human histone deacetylase 4 antisense oligonucleotide seqid 24.
 XX
 XX cytosolic; antimicrobial; antiinflammatory; antisense therapy;
 KW antisense compound; histone deacetylase 4; cancer; infection;
 KW inflammation; diagnostic; prophylaxis; human; antisense oligonucleotide;
 KM ss.
 XX Homo sapiens.
 OS
 XX
 FH Key Location/Qualifiers
 FT modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "OTHER= Phosphorothioate backbone. All cytidines
 FT are 5-methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 FT modified_base 15..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
 XX
 XX US2004077084-A1.
 PN
 XX
 PD 22-APR-2004.
 XX
 PF 17-OCT-2002; 2002US-00274347.
 XX
 PR 17-OCT-2002; 2002US-00274347.
 XX
 PA (ISIS-) ISIS PHARM INC.
 PA (ABBO) ABBOTT LAB.
 XX
 PI Walt AT, Davidsen S, Li J, Glaser K;
 DR WPI; 2004-340009/31.
 XX
 PT New antisense oligonucleotides for modulating human Histone deacetylase 4
 PT expression, useful for diagnosing, preventing or treating diseases
 PT associated with Histone deacetylase 4, e.g. cancer, infection or
 PT inflammation.
 XX
 PS Example 15; SEQ ID NO 24; 46bp; English.
 XX
 CC The invention describes an antisense compound that is 8-50 nucleobases in
 CC length targeted to a nucleic acid molecule encoding human Histone
 CC deacetylase 4 (which comprises a sequence of 8459 bp fully defined in the
 CC specification). The compound specifically hybridizes with and inhibits
 CC the expression of human Histone deacetylase 4. Also described are: a
 CC composition comprising the new antisense compound and a pharmaceutical
 CC carrier or diluent; and a method of inhibiting the expression of Histone
 CC deacetylase 4 in human cells or tissues, comprising contacting the cells
 CC or tissues with the new compound so that the expression of Histone
 CC deacetylase 4 is inhibited. The antisense oligonucleotide is useful for
 CC modulating the expression of Histone deacetylase 4 in cells or tissues.
 CC It is also useful for treating humans having a disease or condition
 CC associated with Histone deacetylase 4, such as cancer, infection or
 CC inflammation. In addition, the compound is used for diagnostics,

CC prophylaxis, or as research reagents or kits. This sequence represents a
 CC human histone deacetylase 4 antisense oligonucleotide.
 XX
 SQ Sequence 20 BP; 3 A; 6 C; 2 G; 9 T; 0 U; 0 Other;
 Query Match 0.6%; Score 15.2; DB 1; Length 20;
 Best Local Similarity 85.0%; Pred. No. 1.4e+02;
 Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 764 CACAGAGTGCACAGAGT 783
 |||||
 DB 20 CACAGAGTGAAGATGAGT 1

RESULT 218
 ADO43909
 ID ADO43909 standard; DNA; 20 BP.
 XX
 XX ADO43909;
 AC
 XX
 DT 15-JUL-2004 (first entry)
 DE PCR primer used to amplify murine Ig kappa leader sequence DNA.
 XX
 XX retina; endostatin; vascular endothelial growth factor receptor;
 KW pigment epithelium-derived factor; angiostatin; plasminogen fragment;
 KW rod-derived cone viability factor; antiangiogenic antithrombin;
 KW cartilage-derived inhibitor; CD59 complement fragment;
 KW fibronectin fragment; Gro-beta; heparinase; chorionic gonadotropin;
 KW interferon; interferon inducible protein; IP-10; interleukin-12;
 KW kringle 5; metalloproteinase inhibitor; placental ribonuclease inhibitor;
 KW plasminogen activator inhibitor; platelet factor-4; PF4; prolactin;
 KW proliferin-related protein; PRP; thrombospondin-1; TSP-1;
 KW transforming growth factor-beta; TGF-b; vasculostatin; vasostatin;
 KW calreticulin; retinal disorder; retinal detachment; diabetic retinopathy;
 KW retinal neovascularization; choroidal neovascularization; retinal edema;
 KW PCR; ss; primer.
 XX
 XX Mus sp.
 OS
 OS Synthetic.
 XX
 PN WO2004028635-A1.
 XX
 PD 08-APR-2004.
 XX
 PF 26-SEP-2003; 2003WO-EP010725.
 XX
 PR 27-SEP-2002; 2002US-0414048P.
 XX
 PA (NOVS) NOVARTIS AG.
 PA (NOVS) NOVARTIS PHARMA GMBH.
 XX
 PI Campochiaro PA, Kaleko M;
 DR WPI; 2004-305131/28.
 XX
 PT Delivering a protein to the retina of a subject for treating retinal
 PT disorders, e.g., retinal detachment, retinal edema or diabetic
 PT retinopathy by periorcularly injecting a viral vector comprising a protein
 PT -encoding nucleic acid.
 XX
 PS Example 1; Page 10; 47bp; English.
 XX
 CC The specification describes a method for delivering a protein to the
 CC retina of a subject. The method comprises periorcularly injecting a viral
 CC vector comprising a nucleic acid encoding endostatin. Alternatively, the
 CC viral vector may encode soluble vascular endothelial growth factor
 CC receptor, pigment epithelium-derived factor, angiostatin (plasminogen
 CC fragment), rod-derived cone viability factor, antiangiogenic antithrombin
 CC HI, cartilage-derived inhibitor (GDI), CD59 complement fragment,
 CC fibronectin fragment, Gro-beta, a heparinase, human chorionic
 CC gonadotropin (hCG), an interferon, interferon inducible protein (IP-10),
 CC interleukin-12, kringle 5 (plasminogen fragment), metalloproteinase

CC inhibitors (TBVIs), placental ribonuclease inhibitor, plasminogen
CC activator-inhibitor, platelet factor-4 (PF4), prolactin 16KD fragment,
CC growth factor-related protein (GRP), thrombospondin-1 (TSP-1), transforming
CC growth factor-beta (TGF-β), vasculostatin or vasostatin (calreticulin
CC fragment). The method is useful in delivering a protein to the retina of
CC a subject for treatment of retinal disorders, e.g., retinal detachment,
CC diabetic retinopathy, retinal neovascularization, choroidal
CC neovascularization or retinal edema. PCR primers ADO43909-ADO43910 were
CC used to amplify DNA encoding murine Ig kappa leader sequence. The
CC amplified fragment was used to construct viral vectors for use in the
CC method of the invention.
CC
XX
SQ Sequence 20 BP; 3 A; 6 C; 4 G; 7 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 518 CACTGATGCTGCGTCATCG 537
1 CACTGCTTACTGCTTATCG 20
Db
RESULT 219
ADM16189/c
ID ADM16189 standard; DNA; 20 BP.
XX
AC ADM16189;
XX
DT 15-JUL-2004 (first entry)
XX
DE Murine SACL DNA PCR primer #416.
XX
KM Mouse; SACL; PCR; ss; carbohydrate; sweetener; ethanol; obesity;
KW diabetes; alcoholism; antidiabetic; alcohol; anorectic; antialcoholic;
XX primer.
XX
OS Mus musculus.
XX
PN US2004081964-A1.
XX
PD 29-APR-2004.
XX
PF 25-OCT-2002; 2002US-00280183.
XX
PR 25-OCT-2002; 2002US-00280183.
XX
PA (BACH/) BACHMANOV A A.
PA (BEAU/) BEAUCHAMP G K.
PA (LISG/) LI S.
PA (LIXX/) LI X.
PA (REED/) REED D R.
PA (TORO/) TORDOFF M G.
PA (ROSS/) ROSS D A.
PA (OHMA/) OHMAN J D.
PA (CHAT/) CHATTERJEE A.
PA (DJON/) DE JONG P J.
XX
PI Bachmanov AA, Beauchamp GK, Li S, Li X, Reed DR, Tordoff MG;
PI Rose DA, Ohman JD, Chatterjee A, De Jong PJ;
XX
DR WPI; 2004-340133/31.
XX
PT New isolated polynucleotides for sensing carbohydrates, other sweeteners,
PT or ethanol, useful for screening drugs for inhibition or restoration of
PT gene function as antidiabetic, antioesity or antialcohol consumption
PT therapies.
XX
PS Example 12; SEQ ID NO 459; 148bp; English.
XX
CC The invention relates to SACL polypeptides and the polynucleotides
CC encoding them. The polynucleotides contain a variation associated with
CC sensing carbohydrates, other sweeteners or ethanol. The invention also

CC relates to a method for analysing a biomolecule in a biological sample,
CC comprising altering SACL activity in the sample and measuring the
CC activity, a method for analysing a polynucleotide in a biological sample,
CC comprising contacting a polynucleotide in a biological sample with a
CC probe where the probe hybridises to a SACL polynucleotide to form a
CC hybridisation complex and detecting the hybridisation complex, a method
CC of identifying susceptibility to obesity or diabetes comprising comparing
CC the nucleotide sequence of the suspected SACL allele with a wild type
CC nucleotide sequence, where the difference between the suspected allele
CC and the wild-type sequence identifies a sequence variation of the SACL
CC nucleotide sequence, and a method of treating or preventing obesity,
CC diabetes or alcoholism associated with expression of SACL, comprising
CC administering to a subject a pharmaceutical composition and a transgenic
CC animal that carries an altered SACL allele. The methods and compositions
CC of the invention are useful for screening drugs for inhibition or
CC restoration of gene function as antidiabetic, antioesity or antialcohol
CC consumption therapies and for identifying sweeteners and alcohols. This
CC sequence represents a PCR primer used to amplify murine SACL DNA of the
CC invention.
XX
SQ Sequence 20 BP; 4 A; 6 C; 4 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 1991 TGGGGTGGCATGACACC 2010
20 TGGAGGTGCAATGATACCC 1
Db
RESULT 220
ADP76517/c
ID ADP76517 standard; DNA; 20 BP.
XX
AC ADP76517;
XX
DT 12-AUG-2004 (first entry)
XX
DE Chimeric phosphorothioate oligonucleotide #316.
XX
KM GFAT; Antidiabetic; Cardiant;
KW Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
XX reperfusion; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..4
FT /*tag= a
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
FT modified_base 17..20
FT /*tag= b
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
XX
PN WO2004035763-A2.
XX
PD 29-APR-2004.
XX
PF 02-OCT-2003; 2003WO-US033332.
XX
PR 17-OCT-2002; 2002US-0419268P.
XX
PA (PHAA) PHARMACIA CORP.
XX
PI Broecheat KO, Crosby SD;
XX
DR WPI; 2004-348453/32.
XX
PT New compounds, particularly antisense oligonucleotides targeted to a
PT nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase

PT (GfAT), for treating diabetes, a cardiovascular or neurologic disorder,
XX ischemia/reperfusion injury.
PS Claim 4; SEQ ID NO 316; 175pp; English.
XX
CC The present invention relates to a compound which specifically hybridizes
CC with a nucleic acid molecule encoding GfAT, and inhibits the expression
CC of GfAT. Specifically claimed are antisense oligonucleotides capable of
CC modulating the expression of GfAT, and which comprise any of the 3063
CC sequences of 20 base pairs, given in the specification. The compound,
CC composition and methods are useful for treating a disease or condition
CC associated with GfAT, such as a disease or condition, e.g. diabetes, a
CC cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC They are also useful in research and diagnostics for modulating the
CC expression of GfAT. The present sequence represents a chimeric
CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC oligonucleotides inhibit human GfAT expression.
SQ
SQ Sequence 20 BP; 3 A; 8 C; 9 G; 0 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 147 CCTGTGCCCCGGCGCGG 166
DB 20 CCTGTGCGCTCGGGCGCTGTG 1
RESULT 221
ADP78659
ID ADP78659 standard; DNA; 20 BP.
AC
XX ADP78659;
XX
DT 12-AUG-2004 (first entry)
DE Chimeric phosphorothioate oligonucleotide #2458.
XX
XX
KW GfAT; Antidiabetic; Cardiant;
KW Glutamine-fructose-6-phosphate amidotransferase; diabetes; ischemia;
KW reperfusion; ss.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 1..4
FT /*tag= a
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
FT modified_base 17..20
FT /*tag= b
FT /mod_base= other
FT /note= "2-methoxyethyl wing"
XX
XX WO2004035763-A2.
XX
XX
XX PD 29-APR-2004.
XX
XX PF 02-OCT-2003; 2003WO-US033332.
XX
XX PF 17-OCT-2002; 2002US-0419268P.
XX
XX PR (PHMA) PHARMACIA CORP.
XX
XX PA Broschat KO, Crosby SD;
XX
XX PI WPI; 2004-348453/32.
XX
XX DR New compounds, particularly antisense oligonucleotides targeted to a
XX PT nucleic acid encoding glutamine-fructose-6-phosphate amidotransferase
XX PT (GfAT), for treating diabetes, a cardiovascular or neurologic disorder,
XX PT ischemia/reperfusion injury.

XX
PS Claim 4; SEQ ID NO 2458; 175pp; English.
XX
CC The present invention relates to a compound which specifically hybridizes
CC with a nucleic acid molecule encoding GfAT, and inhibits the expression
CC of GfAT. Specifically claimed are antisense oligonucleotides capable of
CC modulating the expression of GfAT, and which comprise any of the 3063
CC sequences of 20 base pairs, given in the specification. The compound,
CC composition and methods are useful for treating a disease or condition
CC associated with GfAT, such as a disease or condition, e.g. diabetes, a
CC cardiovascular or neurological disorder, ischemia/reperfusion injury.
CC They are also useful in research and diagnostics for modulating the
CC expression of GfAT. The present sequence represents a chimeric
CC phosphorothioate oligonucleotide with 2'-MOE wings and a deoxy gap, these
CC oligonucleotides inhibit human GfAT expression.
SQ
SQ Sequence 20 BP; 8 A; 5 C; 6 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 416 CAAGGTGGAAGCAGCTTAC 435
DB 1 CAAGGTGGAAGCAGCAAC 20
RESULT 222
ADN49541
ID ADN49541 standard; DNA; 20 BP.
AC
XX ADN49541;
XX
DT 12-AUG-2004 (first entry)
DE Human TDP-1 antisense oligonucleotide ISIS 133400.
XX
XX
KW ss; human; antisense; tyrosyl-DNA phosphodiesterase-1; TDP-1;
KW hyperproliferative disorder.
XX
XX
OS Homo sapiens.
OS Synthetic.
XX
XX US2004097450-A1.
XX
XX PD 20-MAY-2004.
XX
XX PF 19-NOV-2002; 2002US-00300399.
XX
XX PF 19-NOV-2002; 2002US-00300399.
XX
XX PR (ISIS-) ISIS PHARM INC.
XX
XX PA wait AT;
XX
XX PI wait AT;
XX
XX DR WPI; 2004-389191/36.
XX
XX PT New compounds, particularly oligonucleotides targeted to a nucleic acid
XX PT encoding tyrosyl-DNA phosphodiesterase-1 (TDP-1), useful for treating
XX PT diseases associated with TDP-1, e.g. hyperproliferative disorders.
XX
XX PS Example 15; SEQ ID NO 28; 51pp; English.
XX
XX The invention relates to a compound targeted to and which specifically
XX hybridizes with a nucleic acid molecule encoding tyrosyl-DNA
XX phosphodiesterase-1 (TDP-1), and inhibits the expression of TDP-1. The
XX compound, composition and methods are useful for treating a disease or
XX condition associated with TDP-1, such as a hyperproliferative disorder.
XX They are also useful in research and diagnostics for modulating the
XX expression of TDP-1. The present sequence represents a human TDP-1
XX antisense oligonucleotide.
SQ
SQ Sequence 20 BP; 8 A; 6 C; 4 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 ATCACCATCCCAAGCTGA 1273
DB 1 ATCACCATGCCAAGCAGCA 20

RESULT 223
ADN9618/c
ID ADN9618 standard; DNA; 20 BP.

XX AC ADN9618;

XX DT 12-AUG-2004 (first entry)

XX DE Human TDP-1 target sequence ISIS 44337.

XX KM ss; human; tyrosyl-DNA phosphodiesterase-1; TDP-1;
hyperproliferative disorder.

XX OS Homo sapiens.

XX PN US2004097450-A1.

XX PD 20-MAY-2004.

XX PF 19-NOV-2002; 2002US-00300399.

XX PR 19-NOV-2002; 2002US-00300399.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Watt AT;

XX DR WPI; 2004-389191/36.

PT New compounds, particularly oligonucleotides targeted to a nucleic acid
encoding tyrosyl-DNA phosphodiesterase-1 (TDP-1), useful for treating
PT diseases associated with TDP-1, e.g. hyperproliferative disorders.

XX PS Example 15; SEQ ID NO 105; 51pp; English.

XX CC The invention relates to a compound targeted to and which specifically
hybridizes with a nucleic acid molecule encoding tyrosyl-DNA

XX CC phosphodiesterase-1 (TDP-1), and inhibits the expression of TDP-1. The
compound, composition and methods are useful for treating a disease or

XX CC condition associated with TDP-1, such as a hyperproliferative disorder.

XX CC They are also useful in research and diagnostics for modulating the
expression of TDP-1. The present sequence represents a human TDP-1 target
XX sequence.

XX SQ Sequence 20 BP; 2 A; 4 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1254 ATCACCATCCCAAGCTGA 1273
DB 20 ATCACCATGCCAAGCAGCA 1

RESULT 224

ADP22828
ID ADP22828 standard; DNA; 20 BP.

XX AC ADP22828;

XX DT 26-AUG-2004 (first entry)

DE Human BUB1-beta target sequence ISIS 196150.

XX KM ss; BUB1-beta; hyperproliferative disorder; cancer; human.

XX OS Homo sapiens.

XX PN US2004110149-A1.

XX PD 10-JUN-2004.

XX PF 10-DEC-2002; 2002US-00316459.

XX PR 10-DEC-2002; 2002US-00316459.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Jain R;

XX DR WPI; 2004-440338/41.

PT New oligonucleotide compound that inhibits expression of BUB1-beta,
PT useful for preparing a composition for treating hyperproliferative
PT disorder, e.g. cancer.

XX PS Example 15; SEQ ID NO 94; 92pp; English.

XX CC The invention relates to a new compound, having a sequence targeted to a
nucleic acid encoding BUB1-beta, which specifically hybridizes with the
XX CC nucleic acid encoding BUB1-beta and inhibits expression of BUB1-beta. The
XX CC oligonucleotide compound is useful for preparing a composition for
XX CC treating a hyperproliferative disorder, e.g. cancer. The present sequence
XX represents a human BUB1-beta target sequence.

XX SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 132 GTCCTGCGCGAAGCCTG 151
DB 1 GTCCTGAGTGAGCCATG 20

RESULT 225
ADP22750/c
ID ADP22750 standard; DNA; 20 BP.

XX AC ADP22750;

XX DT 26-AUG-2004 (first entry)

XX DE Human BUB1-beta antisense oligonucleotide ISIS 280005.

XX KM ss; BUB1-beta; hyperproliferative disorder; cancer; human; antisense.

XX OS Homo sapiens.

XX PN Synthetic.

XX PD US2004110149-A1.

XX PF 10-JUN-2004.

XX PR 10-DEC-2002; 2002US-00316459.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Bennett CF, Jain R;

XX DR WPI; 2004-440338/41.

```
PT New oligonucleotide compound that inhibits expression of BUB1-beta,
PT useful for preparing a composition for treating hyperproliferative
PT disorder, e.g. cancer.
XX
XX
PS Example 15; SEQ ID NO 16; 92bp; English.
XX
CC The invention relates to a new compound, having a sequence targeted to a
CC nucleic acid encoding BUB1-beta, which specifically hybridises with the
CC nucleic acid encoding BUB1-beta and inhibits expression of BUB1-beta. The
CC oligonucleotide compound is useful for preparing a composition for
CC treating a hyperproliferative disorder, e.g. cancer. The present sequence
CC represents a human BUB1-beta antisense oligonucleotide.
XX
SQ Sequence 20 BP; 5 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      132 GTGCTCTGCGGAGGCCCTG 151
Db      20 GTGCTCTGAGTGAAGCCATG 1

RESULT 226
ADO42827
ID ADO42827 standard; DNA; 20 BP.
XX
AC ADO42827;
XX
DT 26-AUG-2004 (first entry)
XX
DE Human oestrogen receptor-alpha (ER)-related oligonucleotide probe #11.
XX
KW human; oestrogen receptor-alpha; ER; ER activity regulator substance;
XX anti-oestrogen substance; oligonucleotide; probe; ss.
XX
OS Homo sapiens.
XX
PN WO2004046352-A1.
XX
PD 03-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-JP014494.
XX
PR 15-NOV-2002; 2002JP-00331994.
XX 15-NOV-2002; 2002JP-00331995.
XX 15-NOV-2002; 2002JP-00331996.
XX
PA (SUMO ) SUMITOMO CHEM CO LTD.
XX
PI Fujimori K;
XX
DR WPI; 2004-431978/40.
XX
PT New mutant estrogen receptor-alpha useful for determining effectiveness
PT of treatment by estrogen receptor activity regulator substance and
PT antiestrogen substance.
XX
PS Example 25; SEQ ID NO 40; 111bp; Japanese.
XX
CC The invention comprises the amino acid sequences of mutant human
CC oestrogen receptor-alpha (ER) proteins. The mutant ER proteins of the
CC invention are useful for determining the effectiveness of a treatment by
CC an ER activity regulator substance, and for determining the effectiveness
CC of a treatment by an anti-oestrogen substance. The present DNA sequence
CC represents an oligonucleotide probe that was used in an example of the
CC invention.
XX
SQ Sequence 20 BP; 5 A; 4 C; 6 G; 5 T; 0 U; 0 Other;

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1325 CCTGTGAGCTCTTCGACA 1344
Db      1 CATGTGGAGATCTTCGACA 20

RESULT 227
ADO42828
ID ADO42828 standard; DNA; 20 BP.
XX
AC ADO42828;
XX
DT 26-AUG-2004 (first entry)
XX
DE Human oestrogen receptor-alpha (ER)-related oligonucleotide probe #12.
XX
KW human; oestrogen receptor-alpha; ER; ER activity regulator substance;
XX anti-oestrogen substance; oligonucleotide; probe; ss.
XX
OS Homo sapiens.
XX
PN WO2004046352-A1.
XX
PD 03-JUN-2004.
XX
PF 14-NOV-2003; 2003WO-JP014494.
XX
PR 15-NOV-2002; 2002JP-00331994.
XX 15-NOV-2002; 2002JP-00331995.
XX 15-NOV-2002; 2002JP-00331996.
XX
PA (SUMO ) SUMITOMO CHEM CO LTD.
XX
PI Fujimori K;
XX
DR WPI; 2004-431978/40.
XX
PT New mutant estrogen receptor-alpha useful for determining effectiveness
PT of treatment by estrogen receptor activity regulator substance and
PT antiestrogen substance.
XX
PS Example 25; SEQ ID NO 41; 111bp; Japanese.
XX
CC The invention comprises the amino acid sequences of mutant human
CC oestrogen receptor-alpha (ER) proteins. The mutant ER proteins of the
CC invention are useful for determining the effectiveness of a treatment by
CC an ER activity regulator substance, and for determining the effectiveness
CC of a treatment by an anti-oestrogen substance. The present DNA sequence
CC represents an oligonucleotide probe that was used in an example of the
CC invention.
XX
SQ Sequence 20 BP; 4 A; 4 C; 7 G; 5 T; 0 U; 0 Other;

Query Match          0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 1.4e+02;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1328 GGTGAAGCTTTCGACAAAGC 1347
Db      1 GGTGAGATCTTCGACATGC 20

RESULT 228
ADQ14779/C
ID ADQ14779 standard; DNA; 20 BP.
XX
AC ADQ14779;
XX
DT 07-OCT-2004 (first entry)
XX
DE Mouse RANK antisense oligonucleotide ISIS181051.
XX
```

KM Mouse; ss; antisense; RANK; tumour necrosis factor receptor;
 KM bone marrow-derived osteoclast precursor cell; primary osteoclast cell;
 KM osteoclast; non-liposomal transfection agent; osteoclast differentiation;
 KM subnormal bone condition; bone disease; osteoporosis; osteopetrosis.

OS Mus musculus.

XX Key Location/Qualifiers
 FH modified_base 1..20
 FT /*tag= b
 FT /mod_base= OTHER
 FT /note= "Phosphorothioate backbone and all cytidines are 5
 FT -methylcytidines"
 FT modified_base 1..5
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl residue"
 FT modified_base 16..20
 FT /*tag= c
 FT /mod_base= OTHER
 FT /note= "2'-methoxyethyl residue"

US2004137623-A1.

15-JUL-2004.

17-SEP-2003; 2003US-00666909.

30-OCT-2000; 2000WO-US029828.

06-AUG-2002; 2002US-00111868.

(ISIS-) ISIS PHARM INC.

Baker BF, Myers K, Finger J;

WPI; 2004-533382/51.

PT Delivering oligonucleotides into osteoclasts or osteoclast precursor
 cells to modulate osteoclast differentiation comprises transfecting cells
 with the oligonucleotides and a non-liposomal transfection agent (e.g.
 PT FUGENE 6).

XX Example 15; SEQ ID NO 14; 54pp; English.

XX The invention relates to delivering a compound 8-80 nucleobases in length
 CC into bone marrow-derived osteoclast precursor cells, into primary
 CC osteoclast cells or into a cell line whose cells are capable of
 CC differentiating into osteoclasts, comprises transfecting the cells with
 CC the compound in the presence of a non-liposomal transfection agent. Also
 CC included is the method of modulating osteoclast differentiation,
 CC comprising delivering a compound 8-80 nucleobases in length (i.e. an
 CC antisense oligonucleotide) into bone marrow-derived osteoclast precursor
 CC cells, the compound targeted to a nucleic acid molecule encoding RANK
 CC (tumour necrosis factor receptor superfamily, member 11a) and capable of
 CC binding a region of the nucleic acid molecule encoding RANK, where the
 CC osteoclast differentiation of the bone marrow-derived osteoclast
 CC precursor cells is modulated by the compound. The methods and composition
 CC are useful for delivering oligonucleotide compounds into osteoclasts or
 CC osteoclast precursor cells to modulate osteoclast differentiation. These
 CC may be used for treating patients with subnormal bone conditions or for
 CC discovering diagnostics and therapeutics for bone diseases associated
 CC with osteoclast activity (e.g. osteoporosis or osteopetrosis). The
 CC present sequence is an antisense oligonucleotide targeting mouse RANK.

XX Sequence 20 BP; 2 A; 8 C; 10 G; 0 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 11 GCCAGCGCGCGGCTGCGCG 30
 DB 20 GCCCGCGCGGCTGCGCG 1

RESULT 229;
 ID ADQ14827 standard; cDNA; 20 BP.

ADQ14827;

XX ADQ14827;

XX 07-OCT-2004 (first entry)

DE Mouse RANK antisense target region #4.

XX Mouse; ss; antisense; RANK; tumour necrosis factor receptor;
 KM bone marrow-derived osteoclast precursor cell; primary osteoclast cell;
 KM osteoclast; non-liposomal transfection agent; osteoclast differentiation;
 KM subnormal bone condition; bone disease; osteoporosis; osteopetrosis.

OS Mus musculus.

US2004137623-A1.

15-JUL-2004.

17-SEP-2003; 2003US-00666909.

30-OCT-2000; 2000WO-US029828.

06-AUG-2002; 2002US-00111868.

(ISIS-) ISIS PHARM INC.

Baker BF, Myers K, Finger J;

WPI; 2004-533382/51.

PT Delivering oligonucleotides into osteoclasts or osteoclast precursor
 cells to modulate osteoclast differentiation comprises transfecting cells
 with the oligonucleotides and a non-liposomal transfection agent (e.g.
 PT FUGENE 6).

XX Example 15; SEQ ID NO 62; 54pp; English.

XX The invention relates to delivering a compound 8-80 nucleobases in length
 CC into bone marrow-derived osteoclast precursor cells, into primary
 CC osteoclast cells or into a cell line whose cells are capable of
 CC differentiating into osteoclasts, comprises transfecting the cells with
 CC the compound in the presence of a non-liposomal transfection agent. Also
 CC included is the method of modulating osteoclast differentiation,
 CC comprising delivering a compound 8-80 nucleobases in length (i.e. an
 CC antisense oligonucleotide) into bone marrow-derived osteoclast precursor
 CC cells, the compound targeted to a nucleic acid molecule encoding RANK
 CC (tumour necrosis factor receptor superfamily, member 11a) and capable of
 CC binding a region of the nucleic acid molecule encoding RANK, where the
 CC osteoclast differentiation of the bone marrow-derived osteoclast
 CC precursor cells is modulated by the compound. The methods and composition
 CC are useful for delivering oligonucleotide compounds into osteoclasts or
 CC osteoclast precursor cells to modulate osteoclast differentiation. These
 CC may be used for treating patients with subnormal bone conditions or for
 CC discovering diagnostics and therapeutics for bone diseases associated
 CC with osteoclast activity (e.g. osteoporosis or osteopetrosis). The
 CC present sequence is a target region of the mouse RANK cDNA, for the
 CC antisense oligonucleotides.

XX Sequence 20 BP; 0 A; 10 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 15.2; DB 1; Length 20;

Best Local Similarity 85.0%; Pred. No. 1.4e+02;

Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 11 GCCAGCGCGCGGCTGCGCG 30
 DB 1 GCCCGCGCGGCTGCGCG 20

Query Match	Best Local Match	Similarity	Score	DB	Length
Matches 17; Conservative	0.6%;	85.0%;	15.2;	1.4e+02;	20;
	0;	0;	Mismatches 3;	Indels 0;	Gaps 0

Qy	1986 GAGGATGGGGTGGCAATGA 2005
Db	1 GAGGATGGCGATGCAATGA 20
Qy	RESULT 231
	ADJ33612/c
ID	ADJ33612 standard; DNA; 20 BP.
XX	
AC	ADJ33612;
XX	
DT	18-NOV-2004 (first entry)
XX	
DE	Human LAR target oligonucleotide SEQ ID NO:141.
XX	
KW	LAR; leukocyte antigen related protein; LAR inhibitor;
KW	antisense oligonucleotide; cytostatic; gene therapy; metabolic disorder;
KW	hyperproliferative disorder; cancer; human; target; ss.
XX	
OS	Homo sapiens.
XX	
PN	MO2004010956-A2.
XX	
PD	05-FEB-2004.
XX	
PF	31-JUL-2003; 2003WO-US023994.
XX	
PR	31-JUL-2002; 2002US-00210838.
XX	
PA	(ISIS-) ISIS PHARM INC.
PI	
XX	Monia BP, Bhanot S, Dobie KW, Freiler SM,
XX	WPI; 2004-143728/14.
DR	
PT	New compound comprises a sequence targeted to a nucleic acid encoding
PT	Leukocyte Antigen Related protein (LAR), useful for preparing a
PT	composition for treating metabolic or hyperproliferative disorders, e.g.
PT	cancer.
XX	
XX	Example 16; SEQ ID NO 141; 197bp; English.
XX	
CC	The present invention describes a compound (I) comprising a sequence
CC	comprising 8-80 base pairs (bp) targeted to a nucleic acid encoding LAR
CC	(leukocyte antigen related protein), where (I) specifically hybridises
CC	with the nucleic acid and inhibits expression of LAR. Also described: (1)
CC	a composition comprising the compound (I) and a carrier or diluent; (2)
CC	inhibiting the expression of LAR in cells or tissues; (3) treating an
CC	animal having or suspected of having a disease or condition associated
CC	with LAR; and (4) screening for an antisense compound. (I) has cytostatic
CC	activity, and can be used in gene therapy. The antisense oligonucleotide
CC	metabolic or hyperproliferative disorders, particularly cancer. The
CC	present sequence represents a human LAR target oligonucleotide, which is
CC	used in an example from the present invention.
XX	
SEQ	Sequence 20 BP; 3 A; 8 C; 2 G; 7 T; 0 U; 0 Other;
Query Match	0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity	85.0%; Pred. NO. 1.4e+02;
Matches 17; Conservative	0; Mismatches 3; Indels 0; Gaps 0;
Qy	1986 GAGGATGGGGTGGCAATGA 2005
Db	20 GAGGATGGCGATGCAATGA 1
RESULT 232	
ADJ33612/c	
ID	ADJ33612 standard; DNA; 20 BP.
XX	
AC	ADJ33612;

KM fruit ripening; flower pigmentation; lignin production; ss.
 XX
 OS Zea mays.
 XX
 PN WO9710328-A2.
 XX
 PD 20-MAR-1997.
 XX
 PF 12-JUL-1996; 96WO-US011689.
 XX
 PR 13-JUL-1995; 95US-0001135P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX (DOWC) DOWELANCO.
 XX
 PI Zwick MG, Edington BE, Mcswigen JA, Merlo PAO, Guo L, Skokut TA,
 XX Young SA, Folkerts O, Merlo DJ;
 DR WPI; 1997-202224/18.
 XX
 PT Ribozyme which modulates plant gene expression - preferably modulates
 PT expression of DELTA-9 desaturase or granule bound starch synthase in
 PT maize or canola.
 XX
 PS Claim 41; Page 74; 155pp; English.
 XX
 CC The present invention describes an enzymatic nucleic acid molecule (I)
 CC with RNA cleaving activity, which modulates the expression of a plant
 CC gene. Also described is a gene comprising a cDNA sequence encoding maize
 CC Delta-9 desaturase. (I) can be used to modulate expression of a gene,
 CC preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
 CC gene, in a plant (preferably a maize or canola plant). (I) can be used to
 CC modulate caffeine synthesis in a coffee plant, nicotine production in a
 CC tobacco plant, fruit ripening processes in an apple, tomato, pear, plum
 CC or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or
 CC marigold plant or lignin production in a tobacco, aspen, poplar or pine
 CC plant
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 0 T; 2 U; 0 Other;
 XX
 Query Match 0.6%; Score 15; DB 1; Length 17;
 Best Local Similarity 86.7%; Pred. NO. 1.6e+02;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 778 AGAAGTCCCGAGCA 792
 DB 3 AGAAGTCCCGAGCA 17
 RESULT 235
 AAX62280
 ID AAX62280 standard; RNA; 17 BP.
 XX
 AC AAX62280;
 XX
 DT 16-JUL-1999 (first entry)
 XX
 DE Granule bound starch synthase hammerhead substrate SEQ ID NO.155.
 XX
 KM Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
 KM granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
 KM modulation; gene expression; transgenic plant; cleavage; canola plant;
 KM caffeine synthesis; coffee plant; nicotine production; tobacco;
 KM fruit ripening; flower pigmentation; lignin production; ss.
 XX
 OS Zea mays.
 XX
 PN WO9710328-A2.
 XX
 PD 20-MAR-1997.
 XX
 PF 12-JUL-1996; 96WO-US011689.
 XX

PR 13-JUL-1995; 95US-0001135P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX (DOWC) DOWELANCO.
 XX
 PI Zwick MG, Edington BE, Mcswigen JA, Merlo PAO, Guo L, Skokut TA,
 XX Young SA, Folkerts O, Merlo DJ;
 DR WPI; 1997-202224/18.
 XX
 PT Ribozyme which modulates plant gene expression - preferably modulates
 PT expression of DELTA-9 desaturase or granule bound starch synthase in
 PT maize or canola.
 XX
 PS Claim 41; Page 74; 155pp; English.
 XX
 CC The present invention describes an enzymatic nucleic acid molecule (I)
 CC with RNA cleaving activity, which modulates the expression of a plant
 CC gene. Also described is a gene comprising a cDNA sequence encoding maize
 CC Delta-9 desaturase. (I) can be used to modulate expression of a gene,
 CC preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
 CC gene, in a plant (preferably a maize or canola plant). (I) can be used to
 CC modulate caffeine synthesis in a coffee plant, nicotine production in a
 CC tobacco plant, fruit ripening processes in an apple, tomato, pear, plum
 CC or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or
 CC marigold plant or lignin production in a tobacco, aspen, poplar or pine
 CC plant
 XX
 SQ Sequence 17 BP; 6 A; 4 C; 5 G; 0 T; 2 U; 0 Other;
 XX
 Query Match 0.6%; Score 15; DB 1; Length 17;
 Best Local Similarity 86.7%; Pred. NO. 1.6e+02;
 Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 778 AGAAGTCCCGAGCA 792
 DB 2 AGAAGTCCCGAGCA 16
 RESULT 236
 ABZ61331
 ID ABZ61331 standard; RNA; 17 BP.
 XX
 AC ABZ61331;
 XX
 DT 21-MAR-2003 (first entry)
 XX
 DE Human H-Ras DNAzyme target #122.
 XX
 KM Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KM enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytoskeletal; anti-HIV;
 KM anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200297114-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 29-MAY-2002; 2002WO-US016840.
 XX
 PR 29-MAY-2001; 2001US-0294140P.
 XX
 PR 06-JUN-2001; 2001US-0296249P.
 XX
 PR 10-SEP-2001; 2001US-0318471P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswigen J;
 XX
 DR WPI; 2003-140484/13.
 XX
 PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding

PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.

P5 Claim 58; Page 113; 18SPD; English.

XX The invention relates to a novel short interfering RNA (siRNA) nucleic

CC acid molecule or an enzymatic nucleic acid molecule, that modulates

CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,

CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic

CC acid molecule of the invention has cytosstatic, anti-HIV, and anti-

CC rheumatic activity. The nucleic acid molecules are useful for reducing

CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are

CC also useful for treating breast, ovarian, colorectal, lung, prostate,

CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences

CC shown in ABZ653889 - ABZ622216, ABZ64544 - ABZ65351, ABZ66520 - ABZ66524,

CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human

CC ribozymes of the invention

XX SEQ Sequence 17 BP; 0 A; 8 C; 6 G; 0 T; 1 U; 0 Other;

OY Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 1.6e+02;
Matches 14; Conservative 1; Mismatches 0; Indels 0; Gaps 0
146 GCCCAGGCCCGGGG 160
|||:|||:
3 GCCCGGCCCGGGG 17

RESULT 237

ID ADF63854 standard; DNA; 17 BP.

AC ADE63854;

DT 12-FEB-2004 (first entry)

XX Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1758.

DB Human PCCP1 DNA fragment SEQ ID 8-directed probe - SEQ ID 1758.

XX chromatin organisation modifier; CHROMO domain; cytosstatic; PCCP1;

KW prostate cancer candidate protein 1; tumour; gene therapy; vaccine;

XX human; ss; probe.

XX Homo sapiens.

OS WO2003050284-A1.

PN 19-JUN-2003.

PD 22-NOV-2002; 2002WO-US037506.

PP 10-DEC-2001; 2001US-0339764P.

PR (AMSH) AMERSHAM BIOSCIENCES SV CORP.

PA Guo J;

P1 WPI; 2003-532916/50.

DR New prostate cancer candidate protein 1 (PCCP1), useful for preparing a

PT composition for treating or preventing a disorder associated with

FT decreased or increased expression or activity of PCCP1 e.g., tumor.

XX Example 2; SEQ ID NO 1758; 164pp; English.

PS The invention relates to a novel isolated nucleic acid that encodes a

CC protein with a chromatin organisation modifier (CHROMO) domain. The

CC polynucleotide of the invention demonstrates cytosstatic activity and may

CC be useful for preparing a composition for treating or preventing a

CC disorder associated with decreased or increased expression or activity of

CC PCCP1 (prostate cancer candidate protein 1), such as a tumour, as well as

CC during gene therapy and vaccine production procedures. The current

CC sequence is that of the human PCCP1-related DNA fragment SEQ ID 8-

CC directed probe of the invention. Note: The current sequence is not shown

CC	within the specification per se but was retrieved from the Wipoweb database.
CC	
XX	Sequence 17 BP; 0 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
SQ	
XX	Query Match 0.6%; Score 15; DB 1; Length 17;
XX	Best Local Similarity 100.0%; Prod. No. 1,6e+02;
DB	Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0
OY	
DB	727 TGGGCCTGGGTGCCT 741 2 TGGGCGTGGGTGCCT 16
RESULT 238	
ADL48694/C	
ID	ADL48694 standard; RNA; 17 BP.
XX	
AC	ADL48694;
DT	20-MAY-2004 (first entry)
XX	
DE	Human IKK-gamma substrate sequence #1204.
XX	
KM	antisease oligonucleotide; neurite growth inhibitor; NOGO;
KM	proteoglycan D2 receptor; PTGDR; IkappaB kinase; IKK;
KM	protein kinase PKR; cerebrovascular accident;
KM	central nervous system injury; CNS injury; spinal cord injury; cancer;
KV	melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW	restenosis; asthma; Crohn's disease; diabetes; obesity;
KW	autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW	graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW	allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
OS	substrate; ds.
XX	
OS	Unidentified.
XX	
FN	WO200281628-A2.
PD	
XX	17-OCT-2002.
PF	
XX	03-APR-2002; 2002MO-USO10512.
PR	
XX	05-APR-2001; 2001US-00827395.
PR	29-MAY-2001; 2001US-0294412P.
PR	28-AUG-2001; 2001US-0315315P.
PA	(RIBO-) RIBOZYME PHARM INC.
PI	
XX	Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Foenbaugh K,
DR	WPI; 2003-058513/05.
TC	
PT	Novel enzymatic nucleic acid that down-regulates expression of neurite growth inhibitor receptor, proteoglycan D2 receptor, IkappaB kinase or protein kinase PKR genes, for treating cancer and inflammatory disease.
PS	Claim 59; SEQ ID NO 2227; 317bp; English.
XX	
CC	The invention comprises nucleic acids (e.g. antisease oligonucleotides) that down regulate the expression or inhibit the function of a receptor for a neurite growth inhibitor, NOGO, proteoglycan D2 receptor (PTGDR), IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the invention are useful for treating: cerebrovascular accident, central nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma, lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis, restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft rejection, ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The nucleic acids of the invention are also useful for down-regulating the expression of a target gene and as a diagnostic tool to examine genetic drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1184 CCTCTCTCTCCGA 1198
DB 17 CCTCTCTCTCCGA 3
RESULT 239
ADL48695/c
ID ADL48695 standard; RNA; 17 BP.
XX
AC ADL48695;
XX
DT 20-MAY-2004 (first entry)
XX
DE Human IKK-gamma substrate sequence #1205.
XX
KW antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; Ikappab kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
XX Unidentified.
XX
XX WO200281628-A2.
XX
PD 17-OCT-2002.
XX
PD 03-APR-2002; 2002WO-US010512.
XX
PF 05-APR-2001; 2001US-00827395.
XX
PR 29-MAY-2001; 2001US-0294412P.
XX
PR 28-AUG-2001; 2001US-0315315P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatc L, Chowrira B, Haeblerli P, Mcswiggen J, Fornaugh K;
XX
DR WPI; 2003-058513/05.
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, Ikappab kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
XX
PS Claim 59; SEQ ID NO 2228; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC Ikappab kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a

CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 7 A; 1 C; 8 G; 0 T; 1 U; 0 Other;
Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1184 CCTCTCTCTCCGA 1198
DB 15 CCTCTCTCTCCGA 1
RESULT 240
AAF76146/c
ID AAF76146 standard; DNA; 20 BP.
XX
AC AAF76146;
XX
DT 05-JUN-2001 (first entry)
XX
DE Human Interleukin-7 (IL-7) PCR primer, SEQ ID NO:14.
XX
XX Transgenic mouse; immunodeficient; tissue recipient;
KW lymphocyte deficient; human cytokine; Interleukin; IL-7; IL-6; SCF; LIF;
KW stem cell factor; leukemia inhibitory factor; GM-CSF; M-CSF;
KW granulocyte macrophage-colony stimulating factor;
KW macrophage-colony stimulating factor; human MHC class II; DR3;
KW major histocompatibility complex; allergenicity determination;
KW human monoclonal antibody generation; haematopoietic cell development;
KW human immune system animal model; PCR primer; ss.
XX
XX Homo sapiens.
XX
XX WO200115521-A1.
XX
PN 08-MAR-2001.
XX
PD 30-AUG-2000; 2000WO-US023971.
XX
PF 31-AUG-1999; 99US-0151688P.
XX
PR (GENV) GENENCOR INT INC.
XX
PA Huang MA, Harding FA;
XX
PI WPI; 2001-169001/17.
XX
DR New transgenic mice, useful as non-human mammalian models of human
PT disease, comprise recombination activation gene mutations and donor
PT specific transgenes encoding cytokines.
XX
PS Example 2; Page 33; 68pp; English.
XX
XX The invention relates to a transgenic immunodeficient recipient mouse
CC which is capable of supporting the growth of donor cells. In the mouse,
CC both alleles of a gene activated in early lymphocyte development are
CC disrupted, causing it to lack mature B and T cells. In particular, both
CC alleles of the recombination activation gene-2 (RAG-2) gene are
CC disrupted, which in turn prevents VDJ recombination. The mouse also
CC comprises donor (e.g., human) specific transgenes encoding the cytokines
CC interleukin-7 (IL-7), stem cell factor (SCF), leukemia inhibitory factor
CC (LIF), granulocyte macrophage-colony stimulating factor (GM-CSF),
CC macrophage-colony stimulating factor (M-CSF), and IL-6, which enable it
CC to support the growth of transplanted donor cells. In another embodiment
CC of the invention, the mouse comprises DNA encoding the human major
CC histocompatibility complex (MHC) class II DR3 molecule, where the
CC transgene has naturally linked Drab and Dab alleles. The transgenic
CC mouse may be used as a model for determining the allergenicity of non-
CC donor, e.g., non-human, macromolecules, to determine the effect compounds
CC have on a human immune system; to generate fully human polyclonal or
CC monoclonal antibodies to specific antigens; to determine whether

CC humanists or other monoclonal antibodies will raise a response in a human
CC immune system; to investigate the human cell mediated response to
CC pathogens and other immunomodulatory compounds; and to determine the
CC factors involved in regulating the development and function of human
CC haematopoietic cells. The transgenic mouse supports the functional
CC properties of human haematopoietic cells, unlike previous animal models
CC which produce functionally impaired haematopoietic cells or are
CC immunologically dysfunctional. In addition the transgenic mouse provides
CC a unique model system which supports T cell development in a manner which
CC more closely resembles normal ontogeny, as they possess CD4⁺ T cells in
CC the periphery that exhibit MHC-restricted antigen-specific responses.
CC Sequences AAF76133-AAF76192 represent human cytokine PCR primers used in
CC the development of human cytokine-expressing transgenic mice
XX
XX Sequence 20 BP, 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;
XQ

Query Match 0.6%; Score 15; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. NO. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY	1423	GAGGAACCAAGCTGCA	1437
Db	15	GAGGAACCAAGCTGCA	1

RESULT 241
ACC42584/c

AC ACC42584;

DT 26-AUG-2003 (first entry)

DE Human interleukin-7, IL-7, PCR primer 51-IL7R.

KM cytokine; PCR; primer; transgene mouse; lymphocyte maturation; IL-3; IL-7;
KM Htkline; interleukin-3; interleukin-6; IL-6; interleukin-7; M-CSF; SCF;
KM macrophage-colony stimulating factor; stem cell factor; oncostatin M; OM
KM leukemia-colony stimulating factor; GM-CSF; LIF;
KM leukemia inhibitory factor; ss.

OS Homo sapiens.

PN WO2003018744-A2.

PD 06-MAR-2003 .

PF 05-AUG-2002; 2002WO-US024807.

PR 23-AUG-2001; 2001US-00938689.

PA (GEMV) GENENCOR INT INC.

PI Harding FA, Huang M;

DR WPI; 2003-278650/27.

PT New recipient mammal, preferably a mouse, useful as a model of human disease to assess efficacy of therapeutic or prophylactic treatments, or for facilitating production of donor-specific functional immunity.

PS Example; Page 31; 70pp; English.

CC The present invention relates to a new transgenic mouse, which comprises
CC a disruption in both alleles of a gene such that lymphocyte maturation
CC does not occur and exogenous cytokines. The cytokines are selected from:
CC interleukin-3 (IL-3), interleukin-6 (IL-6), interleukin-7 (IL-7),
CC macrophage-colony stimulating factor (M-CSF), granulocyte-colony
CC stimulating factor (GM-CSF), stem cell factor (SCF), leukemia inhibitor
CC factor (LIF) and oncostatin M (OM). The gene disruption is in a gene that
CC modulated VDJ recombination e.g., a RAG gene. The gene is disrupted by
CC insertion of a transgene comprising major histocompatibility complex
CC (MHC) Class II DR3 and DQ2 genes. The transgenic mouse is useful as a

CC model or human disease to assess efficacy of therapeutic or prophylactic
CC treatments, or to assess the antigenic potential of compounds. The
CC transgenic mouse is also useful for supporting donor haematopoietic stem
CC cells or facilitating production of donor-specific functional immunity.
CC PCR primers ACC42571-A/CC42639 were used to generate the transgenic mouse
XX
XX Sequence 20 BP; 2 A; 7 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.6%; Score 15; DB 1; Length 20;
 Best Local Similarity 100.0%; Pred. No. 1.4e+02;
 Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0.

QY	1423	GAGGAACCAAGCTGCA	1437
Db	15	GAGGAACCAAGCTGCA	1

RESULT 242
ABZ88089/c
ID ABZ88089 standard; DNA; 20 BP.

AC ABZ88089

DT 17-OCT-2003 (first entry)

DE Human oligonucleotide sequence.

KM Humani; antihistense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antiallathatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM antihense gene therapy; respiratory; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;
KM lung inflammation; respiratory disease; ds.

OS Homo sapiens.

PN W0200285308-A2.

PD 31-OCT-2002.

PF 23-APR-2002; 2002WO-US013135.

PR 24-APR-2001; 2001US-0286137P.

PA (EPIC-) EPIGENESIS PHARM INC

PI Nyce JW, Li Y, Sandrabagra A, Katz E, Pabalan J, Aguilar D;

XX

Pharmaceutical composition for treating ailments associated with impaired PT respiration, has oligo(s) antisense to specific gene(s) or its PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or ubiquinone.

PS Disclosure; SEQ ID NO 3331; 872pp; English.

The invention relates to a novel pharmaceutical composition, which has a first active agent comprising an oligonucleotide antisense to the initiation codon, coding region, 5' or 3' and genomic flanking regions, 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of junctions of genes encoding a polypeptide associated with lung and/or nasal airway dysfunction and a second active agent comprising an antiinflammatory steroid and ubinonone. A composition of the invention has antiinflammatory, antiallergic, antilasthmatic, hypotensive, immunosuppressive, and cytoskeletal activity. The composition may have a use in antisense gene therapy. The composition is useful for treating or preventing a respiratory, lung or malignant disease or condition, also for enhancing the prophylactic or therapeutic respiratory effect of an antiinflammatory steroid in a subject, for reducing or depleting levels of, or reducing sensitivity to adenosine, reducing levels of adenosine or, or reducing bronchoconstriction, increasing levels of ubinonone or receptor, producing bronchoconstriction, increasing levels of ubinonone or

CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 20 BP; 8 A; 6 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1676 CTCAGCTCTTCTGGG 1690
DB 15 CTCAGCTCTTCTGGG 1
RESULT 243
ABD24319/c
ID ABD24319 standard; DNA; 20 BP.
XX
AC ABD24319;
XX
DT 29-JUN-2004 (first entry)
XX
DE A1095013-derived oligonucleotide DNA SEQ ID 3331.
XX
KW Human; antisense; bronchoconstriction; allergy; hyposecretion; pain;
KW respiratory tract inflammation; adenosine sensitivity; lung; cancer;
KW surfactant depletion; antiasthmatic; antiinflammatory; antiasthmatic;
KW analgesic; hypotensive; immunosuppressive; cytoskeletal; cystic fibrosis;
KW beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;
KW respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;
KW emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;
KW pulmonary transplantation rejection; ss; primer.
XX
OS Homo sapiens.
XX
PN W0200285309-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US013143.
XX
PR 24-APR-2001; 2001US-0286036P.
XX
PA (EPIG-) EPIGENESIS PHARM INC.
XX
PI NYce JM, Li Y, Sandrasagra A, Katz B, Pabalan J, Aguilar D,
PI Miller S, Tang L, Shahbuddin S;
XX
DR WPI; 2003-093058/08.
XX
PT Pharmaceutical composition for treating asthma, has antisense
PT oligonucleotide containing less percentage of adenosine, targeted to
PT nucleic acids associated with lung airway or lung dysfunction, and
PT bronchodilating agent.
XX
PS Claim 15; SEQ ID NO 3331; 763bp; English.
XX
CC This invention describes a novel composition (a) a first active agent,
CC comprising oligonucleotides, effective for alleviating, allergies and
CC bronchoconstriction, respiratory tract inflammation, allergies and
CC reducing adenosine sensitivity, levels of adenosine (A) or (A) receptors,
CC surfactant depletion or hyposecretion, when administered to a mammal. The
CC oligonucleotides are derived from a gene encoding or regulating
CC expression of a target polypeptide associated with lung airway or lung
CC dysfunction or cancer and can be anti-sense to the corresponding mRNA.
CC The invention also describes a kit, that comprises: (a) a delivery
CC device, in separate containers, (b) the oligonucleotides, (c)
CC instructions for adding a carrier and for use of the kit. The composition
CC of the invention has antiasthmatic, antiinflammatory, antiasthmatic,
CC analgesic, hypotensive, immunosuppressive and cytostatic activity, is a

CC beta-adrenergic agonist. The composition is useful for preventing or
CC treating a respiratory, lung or malignant disease. The administered
CC composition comprises oligo and is administered to reduce the production
CC or availability, or to increase the degradation of the target mRNA or to
CC reduce the amount of target polypeptide present in the lungs. The
CC pulmonary obstruction, and/or bronchoconstriction and/or lung
CC inflammation, allergies and/or surfactant hypoproduction are associated
CC with a disease or condition such as pulmonary vasoconstriction,
CC inflammation, allergies, asthma, impeded respiration, respiratory
CC distress syndrome, pain, cystic fibrosis, allergic rhinitis, pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease, pulmonary
CC transplantation rejection, pulmonary infections, bronchitis or cancer.
CC The reduced adenosine content of the anti-sense oligos corresponding to
CC thymidines present in the target RNA serves to prevent the breakdown of
CC the oligonucleotides into products that free adenosine into the system
CC e.g., lung, brain, heart, kidney, etc. tissue environment and thereby, to
CC prevent any unwanted effects due to it
XX
SQ Sequence 20 BP; 8 A; 6 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 15; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1676 CTCAGCTCTTCTGGG 1690
DB 15 CTCAGCTCTTCTGGG 1
RESULT 244
AAQ98499
ID AAQ98499 standard; DNA; 18 BP.
XX
AC AAQ98499;
XX
DT 17-APR-1996 (first entry)
XX
DE 5' primer for human NT2-N receptor coding sequence fragment.
XX
KW Polymerase chain reaction; PCR; primer; amplify; NT2-N; receptor;
KW NT2 cell; cholinergic neuronal cell; N-methyl-D-aspartate receptor;
KW NMDA; human; neurological disorder; central nervous system;
KW excitotoxicity; ss.
XX
OS Synthetic.
XX
PN US5449609-A.
XX
PD 12-SEP-1995.
XX
PF 31-JAN-1994; 94US-00189199.
XX
PR 31-JAN-1994; 94US-00189199.
XX
PA (CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.
XX
PI Pleasure D, Younkin DP;
XX
DR WPI; 1995-327693/42.
XX
PT NT2-N functional glutamate receptor producing clonal neuronal cells -
PT used to screen agents for excitotoxic effects on the neurons of the
PT central nervous system useful in the study of neurological disorders.
XX
PS Example 2; Col 6; 14pp; English.
XX
CC The sequences represented by AAQ98499 and AAQ98500 are primers for a
CC fragment of human NT2-N receptor DNA. The sequence represented by
CC AAQ98501 is a probe for the amplified fragment. NT2-N cells are
CC cholinergic neuronal cells. NT2-N cells are produced by treating NT2
CC cells with retinoic acid. The amplified sequence was found to be a N-
CC methyl-D-aspartate (NMDA) receptor. By comparison with the rat NMDA
CC receptor (NMDAR1). NMDA is a glutamate receptor channel and is expressed

CC in neuronal cells. The NT2-N cells can be used to study agents in
CC relation to human neurological disorders. The agents that are to be
CC studied are compounds that are thought to exhibit excitotoxic effects on
CC the neurons of the central nervous system. A change in cellular response
CC in the presence of the agent as compared to cellular response in the
CC absence of the agent represents a positive screening result
XX

SQ Sequence 18 BP; 7 A; 6 C; 4 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 ACCCTGGCAACCGCAAG 1010
DB 1 AACCTGAGAACCGCAAG 18

RESULT 245
AAT80355/c
ID AAT80355 standard; DNA; 18 BP.
AC AAT80355;
XX
XX
DT 16-OCT-1997 (first entry)
XX
DE Oligo HCV-213, targeted to HCV mRNA position +230 to +235.
XX
XX
KW Complementary; 5' untranslated region; UTR; hepatitis C virus; HCV;
KW inhibition; replication; expression; detection; chronic hepatitis;
KW acute hepatitis; hepatocarcinoma; ss.
XX
OS Synthetic.

XX
FH Key Location/Qualifiers
FT modified_base 1..12
FT /*tag= a
FT /note= "2'-OMe RNA"
FT modified_base 13..18
FT /*tag= b
FT /note= "Comprises phosphorothioate linkages"

XX
PN WO9639500-A2.

PD 12-DEC-1996.

XX
PF 04-JUN-1996; 96WO-EP002427.

XX
PR 06-JUN-1995; 95US-00471968.

XX
PA (HOF) HOFFMANN LA ROCHE & CO AG F.
PA (HYBR-) HYBRIDON INC.

XX
PI Frank BL, Goodchild J, Hamlin HA, Kiluskie RE, Roberts NA,
PI Roberts PC, Walthers DM, Wolfe JL;

XX
PI WPI; 1997-043122/04.

DR Oligo:nucleotide(s) complementary to HCV 5' untranslated region - used in
XX the treatment and detection of HCV infection, esp. hepatitis and hepato-
PT carcinoma.
XX

PS Claim 20; Page 20; 100pp; English.

XX
XX The sequences given in AAT80211-382 represent synthetic oligonucleotides
CC which are complementary to a portion of the 5' untranslated region (UTR)
CC of hepatitis C virus (HCV). These sequences may be used in a
CC pharmaceutical composition for the control or prevention of HCV
CC infection. They may be used to inhibit replication or expression of HCV
CC or for detecting the presence of HCV in a sample. They may be used to
CC inhibit HCV replication in a cell and are therefore useful in the
CC treatment of HCV infections such as chronic and acute hepatitis and
CC hepatocarcinoma. This sequence binds to two non-contiguous regions of the

CC HCV genome. This sequence is anchored at position -219 to -230 and is
CC targeted to position +230 to +235
XX

SQ Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 372 TCCGCCCTCCAGACCTC 389
DB 18 TCAGCCCTCCAGACCTC 1

RESULT 246
AAV18052
ID AAV18052 standard; DNA; 18 BP.
XX
XX
AC AAV18052;
XX
XX
DT 30-JUL-1998 (first entry)
XX
DE NMDA receptor 1 primer (1063-1080).
XX
XX
KW Primer; PCR; amplification; NMDAR1; CNS; proliferation; astrocyte; ss;
KW differentiation; glutamate receptor; neuron; Alzheimer's disease.
XX
OS Synthetic.
OS Homo sapiens.
XX
XX
PN MO9810058-A1.

XX
PD 12-MAR-1998.

XX
PF 02-SEP-1997; 97WO-US015442.

XX
PR 03-SEP-1996; 96US-00711628.

XX
PA (SIGN-) SIGNAL PHARM INC.

XX
PI Sah DWY, Gage FH, Ray J;

XX
PI WPI; 1998-193609/17.

DR
XX
XX Production of conditionally-immortalised human central nervous system
PT progenitor cells - useful for treatment of CNS-related diseases and in
PT assays for study of CNS cell development, death and abnormalities.
XX

PS Example 3; Page 35; 75pp; English.

XX
XX The invention provides for a method for producing conditionally
CC immortalized human CNS progenitor cell lines. One such cell line B4 was
CC tested for the type of native channels and receptors it expressed during
CC proliferating conditions and during differentiating conditions. This
CC involved analysing PCR products from PCR reactions using primers for
CC various channels and receptors. The primer pairs (AAV18052-V18067) used
CC were for detecting NMDAR1, glutamate receptor (GluR) 1, GluR2, GluR3,
CC GluR4, GluR5, GluR6 and GluR7. The present forward primer corresponding
CC to nucleotides 1063-1080 of NMDAR1 cDNA was used with the NMDAR1 reverse
CC primer (AAV18053). Cell line B4 was shown to express GluR1, GluR2, GluR3,
CC GluR4 and GluR5. GluR7 was expressed only under differentiating
CC conditions. The method is claimed to be useful for producing astrocytes
CC and/or neurons by culturing the immortalized human CNS progenitor cells
CC under conditions where the growth-promoting gene expression is inhibited.
CC Cells produced by the method are also claimed to be useful for treating
CC patients where the patient is afflicted with a pathological condition
CC involving degenerated neurons e.g. Alzheimer's disease, Parkinson's
CC disease, amyotrophic lateral sclerosis, stroke and traumatic head injury.
CC These cells may also be useful for screening agents that modulate
CC activity of proteins produced by a CNS cell, for detecting the presence
CC or absence of a protein in a sample and for screening for agents that
CC affect CNS cell death or proteins that regulate CNS cell death
XX

Db 18 GAAGGGCTGCGCCGCT 1
RESULT 249
AAA34640
ID AAA34640 standard; DNA; 18 BP.
XX
AC AAA34640,
XX
DT 28-JUL-2000 (first entry)
XX
DE Human adenosine receptor related polynucleotide SEQ ID NO:2329.
XX
KW Human: adenosine receptor; low adenosine antisense oligonucleotide;
XX phosphorothioate; impaired respiration; inflammation; allergy;
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
KW antiallergic; analgesic; cytoskeletal; analgesic; impaired airway;
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
XX
OS Homo sapiens.
XX
PN WO200009525-A2.
XX
PD 24-FEB-2000.
XX
PF 03-AUG-1999; 99WO-US017712.
XX
PR 03-AUG-1998; 98US-0095212P.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX
NYce JW;
XX
WI; 2000-205971/18.
XX
PT New antisense oligonucleotides useful for treating e.g. pulmonary
PT vasoconstriction, inflammation, allergies, asthma, hypertension,
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT cancers.
XX
PS Disclosure; Page 556; 1343pp; English.
XX
CC The present invention describes a new composition comprising an antisense
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC nucleic acids involved in bronchoconstriction, allergies, and/or
CC inflammation. The ON can have antiinflammatory, antiallergic,
CC antisthmatic, cytoskeletal and analgesic activities. The compositions are
CC useful for the treatment of diseases associated with inflammation,
CC impaired airways, including lung disease and diseases whose secondary
CC effects afflict the lungs of a subject. They can be used for treating
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,
CC impaired respiration, respiratory distress syndrome, pain, cystic
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
CC carcinomas, and cancers which may metastasize to the lungs, including
CC breast and prostate cancer. The reduction of the adenosine content of the
CC ONs reduces side effects. The A-containing ONs break down with the
CC release of deoxyadenosine which activates adenosine receptors causing
CC bronchoconstriction and inflammation. AAA32313 to AAA3312 represent the
CC nucleotide sequences given in the sequence listing from the present
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185
CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ
CC from the previously named sequences. SEQ ID NO:1 to 1680 (AAA32323 to
CC AAA33992) are specifically claimed ONs from the present invention. N.B.
CC Sequences given in the disclosure of the present invention do not match
CC up with their corresponding SEQ ID NO: sequences given in the sequence
CC listing
XX
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 158 GGCGCGGCGCATGGGCC 175
Db 1 GGCGCTGGGCGCTGGGCC 18
RESULT 250
AAZ61530
ID AAZ61530 standard; DNA; 18 BP.
XX
AC AAZ61530;
XX
DT 19-JUN-2000 (first entry)
XX
DE Primer 4L for a human 5'-OT EST (oxytocin expressed sequence tag).
XX
KW Oxytocin expressed sequence tag; 5'-OT EST; obesity; fertility; male;
KW transgenic animal; human late onset obesity; late onset visceral obesity;
KW male infertility; wasting; anorexia; cachexia; malabsorptive state;
KW catabolic state; inflammatory condition; Crohn's disease; AIDS wasting;
KW burn; cancer; bone disease; PCR primer; probe; ss.
XX
OS Homo sapiens.
XX
PN WO200009686-A1.
XX
PD 24-FEB-2000.
XX
PF 12-AUG-1999; 99WO-GB002658.
XX
PR 12-AUG-1998; 98GB-00017566.
XX
PR 06-MAY-1999; 99GB-00010522.
XX
PA (MED1-) MEDICAL RES COUNCIL.
XX
PI Robinson ICAF, Stoye JP, Flavell D, Wells SE, Le Tissier P;
XX
DR WI; 2000-224331/19.
XX
PT New anti-obesity polypeptide useful for treating obesity or infertility
PT in mammals.
XX
PS Disclosure; Page 26; 162pp; English.
XX
CC PCR primers and probes AAZ61529-30 are used to amplify and identify human
CC 5'-OT-EST (oxytocin expressed sequence tag) cDNA sequences. The 5'-OT EST
CC gene is involved in the control of obesity and fertility in males. 5'-OT
CC EST nucleic acids are useful for producing transgenic animals. The
CC transgenic animals created serve as a model for human late onset obesity
CC and other related disorders and are also used for identifying the genetic
CC cause of obesity. Compounds which modulate 5'-OT EST expression or
CC activity are useful in the treatment or modulation of late onset visceral
CC obesity or male infertility particularly in the disorders related to
CC these conditions, such as wasting, or anorexia, or cachexia associated
CC with prolonged illness, or malabsorptive states or catabolic states
CC associated with other diseases such as inflammatory conditions, Crohn's
CC disease or AIDS wasting, or burns, or cancer, or bone disease
XX
SQ Sequence 18 BP; 2 A; 4 C; 11 G; 1 T; 0 U; 0 Other;
Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 281 GGCGGAGCTGACCGGAG 298
Db 1 GGCGGAGCTGACCGGAG 18
RESULT 251

AA52875
ID AA52875 standard; DNA, 18 BP.
XX
AC AA52875;
XX
DT 15-SEP-2000 (first entry)
XX
DE Human CD44 antisense oligonucleotide ISIS# 18764.
XX
KM Human; CD44; cell surface adhesion receptor; cytosolic; antirheumatic;
KM antiinflammatory; antiarthritic; CD44 antisense inhibition;
KM hyperproliferative disorder; cancer; inflammatory disorder;
KM rheumatoid arthritis; ss.
XX
OS Homo sapiens.
XX
PN WO200035935-A1.
XX
PD 22-JUN-2000.
XX
PF 14-DEC-1999; 99WO-US029576.
XX
PR 17-DEC-1998; 98US-00213719.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Bennett CF, Cowser LM;
XX
DR WPI; 2000-431564/37.
XX
PT New antisense compound, that inhibits the expression of human cell
PT surface adhesion receptor CD44, for treating hyperproliferative disorders
PT and inflammatory conditions, such as cancer and rheumatoid arthritis.
XX
PS Claim 3; Page 77; 105pp; English.
XX
SQ The present sequence is one of a large number of antisense
XX oligonucleotides designed to target different regions of the human CD44
XX mRNA. CD44 is a multifunctional human cell surface adhesion receptor. The
XX oligonucleotides were analysed for effect on CD44 mRNA levels by
XX quantitative real-time PCR analysis. Antisense oligonucleotides that
XX inhibit CD44 expression can be used to treat CD44-associated conditions
XX including hyperproliferative disorders, such as cancer, and inflammatory
XX conditions, such as rheumatoid arthritis. The antisense compounds
XX hybridize to CD44 nucleic acids, thus allowing sandwich and other assays
XX to be easily constructed. Note: The sequence has a phosphorothioate
XX backbone and may be either an oligodeoxynucleotide or a chimeric
XX oligonucleotide containing 2'-methoxyethyl (2'-MOE) wings and a deoxy
XX gap. The ISIS number given above corresponds to the oligodeoxynucleotide
XX sequence
SQ Sequence 18 BP; 4 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 18;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 502 TCATGTACATATTCTGCA 519
DB 1 TCATGTCCACATTCTGCA 18
RESULT 252
AAF20762
ID AAF20762 standard; DNA, 18 BP.
XX
AC AAF20762;
XX
DT 14-MAR-2001 (first entry)
XX
DE Human multiple target antisense (MTA) oligonucleotide #2329.
XX
KM Low adenosine antisense oligonucleotide; phosphorothioate; allergy;

KM human; airway disorder; bronchoconstriction; lung inflammation;
KM surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KM immunosuppressive; antiaesthetic; analgesic; hypotensive; cytosolic;
KM respiratory obstruction; pulmonary obstruction; impeded respiration;
KM surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KM respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KM pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KM chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KM cancer; ss.
XX
OS Homo sapiens.
XX
PN WO200062736-A2.
XX
PD 26-OCT-2000.
XX
PF 24-MAR-2000; 2000WO-US008020.
XX
PR 06-APR-1999; 99US-0127958P.
XX
PA (UYEC-) UNIV EAST CAROLINA.
XX (NYCE/) NYCE J W.
XX
PI Nyce JW;
XX
DR WPI; 2000-679539/66.
XX
PT Low adenosine (A) content antisense oligonucleotides which do not trigger
PT adenosine receptors during metabolism, useful e.g. for treating cancers
PT and respiratory obstructions.
XX
PS Claim 14; Page 624; 1592pp; English.
XX
SQ The present invention describes low adenosine (A) content antisense
XX oligonucleotides and compositions (I) comprising them. In the antisense
XX oligonucleotides the A is replaced by a 'Universal' or alternative base.
XX (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
XX immunosuppressive, antiaesthetic, hypotensive and cytosolic activities.
XX The antisense oligonucleotides and (I) can be used to down-regulate the
XX expression and/or activity of target polypeptides associated with
XX lung/respiratory disorders and malignancies, such as stimulating and
XX activating peptide factors and transmitters, such as stimulating and
XX immunoglobulins and antibodies, antibody receptors, cytokines and
XX chemokines, endogenously produced specific and non-specific enzymes,
XX binding proteins, adhesion molecules and their receptors, cytokine and
XX chemokine receptors, adenosine receptors, bradykinin receptors, central
XX nervous system (CNS) and peripheral nervous and non-nervous system
XX receptors, CNS and peripheral nervous and non-nervous system
XX transmitters, defensive, growth factors, vasoactive peptide
XX receptors, binding proteins and malignancy associated proteins and
XX antisense oligonucleotides may be used in this way to treat disorders
XX including respiratory obstruction (especially pulmonary obstruction
XX and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
XX surfactant hypoproduction which are associated with a disease or
XX condition selected from pulmonary vasoconstriction, inflammation,
XX allergies, asthma, impeded respiration, respiratory distress syndrome
XX (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
XX pulmonary transplantation rejection, pulmonary infections, bronchitis,
XX and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
XX fragments and antisense oligonucleotides used in the exemplification of
XX the present invention
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 18;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 158 GGGGCGGGGCGGCGGCGC 175
DB 1 GGGGCTGGGGCTGGGGCC 18

RESULT 253
AA21465
ID AAF21465 standard; DNA; 18 BP.
AC AAF21465;
XX
XX 14-MAR-2001 (first entry)
XX
XX Human multiple target antisense (MTA) oligonucleotide #3032.
XX
XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KM human; airway disorder; bronchoconstriction; lung inflammation;
KM surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KM immunosuppressive; antiaesthetic; analgesic; hypotensive; cytotatic;
KM respiratory obstruction; pulmonary obstruction; impeded respiration;
KM surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KM respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KM pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KM chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KM cancer; 88.
XX
XX Homo sapiens.
OS
PN WO200062736-A2.
XX
XX 26-OCT-2000.
XX
XX 24-MAR-2000; 2000WO-US008020.
XX
XX 06-APR-1999; 99US-0127958P.
XX
XX (UYEC-) UNITV EAST CAROLINA.
PA (NYCE/) NYCE J W.
XX
XX Nyce JW;
PI
DR WPI; 2000-679539/66.
XX
XX Low adenosine (A) content antisense oligonucleotides which do not trigger
PT adenosine receptors during metabolism, useful e.g. for treating cancers
PT and respiratory obstructions.
XX
XX
XX Disclosure; Page 297; 1592pp; English.
XX
XX The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising chem. in the antisense
CC oligonucleotides the A is replaced by a 'universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiaesthetic, hypotensive and cytostatic activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulin and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adhesion molecules and their receptors, cytokine and
CC chemokine receptors, adenosine receptors, bradykinin receptors, central
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or
CC surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of

CC the present invention
XX
XX Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
SO
XX Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 158 GGGGCGGGGCGATCGGCC 175
DB 1 GGGGCTGGGCGCTGGGCC 18
RESULT 254
ID AAS05704 standard; DNA; 18 BP.
AC AAS05704;
XX
XX AAS05704;
XX
XX 07-SEP-2001 (first entry)
XX
XX Polypyrimidine region of SNP DYS271 target sequence.
XX
XX Triplex forming oligonucleotide; TFO; protected nucleic acid sequence;
KM PNAS; single nucleotide polymorphism; SNP; short tandem repeat; cancer;
KM SNP DYS271; 88.
XX
XX Synthetic.
OS
PN WO200132929-A1.
XX
XX 10-MAY-2001.
XX
XX 03-NOV-2000; 2000WO-US030534.
XX
XX 03-NOV-1999; 99US-0163356P.
PR 03-NOV-1999; 99US-0163416P.
PR 21-DEC-1999; 99US-0173348P.
PR 07-UTL-2000; 2000US-0216579P.
XX
XX (CYGE-) CYGENE INC.
PA (OSTE-) OSTE C C.
XX
XX Oste CC, Ramberg ER;
PI
DR WPI; 2001-343488/36.
XX
XX Analyzing target nucleic acid sequences, useful for population genetics,
PT drug development and diagnosing cancer, comprises hybridizing triple
PT forming oligonucleotide and probe to target sequence.
XX
XX Example 1; Page 64; 141pp; English.
XX
XX The sequence is the polypyrimidine region of SBNP DYS271 on the Crick
CC strand, 3' to the SNP score site used in the method of the invention. The
CC invention relates to analysing target nucleic acid sequences comprising
CC restricting isolated DNA, hybridizing at least one triplex forming
CC oligonucleotide (TFO), adding a 3' to 5' exonuclease to form a protected
CC nucleic acid sequence (PNAS) tail structure, hybridizing the captured
CC structure with a single nucleotide polymorphisms (SNP) identification
CC probe and determining the SNP score. The methods can be used for
CC analysing target nucleic acid sequences, especially genomic DNA
CC sequences, to determine if they contain SNPs or short tandem repeats
CC (STRs). The methods can be used to detect SNPs for use in population
CC genetic, drug development, forensics, cancer, genetic disease research,
CC genomic analysis, diagnostics and therapeutics in humans, plants and
CC animals
XX
XX Sequence 18 BP; 8 A; 1 C; 9 G; 0 T; 0 U; 0 Other;
SO
XX Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1642 CTCCTCTCTCCCTCTCT 1659
 DB 18 CCCCTCTCTGCTCTCTCT 1
 RESULT 255
 ID ABL30863 standard; DNA; 18 BP.
 AC ABL30863;
 XX
 XX 21-MAR-2002 (first entry)
 XX
 DE Human HLA genotyping oligonucleotide SEQ ID NO 352.
 XX
 KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KM immunogenetic; transplantation; genetic disease; ss.
 OS Homo sapiens.
 XX
 XX WO200192572-A1.
 XX
 XX 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-JP004662.
 XX
 XX 01-JUN-2000; 2000JP-00164798.
 XX
 PA (NINSEN) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M,
 PI
 DR WPI; 2002-122074/16.
 XX
 PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes of
 PT individuals e.g. by determining immunogenetic differences when
 XX transplanting between them.
 XX
 PS Claim 10; Page 160; 345pp; Japanese.
 XX
 CC The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridizing a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals
 CC
 SQ Sequence 18 BP; 7 A; 2 C; 5 G; 4 T; 0 U; 0 Other;
 Query Match 0.6%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1071 GAGGATGAAGTGTACAG 1088
 DB 1 GAGGATGAAGTGTACAG 18
 RESULT 256
 ID ABL30863 standard; DNA; 18 BP.
 AC ABL30863;
 XX
 XX 15-NOV-2002 (first entry)
 DT

XX
 DE Inhibitory oligonucleotide specific for hepatitis C virus #145.
 XX
 XX Hepatitis C virus; HCV; hepatocyte infection; non-A hepatitis;
 KM non-B hepatitis; acute hepatitis; chronic hepatitis;
 KM hepatocellular carcinoma; virucide; cytostatic; antisense therapy;
 KM gene therapy; ss; DNA-RNA hybrid.
 XX
 OS Synthetic.
 XX
 XX US2002081577-A1.
 XX
 XX 27-JUN-2002.
 XX
 XX 02-JUL-1997; 97US-00887505.
 XX
 XX 06-JUN-1995; 95US-00471968.
 PR 02-JUL-1996; 96US-0021104P.
 XX
 PA (KILK/) KILKUSKIE R L.
 PA (FRAN/) FRANK B L.
 PA (GOOD/) GOODCHILD J.
 PA (WOLF/) WOLFE J L.
 PA (ROBE/) ROBERTS P C.
 PA (HAML/) HAMLIN H A.
 PA (ROBE/) ROBERTS N A.
 PA (WALT/) WALTHER D M.
 XX
 XX Kilkuskie RL, Frank BL, Goodchild J, Wolfe JL, Roberts PC,
 PI Hamlin HA, Roberts NA, Walther DM;
 XX
 DR WPI; 2002-537132/57.
 XX
 PT Synthetic oligonucleotides complementary to a portion of the 5'
 PT untranslated region of hepatitis C virus (HCV), useful for diagnosing and
 PT treating HCV infections and hepatocellular carcinoma.
 XX
 PS Claim 23; Page 7; 74pp; English.
 XX
 CC The invention describes synthetic oligonucleotides complementary to a
 CC portion of the 5' untranslated region of hepatitis C virus. The
 CC oligonucleotides may be used in methods for controlling, preventing, and
 CC treating hepatitis C virus infection, in antisense technology and gene
 CC therapy, and of detecting the presence of hepatitis C virus in a sample.
 CC Hepatitis C virus (HCV) is an enveloped, positive sense, single-stranded
 CC RNA virus which infects hepatocytes. HCV is the major cause of non-A, non
 CC -B, acute and chronic hepatitis, and has been associated with
 CC hepatocellular carcinoma. The invention describes methods and kits for
 CC inhibiting replication of HCV, inhibiting the expression of HCV nucleic
 CC acid and protein, and for treating HCV infections. This sequence
 CC represents a synthetic DNA-RNA hybrid oligonucleotide used for inhibiting
 CC HCV replication and expression of HCV
 XX
 SQ Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 Other;
 Query Match 0.6%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 372 TCCGCTCTCCAGACCTC 389
 DB 18 TCAGCCTCCAGACCTC 1
 RESULT 257
 ID AB296456 standard; DNA; 18 BP.
 AC AB296456;
 XX
 XX 17-OCT-2003 (first entry)
 DT Human nucleic acid sequence.

XX Human; antiense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM antiseptic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM adenosine receptor; bronchodilation; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; lung; adenosine sensitivity;
KM lung inflammation; respiratory disease; de.
XX
XX Homo sapiens.
OS
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US01135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI NYce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antiense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ublquinone.
XX
PS Disclosure; SEQ ID NO 11698; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antiense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ublquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antiense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 158 GGGGCGGGGCGATGGGCC 175
DB 1 GGGGCTGGGGCTGGGCC 18
XX
RESULT 258
AB297159
ID AB297159 standard; DNA; 18 BP.
XX
AC AB297159;
XX
DT 17-OCT-2003 (first entry)
XX
DE Human MTA oligonucleotide.

XX Human; antiense; lung dysfunction; nasal airway dysfunction;
KM antiinflammatory steroid; ubiquinone; antiinflammatory; antiallergic;
KM antisthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM antiseptic; hypotensive; immunosuppressive; cytostatic; gene therapy;
KM adenosine receptor; bronchodilation; lung; adenosine sensitivity;
KM adenosine receptor; bronchodilation; lung; adenosine sensitivity;
KM lung inflammation; respiratory disease; de.
XX
XX Homo sapiens.
OS
PN WO200285308-A2.
XX
PD 31-OCT-2002.
XX
PF 23-APR-2002; 2002WO-US01135.
XX
PR 24-APR-2001; 2001US-0286137P.
XX
PA (EPIC-) EPIGENESIS PHARM INC.
XX
PI NYce JM, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;
PI Miller S, Tang L, Shahabuddin S;
DR WPI; 2003-229219/22.
XX
PT Pharmaceutical composition for treating ailments associated with impaired
PT respiration, has oligo(s) antiense to specific gene(s) or its
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or
PT ublquinone.
XX
PS Disclosure; SEQ ID NO 12401; 872pp; English.
XX
CC The invention relates to a novel pharmaceutical composition, which has a
CC first active agent comprising an oligonucleotide antiense to the
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of
CC junctions of genes encoding a polypeptide associated with lung and/or
CC nasal airway dysfunction and a second active agent comprising an
CC antiinflammatory steroid and ublquinone. A composition of the invention
CC has antiinflammatory, antiallergic, antisthmatic, hypotensive,
CC immunosuppressive, and cytostatic activity. The composition may have a
CC use in antiense gene therapy. The composition is useful for treating or
CC preventing a respiratory, lung or malignant disease or condition, also
CC for enhancing the prophylactic or therapeutic respiratory effect of an
CC antiinflammatory steroid in a subject, for reducing or depleting levels
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine
CC receptor, producing bronchodilation, increasing levels of ubiquinone or
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,
CC lung inflammation, lung allergies, or a respiratory disease or condition.
CC Note: The sequence data for this patent is not represented in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 18 BP; 0 A; 5 C; 11 G; 2 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 158 GGGGCGGGGCGATGGGCC 175
DB 1 GGGGCTGGGGCTGGGCC 18
XX
RESULT 259
ABD20418
ID ABD20418 standard; DNA; 18 BP.
XX
AC ABD20418;
XX
DT 29-JUL-2004 (first entry)
XX
DE Human pulmonary and inflammatory target DNA #29.

CC the oligonucleotides into products that free adenosine into the system
 CC e.g., lung, brain, heart, kidney, etc, tissue environment and thereby, to
 CC prevent any unwanted effects due to it

XX Sequence 18 BP, 0 A, 5 C, 11 G, 2 T, 0 U, 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 1.6e+02;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 158 GGGGCGGGCGATGGCC 175

DB 1 GGGGCTGGGGCTGGGCC 18

RESULT 261

ID ADH08326/c

ADH08326 standard; DNA, 18 BP.

XX AC ADH08326;

DT 11-MAR-2004 (first entry)

XX DE Mutant gene fragment designated 175AS1.

XX KM Biochip; target; ligand; analysis; molecular biology; db.

XX OS Homo sapiens.

XX PN WO2003100423-A2.

XX PD 04-DEC-2003.

XX PF 23-MAY-2003; 2003WO-FR001574.

XX PR 24-MAY-2002; 2002FR-00070739.

XX PA (APIB-) APIBIO.

XX PI Cuzin M, Mandrand B, Cleuziat P, Abaibou H;

XX DR WPI; 2004-042856/04.

XX PT Biochip, useful in molecular biology, comprises a central array of sites

XX PT carrying analytical ligands and a peripheral region containing control

XX PS sites.

XX PS Example 2; Page 17; 28pp; French.

XX CC The invention relates to a biochip (1) that comprises a support (2) the

XX CC functional side of which has a working surface (3) with a network of

XX CC elementary sites (Xn), with many ligands, different for each Xn, attached

XX CC to them. The new feature is that Xn are distributed between: a central

XX CC zone (4), designed for detection of at least one target species, with

XX CC each site containing ligands for a particular target; and a peripheral

XX CC zone (5), surrounding (4) and containing control sites, which optionally

XX CC carry control ligands. The biochip is used for analysis in molecular

XX CC biology. The specified arrangement of sites allows not only determination

XX CC of many targets but also monitoring of the determination and of the

XX CC operating conditions. The signals emitted from the chip are not affected

XX CC by the geometrical environment of the chip, for any of the elementary

XX CC sites. The current sequence represents a fragment of a mutant gene that

XX CC is related to cancer.

XX CC Sequence 18 BP, 2 A, 4 C, 9 G, 3 T, 0 U, 0 Other;

XX CC Query Match 0.6%; Score 14.8; DB 1; Length 18;

XX CC Best Local Similarity 88.9%; Pred. No. 1.6e+02;

XX CC Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2052 GATGCCGCCACATGAGC 2069

DB 18 GCTGCCGCCACATGAGC 1

RESULT 262

ID ADM69504/c

ADM69504 standard; DNA, 18 BP.

XX AC ADM69504;

XX XX 03-JUN-2004 (first entry)

XX DE Plant gene polymorphism marker related primer, SEQ ID 383.

XX KM Primer; variation mapping; mutation mapping; plant;

XX KM Gene polymorphism marker; ss.

XX OS Synthetic.

XX PN JP2003289885-A.

XX PD 14-OCT-2003.

XX PF 31-JUN-2003; 2003JP-00024620.

XX PR 01-FEB-2002; 2002JP-00025338.

XX PA (RIKA) RIKAGAKU KENKYUSHO.

XX PA (SAIM-) SAI MEDIA KK.

XX PA (MATS/) MATSUT M.

XX PA (NAKA/) NAKAZAWA M.

XX DR WPI; 2004-126231/13.

XX PT A primer set and method useful for mapping at least the

XX PT variation/mutation part of a plant gene using a gene polymorphism marker.

XX PT Claim 7; SEQ ID NO 383; 120bp; Japanese.

XX XX The present invention relates to a primer set and method for mapping at

XX CC least the variation/mutation part of a plant gene using a gene

XX CC polymorphism marker. A mutation site of the plant gene is mapped by

XX CC utilizing a genetic polymorphism marker as follows: (a) genomic DNA is

XX CC prepared from a plant homozygously having a mutation to be an object of

XX CC the mapping; (b) A forward primer 1 containing a base corresponding to

XX CC the gene polymorphic marker of one ecotype plant, a forward primer 2

XX CC containing a base corresponding to the genetic polymorphism of the other

XX CC ecotype plant and a reverse primer 3 based on the base sequence common

XX CC with both the ecotype plants are prepared; (c) two kinds of

XX CC oligonucleotides emitting fluorescence of different colors when the

XX CC genetic polymorphism marker is detected are prepared; (d) an

XX CC amplification reaction of the genomic DNA is carried out in the presence

XX CC of the primers 1, 2 and 3 and the two kinds of the oligonucleotides; (e)

XX CC the fluorescence intensely emitted from the resultant reaction product

XX CC is detected and (f) the position on the genome of the mutation site is

XX CC determined from the results of detection. The present sequence is a

XX CC primer, used to illustrate the invention.

XX CC Sequence 18 BP, 7 A, 6 C, 4 G, 1 T, 0 U, 0 Other;

XX CC Query Match 0.6%; Score 14.8; DB 1; Length 18;

XX CC Best Local Similarity 88.9%; Pred. No. 1.6e+02;

XX CC Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 547 ACTTCACTTGGCTGGTGT 564

DB 18 ACTTCACTTGGCTGGTGT 1

RESULT 263

ID ADM76423/c

ADM76423 standard; DNA, 18 BP.

XX AC ADM76423;

XX XX

XX XX

DT 01-JUL-2004 (first entry)
 XX Human myeloid leukemia related gene RHBDF1 oligonucleotide #12.
 DE
 XX ss; primer: cytosstatic; gene therapy; myeloid leukemia gene; RHBDF1;
 KM cell proliferative disease; cancer; diagnosis.
 XX
 OS Homo sapiens.
 XX
 PN WO2004031237-A1.
 XX
 PD 15-APR-2004.
 XX
 PP 29-JUL-2003; 2003WO-JP009589.
 XX
 PR 30-SEP-2002; 2002US-0414867P.
 XX
 PA (ONCO-) ONCOTHERAPY SCI INC.
 PA (UYTY) UNIV TOKYO.
 XX
 PI Nakamura Y, Katagiri T;
 PI
 XX MPI; 2004-347962/32.
 XX
 PT New RHBDF1 polypeptide useful for diagnosing, treating or preventing a
 PT cell proliferative disease, e.g. cancer or as a target molecule for a
 PT developing drugs against the disease.
 XX
 PS Disclosure; SEQ ID NO 12; 90pp; English.
 XX
 CC The invention elates to a novel myeloid leukemia related gene RHBDF1. The
 CC polypeptides, polynucleotides and antibodies are useful for treating or
 CC preventing a cell proliferative disease, preferably cancer. They can also
 CC be used for diagnosing cell proliferative disease and as target molecules
 CC for developing drugs against the disease. The genes may also serve as a
 CC diagnostic marker of cancer and the proteins encoded may be used in
 CC diagnostic assays of cancer. This sequence corresponds to the human
 CC RHBDF1 gene.
 CC
 XX Sequence 18 BP; 2 A; 3 C; 7 G; 6 T; 0 U; 0 Other;
 XX
 SQ
 Query Match 0.6%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 668 GACACACACCTGCTGAC 685
 DB 18 GACACACTACCTGCAGAC 1
 RESULT 264
 ADR72762
 ID ADR72762 standard; DNA; 18 BP.
 XX
 AC ADR72762;
 XX
 DT 02-DEC-2004 (first entry)
 XX
 DE Monoclonal antibody-related HOAKs-1 PCR primer - SEQ ID 128.
 XX
 KM monoclonal antibody; cytosstatic; immunotherapy;
 KM non-small cell lung cancer; pancreatic carcinoma; stomach cancer; PCR;
 KM primer; ss.
 XX
 OS Unidentified.
 XX
 PN WO2004076658-A1.
 XX
 PD 10-SEP-2004.
 XX
 PP 27-FEB-2004; 2004WO-JP002402.
 XX
 PR 28-FEB-2003; 2003JP-00054670.

PR 09-JUL-2003; 2003JP-00194643.
 XX
 PA (MITS-) MITSUBISHI PHARMA CORP.
 PA (UYKE-) UNIV KEIO.
 XX
 PI Hosokawa S, Aoki M, Hirakawa Y, Itami S, Umeki H, Saikawa Y;
 PI Kumai K, Fukuda K;
 XX
 DR MPI; 2004-662011/64.
 XX
 XX Novel monoclonal antibody useful as drug for treating cancer such as non-
 PT small cell lung cancer, pancreatic carcinoma and stomach cancer.
 PT
 PS Example 13; SEQ ID NO 128; 133pp; Japanese.
 XX
 CC The invention relates to a novel monoclonal antibody which is produced by
 CC hybridomas that are obtained by fusing lymphocytes originating in a
 CC cancer tissue of a cancer patient with mouse myeloma cells. The antibody
 CC of the invention demonstrates cytosstatic activity and may be useful
 CC during immunotherapy for treating cancer, such as non-small cell lung
 CC cancer, pancreatic carcinoma and stomach cancer. The antibody may be used
 CC alone or may be bound to the surface of a liposome encapsulating a toxin
 CC or anticancer drug. The current sequence is that of a monoclonal antibody
 CC -related HOAKs-1 PCR primer of the invention.
 CC
 XX Sequence 18 BP; 2 A; 2 C; 10 G; 4 T; 0 U; 0 Other;
 XX
 SQ
 Query Match 0.6%; Score 14.8; DB 1; Length 18;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1091 GGTGATCTTCGACGAGCG 1108
 DB 1 GGTGCTCTTCGACGAGCG 18
 RESULT 265
 AAT00705/c
 ID AAT00705 standard; DNA; 19 BP.
 XX
 AC AAT00705;
 XX
 DT 08-JUL-1996 (first entry)
 XX
 DE Human trkC receptor TK insert sense DNA primer.
 XX
 KM trkC receptor; tyrosine-kinase; enzyme; procease; inflammation; pain;
 KM diagnosis; neurotrophic factor; kidney; lung; psychiatric disorder;
 KM DNA primer; PCR; polymerase chain reaction; ss.
 XX
 OS Synthetic.
 XX
 PN WO9525795-A1.
 XX
 PD 28-SEP-1995.
 XX
 PF 17-MAR-1995; 95WO-US003426.
 XX
 PR 18-MAR-1994; 94US-00215139.
 PR 05-AUG-1994; 94US-00286846.
 PR 20-DEC-1994; 94US-00359705.
 XX
 PA (GETH) GENENTECH INC.
 XX
 PI Presta LG, Shelton DL, Ufer R;
 PI
 XX MPI; 1995-344616/44.
 XX
 PT New human trkB and trkC polypeptide(s) and fusion proteins contg. them -
 PT also DNA, vectors and transformed cells useful in treatment and diagnosis
 PT of abnormal neurotrophic factor expression, e.g. inflammatory pain.
 XX
 PS Disclosure; Page 70; 117pp; English.

XX This TK insert sense DNA primer was used in a Northern blot analysis to
 CC examine expression patterns of the trkC receptor in human tissue
 CC
 XX
 SQ Sequence 19 BP; 5 A; 5 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTGAGCCTTGCCCTGAG 2141
 DB 19 CTCACCTTGCCCTGCG 2

RESULT 266
 AAT7561/c
 ID AAT7561 standard; DNA; 19 BP.

XX AAT7561;
 XX
 DT 11-SEP-1997 (first entry)

XX Wheat microsatellite WMS122 left primer.

XX Microsatellite marker; hypervariable genomic fragment; Triticum aestivum;
 KM wheat; Triticeae; sequence tagged site; STS; primer; PCR; amplify;
 KM polymorphism; genetic analysis; hexaploid; tetraploid; mapping; ss.
 OS Synthetic.

XX DE19525284-A1.

XX 02-JUN-1997.

XX 28-JUN-1995; 95DE-01025284.

XX 28-JUN-1995; 95DE-01025284.

XX (PFLA-) INST PFLANZENGENETIK & KULTURPFLANZENFOR.

XX Roeder M, Plaschke J, Ganal M;

XX WPI; 1997-053731/06.

XX Primers for STS microsatellite markers for wheat and related species -
 PT useful for genetic mapping, analysis and labelling etc. of wheat.

XX Claim 5; Page 7; 8pp; German.

XX Microsatellite markers based on hypervariable genomic fragments, from
 CC Triticum aestivum (wheat) or the tribe Triticeae, consist of a sequence
 CC tagged site (STS), defined by 2 specific primers (of mean size 17-23
 CC bases) that flank a microsatellite sequence at both ends, which can be
 CC amplified to polymorphisms (PCR products of different sizes). The
 CC microsatellites are n-fold tandem repeats (n = 10 or more) of di-, tri-
 CC or tetra-nucleotide sequences, combination microsatellite sequences or an
 CC imperfect sequence in which individual bases are mutated. The
 CC microsatellite markers can be used for genetic analysis of hexaploid and
 CC tetraploid forms of wheat and for genetic mapping or labelling of
 CC monogenic and polygenic properties, and for their selection; for
 CC analyzing relationships and identifying varieties; and for evaluating
 CC varietal purity, hybrid identification and plant growth. The markers can
 CC differentiate between almost all European wheat lines and show a higher
 CC degree of DNA polymorphism than known probes for the wheat genome. They
 CC can be detected by PCR, so large numbers of samples can be analyzed
 CC easily (e.g. several hundred per day). Microsatellite marker-related
 CC polymorphisms are stably inherited so can also serve as genetic markers.
 CC AAT7003-22 and AAT77535-716 are primer pairs that define the
 CC microsatellite markers. WMS122 has CT and CA type repeats
 CC
 SQ Sequence 19 BP; 6 A; 0 C; 11 G; 2 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 ATCTCCCTTCTGCACCC 1935
 DB 18 ATCTCCCTTCTGCACCC 1

RESULT 267
 AAZ01319
 ID AAZ01319 standard; DNA; 19 BP.

XX AAZ01319;

XX 27-SEP-1999 (first entry)

XX PCR primer for PGI biallelic marker 99-140-130.

XX PGI gene; biallelic marker; PCR primer; PGI-related biallelic marker;
 KM cancer; prostate cancer; diagnosis; therapy; prostate specific antigen;
 KM PSA; human; ss.

XX Synthetic.

XX Homo sapiens.

XX WO992644-A2.

XX 01-JUL-1999.

XX 22-DEC-1998; 98WO-1B002133.

XX 22-DEC-1997; 97US-00996306.

XX 09-SEP-1998; 98US-0099658P.

XX (GENT) GENSET.

XX Cohen D, Blumenfeld M, Chumakov I, Bougueteloret L;

XX WPI; 1999-405178/34.

XX Use of a prostate cancer associated gene and biallelic markers derived
 PT from it.

XX Claim 4; Page 368; 385pp; English.

XX The invention relates to a mammalian PGI gene and protein, and a set of
 CC PGI biallelic markers. The PGI polymucleotide and biallelic markers are
 CC used in a hybridization assay, a sequencing assay, or in an allele-
 CC specific amplification assay for determining the identity of a nucleotide
 CC at a PGI-related biallelic marker. The methods can be used to detect and
 CC to assess the risk of developing cancer or prostate cancer. Early-stage
 CC diagnosis of prostate cancer relies on prostate specific antigen (PSA)
 CC dosage. However, the effectiveness of this is limited due to its
 CC inability to discriminate between malignant and non-malignant affections
 CC of the organ. A need exists for both a reliable diagnostic procedure
 CC which would enable early-stage diagnosis, and for preventative and
 CC curative treatments of the disease. The PGI gene can be used for
 CC detection of prostate cancer, and the risk of developing it in the
 CC future, and can also be used to determine therapies for the disease
 CC
 SQ Sequence 19 BP; 9 A; 6 C; 3 G; 1 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 424 AAAAGCACTACAGCTCA 441
 DB 2 AAAAGCACTACAGCA 19

RESULT 268

```
AA288855/c
ID AA288855 standard; DNA; 19 BP.
XX
AC AA288855;
XX
DT 30-MAY-2000 (first entry)
XX
DE Human trkB receptor TK insert sense primer.
XX
KW trkB; human; receptor tyrosine kinase; trkB; diagnosis; neurotrophin;
KW neurotrophic factor; primer; trkA; ss.
XX
OS Homo sapiens.
XX
PN US6027927-A.
XX
PD 22-FEB-2000.
XX
PF 01-OCT-1997; 97US-00942562.
XX
PR 18-MAR-1994; 94US-00215139.
PR 05-AUG-1994; 94US-00286846.
PR 19-MAY-1995; 95US-00444597.
XX
PA (GETH ) GENENTECH INC.
XX
PI Uffer R, Shelton DL, Presta LG;
XX
DR WPI; 2000-194832/17.
XX
PT New human trk receptors useful in the diagnosis of various human
PT pathological conditions associated with elevated or reduced levels of
PT neurotrophins capable of binding trkB and/or trkC.
XX
PS Disclosure; Col 93-94; 78pp; English.
XX
CC This invention describes a novel isolated and purified polypeptide (I),
CC belonging to the trk family of receptor tyrosine kinases, trkB and trkC.
CC (I) are useful in the purification of human neurotrophic factors and in
CC the diagnosis of various human pathological conditions associated with
CC elevated or reduced levels of neurotrophins capable of binding trkB
CC and/or trkC. AA288843-288868 represent primers used in the isolation of
CC the trkA, trkB and trkC receptor proteins described in the method of the
CC invention
XX
SQ Sequence 19 BP; 5 A; 5 C; 8 G; 1 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2124 CTCAGCCTTGCGCTGGAG 2141
DB 19 CTCACCTTGCGCTGGCG 2
RESULT 269
AAA46217/c
ID AAA46217 standard; DNA; 19 BP.
XX
AC AAA46217;
XX
DT 04-SEP-2000 (first entry)
XX
DE Primer IPM14F for interphotoreceptor matrix proteoglycan IPM150 cDNA.
XX
KW interphotoreceptor matrix; IPM; proteoglycan; IPM150; IPMC; IPM200;
KW chromosome 6q13-q15; ocular disease; retinal detachment;
KW choriorretinal degeneration; retinal degeneration; cone degeneration;
KW age related macular degeneration; photoreceptor degeneration;
KW retinal pigment epithelium degeneration; mucopolysaccharidosis;
KW rod-cone dystrophy; cone-rod dystrophy; PCR primer; ss.
XX
```

```
OS Unidentified.
XX
PN WO200026367-A2.
XX
PD 11-MAY-2000.
XX
PF 29-OCT-1999; 99WO-US025440.
XX
PR 29-OCT-1998; 98US-00183972.
XX
PA (IOWA ) UNIV IOWA RES FOUND.
XX
PI Hageman GS, Kuehn MH;
XX
DR WPI; 2000-365616/31.
XX
PT Nucleic acids encoding interphotoreceptor matrix proteoglycans useful for
PT preventing, diagnosing and treating ocular disorders such as retinal
PT detachment and choriorretinal degeneration.
XX
PS Claim 43; Page 44; 183pp; English.
XX
CC PCR primers AAA46209-42 were used to amplify cDNA encoding an
CC interphotoreceptor matrix (IPM) proteoglycan, designated IPM150. The
CC protein is an IPM component (IPMC). Two subfamilies of IPMCs, IPM150 and
CC IPM200, exist. The human IPM150 gene is located on chromosome 6q13-q15,
CC between markers CHLC.GAVAL1F10 and D6S284. The IPM proteins may be used
CC to supplement a patient's own production of the protein or to rectify
CC alterations in their nucleic acids that result in expression of an
CC inactive protein. The IPM nucleic acids may be used in this way to treat
CC ocular diseases such as retinal detachment, choriorretinal degeneration,
CC retinal degeneration, age related macular degeneration, photoreceptor
CC degeneration, RPE (retinal pigment epithelium) degeneration, cone
CC degeneration, mucopolysaccharidosis, rod-cone dystrophy and cone-rod
CC dystrophy. The nucleic acids and proteins may also be used to assay for
CC other modulators of IPM proteoglycan expression and activity that may be
CC used to treat ocular diseases. The nucleic acids and proteins may also be
CC and their products in samples from patients according to standard
CC methodologies
XX
SQ Sequence 19 BP; 4 A; 1 C; 10 G; 4 T; 0 U; 0 Other;
XX
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1184 CCTCTTCTCGGACAC 1201
DB 19 CCTGCTCTCTCAACAC 2
RESULT 270
AAA4585/c
ID AAA4585 standard; DNA; 19 BP.
XX
AC AAA4585;
XX
DT 04-DEC-2000 (first entry)
XX
DE Cyclin E ribozyme binding site #118.
XX
KW Ribozyme; hairpin; hammerhead; gene therapy; vasotrophic; restenosis; ss.
XX
OS Mammalia.
XX
PN WO200032765-A2.
XX
PD 08-JUN-2000.
XX
PR 06-DEC-1999; 99WO-US028772.
XX
PR 04-DEC-1998; 98US-0110954P.
```


CC a second specific forward primer (see ABL57140). PKM nucleic acid is
CC upregulated in tumour cells, especially in mammary carcinoma cells. It
CC codes for a protein that induces tumour progression or metastasis. PKM is
CC useful as a marker in the diagnosis and characterisation of mammary
CC tumours. PKM nucleic acids, expression vectors, host cells, and
CC polypeptides are claimed. Hybridisation probes comprising a PKM nucleic
CC acid are used in a claimed process for determining whether a test sample
CC of human cells has a tumour progression potential. The invention also
CC relates to the detection of tumour cells and to gene therapy methods that
CC modulate or inhibit PKM function in tumour cells
XX

SO Sequence 19 BP, 5 A; 5 C; 1 G; 8 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2395 CTGGAATTAATGAAG 2412
Db 19 CTGGAATTAATGAATG 2

RESULT 273

ADB25800
ID ADB25800 standard; DNA; 19 BP.

AC ADB25800;

DT 20-NOV-2003 (first entry)

DE Human CYP2D6-related PCR primer #21.

KW human; mutant CYP2D6 gene; drug analysis; drug testing; PCR; ss; primer.

OS Homo sapiens.

PN WO2003050282-A1.

PD 19-JUN-2003.

PF 05-DEC-2002; 2002WO-JP012748.

PR 06-DEC-2001; 2001JP-00372548.

PA (TSUR) TSUMURA & CO.

PI Taniyama M, Ogawa K, Tsuchiya N, Hibino T;

DR WPI; 2003-505401/47.

PT Genetic polymorphisms of CYP2D6 gene in human population for analysis of
PT drug effect on individual patients and testing of new drugs.

PS Example 1; Page 18; 75pp; Japanese.

CC The invention comprises mutant forms of the human CYP2D6 gene, containing
CC one or more of the following mutations G125A, C1858T, T2874C and C2875T.
CC The mutant human CYP2D6 genes of the invention are useful for analysing
CC the effect of drugs on individual patients and testing of new drugs. The
CC present DNA sequence represents a PCR primer used in an example of the
CC invention.
XX

SO Sequence 19 BP, 2 A; 11 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 378 CTCGAGACCTCTCTCT 395
Db 1 CTCGAGACCTCTCTCT 18

RESULT 274
ACF79453/C
ID ACF79453 standard; DNA; 19 BP.

AC ACF79453;

DT 18-DEC-2003 (first entry)

DE Serum amyloid A1 modified promoter GREI primer GREIR.

KW Glucocorticoid responsive element; GRE; serum amyloid A1; SAA1; promoter;
KW human; steroid responsiveness; PCR; primer; ss.

OS Homo sapiens.

PN WO2003062792-A2.

PD 31-JUL-2003.

PF 22-JAN-2003; 2003WO-US001651.

PR 22-JAN-2002; 2002US-00045360.

PR 03-APR-2002; 2002US-0370008P.

PA (UYPE-) UNIV PENNSYLVANIA.

PI Whitehead AS, Chailberg SS, Lazar JG;

DR WPI; 2003-748014/70.

PT Determining steroid responsiveness, useful e.g. for monitoring, or
PT assessing likely success of therapy, comprises measuring relative
PT expression of responsive and non-responsive genes.

PS Example 1; Page 29; 0pp; English.

CC The present sequence is that of primer GREIR, which was used in the PCR
CC mutagenesis of the human serum amyloid A1 (SAA1) gene promoter to produce
CC construct GREI (see ACF79453). GREI was used to confirm that a putative
CC glucocorticoid responsive element of SAA1 is functional. A method for
CC determining steroid responsiveness involves determining, in a tissue,
CC body fluid or cell sample from a subject being treated with steroids, the
CC RNA expression levels of genes that are known to be, or suspected of,
CC being, respectively, responsive and non-responsive to steroids. The first
CC gene is preferably the SAA1 gene controlled by a GRE, and the second gene
CC is the SAA2 gene; the responses of only the SAA1 gene are augmented by
CC glucocorticoid administration. The method is applied to subjects being
CC treated with steroids for a very wide range of diseases (e.g.
CC inflammation, cancer, autoimmune disease, arthritic disease, coronary
CC artery disease, endocrine disease, stroke etc.), e.g. for monitoring to
CC detect loss of responsiveness, to detect response when a combination of
CC stimuli or drugs is administered and to assess side effects, to evaluate
CC subjects for transplantation or steroid therapy, and to determine
CC suitable doses of steroids
XX

SO Sequence 19 BP, 3 A; 3 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;

Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1630 GGCTGAGTACCTCTCT 1647
Db 18 GGCTGAGTACCTCTCT 1

RESULT 275

ADB65548/C
ID ADB65548 standard; RNA; 19 BP.

AC ADB65548;

XX

DT 29-JAN-2004 (first entry)
XX Human c-fos transcript target sequence/siNA upper strand, SEQ ID NO:3.
DE
XX RNA interference; short interfering nucleic acid; siNA;
XX short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
XX short hairpin RNA; shRNA; expression modulation; gene therapy;
XX drug screening; diagnosis; therapeutic target identification;
XX pharmacogenomics; gene function analysis; gene mapping;
XX central nervous system disorder; Alzheimer's disease;
XX Parkinson's disease; Huntington's disease; epilepsy; dementia;
XX amyotrophic lateral sclerosis; cancer; proliferative disease; restenosis;
XX polycystic kidney disease; inflammatory disease; allergic disease;
XX viral infection; HIV infection; autoimmune disease; transplant rejection;
XX vasotropic; neurotropic; antiparkinsonian; neuroprotective; cytostatic;
XX antiinflammatory; antiallergic; virucide; anti-HIV; immunosuppressive;
XX anticonvulsant; nephrotropic; human; c-fos; target sequence; ss.
OS Homo sapiens.
XX
XX MO2003070914-A2.
PN
XX 28-AUG-2003.
PD
XX 20-FEB-2003; 2003WO-US005162.
PF
XX 20-FEB-2002; 2002US-0356580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PA
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Mcswiggen J, Belgelman L;
PI
XX WPI; 2003-679877/64.
DR
XX
XX New short interfering nucleic acid downregulates expression of the c-fos
PT gene useful for treatment and diagnosis of diseases, e.g. cancer and
PT inflammation.
XX
XX Example 3; SEQ ID NO 3; 145pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human c-fos gene by RNA interference. The
CC siNA may or may not comprise ribonucleotides and may be double or single
CC stranded. They further comprise sense and antisense regions, or
CC alternatively are assembled from a sense oligonucleotide and an antisense
CC oligonucleotide. Specifically, the siNA include short interfering RNA
CC (siRNA), double-stranded RNA, micro-RNA (miRNA) and short hairpin RNA
CC (shRNA). The siNA can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC of siNA, and vectors that express siNA. The siNA are used to modulate
CC expression of the c-fos gene in cells, tissue explants or organisms
CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the
CC treatment of a variety of conditions. They may be used for treating
CC central nervous system lesions and injuries (e.g., Alzheimer's disease,
CC Parkinson's disease, Huntington's disease, epilepsy, dementia or
CC amyotrophic lateral sclerosis); various cancers; other proliferative
CC diseases (e.g., restenosis and polycystic kidney disease); inflammatory
CC and/or allergic diseases; viral infections (including HIV infection);
CC autoimmune diseases; and transplant rejection. The siNA are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the upper strand of a human c-fos-
CC targeted double-stranded siNA, which is identical to the c-fos transcript
CC target sequence.

XX
SQ Sequence 19 BP; 2 A; 8 C; 9 G; 0 T; 0 U; 0 Other;
XX
XX Query Match: 0.6%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 88.9%; Pred. No. 1.6e+02;
XX Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 15 GCGCGGCGCTGCGCGCT 32
DB 18 GCGCGGCGGCGCGCGCT 1
RESULT 276
ID ADE65664
ID ADE65664 standard; RNA; 19 BP.
AC ADE65664;
XX
XX 29-JAN-2004 (first entry)
DT
XX
XX
DE Human c-fos siNA lower strand, SEQ ID NO:119.
XX
XX RNA interference; short interfering nucleic acid; siNA;
XX short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
XX short hairpin RNA; shRNA; expression modulation; gene therapy;
XX drug screening; diagnosis; therapeutic target identification;
XX pharmacogenomics; gene function analysis; gene mapping;
XX central nervous system disorder; Alzheimer's disease;
XX Parkinson's disease; Huntington's disease; epilepsy; dementia;
XX amyotrophic lateral sclerosis; cancer; proliferative disease; restenosis;
XX polycystic kidney disease; inflammatory disease; allergic disease;
XX viral infection; HIV infection; autoimmune disease; transplant rejection;
XX vasotropic; neurotropic; antiparkinsonian; neuroprotective; cytostatic;
XX antiinflammatory; antiallergic; virucide; anti-HIV; immunosuppressive;
XX anticonvulsant; nephrotropic; human; c-fos; ss.
OS Homo sapiens.
XX
XX
XX MO2003070914-A2.
PN
XX 28-AUG-2003.
PD
XX 20-FEB-2003; 2003WO-US005162.
PF
XX 20-FEB-2002; 2002US-0356580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
PA
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Mcswiggen J, Belgelman L;
PI
XX WPI; 2003-679877/64.
DR
XX
XX New short interfering nucleic acid downregulates expression of the c-fos
PT gene useful for treatment and diagnosis of diseases, e.g. cancer and
PT inflammation.
XX
XX Example 3; SEQ ID NO 119; 145pp; English.
XX
XX The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human c-fos gene by RNA interference. The
CC siNA may or may not comprise ribonucleotides and may be double or single
CC stranded. They further comprise sense and antisense regions, or
CC alternatively are assembled from a sense oligonucleotide and an antisense
CC oligonucleotide. Specifically, the siNA include short interfering RNA
CC (siRNA), double-stranded RNA, micro-RNA (miRNA) and short hairpin RNA
CC (shRNA). The siNA can be unmodified or chemically modified, can contain
CC deoxyribonucleotides, and can be chemically synthesised, expressed from a

```
CC vector or enzymatically synthesised. The invention also relates to kits
CC for the in vitro or in vivo delivery of siNA; conjugates and/or complexes
CC of siNA; and vectors that express siNA. The siNAs are used to modulate
CC expression of the c-fos gene in cells, tissue explants or organisms
CC (e.g., by ex vivo gene therapy), or in grafts and transplants for the
CC treatment of a variety of conditions. They may be used for treating
CC central nervous system lesions and injuries (e.g., Alzheimer's disease,
CC Parkinson's disease, Huntington's disease, epilepsy, dementia or
CC amyotrophic lateral sclerosis); various cancers; other proliferative
CC diseases (e.g., restenosis and polycystic kidney disease); inflammatory
CC and/or allergic diseases; viral infections (including HIV infection);
CC autoimmune diseases; and transplant rejection. The siNAs are also useful
CC for drug screening, diagnosis, therapeutic target identification and
CC validation, genetic engineering, pharmacogenomics, studying gene
CC function, and gene mapping (e.g., of single nucleotide polymorphisms).
CC The present sequence represents the lower strand of a human c-fos-
CC targeted double-stranded siNA.
CC
XX SQ Sequence 19 BP; 0 A; 9 C; 8 G; 0 T; 2 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 83.3%; Pred. No. 1.6e+02;
XX Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
XX 15 GCGCCGCGGCTGCCGCT 32
XX ||||| |||||
XX 2 GCGCCGCGGCGCGGCGCU 19
XX
XX RESULT 277
XX ADE29461
XX ID ADE29461 standard; RNA; 19 BP.
XX AC ADE29461;
XX XX
XX 29-JAN-2004 (first entry)
XX
XX Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:83.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition;
XX mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
XX cytosolic; anorectic; antidiabetic; antiinflammatory; antiaesthetic;
XX immunosuppressive; antibacterial; antirheumatic; antiarthritic;
XX antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
XX inflammatory disease; asthma; septic shock; rheumatoid arthritis;
XX psoriasis; inflammatory bowel disease; drug screening;
XX genetic engineering; pharmacogenomic; gene mapping; ss.
XX
XX Synthetic.
XX
XX WO2003072590-A1.
XX
XX 04-SEP-2003.
XX
XX 28-JAN-2003; 2003WO-US002510.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRNA) SIRNA THERAPEUTICS INC.
XX
XX Mcswigen J, Beigelman L, Usman N, Haeblerl P, Chowrira B;
XX WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
XX PT diagnosis of cancer, downregulates expression of mitogen-activated
XX PT protein kinase genes.
```

```
XX
XX PS Example 3; SEQ ID NO 83; 164pp; English.
XX
XX The present invention describes a short interfering nucleic acid (siNA)
XX that downregulates expression of a mitogen-activated protein kinase
XX (MAPK) genes by RNA interference. Also described: (1) a method for
XX modulating expression of MAPK genes in cells, tissue explants or
XX organisms by introduction of siNA; (2) kits for in vitro or in vivo
XX delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
XX vectors that express siNA and cells containing these vectors. MAPK siNAs
XX have cytosolic, anorectic, antidiabetic, antiinflammatory,
XX antiaesthetic, immunosuppressive, antibacterial, antirheumatic,
XX antiarthritic, antipsoriatic and gastrointestinal activities. The MAPK
XX siNAs can be used to modulate the expression of MAPK genes, in cells,
XX tissue explants or organisms, e.g. for treating obesity; diabetes types I
XX and II; a wide range of tumours, and inflammatory diseases (asthma,
XX septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
XX disease). They can also be used for drug screening; diagnosis; target
XX identification and validation; genetic engineering; pharmacogenomics;
XX studying gene function and gene mapping (e.g. of single-nucleotide
XX polymorphisms). The present sequence represents a MAPK siNA which is used
XX in the exemplification of the present invention.
XX
XX SQ -Sequence 19 BP; 6 A; 2 C; 2 G; 0 T; 9 U; 0 Other;
XX
XX Query Match 0.6%; Score 14.8; DB 1; Length 19;
XX Best Local Similarity 50.0%; Pred. No. 1.6e+02;
XX Matches 9; Conservative 7; Mismatches 2; Indels 0; Gaps 0;
XX
XX 897 TATTGCTTTCAGGAAT 914
XX : : : : :
XX 2 UUAUGCUUCCAGGAAT 19
XX
XX RESULT 278
XX ADE29624/C
XX ID ADE29624 standard; RNA; 19 BP.
XX AC ADE29624;
XX XX
XX 29-JAN-2004 (first entry)
XX
XX Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:246.
XX
XX short interfering nucleic acid; siNA; downregulation; inhibition;
XX mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
XX cytosolic; anorectic; antidiabetic; antiinflammatory; antiaesthetic;
XX immunosuppressive; antibacterial; antirheumatic; antiarthritic;
XX antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
XX inflammatory disease; asthma; septic shock; rheumatoid arthritis;
XX psoriasis; inflammatory bowel disease; drug screening;
XX genetic engineering; pharmacogenomic; gene mapping; ss.
XX
XX Synthetic.
XX
XX WO2003072590-A1.
XX
XX 04-SEP-2003.
XX
XX 28-JAN-2003; 2003WO-US002510.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
XX
XX Mcswigen J, Beigelman L, Usman N, Haeblerl P, Chowrira B;
XX WPI; 2003-689980/65.
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
XX PT diagnosis of cancer, downregulates expression of mitogen-activated
XX PT protein kinase genes.
```

DR WPI; 2003-689980/65.
 XX New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer, downregulates expression of mitogen-activated
 PT protein kinase genes.
 XX
 PS Example 3; SEQ ID NO 246; 164pp; English.
 XX
 CC The present invention describes a short interfering nucleic acid (siNA)
 CC that downregulates expression of a mitogen-activated protein kinase
 CC (MAPK) genes by RNA interference. Also described: (1) a method for
 CC modulating expression of MAPK genes in cells, tissue explants or
 CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
 CC vectors that express siNA and cells containing these vectors. MAPK siNA
 CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
 CC antiallergic, immunosuppressive, antibacterial, antirheumatic,
 CC antiasthmatic, antipsoriatic and gastrointestinal activities. The MAPK
 CC siNA can be used to modulate the expression of MAPK genes, in cells,
 CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
 CC and II; a wide range of tumors, and inflammatory diseases (asthma,
 CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
 CC disease). They can also be used for drug screening; diagnosis; target
 CC identification and validation; genetic engineering; pharmacogenomics;
 CC studying gene function and gene mapping (e.g. of single-nucleotide
 CC polymorphisms). The present sequence represents a MAPK siNA which is used
 CC in the exemplification of the present invention.
 CC
 SQ Sequence 19 BP; 9 A; 2 C; 2 G; 0 T; 6 U; 0 Other;
 XX
 Query Match 0.6%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 88.9%; Pred. No. 1.6e+02;
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 OY 897 TATTGCTTCAAGAAAT 914
 |||||
 18 TTTATGCTTCAAGAAAT 1
 Db
 RESULT 279
 ADE29711
 ID ADE29711 standard; RNA; 19 BP.
 XX
 AC ADE29711;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:333.
 XX
 KW short interfering nucleic acid; siNA; downregulation; inhibition;
 KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
 KW cytosolic; anorectic; antidiabetic; antiinflammatory; antiallergic;
 KW immunosuppressive; antibacterial; antirheumatic; antiasthmatic;
 KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
 KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
 KW psoriasis; inflammatory bowel disease; drug screening;
 KW genetic engineering; pharmacogenomic; gene mapping; ss.
 XX
 OS Synthetic.
 XX
 PN WO2003072590-A1.
 XX
 PD 04-SEP-2003.
 XX
 PF 28-JAN-2003; 2003WO-US002510.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.

XX
 PA (SIRN-) SIRNA THERAPEUTICS INC.
 XX
 PI McSwiggen J, Beigelman L, Usman N, Haeblerli P, Chowitra B;
 XX
 DR WPI; 2003-689980/65.
 XX
 PT New short interfering nucleic acid, useful e.g. for treatment and
 PT diagnosis of cancer, downregulates expression of mitogen-activated
 PT protein kinase genes.
 XX
 PS Example 3; SEQ ID NO 333; 164pp; English.
 XX
 CC The present invention describes a short interfering nucleic acid (siNA)
 CC that downregulates expression of a mitogen-activated protein kinase
 CC (MAPK) genes by RNA interference. Also described: (1) a method for
 CC modulating expression of MAPK genes in cells, tissue explants or
 CC organisms by introduction of siNA; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; and (4)
 CC vectors that express siNA and cells containing these vectors. MAPK siNA
 CC have cytostatic, anorectic, antidiabetic, antiinflammatory,
 CC antiallergic, immunosuppressive, antibacterial, antirheumatic,
 CC antiasthmatic, antipsoriatic and gastrointestinal activities. The MAPK
 CC siNA can be used to modulate the expression of MAPK genes, in cells,
 CC tissue explants or organisms, e.g. for treating obesity; diabetes types I
 CC and II; a wide range of tumors, and inflammatory diseases (asthma,
 CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
 CC disease). They can also be used for drug screening; diagnosis; target
 CC identification and validation; genetic engineering; pharmacogenomics;
 CC studying gene function and gene mapping (e.g. of single-nucleotide
 CC polymorphisms). The present sequence represents a MAPK siNA which is used
 CC in the exemplification of the present invention.
 CC
 SQ Sequence 19 BP; 1 A; 4 C; 13 G; 0 T; 1 U; 0 Other;
 XX
 Query Match 0.6%; Score 14.8; DB 1; Length 19;
 Best Local Similarity 83.3%; Pred. No. 1.6e+02;
 Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 OY 2300 GAGGGGGTTGGCGCGGG 2317
 |||||
 1 GAGGGGGGUCGCCCGCGGG 18
 Db
 RESULT 280
 ADE29816/C
 ID ADE29816 standard; RNA; 19 BP.
 XX
 AC ADE29816;
 XX
 DT 29-JAN-2004 (first entry)
 XX
 DE Mitogen activated protein kinase siNA oligonucleotide SEQ ID NO:438.
 XX
 KW short interfering nucleic acid; siNA; downregulation; inhibition;
 KW mitogen-activated protein kinase; MAP kinase; MAPK; RNA interference;
 KW cytosolic; anorectic; antidiabetic; antiinflammatory; antiallergic;
 KW immunosuppressive; antibacterial; antirheumatic; antiasthmatic;
 KW antipsoriatic; gastrointestinal; obesity; diabetes; tumour;
 KW inflammatory disease; asthma; septic shock; rheumatoid arthritis;
 KW psoriasis; inflammatory bowel disease; drug screening;
 KW genetic engineering; pharmacogenomic; gene mapping; ss.
 XX
 OS Synthetic.
 XX
 PN WO2003072590-A1.
 XX
 PD 04-SEP-2003.
 XX
 PF 28-JAN-2003; 2003WO-US002510.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.

PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (SIRN-) SIRNA THERAPEUTICS INC.
PI Mcswiggen J, Beigelman L, Usman N, Haeblerl P, Chowrira B,
XX WPI; 2003-689980/65.
DR
XX
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of cancer, downregulates expression of mitogen-activated
PT protein kinase genes.
XX
XX
XX Example 3, SEQ ID NO 438; 164bp; English.
XX
XX The present invention describes a short interfering nucleic acid (siRNA)
CC that downregulates expression of a mitogen-activated protein kinase
CC (MAPK) genes by RNA interference. Also described: (1) a method for
CC modulating expression of MAPK genes in cells, tissue explants or
CC organisms by introduction of siRNA; (2) kits for in vitro or in vivo
CC delivery of siRNA; (3) conjugates and/or complexes of siRNA; and (4)
CC vectors that express siRNA and cells containing these vectors. MAPK siRNAs
CC have cytostatic, anorectic, antidiabetic, antibacterial, antiinflammatory,
CC antiasthmatic, immunosuppressive, antibacterial, antiinflammatory,
CC antidiabetic, antiproliferative and gastrointestinal activities. The MAPK
CC siRNAs can be used to modulate the expression of MAPK genes, in cells,
CC and in a wide range of organisms, e.g. for treating obesity, diabetes types I
CC and II, a wide range of tumors, and inflammatory diseases (asthma,
CC septic shock, rheumatoid arthritis, psoriasis and inflammatory bowel
CC disease). They can also be used for drug screening; diagnosis; target
CC identification and validation; genetic engineering; pharmacogenomics;
CC studying gene function and gene mapping (e.g. of single-nucleotide
CC polymorphisms). The present sequence represents a MAPK siRNA which is used
CC in the exemplification of the present invention.
XX
XX
SQ Sequence 19 BP; 1 A; 13 C; 4 G; 0 T; 1 U; 0 Other;
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2300 GAGGGGCTTGGCCGGGG 2317
DB 19 GAGGGGCTTGGCCGGGG 2
RESULT 281
ACH00745/C
ID ACH00745 standard; DNA; 19 BP.
XX
XX ACH00745;
AC
XX
XX 12-FEB-2004 (first entry)
DT
XX
XX Albino and pigmented rat GAPDH gene PCR primer #2.
DE
XX
XX Rat; albino; pigment; eye; inner ear; central nervous system; CNS; CD;
KW 5,6-dihydroxyindol; DHI; 5,6-dihydroxyindole-2-carboxylic acid; DHICA;
KW cysteinyl-dopa; tyrosinase; oxidative stress; gene therapy; PCR; primer;
KW ss; auditory; ophthalmological; antidiabetic; antiparkinsonian; GAPDH.
XX
XX Rattus sp.
OS
XX
XX WO2003070269-A1.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 12-FEB-2003; 2003WO-DE000415.
PR
XX
XX 18-FEB-2002; 2002DE-01006723.
PR

XX
XX (SCHR/) SCHRAERMAYER U.
PA
XX
XX Schraermayer U;
PI
XX
XX WPI; 2003-689740/65.
DR
XX
XX
XX Medicaments used for treating inner ear, eye or central nervous
PT disorders, e.g. macular degeneration or Parkinson's disease, comprise
PT e.g. tyrosinase, 5,6-dihydroxyindole or 5,6-dihydroxyindole-2-carboxylic
PT acid.
XX
XX
XX Example 11; Page 16; 34pp; German.
XX
XX
XX The present invention relates to the use of 5,6-dihydroxyindole (DHI),
CC 5,6-dihydroxyindole-2-carboxylic acid (DHICA) and/or 5-s-cysteinyl-dopa
CC (CD) in the treatment of diseases of the inner ear, eye and central
CC nervous system. It also relates to the use of tyrosinase in the
CC production of such a treatment. These can be used for the prevention or
CC therapy of 'Druesen' (cell residue material), elevated lipofuscin levels,
CC degenerative diseases of the inner ear (presbycusis), eye diseases
CC (especially age-associated macular degeneration, Henmanky-Pudlak
CC syndrome, Chediak-Higashi syndrome, choroidal and retinal
CC neovascularization, diabetic retinopathy or neonatal retinopathy) or
CC central nervous diseases (especially Parkinson's disease) or
CC the treatment is effective against eye, inner ear or CNS disorders
CC associated with deficiency of melanin (which has antiradical activity and
CC protects against oxidative stress) and deposition of 'Druesen' (cell
CC residue material) or the pigment lipofuscin. The present sequence is a
CC PCR primer used to isolate the coding sequence of the rat GAPDH protein
CC in a katalase enzyme assay
XX
XX
SQ Sequence 19 BP; 0 A; 4 C; 9 G; 6 T; 0 U; 0 Other;
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1273 AGCACCCACCCGCAAG 1290
DB 19 ACCACCCAGCCGCAAG 2
RESULT 282
ADP83712/C
ID ADP83712 standard; RNA; 19 BP.
XX
XX ADP83712;
AC
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Human breakpoint cluster region-targeted siRNA - SEQ ID 6.
DE
XX
XX short interfering nucleic acid; siRNA; breakpoint cluster region;
KW v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW cytosolic; leukaemia; lymphoma; human; BCR; ss; siRNA.
XX
XX Homo sapiens.
OS
XX
XX WO2003070972-A2.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US005234.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 15-AUG-2002; 2002US-0404039P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 14-JAN-2003; 2003US-0439922P.
PR

```
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Mcswiggen J, Beigelman L, Chowrira B,
XX WPI; 2003-679889/64.
DR
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
XX Example 7; SEQ ID NO 6; 197bp; English.
PS
XX The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human BCR-targeted siRNA of the invention.
SQ
XX Sequence 19 BP; 1 A; 5 C; 13 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 16 CGCCGGCGCTGGCGCTC 33
DB 18 CGCCCGCGCGCGCGCTC 1
RESULT 283
ADF84593/C
ID ADF84593 standard; RNA; 19 BP.
XX
XX ADF84593;
AC
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Human ABL1-targeted siRNA - SEQ ID 887.
DE
XX short interfering nucleic acid; siNA; breakpoint cluster region;
KW v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
XX Homo sapiens.
OS
XX WO2003070972-A2.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US005234.
PE
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 15-AUG-2002; 2002US-0404039P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 14-JAN-2003; 2003US-0439922P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Mcswiggen J, Beigelman L, Chowrira B,
XX WPI; 2003-679889/64.
DR
XX
```

```
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
XX Example 7; SEQ ID NO 887; 197bp; English.
PS
XX The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human ABL1-targeted siRNA of the invention.
SQ
XX Sequence 19 BP; 5 A; 6 C; 6 G; 0 T; 2 U; 0 Other;
SQ
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
OY 717 CATGCTATCATGGCGCTG 734
DB 19 CTTGCTACCATGGCGCTG 2
RESULT 284
ADF84274
ID ADF84274 standard; RNA; 19 BP.
XX
XX ADF84274;
AC
XX
XX 26-FEB-2004 (first entry)
DT
XX
XX Human ABL1-targeted siRNA - SEQ ID 568.
DE
XX short interfering nucleic acid; siNA; breakpoint cluster region;
KW v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW cytostatic; leukaemia; lymphoma; human; ss; siRNA; ABL1.
XX
XX Homo sapiens.
OS
XX WO2003070972-A2.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US005234.
PE
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 15-AUG-2002; 2002US-0404039P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 14-JAN-2003; 2003US-0439922P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX Mcswiggen J, Beigelman L, Chowrira B,
XX WPI; 2003-679889/64.
DR
XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
XX Example 7; SEQ ID NO 568; 197bp; English.
PS
XX The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
```

CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human ABL1-targeted siRNA of the invention.
XX
SQ Sequence 19 BP; 2 A; 6 C; 6 G; 0 T; 5 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 66.7%; Pred. No. 1.6e+02;
Matches 12; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

OY 717 CATGGATCATGGGCGCTG 734
| : : : : : | : : : : : |
Db 1 CCUGGUAACCAUGGCCUUG 18

RESULT 285
ADF83975
ID ADF83975 standard; RNA; 19 BP.
XX
AC ADF83975;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human breakpoint cluster region-targeted siRNA - SEQ ID 269.
XX
KW short interfering nucleic acid, siRNA; breakpoint cluster region;
KW v-abl Abelson murine leukaemia viral oncogene homologue 1; BCR-ABL;
KW cytostatic; leukaemia; lymphoma; human; BCR; ss; siRNA.
XX
OS Homo sapiens.
XX
FN WO2003070972-A2.
XX
PD 28-AUG-2003.
XX
PE 20-FEB-2003; 2003WO-US005234.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 15-AUG-2002; 2002US-0404039P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 14-JAN-2003; 2003US-0439922P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI McSwiggen J, Beigelman L, Chowrira B;
XX
DR WPI; 2003-679889/64.
XX
PT New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of leukemia and lymphoma, downregulates the breakpoint
PT cluster region-Abelson (BCR-ABL) gene.
XX
PT
XX
XX Example 7; SEQ ID NO 269; 197pp; English.
XX
CC The invention relates to a novel double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the breakpoint
CC cluster region-v-abl Abelson murine leukaemia viral oncogene homologue 1
CC (BCR-ABL) gene. The siRNA of the invention demonstrates cytostatic
CC activity and may be useful for modulating expression of the BCR-ABL gene,
CC as well as for treating leukaemia or lymphoma and in diagnosis, drug
CC screening, target identification and validation, genetic engineering,
CC gene function studies and gene mapping. The current sequence is that of
CC the human BCR-targeted siRNA of the invention.
CC
XX

SQ Sequence 19 BP; 0 A; 13 C; 5 G; 0 T; 1 U; 0 Other;

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 16 CGCCGCGGCTCCGCGCTC 33
| : : : : : | : : : : : |
Db 2 CGCCGCGGCTCCGCGCTC 19

RESULT 286
ADG34885
ID ADG34885 standard; RNA; 19 BP.
XX
AC ADG34885;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human TNF receptor siNA oligonucleotide SEQ ID NO:237.
XX
KW RNA interference; short interfering nucleic acid; siNA;
KW short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
KW short hairpin RNA; shRNA; expression modulation; gene therapy;
KW drug screening; diagnosis; therapeutic target identification;
KW pharmacogenomics; gene function analysis; gene mapping;
KW tumour necrosis factor receptor; TNF receptor; human; DNA-RNA hybrid; ss;
KW antibacterial; immunosuppressive; antineoplastic; antiarthritic; anti-HIV;
KW HIV/AIDS; psoriasis; inflammation; autoimmune disease; target sequence.
XX
XX Synthetic.
XX
OS Homo sapiens.
XX
FN WO2003070897-A2.
XX
PD 28-AUG-2003.
XX
PE 20-FEB-2003; 2003WO-US004741.
XX
PR 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 28-NOV-2002; 2002US-0429359P.
PR 15-JAN-2003; 2003US-0440129P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI McSwiggen J, Beigelman L;
XX
DR WPI; 2003-697609/66.
XX
PT New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of septic shock or rheumatoid arthritis, downregulates
PT expression of the tumor necrosis factor gene.
XX
PT
XX
XX Example 3; SEQ ID NO 237; 141pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human tumour necrosis factor (TNF)
CC receptor gene by RNA interference. The siNAs may or may not comprise
CC ribonucleotides and may be double or single stranded. They further
CC comprise sense and antisense regions, or alternatively are assembled from
CC a sense oligonucleotide and an antisense oligonucleotide. Specifically,
CC the siNAs include short interfering RNA (siRNA), double-stranded RNA,
CC micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs can be
CC unmodified or chemically modified, can contain deoxyribonucleotides, and
CC can be chemically synthesised, expressed from a vector or enzymatically
CC synthesised. The invention also relates to kits for the in vitro or in
CC vivo delivery of siNA; conjugates and/or complexes of siNA; and vectors

CC that express siNA. The siNAs are used to modulate expression of the TNF
CC receptor gene in cells, tissue explants or organisms (e.g., by ex vivo
CC gene therapy), or in grafts and transplants for the treatment of a
CC variety of conditions. The TNF receptor siNAs have antibacterial,
CC immunosuppressive, antirheumatic, antiarthritic, anti-HIV, antipsoriatic
CC and antiinflammatory activities. They may be used for treating septic
CC shock, rheumatoid arthritis, HIV/AIDS, psoriasis, inflammation and
CC autoimmune diseases. The siNAs are also useful for drug screening,
CC diagnosis, therapeutic target identification and validation, genetic
CC engineering, pharmacogenomics, studying gene function, and gene mapping
CC (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the upper strand of a human TNF receptor-targeted double-
CC stranded siNA, which is identical to the TNF receptor transcript target
CC sequence.
SQ Sequence 19 BP; 6 A; 9 C; 2 G; 0 T; 2 U; 0 Other;
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 83.3%; Pred. No. 1.6e+02;
Matches 15; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 2265 CCCCAGACCCAGCTCA 2282
Db 2 CCCCAGACCCAGCTCA 19
RESULT 287
ADG35008/c
ID ADG35008 standard; RNA; 19 BP.
AC ADG35008;
XX
XX 26-FEB-2004 (first entry)
DT
XX
DE Human TNF receptor siNA oligonucleotide SEQ ID NO:360.
XX
XX RNA interference; short interfering nucleic acid; siNA;
XX short interfering RNA; siRNA; double-stranded RNA; micro-RNA; miRNA;
XX short hairpin RNA; shRNA; expression modulation; gene therapy;
XX drug screening; diagnosis; therapeutic target identification;
XX pharmacogenomics; gene function analysis; gene mapping;
XX tumour necrosis factor receptor; TNF receptor; human; DNA-RNA hybrid; ss;
XX antibacterial; immunosuppressive; antirheumatic; antiarthritic; anti-HIV;
XX anti-psoriatic; antiinflammatory; septic shock; rheumatoid arthritis;
XX HIV/AIDS; psoriasis; inflammation; autoimmune disease.
XX
XX Synthetic.
OS
OS Homo sapiens.
XX
XX WO2003070897-A2.
PN
XX
XX 28-AUG-2003.
PD
XX
XX 20-FEB-2003; 2003WO-US004741.
PF
XX
XX 20-FEB-2002; 2002US-0358580P.
PR 11-MAR-2002; 2002US-0363124P.
PR 06-JUN-2002; 2002US-0386782P.
PR 29-AUG-2002; 2002US-0406784P.
PR 05-SEP-2002; 2002US-0408378P.
PR 09-SEP-2002; 2002US-0409293P.
PR 28-NOV-2002; 2002US-0428359P.
PR 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA
XX
XX Mcawiggen J, Beigelman L;
PI
XX
XX WPI; 2003-697609/66.
DR
XX
XX New short interfering nucleic acid, useful e.g. for treatment and
PT diagnosis of septic shock or rheumatoid arthritis, downregulates
PT expression of the tumor necrosis factor gene.

XX
PS Example 3; SEQ ID NO 360; 141pp; English.
XX
CC The invention relates to short interfering nucleic acids (siNA) which
CC downregulate expression of the human tumour necrosis factor (TNF)
CC receptor gene by RNA interference. The siNAs may or may not comprise
CC ribonucleotides and may be double or single stranded. They further
CC comprise sense and antisense regions, or alternatively are assembled from
CC a sense oligonucleotide and an antisense oligonucleotide. Specifically,
CC the siNAs include short interfering RNA (siRNA), double-stranded RNA,
CC micro-RNA (miRNA) and short hairpin RNA (shRNA). The siNAs can be
CC unmodified or chemically modified, can contain deoxyribonucleotides, and
CC can be chemically synthesized, expressed from a vector or enzymatically
CC synthesised. The invention also relates to kits for the in vitro or in
CC vivo delivery of siNA, conjugates and/or complexes of siNA, and vectors
CC that express siNA. The siNAs are used to modulate expression of the TNF
CC receptor gene in cells, tissue explants or organisms (e.g., by ex vivo
CC gene therapy), or in grafts and transplants for the treatment of a
CC variety of conditions. The TNF receptor siNAs have antibacterial,
CC immunosuppressive, antirheumatic, antiarthritic, anti-HIV, antipsoriatic
CC and antiinflammatory activities. They may be used for treating septic
CC shock, rheumatoid arthritis, HIV/AIDS, psoriasis, inflammation and
CC autoimmune diseases. The siNAs are also useful for drug screening,
CC diagnosis, therapeutic target identification and validation, genetic
CC engineering, pharmacogenomics, studying gene function, and gene mapping
CC (e.g., of single nucleotide polymorphisms). The present sequence
CC represents the lower strand of a human TNF receptor-targeted double-
CC stranded siNA.
XX
SQ Sequence 19 BP; 2 A; 2 C; 9 G; 0 T; 6 U; 0 Other;
Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 1.6e+02;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2265 CCCCAGACCCAGCTCA 2282
Db 18 CCCCAGACCCAGCTCA 1

Search completed: August 8, 2005, 09:56:56
Job time : 10 secs

THIS PAGE BLANK (USPTO)

FEATURES	source	location/Qualifiers
REFERENCE		
AUTHORS		1 Shoshani, A., Masserman, A., Mintz, E., Mintz, L. and Faigler, S.
TITLE		Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcrip
JOURNAL		Patent: WO 0210449-A 16614 07-FEB-2002;
FEATURES		Compugen Inc. (US)
source		Location/Qualifiers
		1..60
		/organism="Homo sapiens"
		/mol_type="unassigned DNA"
		/db_xref="taxon:9606"
Query Match	2.5%; Score 60; DB 1; Length 60;	
Best Local Similarity	100.0%; Pred. No. 2.9e-05;	
Matches	60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Db	1767	ACTTCTCATCAAGCCCTTTATTCGCCACTACCCAGCGTGTCTAGTCTGAAGTCA 1826
	60	ACTTCTCATCAAGCCCTTTATTCGCCACTACCCAGCGTGTCTAGTCTGAAGTCA 1
RESULT 2		
LOCUS	BD181456	65 bp DNA linear PAT 15-MAY-2003
DEFINITION		A gene of which expression changes in psoriasis and a method for e
ACCESSION	BD181456	BD181456.1 GI:30792374
VERSION		JP 2002330770-A/4.
KEYWORDS		Homo sapiens (human)
SOURCE		Homo sapiens
ORGANISM		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.
REFERENCE		1 (bases 1 to 65)
AUTHORS		Imai, Y., Wakimoto, K., Yamada, E., Chiba, H. and Okubo, K.
TITLE		A gene of which expression changes in psoriasis and a method for e
JOURNAL		Patent: JP 2002330770-A 4 19-NOV-2002;
COMMENT		TANABE SEIYAKU CO LTD
		OS Homo sapiens (human)
		PN JP 2002330770-A/4
		PD 19-NOV-2002
		PF 25-MAY-2001 JP 2001156529
		PI YUJI IMAI, KOJI WAKIMOTO, ERIKO YAMADA, HIROAKI CHIBA, KOSAKU PI
		OKUBO
		PC C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,C12N1/21 PC
		PC C12N5/10,C12Q1/68,
		PC G01N33/53,G01N33/566,C12N15/00,C12N5/00 CC A gene
		of which expression changes in psoriasis and a method CC
		for e
		CC examination directed to said gene
		FT key Location/Qualifiers
		FT source 1..65
		/organism='Homo sapiens (human)'. Location/Qualifiers
		1..65
		/organism="Homo sapiens"
		/mol_type="genomic DNA"
		/db_xref="taxon:9606"
Query Match	2.5%; Score 60; DB 1; Length 65;	
Best Local Similarity	100.0%; Pred. No. 3.1e-05;	
Matches	60; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
Db	2362	GATATTGCACCATGTGAGACTTTGTATATGCTTGAATAATAATGAAGTGAATCC 2421
	1	GATATTGCACCATGTGAGACTTTGTATATGCTTGAATAATAATGAAGTGAATCC 60
RESULT 3		
LOCUS	CC0007002/c	51 bp DNA linear PAT 16-JAN-2004

LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	FEATURES
LOCUS	Sequence 5642 from Patent WO0147944.	CQ007002									
DEFINITION	Sequence 5642 from Patent WO0147944.	CQ007002									
ACCESSION	CQ007002.1	GI:41013634									
VERSION											
KEYWORDS											
SOURCE											
ORGANISM	Homo sapiens (human)										
REFERENCE	Shinkens, R.A. and Leach, M.										
AUTHORS	Nucleic acids containing single nucleotide polymorphisms and										
TITLE	methods of use thereof										
JOURNAL	Patent: WO 0147944-A 5642 05-JUL-2001;										
FEATURES	Curagen Corporation (US)										
SOURCE	Location/Qualifiers										
	1..51										
	/organism="Homo sapiens"										
	/mol_type="unassigned DNA"										
	/db_xref="taxon:9606"										
	/note="Accession number cg34393352"										
Query Match	1.7%: Score 40.5; DB 1; Length 51;										
Best Local Similarity	98.1%: Pred. No. 0.017; Mismatches 0; Indels 1; Gaps 1;										
Match	51; Conservative 0; Mismatches 0; Indels 1; Gaps 1;										
LOCUS	AX697225	24 bp	DNA	linear	PAT 02-APR-2003						
DEFINITION	Sequence 293 from Patent WO0078961.										
ACCESSION	AX697225										
VERSION	AX697225.1	GI:29498160									
KEYWORDS											
SOURCE											
ORGANISM	Synthetic construct										
REFERENCE	Synthetic construct										
AUTHORS	other sequences; artificial sequences.										
TITLE	1										
JOURNAL	Ferrara, N., Stewart, T. A., Williams, P. M., Baker, K. P., Desnoyers, L.,										
FEATURES	Edson, D. L., Gao, W. Q., Pan, J., Botstein, D., Fong, S., Goddard, A.,										
SOURCE	Godowski, P. J., Gurney, A. L., Smith, V., Tuma, D., Wood, W. I.,										
	Grimaldi, C. J., Hillan, K. J., Paoni, N. F., Roy, W. A., and Watanabe, C. K.										
	Secreted and transmembrane polypeptides and nucleic acids encoding										
	the same										
	Patent: WO 0078961-A 293 28-DEC-2000;										
	Genentech Inc. (US)										
	Location/Qualifiers										
	1..24										
	/organism="Synthetic construct"										
	/mol_type="unassigned DNA"										
	/db_xref="taxon:32630"										
Query Match	1.0%: Score 24; DB 1; Length 24;										
Best Local Similarity	100.0%: Pred. No. 2.7; Mismatches 0; Indels 0; Gaps 0;										
Match	24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										
LOCUS	AX697226	24 bp	DNA	linear	PAT 02-APR-2003						

other sequences; artificial sequences.

REFERENCE 1
AUTHORS Ferrara, N., Stewart, T.A., Williams, P.M., Baker, K.P., Desnoyers, L., Eaton, D.L., Gao, W.Q., Pan, J., Bocstein, D., Fong, S., Goddard, A., Godowski, P.J., Guirney, A.L., Smith, V., Tumas, D., Wood, W.I., Grimaldi, C.J., Hillan, K.J., Paoni, N.F., Roy, M.A. and Watanabe, C.K.
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding the same
JOURNAL Patent: WO 0078961-A 294 28-DEC-2000;
Genentech Inc. (US)
FEATURES
SOURCE Location/Qualifiers
1. .24
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"

Query Match 1.0%; Score 24; DB 1; Length 24;
Best Local Similarity 100.0%; Pred. No. 2.7;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1463 GGAACTGTCATGGCTGCTGTGGG 1486
Db 24 GGAAGTGTCAATGGCTGCTGTGGG 1
|||||

RESULT 6
LOCUS BD181464 22 bp DNA linear PAT 15-MAY-2003
DEFINITION A gene of which expression changes in psoriasis and a method for e
ACCESSION BD181464.1 GI:30792382
VERSION JP 2002330770-A/12.
KEYWORDS synthetic construct
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 22)
AUTHORS Imai, Y., Wakimoto, K., Yamada, E., Chiba, H. and Okubo, K.
TITLE A gene of which expression changes in psoriasis and a method for e
JOURNAL Patent: JP 2002330770-A 12 19-NOV-2002;
TANABE SEIYAKU CO LTD
COMMENT OS Artificial Sequence
PN JP 2002330770-A/12
PD 19-NOV-2002
PF 25-MAY-2001 JP 2001156529
PI YUJI IMAI, KOJI WAKIMOTO, ERIKO YAMADA, HIROAKI CHIBA, KOSAKU PI
OKUBO
PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21 PC
, C12N5/10, C12Q1/68,
PC G01N33/53, G01N33/56, C12N15/00, C12N5/00 CC
Artificially synthesized primer sequence
FH Key Location/Qualifiers
FT source 1. .22
/organism="Artificial Sequence".
FEATURES
SOURCE Location/Qualifiers
1. .22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2057 CGCCACCATGAGCTAGTGGAG 2078
Db 1 CGCCACCATGAGCTAGTGGAG 22
|||||

RESULT 7
LOCUS BD181465/c 22 bp DNA linear PAT 15-MAY-2003

A gene of which expression changes in psoriasis and a method for e
xamination directed to said gene.

ACCESSION BD181465.1 GI:30792383
VERSION JP 2002330770-A/13.
KEYWORDS synthetic construct
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 22)
AUTHORS Imai, Y., Wakimoto, K., Yamada, E., Chiba, H. and Okubo, K.
TITLE A gene of which expression changes in psoriasis and a method for e
JOURNAL Patent: JP 2002330770-A 13 19-NOV-2002;
TANABE SEIYAKU CO LTD
COMMENT OS Artificial Sequence
PN JP 2002330770-A/13
PD 19-NOV-2002
PF 25-MAY-2001 JP 2001156529
PI YUJI IMAI, KOJI WAKIMOTO, ERIKO YAMADA, HIROAKI CHIBA, KOSAKU PI
OKUBO
PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21 PC
, C12N5/10, C12Q1/68,
PC G01N33/53, G01N33/56, C12N15/00, C12N5/00 CC
Artificially synthesized primer sequence
FH Key Location/Qualifiers
FT source 1. .21
/organism="Artificial Sequence".
FEATURES
SOURCE Location/Qualifiers
1. .21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.9%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 4.9;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2357 GATGAGTCATGGACCATGTC 2378
Db 22 GATGAGTCATGGACCATGTC 1
|||||

RESULT 8
LOCUS BD181460/c 21 bp DNA linear PAT 15-MAY-2003
DEFINITION A gene of which expression changes in psoriasis and a method for e
ACCESSION BD181460
VERSION JP 2002330770-A/8.
KEYWORDS synthetic construct
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 21)
AUTHORS Imai, Y., Wakimoto, K., Yamada, E., Chiba, H. and Okubo, K.
TITLE A gene of which expression changes in psoriasis and a method for e
JOURNAL Patent: JP 2002330770-A 8 19-NOV-2002;
TANABE SEIYAKU CO LTD
COMMENT OS Artificial Sequence
PN JP 2002330770-A/8
PD 19-NOV-2002
PF 25-MAY-2001 JP 2001156529
PI YUJI IMAI, KOJI WAKIMOTO, ERIKO YAMADA, HIROAKI CHIBA, KOSAKU PI
OKUBO
PC C12N15/09, C07K14/47, C07K16/18, C12N1/15, C12N1/19, C12N1/21 PC
, C12N5/10, C12Q1/68,
PC G01N33/53, G01N33/56, C12N15/00, C12N5/00 CC
Artificially synthesized primer sequence
FH Key Location/Qualifiers
FT source 1. .21
/organism="Artificial Sequence".
FEATURES
SOURCE Location/Qualifiers
1. .21
/organism="Artificial Sequence".

source 1. .21
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.8%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.1;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2364 TCATTGCACGATCAGACT 2383
|||||

Db 21 TCATTGCACGATCAGACT 2

RESULT 9
AX476295/c 25 bp DNA linear PAT 12-AUG-2002
LOCUS Sequence 1516 from Patent WO0224750.
DEFINITION AX476295
ACCESSION AX476295
VERSION AX476295.1 GI:22215580
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
Zhang, J.
Human kidney tumor overexpressed membrane protein 1
Patent: WO 0224750-A 1516 28-MAR-2002;
Aeomica, Inc. (US)
Location/Qualifiers
1. .25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 13;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1419 CCTGAGGACGCTGCAATCA 1442
|||||

Db 25 CCTGAGGCTCTGCTGCAATCA 2

RESULT 10
AX476296/c 25 bp DNA linear PAT 12-AUG-2002
LOCUS Sequence 1517 from Patent WO0224750.
DEFINITION AX476296
ACCESSION AX476296
VERSION AX476296.1 GI:22215581
KEYWORDS
SOURCE
ORGANISM Homo sapiens (human)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
1
Zhang, J.
Human kidney tumor overexpressed membrane protein 1
Patent: WO 0224750-A 1517 28-MAR-2002;
Aeomica, Inc. (US)
Location/Qualifiers
1. .25
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.8%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 13;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1419 CCTGAGGACGCTGCAATCA 1442
|||||

Db 25 CCTGAGGCTCTGCTGCAATCA 2

Db 24 CCTGAGGCTCTGCTGCAATCA 1

RESULT 11
AX838503 23 bp DNA linear PAT 15-DEC-2003
LOCUS Sequence 3 from Patent WO03076654.
DEFINITION AX838503
ACCESSION AX838503
VERSION AX838503.1 GI:39922106
KEYWORDS
SOURCE
ORGANISM synthetic construct
synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS Palecek, E. and Kosak, H.
TITLE Method for identifying, quantifying and/or characterizing an
analyte
JOURNAL Patent: WO 03076654-A 3 18-SEP-2003;
November Aktiengesellschaft Gesellschaft fuer Molekulare Medizin
(DE)
Location/Qualifiers
1. .23
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz:
Willkuerliche Sequenz"

FEATURES
source

Query Match 0.7%; Score 17.8; DB 1; Length 23;
Best Local Similarity 90.5%; Pred. No. 19;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1536 TCTTTTGAAGCAAAAAG 1556
|||||

Db 3 TTTTGTGAGAGAAAAG 23

RESULT 12
AR489241/c 22 bp DNA linear PAT 15-MAY-2004
LOCUS Sequence 20 from patent US 6709860.
DEFINITION AR489241
ACCESSION AR489241
VERSION AR489241.1 GI:47256198
KEYWORDS
SOURCE
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 22)
AUTHORS Enerback, S. and Carlsson, P.
TITLE Animal model
JOURNAL Patent: US 6709860-A 20 23-MAR-2004;
Location/Qualifiers
1. .22
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 22;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 239 CCTCATAGCGCTACTCGGG 260
|||||

Db 22 CTCATTGGCGCTACTCAGGG 1

RESULT 13
AR299945 21 bp DNA linear PAT 12-JUN-2003
LOCUS Sequence 11680 from patent US 6537751.
DEFINITION AR299945
ACCESSION AR299945
VERSION AR299945.1 GI:31687229
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Cohen,D., Chumakov,I. and Blumenfeld,M.
TITLE Biallelic markers for use in constructing a high density
JOURNAL disequilibrium map of the human genome
FEATURES Patent: US 6537751-A 11680 25-MAR-2003;
LOCATION/Qualifiers
1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred.No.23;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1643 TCTCTTCTTCCTTCT 1659
Db 1 TCTCTTCTTCCTTCT 17

RESULT 14
LOCUS AR266033 20 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 40 from patent US 6492171.
ACCESSION AR266033
VERSION AR266033.1 GI:29694879
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 20)
AUTHORS Montia,B.P., Gaarde,W.A., Freier,S.M. and Wanciewicz,E.
TITLE Antisense modulation of TERT expression
JOURNAL Patent: US 6492171-A 40 10-DEC-2002;
FEATURES Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred.No.24;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 139 GCGCGAAGCCCTGCGCCCG 158
Db 20 GTGGGAAGCCCTGCGCCCG 1

RESULT 15
LOCUS AR139944 21 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 16 from patent US 6207417.
ACCESSION AR139944
VERSION AR139944.1 GI:14482440
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE DNA encoding stem cell factor
JOURNAL Patent: US 6207417-A 16 27-MAR-2001;
FEATURES Location/Qualifiers
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred.No.25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATTAATGCAAGTGAGATCC 2421

Db 2 ATTAATGCAAGTGATATCC 21
|||||

RESULT 16
LOCUS AR140263 21 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 16 from patent US 6207454.
ACCESSION AR140263
VERSION AR140263.1 GI:14482759
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Method for enhancing the efficiency of gene transfer with stem cell
JOURNAL factor (SCF) polypeptide
FEATURES Patent: US 6207454-A 16 27-MAR-2001;
LOCATION/Qualifiers
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred.No.25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATTAATGCAAGTGAGATCC 2421
Db 2 ATTAATGCAAGTGATATCC 21
|||||

RESULT 17
LOCUS AR140541 21 bp DNA linear PAT 16-JUN-2001
DEFINITION Sequence 16 from patent US 6207802.
ACCESSION AR140541
VERSION AR140541.1 GI:14483037
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.
TITLE Stem cell factor and compositions
JOURNAL Patent: US 6207802-A 16 27-MAR-2001;
FEATURES Location/Qualifiers
1..21
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred.No.25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATTAATGCAAGTGAGATCC 2421
Db 2 ATTAATGCAAGTGATATCC 21
|||||

RESULT 18
LOCUS AR562140 21 bp DNA linear PAT 08-OCT-2004
DEFINITION Sequence 16 from patent US 6759215.
ACCESSION AR562140
VERSION AR562140.1 GI:53976003
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Zeebo,K.M., Bosselman,R.A., Suggs,S.V. and Martin,F.H.

TITLE Method of preparing human stem cell factor polypeptide
JOURNAL Patent: US 6759215-A 16 06-JUL-2004;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2402 ATAAATGCAAGTGAATCC 2421
|||||
2 ATAAATGCAAGTGAATATCC 21

RESULT 19
AR126157
LOCUS AR126157 22 bp DNA linear PAT 16-MAY-2001
DEFINITION Sequence 17 from patent US 6177614.
ACCESSION AR126157
VERSION AR126157.1 GI:14112219
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 22)
AUTHORS Colasanti,J.J. and Sundaresan,V.
JOURNAL Control of floral induction in plants and uses therefor
FEATURES Patent: US 6177614-A 17 23-JAN-2001;
Location/Qualifiers
1..22
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 85.7%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 364 GCATCCTCTCCGCCCTCCAGG 384
|||||
2 GCATCCTCTTCCCTCCAGG 22

RESULT 20
AX746091/c
LOCUS AX746091 22 bp DNA linear PAT 14-MAY-2003
DEFINITION Sequence 41 from Patent WO03031459.
ACCESSION AX746091
VERSION AX746091.1 GI:30724741
KEYWORDS
SOURCE Synthetic construct
ORGANISM Synthetic construct
REFERENCE 1
AUTHORS other sequences; artificial sequences.
TITLES
JOURNAL Hecker,M. and Wagner,A.H.
Avotec GmbH (DE) Modulation of the expression of genes dependent on stat-1
Patent: WO 03031459-A 41 17-APR-2003;
Location/Qualifiers
1..22
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
/note="antisense oligo"

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 589 GTGCAGAGGTCTCAGTGG 608
|||||
22 GTGCAGAGGTCTCAGTGG 3

RESULT 21
AX770442/c
LOCUS AX770442 22 bp DNA linear PAT 02-JUL-2003
DEFINITION Sequence 41 from Patent WO03030944.
ACCESSION AX770442
VERSION AX770442.1 GI:32437843
KEYWORDS
SOURCE Synthetic construct
ORGANISM Synthetic construct
REFERENCE 1
AUTHORS other sequences; artificial sequences.
TITLES
JOURNAL Hecker,M. and Wagner,A.H.
Avotec GmbH (DE) Inhibition of stat-1
Patent: WO 03030944-A 41 17-APR-2003;
Location/Qualifiers
1..22
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="antisense oligo"

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 90.0%; Pred. No. 25;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 589 GTGCAGAGGTCTCAGTGG 608
|||||
22 GTGCAGAGGTCTCAGTGG 3

RESULT 22
AR223394
LOCUS AR223394 21 bp DNA linear PAT 26-SEP-2002
DEFINITION Sequence 39 from patent US 6436399.
ACCESSION AR223394
VERSION AR223394.1 GI:23331561
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 21)
AUTHORS Rikihisa,Y., Zhi,N. and Ohashi,N.
TITLES Nucleic acid encoding the major outer membrane protein of the
JOURNAL causative agent of human granulocytic ehrlichiosis and peptides
Patent: US 6436399-A 39 20-AUG-2002;
Location/Qualifiers
1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 28;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 563 GTTGACTGGAACACACC 580
|||||
4 GTTGACTGGAACACTCC 21

RESULT 23
AR240913/c
LOCUS AR240913 19 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 80 from patent US 6468791.
ACCESSION AR240913
VERSION AR240913.1 GI:27286114
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.

REFERENCE 1 (bases 1 to 19)
AUTHORS Tanzi, R.E., Schejtleberg, G.D., Masco, W., Levy-Lahad, E., Bird, T.D.
and Galas, D.J.
TITLE Chromosome 1 gene and gene products related to Alzheimer's Disease
JOURNAL Patent: US 6468791-A 80 22-OCT-2002;
FEATURES
source
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1842 CCAAGGGAGAGCTGAG 1860
Db 19 CCCAGGGAGAGCTGAG 1

RESULT 24
LOCUS AR279716 19 bp DNA linear PAT 10-APR-2003
DEFINITION Sequence 22 from patent US 6518012.
ACCESSION AR279716
VERSION AR279716.1 GI:29714650
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 19)
AUTHORS Tomasi, T.B.
TITLE Method for regulating the expression of MHC antigens and CD40 by
JOURNAL Patent: US 6518012-A 22 11-FEB-2003;
FEATURES
source
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1999 GCAATGACACCTGAGGG 2017
Db 19 GCAAGACACCATGAGGG 1

RESULT 25
LOCUS AX353084 19 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 290 from Patent EP1174518.
ACCESSION AX353084
VERSION AX353084.1 GI:18618166
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Loukachov, V.V., van Gemen, B. and Goudsmilt, J.
TITLE Collection of binding molecules
JOURNAL Patent: EP 1174518-A 290 23-JAN-2002;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 103"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1543 TAAAGAGAAAAGTCACT 1561
Db 1 TAAAGAGAAAAGTCACT 19

RESULT 26
LOCUS AX353089 19 bp DNA linear PAT 06-FEB-2002
DEFINITION Sequence 295 from Patent EP1174518.
ACCESSION AX353089
VERSION AX353089.1 GI:18618171
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Loukachov, V.V., van Gemen, B. and Goudsmilt, J.
TITLE Collection of binding molecules
JOURNAL Patent: EP 1174518-A 295 23-JAN-2002;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 103"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1543 TAAAGAGAAAAGTCACT 1561
Db 1 TAAAGAGAAAAGTCACT 19

RESULT 27
LOCUS AX362929 19 bp DNA linear PAT 15-FEB-2002
DEFINITION Sequence 290 from Patent WO0208463.
ACCESSION AX362929
VERSION AX362929.1 GI:18695069
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Loukachov, V.V., Goudsmilt, J. and van Gemen, B.
TITLE Collection of binding molecules
JOURNAL Patent: WO 0208463-A 290 31-JAN-2002;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 103"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1543 TAAAGAGAAAAGTCACT 1561
Db 1 TAAAGAGAAAAGTCACT 19

RESULT 28
LOCUS AX362934 19 bp DNA linear PAT 15-FEB-2002
DEFINITION Sequence 295 from Patent WO0208463.
ACCESSION AX362934

VERSION AX362934.1 GI:18695074
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE
1 Loukachov,V.V., Goudsmit,J. and van Gemen,B.
AUTHORS Collection of binding molecules
TITLE Patent: WO 0208463-A 295 31-JAN-2002;
JOURNAL Amsterdam Support Diagnostics B.V. (NL)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="position 103"

Query Match 0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1543 TAAAGAGAAAATCAGT 1561
Db 1 TAAAGAGAAAATCAGT 19

RESULT 29
BD196165 20 bp DNA linear PAT 17-JUL-2003
LOCUS
DEFINITION Antisense oligonucleotide sequences as inhibitors of microorganisms.
ACCESSION BD196165
VERSION BD196165.1 GI:33005935
KEYWORDS JP 2002514093-A/196.
SOURCE Escherichia coli
ORGANISM Escherichia coli
Bacteria; Proteobacteria; Gammaproteobacteria; Enterobacteriales; Enterobacteriaceae; Escherichia.
REFERENCE
1 (bases 1 to 20)
Wright,J.A., Young,A.H. and Dugourd,D.
AUTHORS Antisense oligonucleotide sequences as inhibitors of microorganisms
TITLE Patent: JP 2002514093-A 196 14-MAY-2002;
JOURNAL GENESSENSE TECHNOLOGIES INC
COMMENT
OS Escherichia coli
PN JP 2002514093-A/196
PD 14-MAY-2002
PF 10-JUL-1998 JP 1999507930
PI 10-JUL-1997 US 60/052160
P1 JIM A WRIGHT,ALPING H YOUNG,DOMINIQUE DUGOURD PC
C12N15/11,C12N15/31
CC Antisense oligonucleotide sequences as inhibitors of CC
microorganisms
FH Key Location/Qualifiers
FT source 1. .20
Location/Qualifiers
source 1. .20
/organism="Escherichia coli"
/mol_type="genomic DNA"
/db_xref="taxon:562"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1345 AGCACAGACCAAGTTCGG 1363
Db 2 AGCACAGACCAAGTTCGG 20

RESULT 30
AR261856/c 20 bp DNA linear PAT 29-JAN-2003
LOCUS

DEFINITION Sequence 8 from patent US 6323000.
ACCESSION AR261856
VERSION AR261856.1 GI:28073046
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 20)
Briggs,C.A., Gopalakrishnan,M., McKenna,D.G., Monteggia,L.M.,
AUTHORS Roch,J.-M., Sullivan,J.P. and Touma,E.
TITLE Variant human .alpha.7 acetylcholine receptor subunit, and methods
JOURNAL of production and uses thereof
PATENT: US 6323000-A 8 27-NOV-2001;
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 819 GGCAACTTCGAGATCCTG 837
Db 20 GGCAAGCTCCGAGATCCTG 2

RESULT 31
AR382956 20 bp DNA linear PAT 18-DEC-2003
LOCUS
DEFINITION Sequence 196 from patent US 6610539.
ACCESSION AR382956
VERSION AR382956.1 GI:40091769
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 20)
Wright,J.A., Young,A.H. and Dugourd,D.
AUTHORS Antisense oligonucleotide sequences as inhibitors of microorganisms
TITLE Patent: US 6610539-A 196 26-AUG-2003;
JOURNAL Location/Qualifiers
FEATURES
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1345 AGCACAGACCAAGTTCGG 1363
Db 2 AGCACAGACCAAGTTCGG 20

RESULT 32
AR454983 20 bp DNA linear PAT 20-FEB-2004
LOCUS
DEFINITION Sequence 8 from patent US 6663157.
ACCESSION AR454983
VERSION AR454983.1 GI:42689495
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
1 (bases 1 to 20)
Briggs,C.A., Gopalakrishnan,M., McKenna,D.G., Monteggia,L.M.,
AUTHORS Roch,J.-M., Sullivan,J.P. and Touma,E.
TITLE Variant human .alpha.7 acetylcholine receptor subunit, and methods
JOURNAL of production and uses thereof
PATENT: US 6663157-A 8 27-JAN-2004;
FEATURES
source
1. .20
Location/Qualifiers


```

/organism="unknown"
/mol_type="genomic DNA"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      819 GGCACTTCGGAATGCGCTG 837
      ||||| ||||| ||||| |||||
Db      20 GGCAAGCTCCGAATGCGCTG 2

RESULT 33
AX294475/c      20 bp      DNA      linear      PAT 22-NOV-2001
LOCUS      AX294475
DEFINITION      Sequence 6237 from Patent WO0179548.
ACCESSION      AX294475
VERSION      AX294475.1 GI:17056158
KEYWORDS
SOURCE
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE
1 Barany, F., Zivvi, M., Gerry, N.P., Favis, R. and Kliman, R.
AUTHORS      Method of designing addressable array for detection of nucleic acid
TITLE      sequence differences using ligase detection reaction
JOURNAL      Patent: WO 0179548-A 6237 25-OCT-2001;
CORNELIUS RESEARCH FOUNDATION, INC. (US)
FEATURES
source
1. 20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/Note="Hypothetical Probe Sequence"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1113 TGGGGCCGATGGCTCAGA 1131
      ||||| ||||| ||||| |||||
Db      19 TGGGGCTGATGCTCAGA 1

RESULT 34
BD023662/c      20 bp      DNA      linear      PAT 27-AUG-2002
LOCUS      BD023662
DEFINITION      Variant human alpha-7 acetylcholine receptor subunit and production
process and use thereof.
ACCESSION      BD023662
VERSION      BD023662.1 GI:22564885
KEYWORDS      JP 2001506135-A/7.
SOURCE      unidentified
ORGANISM      unidentified
REFERENCE
1 (bases 1 to 20)
Briggs, C.A., Gopalakrishnan, M., McKenna, D.G., Monteggia, L.M.,
AUTHORS      Roch, J.M., Sullivan, J.P. and Youma, E.
TITLE      Variant human alpha-7 acetylcholine receptor subunit and production
process and use thereof
JOURNAL      Patent: JP 2001506135-A 7 15-MAY-2001;
ABOTT LABORATORIES
COMMENT
PN      JP 2001506135-A/7
PD      15-MAY-2001
PF      22-DEC-1997 JP 1998528933
PR      20-DEC-1996 US 08/771737
PI      CLARK A BRIGGS, MURALI GOPALAKRISHNAN, DAVID G MCKENNA, LISA M
PI      MONTEGGIA,
PI      JEAN MARC ROCH, JAMES P SULLIVAN, EDWARD TOURNA
PC      C12N15/09, C07K14/705, C12N1/15, C12N1/19, C12N1/21, C12N5/10 PC
PC      C12Q1/02, C12Q1/68,
PC      G01N33/15, G01N33/50, G01N33/566, C12N15/00, C12N5/00 CC
Strandedness: Single;

```

```

CC      Topology: linear;
FH      Key      Location/Qualifiers
FEATURES
source      1..20
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 33;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      819 GGCACTTCGGAATGCGCTG 837
      ||||| ||||| ||||| |||||
Db      20 GGCAAGCTCCGAATGCGCTG 2

RESULT 35
BD223195/c      21 bp      DNA      linear      PAT 17-JUL-2003
LOCUS      BD223195
DEFINITION      Human CCR-2 gene polymorphism.
ACCESSION      BD223195
VERSION      BD223195.1 GI:33032965
KEYWORDS      JP 2002521063-A/8.
SOURCE      Homo sapiens (human)
ORGANISM      Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
1 (bases 1 to 21)
Smith, J.C., Anand, R. and Morten, J.E.N.
AUTHORS      Human CCR-2 gene polymorphism
TITLE      Patent: JP 2002521063-A 8 16-JUL-2002;
JOURNAL      ASTRAZENCA AB
COMMENT
OS      Homo sapiens (human)
PN      JP 2002521063-A/8
PD      16-JUL-2002
PF      20-JUL-1999 JP 2000562551
PR      25-JUL-1998 GB 9816193.8 28-JAN-1999 GB 9901844.2 PI
PI      JOHN CRAIG SMITH, RAKESH ANAND, JOHN EDWARD NORRIS, MORTEN PC
PC      C12N15/09, A61K45/00, C12Q1/68//A61P19/02, A61P29/00, C12N15/00 CC
Human CCR-2 gene polymorphism
FH      Key      Location/Qualifiers
FT      source      1..21
/organism="Homo sapiens (human)".

FEATURES
source
1. 21
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match      0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1208 GCTGGTGGCTTACTCCAG 1226
      ||||| ||||| ||||| |||||
Db      20 GCTGGTGGCTTACTCCAG 2

RESULT 36
AR529846/c      21 bp      DNA      linear      PAT 08-OCT-2004
LOCUS      AR529846
DEFINITION      Sequence 1049 from patent US 6727063.
ACCESSION      AR529846
VERSION      AR529846.1 GI:53918283
KEYWORDS
SOURCE      Unknown.
ORGANISM      Unknown.
REFERENCE
1 (bases 1 to 21)
Lander, E.S., Cantill, M., Bolk, S., Daley, G.O. and
AUTHORS      McCarthy, J.J.
TITLE      Single nucleotide polymorphisms in genes

```

JOURNAL Patent: US 6727063-A 1049 27-APR-2004;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 34;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 745 GCAACTTCAGCAGACAGGCCA 765
1 GTAACTTCAGTAACAGGCCA 21

RESULT 37
ABS29850 21 bp DNA linear PAT 08-OCT-2004
LOCUS AR529850
DEFINITION Sequence 1053 from patent US 6727063.
ACCESSION AR529850
VERSION AR529850.1 GI:53918287
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE Unclassified.
1 (bases 1 to 21)
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: US 6727063-A 1053 27-APR-2004;
FEATURES Location/Qualifiers
source 1..21
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 34;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 745 GCAACTTCAGCAGACAGGCCA 765
1 GTAACTTCAGTAACAGGCCA 21

RESULT 38
AX095871 21 bp DNA linear PAT 30-MAR-2001
LOCUS AX095871
DEFINITION Sequence 1049 from Patent WO0118250.
ACCESSION AX095871
VERSION AX095871.1 GI:13512098
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 1049 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES Location/Qualifiers
source 1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 34;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 745 GCAACTTCAGCAGACAGGCCA 765

DB 1 GTAACTTCAGTAACAGGCCA 21

RESULT 39
AX095875 21 bp DNA linear PAT 30-MAR-2001
LOCUS AX095875
DEFINITION Sequence 1053 from Patent WO0118250.
ACCESSION AX095875
VERSION AX095875.1 GI:13512102
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
1 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 1053 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES Location/Qualifiers
source 1..21
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 34;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 745 GCAACTTCAGCAGACAGGCCA 765
1 GTAACTTCAGTAACAGGCCA 21

RESULT 40
AX453141 21 bp DNA linear PAT 06-JUL-2002
LOCUS AX453141/c
DEFINITION Sequence 20 from Patent WO0242444.
ACCESSION AX453141
VERSION AX453141.1 GI:21712648
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE Yoder,O., Turgeon,B.G. and Lu,S.W.
1 Fungal gene cluster associated with pathogenesis
AUTHORS Patent: WO 0242444-A 20 30-MAY-2002;
JOURNAL Syngenta Participations AG (CH) ; CORNELL RESEARCH FOUNDATION, INC.
(US) ; Yoder, Olen (US) ; Turgeon, Barbara G. (US) ; Lu, Shen-wen
(US)
FEATURES Location/Qualifiers
source 1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer"

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 89.5%; Pred. No. 34;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 510 ATATTTCGACGTGATTGCT 528
1 ATATTTCGACGTGATTGCT 2

DB 20 ATGTTTCGACGTGATCGCT 2

RESULT 41
CO617281 17 bp DNA linear PAT 02-FEB-2004
LOCUS CO617281

DEFINITION Sequence 2021 from Patent WO0192524.
ACCESSION CQ617281
VERSION CQ617281.1 GI:41667499
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2021 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 731 CCTGGTGCTTCTGCA 747
Db 1 CCTGGTGCTTCTGCA 17

RESULT 42
LOCUS CQ618102 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 2842 from Patent WO0192524.
ACCESSION CQ618102
VERSION CQ618102.1 GI:41668320
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 2842 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1974 GGCTTCGAGATGAGCA 1990
Db 1 GGCTTCGAGATGAGCA 17

RESULT 43
LOCUS AR458344 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2021 from patent US 6686188.
ACCESSION AR458344
VERSION AR458344.1 GI:42693401
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and

Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL predominantly in heart and muscle
PATENT: US 6686188-A 2021 03-FEB-2004;
LOCATION/Qualifiers
source 1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 731 CCTGGTGCTTCTGCA 747
Db 1 CCTGGTGCTTCTGCA 17

RESULT 44
LOCUS AR459165 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 2842 from patent US 6686188.
ACCESSION AR459165
VERSION AR459165.1 GI:42694222
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE
AUTHORS 1 (bases 1 to 17)
Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
JOURNAL predominantly in heart and muscle
PATENT: US 6686188-A 2842 03-FEB-2004;
LOCATION/Qualifiers
source 1. .17
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1974 GGCTTCGAGATGAGCA 1990
Db 1 GGCTTCGAGATGAGCA 17

RESULT 45
LOCUS AX423205 17 bp RNA linear PAT 18-JUN-2002
DEFINITION Sequence 1541 from Patent WO0188124.
ACCESSION AX423205
VERSION AX423205.1 GI:21526587
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE
AUTHORS 1 Jarvis,T., von Carlwiltz,I., McGwigen,J.A., McLaughlin,F.G. and
Randi,A.M.
TITLE Method and reagent for the inhibition of erg
JOURNAL Patent: WO 0188124-A 1541 22-NOV-2001;
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)
FEATURES
source 1. .17
/organism="Homo sapiens"
/mol_type="unassigned RNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;

Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1072 AGAATGAGTCTCAAG 1088
Db 1 AGAATGAGTCTCAAG 17

RESULT 46
AX688559
LOCUS Sequence 1291 from Patent EP1281758.
DEFINITION AX688559
ACCESSION AX688559.1 GI:29411261
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Shannon, M., Gu, Y. and Nguyen, C. T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12
JOURNAL Patent: EP 1281758-A 1291 05-FEB-2003;
Aeomica, Inc. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 841 TGAGGAGTACCTGATG 857
Db 1 TGAGGAGTACCTGATG 17

RESULT 47
AX783426
LOCUS Sequence 1757 from Patent WO03050284.
DEFINITION AX783426
ACCESSION AX783426
VERSION
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1757 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 725 CATGGGCTGGGTGCTT 741
Db 1 CCTGGGCTGGGTGCTT 17

RESULT 48
AX783428
LOCUS 17 bp DNA linear PAT 17-JUL-2003
AX783428 17 bp DNA linear PAT 17-JUL-2003

DEFINITION Sequence 1759 from Patent WO03050284.
ACCESSION AX783428
VERSION AX783428.1 GI:32951277
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE
AUTHORS Guo, J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1759 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES
source Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 35;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 727 TGGGCTGGGTGCTTC 743
Db 1 TGGGCTGGGTGCTTC 17

RESULT 49
AR474174
LOCUS Sequence 2 from patent US 6689875.
DEFINITION AR474174
ACCESSION AR474174
VERSION
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.

REFERENCE
AUTHORS Dierlamm, J., Baens, M. and Marijnen, P.
TITLE Molecular characterization of chromosome translocation t(11;18)(q21;q21) and its correlation to carcinogenesis
JOURNAL Patent: US 6689875-A 2 10-FEB-2004;
Location/Qualifiers
1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 15.4; DB 1; Length 20;
Best Local Similarity 94.1%; Pred. No. 37;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 739 CCTTCTGCACTTCAGC 755
Db 1 CCTTCTGCACTTCATC 17

RESULT 50
AX055866
LOCUS Sequence 2 from Patent WO073500.
DEFINITION AX055866
ACCESSION AX055866
VERSION
KEYWORDS
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.

REFERENCE
AUTHORS Baens, M., Marynen, P. and Dierlamm, J.
TITLE Molecular characterisation of chromosome translocation t(11;18)(q21;q21) and its correlation to carcinogenesis
JOURNAL Patent: WO 0073500-A 2 07-DEC-2000;
Vlaams Interuniversitair Instituut voor Biotechnologie vzw. (BR)

FEATURES

Location/Qualifiers

source

1..20

/organism="synthetic construct"

/mol_type="unassigned DNA"

/db_xref="taxon:32630"

/note="primer MLT1"

Query Match

0.6%; Score 15.4; DB 1; Length 20;

Best Local Similarity 94.1%; Pred. No. 37; Mismatches 1; Indels 0; Gaps 0;

Matches 16; Conservative 0;

Qy 739 CCTTCTGCACTTCTCAGC 755

Db 1 CCTTCTGCACTTCTC 17

RESULT 51

AR067195

Sequence 543 from patent US 5851760.

20 bp DNA linear PAT 29-SEP-1999

LOCUS

AR067195

DEFINITION

Sequence 543 from patent US 5851760.

ACCESSION

AR067195

VERSION

AR067195.1 GI:5998417

KEYWORDS

Unknown.

SOURCE

Unknown.

REFERENCE

1 (bases 1 to 20)

AUTHORS

Evans, G.A. and Smith, M.W.

TITLE

Method for generation of sequence sampled maps of complex genomes

JOURNAL

Patent: US 5851760-A 543 22-DEC-1998;

FEATURES

Location/Qualifiers

source

1..20

Qy

499 TCCATGATACATTTCTGC 518

Db

20 TCTTCATGTCACATTTCTGC 1

RESULT 52

AR158930

Sequence 552 from patent US 6251588.

20 bp DNA linear PAT 17-OCT-2001

LOCUS

AR158930

DEFINITION

Sequence 552 from patent US 6251588.

ACCESSION

AR158930

VERSION

AR158930.1 GI:16221339

KEYWORDS

Unknown.

SOURCE

Unknown.

REFERENCE

1 (bases 1 to 20)

AUTHORS

Shannon, K.W., Wolber, P.K., Delenstarr, G.C., Webb, P.G. and Kincaid, R.H.

TITLE

Method for evaluating oligonucleotide probe sequences

JOURNAL

Patent: US 6251588-A 552 26-JUN-2001;

FEATURES

Location/Qualifiers

source

1..20

Qy

1543 TAAGAGGAAAAAGTCAGTA 1562

Db

20 TAAAAAGAAAAATCAGTA 1

RESULT 53

AR158931

Sequence 553 from patent US 6251588.

20 bp DNA linear PAT 17-OCT-2001

LOCUS

AR158931

DEFINITION

Sequence 553 from patent US 6251588.

ACCESSION

AR158931

VERSION

AR158931.1 GI:16221341

KEYWORDS

Unknown.

SOURCE

Unknown.

REFERENCE

1 (bases 1 to 20)

AUTHORS

Shannon, K.W., Wolber, P.K., Delenstarr, G.C., Webb, P.G. and Kincaid, R.H.

TITLE

Method for evaluating oligonucleotide probe sequences

JOURNAL

Patent: US 6251588-A 553 26-JUN-2001;

FEATURES

Location/Qualifiers

source

1..20

Qy

1542 TTAAGAGGAAAAAGTCAGT 1561

Db

20 TTAAGAGGAAAAATCAGT 1

RESULT 54

AR163820

Sequence 18 from patent US 6271030.

20 bp DNA linear PAT 17-OCT-2001

LOCUS

AR163820

DEFINITION

Sequence 18 from patent US 6271030.

ACCESSION

AR163820

VERSION

AR163820.1 GI:16234587

KEYWORDS

Unknown.

SOURCE

Unknown.

REFERENCE

1 (bases 1 to 20)

AUTHORS

Monta, B.P., Butler, M.M. and Wyatt, J.

TITLE

Antisense inhibition of C/EBP beta expression

JOURNAL

Patent: US 6271030-A 18 07-AUG-2001;

FEATURES

Location/Qualifiers

source

1..20

Qy

21 CGGCTGCCGCTCTGCTGGG 40

Db

1 CTGCTGCCGCTGCTGCTGGG 20

RESULT 55

BD225099

Antisense modulation of expression of tumor necrosis factor receptor-associated factor (TRAF).

LOCUS

BD225099

DEFINITION

Antisense modulation of expression of tumor necrosis factor receptor-associated factor (TRAF).

ACCESSION

BD225099

VERSION

BD225099.1 GI:33034869

KEYWORDS

JP 2002526095-A/234.

SOURCE

synthetic construct

ORGANISM

other sequences: artificial sequences.

REFERENCE

1 (bases 1 to 20)

AUTHORS

Baker, B.F., Cowart, L.M., Monta, B.P. and Xu, X.S.

TITLE

Antisense modulation of expression of tumor necrosis factor receptor-associated factor (TRAF)

JOURNAL

Patent: JP 2002526095-A 234 20-AUG-2002;

COMMENT ISIS PHARMACEUTICALS INC
OS Artificial Sequence
PN JP 2002526095-A/234
PD 20-AUG-2002

PF 05-OCT-1999 JP 2000574546
PR 06-OCT-1998 US 09/167109
PI BRENDIA F BAKER, LEX M COMSERT, BRETT P MONIA, XIAOXING S XU PC
C12N15/09, A61K31/7105, A61K48/00, A61P29/00, A61P35/04, C12N15/00 CC
antisense sequence

FT Key Location/Qualifiers
FT source 1..20
/organism='Artificial Sequence'.
1..20
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

FEATURES
source Location/Qualifiers

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 436 AGTCATCTCATGCTCCG 455
Db 1 AGGCCATCTCAGGTTCCAG 20

RESULT 56
BD235616

LOCUS BD235616 20 bp DNA linear PAT 17-JUL-2003
DEFINITION Gene.
ACCESSION BD235616 GI:33045386
VERSION JP 2002522073-A/17.

KEYWORDS JP 2002522073-A/17.
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
1 (bases 1 to 20)
Robinson, I.C.A.F., Stoye, J.P., Flavell, D., Wells, S.E. and
Tiesier, P.L.

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT Patent: JP 2002522073-A 17 23-JUL-2002;
MEDICAL RESEARCH COUNCIL
OS Artificial Sequence
PN JP 2002522073-A/17
PD 23-JUL-2002
PF 12-AUG-1999 JP 2000565123
PR 12-AUG-1998 GB 9817566.4, 06-MAY-1999 GB 9910522.3 PI
IAIN CLIVE ANDREW FRANKLIN ROBINSON, JONATHAN PAUL STOYE, DAVID PI
FLAVELL,
PI SARA ELIZABETH WELLS, PAUL LE TISSIER
PC C12N15/09, A01K67/027, C07K14/47, C12N1/15, C12N1/19, C12N1/21, PC
C12N5/10.
PC C12P21/02, C12Q1/68, G01N33/15, G01N33/50, C12N15/00, C12N5/00 CC
Gene
FT Key Location/Qualifiers
FT source 1..20
/organism='Artificial Sequence'.
1..20
/organism='synthetic construct'
/mol_type='genomic DNA'
/db_xref='taxon:32630'

FEATURES
source Location/Qualifiers

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 358 GATCAGCATCTCTCCGCC 377
Db 1 GAATCAGACCCCTCTCCGCC 20

RESULT 57
CQ764765

LOCUS CQ764765 20 bp DNA linear PAT 03-MAR-2004
DEFINITION Sequence 3383 from Patent WO2004003201.
ACCESSION CQ764765
VERSION CQ764765.1 GI:44908001

KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS Kane, C.D.
TITLE Antisense modulation of lph1 expression
JOURNAL Patent: WO 2004003201-A 3383 08-JAN-2004;
Pharmacia Corporation (US)
FEATURES
source Location/Qualifiers
1..20
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'
/note='Human LRH1 antisense'

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 2378 CAGACTTTGCTATGCTT 2397
Db 1 CAGACTTTGCTATGACTT 20

RESULT 58
CQ786675

LOCUS CQ786675 20 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 8 from Patent WO2004020469.
ACCESSION CQ786675
VERSION CQ786675.1 GI:45721691

KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
AUTHORS Campochiaro, P.A. and Kaleko, M.
TITLE Ocular gene therapy
JOURNAL Patent: WO 2004020469-A 8 11-MAR-2004;
Novartis AG (CH); Novartis Pharma GmbH (AT)
FEATURES
source Location/Qualifiers
1..20
/organism='synthetic construct'
/mol_type='unassigned DNA'
/db_xref='taxon:32630'
/note='PCR Primer'

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 518 CACTGATTGCTGCTATCG 537
Db 1 CACTGTTACTGCTTATCG 20

RESULT 59
CQ798040
LOCUS CQ798040 20 bp DNA linear PAT 20-APR-2004
DEFINITION Sequence 8 from Patent WO2004028635.
ACCESSION CQ798040
VERSION CQ798040.1 GI:46426492

KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE
1

AUTHORS Compton, P. A. and Kaleko, M.
TITLE Ocular gene therapy
JOURNAL Patent: WO 2004028635-A 8 08-APR-2004;
Novartis AG (CH); Novartis Pharma GmbH (AT)
FEATURES Location/Qualifiers
1. 20

Query Match	0.6%	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 40;		
Matches 17; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0

Qy	518	CACTGATTGCTGGCTCATCG	537
Db	1	CACTGCTTACTGGCTTATCG	20

RESULT	60			
LOCUS	131301			
DEFINITION	Sequence 213 from patent US 5582979.	20 bp	DNA	1 linear
ACCESSION	131301			
VERSION	131301.1	GI:1822092		
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			

REFERENCE	1 (bases 1 to 20)
AUTHORS	Weber, J. L.
TITLE	Length polymorphisms in (dc-da). sub.n. (dg-dt). sub.n sequences and method of using the same
JOURNAL	Patent: US 5583979-A 213 10-DEC-1996;
FEATURES	Location/Qualifiers
Source	1..20

	Query March	0.6%	Score 15.2;	DB 1;	Length 20;
	Best Local Similarity	85.0%	Pred. No. 40;		
	Matches 17; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0
QY	660 CTGCTGAAGACACCAACTT	679			
Db	1 CTGTGTGAATTCAAACAACCT	20			

RESULT 61					
ARI99798/c					
LOCUS	ARI99798	20 bp	DNA	linear	PAT 20-APR-2002
DEFINITION	Sequence 59 from patent US 6355482.				
ACCESSION	ARI99798				
VERSION	ARI99798.1	GI:20249872			
KEYWORDS					
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 20)				
TITLE	Bennett,C.Frank. and Freier,S.M.				
JOURNAL	Antisense inhibition of integrin beta 4 binding protein expression				
FEATURES	Patent: US 6355482-A 59 12-Mar-2002;				
source	Location/Qualifiers				
	1..20				

Query Match	0.64	Score 15.2	DB 1	Length 20
Best Local Similarity	85.04	Pred. No. 40		
Matches 17	Conservative	0	Mismatches 3	Indels 0
			Gaps	0

QY 1633 TCAGCTAACCTCTCTTCTC 1652

Db 20 TGAGCTGTCTCTCTTTC 1

RESULT 62	LOCUS	DEFINITION	ACCESSION	VERSION	CD	FEATURES
AR203182/c	AR203182	Sequence 101 from patent US 6365354.	AR203182	AR203182.1	GI:214959505	20 bp DNA linear PAT 20-JUN-2002

Query Match	0.6%	Score 15.2;	DB 1;	length 20;
Best Local Similarity	85.0%;	Pred. No. 40;		
Matches 17; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;

QY 4 CCGGAACGCCAGCCGCCGG 23
| | | | | | | | | |
Db 20 CCGGAAGCCACCGCCGG 1

RESULT 63				
AR216033/c				
LOCUS	AR216033	20 bp	DNA	linear
DEFINITION	Sequence	80 from patent	US 6410518.	
ACCESSION	AR216033			
VERSION	AR216033.1	GI:23314321		
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			
	Unclassified.			
REFERENCE	1 (bases 1 to 20)			
AUTHORS	Monia,B.P.			
TITLE	Antisense oligonucleotide inhibition of raf gene expression			
JOURNAL	Patent: US 6410518-A 80 25-JUN-2002;			
FEATURES	Location/Qualifiers			
source	1..20			

Query Match	0.6%	Score 15.2;	DB 1;	Length 20;
Best Local Similarity	85.0%;	Pred. No. 40;		
Matches 17; Conservative	0;	Mismatches 3;	Indels 0;	Gaps 0;

```

QY      1873  CCGTTGTGTGAGGGCAGTAG  1892
          ||| ||||| ||||| |||
Db      20    CAGTGGTGTGAGGGCAGCAG  1

```

RESULT 64					
AR312819					
LOCUS	AR312819	20 bp	DNA	linear	PAT 12-JUN-2003
DEFINITION	Sequence 3356 from patent US 6559294.				
ACCESSION	AR312819				
VERSION	AR312819.1	GI:31706245			
KEYWORDS	.				
SOURCE	Unknown.				
ORGANISM	Unknown.				
REFERENCE	Unclassified.				
AUTHORS	1 (bases 1 to 20)				
	Griffieis,R., Hoisech,S.K., Zagursky,R.J., Metcalf,B.J., Peek,J.A.,				
	Senkaran,B. and Fletcher,L.D.				

TITLE Chlamydia pneumoniae polymucleotides and uses thereof
JOURNAL Patent: US 6559234-A 3356 06-MAY-2003;
FEATURES Location/Qualifiers
SOURCE 1..20
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 386 CCTCTTCTCTGTCACCTGCG 405
Db 1 CCTCTTCTCTATCACGTTGC 20

RESULT 65
AX084397 20 bp DNA linear PAT 28-FEB-2001
LOCUS AX084397 Sequence 3 from Patent WO0112830.
ACCESSION AX084397
VERSION AX084397.1 GI:13185848
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Hallenbeck, P.L. and Chen, C.T.
TITLE Adenoviral vectors including dna sequences encoding angiogenic inhibitors
JOURNAL Patent: WO 0112830-A 3 22-FEB-2001;
FEATURES Location/Qualifiers
SOURCE 1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="primer"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 518 CACTGATTGCTGCTCATCG 537
Db 1 CACTGCTTACTGCTTATCG 20

RESULT 66
AX148978/c 20 bp DNA linear PAT 08-JUN-2001
LOCUS AX148978 Sequence 180 from Patent WO0136625.
ACCESSION AX148978
VERSION AX148978.1 GI:14347502
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Wright, J.A., Young, A.H. and Dugourd, D.
TITLE Antisense oligonucleotide sequences derived from groel and groes as inhibitors of microorganisms
JOURNAL Patent: WO 0136625-A 180 25-MAY-2001;
FEATURES Genesense Technologies Inc. (CA)
SOURCE location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Antisense oligonucleotide"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1548 AGGAAAAGTCAGTATTTC 1567
Db 20 AGGAGAAAAGTAAGTATGTCA 1

RESULT 67
AX204801/c 20 bp DNA linear PAT 30-AUG-2001
LOCUS AX204801 Sequence 20 from Patent WO0153345.
ACCESSION AX204801
VERSION AX204801.1 GI:15394138
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Harper, S.J.
TITLE Vegf148 isoform, a truncated splice variant of vegf. vegf heterodimers and therapeutical uses thereof
JOURNAL Patent: WO 0153345-A 20 26-JUL-2001;
FEATURES North Bristol NHS Trust (GB)
SOURCE location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="DNA probe"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1121 ATGGGTCGAGAGAGTTCC 1140
Db 20 ATGGACCCAGATGAATTCC 1

RESULT 68
AX253270 20 bp DNA linear PAT 10-OCT-2001
LOCUS AX253270 Sequence 13 from Patent WO0168907.
ACCESSION AX253270
VERSION AX253270.1 GI:16073816
KEYWORDS
SOURCE
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Doehmer, J., Krebsfeenger, N., Eichelbaum, M. and Zanger, U.M.
TITLE Stable expression of polymorphous forms of human cytochrome p450 2d6 as an analytic in the pre-clinical development of medicaments
JOURNAL Patent: WO 0168907-A 13 20-SEP-2001;
FEATURES DOEHMER, Johannes (DE)
SOURCE location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Beschreibung der kuenstlichen Sequenz: oligonukleotid"

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 518 CACTGATTGCTGCTCATCG 537
Db 1 CACTGCTTACTGCTTATCG 20

RESULT 69
AX298825/c

LOCUS AX298825 20 bp DNA linear PAT 26-NOV-2001
DEFINITION Sequence 459 from Patent WO0183749.
ACCESSION AX298825
VERSION AX298825.1 GI:17128815
KEYWORDS
SOURCE Mus sp.
ORGANISM Mus sp.
REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
TITLE Bachmanov, A.A., Beauchamp, G.K., Chatterjee, A., de Jong, P.J., Li, S.,
Li, X., Ohmen, J.D., Reed, D.R., Rose, D. and Tordoff, M.G.
Gene and sequence variation associated with sensing carbohydrate
compounds and other sweeteners
Patent: WO 0183749-A 459 08-NOV-2001;
JOURNAL WARNER-LAMBERT COMPANY (US) ; The Monell Chemical Senses Center
(US)
FEATURES
source location/Qualifiers
1..20
/organism="Mus sp."
/mol_type="unassigned DNA"
/db_xref="taxon:10095"
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 1991 TGGGCGTGCATGACACCC 2010
DB 20 TGGAGTGCATGATACCC 1
RESULT 70
LOCUS AX463759 20 bp DNA linear PAT 15-JUL-2002
DEFINITION Sequence 22 from Patent WO0250111.
ACCESSION AX463759
VERSION AX463759.1 GI:21886509
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Doi, M., Thyboll, J. and Trygsvaen, K.
TITLE Isolated laminin 10
JOURNAL Patent: WO 0250111-A 22 27-JUN-2002;
BIOSTRATUM INC (US)
FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Primer Baxr"
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 450 CTCGAGTGGTCTGCTCTT 469
DB 20 CCCGAGTGGATCTGCTCTT 1
RESULT 71
LOCUS AX925251 20 bp DNA linear PAT 19-DEC-2003
DEFINITION Sequence 8 from Patent WO02067971.
ACCESSION AX925251
VERSION AX925251.1 GI:40243420
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Brazzall, R.K., Campochiaro, P.A. and Dixon, K.H.
TITLE Use of endostatin in the treatment of ocular neovascularization
JOURNAL Patent: WO 02067971-A 8 06-SEP-2002;
Novartis AG (CH)
FEATURES
source location/Qualifiers
1..20
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="PCR primer"
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 518 CACTGATTGCTGCTCATCG 537
DB 1 CACTGCTTACTGCGCTTATCG 20
RESULT 72
LOCUS BD012251 20 bp DNA linear PAT 02-AUG-2002
DEFINITION A novel gene encoding a serine protease-like protein.
ACCESSION BD012251
VERSION BD012251.1 GI:22092440
KEYWORDS WO 0109349-A/18.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
TITLE 1 (bases 1 to 20)
Ota, T., Isogai, T., Nishikawa, T., Hayashi, K., Saito, K., Yamamoto, J.,
Ishii, S., Sugiyama, T., Wakamatsu, A., Nagai, K., Otsuki, T., Yano, K.,
Murakami, K., Kanazaki, K., Inoue, Y., Hashimoto, B. and Kashima, A.
A novel gene encoding a serine protease-like protein
Patent: WO 0109349-A 18 08-FEB-2001;
JOURNAL HELIX RESEARCH INSTITUTE, TOSHIO OTA, TAKAO ISOGAI, TETSUO NISHIKAWA,
KOJI HAYASHI, KAORU SAITO, JUNICHI YAMAMOTO, SHIZUKO ISHII, OKUYASU
SUGIYAMA, AI WAKAMATSU, KEIICHI NAGAI, TETSUJI OTSUKI, KAZUHIRO YANO,
OUTI MURAKAMI, KOJI KANZAKI, YOSHIOHISA INOUE, EMI HASHIMOTO, AKIKO
KASHIMA
COMMENT PN WO 0109349-A/18
PD 08-FEB-2001
PF 28-JUL-2000 WO 2000JP005062
PR 29-JUL-1999 JP 99P 248036, 27-AUG-1999 JP 99P 300253 PR
11-JAN-2000 JP 00P 118776, 02-MAY-2000 JP 00P 183767 PR
18-OCT-1999 US 60/159590, 17-FEB-2000 US 60/183322 PI TOSHIO
OTA, TAKAO ISOGAI, TETSUO NISHIKAWA, KOJI HAYASHI, PI KAORU SAITO,
PI JUNICHI YAMAMOTO, SHIZUKO ISHII, TOMOYASU SUGIYAMA, AI WAKAMATSU,
PI KEIICHI NAGAI, TETSUJI OTSUKI, KAZUHIRO YANO, KOJI MURAKAMI, PI
KOJI KANZAKI,
PI YOSHIOHISA INOUE, EMI HASHIMOTO, AKIKO KASHIMA
PC C12N15/57, C12N9/64, C12N15/63, C12N5/06, C07K16/40, C12Q1/68, PC
G01N33/573,
PC A61K38/48, A61K31/7052, A61K48/00/C12P21/08, C12N9/64, C12R1/91
CC Description of Artificial Sequence: an artificially
synthesized primer
CC G01N33/573,
CC sequence
FH key location/Qualifiers
1..20
/organism="Mus musculus"
/mol_type="genomic DNA"
/db_xref="taxon:10090"
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 40;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
OY 518 CACTGATTGCTGCTCATCG 537

Db 1 CACTGCTACTGGCTATCG 20

RESULT 73
LOCUS AR195688 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 153 from patent US 6350934.
ACCESSION AR195688
VERSION AR195688.1 GI:20245125
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Zwirk,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
TITLE Nucleic acid encoding delta-9 desaturase
JOURNAL Patent: US 6350934-A 153 26-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 778 AGAAGTCCCGAGCA 792
Db 3 AGAAGTCCCGAGCA 17

RESULT 74
LOCUS AR195690 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 155 from patent US 6350934.
ACCESSION AR195690
VERSION AR195690.1 GI:20245127
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Zwirk,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,
Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.
TITLE Nucleic acid encoding delta-9 desaturase
JOURNAL Patent: US 6350934-A 155 26-FEB-2002;
FEATURES Location/Qualifiers
source 1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 778 AGAAGTCCCGAGCA 792
Db 2 AGAAGTCCCGAGCA 16

RESULT 75
LOCUS AX783427 17 bp DNA linear PAT 17-JUL-2003
DEFINITION Sequence 1758 from Patent WO03050284.
ACCESSION AX783427
VERSION AX783427.1 GI:32951276
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.

REFERENCE 1
AUTHORS Guo,J.
TITLE Human prostate cancer candidate protein 1
JOURNAL Patent: WO 03050284-A 1758 19-JUN-2003;
Amersham Biosciences (SV) Corp. (US)
FEATURES Location/Qualifiers
source 1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 40;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 727 TGGGCTGGTGCTCT 741
Db 2 TGGGCTGGTGCTCT 16

RESULT 76
LOCUS BD235620 18 bp DNA linear PAT 17-JUL-2003
DEFINITION Gene.
ACCESSION BD235620
VERSION BD235620.1 GI:33045390
KEYWORDS JP 2002522073-A/21.
SOURCE JP 2002522073-A/21.
ORGANISM synthetic construct
REFERENCE 1 (bases 1 to 18)
AUTHORS Robinson,I.C.A.F., Stoye,J.P., Flavell,D., Wells,S.E. and
Tissler,P.L.
TITLE Gene
JOURNAL Patent: JP 2002522073-A 21 23-JUL-2002;
COMMENT MEDICAL RESEARCH COUNCIL
OS Artificial Sequence
PN JP 2002522073-A/21
PD 23-JUL-2002 JP 2000565123
PF 12-AUG-1999 JP 9817566.4,06-MAY-1999 GB 9910522.3 PI
PR 12-AUG-1998 GB 9817566.4,06-MAY-1999 GB 9910522.3 PI
PAIN CLIVE ANDREW FRANKLIN ROBINSON, JONATHAN PAUL STOYE, DAVID PI
FLAVELL,
PI SARA ELIZABETH WELLS, PAUL LE TISSIER
PC C12N15/09,A01K67/027,C07K14/47,C12N1/15,C12N1/19,C12N1/21, PC
C12N5/10, C12P21/02,C12Q1/68,G01N33/15,G01N33/50,C12N15/00,C12N5/00 CC
Gene
FH Key Location/Qualifiers
FT source 1..18
Location/Qualifiers
source 1..18
/organism="Artificial Sequence".
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 281 GGCCGAGGCTGACCGAG 298
Db 1 GGCCGAGGCTGACCGAG 18

RESULT 77
LOCUS CQ771686/c 18 bp DNA linear PAT 04-MAR-2004
DEFINITION Sequence 113 from Patent WO2003100423.
ACCESSION CQ771686
VERSION CQ771686.1 GI:45125676
KEYWORDS

SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.

REFERENCE 1
AUTHORS Cuzin, M., Mandrand, B., Cleuziat, P. and Abaibou, H.
TITLE Better organised biochip
JOURNAL Patent: WO 2003100423-A 113 04-DEC-2003;
Aptbio (FR)

FEATURES
source location/Qualifiers
1. .18
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2052 GATGCCGCCACCATGAGC 2069
Db 18 GCTGCCCCACCATGAGC 1

RESULT 78
LOCUS CQ798833 18 bp DNA linear PAT 28-APR-2004
DEFINITION Sequence 12 from Patent WO2004031237.
ACCESSION CQ798833
VERSION CQ798833.1 GI:46847870
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.

REFERENCE 1
AUTHORS Nakamura, Y. and Katagiri, T.
TITLE Genes and polypeptides relating to human myeloid leukemia
JOURNAL Patent: WO 2004031237-A 12 15-APR-2004;
Oncotherapy Science, Inc. (JP); Japan as represented by the
president of the university of Tokyo (JP)

FEATURES
source location/Qualifiers
1. .18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Artificially synthesized S-oligonucleotides for
Antisense"

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 668 GACACACCACTGCTGAC 685
Db 18 GACACACCACTGCTGAC 1

RESULT 79
LOCUS I14363 18 bp DNA linear PAT 26-SEP-1995
DEFINITION Sequence 5 from patent US 5449609.
ACCESSION I14363
VERSION I14363.1 GI:996854
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
1 (bases 1 to 18)
REFERENCE Younkin, D. P. and Pleasure, D.
AUTHORS Methode for screening for neurotoxicity using a clonal human
TITLE teratocarcinoma cell line
JOURNAL Patent: US 5449609-A 5 12-SEP-1995;
FEATURES location/Qualifiers

source 1. .18
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 ACCCTGGCGAACCGCAG 1010
Db 1 AACCTGGCGAACCGCAG 18

RESULT 80
LOCUS AR490327 18 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 1 from patent US 6713247.
ACCESSION AR490327
VERSION AR490327.1 GI:47257699
KEYWORDS
SOURCE
ORGANISM
Unknown.
Unclassified.
1 (bases 1 to 18)
REFERENCE Sah, D. W. Y., Gage, F. H. and Ray, J.
AUTHORS Human CNS cell lines and methods of use therefor
JOURNAL Patent: US 6713247-A 1 30-MAR-2004;
FEATURES location/Qualifiers
1. .18
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 43;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 ACCCTGGCGAACCGCAG 1010
Db 1 AACCTGGCGAACCGCAG 18

RESULT 81
LOCUS BD104248 18 bp DNA linear PAT 27-AUG-2002
DEFINITION Kit and method for determining HLA type.
ACCESSION BD104248
VERSION BD104248.1 GI:22649822
KEYWORDS
SOURCE
ORGANISM
synthetic construct
other sequences; artificial sequences.
1 (bases 1 to 18)
REFERENCE Inoko, H., Kagiya, T., Ichihara, T., Matsumura, Y., Moriya, S. and
AUTHORS Nishida, M.
TITLE Kit and method for determining HLA type
JOURNAL Patent: WO 0192572-A 352 06-DEC-2001;
NISHINO INDUSTRIES INC., SYSTEM RESEARCH INC, HIDEOTOSHI INOKO, TAEKO
KAGIYA, TATSUO ICHIHARA, YOSHIYUKI MATSUMURA, SHOGO MORIYA, MICHIO
NISHIDA

COMMENT
OS Artificial Sequence
PN WO 0192572-A/352
PD 06-DEC-2001
PF 01-JUN-2001 WO 2001JP004662
PR 01-JUN-2000 JP 00P 164798
PI HIDEOTOSHI INOKO, TAEKO KAGIYA, TATSUO ICHIHARA, YOSHIYUKI PI
MATSUMURA,
PI SHOGO MORIYA, MICHIO NISHIDA
PC C1201/68, C12M1/00, C12N15/09, G01N33/53
CC Description of Artificial Sequence: capture
FH Key location/Qualifiers
FT source 1. .18
/organism="Artificial Sequence".
FEATURES location/Qualifiers

[illegible]

LOCUS	DEFINITION	ACCESSION	VERSION	KEYWORDS	SOURCE	ORGANISM	REFERENCE	AUTHORS	TITLE	JOURNAL	FEATURES	source
BD196861	Sequence 22 from patent US 6153189.	AR119350	AR119350.1	GI:14102049	Unknown.	Unknown.	Unclassified.	1 (bases 1 to 19)	Preseata, J.G., Shelton, D.L. and Ufer, R.	Human TRK receptors and neurotrophic factor inhibitors	Patent: US 6153189-A 22 28-NOV-2000;	Location/Qualifiers
QY	2124 CTCAGCCTTGCGCTGAG 2141											
Db	19 CTCACCTTGCGCTGAG 2											
RESULT 85	BD196861	19 bp	DNA	linear	PAT 17-JUL-2003							
LOCUS	BD196861	19 bp	DNA	linear	PAT 17-JUL-2003							
DEFINITION	Prostatic cancer gene.											
ACCESSION	BD196861											
VERSION	BD196861.1											
KEYWORDS	JP 2002516657-A/450.											
SOURCE	Homo sapiens (human)											
ORGANISM	Homo sapiens											
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.											
AUTHORS	1 (bases 1 to 19)											
TITLE	Cohen, D., Blumenfeld, M., Chuankov, I. and Bouguetel, L.											
JOURNAL	Prostatic cancer gene											
GENSET	Patent: JP 2002516657-A 450 11-JUN-2002;											
COMMENT	OS Homo sapiens (human)											
	PN JP 2002516657-A/450											
	PD 11-JUN-2002											
	PF 22-DEC-1998 JP 2000525562											
	PR 22-DEC-1997 US 08/969606, 09-SEP-1998 US 60/099658 PI											
	DANIEL COHEN, MARTA BLUMENFELD, ILYA CHUANKOV, LYDIE BOUGUETEL											
	PC C12N15/09, C12N15/09, A01K67/027, C07K4/47, C07K16/18, C12N1/15, PC											
	C12N1/19.											
	PC C12N1/21, C12N5/10, C12N5/10, C12P21/08, C12O1/68, GOIN33/50 PC											
	, C12N15/00, C12N5/00.											
	PC C12N5/00, C12N15/00											
	CC microsequencing oligo for 99-140-130.m1											
	FH Key Location/Qualifiers											
	FT primer bind 1..19.											
	Location/Qualifiers											
	1..19											
	/organism="Homo sapiens"											
	/mol_type="genomic DNA"											
	/db_xref="taxon:9606"											
FEATURES	source											
Query Match	0.6%; Score 14.8; DB 1; Length 19;											
Best Local Similarity	88.9%; Pred. No. 44;											
Matches	16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;											
QY	424 AAAAGCAGCTACAGGTCA 441											
Db	2 AAAAGCAGCTACAGGTCA 19											
RESULT 86	BD196861	19 bp	DNA	linear	PAT 29-SEP-1997							
LOCUS	BD196861	19 bp	DNA	linear	PAT 29-SEP-1997							

DEFINITION Primer.
ACCESSION E05122
VERSION E05122.1 GI:2173315
KEYWORDS JP 1993184400-A/5.
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 19)
AUTHORS Komata,M. and Ebata,T.
TITLE CHRONICALLY ACTIVE HEPATITIS B VIRUS AND METHOD FOR DETECTING THE
JOURNAL Patent: JP 1993184400-A 5 27-JUL-1993;
TSUMURA & CO
COMMENT OS Artificial gene
OC Artificial sequence; Genes.
PN JP 1993184400-A/5
PD 27-JUL-1993
PF 17-JAN-1992 JP 1992025887
PI KOMATA MASAO, EBATA TOSHIKI
PC C12Q1/70, C12N7/00, C12Q1/68, G01N33/50//A61B10/00, A61K39/29, PC
C12N15/00.
PC C12N15/51;
CC strandedness: Single;
topology: Linear.
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1828 GACGAGTTTCTGTGCCAA 1845
Db 18 GACGAGTTTCTGTGCCAA 1

RESULT 87
E05126 19 bp DNA linear PAT 29-SEP-1997
LOCUS Primer.
DEFINITION E05126
ACCESSION E05126
VERSION E05126.1 GI:2173319
KEYWORDS JP 1993184400-A/9.
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 19)
AUTHORS Komata,M. and Ebata,T.
TITLE CHRONICALLY ACTIVE HEPATITIS B VIRUS AND METHOD FOR DETECTING THE
JOURNAL Patent: JP 1993184400-A 9 27-JUL-1993;
TSUMURA & CO
COMMENT OS Artificial gene
OC Artificial sequence; Genes.
PN JP 1993184400-A/9
PD 27-JUL-1993
PF 17-JAN-1992 JP 1992025887
PI KOMATA MASAO, EBATA TOSHIKI
PC C12Q1/70, C12N7/00, C12Q1/68, G01N33/50//A61B10/00, A61K39/29, PC
C12N15/00.
PC C12N15/51;
CC strandedness: Single;
topology: Linear.
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1828 GACGAGTTTCTGTGCCAA 1845
Db 2 GACGAGTTTCTGTGCCAA 19

RESULT 88
AR493023/c 19 bp DNA linear PAT 15-MAY-2004
LOCUS Sequence 55 from patent US 6720137.
DEFINITION AR493023
ACCESSION AR493023
VERSION AR493023.1 GI:47264371
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 19)
AUTHORS Roder,M., Plaschke,J. and Ganai,M.
TITLE Microsatellite markers for plants of the species Triticum aestivum
JOURNAL and Tribe triticeae and the use of said markers
Patent: US 6720137-A 55 13-APR-2004;
Location/Qualifiers
1..19
/organism="unknown"
/mol_type="genomic DNA"

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1918 ATCTCCCTTCTGCGACCC 1935
Db 18 ATCTCCCTTCTGCGACCC 1

RESULT 89
AX130953/c 19 bp DNA linear PAT 15-MAY-2001
LOCUS Sequence 2171 from Patent WO0130362.
DEFINITION AX130953
ACCESSION AX130953
VERSION AX130953.1 GI:14137258
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1
AUTHORS Robbins,J.M. and Tritz,R.
TITLE Ribozyme therapy for the treatment of proliferative skin and eye
JOURNAL diseases
Patent: WO 0130362-A 2171 03-MAY-2001;
IMMUSOL, INC. (US)
Location/Qualifiers
1..19
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/note="Cyclin B ribozyme binding site"

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 877 TCAGCCGGGACACCATAG 894
Db 18 TCAGCCGAGACACATAG 1

RESULT 90
AX304853/c 19 bp DNA linear PAT 11-DEC-2001
LOCUS Sequence 8 from Patent EP1158001.
DEFINITION AX304853
ACCESSION AX304853

```

VERSION      AX304853.1  GI:17644532
KEYWORDS     .
SOURCE       synthetic construct
ORGANISM     synthetic construct
REFERENCE    1 other sequences; artificial sequences.
AUTHORS      Kaul,S.; Preherr,J. and Weidle,U.
TITLE        A nucleic acid which is upregulated in human tumor cells, a protein
JOURNAL      encoded thereby and a process for tumor diagnosis
              Patent: EP 1158001-A 8-28-NOV-2001;
              F. HOFMANN-LA ROCHE AG (CH)
FEATURES     Location/Qualifiers
              1..19
              source          /organism="synthetic construct"
                             /mol_type="unassigned DNA"
                             /db_xref="taxon:32630"
                             /note="primer RTR-5"

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred.No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      2395 CTTGAAATTAATGAAAG 2412
        |||||
        19 CTTGAAATGAATGAATG 2

RESULT 91
AX823814/c      19 bp      DNA      linear      PAT 11-DEC-2003
LOCUS           AX823814
DEFINITION      Sequence 4 from Patent WO03070269.
ACCESSION       AX823814
VERSION         AX823814.1  GI:39750134
KEYWORDS        .
SOURCE          synthetic construct
ORGANISM        synthetic construct
REFERENCE       1 other sequences; artificial sequences.
AUTHORS         1 Schraermeyer,U.
TITLE           Treatment for diseases of the eye, inner ear and central nervous
JOURNAL        system
              Patent: WO 03070269-A 4-28-AUG-2003;
              Schraermeyer, Ulrich (DE)
FEATURES        Location/Qualifiers
              1..19
              source          /organism="synthetic construct"
                             /mol_type="unassigned DNA"
                             /db_xref="taxon:32630"
                             /note="primer"

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred.No. 44;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1273 AGCACCAACCCAGCAAG 1290
        |||||
        19 ACCACCCAGCCAGCAAG 2

Db

```

Search completed: August 8, 2005, 09:54:52
 Job time : 3 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 8, 2005, 09:59:19 : Search time 3 Seconds
(without alignments)
4.272 Million cell updates/sec

Title: US-10-643-801-4
Perfect score: 2421
Sequence: 1 ctccgggagccagccgccccg.....ataatgaagtgagatcc 2421

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 147 seqs, 2647 residues

Total number of hits satisfying chosen parameters: 294

Minimum DB seq length: 8
Maximum DB seq length: 80

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 147 summaries

Database : fetcham1.seq:*

Pred. No. is the number of results predicted by chance to have a
score greater than or equal to the score of the result being printed,
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	19.2	0.8	25	1	US-09-396-196G-52073
2	17.2	0.7	22	1	US-09-587-945-20
3	17	0.7	21	1	US-09-432-978-11680
4	16.8	0.7	20	1	US-09-733-294A-40
5	16.8	0.7	21	1	US-08-482-918-16
6	16.8	0.7	21	1	US-09-824-681-16
7	16.8	0.7	21	1	US-08-336-728A-16
8	16.8	0.7	21	1	US-09-635-251-16
9	16.8	0.7	22	1	US-09-056-226-17
10	16.4	0.7	20	1	US-09-467-082-10
11	16.4	0.7	21	1	US-09-288-339-39
12	15.8	0.7	19	1	US-08-791-883-5
13	15.8	0.7	19	1	US-09-023-318-80
14	15.8	0.7	19	1	US-09-375-318-80
15	15.8	0.7	19	1	US-09-540-257B-22
16	15.8	0.7	20	1	US-09-344-001-19
17	15.8	0.7	20	1	US-09-344-001-20
18	15.8	0.7	20	1	US-08-771-737-8
19	15.8	0.7	20	1	US-09-112-580-196
20	15.8	0.7	21	1	US-09-954-936-8
21	15.8	0.7	21	1	US-09-657-472-1049
22	15.8	0.7	21	1	US-09-657-472-1053
23	15.4	0.6	17	1	US-09-866-108A-2021
24	15.4	0.6	17	1	US-09-866-108A-2021
25	15.4	0.6	20	1	US-09-433-699-12
26	15.4	0.6	20	1	US-09-579-692B-2
27	15.2	0.6	20	1	US-08-222-177A-213
28	15.2	0.6	20	1	US-08-117-952-543
29	15.2	0.6	20	1	US-09-021-701-552
30	15.2	0.6	20	1	US-09-021-701-553
31	15.2	0.6	20	1	US-09-593-711A-18
32	15.2	0.6	20	1	US-09-716-161A-59
33	15.2	0.6	20	1	US-09-629-645A-101

34	15.2	0.6	20	1	US-09-506-073-80	Sequence 80, Appl
35	15.2	0.6	20	1	US-09-198-452A-3356	Sequence 3356, Ap
36	15	0.6	17	1	US-08-679-645-153	Sequence 153, App
37	15	0.6	17	1	US-08-679-645-155	Sequence 155, App
38	14.8	0.6	18	1	US-08-189-199A-5	Sequence 5, Appl1
39	14.8	0.6	18	1	US-09-213-719-65	Sequence 65, Appl
40	14.8	0.6	18	1	US-08-711-628-1	Sequence 1, Appl1
41	14.8	0.6	19	1	US-08-359-705B-22	Sequence 22, Appl
42	14.8	0.6	19	1	US-08-286-846A-22	Sequence 22, Appl
43	14.8	0.6	19	1	US-08-457-880A-22	Sequence 22, Appl
44	14.8	0.6	19	1	US-08-444-622A-22	Sequence 22, Appl
45	14.8	0.6	19	1	US-08-942-562-22	Sequence 22, Appl
46	14.8	0.6	19	1	US-09-156-923-22	Sequence 22, Appl
47	14.8	0.6	19	1	US-09-338-907-476	Sequence 476, App
48	14.8	0.6	19	1	US-09-218-207-476	Sequence 476, App
49	14.8	0.6	19	1	US-08-983-605-55	Sequence 55, Appl
50	14.8	0.6	19	1	US-09-696-791-2171	Sequence 2171, Ap
51	14.4	0.6	16	1	US-08-464-514-9	Sequence 9, Appl1
52	14.4	0.6	16	1	US-08-486-403-9	Sequence 9, Appl1
53	14.4	0.6	16	1	US-07-672-530C-39	Sequence 39, Appl
54	14.4	0.6	16	1	US-09-479-005A-1	Sequence 1, Appl1
55	14.4	0.6	17	1	US-08-758-306-147	Sequence 147, App
56	14.4	0.6	17	1	US-09-866-108A-798	Sequence 798, App
57	14.4	0.6	17	1	US-09-866-108A-799	Sequence 799, App
58	14.4	0.6	17	1	US-09-866-108A-1294	Sequence 1294, Ap
59	14.4	0.6	17	1	US-09-866-108A-1295	Sequence 1295, Ap
60	14.4	0.6	17	1	US-09-866-108A-2020	Sequence 2020, Ap
61	14.4	0.6	17	1	US-09-866-108A-2022	Sequence 2022, Ap
62	14.4	0.6	17	1	US-09-866-108A-2841	Sequence 2841, Ap
63	14.4	0.6	17	1	US-09-866-108A-2843	Sequence 2843, Ap
64	14.4	0.6	17	1	US-09-866-108A-6608	Sequence 6608, Ap
65	14.4	0.6	18	1	US-08-758-306-523	Sequence 6609, Ap
66	14.4	0.6	18	1	US-08-758-306-523	Sequence 6609, Ap
67	14.4	0.6	18	1	US-09-177-359-15	Sequence 523, App
68	14.4	0.6	18	1	US-09-474-922A-46	Sequence 46, Appl
69	14	0.6	17	1	US-08-974-549A-479	Sequence 479, App
70	14	0.6	17	1	US-08-912-951-246	Sequence 479, App
71	14	0.6	17	1	US-09-402-181B-479	Sequence 479, App
72	14	0.6	17	1	US-09-721-456-479	Sequence 479, App
73	14	0.6	17	1	US-09-866-108A-1534	Sequence 1534, Ap
74	14	0.6	17	1	US-09-866-108A-1535	Sequence 1535, Ap
75	14	0.6	17	1	US-09-866-108A-1536	Sequence 1536, Ap
76	14	0.6	17	1	US-09-866-108A-1537	Sequence 1537, Ap
77	13.8	0.6	17	1	US-08-129-719-18	Sequence 18, Appl
78	13.8	0.6	17	1	US-08-306-871-18	Sequence 18, Appl
79	13.8	0.6	17	1	US-08-565-959-18	Sequence 18, Appl
80	13.8	0.6	17	1	US-08-985-162-52	Sequence 52, Appl
81	13.8	0.6	17	1	US-09-371-772B-3075	Sequence 3075, Ap
82	13.8	0.6	17	1	US-08-584-040-7471	Sequence 7471, Ap
83	13.8	0.6	17	1	US-09-474-432B-322	Sequence 322, App
84	13.8	0.6	17	1	US-09-371-772B-3075	Sequence 3075, Ap
85	13.8	0.6	17	1	US-09-371-772B-3277	Sequence 3277, Ap
86	13.8	0.6	17	1	US-09-476-387-321	Sequence 4988, Ap
87	13.8	0.6	17	1	US-09-476-387-321	Sequence 321, App
88	13.8	0.6	17	1	US-09-401-063-52	Sequence 52, Appl
89	13.8	0.6	17	1	US-09-827-998-313	Sequence 313, App
90	13.8	0.6	17	1	US-09-866-108A-230	Sequence 230, App
91	13.8	0.6	17	1	US-09-866-108A-2018	Sequence 2018, Ap
92	13.8	0.6	17	1	US-09-866-108A-2019	Sequence 2019, Ap
93	13.8	0.6	17	1	US-09-685-666B-1075	Sequence 3075, Ap
94	13.8	0.6	17	1	US-09-685-666B-1277	Sequence 3277, Ap
95	13.8	0.6	18	1	US-08-050-073-148	Sequence 148, App
96	13.8	0.6	18	1	US-08-210-762E-45	Sequence 45, Appl
97	13.8	0.6	18	1	US-09-161-015-9	Sequence 9, Appl1
98	13.8	0.6	18	1	US-09-205-860-10	Sequence 10, Appl
99	13.8	0.6	18	1	US-09-200-141-40	Sequence 40, Appl
100	13.8	0.6	18	1	US-09-106-038A-85	Sequence 85, Appl
101	13.8	0.6	18	1	US-09-358-381-23	Sequence 23, Appl
102	13.8	0.6	18	1	US-09-577-902-23	Sequence 23, Appl
103	13.8	0.6	18	1	US-09-106-075A-45	Sequence 45, Appl
104	13.8	0.6	18	1	US-08-584-040-8326	Sequence 8326, Ap
105	13.8	0.6	18	1	US-09-387-341-152	Sequence 152, App
106	13.8	0.6	18	1	US-09-422-978-4223	Sequence 4223, Ap

```
107 13.8 0.6 18 1 US-09-422-978-5061 Sequence 5061, Ap
108 13.8 0.6 18 1 US-09-422-978-11430 Sequence 11430, A
109 13.8 0.6 18 1 US-09-371-7728-3984 Sequence 3984, Ap
C 110 13.8 0.6 18 1 US-09-954-736A-117 Sequence 17, Appl
C 111 13.8 0.6 18 1 US-09-155-885A-247 Sequence 247, Appl
112 13.8 0.6 18 1 US-10-071-411A-22 Sequence 22, Appl
113 13.8 0.6 18 1 US-09-685-664B-3984 Sequence 3984, Ap
C 114 13.8 0.6 18 1 PCT-US93-12603-11 Sequence 11, Appl
115 13.4 0.6 15 1 US-08-363-240A-622 Sequence 622, App
C 116 13.4 0.6 15 1 US-08-585-684B-91 Sequence 91, Appl
C 117 13.4 0.6 15 1 US-09-038-073-91 Sequence 91, Appl
C 118 13.4 0.6 17 1 US-08-233-608-25 Sequence 25, Appl
C 119 13.4 0.6 17 1 US-08-887-480-25 Sequence 25, Appl
C 120 13.4 0.6 17 1 US-08-722-187-25 Sequence 25, Appl
C 121 13.4 0.6 17 1 US-08-985-162-53 Sequence 53, Appl
122 13.4 0.6 17 1 US-09-474-432B-487 Sequence 326, App
123 13.4 0.6 17 1 US-09-474-432B-691 Sequence 487, App
124 13.4 0.6 17 1 US-09-371-772B-4986 Sequence 4986, Ap
125 13.4 0.6 17 1 US-09-371-772B-4987 Sequence 4987, Ap
126 13.4 0.6 17 1 US-09-476-387-486 Sequence 486, App
127 13.4 0.6 17 1 US-09-476-387-690 Sequence 690, App
128 13.4 0.6 17 1 US-09-401-063-53 Sequence 53, Appl
C 129 13.4 0.6 17 1 US-09-401-063-326 Sequence 326, App
C 130 13.4 0.6 17 1 US-09-866-108A-800 Sequence 800, App
C 131 13.4 0.6 17 1 US-09-866-108A-1293 Sequence 1293, Ap
132 13.4 0.6 17 1 US-09-866-108A-2823 Sequence 1296, Ap
133 13.4 0.6 17 1 US-09-866-108A-2840 Sequence 2840, Ap
134 13.4 0.6 17 1 US-09-866-108A-2844 Sequence 2844, Ap
135 13.4 0.6 17 1 US-09-866-108A-6040 Sequence 6040, Ap
136 13.4 0.6 17 1 US-09-866-108A-6041 Sequence 6041, Ap
137 13.4 0.6 17 1 US-09-866-108A-6042 Sequence 6042, Ap
138 13.4 0.6 17 1 US-09-866-108A-6607 Sequence 6607, Ap
139 13.4 0.6 17 1 US-09-866-108A-10512 Sequence 10512, A
140 13.4 0.6 17 1 US-09-866-108A-10513 Sequence 10513, A
141 13.4 0.6 17 1 US-09-866-108A-10514 Sequence 10514, A
142 13.4 0.6 17 1 US-09-404-912-151 Sequence 151, App
143 13.4 0.6 17 1 PCT-US95-04712-25 Sequence 25, Appl
C 144 13.4 0.6 17 1
C 145 13.4 0.6 17 1
C 146 13.4 0.6 17 1
C 147 13.4 0.6 17 1
```

ALIGNMENTS

```
RESULT 1
US-09-396-196G-52073/C
; Sequence 52073, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittlemann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 52073
; LENGTH: 25
; TYPE: DNA
; ORGANISM: mus musculus
; US-09-396-196G-52073
```

```
Query Match 0.8%; Score 19.2; DB 1; Length 25;
Best Local Similarity 87.5%; Pred. No. 7.1;
Matches 21; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```
Qy 1311 ATGTACATGAGCGCCCTGTGAG 1334
|||||
Db 25 ATGTAGTTGAGAGACCTGTGTGAG 2
```

```
RESULT 2
US-09-587-945-20/C
; Sequence 20, Application US/09587945
; Patent No. 6709860
; GENERAL INFORMATION:
; APPLICANT: Enerback, Sven
; APPLICANT: Carlsson, Peter
; TITLE OF INVENTION: Animal Model
; FILE REFERENCE: 10806-117A
; CURRENT APPLICATION NUMBER: US/09/587,945
; PRIOR FILING DATE: 2000-06-06
; PRIOR APPLICATION NUMBER: US 60/190,692
; PRIOR FILING DATE: 2000-03-20
; PRIOR APPLICATION NUMBER: US 09/085,380
; PRIOR FILING DATE: 1998-05-26
; PRIOR APPLICATION NUMBER: SE 9701963-2
; PRIOR FILING DATE: 1997-05-26
; NUMBER OF SEQ ID NOS: 26
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 20
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: 3' primer
US-09-587-945-20
```

```
Query Match 0.7%; Score 17.2; DB 1; Length 22;
Best Local Similarity 86.4%; Pred. No. 16;
Matches 19; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 239 CCTCATGCGCGCCCTACTCCGCG 260
|||||
Db 22 CCTATTGGCGCCCTACTCAGG 1
```

```
RESULT 3
US-09-422-978-11680
; Sequence 11680, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSRT 0200C1
; CURRENT APPLICATION NUMBER: US/09/422,978
; PRIOR FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11680
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: 1..21
; OTHER INFORMATION: downstream amplification primer 99-22404 for SEQ 3815, in complem
US-09-422-978-11680
```

```
Query Match 0.7%; Score 17; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 16;
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```


OY 1643 TCTCTCTCCCTCTCT 1659
1 TCTCTCTCTCTCTCT 17

RESULT 4
US-09-733-294A-40/c
Sequence 40, Application US/09733294A
Patent No. 6492171
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: William Gaarde
APPLICANT: Susan M. Preler
APPLICANT: Edward V. Wanciewicz
TITLE OF INVENTION: ANTISENSE MODULATION OF TEXT EXPRESSION
FILE REFERENCE: ISPH-0527
CURRENT APPLICATION NUMBER: US/09/733,294A
CURRENT FILING DATE: 2000-12-07
PRIOR APPLICATION NUMBER: 09/572,423
PRIOR FILING DATE: 2000-05-16
NUMBER OF SEQ ID NOS: 108
SEQ ID NO 40
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-733-294A-40

Query Match 0.7%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 17;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 139 GCGGAGCCCTGCGCCCG 158
DB 20 GTGGAGCCCTGCGCCCG 1

RESULT 5
US-08-482-918-16
Sequence 16, Application US/08482918
Patent No. 6207417
GENERAL INFORMATION:
APPLICANT: Zeebo, Kristina M.
APPLICANT: Bosseiman, Robert A.
APPLICANT: Suggs, Sidney V.
APPLICANT: Martin, Francis H.
TITLE OF INVENTION: Stem Cell Factor
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/482,918
FILING DATE: 07-JUN-1995
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/33005
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448

TELEX: 25-3856
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-482-918-16

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2402 ATAAATGAAGTGAATCC 2421
DB 2 ATAAATGAAGTGAATCC 21

RESULT 6
US-09-224-681-16
Sequence 16, Application US/09224681
Patent No. 6207454
GENERAL INFORMATION:
APPLICANT: Zeebo, Kristina M.
APPLICANT: Bosseiman, Robert A.
APPLICANT: Suggs, Sidney V.
APPLICANT: Martin, Francis H.
TITLE OF INVENTION: Method for Enhancing the Efficiency of Gene
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/224,681
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 09/005,893
FILING DATE: 12-JAN-1998
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/449,653
FILING DATE: 24-MAY-1995
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/589,701
FILING DATE: 01-OCT-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107

REFERENCE/DOCKET NUMBER: 01017/35199
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX:
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-224-681-16

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATAAATGCAAGTGAATCC 2421
DB 2 ATAAATGCAAGTGAATCC 21

RESULT 7
US-08-336-728A-16
Sequence 16, Application US/08336728A
Patent No. 6207802
GENERAL INFORMATION:
APPLICANT: Zeebo, Kristina M.
Bosselman, Robert A.
APPLICANT: Suggs, Sidney V.
APPLICANT: Martin, Francis H.
TITLE OF INVENTION: Stem Cell Factor
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/336,728A
FILING DATE: 09-NOV-1994
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/589,701
FILING DATE: 01-OCT-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/32956
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: 25-3856

INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-336-728A-16

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATAAATGCAAGTGAATCC 2421
DB 2 ATAAATGCAAGTGAATCC 21

RESULT 8
US-09-635-251-16
Sequence 16, Application US/09635251
Patent No. 6759215
GENERAL INFORMATION:
APPLICANT: Zeebo, Kristina M.
Bosselman, Robert A.
Suggs, Sidney V.
Martin, Francis H.
TITLE OF INVENTION: Stem Cell Factor
NUMBER OF SEQUENCES: 104
CORRESPONDENCE ADDRESS:
ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
STREET: 6300 Sears Tower, 233 South Wacker Drive
CITY: Chicago
STATE: Illinois
COUNTRY: United States of America
ZIP: 60606-6402
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/635,251
FILING DATE: 07-AUG-2000
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/449,182
FILING DATE: 24-MAY-1995
APPLICATION NUMBER: 08/172,329
FILING DATE: 21-DEC-1993
APPLICATION NUMBER: 07/982,255
FILING DATE: 25-NOV-1992
APPLICATION NUMBER: 07/684,535
FILING DATE: 04-OCT-1991
APPLICATION NUMBER: 07/589,701
FILING DATE: 01-OCT-1990
APPLICATION NUMBER: 07/573,616
FILING DATE: 24-AUG-1990
APPLICATION NUMBER: 07/537,198
FILING DATE: 11-JUN-1990
APPLICATION NUMBER: 07/422,383
FILING DATE: 16-OCT-1989
ATTORNEY/AGENT INFORMATION:
NAME: Clough, David W.
REGISTRATION NUMBER: 36,107
REFERENCE/DOCKET NUMBER: 01017/32957A
TELECOMMUNICATION INFORMATION:
TELEPHONE: 312/474-6300
TELEFAX: 312/474-0448
TELEX: <Unknown>
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-09-635-251-16

Query Match 0.7%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 18;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2402 ATAAATGAAAGTGAGATCC 2421
DB 2 ATAAATGCAAGTGATATCC 21

RESULT 9
US-09-056-226-17
Sequence 17, Application US/09056226B
Patent No. 6177614
GENERAL INFORMATION:
APPLICANT: Colasanti, Joseph J.
APPLICANT: Sundaresan, Venkatesan
TITLE OF INVENTION: Control of Floral Induction in Plants
FILE REFERENCE: CSHL94-0444
CURRENT APPLICATION NUMBER: US/09/056,226B
CURRENT FILING DATE: 1998-04-07
EARLIER APPLICATION NUMBER: US 09/000,640
EARLIER FILING DATE: 1997-12-30
EARLIER APPLICATION NUMBER: US 08/804,104
EARLIER FILING DATE: 1997-02-20
EARLIER APPLICATION NUMBER: PCT/US96/03466
EARLIER FILING DATE: 1996-03-15
EARLIER APPLICATION NUMBER: US 08/406,186
EARLIER FILING DATE: 1995-03-16
NUMBER OF SEQ ID NOS: 20
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 17
LENGTH: 22
TYPE: DNA
ORGANISM: Zea mays
FEATURE:
NAME/KEY: misc feature
LOCATION: (16)...(16)
OTHER INFORMATION: 'N' at position 16 represents an insertion of 3
OTHER INFORMATION: nucleotides, producing a mutation.
FEATURE:
NAME/KEY: misc feature
LOCATION: (1)...(22)
OTHER INFORMATION: n = A,T,C or G
US-09-056-226-17

Query Match 0.7%; Score 16.8; DB 1; Length 22;
Best Local Similarity 85.7%; Pred. No. 19;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 364 GCATCTCTCCGCCCTCCAGG 384
DB 2 GCATCTCTCTCCGCCCTCCAGG 22

RESULT 10
US-09-467-082-10/c
Sequence 10, Application US/09467082
GENERAL INFORMATION:
APPLICANT: Bretz P. Monia
APPLICANT: Lex M. Cowgert
TITLE OF INVENTION: ANTISENSE MODULATION OF PKA CATALYTIC SUBUNIT C-ALPHA EXPRESSION
FILE REFERENCE: RTS-0088
CURRENT APPLICATION NUMBER: US/09/467,082
CURRENT FILING DATE: 1999-12-17
NUMBER OF SEQ ID NOS: 49

SEQ ID NO 10
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-467-082-10

Query Match 0.7%; Score 16.4; DB 1; Length 20;
Best Local Similarity 94.4%; Pred. No. 20;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 68 CTGGCCCGCCGCCGCGCAGC 85
DB 20 CCGGCCCGCCGCCGCGCAGC 3

RESULT 11
US-09-288-339-39
Sequence 39, Application US/09288339
Patent No. 6436399
GENERAL INFORMATION:
APPLICANT: Rikihisa, Yasuko
APPLICANT: Zhi, Ning
APPLICANT: Ohashi, No. 6436399
TITLE OF INVENTION: Nucleic Acid Encoding the Major Outer Membrane Protein of
TITLE OF INVENTION: the Causative Agent of Human Granulocytic Ehrlichiosis
TITLE OF INVENTION: and Peptides Encoded Thereby
FILE REFERENCE:
CURRENT APPLICATION NUMBER: US/09/288,339
CURRENT FILING DATE: 1999-04-08
NUMBER OF SEQ ID NOS: 44
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 39
LENGTH: 21
TYPE: DNA
ORGANISM: Primer pnf12
US-09-288-339-39

Query Match 0.7%; Score 16.4; DB 1; Length 21;
Best Local Similarity 94.4%; Pred. No. 21;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 563 GTTGACTGGAACACACC 580
DB 4 GTTGACTGGAACACTCC 21

RESULT 12
US-08-791-883-5
Sequence 5, Application US/08791883
Patent No. 5879890
GENERAL INFORMATION:
APPLICANT: LAKEN, STEVE
APPLICANT: GRUBER, STEPHEN
APPLICANT: PETERSEN, GLORIA
APPLICANT: KINZLER, KENNETH
APPLICANT: VOGELSTEIN, BERT
TITLE OF INVENTION: APC MUTATION ASSOCIATED WITH
TITLE OF INVENTION: FAMILIAL COLORECTAL CANCER IN ASHKENAZI JEWS
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Banner & Witcoff, Ltd.
STREET: 1001 G Street, N.W.
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20001
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0

```

; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/791,883
; FILING DATE: 31-JAN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A
; REGISTRATION NUMBER: 32,145
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; TELEX: 97430 BMB UT
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-791-883-5

```

```

Query Match          0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 25;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1040 AGCTGACCTGGTCCCATC 1058
DB      1 AGCTGACCTAGTTCATC 19

```

```

RESULT 13
; US-09-023-673-5
; Sequence 5, Application US/09023673
; Patent No. 6033461
; GENERAL INFORMATION:
; APPLICANT: LAKEN, STEVE
; APPLICANT: GRUBER, STEPHEN
; APPLICANT: PETERSEN, GLORIA
; APPLICANT: KINZLER, KENNETH
; APPLICANT: VOGELSTEIN, BERT
; TITLE OF INVENTION: APC MUTATION ASSOCIATED WITH
; TITLE OF INVENTION: FAMILIAL COLORECTAL CANCER IN ASHKENAZI JEWS
; NUMBER OF SEQUENCES: 11
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Ltd.
; STREET: 1001 G Street, N.W.
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20001
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/023,673
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/791,883
; FILING DATE: 31-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A
; REGISTRATION NUMBER: 32,145
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; TELEX: 97430 BMB UT
; INFORMATION FOR SEQ ID NO: 5:

```

```

; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-023-673-5

```

```

Query Match          0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 25;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1040 AGCTGACCTGGTCCCATC 1058
DB      1 AGCTGACCTAGTTCATC 19

```

```

RESULT 14
; US-09-375-318-80/c
; Sequence 80, Application US/09375318
; Patent No. 6468791
; GENERAL INFORMATION:
; APPLICANT: Tanzi, Rudolph E.
; APPLICANT: Schellenberg, Gerard D.
; APPLICANT: Masco, Wilma
; APPLICANT: Levy-Ishad, Ephrat
; APPLICANT: Bird, Thomas D.
; APPLICANT: Galas, David J.
; TITLE OF INVENTION: CHROMOSOME 1 GENE AND GENE PRODUCTS RELATED TO
; TITLE OF INVENTION: ALZHEIMER'S DISEASE
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED AND BEERY LLP
; STREET: 701 Fifth Ave, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/375,318
; FILING DATE: 16-Aug-1999
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Verna, James M.
; REGISTRATION NUMBER: 33,287
; REFERENCE/DOCKET NUMBER: 920010.571C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4800
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 80:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 80:
; US-09-375-318-80

```

```

Query Match          0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 25;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY      1842 CCAAGGGAGAGAGCTTGAG 1860
DB      19 CCAAGGGAGAGAGCTTGAG 1

```

```

RESULT 15
US-09-540-257B-22/c

```

```
; Sequence 22, Application US/09540257B
; Patent No. 6518012
; GENERAL INFORMATION:
; APPLICANT: Tomasi, Thomas
; TITLE OF INVENTION: Method for Regulating the Expression of MHC Antigens and
; FILE REFERENCE: 03551.0048
; CURRENT APPLICATION NUMBER: US/09/540,257B
; PRIOR FILING DATE: 2000-03-31
; PRIOR APPLICATION NUMBER: US 60/146,275; US 60/127,591
; PRIOR FILING DATE: 1999-07-29; 1999-04-02
; NUMBER OF SEQ ID NOS: 26
; SEQ ID NO 22
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Forward primer for Mouse CD40
US-09-540-257B-22

Query Match      0.7%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 25;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1999 GCAATGACACCTGACAGG 2017
Db      19 GCAAGACACATGCGCGG 1

RESULT 16
US-09-344-001-19
; Sequence 19, Application US/093444001
; Patent No. 6054440
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF JUN N-TERMINAL KINASE KINASE-2 EXPRESSION
; FILE REFERENCE: RTS-0067
; CURRENT APPLICATION NUMBER: US/09/344,001
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-001-19

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2045 CAGGAGATGCCGCCACC 2063
Db      1 CAGGAGAGCGCCGCCATC 19

RESULT 17
US-09-344-001-20
; Sequence 20, Application US/093444001
; Patent No. 6054440
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF JUN N-TERMINAL KINASE KINASE-2 EXPRESSION
; FILE REFERENCE: RTS-0067
; CURRENT APPLICATION NUMBER: US/09/344,001
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-344-001-20

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2043 TCCAGGAGATGCCGCCA 2061
Db      1 TCCAGGAGAGCGCCGCCA 19

RESULT 18
US-08-771-737-8/c
; Sequence 8, Application US/08771737
; Patent No. 6323000
; GENERAL INFORMATION:
; APPLICANT: Briggs, Clark A.
; APPLICANT: Gopalakrishnan, Murali
; APPLICANT: McKenna, David G.
; APPLICANT: Monteggia, Lisa M.
; APPLICANT: Roch, Jean-Marc
; APPLICANT: Sullivan, James P.
; APPLICANT: Touma, Edward
; APPLICANT: Abbott Laboratories
; TITLE OF INVENTION: A VARIANT HUMAN ALPHA 7 ACETYLCHOLINE
; FILE REFERENCE: 6017.US.01
; CURRENT APPLICATION NUMBER: US/08/771,737
; CURRENT FILING DATE: 1996-12-20
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FASTSEQ for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapien
US-08-771-737-8

Query Match      0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      819 GCGAAGCTCCGATGCTG 837
Db      20 GCGAAGCTCCGATGCTG 2

RESULT 19
US-09-112-580-196
; Sequence 196, Application US/09112580
; Patent No. 6610539
; GENERAL INFORMATION:
; APPLICANT: Wright, Jim A.
; APPLICANT: Young, Aiping
; APPLICANT: DUGOURD, Dominique
; TITLE OF INVENTION: ANTISENSE OLIGONUCLEOTIDE SEQUENCES AS INHIBITORS OF
; FILE REFERENCE: 032396-016
; CURRENT APPLICATION NUMBER: US/09/112,580
; CURRENT FILING DATE: 1998-07-09
; EARLIER APPLICATION NUMBER: US 60/052,160
; EARLIER FILING DATE: 1997-07-10
; NUMBER OF SEQ ID NOS: 265
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 196
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Escherichia coli
US-09-112-580-196

Query Match      0.7%; Score 15.8; DB 1; Length 20;
```

Best Local Similarity 89.5%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1345 AGCAGCAGCAGCAGCTTGG 1363
Db 2 AGCAGCAGCAGCAGCTTGG 20

RESULT 20

US-09-954-936-8/C
; Sequence 8, Application US/09954936
; Patent No. 6683157
; GENERAL INFORMATION:
; APPLICANT: Briggs, Clark A.
; APPLICANT: Gopalakrishnan, Murali
; APPLICANT: McKenna, David G.
; APPLICANT: Monteggia, Lisa M.
; APPLICANT: Roch, Jean-Marc
; APPLICANT: Sullivan, James P.
; APPLICANT: Touma, Edward
; APPLICANT: Abbott Laboratories
; TITLE OF INVENTION: A VARIANT HUMAN ALPHA 7 ACETYLCHOLINE
; RECEPTOR SUBUNIT, AND METHODS OF PRODUCTION AND USES THEREOF
; FILE REFERENCE: 6017.US.01
; CURRENT APPLICATION NUMBER: US/09/954,936
; PRIOR FILING DATE: 2001-09-18
; PRIOR APPLICATION NUMBER: 08/771,737
; PRIOR FILING DATE: 1996-12-20
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapien
US-09-954-936-8

Query Match 0.7%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 27;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 819 GGCAGCTCCGAGATGCTG 837
Db 20 GGCAGCTCCGAGATGCTG 2

RESULT 21

US-09-657-472-1049
; Sequence 1049, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolik, Stacey
; APPLICANT: Daley, George O.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; PRIOR FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1049
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-1049

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 28;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 745 GCACTTCAGCAGCAGGCCA 765
Db 1 GCACTTCAGCAGCAGGCCA 21

RESULT 22

US-09-657-472-1053
; Sequence 1053, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolik, Stacey
; APPLICANT: Daley, George O.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; PRIOR FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 1053
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-1053

Query Match 0.7%; Score 15.8; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 28;
Matches 17; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 745 GCACTTCAGCAGCAGGCCA 765
Db 1 GCACTTCAGCAGCAGGCCA 21

RESULT 23

US-09-866-108A-2021
; Sequence 2021, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Shangang
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See file Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2021
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108A-2021

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 731 CCTGGGTCCTCTGCA 747
DB 1 CCTGGGTCCTCTGCA 17

RESULT 24
US-09-866-108A-2842
; Sequence 2842, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECMCA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See file Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecmca Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2842
; LENGTH: 17
; TYPE: DNA
```

```

; ORGANISM: Homo sapiens
; US-09-866-108A-2842

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 17;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1974 GGCTCCAGATGAGGA 1990
DB 1 GGCTCCAGATGAGGA 17

RESULT 25
US-09-433-699-12
; Sequence 12, Application US/09433699B
; Patent No. 6165786
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowest
; TITLE OF INVENTION: ANTISENSE MODULATION OF NUCLEOLIN EXPRESSION
; FILE REFERENCE: RTS-0109
; CURRENT APPLICATION NUMBER: US/09/433,699B
; CURRENT FILING DATE: 1999-11-03
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 12
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
; US-09-433-699-12

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1120 GATGGTCAGAGAAG 1136
DB 2 GATGGTCAGAGAAG 18

RESULT 26
US-09-579-692B-2
; Sequence 2, Application US/09579692B
; Patent No. 6689875
; GENERAL INFORMATION:
; APPLICANT: Vlaams Internationaal Instituut voor Biotechnol
; TITLE OF INVENTION: Molecular characterisation of chromosome translocation t(11,18)
; FILE REFERENCE: PMA/MALT/V043; 2676-4090.1
; CURRENT APPLICATION NUMBER: US/09/579,692B
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/138,834
; PRIOR FILING DATE: 1999-06-09
; NUMBER OF SEQ ID NOS: 60
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer Mult1
; US-09-579-692B-2

Query Match
Best Local Similarity 94.1%; Score 15.4; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 739 CCTTGTGCACTTCAGC 755
DB 1 CCTTGTGCACTTCATC 17
```

RESULT 27
US-08-222-177A-213
; Sequence 213, Application US/08222177A
; Patent No. 5582979
; GENERAL INFORMATION:
; APPLICANT: Weber, James L.
; TITLE OF INVENTION: LENGTH POLYMORPHISMS IN
; TITLE OF INVENTION: (dc-da)n (dg-dt)n SEQUENCES AND METHODS OF USING SAME
; NUMBER OF SEQUENCES: 460
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dewitt Ross & Stevens, S.C.
; STREET: 8000 Excelsior Drive, Suite 401
; CITY: Madison
; STATE: Wisconsin
; COUNTRY: USA
; ZIP: 53717-1914
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/222,177A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/341,562
; FILING DATE: 21-APR-1989
; ATTORNEY/AGENT INFORMATION:
; NAME: Sara, Charles S.
; REGISTRATION NUMBER: 30,492
; REFERENCE/DOCKET NUMBER: 09865,601
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (608) 831-2100
; TELEFAX: (608) 831-2106
; TELEX:
; INFORMATION FOR SEQ ID NO: 213:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; IMMEDIATE SOURCE:
; CLONE: mfd56p1
; US-08-222-177A-213
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 660 CTGGTGAAGACACACACT 679
DB 1 CTGTGTAATTCAAAACACT 20
RESULT 28
US-08-117-952-543/c
; Sequence 543, Application US/08117952
; Patent No. 5851760
; GENERAL INFORMATION:
; APPLICANT: Evans, Glen A.
; APPLICANT: Smith, Michael W.
; TITLE OF INVENTION: METHOD FOR GENERATION OF SEQUENCE
; TITLE OF INVENTION: SAMPLED MAPS OF COMPLEX GENOMES
; NUMBER OF SEQUENCES: 797
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
; STREET: 444 South Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90071

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,952
; FILING DATE: 07-SEP-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/078,471
; FILING DATE: 15-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Reiter, Stephen E.
; REGISTRATION NUMBER: 31,192
; REFERENCE/DOCKET NUMBER: P41 9423
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-546-4737
; TELEFAX: 619-546-9392
; INFORMATION FOR SEQ ID NO: 543:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Oligonucleotide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-117-952-543
Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 499 TCCATCATCATATTCCTGC 518
DB 20 TCTTCATGTCACATTCGTC 1
RESULT 29
US-09-021-701-552/c
; Sequence 552, Application US/09021701
; Patent No. 6251588
; GENERAL INFORMATION:
; APPLICANT: Shannon, Karen W.
; APPLICANT: Wolber, Paul K.
; APPLICANT: Delenstarr, Glenda C.
; APPLICANT: Webb, Peter G.
; APPLICANT: Kincaid, Robert H.
; TITLE OF INVENTION: Methods for evaluating oligonucleotide
; TITLE OF INVENTION: probe sequences
; NUMBER OF SEQUENCES: 1165
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
; STREET: 3000 Hanover Street
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/021,701
; FILING DATE: 10-FEB-1998
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Choi, Wendy A.
; REGISTRATION NUMBER: 36,697
; REFERENCE/DOCKET NUMBER: 10971464-1
; TELECOMMUNICATION INFORMATION:

TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 552:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-09-021-701-552

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1543 TAAAGAGAAAAGTCAGTA 1562
DB 20 TAAAAAGAAAATCAGTA 1

RESULT 30
US-09-021-701-553/C
Sequence 553, Application US/09021701
Patent No. 6251588
GENERAL INFORMATION:
APPLICANT: Shannon, Karen W.
APPLICANT: Wolber, Paul K.
APPLICANT: Delenstarr, Glenda C.
APPLICANT: Webb, Peter G.
APPLICANT: Kincaid, Robert H.
TITLE OF INVENTION: Methods for evaluating oligonucleotide
TITLE OF INVENTION: probe sequences
NUMBER OF SEQUENCES: 1165
CORRESPONDENCE ADDRESS:
ADDRESSER: Records Manager, Legal Department, Hewlett-Packard Company W/S 20
STREET: 3000 Hanover Street
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304
COMPUTER READABLE FORM:
MEDIUM TYPE: floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/021,701
FILING DATE: 10-FEB-1998
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Choi, Wendy A.
REGISTRATION NUMBER: 36,697
REFERENCE/DOCKET NUMBER: 10971464-1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-236-2386
TELEFAX: 650-852-8063
INFORMATION FOR SEQ ID NO: 553:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-09-021-701-553

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1542 TTAAGAGAAAAGTCAGT 1561
DB 20 TAAAAAGAAAATCAGT 1

RESULT 31
US-09-593-711A-18
Sequence 18, Application US/09593711A
Patent No. 6271030
GENERAL INFORMATION:
APPLICANT: Brett P. Monia
APPLICANT: Madeline M. Butler
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF C/EBP BETA EXPRESSION
FILE REFERENCE: RTS-0118
CURRENT APPLICATION NUMBER: US/09/593,711A
CURRENT FILING DATE: 2000-06-14
NUMBER OF SEQ ID NOS: 244
SEQ ID NO 18
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-593-711A-18

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 21 CGGCTGCCGCTCTGCTGGG 40
DB 1 CTGCTGCCGCTCTGCTGGG 20

RESULT 32
US-09-716-161A-59/C
Sequence 59, Application US/09716161A
Patent No. 6355482
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Susan M. Freiler
TITLE OF INVENTION: ANTISENSE MODULATION OF INTEGRIN BETA 4 BINDING PROTEIN EXPRESSION
FILE REFERENCE: RTS-0176
CURRENT APPLICATION NUMBER: US/09/716,161A
CURRENT FILING DATE: 2000-11-07
NUMBER OF SEQ ID NOS: 89
SEQ ID NO 59
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-716-161A-59

Query Match 0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1633 TCAGCTACCTCTCTTCTTC 1652
DB 20 TGAGCTGCTCTCTTCTTC 1

RESULT 33
US-09-629-645A-101/C
Sequence 101, Application US/09629645A
Patent No. 6365354
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett
APPLICANT: Jacqueline Wyatt
TITLE OF INVENTION: ANTISENSE MODULATION OF LYSOPHOSPHOLIPASE I EXPRESSION
FILE REFERENCE: RTS-0137

```

; CURRENT APPLICATION NUMBER: US/09/629,645A
; CURRENT FILING DATE: 2000-07-31
; NUMBER OF SEQ ID NOS: 164
; SEQ ID NO 101
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-629-645A-101

Query Match      0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      4 CCGGAACGCGAGCGCGG 23
Db      20 CCGGAAGCCACCGCGCGG 1

RESULT 34
US-09-506-073-80/C
; Sequence 80, Application US/09506073
; Patent No. 6410518
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: Antisense Oligonucleotide Modulation of raf Gene Expression
; FILE REFERENCE:
; CURRENT APPLICATION NUMBER: US/09/506,073
; CURRENT FILING DATE: 2000-02-18
; EARLIER APPLICATION NUMBER: US 09/143,214
; EARLIER FILING DATE: 1998-08-28
; EARLIER APPLICATION NUMBER: PCT/US98/13961
; EARLIER FILING DATE: 1998-07-06
; EARLIER APPLICATION NUMBER: US 08/888,982
; EARLIER FILING DATE: 1997-07-07
; EARLIER APPLICATION NUMBER: US 08/756,806
; EARLIER FILING DATE: 1996-11-26
; EARLIER APPLICATION NUMBER: PCT/US95/07111
; EARLIER FILING DATE: 1995-05-31
; EARLIER APPLICATION NUMBER: US 08/250,856
; EARLIER FILING DATE: 1994-05-31
; NUMBER OF SEQ ID NOS: 130
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-09-506-073-80

Query Match      0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      1873 CCGTGTGTGAGGCGAGTNG 1892
Db      20 CAGTGTGTGAGGCGAGCAG 1

RESULT 35
US-09-198-452A-3356
; Sequence 3356, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Grifais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; TITLE OF INVENTION: thereof and uses thereof, in particular for the diagnosis, prevention
; FILE REFERENCE: 9710-003-999
; CURRENT APPLICATION NUMBER: US/09/198,452A
; CURRENT FILING DATE: 1998-11-24
; NUMBER OF SEQ ID NOS: 6849
```

```

; SEQ ID NO 3356
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-3356

Query Match      0.6%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 35;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      386 CCTCTTCTCTGTCACCTGCG 405
Db      1 CCTCTTCTCTATCAGTTGC 20

RESULT 36
US-08-679-645-153
; Sequence 153, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwigen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 153:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-153

Query Match      0.6%; Score 15; DB 1; Length 17;
```

Best Local Similarity 86.7%; Pred. No. 31;
Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 778 AGAAGTCCCGACCA 792

DB 3 AGAAGTCCCGACCA 17

RESULT 37

US-08-679-645-155

Sequence 155, Application US/08679645

Patent No. 6350934

GENERAL INFORMATION:

APPLICANT: Zwick, Michael G.

APPLICANT: Edington, Brent E.

APPLICANT: McSwiggen, James A.

APPLICANT: Merlo, Patricia Ann Owens

APPLICANT: Guo, Lining

APPLICANT: Skokut, Thomas A.

APPLICANT: Folkerth, Otto

APPLICANT: Merlo, Donald J.

TITLE OF INVENTION: COMPOSITION AND METHODS FOR

TITLE OF INVENTION: MODULATION OF GENE EXPRESSION

TITLE OF INVENTION: IN PLANTS

NUMBER OF SEQUENCES: 1263

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/679,645

FILING DATE: July 12, 1996

CLASSIFICATION: 800

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 60/001,135

FILING DATE: July 13, 1995

APPLICATION NUMBER: 08/300,726

FILING DATE: September 2, 1994

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 219/247

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 155:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-679-645-155

Query Match 0.6%; Score 15; DB 1; Length 17;

Best Local Similarity 86.7%; Pred. No. 31;

Matches 13; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY 778 AGAAGTCCCGACCA 792

DB 2 AGAAGTCCCGACCA 16

RESULT 38

US-08-189-199A-5

Sequence 5, Application US/08189199A

Patent No. 5449609

GENERAL INFORMATION:

APPLICANT: Younkun, Donald P.

APPLICANT: Pleasure, David

TITLE OF INVENTION: Methods for Screening for Neurotoxicity

TITLE OF INVENTION: Using a Clonal Human Teratocarcinoma Cell Line

NUMBER OF SEQUENCES: 7

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5449609x1e

STREET: One Liberty Place - 46th Floor

CITY: Philadelphia

STATE: PA

COUNTRY: USA

ZIP: 19103

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/189,199A

FILING DATE:

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Gaumond, Rebecca R.

REGISTRATION NUMBER: 35,152

REFERENCE/DOCKET NUMBER: CH-0407

TELECOMMUNICATION INFORMATION:

TELEPHONE: 215-568-3100

TELEFAX: 215-564-3439

INFORMATION FOR SEQ ID NO: 5:

SEQUENCE CHARACTERISTICS:

LENGTH: 18 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

US-08-189-199A-5

Query Match 0.6%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 37;

Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 ACCCTGCGAGCCGCAAG 1010

DB 1 AACCTGCGAGCCGCAAG 18

RESULT 39

US-09-213-719-65

Sequence 65, Application US/09213719B

Patent No. 6150162

GENERAL INFORMATION:

APPLICANT: C. Frank Bennett

APPLICANT: Lex M. Cowsett

TITLE OF INVENTION: ANTISENSE MODULATION OF CD44 EXPRESSION

FILE REFERENCE: RTS-0006

CURRENT APPLICATION NUMBER: US/09/213,719B

CURRENT FILING DATE: 1998-12-17

NUMBER OF SEQ ID NOS: 91

SEQ ID NO 65

LENGTH: 18

TYPE: DNA

ORGANISM: Artificial Sequence

OTHER INFORMATION: Antisense Oligonucleotide

US-09-213-719-65

Query Match 0.6%; Score 14.8; DB 1; Length 18;

Best Local Similarity 88.9%; Pred. No. 37;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 502 TCATGACATATTTCTGCA 519
DB 1 TCATGTCACATTTCTGCA 18

RESULT 40

US-08-711-628-1
Sequence 1, Application US/08711628
Patent No. 6713247
GENERAL INFORMATION:
APPLICANT: Sah, Dinah W.Y.
APPLICANT: Gage, Fred H.
APPLICANT: Ray, Jasodhara
TITLE OF INVENTION: HUMAN CNS CELL LINES AND METHODS OF USE
TITLE OF INVENTION: THEREFOR
NUMBER OF SEQUENCES: 16
CORRESPONDENCE ADDRESS:
ADDRESSEE: SEED and BERRY LLP
STREET: 6300 Columbia Center, 701 Fifth Avenue
CITY: Seattle
STATE: Washington
COUNTRY: USA
ZIP: 98104-7092
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/711,628
FILING DATE: 03-SEP-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Maki, David J.
REGISTRATION NUMBER: 31,392
REFERENCE/DOCKET NUMBER: 860098, 415
TELECOMMUNICATION INFORMATION:
TELEPHONE: (206) 622-4900
TELEFAX: (206) 682-6031
INFORMATION FOR SEQ ID NO: 1:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-711-628-1

Query Match 0.6%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 37;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 993 ACCCTGCGAACCAG 1010
DB 1 AACCTGACAGACCGCAG 18

RESULT 41

US-08-359-705B-22/c
Sequence 22, Application US/08359705B
Patent No. 5844092
GENERAL INFORMATION:
APPLICANT: Presta, Leonard G.
APPLICANT: Shelton, David L.
APPLICANT: Ufer, Roman
TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor Inhibitors
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco

STATE: California
COUNTRY: USA

ZIP: 94080

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: WinPatIn (Genentech)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/359,705B

FILING DATE: 20-Dec-1994

CLASSIFICATION: 424

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/286846

FILING DATE: 08/10/94

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/215139

FILING DATE: 03/18/94

ATTORNEY/AGENT INFORMATION:
NAME: Torchia, PhD., Timothy E.

REGISTRATION NUMBER: 36,700

REFERENCE/DOCKET NUMBER: P0873P2

TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-8674

TELEFAX: 650/952-9881

INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:

LENGTH: 19 base pairs

TYPE: Nucleic Acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-359-705B-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTGGCCGCGAG 2141
DB 19 CTCACCTTGCGCTGCGC 2

RESULT 42

US-08-286-846A-22/c
Sequence 22, Application US/08286846A
Patent No. 5877016
GENERAL INFORMATION:
APPLICANT: Presta, Leonard G.
APPLICANT: Shelton, David L.
APPLICANT: Ufer, Roman
TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor Inhibitors
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/286,846A
FILING DATE: 05-Aug-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Torchia, PhD., Timothy E.
REGISTRATION NUMBER: 36,700
REFERENCE/DOCKET NUMBER: P0873P1
TELECOMMUNICATION INFORMATION:

TELEPHONE: 415/225-8674
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-08-286-846A-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTTGCGCTGGAG 2141
DB 19 CTCACCTTGCGCTGGCG 2

RESULT 43
US-08-457-880A-22/C
Sequence 22, Application US/08457880A
Patent No. 5910574
GENERAL INFORMATION:
APPLICANT: Leonard G. Presta
APPLICANT: David L. Shelton
APPLICANT: Roman Ulfert
TITLE OF INVENTION: HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR
TITLE OF INVENTION: INHIBITORS
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/457,880A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/444,622
FILING DATE: 19-May-1995
APPLICATION NUMBER: 08/286846
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Torchia, Ph.D., Timothy E.
REGISTRATION NUMBER: 36,700
REFERENCE/DOCKET NUMBER: P0873P1C3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-8674
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-08-457-880A-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 2124 CTCAGCCTTGCGCTGGAG 2141
DB 19 CTCACCTTGCGCTGGCG 2

DB 19 CTCACCTTGCGCTGGCG 2

RESULT 44
US-08-444-622A-22/C
Sequence 22, Application US/08444622A
Patent No. 6025166
GENERAL INFORMATION:
APPLICANT: Leonard G. Presta
APPLICANT: David L. Shelton
APPLICANT: Roman Ulfert
TITLE OF INVENTION: HUMAN trk RECEPTORS AND NEUROTROPHIC FACTOR INHIBITORS
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 1 DNA Way
CITY: South San Francisco
STATE: California
COUNTRY: USA
ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Winpatin (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/444,622A
FILING DATE: 19-May-1995
CLASSIFICATION: 424
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/286846
FILING DATE: 5
ATTORNEY/AGENT INFORMATION:
NAME: Torchia, Ph.D., Timothy E.
REGISTRATION NUMBER: 36,700
REFERENCE/DOCKET NUMBER: P0873P1C3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650/225-8674
TELEFAX: 650/952-9881
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-08-444-622A-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTTGCGCTGGAG 2141
DB 19 CTCACCTTGCGCTGGCG 2

RESULT 45
US-08-942-562-22/C
Sequence 22, Application US/08942562
Patent No. 6027927
GENERAL INFORMATION:
APPLICANT: Presta, Leonard G.
APPLICANT: Shelton, David L.
APPLICANT: Ulfert, Roman
TITLE OF INVENTION: Human trk Receptors and Neurotrophic
TITLE OF INVENTION: Factor Inhibitors
NUMBER OF SEQUENCES: 37
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genentech, Inc.
STREET: 460 Point San Bruno Blvd
CITY: South San Francisco
STATE: California
COUNTRY: USA

ZIP: 94080
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/942,562
FILING DATE: 01-OCT-1997
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/444,597
FILING DATE: 19-May-1995
ATTORNEY/AGENT INFORMATION:
NAME: Torchia, Phd., Timothy E.
REGISTRATION NUMBER: 36,780
REFERENCE/DOCKET NUMBER: P0873P1C2
TELEPHONE: 415/225-8674
TELEFAX: 415/952-9881
TELEX: 910/371-7168
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-08-942-562-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTTGCGCTGGAG 2141
DB 19 CTCACCTTGCGCTGGCG 2

RESULT 46
US-09-156-923-22/C
Sequence 22, Application US/09156923
Patent No. 6153189
GENERAL INFORMATION:
APPLICANT: Presta, Leonard G.
APPLICANT: Shelton, David L.
APPLICANT: Urfert, Roman
TITLE OF INVENTION: Human trk Receptors and Neurotrophic Factor Inhibitors
NUMBER OF SEQUENCES: 41
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knodbe, Martens, Olson & Bear
STREET: 620 Newport Center Drive 16th Floor
CITY: Newport Beach
STATE: California
COUNTRY: USA
ZIP: 92660

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: WinPatIn (Genentech)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/156,923
FILING DATE: 18-SEP-1998
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/359,705
FILING DATE: 20-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/286846
FILING DATE: 10-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/215139
FILING DATE: 18-MAR-1994

ATTORNEY/AGENT INFORMATION:
NAME: Dreger, Ginger
REGISTRATION NUMBER: 33,055
REFERENCE/DOCKET NUMBER: GENENT.33CP2C1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 949/760-0404
TELEFAX: 949/760-9502
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: Single
TOPOLOGY: Linear
US-09-156-923-22

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2124 CTCAGCCTTGCGCTGGAG 2141
DB 19 CTCACCTTGCGCTGGCG 2

RESULT 47
US-09-338-907-476
Sequence 476, Application US/09338907
Patent No. 6265346
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Ilya, Chumakov
APPLICANT: Bouguetelret, Lydie
TITLE OF INVENTION: PROSTATE CANCER GENE
FILE REFERENCE: GENSET.18CP1C
CURRENT APPLICATION NUMBER: US/09/338,907
CURRENT FILING DATE: 1999-06-23
EARLIER APPLICATION NUMBER: 08/996,306
EARLIER FILING DATE: 1997-12-22
EARLIER APPLICATION NUMBER: 607/099,658
EARLIER FILING DATE: 1998-09-09
EARLIER APPLICATION NUMBER: 09/218,207
EARLIER FILING DATE: 1998-12-22
NUMBER OF SEQ ID NOS: 578
SOFTWARE: Patent.pm
SEQ ID NO 476
LENGTH: 19
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..15
OTHER INFORMATION: microsequencing oligo for 99-140-130.misl
US-09-338-907-476

Query Match 0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 424 AAAAGCAGTACAGGTCA 441
DB 2 AAAAGCAGTACAGACCA 19

RESULT 48
US-09-218-207-476
Sequence 476, Application US/09218207
Patent No. 6346381
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Ilya, Chumakov
APPLICANT: Bouguetelret, Lydie

```

; TITLE OF INVENTION: Prostate cancer gene
; FILE REFERENCE: GENSET. 018CPI
; CURRENT APPLICATION NUMBER: US/09/218,207
; CURRENT FILING DATE: 1998-12-22
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 476
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..19
; OTHER INFORMATION: microsequencing oligo for 99-140-130.mls1
US-09-218-207-476

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      424 AAAGCAGCTACAGTCA 441
Db      2 AAAGCAGCTACAGACCA 19

RESULT 49
US-08-983-605-55/c
; Sequence 55, Application US/08983605A
; Patent No. 6720137
; GENERAL INFORMATION:
; APPLICANT: Roder, Marion
; TITLE OF INVENTION: Microsatellite Markers for Plants of the Species
; TITLE OF INVENTION: Trifolium aestivum and Tribe Trifoliales and the Use of
; TITLE OF INVENTION: Said Markers
; FILE REFERENCE: 2936.10400
; CURRENT APPLICATION NUMBER: US/08/983,605A
; CURRENT FILING DATE: 1998-05-01
; EARLIER APPLICATION NUMBER: DE 195 25 284.5
; EARLIER FILING DATE: 1995-06-28
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 55
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Trifolium aestivum
US-08-983-605-55

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      1918 ATCTCCCTTCGCCACCC 1935
Db      18 ATCTCCTTCTCCACCC 1

RESULT 50
US-09-696-791-2171/c
; Sequence 2171, Application US/09696791
; Patent No. 6770633
; GENERAL INFORMATION:
; APPLICANT: Robbins, Joan M.
; APPLICANT: Tritz, Richard
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT OF PROLIFERATIVE
; TITLE OF INVENTION: SKIN AND EYE DISEASES
; FILE REFERENCE: 480124.407
; CURRENT APPLICATION NUMBER: US/09/696,791
; CURRENT FILING DATE: 2000-10-25
; NUMBER OF SEQ ID NOS: 4523
```

```

; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 2171
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Cyclin E ribozyme binding site
US-09-696-791-2171

Query Match      0.6%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 39;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy      877 TCAGCCGGAGACCATAG 894
Db      18 TCAGCCAGACCATAG 1

RESULT 51
US-08-464-514-9
; Sequence 9, Application US/08464514
; Patent No. 6265173
; GENERAL INFORMATION:
; APPLICANT: EVANS, RONALD M.
; APPLICANT: MCKEOWN, MICHAEL B.
; APPLICANT: ORO, ANTHONY E.
; APPLICANT: SEGRAVES, WILLIAM A.
; APPLICANT: YAO, TSO-PANG
; TITLE OF INVENTION: MULTIMERIC FORMS OF MEMBERS OF THE
; TITLE OF INVENTION: STEROID/THYROID SUPERFAMILY OF RECEPTORS WITH THE
; TITLE OF INVENTION: ULTRASPACILE RECEPTOR
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSER: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
; STREET: 444 South Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: California
; COUNTRY: United States
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/464,514
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/907,908
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Reiter, Stephen B.
; REGISTRATION NUMBER: 31192
; REFERENCE/DOCKET NUMBER: P41 9321
; TELEPHONE: (619) 546-4737
; TELEFAX: (619) 546-9392
; INFORMATION FOR SEQ ID NO: 9:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-464-514-9

Query Match      0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Oy      587 AGGTGACGAGAGTCA 602
Db      1 AGGTGACGAGAGTCA 16
```

RESULT 52
US-08-486-403-9
Sequence 9, Application US/08486403
Patent No. 6281330
GENERAL INFORMATION:
APPLICANT: EVANS, RONALD M.
APPLICANT: MCKEOWN, MICHAEL B.
APPLICANT: ORO, ANTHONY E.
APPLICANT: SEGRAVES, WILLIAM A.
APPLICANT: YAO, TSO-PANG
TITLE OF INVENTION: MULTIMERIC FORMS OF MEMBERS OF THE
TITLE OF INVENTION: STEROID/THYROID SUPERFAMILY OF RECEPTORS WITH THE
TITLE OF INVENTION: ULTRASPIRACLE RECEPTOR
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSEE: PRETTY, SCHROEDER, BRUEGGEMANN & CLARK
STREET: 444 South Flower Street, Suite 2000
CITY: Los Angeles
STATE: California
COUNTRY: United States
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/486,403
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/907,908
FILING DATE: 02-JUL-1992
ATTORNEY/AGENT INFORMATION:
NAME: Reiter, Stephen E.
REGISTRATION NUMBER: 31192
REFERENCE/DOCKET NUMBER: P41 9321
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 546-4737
TELEFAX: (619) 546-9392
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-486-403-9

Query Match 0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 587 AGTGGCAGAGGTCA 602
|||||
DB 1 AGTGCACAGAGGTCA 16

RESULT 53
US-07-672-530C-39
Sequence 39, Application US/07672530C
Patent No. 6492137
GENERAL INFORMATION:
APPLICANT: SUICOV, HENRY M
APPLICANT: EVANS, RONALD M
APPLICANT: UMESONO, KAZUHIKO
TITLE OF INVENTION: RESPONSE ELEMENT COMPOSITIONS AND ASSAYS EMPLOYING SAME
FILE REFERENCE: 088802/1552
CURRENT APPLICATION NUMBER: US/07/672,530C
CURRENT FILING DATE: 1991-03-19
PRIOR APPLICATION NUMBER: 07/438,757
PRIOR FILING DATE: 1989-11-16

NUMBER OF SEQ ID NOS: 51
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 39
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence:
US-07-672-530C-39

Query Match 0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 587 AGTGGCAGAGGTCA 602
|||||
DB 1 AGTGCACAGAGGTCA 16

RESULT 54
US-09-479-005A-1/c
Sequence 1, Application US/09479005A
Patent No. 6656731
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Nucleic Acid Catalysts with Endonuclease Activity
FILE REFERENCE: MBHB00-884-C
CURRENT APPLICATION NUMBER: US/09/479,005A
CURRENT FILING DATE: 2000-01-07
PRIOR APPLICATION NUMBER: US 09/444,209
PRIOR FILING DATE: 1999-11-19
PRIOR APPLICATION NUMBER: US 09/159,274
PRIOR FILING DATE: 1998-09-22
PRIOR APPLICATION NUMBER: US 60/059,473
PRIOR FILING DATE: 1997-09-22
NUMBER OF SEQ ID NOS: 1208
SOFTWARE: PatentIn version 3.0
SEQ ID NO 1
LENGTH: 16
TYPE: RNA
ORGANISM: Homo sapiens
US-09-479-005A-1

Query Match 0.6%; Score 14.4; DB 1; Length 16;
Best Local Similarity 93.8%; Pred. No. 39;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 16 CGCCGCGGCTGCGGCC 31
|||||
DB 16 CGCCGCGGCGCGGCC 1

RESULT 55
US-08-758-306-147/c
Sequence 147, Application US/08758306
Patent No. 5807743
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: McSwigen, James A.
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES
TITLE OF INVENTION: ASSOCIATED WITH
TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
NUMBER OF SEQUENCES: 1379
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.

ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/758,306
FILING DATE: December 3, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 212/132
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 147:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-758-306-147

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1379 GGTCTGAGGTGAC 1394
Db 16 GGTCTGAGGTGAC 1

RESULT 56
US-09-866-108A-798/c
Sequence 798, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER-OF-SEQ ID NOS: 15755
SOFTWARE: Aeoica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 798
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-798

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1400 CAGCTTCGGGCGCAA 1415
Db 17 CAGCTTCGGGCGCAA 2

RESULT 57
US-09-866-108A-799/c
Sequence 799, Application US/09866108A
Patent No. 6686188
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
FILE REFERENCE: AEOICA-7
CURRENT APPLICATION NUMBER: US/09/866,108A
CURRENT FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263.6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00663
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER-OF-SEQ ID NOS: 15755
SOFTWARE: Aeoica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 799
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-799

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 1400 CAGCTTCGGGCGCAA 1415
|||||

Db 16 CAGCTTCGGCGCCA 1

RESULT 58
US-09-866-108A-1294
Sequence 1294, Application US/09866108A
Patent No. 6686188

GENERAL INFORMATION:
APPLICANT: GU Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeomica Sequence Listing Engine

PATENT NO. 6686188

SEQ ID NO 1294

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-1294

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1086 AAGCAGTGATCTTCG 1101
|||||

Db 2 AAGCAGTGATCTTCG 17
|||||

RESULT 59
US-09-866-108A-1295
Sequence 1295, Application US/09866108A
Patent No. 6686188

GENERAL INFORMATION:
APPLICANT: GU Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeomica Sequence Listing Engine

PATENT NO. 6686188

SEQ ID NO 1295

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-1295

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1086 AAGCAGTGATCTTCG 1101
|||||

Db 1 AAGCAGTGATCTTCG 16
|||||

RESULT 60
US-09-866-108A-2020
Sequence 2020, Application US/09866108A
Patent No. 6686188

GENERAL INFORMATION:
APPLICANT: GU Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharron G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeomica Sequence Listing Engine

PATENT NO. 6686188

SEQ ID NO 1295

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-1295

Query Match 0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1086 AAGCAGTGATCTTCG 1101
|||||

Db 1 AAGCAGTGATCTTCG 16
|||||

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2020
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2020

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      731 CTTGGGTGCTTCTGC 746
Db      2 CTTGGGTGCTTCTGC 17

RESULT 61
US-09-866-108A-2022
; Sequence 2022, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2022
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2022

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      732 CTTGGGTGCTTCTGCA 747
```

```

Db      1 CTTGGGTGCTTCTGCA 16

RESULT 62
US-09-866-108A-2841
; Sequence 2841, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2841
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2841

Query Match      0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1974 GGCTTCAGATGAGG 1989
Db      2 GGCTTCAGATGAGG 17

RESULT 63
US-09-866-108A-2843
; Sequence 2843, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
```

```

; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2843
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2843

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1975 GCCTCCAGATGAGGA 1990
Db      1 GCCTCGAGATGAGGA 16

RESULT 64
US-09-866-108A-6608/c
; Sequence 6608, Application US/09866108A
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6609
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6609
```

```

; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6608
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6608

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1975 GCCTCCAGATGAGGA 1990
Db      17 GCCTCGAGATGAGGA 2

RESULT 65
US-09-866-108A-6609/c
; Sequence 6609, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6609
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6609

Query Match          0.6%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 41;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

OY 1975 GCCTCCGAGATGAGCA 1990
|||
Db 16 GCCTCCGAGATGAGCA 1

RESULT 66
US-08-758-306-523/c
; Sequence 523, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: Storage
; COMPUTER: IBM Compatibld
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 523:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-758-306-523

Query Match 0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 44;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1379 GGCTCTGAGGTGAGC 1394
|||
Db 18 GGCTCTGAGGTGAGC 3

RESULT 67
US-09-177-359-15/c
; Sequence 15, Application US/09177359B
; Patent No. 6183963
; GENERAL INFORMATION:
; APPLICANT: Sinner, Daniel
; APPLICANT: Labuda, Damian
; TITLE OF INVENTION: DETECTION OF CYP1A, CYP3A4, CYP2D6 AND
; TITLE OF INVENTION: NAT2 VARIANTS BY PCR-ALBELE-SPECIFIC OLIGONUCLEOTIDE (ASO)

; TITLE OF INVENTION: ASSAY
; FILE REFERENCE: 12667-17"US" FC/1d
; CURRENT APPLICATION NUMBER: US/09/177,359B
; CURRENT FILING DATE: 1998-10-23
; NUMBER OF SEQ ID NOS: 37
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 15
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: cDNA for use as primers
US-09-177-359-15

Query Match 0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 44;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 414 TCCAGGTGAGAAAGC 429
|||
Db 16 TCCAGGTGAGAAAGC 1

RESULT 68
US-09-474-922A-46/c
; Sequence 46, Application US/09474922A
; Patent No. 6187586
; GENERAL INFORMATION:
; APPLICANT: Bretz P. Monia
; APPLICANT: Lex M. Cowart
; APPLICANT: Richard A. Roth
; TITLE OF INVENTION: ANTISENSE MODULATION OF Akt-3 EXPRESSION
; FILE REFERENCE: RTS-0036
; CURRENT APPLICATION NUMBER: US/09/474,922A
; CURRENT FILING DATE: 1999-12-29
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 46
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-474-922A-46

Query Match 0.6%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 44;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1068 GGAGAGAAATGAGTGT 1083
|||
Db 16 GGAGAGAAATGAGTGT 1

RESULT 69
US-08-974-549A-479
; Sequence 479, Application US/08974549A
; Patent No. 6166178
; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; APPLICANT: Linsmer, Joachim
; APPLICANT: Nakamura, Toru
; APPLICANT: Chapman, Karen B.
; APPLICANT: Morin, Gregg B.
; APPLICANT: Harley, Calvin B.
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: Human Telomerase Catalytic Subunit
; NUMBER OF SEQUENCES: 727
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA

```

; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/974,549A
; FILING DATE: 19-NOV-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/844,419
; FILING DATE: 18-APR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/846,017
; FILING DATE: 25-APR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/851,843
; FILING DATE: 06-MAY-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/854,050
; FILING DATE: 09-MAY-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/911,312
; FILING DATE: 14-AUG-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/912,951
; FILING DATE: 14-AUG-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/915,503
; FILING DATE: 14-AUG-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: NO PCT/US97/17618
; FILING DATE: 01-OCT-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: NO PCT/US97/17885
; FILING DATE: 01-OCT-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph Ted
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-002610US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 479:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY:
; LOCATION: 1..17
; OTHER INFORMATION: /note="Nam2 primer"
US-08-974-549A-479

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 145 AGCCTGGCCCCGG 158
Db 1 AGCCTGGCCCCGG 14

```

```

; GENERAL INFORMATION:
; APPLICANT: Cech, Thomas R.
; APPLICANT: Lingner, Joachim
; APPLICANT: Nakamura, Toru
; APPLICANT: Chapman, Karen B.
; APPLICANT: Morin, Gregg B.
; APPLICANT: Harley, Calvin
; APPLICANT: Andrews, William H.
; TITLE OF INVENTION: HUMAN TELOMERASE CATALYTIC SUBUNIT:
; TITLE OF INVENTION: THERAPEUTIC METHODS
; NUMBER OF SEQUENCES: 335
; CORRESPONDENCE ADDRESS:
; ADDRESS: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, 8th Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: United States of America
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/912,951
; FILING DATE: 14-AUG-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/854,050
; FILING DATE: 09-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/851,843
; FILING DATE: 06-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/846,017
; FILING DATE: 25-APR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/844,419
; FILING DATE: 18-APR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/724,643
; FILING DATE: 01-OCT-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 015389-002600US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 246:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
US-08-912-951-246

Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 145 AGCCTGGCCCCGG 158
Db 1 AGCCTGGCCCCGG 14

```

RESULT 71

```

US-09-402-181B-479
Sequence 479: Application US/09402181B
Patent No. 6610839
GENERAL INFORMATION:
APPLICANT: Cech, Thomas R.
Lingner, Joachim
Nakamura, Toru
Chapman, Karen B.
Morin, Gregg B.
Harley, Calvin B.
Andrews, William H.
TITLE OF INVENTION: Human Telomerase Catalytic Subunit
NUMBER OF SEQUENCES: 633
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend and Crew LLP
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/402,181B
FILING DATE: 29-Sep-1997
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/724,643
FILING DATE: 01-OCT-1996
APPLICATION NUMBER: US 08/844,419
FILING DATE: 18-APR-1997
APPLICATION NUMBER: US 08/846,017
FILING DATE: 25-APR-1997
APPLICATION NUMBER: US 08/851,843
FILING DATE: 06-MAY-1997
APPLICATION NUMBER: US 08/854,050
FILING DATE: 09-MAY-1997
APPLICATION NUMBER: US 08/911,312
FILING DATE: 14-AUG-1997
APPLICATION NUMBER: US 08/912,951
FILING DATE: 14-AUG-1997
APPLICATION NUMBER: US 08/915,503
FILING DATE: 14-AUG-1997
APPLICATION NUMBER: WO PCT/US97/17885
FILING DATE: 01-OCT-1997
ATTORNEY/AGENT INFORMATION:
NAME: Ausenhub, Scott L.
REGISTRATION NUMBER: 42,271
REFERENCE/DOCKET NUMBER: 01389-002620US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300
INFORMATION FOR SEQ ID NO: 479:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: -
LOCATION: 1..17
OTHER INFORMATION: /note="Nam2 primer"
US-09-402-181B-479
Query Match 0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0

```

```

01 145 AGCCTGGGCCCCCG 158
02 |||||||
03 |||||||
04 |||||||
05 DB 145 AGCCTGGGCCCCCG 14
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99

```

```

; NAME/KEY: -
; LOCATION: 1..17
; OTHER INFORMATION: /note="Nam2 primer"
; SEQUENCE DESCRIPTION: SEQ ID NO: 479:
US-09-721-456-479

Query Match
Best Local Similarity 100.0%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0

QY      145 AGCCTTGCCCCCG 158
      |||||
Db      1 AGCCTTGCCCCCG 14

RESULT 73
US-09-866-108A-1534
; Sequence 1534, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1534
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1534

Query Match
Best Local Similarity 100.0%; Score 14; DB 1; Length 17;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1205 GGGGCTGGTGCCCT 1218
      |||||
Db      4 GGGGCTGGTGCCCT 17

RESULT 74
US-09-866-108A-1535
; Sequence 1535, Application US/09866108A

```

```

; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1535
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1535

Query Match      0.6%, Score 14, DB 1, Length 17,
Best Local Similarity 100.0%, Pred. No. 50,
Matches 14, Conservative 0, Mismatches 0, Indels 0, Gaps 0,

Cy      1205 GGGGCTGGTGCCCT 1218
      |||||
      3 GGGGCTGGTGCCCT 16

RESULT 75
US-09-866-108A-1536
; Sequence 1536, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1535
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1535

```



```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1536
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1536

Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1205 GGGGCTGTGTCCT 1218
DB      2 GGGGCTGTGTCCT 15

RESULT 76
US-09-866-108A-1537
; Sequence 1537, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeonica Sequence Listing Engine
```

```

; Patent No. 6686188
; SEQ ID NO 1537
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1537

Query Match          0.6%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1205 GGGGCTGTGTCCT 1218
DB      1 GGGGCTGTGTCCT 14

RESULT 77
US-08-129-719-18/c
; Sequence 18, Application US/08129719
; Patent No. 5556755
; GENERAL INFORMATION:
; APPLICANT: Timothy F. Murphy
; TITLE OF INVENTION: Vaccine For Branhamella catarrhalis
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
; STREET: 1800 One Mt Plaza
; CITY: Buffalo
; STATE: New York
; COUNTRY: United States
; ZIP: 14203-2391
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.5 inch, 720 Kb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: MS-DOS/ Microsoft windows 3.1
; SOFTWARE: Wordperfect for windows 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/129,719
; FILING DATE: September 29, 1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Nelson, M. Bud
; REGISTRATION NUMBER: 35,300
; REFERENCE/DOCKET NUMBER: 11520, 0050
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (716) 856-4000
; TELEFAX: (716) 849-0349
; INFORMATION FOR SEQ ID NO: 18:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single-stranded
; TOPOLOGY: linear
; ORIGINAL SOURCE:
; ORGANISM: Branhamella catarrhalis
; STRAIN: 25240
; FEATURE:
; LOCATION: CD gene region, 1048-1064
; IDENTIFICATION METHOD: By experiment
; OTHER INFORMATION: hybridizes to Branhamella catarrhalis gene region
US-08-129-719-18

Query Match          0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1327 TGGTGAAGCTCTTCGAC 1343
DB      17 TGGCGAAGCTCTTCAC 1

RESULT 78
US-08-306-871-18/c
; Sequence 18, Application US/08306871
```

Patent No. 5712118
GENERAL INFORMATION:
APPLICANT: Timothy F. Murphy
TITLE OF INVENTION: Vaccine For Brachnamella catarrhalis
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
STREET: 1800 One Mkt Plaza
CITY: Buffalo
STATE: New York
COUNTRY: United States
ZIP: 14203-2391
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 1.4 Mb storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS/ Microsoft Windows 3.1
SOFTWARE: Wordperfect for Windows 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/306,871
FILING DATE: 20-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/129,719
FILING DATE: September 29, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Nelson, M. Bud
REGISTRATION NUMBER: 35,300
REFERENCE/DOCKET NUMBER: 11520.0053
TELECOMMUNICATION INFORMATION:
TELEPHONE: (716) 856-4000
TELEFAX: (716) 849-0349
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single-stranded
TOPOLOGY: linear
ORIGINAL SOURCE:
ORGANISM: Brachnamella catarrhalis
STRAIN: 25240
FEATURE:
LOCATION: CD gene region, 1048-1064
IDENTIFICATION METHOD: by experiment
OTHER INFORMATION: hybridizes to Brachnamella catarrhalis gene region
US-08-306-871-18
Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1327 TGGTGAAGCTCTTCGAC 1343
DB 17 TGGCGAAGCTCTTCTAC 1
RESULT 79
US-08-569-959-16/c
Sequence 18, Application US/08569959
Patent No. 5725862
GENERAL INFORMATION:
APPLICANT: Timothy F. Murphy
TITLE OF INVENTION: Vaccine For Brachnamella catarrhalis
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hodgson, Russ, Andrews, Woods & Goodyear
STREET: 1800 One Mkt Plaza
CITY: Buffalo
STATE: New York
COUNTRY: United States
ZIP: 14203-2391
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.5 inch, 1.4 Mb storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: MS-DOS/ Microsoft Windows 3.1

SOFTWARE: Wordperfect for Windows 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/569,959
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: U.S. 08/129,719
FILING DATE: September 29, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Nelson, M. Bud
REGISTRATION NUMBER: 35,300
REFERENCE/DOCKET NUMBER: 11520.0053
TELECOMMUNICATION INFORMATION:
TELEPHONE: (716) 856-4000
TELEFAX: (716) 849-0349
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single-stranded
TOPOLOGY: linear
ORIGINAL SOURCE:
ORGANISM: Brachnamella catarrhalis
STRAIN: 25240
FEATURE:
LOCATION: CD gene region, 1048-1064
IDENTIFICATION METHOD: by experiment
OTHER INFORMATION: hybridizes to Brachnamella
catarrhalis gene region
US-08-569-959-18

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1327 TGGTGAAGCTCTTCGAC 1343
DB 17 TGGCGAAGCTCTTCTAC 1

RESULT 80
US-08-985-162-52/c
Sequence 52, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwigen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TO LESIONS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476

FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 52:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-52

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1539 TTTTAAAGAGAAAA 1555
DB 17 TCTTAAGAGAAAGA 1

RESULT 81
US-08-584-040-7266/c
Sequence 7266, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESSES:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7266:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7266

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 854 GATGCTGAGCTATCT 870
DB 17 GATGTAGGAGGATCT 1

RESULT 82
US-08-584-040-7471
Sequence 7471, Application US/08584040
Patent No. 6346398
GENERAL INFORMATION:
APPLICANT: Pavco, Pamela
APPLICANT: McSwigen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESSES:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7471:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7471

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 54;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 613 GAACCTGGAGCTGTG 629
DB 1 GAACCTGGAGCTGTG 17

RESULT 83

US-09-474-432B-322/C
; Sequence 322, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MEB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 322
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-322

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 173 GCCAGGGCGCGGGGTG 189
DB 17 GCCGGGGCGCGGGGTG 1

RESULT 84

US-09-371-772B-3075/C
; Sequence 3075, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3075
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3075

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 854 GATGCTGGAGGTATCT 870
DB 17 GATGTAGGAGGTATCT 1

RESULT 85

US-09-371-772B-3277
; Sequence 3277, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3277
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3277

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 54;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
QY 613 GAACTGGGCTGTCTGG 629
DB 1 GAAACUGUCUGUGUG 17

RESULT 86

US-09-371-772B-4985
; Sequence 4985, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwigen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4985
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4985

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 54;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;


```

; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 230
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-230

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1247 AGAGCCATCACCATCC 1263
Db      1 AGAGCCCTCACCATCC 17

RESULT 91
US-09-866-108A-2018
; Sequence 2018, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```

```

; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2018
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2018

Query Match      0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      728 GGGCTGGTGCTCTCT 744
Db      1 GGCCCTGGTGCTCTCT 17

RESULT 92
US-09-866-108A-2019
; Sequence 2019, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
```

Patent No. 6686188
SEQ ID NO 2019
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-2019

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 729 GGCCTGCGTCCCTCTG 745
DB 1 GCCCTCGTCCCTCTG 17

RESULT 93
US-09-685-664B-3075/C
Sequence 3075, Application US/09685664B
Patent No. 6818447
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: MCSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH800-876-K (400/021)
CURRENT APPLICATION NUMBER: US/09/685,664B
PRIOR FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR FILING DATE: 1996-01-08
PRIOR APPLICATION NUMBER: US 09/371,772
PRIOR FILING DATE: 1999-08-10
NUMBER OF SEQ ID NOS: 8231
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3075
LENGTH: 17
TYPE: RNA
ORGANISM: Mus musculus
US-09-685-664B-3075

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 54;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 854 GATGCTGGAGGTATCT 870
DB 17 GATGAGGAGGTATCT 1

RESULT 94
US-09-685-664B-3277
Sequence 3277, Application US/09685664B
Patent No. 6818447
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: MCSwigen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MBH800-876-K (400/021)
CURRENT APPLICATION NUMBER: US/09/685,664B
PRIOR FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08

PRIOR APPLICATION NUMBER: US 09/371,772
PRIOR FILING DATE: 1999-08-10
NUMBER OF SEQ ID NOS: 8231
SOFTWARE: PatentIn version 3.0
SEQ ID NO 3277
LENGTH: 17
TYPE: RNA
ORGANISM: Mus musculus
US-09-685-664B-3277

Query Match 0.6%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 54;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 613 GAACCTGGGCTGTG 629
DB 1 GAACCTGGGCTGTG 17

RESULT 95
US-08-050-073-148
Sequence 148, Application US/08050073
Patent No. 5567809
GENERAL INFORMATION:
APPLICANT: Apple, Raymond J.
APPLICANT: Begovich, Ann B.
APPLICANT: Bugawan, Teodorica L.
APPLICANT: Erlich, Henry A.
APPLICANT: Griffith, Robert L.
APPLICANT: Schaff, Stephen J.
TITLE OF INVENTION: Methods and Reagents for HLA DRbeta DNA
TITLE OF INVENTION: Typing
NUMBER OF SEQUENCES: 315
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07110
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
OPERATING SYSTEM: IBM PC compatible
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/050,073
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Petry, Douglas A.
REGISTRATION NUMBER: 35,321
REFERENCE/DOCKET NUMBER: 8769
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 148:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: genomic DNA
US-08-050-073-148

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1970 GACTGCGCTCCAGATG 1986
DB 2 GCTGCTCCGAGATG 18

RESULT 96
US-08-210-762E-45/C
Sequence 45, Application US/08210762E
Patent No. 5837441
GENERAL INFORMATION:
APPLICANT: Hjelte, Brian
APPLICANT: Jensen, Steve
TITLE OF INVENTION: Molecular Clones Producing Recombinant DNA Antigens of
TITLE OF INVENTION: the HARDS virus.
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffman, Masson & Giller
STREET: 2361 Jefferson Davis Highway
CITY: Arlington
STATE: Virginia
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3.50 inch, 500 Kb storage
COMPUTER: Accel 486
OPERATING SYSTEM: Windows 3.1
SOFTWARE: Wordperfect 6.1 for Windows
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/210,762E
FILING DATE: 22-MAR-94
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/141,035
FILING DATE: 26-OCT-93
APPLICATION NUMBER: 08/120,096
FILING DATE: 13-SEP-93
APPLICATION NUMBER: 08/111,519
FILING DATE: 25-AUG-93
ATTORNEY/AGENT INFORMATION:
NAME: Bultm1, Jean A.
REGISTRATION NUMBER: 24,236
REFERENCE/DOCKET NUMBER: A4710CIP3.SL3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703)415-0100
TELEFAX: (703)418-2768
INFORMATION FOR SEQ ID NO: 45:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA viral
HYPOTHETICAL: no
ANTI-SENSE: no
ORIGINAL SOURCE:
ORGANISM: Four Corners Hantavirus
INDIVIDUAL ISOLATE: 3H226
IMMEDIATE SOURCE:
LIBRARY:
CLONE:
PUBLICATION INFORMATION:
AUTHORS: Hjelte, Brian
AUTHORS: Jensen, Steven
AUTHORS: Torres-Martinez, No. 5837441ah
AUTHORS: Yamada, Takashi
AUTHORS: No. 5837441te, Kurt
AUTHORS: Zummalt, Ross
AUTHORS: MacInnes, Kersti
AUTHORS: Myers, Gerald
TITLE: A No. 5837441e1 Hantavirus Associated with an Outbreak of Fatal Respirat
TITLE: Disease in the Southwestern United States: Evolutionary Relationships to
TITLE: Hantaviruses-Running Title: Hantavirus-associated ARDS
JOURNAL: Journal of Virology
VOLUME: 68
PAGES: in press
DATE: 1994
RELEVANT RESIDUES IN SEQ ID NO: 1: FROM 1 TO 18

US-08-210-762E-45
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 2025 CTGCCCCCATGCACCA 2041
Db 17 CTGAGCCCCATGCACCA 1
RESULT 97
US-09-161-015-9/C
Sequence 9, Application US/09161015A
Patent No. 5965370
GENERAL INFORMATION:
APPLICANT: Lex M. Cowseart
TITLE OF INVENTION: ANTISENSE MODULATION OF RHOG EXPRESSION
FILE REFERENCE: RTS-0015
CURRENT APPLICATION NUMBER: US/09/161,015A
CURRENT FILING DATE: 1998-09-25
NUMBER OF SEQ ID NOS: 47
SEQ ID NO 9
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-161-015-9
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1118 CCGATGGGTCCAGAGA 1134
Db 17 CAGAGGGGTCCAGAGA 1
RESULT 98
US-09-205-860-10
Sequence 10, Application US/09205860
Patent No. 5981732
GENERAL INFORMATION:
APPLICANT: Lex M. Cowseart
TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION
FILE REFERENCE: RTS-0031
CURRENT APPLICATION NUMBER: US/09/205,860
CURRENT FILING DATE: 1998-12-04
NUMBER OF SEQ ID NOS: 87
SEQ ID NO 10
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-860-10
Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 17 GCCGGCGCTGCCGCTC 33
Db 1 GCCGGCGCGCGGCTC 17
RESULT 99
US-09-200-141-40/C
Sequence 40, Application US/09200141
Patent No. 5985663
GENERAL INFORMATION:
APPLICANT: C. Frank Bennett


```

; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF Interleukin-15 EXPRESSION
; FILE REFERENCE: RTS-0022
; CURRENT APPLICATION NUMBER: US/09/200,141
; CURRENT FILING DATE: 1998-11-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 40
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-200-141-40

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1563 TTTCAGTCTTCTACT 1579
DB      17 TTACAGTATTCTACT 1

RESULT 100
US-09-106-038A-85
; Sequence 85, Application US/09106038A
; Patent No. 6007995
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker and Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF TNFR1
; NUMBER OF SEQUENCES: 91
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Isis Pharmaceuticals, Inc.
; STREET: 2292 Faraday Avenue
; CITY: Carlsbad
; STATE: CA
; COUNTRY: U.S.A.
; ZIP: 92008
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 1.44 MB
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: Windows NT
; SOFTWARE: Microsoft Word 97
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/106,038A
; FILING DATE: June 26, 1998
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Laurel Spear Bernstein
; REGISTRATION NUMBER: 37,280
; REFERENCE/DOCKET NUMBER: RTS-0004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (760) 931-9200
; TELEFAX: (760) 603-3820
; INFORMATION FOR SEQ ID NO: 85:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-106-038A-85

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      757 CAGAGCCACAGAGTG 773
DB      2 CAGAGGCGACAGAGTG 18

RESULT 101
```

```

US-09-358-381-23
; Sequence 23, Application US/09358381
; Patent No. 6020199
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowseart
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
; FILE REFERENCE: RTS-0079
; CURRENT APPLICATION NUMBER: US/09/358,381
; CURRENT FILING DATE: 1999-07-21
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-358-381-23

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1456 TAAATTGGAGGTGCA 1472
DB      2 TAAATTGGCGGTGCA 18

RESULT 102
US-09-577-902-23
; Sequence 23, Application US/09577902
; Patent No. 6284538
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowseart
; APPLICANT: Robert McKay
; TITLE OF INVENTION: ANTISENSE MODULATION OF PTEN EXPRESSION
; FILE REFERENCE: ISPH-0463
; CURRENT APPLICATION NUMBER: US/09/577,902
; CURRENT FILING DATE: 2000-05-24
; PRIOR APPLICATION NUMBER: US 09/358,381
; PRIOR FILING DATE: 1999-07-21
; PRIOR APPLICATION NUMBER: PCT/US99/29594,
; PRIOR FILING DATE: 1999-12-14
; NUMBER OF SEQ ID NOS: 51
; SEQ ID NO 23
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-577-902-23

Query Match          0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1456 TAAATTGGAGGTGCA 1472
DB      2 TAAATTGGCGGTGCA 18

RESULT 103
US-09-106-075A-45/C
; Sequence 45, Application US/09106075A
; Patent No. 6316250
; GENERAL INFORMATION:
; APPLICANT: Hjelte MD, Brian
; APPLICANT: Jensen, Steve
; TITLE OF INVENTION: Molecular Clones Producing Recombinant DNA Antigens of
; FILE REFERENCE: 10312-8U1, Hjelte et al. (210312.0009)
; CURRENT APPLICATION NUMBER: US/09/106,075A
```

```
; CURRENT FILING DATE: 1998-06-29
; PRIOR APPLICATION NUMBER: 08/210,762
; PRIOR FILING DATE: 1994-03-22
; PRIOR APPLICATION NUMBER: 08/141,035
; PRIOR FILING DATE: 1993-10-26
; PRIOR APPLICATION NUMBER: 08/120,096
; PRIOR FILING DATE: 1993-09-13
; PRIOR APPLICATION NUMBER: 08/111,519
; PRIOR FILING DATE: 1993-08-25
; NUMBER OF SEQ ID NOS: 90
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 45
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Prospect Hill virus
US-09-106-075A-45

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      2025 CTGCCCCCATGCACCA 2041
Db      17 CTGAGCCCATGCACCA 1

RESULT 104
US-08-584-040-8326
; Sequence 8326, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggan, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 MB
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Wardburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8326:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
```

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-8326

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 64.7%; Pred. No. 58;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy      613 GAACCTGGCTGTGTG 629
Db      2 GAACCTGCTGTGTG 18

RESULT 105
US-09-387-341-152/c
; Sequence 152, Application US/09387341
; Patent No. 6410323
; GENERAL INFORMATION:
; APPLICANT: Roberts, M. Luisa
; APPLICANT: Cowser, Lex M.
; TITLE OF INVENTION: Antisense Modulation of Human Rho Family Gene
; FILE REFERENCE: ISPH-0404
; CURRENT APPLICATION NUMBER: US/09/387,341
; CURRENT FILING DATE: 1999-08-31
; EARLIER APPLICATION NUMBER: 09/156,424
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,979
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/156,807
; EARLIER FILING DATE: 1998-09-18
; EARLIER APPLICATION NUMBER: 09/161,015
; NUMBER OF SEQ ID NOS: 233
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 152
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-387-341-152

Query Match      0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1118 CCGATGGTCCAGAGA 1134
Db      17 CAGAGGCTCCAGAGA 1

RESULT 106
US-09-422-978-4223
; Sequence 4223, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020C91
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4223
```

```
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Homo Sapiens
/ FEATURE:
/ NAME/KEY: primer_bind
/ LOCATION: 1..18
/ OTHER INFORMATION: upstream amplification primer 99-14013 for SEQ 289,
US-09-422-978-4223

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2344 TCTGTATCTCTGTGATG 2360
DB 2 TCTGTATCTCTGTGATG 18

RESULT 107
US-09-422-978-5061
/ Sequence 5061, Application US/09422978
/ Patent No. 6537751
/ GENERAL INFORMATION:
/ APPLICANT: Cohen, Daniel
/ APPLICANT: Blumenfeld, Marla
/ APPLICANT: Chumakov, Ilya
/ TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
/ FILE REFERENCE: GENSET.020CPI
/ CURRENT APPLICATION NUMBER: US/09/422,978
/ EARLIER FILING DATE: 1999-10-20
/ EARLIER APPLICATION NUMBER: US 09/298,850
/ EARLIER FILING DATE: 1999-04-21
/ EARLIER APPLICATION NUMBER: US 60/109,732
/ EARLIER FILING DATE: 1998-11-23
/ EARLIER APPLICATION NUMBER: US 60/082,614
/ EARLIER FILING DATE: 1998-04-21
/ NUMBER OF SEQ ID NOS: 11796
/ SEQ ID NO 5061
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Homo Sapiens
/ FEATURE:
/ NAME/KEY: primer_bind
/ LOCATION: 1..18
/ OTHER INFORMATION: upstream amplification primer 99-2058 for SEQ 1127,
US-09-422-978-5061

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1381 TCCTGGAGGTGAAGTGA 1397
DB 1 TCCTGGAGGTGAAGTGA 17

RESULT 108
US-09-422-978-11430
/ Sequence 11430, Application US/09422978
/ Patent No. 6537751
/ GENERAL INFORMATION:
/ APPLICANT: Cohen, Daniel
/ APPLICANT: Blumenfeld, Marla
/ APPLICANT: Chumakov, Ilya
/ TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
/ FILE REFERENCE: GENSET.020CPI
/ CURRENT APPLICATION NUMBER: US/09/422,978
/ EARLIER FILING DATE: 1999-10-20
/ EARLIER APPLICATION NUMBER: US 09/298,850
/ EARLIER FILING DATE: 1999-04-21
/ EARLIER APPLICATION NUMBER: US 60/109,732
/ EARLIER FILING DATE: 1998-11-23
/ EARLIER APPLICATION NUMBER: US 60/082,614
```

```
/ EARLIER FILING DATE: 1998-04-21
/ NUMBER OF SEQ ID NOS: 11796
/ SEQ ID NO 11430
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Homo Sapiens
/ FEATURE:
/ NAME/KEY: primer_bind
/ LOCATION: 1..18
/ OTHER INFORMATION: downstream amplification primer 99-5987 for SEQ 3565, in complement
US-09-422-978-11430

Query Match
Best Local Similarity 88.2%; Score 13.8; DB 1; Length 18;
Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 699 ATCTTTGATACCAACC 715
DB 2 ATCTTTGATACCAACC 18

RESULT 109
US-09-371-772B-3984
/ Sequence 3984, Application US/0931772B
/ Patent No. 6566127
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Favco, Pam
/ APPLICANT: MCSwigen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MBH00,876-J (237/198)
/ CURRENT APPLICATION NUMBER: US/09/371,772B
/ EARLIER FILING DATE: 1999-08-10
/ EARLIER APPLICATION NUMBER: US 60/005,974
/ EARLIER FILING DATE: 1995-10-26
/ EARLIER APPLICATION NUMBER: US 08/584,040
/ EARLIER FILING DATE: 1996-01-08
/ EARLIER APPLICATION NUMBER: US 08/584,040
/ PRIOR FILING DATE: 1995-10-26
/ PRIOR APPLICATION NUMBER: US 08/584,040
/ NUMBER OF SEQ ID NOS: 14225
/ SOFTWARE: Patencin version 3.0
/ SEQ ID NO 3984
/ LENGTH: 18
/ TYPE: RNA
/ ORGANISM: Mus sp.
/ OTHER INFORMATION: Mus sp.
US-09-371-772B-3984

Query Match
Best Local Similarity 64.7%; Score 13.8; DB 1; Length 18;
Pred. No. 58;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 613 GAACCTGGCTGTGTGG 629
DB 2 GAACCTGGCTGTGTGG 18

RESULT 110
US-09-954-736A-17/C
/ Sequence 17, Application US/09954736A
/ Patent No. 6689744
/ GENERAL INFORMATION:
/ APPLICANT: Gao, Wei-Qiang
/ APPLICANT: Koepfen, Hartmut
/ APPLICANT: Ross, Sarajane
/ APPLICANT: Shou, Jianyong
/ TITLE OF INVENTION: NOTCH RECEPTOR AGONISTS AND USES
/ FILE REFERENCE: P1848R1
/ CURRENT APPLICATION NUMBER: US/09/954,736A
/ EARLIER FILING DATE: 2001-09-17
/ EARLIER APPLICATION NUMBER: US 60/234,674
/ EARLIER FILING DATE: 2000-09-22
/ EARLIER APPLICATION NUMBER: US 60/082,614
```

SEQ ID NO 17
LENGTH: 18
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Synthetic Oligonucleotide Probe
US-09-954-736A-17

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 737 TGCCTTCGCACTCA 753
18 TGCCTTCGCACTCA 2

RESULT 111
US-09-155-885A-247/c
Sequence 247, Application US/09155885A
Patent No. 6709812
GENERAL INFORMATION:
APPLICANT: STUYVER, LIEVEN
ROSSAU, RUDI
MAERTENS, GEERT

TITLE OF INVENTION: METHOD FOR TYPING AND DETECTING HBV
NUMBER OF SEQUENCES: 313
CORRESPONDENCE ADDRESS:
ADDRESSEE: NIXON & VANDERHAYE P.C.
STREET: 1100 NORTH GLEBE ROAD
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: U.S.A.
ZIP: 22201-4714

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.30 (EPO)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/155,885A
FILING DATE: 08-Oct-1998
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/EP97/02002
FILING DATE: 21-APR-1997
APPLICATION NUMBER: EP 96870053.4
FILING DATE: 19-APR-1996

ATTORNEY/AGENT INFORMATION:
NAME: SADOFF, B.J.
REGISTRATION NUMBER: 36,663
REFERENCE/DOCKET NUMBER: 2551-5
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 816-4000
TELEFAX: (703) 816-4100

INFORMATION FOR SEQ ID NO: 247:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
SEQUENCE DESCRIPTION: SEQ ID NO: 247:
US-09-155-885A-247

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1302 TACGACCATGTACAT 1318
||||| ||| |||||

Db 18 TACGACCATGTACAT 2

RESULT 112
US-10-071-411A-22
Sequence 22, Application US/10071411A
Patent No. 6797475
GENERAL INFORMATION:
APPLICANT: Glenn Barnes
APPLICANT: Joanne Meyer

TITLE OF INVENTION: Detection of Polymorphisms in the Human
FILE REFERENCE: MRI-021
CURRENT APPLICATION NUMBER: US/10/071,411A
CURRENT FILING DATE: 2002-02-07
PRIOR APPLICATION NUMBER: 60/267,515
PRIOR FILING DATE: 2001-02-08
PRIOR APPLICATION NUMBER: 60/314,248
PRIOR FILING DATE: 2001-08-21

NUMBER OF SEQ ID NOS: 66
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 22
LENGTH: 18
TYPE: DNA

ORGANISM: Homo sapiens
US-10-071-411A-22

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 2018 GAAAGACTGCCCCCA 2034
1 GAAAGTGTGCCCCCA 17

RESULT 113
US-09-685-664B-3984
Sequence 3984, Application US/09685664B
Patent No. 6818447
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwigen, Jim
APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate

FILE REFERENCE: MEHBOO-876-K (400/021)
CURRENT APPLICATION NUMBER: US/09/685,664B
CURRENT FILING DATE: 2000-10-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
PRIOR APPLICATION NUMBER: US 09/371,772
PRIOR FILING DATE: 1999-08-10

NUMBER OF SEQ ID NOS: 8231
SOFTWARE: Patentin version 3.0
SEQ ID NO 3984
LENGTH: 18
TYPE: RNA

ORGANISM: Mus musculus
US-09-685-664B-3984

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 64.7%; Pred. No. 58;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Db 613 GAAAGTGGCTGGTGG 629
2 GAAAGTGGCTGGTGG 18
||||| :|:|:|

RESULT 114
PCT-US93-12603-11/c
Sequence 11, Application PC/TUS9312603
GENERAL INFORMATION:
APPLICANT: Denner, Larry A
APPLICANT: Rege, Ajay A
APPLICANT: Dixon, Richard AF
TITLE OF INVENTION: ANTISENSE MOLECULES DIRECTED AGAINST
TITLE OF INVENTION: GENES OF THE RAF ONCOGENE FAMILY
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dressler, Goldsmith, Shore & Milnamov, Ltd.
STREET: 180 North Steeles, Suite 4700
CITY: Chicago
STATE: IL
COUNTRY: USA
ZIP: 60601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/12603
FILING DATE:
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Katz, Martin L.
REGISTRATION NUMBER: 25,011
TELECOMMUNICATION INFORMATION:
TELEPHONE: (312)616-5400
TELEFAX: (312)616-5460
INFORMATION FOR SEQ ID NO: 11:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US93-12603-11

Query Match 0.6%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 58;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1871 CCCCGTGTGTAGGCG 1887
DB 17 CCCAGTGTGTGAGGCG 1

RESULT 115
US-08-363-240A-622
Sequence 622, Application US/08363240A
Patent No. 5705388
GENERAL INFORMATION:
APPLICANT: Couture, Larry
APPLICANT: McSwigen, James
APPLICANT: Bisgaler, Charles
APPLICANT: Pape, Michael
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: PREVENTION, INHIBITION OF
TITLE OF INVENTION: PROGRESSION AND REGRESSION
TITLE OF INVENTION: OF VASCULAR DISEASES
NUMBER OF SEQUENCES: 1243
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/363,240A
FILING DATE: December 23, 1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 210/096
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 622:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-363-240A-622

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 56;
Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 361 CCAGCATCTCTCCG 375
DB 1 CCAGCAUCCUCCAG 15

RESULT 116
US-08-585-684B-91/c
Sequence 91, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwigen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Pasteo Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078

TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 91:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-585-684B-91

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 56;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 766 CAGAGTGAGCAAGA 780
DB 15 CAGAGTGAGCAAGA 1

RESULT 117
US-09-038-073-91/c
Sequence 91, Application US/09038073
Patent No. 6194150
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 91:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-91

Query Match 0.6%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 56;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 766 CAGAGTGAGCAAGA 780
DB 15 CAGAGTGAGCAAGA 1

RESULT 118
US-08-233-608-25/c
Sequence 25, Application US/08233608
Patent No. 5585238
GENERAL INFORMATION:
APPLICANT: Ligon, James M
APPLICANT: Beck, James J
TITLE OF INVENTION: Detection of Fungal Pathogens Using the
TITLE OF INVENTION: Polymerase Chain Reaction
NUMBER OF SEQUENCES: 49
CORRESPONDENCE ADDRESS:
ADDRESSEE: Clida-Geigy Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: NY
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/233,608
FILING DATE:
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Spruill, W. Murray
REGISTRATION NUMBER: 32,943
REFERENCE/DOCKET NUMBER: CGC 1739
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8615
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
DESCRIPTION: Oligonucleotide primer JB442
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-233-608-25

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2256 GCAGGTGCCCCCGA 2270
DB 15 GCAGGTGCCCCCGA 1

RESULT 119
US-08-887-480-25/c
Sequence 25, Application US/08887480
Patent No. 5814453
GENERAL INFORMATION:
APPLICANT: Beck, James J
TITLE OF INVENTION: Detection of Fungal Pathogens Using the
TITLE OF INVENTION: Polymerase Chain Reaction
NUMBER OF SEQUENCES: 96
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 5814453artis Corporation
STREET: 520 White Plains Road
CITY: Tarrytown
STATE: NY

COUNTRY: USA
ZIP: 10591
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/887,480
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/722,187
FILING DATE: 15-OCT-1996
ATTORNEY/AGENT INFORMATION:
NAME: Meigs, J. Timothy
REGISTRATION NUMBER: 38,241
REFERENCE/DOCKET NUMBER: CGC 1739/PCT/CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
DESCRIPTION: Oligonucleotide primer JB442
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-887-480-25

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2256 GCAGGTGCGCCCGA 2270
DB 15 GCAGGTGCGCCCGA 1

RESULT 120
US-08-722-187-25/C
Sequence 25, Application US/08722187
Patent No. 5955274
GENERAL INFORMATION:
APPLICANT: Ligon, James M
TITLE OF INVENTION: Detection of Fungal Pathogens Using the
TITLE OF INVENTION: Polymerase Chain Reaction
NUMBER OF SEQUENCES: 86
CORRESPONDENCE ADDRESS:
ADDRESSER: Ciba-Geigy Corporation
STREET: 7 Skyline Drive
CITY: Hawthorne
STATE: NY
COUNTRY: USA
ZIP: 10532
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patentin Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/722,187
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/233,608
FILING DATE: 04-APR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Walsh, Andrea C.

REGISTRATION NUMBER: 34,988
REFERENCE/DOCKET NUMBER: CGC 1739
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8666
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
DESCRIPTION: Oligonucleotide primer JB442
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-722-187-25

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2256 GCAGGTGCGCCCGA 2270
DB 15 GCAGGTGCGCCCGA 1

RESULT 121
US-08-985-162-53/C
Sequence 53, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Bell, Patricia
TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELFX: 67-3510
INFORMATION FOR SEQ ID NO: 53:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

```

; TOPOLOGY: linear
US-08-985-162-53

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy      1539 TTTTAAAGAGGAAA 1553
Db      16 TCTTTAAGAGGAAA 2

RESULT 122
US-08-985-162-326
; Sequence 326, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhear, Saghir
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FASTSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 326:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-326

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 60.0%; Pred. No. 65;
Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy      853 TGATGCTGAGGTA 867
Db      3 UGAUGUCUGAGCUA 17

RESULT 123
US-09-474-432B-487

; Sequence 487, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beigelman, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 487
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-487

Query Match      0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      2021 AGGACTGCCCCCAT 2035
Db      3 AGUACUGCCCCCAU 17

RESULT 124
US-09-474-432B-691
; Sequence 691, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpelsky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; PRIOR FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 691
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-691
```



```

Best Local Similarity 66.7%; Pred. No. 65;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1824 GCAGGACCAGTTTCT 1838
          ||||| |||||::||:
Db       1 GCAGGCCAGUUDUC 15

RESULT 127
US-09-476-387-486
; Sequence 486,, Application US/09476387
; Patent No. 6617438
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka Matulic
; APPLICANT: Sweedler, Dave
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleoside Triphosphate and their Incorporation into Oli
; FILE REFERENCE: MHB00-831-C (249/073)
; CURRENT APPLICATION NUMBER: US/09/476,387
; CURRENT FILING DATE: 2001-04-04
; PRIOR APPLICATION NUMBER: 09/474,432
; PRIOR FILING DATE: 1999-12-29
; PRIOR APPLICATION NUMBER: 09/301,511
; PRIOR FILING DATE: 1999-04-28
; PRIOR APPLICATION NUMBER: 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: 60/083,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: 60/064,866
; PRIOR FILING DATE: 1997-11-05
; NUMBER OF SEQ ID NOS: 1524

```

```

? SOFTWARE: Patent.in version 3.0
? SEQ ID NO 486
? LENGTH: 17
? TYPE: RNA
? ORGANISM: Homo sapiens
US-09-476-387-486

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 65;
Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy      2021 AGGACTGCCCCCAT 2035
      |||:|||||:
Db      3  AGUACUGCCCCCAU 17

RESULT 128
US-09-476-387-690
? Sequence 690, Application US/09476387
? Patent No. 6617438
? GENERAL INFORMATION:
? APPLICANT: Ribozyme Pharmaceuticals, Inc.
? APPLICANT: Beigelman, Leo
? APPLICANT: Beaudry, Amber
? APPLICANT: Karpeisky, Alex
? APPLICANT: Adamic, Jasenka Matulic.
? APPLICANT: Sweedler, Dave
? APPLICANT: Zinnen, Shawn
? TITLE OF INVENTION: Nucleotide Triphosphate and their Incorporation into Olig
? FILE REFERENCE: MBH800-831-C (249/073)
? CURRENT APPLICATION NUMBER: US/09/476,387
? CURRENT FILING DATE: 2001-04-04
? PRIOR APPLICATION NUMBER: 09/474,432
? PRIOR FILING DATE: 1999-12-29
? PRIOR APPLICATION NUMBER: 09/301,511
? PRIOR FILING DATE: 1999-04-28

```

; PRIOR APPLICATION NUMBER: 09/186,675
 ;
 ; PRIOR FILING DATE: 1998-11-04
 ;

THIS PAGE BLANK (USPTO)

; PRIOR APPLICATION NUMBER: 60/083,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; NUMBER OF SEQ ID NOS: 1524
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 690
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-476-387-690

Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 73.3%; Pred. No. 65;
 Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 33 CTGCTGGGCTCTAGG 47
 1 CUGCUGGGGUCCAGG 15

RESULT 129

US-09-401-063-53/c
 ; Sequence 53, Application US/09401063
 ; Patent No. 6623962
 ; GENERAL INFORMATION:
 ; APPLICANT: Akhtar, Saghir
 ; APPLICANT: Fell, Patricia
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
 ; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
 ; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
 ; TITLE OF INVENTION: FACTOR RECEPTORS
 ; NUMBER OF SEQUENCES: 1877
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSeq for Windows 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/401,063
 ; FILING DATE:
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/985,162
 ; FILING DATE: 04 December 1997
 ; APPLICATION NUMBER: 60/036,476
 ; FILING DATE: 31 January 1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 230/107
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 53:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 US-09-401-063-53

Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 65;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1539 TTTTAAAGAGAA 1553
 16 TCTTTAAGAGAA 2

RESULT 130

US-09-401-063-326
 ; Sequence 326, Application US/09401063
 ; Patent No. 6623962
 ; GENERAL INFORMATION:
 ; APPLICANT: Akhtar, Saghir
 ; APPLICANT: Fell, Patricia
 ; APPLICANT: McSwiggen, James
 ; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
 ; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
 ; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
 ; TITLE OF INVENTION: FACTOR RECEPTORS
 ; NUMBER OF SEQUENCES: 1877
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: FastSeq for Windows 2.0
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/401,063
 ; FILING DATE:
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 08/985,162
 ; FILING DATE: 04 December 1997
 ; APPLICATION NUMBER: 60/036,476
 ; FILING DATE: 31 January 1997
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 230/107
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 326:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 17 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 US-09-401-063-326

Query Match 0.6%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 60.0%; Pred. No. 65;
 Matches 9; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 853 TGATGCTGGAGTA 867
 3 UGAUGUCUGGAGCUA 17

RESULT 131

US-09-866-108A-797/c
 ; Sequence 797, Application US/09866108A

THIS PAGE BLANK (USPTO)

RESULT 132
US-09-866-108A-800/c
; Sequence 800, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MCA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359

RESULT 133

US-09-866-108A-1293

Sequence 1293, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wenaheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: AEOICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Aeoica Sequence Listing Engine

THIS PAGE BLANK (USPTO)

; Patent No. 6686188
; SEQ ID NO 1293
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1293

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1086 AAGCAGGTGATCTTC 1100
|||||
Db 3 AAGCAGGTGAGCTTC 17

RESULT 134

US-09-866-108A-1296
; Sequence 1296, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 1296
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-1296

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1087 AAGCAGGTGATCTTCG 1101
|||||
Db 1 AAGCAGGTGAGCTTCG 15

RESULT 135

US-09-866-108A-2023

; Sequence 2023, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2023
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2023

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 733 TCGGTGCCTTCGCA 747
|||||
Db 1 TCGGTGCCTTCGCA 15

RESULT 136

US-09-866-108A-2840
; Sequence 2840, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04

THIS PAGE BLANK (USPTO)


```
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2840
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2840

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1974 GCCTCCAGGATGAG 1988
DB 3 GCCTCCAGGATGAG 17

RESULT 137
US-09-866-108A-2844
; Sequence 2844, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2840
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2840

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1974 GCCTCCAGGATGAG 1988
DB 3 GCCTCCAGGATGAG 17

RESULT 137
US-09-866-108A-2844
; Sequence 2844, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
```

```
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2844
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2844

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1976 CCTCCAGGATGAGGA 1990
DB 1 CCTCCAGGATGAGGA 15

RESULT 138
US-09-866-108A-6040
; Sequence 6040, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 6040
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-6040

Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 629 GCGCTACTTTCGAGA 643
DB 3 GTGCTACTTTCGAGA 17

RESULT 139
```

THIS PAGE BLANK (USPTO)

```
Query Match          0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

RESULT 140
US-09-866-108A-6042
; Sequence 6042, Application US/09866108A
. Patent NO. 6586188

; GENERAL INFORMATION:
 ; APPLICANT: GU, Yizhong
 ; APPLICANT: JI, Yonggang
 ; APPLICANT: PENN, Sharron G.
 ; APPLICANT: HANZEL, David K.
 ; APPLICANT: RANK, David R.
 ; APPLICANT: CHEN, Wensheng
 ; APPLICANT: SHANNON, Mark
 ; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
 ; FILE REFERENCE: AEOMIC-7
 ; CURRENT APPLICATION NUMBER: US/09/866,108A
 ; CURRENT FILING DATE: 2001-05-25
 ; PRIOR APPLICATION NUMBER: US 60/207,456
 ; PRIOR FILING DATE: 2000-05-26
 ; PRIOR APPLICATION NUMBER: GB 24263.6

Query Match 0.68; Score 13.4; DB 1; Length 17;

```
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

RESULT 141

US-09-866-108A-6607/c
 . Sequence 6607 Application US/09866108A

; Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhe

APPLICANT: JI, Yonggang

APPLICANT: HANZEL. David K

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

; APPLICANT: SHANNON, Mark

; TITLE OF INVENTION: MYOSIN-L

```

; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER:

```

; CURRENT AFFILIATION NUMBER: 2001-0
 ; CURRENT FILING DATE: 2001-0

PRIOR APPLICATION NUMBER: US

; PRIOR FILING DATE: 2000-05-22

;; PRIOR APPLICATION NUMBER: GE
;; PRIOR FILING DATE: 2000-10-0

;; PRIOR FILING DATE: 2000-10-0
; PRIOR APPLICATION NUMBER: US

PRIOR FILING DATE: 2000-09-2

PC

; PRIOR FILING DATE: 2001-01-31

; PRIOR APPLICATION NUMBER: PC
; PRIOR FILING DATE: 2001-01-31

; PRIOR FILING DATE: 2001-01-31
; PRIOR APPLICATION NUMBER: PC

; PRIOR FILING DATE: 2001-01-3

PC

3
; PRIOR FILING DATE: 2001-01-3
PRIOR APPLICATION NUMBER: 00

;; PRIOR APPLICATION NUMBER: EC
; PRIOR FILING DATE: 2001-01-31

: PRIOR APPLICATION NUMBER: PC

;
; PRIOR FILING DATE: 2001-01-3

; PRIOR APPLICATION NUMBER: PC

; PRIOR FILING DATE: 2001-01-31
: Remaining Prior Application

; remaining floor application

THIS PAGE BLANK (USPTO)

NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Acomica Sequence Listing Engine
Patent No. 6686188
SEQ ID NO 6607
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-09-866-108A-6607

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1976 CCTCCAGGATGAGGA 1990

Db 17 CCTCCAGGATGTGGA 3

RESULT 142

US-09-866-108A-6610/c
Sequence 6610, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: ACOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Acomica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 6610

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-6610

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1975 GCCTCAGGATGAGG 1989

Db 15 GCCTCAGGATGTGG 1

RESULT 143

US-09-866-108A-10512
Sequence 10512, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: ACOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

PRIOR APPLICATION NUMBER: GB 24263.6

PRIOR FILING DATE: 2000-10-04

PRIOR APPLICATION NUMBER: US 60/236,359

PRIOR FILING DATE: 2000-09-27

PRIOR APPLICATION NUMBER: PCT/US01/00666

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00667

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00664

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00665

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00668

PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00663

PRIOR FILING DATE: 2001-01-30

Remaining Prior Application data removed - See File Wrapper or PALM.

NUMBER OF SEQ ID NOS: 15755

SOFTWARE: Acomica Sequence Listing Engine

Patent No. 6686188

SEQ ID NO 10512

LENGTH: 17

TYPE: DNA

ORGANISM: Homo sapiens

US-09-866-108A-10512

Query Match 0.6%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 65;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2309 GGGCGGGGAGGAAA 2323

Db 3 GGGCGGGGAGGAAA 17

RESULT 144

US-09-866-108A-10513
Sequence 10513, Application US/09866108A

Patent No. 6686188

GENERAL INFORMATION:

APPLICANT: GU, Yizhong

APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.

APPLICANT: HANZEL, David K.

APPLICANT: RANK, David R.

APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark

TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE

FILE REFERENCE: ACOMICA-7

CURRENT APPLICATION NUMBER: US/09/866,108A

CURRENT FILING DATE: 2001-05-25

PRIOR APPLICATION NUMBER: US 60/207,456

PRIOR FILING DATE: 2000-05-26

THIS PAGE BLANK (USPTO)

; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10513
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10513

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2309 GGGCCGGGGAGGAAA 2323
DB 2 GGGACGGGGAGGAAA 16

RESULT 145
US-09-866-108A-10514
; Sequence 10514, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ACOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10514
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10514

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2309 GGGCCGGGGAGGAAA 2323
DB 1 GGGACGGGGAGGAAA 15

RESULT 146
US-09-404-912-151/c
; Sequence 151, Application US/09404912
; Patent No. 6703228
; GENERAL INFORMATION:
; APPLICANT: John Landers
; APPLICANT: David Houseman
; APPLICANT: Barbara Jordan
; APPLICANT: Alain Charest
; TITLE OF INVENTION: Methods and Products Related to
; FILE REFERENCE: M0656/7045 (HCL/MAT)
; CURRENT APPLICATION NUMBER: US/09/404,912
; PRIOR FILING DATE: 1999-09-24
; PRIOR APPLICATION NUMBER: US 60/101,757
; PRIOR FILING DATE: 1998-09-25
; PRIOR APPLICATION NUMBER: PCT/US99/22283
; NUMBER OF SEQ ID NOS: 691
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 151
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo Sapiens
US-09-404-912-151

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1065 TTGGAGAGAAATGAA 1079
DB 15 TTGGAGAGAAATTA 1

RESULT 147
PCT-US95-04712-25/c
; Sequence 25, Application PC/TUS9504712
; GENERAL INFORMATION:
; APPLICANT: Ligon, James M
; APPLICANT: Beck, James J
; TITLE OF INVENTION: Detection of Fungal Pathogens Using the
; TITLE OF INVENTION: Polymerase Chain Reaction
; NUMBER OF SEQUENCES: 86
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Ciba-Geigy Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne
; STATE: NY
; COUNTRY: USA
; ZIP: 10532
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible

THIS PAGE BLANK (USPTO)

OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/04712
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/233,608
FILING DATE: 04-APR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Walsh, Andrea C.
REGISTRATION NUMBER: 34,988
REFERENCE/DOCKET NUMBER: CGC 1739
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8666
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: Other nucleic acid
DESCRIPTION: Oligonucleotide primer JB442
HYPOTHETICAL: NO
ANTI-SENSE: NO
PCT-US95-04712-25

Query Match 0.6%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 65;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2256 GCAGGTGCCCCCGA 2270
|||
Db 15 GCAGGTGCCCCCGA 1

Search completed: August 8, 2005, 09:59:24
Job time : 4 secs

THIS PAGE BLANK (USPTO)